<SEC-DOCUMENT>0001564590-14-003557.txt : 20140813
<SEC-HEADER>0001564590-14-003557.hdr.sgml : 20140812
<ACCEPTANCE-DATETIME>20140812160056
ACCESSION NUMBER:		0001564590-14-003557
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20140630
FILED AS OF DATE:		20140812
DATE AS OF CHANGE:		20140812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		141033930

	BUSINESS ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arwr-10q_20140630.htm
<DESCRIPTION>10-Q
<TEXT>
<html>
<body>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, DC 20549 </p>
<p style="margin-top:6pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q </p>
<p style="margin-top:6pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Wingdings'">&#120;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended June 30, 2014 </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number 000-21898 </p>
<p style="margin-top:6pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD RESEARCH CORPORATION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="margin-top:6pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:0.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">46-0408024</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State of incorporation)</p></td>
<td valign="bottom"  style="width:0.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:49.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">225 S. Lake Avenue, Suite 1050 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pasadena, California 91101 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(626) 304-3400 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address and telephone number of principal executive offices) </p>
<p style="margin-top:6pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
</tr>
<tr style="height:3.75pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font><font style="font-family:Times New Roman;">&#160;&#160;(Do not check if a smaller reporting company)</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom"  style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#120;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of the registrant&#8217;s common stock outstanding as of August 11, 2014 was 52,908,567. </p>
<p style="margin-top:4pt;text-align:center;border-top:Solid 1pt;padding-top:1pt;line-height:1pt;margin-bottom:0pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:94.36%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5.64%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page(s)</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:none;">PART I &#8212; FINANCIAL INFORMATION</font></a></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1"><font style="text-decoration:none;">ITEM&#160;1. FINANCIAL STATEMENTS (unaudited)</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Balance_Sheets"><font style="text-decoration:none;">Consolidated Balance Sheets</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Operations"><font style="text-decoration:none;">Consolidated Statements of Operations</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statement_of_Stockholders"><font style="text-decoration:none;">Consolidated Statement of Stockholders&#8217; Equity</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Cash_Flows"><font style="text-decoration:none;">Consolidated Statements of Cash Flows</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Notes_to_Consolidated_Financial_Statemen"><font style="text-decoration:none;">Notes to Consolidated Financial Statements</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-39pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.9pt;;text-indent:-38.9pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2"><font style="text-decoration:none;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF <br>OPERATIONS</font><font style="font-size:10pt;"></font></a></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3"><font style="text-decoration:none;">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4"><font style="text-decoration:none;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;;font-size:9.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9.5pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II_OTHER_INFORMATION"><font style="text-decoration:none;">PART II &#8212; OTHER INFORMATION</font></a></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9.5pt;font-weight:bold;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_2"><font style="text-decoration:none;">ITEM&#160;1. LEGAL PROCEEDINGS</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_2"><font style="text-decoration:none;">ITEM&#160;1A. RISK FACTORS</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_2"><font style="text-decoration:none;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_2"><font style="text-decoration:none;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_2"><font style="text-decoration:none;">ITEM&#160;4. MINE SAFETY DISCLOSURES</font><font style="font-size:10pt;"></font></a></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_2"><font style="text-decoration:none;">ITEM&#160;5. OTHER INFORMATION</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.85pt;;text-indent:-40.85pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_2"><font style="text-decoration:none;">ITEM&#160;6. EXHIBITS</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:9.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURE"><font style="text-decoration:none;">SIGNATURE</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="bottom"  style="width:5.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PART I. FINANCIAL INFORMATION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1"></a>ITEM&#160;1. FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation and Subsidiaries </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Balance_Sheets"></a>Consolidated Balance Sheets </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700,063</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">538,742</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,660</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,834,408</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,030,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,422,946</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,843,719</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,674,131</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,513,235</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents and other intangible assets, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,199,523</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240,513</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,284,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702,153</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,414</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,011</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:61.55pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">196,622,876</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">37,329,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,158,133</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,199,632</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638,884</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611,092</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">905,771</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,125</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,018,719</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096,363</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital lease obligation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,110</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,345</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971,557</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">588,343</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,250,096</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,725,020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LONG-TERM LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital lease obligation, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">812,169</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,061,113</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,752,822</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,758,709</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LONG-TERM LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,564,991</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,869,822</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation stockholders' equity:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock,<font style="font-style:italic;"> </font>$0.001 par value; 5,000,000 shares authorized; 21,291 and 9,900 shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued and outstanding as of June 30, 2014 and September 30, 2013, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 145,000,000 shares authorized; 52,908,567 and 32,489,444 shares issued and outstanding as of June 30, 2014 and September 30, 2013, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,278</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,859</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388,558,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,514,766</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202,340,717</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(166,140,969</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Arrowhead Research Corporation stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,362,887</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,498,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(555,098</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,763,877</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185,807,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,734,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">196,622,876</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">37,329,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation and Subsidiaries </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Statements_of_Operations"></a>Consolidated Statements of Operations </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REVENUE</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">43,750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">43,750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">131,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">246,516</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OPERATING EXPENSES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries and payroll-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,454,449</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,651,729</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,634,142</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,006,328</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,582,465</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">899,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,865,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,597,279</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,392,200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,756,527</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,719,739</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458,212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,038,682</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">363,593</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,758,264</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,114,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">276,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454,086</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075,238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,352,448</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,308,047</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,308,047</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL OPERATING EXPENSES</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12,743,850</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6,433,615</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">31,053,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16,836,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPERATING LOSS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,700,100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,389,865</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,921,978</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,590,173</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER INCOME (EXPENSE)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity in income (loss) of unconsolidated affiliates</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,702</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,350</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(380,699</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain (loss) on sale of fixed assets, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,949</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,878</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,388</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226,424</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,252</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">386,392</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,403</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of derivatives</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">758,469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,747</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,712,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215,620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,054</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,221</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,269</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(997,976</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL OTHER INCOME (EXPENSE)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1,073,649</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">212,237</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(5,372,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1,307,846</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,626,451</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6,177,628</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(36,294,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(17,898,019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LOSS FROM CONTINUING OPERATIONS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,626,451</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6,177,628</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(36,294,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(17,898,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (loss) from discontinued operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET LOSS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,626,451</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6,177,628</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(36,294,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(17,898,373</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (gain) loss attributable to non-controlling interests</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,468</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET LOSS ATTRIBUTABLE TO ARROWHEAD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11,628,919</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6,079,010</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(36,199,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(17,451,105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:61.55pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.81</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SHAREHOLDERS - BASIC &amp; DILUTED:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding - basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,931,989</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,134,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,565,008</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:11%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,893,197</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:11%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation and Subsidiaries </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Statement_of_Stockholders"></a>Consolidated Statement of Stockholders&#8217; Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman Bold;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Common Stock</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Preferred Stock</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional Paid-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">32,489,444</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">124,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">193,514,766</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(166,140,969</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1,763,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">25,734,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,875,727</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,875</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,001,918</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004,793</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,112</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,368,885</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,369,262</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,758,264</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,758,264</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued @ $5.86</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,071,672</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,072</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,057,040</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,060,112</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued @ $18.95</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,325,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,575,234</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,581,559</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock issued @ $1,000 per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,999,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued to Galloway</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,868</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Settlements related to derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,789,979</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,789,979</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock converted to common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,638,033</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,638</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,603</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deconsolidation of Calando Pharmaceuticals, Inc.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,303,911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,303,911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss for the nine months ended June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,199,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,294,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">52,908,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">145,278</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">21,291</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">388,558,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(202,340,717</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(555,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">185,807,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation and Subsidiaries </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Statements_of_Cash_Flows"></a>Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM OPERATING ACTIVITIES OF CONTINUING OPERATIONS:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,294,880</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,898,373</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (income) loss attributable to non-controlling interests</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) attributable to Arrowhead</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,199,748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,451,105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Income) loss from discontinued operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on disposal of fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,878</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,388</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of derivatives</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,712,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(215,620</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,758,264</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,114,375</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,352,448</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization (accretion) of note discounts, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">416,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,341</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash gain in equity investment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,197</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash impairment expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,315,721</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447,268</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(517,986</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127,248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441,373</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,402</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">990,929</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459,690</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,480</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(313,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATIONS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,496,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,639,360</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM INVESTING ACTIVITIES OF CONTINUING OPERATIONS:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,251,987</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(191,656</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,505</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,365,528</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,058,003</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,590,824</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,160,181</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,026,691</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,999,973</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM FINANCING ACTIVITIES OF CONTINUING OPERATIONS:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal payments on capital leases</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(257,178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(160,495</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock and preferred stock, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,641,720</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,448,824</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the exercise of warrants and stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,374,005</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,758,547</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,288,329</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from discontinued operations:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing cash flows</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) discontinued operations:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(354</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:47.9pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCREASE IN CASH</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,235,289</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,648,642</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH AT BEGINNING OF PERIOD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,377,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH AT END OF PERIOD</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,025,930</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplementary disclosures:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest paid</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,478</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these unaudited consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUPPLEMENTARY NON CASH TRANSACTIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 18, 2014, Arrowhead issued 131,579 shares of Common Stock valued at $500,000 to Galloway Limited, in settlement of a services agreement dated September 30, 2011.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 21, 2012, Arrowhead issued 239,894 shares of Common Stock to Roche in accordance with the terms of the Stock and Asset Purchase Agreement for Roche Madison Inc., to settle a liability of $986,049, which the Company had recorded upon the acquisition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Notes_to_Consolidated_Financial_Statemen"></a>Notes to Consolidated Financial Statements </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise noted: (1)&#160;the term &#8220;Arrowhead&#8221; refers to Arrowhead Research Corporation, a Delaware corporation, (2)&#160;the terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3)&#160;the term &#8220;Subsidiaries&#8221; refers collectively to Arrowhead Madison Inc. (&#8220;Madison&#8221;), Ablaris Therapeutics, Inc. (&#8220;Ablaris&#8221;), and Tego Biosciences Corporation (&#8220;Tego&#8221;), as well as our former subsidiaries,&nbsp;&nbsp;Alvos Therapeutics, Inc. (&#8220;Alvos&#8221;) and Agonn Systems, Inc. (&#8220;Agonn&#8221;),which were merged into Arrowhead during 2013, and Calando Pharmaceuticals, Inc. (&#8220;Calando&#8221;), which was deconsolidated as of June 30, 2014, (4)&#160;the term &#8220;Minority Investments&#8221; refers collectively to Nanotope, Inc. (&#8220;Nanotope&#8221;), which was dissolved during 2013, and Leonardo Biosystems, Inc. (&#8220;Leonardo&#8221;) in which the company holds a less than majority ownership position, (5)&#160;the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, (6) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock and the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead Common Stock. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1. <font style="font-style:italic;">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nature of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary Dynamic Polyconjugate (DPC) delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead&#8217;s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Company&#8217;s primary source of financing has been through the sale of equity securities.&nbsp;&nbsp;Research and development activities have required significant capital investment since the Company&#8217;s inception and the Company expects its operations to continue to require cash investment in fiscal 2014 and beyond as the Company advances its research and development efforts, including clinical trials, and related drug manufacturing costs.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 201<font style="color:#;">4</font>, the Company had $138.3 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 27 months.&nbsp;&nbsp;These bonds provide a source of liquidity, though the Company plans to hold them until maturity.&nbsp;&nbsp;At June 30, 2014, the Company had invested $50.1 million in bonds.&nbsp;&nbsp;During the nine months ended June 30, 2014, the Company&#8217;s cash position increased by $119.2 million, which was the result of the receipt of cash from the issuance of equity of $172.6 million and cash from the exercise of warrants and options of $12.4 million, partially offset by net cash invested in fixed income investments of $39.8 million, cash outflows of $24.5 million related to continuing operating activities and capital expenditures of $<font style="color:#;">1.3</font> million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries.&nbsp;&nbsp;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facilities are located.&nbsp;&nbsp;All significant intercompany accounts and transactions are eliminated in consolidation, and non-controlling interests are accounted for in the Company&#8217;s financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation&#8212;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Article&#160;8 of Regulation S-X.&nbsp;&nbsp;Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year.&nbsp;&nbsp;The September 30, 2013 Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended September&#160;30, 2013.&nbsp;&nbsp;Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates&#8212;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&nbsp;&nbsp;The Company had no restricted cash at June 30, 2014 and September 30, 2013.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several checking accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities.&#160;This statement requires certain securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At <font style="color:#;">June 30, 2014</font>, the Company classified all of its investments as held-to-maturity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.&nbsp;&nbsp;See further information regarding the Company&#8217;s short and long term investments in Note 2 &#8211; Investments.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See further information regarding fair market value of marketable debt securities in Note 10 &#8211; Fair Value Measurements, such fair market data is obtained from independent pricing services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization included certain license agreements acquired through business combinations. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-Process Research&#160;&amp; Development (IPR&amp;D)&#8212;IPR&amp;D assets represent capitalized on-going research projects that Arrowhead acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&amp;D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets are impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration - The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event.&nbsp;&nbsp;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&nbsp;&nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within our consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minority Equity Investments&#8212;The Company had a minority equity investment in Leonardo, a privately held biotechnology company.&nbsp;&nbsp;Based on the status of the development of Leonardo&#8217;s program, this investment has been fully impaired and the net book value at June 30, 2014 is $0.&nbsp;&nbsp;The operations of Leonardo ceased in December 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling Interests in Majority-Owned Subsidiaries&#8212;Operating losses applicable to majority-owned Calando, Ablaris and, prior to its disposal, Unidym have periodically exceeded the non-controlling interests in the equity capital of either Subsidiary. Such excess losses applicable to the non-controlling interests have been and are borne by the Company as there is no obligation of the non-controlling interests to fund any losses in excess of their original investment. There is also no obligation or commitment on the part of the Company to fund operating losses of any Subsidiary whether wholly-owned or majority-owned. The Company allocates the non-controlling interests&#8217; share of net loss in excess of the non-controlling interests&#8217; initial investment in accordance with FASB ASC 810-10. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When there is a change in the Company&#8217;s proportionate ownership share of a development-stage Subsidiary resulting from additional equity transactions in the Subsidiary, the change is accounted for as an equity transaction in consolidation. To the extent that the increase in the calculated value of the Company&#8217;s interest in the equity of the Subsidiary exceeds the Company&#8217;s investment in the transaction, that increase in value is referred to as the Company&#8217;s &#8220;increase in its proportionate share of the Subsidiary&#8217;s equity&#8221; and the amount is recorded as an increase in the Company&#8217;s Additional Paid-in Capital. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212;Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. The Company may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments under collaborative research and development agreements are recognized ratably over the relevant periods specified in the agreement, generally the period during which research and development is conducted. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earnings (Loss) per Share&#8212;Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options issued to employees and consultants and warrants to purchase Common Stock of the Company.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative Assets and Liabilities &#8211; The Company accounts for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on the Company&#8217;s Consolidated Balance Sheet and no further adjustments to their valuation are made. Some of the Company&#8217;s warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on the Company&#8217;s Consolidated Balance Sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the FASB issued ASU 2014-10, <font style="font-style:italic;">Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance</font>, which eliminates the distinction and separate requirements for development stage entities and other reporting entities under U.S. GAAP.&nbsp;&nbsp;Specifically the amendment eliminates the requirement for development stage entities to 1) present inception-to-date information in the statements of income, cash flow and shareholders&#8217; equity, 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.&nbsp;&nbsp;ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 with early adoption permitted.&nbsp;&nbsp;The Company has adopted ASU 2014-10 effectively with the filing of this Form 10-Q.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font>, which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and will become effective for the Company in the first quarter of 2018. The Company is evaluating the potential effects of the adoption of this update on its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the FASB issued ASU 2013-11, <font style="font-style:italic;">Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</font>, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity&#8217;s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. The Company is evaluating the impact, if any, of the adoption of ASU 2013-11 on its Consolidated Balance Sheet.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2. <font style="font-style:italic;">INVESTMENTS</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash balances in short-term and long-term debt securities.&nbsp;&nbsp;Investments at June 30, 2014 consisted of corporate bonds with maturities remaining of less than three years at the time of purchase.&nbsp;&nbsp;The Company may also invest excess cash balances in certificates of deposit, money market accounts, US Treasuries, US government agency obligations, corporate debt securities, and/or commercial paper.&nbsp;&nbsp;The Company accounts for its investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities.&nbsp;&nbsp;At <font style="color:#;">June 30, 2014</font>, all investments were classified as held-to-maturity securities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short and long-term investments as of June 30, 2014, and September 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom"  style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,834,408</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,850</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(237,181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,599,077</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due after one year within three years)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,284,862</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,899</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,222</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,136,599</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,119,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,749</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(389,403</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,735,616</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom"  style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2013</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,030,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,998,480</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due after one year within three years)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702,153</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,362</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699,791</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,732,414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,643</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,698,271</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3. <font style="font-style:italic;">FIXED ASSETS</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and other fixed assets are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2013</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,162</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323,376</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,248,606</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,452,013</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,623</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,955,217</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,749,409</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,607,608</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,594,421</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&nbsp;&nbsp; Accumulated depreciation and amortization</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,933,477</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,081,186</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,674,131</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,513,235</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4. <font style="font-style:italic;">ACQUISITIONS </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Roche Madison </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;21, 2011, the Company entered into a Stock and Asset Purchase Agreement (the &#8220;RNAi Purchase Agreement&#8221;) with Hoffmann-La Roche Inc. and F Hoffmann-La Roche Ltd (collectively, &#8220;Roche&#8221;), pursuant to which the Company purchased from Roche (i)&#160;all of the outstanding common stock of Roche Madison Inc. (&#8220;Roche Madison&#8221;, now &#8220;Arrowhead Madison&#8221;) and (ii)&#160;the intellectual property rights then held by Roche related to its RNAi business and identified in the RNAi Purchase Agreement (the &#8220;Transaction&#8221;). In consideration for the purchase of Roche Madison and the Roche RNAi assets, the Company issued to Roche a promissory note with a principal value of $50,000 and 1,288,158 shares of Common Stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the RNAi Purchase Agreement, Roche has a right of first negotiation on certain product candidates developed by the Company and its affiliates relating to the purchased assets. If the Company proposes to out-license or enters into substantive negotiations to out-license, any Clinical Candidate or Existing Candidate (as such terms are defined in the RNAi Purchase Agreement), the Company must give notice of the Candidate it proposes to out-license and negotiate exclusively and in good faith with Roche for 90 days regarding the applicable out-license. This right of first negotiation applies to all Existing Candidates (as defined in the RNAi Purchase Agreement) and the first five Clinical Candidates for which the Company delivers notice to Roche and subsequently enters into an out-license. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the consideration paid by the Company as per the closing terms, the Company is obligated to make certain royalty and milestone payments to Roche upon the occurrence of certain events. For certain product candidates that are developed by the Company that are covered by a valid claim by the patent rights transferred in the Transaction for which the Company and Roche do not enter into a licensing arrangement, the Company will be obligated to pay a 3% royalty on Net Sales (as defined in the RNAi Purchase Agreement), provided that the royalty rate may be reduced or offset in certain circumstances. The obligation to pay royalties on such candidates will last until the later of (i)&#160;the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii)&#160;ten years after the first commercial sale of such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also be obligated to make cash payments to Roche upon the achievement of various milestones for certain clinical candidates, for which the Company and Roche do not enter into a licensing arrangement, including the first regulatory approval in certain jurisdictions, and upon certain annual sales milestones for candidates that receive regulatory approval. The potential payments range from $2,500,000 to $6,000,000 per milestone. At the time of acquisition, the Company&#8217;s estimate of future payments for potential royalties and milestones had a net present value of $84,935 which was recorded as contingent consideration as a part of other non-current liabilities.&nbsp;&nbsp;Contingent consideration is calculated by modeling research and development activities for clinical candidates, forecasting timelines to market, and using &#8220;peak sales&#8221; estimate modeling, cash flows and potential milestone and royalty payments are calculated.&nbsp;&nbsp;The modeling assumes certain success rates, and discount factors related to riskiness of projects and the time value of money to calculate a net present value of future consideration payments to Roche.&nbsp;&nbsp;These estimates are based on many unknown variables that are difficult to estimate, and due to the extended process of drug development prior to marketing of drug candidates, the models must extend many years into the future.&nbsp;&nbsp;Such predictions are inherently uncertain.&nbsp;&nbsp;On a quarterly basis, the Company re-evaluates its contingent consideration, and if material, makes adjustments to the recorded liability.&nbsp;&nbsp;Any adjustment to the contingent consideration liability is reflected in the Company&#8217;s Statement of Operations.&nbsp;&nbsp;During fiscal 2013, the contingent consideration liability was increased by $1.4 million, which is recorded as a part of other non-current liabilities on the Company&#8217;s Consolidated Balance Sheet. There have been no changes to the liability during the nine months ended June 30, 2014.&nbsp;&nbsp;For additional information related to our valuation of this obligation, see <font style="font-style:italic;">Note 10, Fair Value Measurements</font>.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5. <font style="font-style:italic;">INTANGIBLE ASSETS</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets consist of in-process research and development (&#8220;IPR&amp;D&#8221;) not subject to amortization, and other intangible assets subject to amortization, which were capitalized as a part of a business combination. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&amp;D represents projects that have not yet received regulatory approval and are required to be classified as indefinite assets until the successful completion or the abandonment of the associated R&amp;D efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in one or more jurisdictions which, individually or combined, are expected to generate a significant portion of the total revenue expected to be earned by an IPR&amp;D project. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is abandoned the related IPR&amp;D assets will likely be written off and we would record an impairment loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization include patents capitalized as part of a business combination as well as license agreements capitalized as part of a business combination from the acquisition of Roche Madison.&nbsp;&nbsp; The license agreements are being amortized over the estimated life remaining at the time of acquisition which was 4 years, and the accumulated amortization of the assets is approximately $147,800. Patents have been amortized over a period of three years to twenty years, however the patent assets were fully impaired as of September 30, 2013. Amortization expense for the three and nine months ended June 30, 2014 was approximately $13,663 and $40,990, respectively.&nbsp;&nbsp;Amortization expense for the three and nine months ended June 30, 2013 was approximately $74,115 and $222,345, respectively. Amortization of license agreements is expected to be approximately $14,000 for the remainder of fiscal year 201<font style="color:#;">4, $55,000 in </font>201<font style="color:#;">5</font>, $14,000 in 2016, and zero thereafter. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review amounts capitalized as IPR&amp;D for impairment at least annually in the fourth quarter, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In the event the carrying value of the assets is not expected to be recovered, the assets are written down to their estimated fair values. We continue to test our indefinite-lived IPR&amp;D assets for potential impairment until the projects are completed or abandoned. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on our intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;">
<tr>
<td valign="bottom"  style="width:46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible&#160;assets<font style="font-weight:normal;"><br></font>not subject to<br>amortization</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible&#160;assets<br>subject to<br>amortization</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total<br>Intangible&#160;assets</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September&#160;30, 2012</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667,247</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,784,569</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,308,047</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,308,047</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(236,009 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(236,009</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September&#160;30, 2013</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,191</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240,513</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,990</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,990</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2014</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,201</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,199,523</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6. <font style="font-style:italic;">INVESTMENT IN SUBSIDIARIES</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to 100% ownership interest in Arrowhead Madison Inc., Arrowhead also maintains majority ownership in Calando Pharmaceuticals, Ablaris Therapeutics, Inc., and a minority investment in Leonardo Biosystems, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Calando Pharmaceuticals, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calando is a developer of polymer delivery systems for siRNA and small molecule based therapeutics.&nbsp;&nbsp;Calando&#8217;s current cash resources preclude additional development of its platform technology and therapeutic candidates.&nbsp;&nbsp;Arrowhead has determined that it will not provide substantial further investment to Calando based on Arrowhead evaluation of Calando&#8217;s development and business prospects and Calando has been unsuccessful in its efforts to obtain capital from other sources.&nbsp;&nbsp;Calando has ceased operations and terminated its technology license with the California Institute of Technology on which its siRNA therapeutic development efforts were based.&nbsp;&nbsp;Further, pursuant to an involuntary petition by an unpaid Noteholder, Calando is undergoing Chapter 7 bankruptcy proceedings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2009, Calando outlicensed its small molecule program to Cerulean Pharma, Inc., a Boston, MA-based biotech company which has continued the development of the program.&nbsp;&nbsp;Under the license, as the development program progresses, Calando could collect partnership, milestone and royalty payments from Cerulean.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calando has an outstanding promissory note with a balance of principal and interest totaling $1,253,000 as of June 30, 2014.&nbsp;&nbsp;The promissory note became due on November 26, 2013, but was not repaid due to lack of cash resources at Calando.&#160;&#160;The holder of the Note initiated an involuntary petition of bankruptcy against Calando.&#160;&#160;A trustee has been appointed and a meeting of Calando creditors has occurred.&#160;&#160;It is expected that the trustee will dispose of Calando assets, primarily its license agreement with Cerulean.&#160;&#160;The Company cannot estimate the proceeds from the disposition of Calando&#8217;s assets, nor how it will be distributed amongst its various creditors, which includes Arrowhead and the holder of the Note.&nbsp;&nbsp;During the nine months ended June 30, 2014, Arrowhead deconsolidated Calando based on the fact that Calando is now subject to the control of the bankruptcy trustee.&nbsp;&nbsp;The deconsolidation of Calando resulted in an approximately $87,000 gain to the Company&#8217;s Consolidated Statement of Operations.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, Calando owed to Arrowhead $<font style="color:#;">4.5</font> million under a series of 8% simple interest notes and advances. It is unlikely these notes will be repaid in full. The balance of the notes and advances has been fully reserved.  &nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, Arrowhead owned <font style="color:#;">79</font>% of the outstanding shares of Calando and <font style="color:#;">76</font>% on a fully diluted basis.&nbsp;&nbsp;As a result of the ongoing bankruptcy proceeding for Calando, we do not expect our equity ownership to result in any return of capital as part of the liquidation of Calando.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ablaris Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ablaris was formed and began operations in fiscal 2011, based on the license of certain anti-obesity technology developed at the MD Anderson Cancer Center at the University of Texas. During fiscal 2011, Ablaris raised $2.9 million in cash, of which $1.3 million was invested by Arrowhead and $1.6 million was invested by outside investors, through the issuance of Ablaris Series A Preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, Arrowhead owned <font style="color:#;">64</font>% of the outstanding shares of Ablaris and <font style="color:#;">64</font>% on a fully diluted basis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Leonardo Biosystems, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leonardo, a privately-held drug-delivery company in which Arrowhead has a 3% ownership interest, ceased operations in December 2013. Arrowhead&#8217;s investment in Leonardo and its receivable from Leonardo have been fully reserved.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7. <font style="font-style:italic;">STOCKHOLDERS&#8217; EQUITY</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2014, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001, and 5,000,000 shares of Preferred Stock, par value $0.001. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2014, <font style="color:#;">52,908,567</font> shares of Common Stock were outstanding.&nbsp;&nbsp;Additionally, 21,291 shares of Preferred Stock were outstanding, including 5,291 shares of Series B Preferred Stock, convertible into 2,891,257 shares of Common Stock, and 16,000 shares of Series C Preferred Stock, convertible into 2,730,375 shares of Common Stock, (collectively, the &#8220;Outstanding Preferred Stock&#8221;). At June 30, 2014, 7,182,925 shares were reserved for issuance upon vesting of restricted stock units and exercise of stock options granted under Arrowhead&#8217;s 2000 Stock Option Plan, 2004 Equity Incentive Plan, and 2013 Incentive Plan, as well as for inducement grants made to new employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Outstanding Preferred Stock is convertible to Common Stock by each holder at its stated conversion price, subject to a 9.99% beneficial ownership limit for each holder.&nbsp;&nbsp;The holders of Outstanding Preferred Stock are eligible to vote with the Common Stock of the Company on an as-converted basis, but only to the extent they are eligible for conversion without exceeding the 9.99% ownership limitation. The Outstanding Preferred Stock does not carry a coupon, but is entitled to receive dividends on a pari passu basis with the Common Stock, when and if declared.&nbsp;&nbsp;In any liquidation or dissolution of the Company, the holders of Outstanding Preferred Stock are entitled to participate in the distribution of the assets, to the extent legally available for distribution, on a pari passu basis with the Common Stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;20, 2011, the Company and Lincoln Park Capital Fund, LLC, an Illinois limited liability company (&#8220;LPC&#8221;) entered into a $15 million purchase agreement (the &#8220;Purchase Agreement&#8221;), whereby LPC agreed to purchase up to $15 million of Common Stock, subject to certain limitations, from time to time during the three-year term of the Purchase Agreement. The Company has the right, in its sole discretion, over a 36-month period to sell up to $15 million of Common Stock (subject to certain limitations) to LPC, depending on certain conditions as set forth in the Purchase Agreement. As of June 30, 2014, the Company had drawn $1 million from the facility. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;11, 2013, the Company sold 3,071,672 shares of common stock, at a price of $5.86 per share, and 46,000 shares of Series&#160;C Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;), at a price of $1,000 per share. The Preferred Shares are convertible into shares of common stock at a conversion price of $5.86. The aggregate purchase price paid by the Purchasers for the Shares and Preferred Shares was $64,000,000 and the Company received net proceeds of approximately $60,000,000, after advisory fees and offering expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 24, 2014, the Company sold 6,325,000 shares of common stock, at a public offering price of $18.95 per share.&nbsp;&nbsp;Net proceeds were approximately $112.6 million after underwriting commissions and discounts and other offering expense.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about warrants outstanding at June 30, 2014: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td colspan="3" valign="top"  style="width:58.84%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;prices</p></td>
<td valign="top"  style="width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;<br>Warrants</p></td>
<td valign="bottom"  style="width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.44%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining<font style="font-weight:normal;"><br></font>Life&#160;in&#160;Years</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,897</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom"  style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">416,225</p></td>
<td valign="bottom"  style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="bottom"  style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="bottom"  style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,324</p></td>
<td valign="bottom"  style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="bottom"  style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.25</p></td>
<td valign="bottom"  style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,347 </p></td>
<td valign="bottom"  style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom"  style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.12</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:8.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom"  style="width:48.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td>
<td valign="top"  style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:16.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,784</p></td>
<td valign="bottom"  style="width:1.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:16.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom"  style="width:1.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  BGCOLOR="#CFF0FC" style="width:58.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total warrants outstanding</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,526,781 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:16.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8. <font style="font-style:italic;">LEASES</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters in Pasadena, California. In March 2014, the Company signed a lease addendum to expand its corporate headquarters.&nbsp;&nbsp;It is expected the new space will be available in September 2014.&nbsp;&nbsp;The leases for the expansion space and the current space will expire in August 2019.&nbsp;&nbsp; Rental costs, including the expansion space are approximately $22,000 per month, increasing approximately 3% annually.  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s research facility in Madison, Wisconsin is leased through February&#160;28, 2019. Monthly rental expense is approximately $25,000. Other monthly rental expenses include common area maintenance and real estate taxes totaling approximately $16,000 per month. Utilities costs are approximately $15,000 per month. Including monthly payments recorded under a capital lease of approximately $19,000, total monthly costs are approximately $75,000 per month. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility and equipment rent expense, related to continuing operations, for the three and nine months ended June 30, 2014 was $138,000 and $403,000, respectively.&nbsp;&nbsp;Facility and equipment rent expense, related to continuing operations, for the three and nine months ended June 30, 2013 was $126,000 and $407,000, respectively.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, future minimum lease payments due in fiscal years under capitalized leases are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4 (remainder of)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">5 </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">6 </font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">7 </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">8 </font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">9 </font>and thereafter</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,175</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,681 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,025,279</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,110 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">812,169</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, future minimum lease payments due in fiscal years under operating leases are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;">
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4 (remainder of)</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,164</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">5 </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580,626</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">6 </font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597,196</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">7 </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613,984</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">8 </font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638,217</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">9 </font>and thereafter</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,861 </p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,997,048</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9. <font style="font-style:italic;">STOCK-BASED COMPENSATION</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has three plans that provide for equity-based compensation. Under the 2000 Stock Option Plan, 38,000 shares of Arrowhead&#8217;s Common Stock are reserved for issuance upon exercise of non-qualified stock options. No further grants can be made under the 2000 Stock Option Plan. The 2004 Equity Incentive Plan reserves 2,734,840 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others.&nbsp;&nbsp;The 2013 Incentive Plan reserves 4,000,000 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance awards to employees, consultant and others.&nbsp;&nbsp;As of June 30, 2014, there were options granted and outstanding to purchase 38,000, 2,638,652 and 736,875 shares of Common Stock under the 2000 Stock Option Plan, the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively. Also, as of June 30, 2014, there were 410,085 shares reserved for options issued outside of equity compensation plans as inducement grants to new employees. During the nine months ended June 30, 2014, no options were granted under the 2004 Equity Incentive Plan, 765,000 were issued under the 2013 Incentive Plan and 165,000 options were granted outside of equity incentive plans as inducement stock options to new employees. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom"  style="width:41%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of<br>Options<br>Outstanding</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br>Average<br>Exercise<br>Price<br>Per&#160;Share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br>Average<br>Remaining<br>Contractual<br>Term</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate<br>Intrinsic<br>Value</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,794</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,509,166</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(675 </p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)<font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.93</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419,285 </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.68</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">930,000</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.05</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148,561</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(377,112</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.28</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,823,612</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,271,011</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At June 30, 2014</p></td>
<td valign="bottom"  style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532,180 </p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.80</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3 years</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,666,712</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the three and nine months ended June 30, 2014 was $1,070,631 and $2,186,653, respectively. Stock-based compensation expense for the three and nine months ended June 30, 201<font style="color:#;">3</font> was $363,593 and $1,114,375, respectively. There is no income tax benefit as the Company is currently operating at a loss and an actual income tax benefit may not be realized. The loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate grant date fair value of the options granted by the Company during the three and nine months ended June 30, 2014 is estimated at $<font style="color:#;">1,176,000</font> and $<font style="color:#;">8,295,600</font>, respectively. The aggregate grant date fair value of the options granted by the Company during the three and nine months ended June 30, 2013 is estimated at $<font style="color:#;">1,094,295</font> and $<font style="color:#;">1,197,588</font>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of the options exercised during the three and nine months ended June 30, 2014 was $371,334 and $3,606,061, respectively.&nbsp;&nbsp;No options were exercised during the three and nine months ended June 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, the pre-tax compensation expense for all unvested stock options in the amount of approximately $10,514,619 will be recognized in the Company&#8217;s results of operations over a weighted average period of <font style="color:#;">3.2 </font>years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="width:62.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:36.22%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months&#160;ended&#160;June 30,</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:62.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4</font><font style="font-weight:normal;"> </font></p></td>
<td valign="bottom"  style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">3</font><font style="font-weight:normal;"> </font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="top"  style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8% to 2.5%&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7%&#160; to&#160;1.3%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td valign="top"  style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25 to 9.72</p></td>
<td valign="bottom"  style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 to 6.25</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value per share of options granted</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.26</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dividend yield is zero as the Company currently does not pay a dividend. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on the U.S. Treasury bond. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (RSUs) are granted under the Company&#8217;s 2013 Incentive Plan.&nbsp;&nbsp;During the nine months ended June 30, 2014, the Company issued 470,000 restricted stock units to certain members of management and certain members of its Board of Directors.&nbsp;&nbsp;At vesting each RSU will be exchanged for one share of the Company&#8217;s Common Stock. The RSUs issued to management vest in equal installments on the one and two year anniversary of the date of grant.&nbsp;&nbsp;The RSUs issued to the members of the Board of Directors vest upon the one year anniversary of the date of grant.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s Restricted Stock Units:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="width:64.68%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br>Number of<br>RSUs</p></td>
<td valign="bottom"  style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br>Average<br>Grant<br>Date<br>Fair Value</p></td>
<td valign="bottom"  style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1.38%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- </p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,000</p></td>
<td valign="bottom"  style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td valign="bottom"  style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:15.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  style="width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:0.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $968,051 and $1,571,611 of expense relating to restricted stock units during the three and nine months ended June 30, 2014 respectively, and such expense is included in stock-based compensation expense.&nbsp;&nbsp;There was no expense relating to restricted stock units during the three and nine months ended June 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, the pre-tax compensation expense for all unvested restricted stock units in the amount of approximately $5,291,302 will be recognized in the Company&#8217;s results of operations over a weighted average period of <font style="color:#;">1.5 </font>years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10. <font style="font-style:italic;">FAIR VALUE MEASUREMENTS</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at June 30, 2014 and September&#160;30, 2013 for assets and liabilities measured at fair value on a recurring basis: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom"  style="width:41%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative assets</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,018,719</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,018,719</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations related to acquisitions</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <font style="color:#;">2013</font>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom"  style="width:41%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative assets</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations related to acquisitions</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash balances in short and long-term corporate bonds, generally with remaining maturities of less than two years.&nbsp;&nbsp;At June 30, 2014, the Company had short-term investments of $23,834,408, and long-term investments of $26,284,862, for a total of $50,119,270.&nbsp;&nbsp;The fair value of its investment at June 30, 2014 was $49,735,616.&nbsp;&nbsp;The Company expects to hold such investments until maturity, and thus unrealized gains and losses from the fluctuations in the fair value of the securities are not likely to be realized.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the proceeds from the sale of Unidym in January 2011, Arrowhead received a bond from Wisepower in the face amount of $2.5 million. The bond is convertible to Wisepower common stock at a price of $2.00 per share. The conversion feature is subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the conversion feature on the date of issuance was estimated using an option pricing model and recorded on the Company&#8217;s Consolidated Balance Sheet as a derivative asset. The fair value of the conversion feature is estimated at the end of each reporting period and the change in the fair value of the conversion feature is recorded as a non-operating gain/loss as change in value of derivatives in Company&#8217;s Consolidated Statement of Operations. During the quarter ended March&#160;31, 2013, the trading of Wisepower stock was halted. Trading resumed in July 2013, but the trading price is significantly below the conversion price.&nbsp;&nbsp;During fiscal 2013, the Company determined that the probability of realizing value from the conversion feature was remote, and the derivative asset value was reduced to zero.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended June 30, 2014, there was no change in the fair value of the derivative asset. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in valuing the derivative asset were not applicable as the value has been determined to be zero at June 30, 2014 and September 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the derivative asset: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2012</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of instruments</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease <font style="color:#000000;">in value</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements<font style="color:#000000;"></font></p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of instruments</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease in value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of an equity financing in June 2010, Arrowhead issued warrants to acquire up to 329,649 shares of Common Stock (the &#8220;2010 Warrants&#8221;), of which 24,324 warrants were outstanding at June 30, 2014. Similarly, as part of a financing in December 2012, Arrowhead issued warrants to acquire up to 912,543 shares of Common Stock (the &#8220;2012 Warrants&#8221;) of which 265,161 warrants were outstanding at June 30, 2014.&nbsp;&nbsp;Further, as part of a financing in January 2013, Arrowhead issued warrants to acquire up to 833,530 shares of Common Stock (the &#8220;2013 Warrants&#8221;) of which 24,623 warrants were outstanding at June 30, 2014.&nbsp;&nbsp;Each of the warrants discussed above contains a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the terms of the Warrants, the Company issues Common Stock at a price lower than the exercise price for the Warrants, the exercise price would be reduced to the amount equal to the issuance price of the Common Stock.&nbsp;&nbsp;As a result of these features, the 2010 Warrants, the 2012 Warrants, and the 2013 Warrants are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the Warrants on the date of issuance was estimated using an option pricing model and recorded on the Company&#8217;s Consolidated Balance Sheet as a derivative liability. The fair value of the Warrants is estimated at the end of each reporting period and the change in the fair value of the Warrants is recorded as a non-operating gain or loss as change in value of derivatives in the Company&#8217;s Consolidated Statement of Operations. During the nine months ended June 30, 2014, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $5,680,544. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in valuing the derivative liability were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2010 Warrants</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom"  style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September&#160;30,&#160;2013</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.11%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 Years</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom"  style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2012 Warrants</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom"  style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September 30, 2013</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5 Years</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom"  style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013 Warrants</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom"  style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September 30, 2013</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6 Years</p></td>
<td valign="bottom"  style="width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom"  style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the derivative liability related to these warrants: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2012</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626,195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,153,819</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,066,591</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements<font style="color:#000000;"></font></p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,754,808 </p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,091,797</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,680,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,789,982)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,982,359</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:1pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:1pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the financing of Ablaris in fiscal 2011, Arrowhead sold exchange rights to certain investors whereby the investors have the right to exchange their shares of Ablaris for a prescribed number of Arrowhead shares based upon a predefined ratio. The exchange rights have a seven-year term. During the first year, the exchange right allows the holder to exchange one Ablaris share for 0.06 Arrowhead shares (as adjusted for a subsequent reverse stock split). This ratio declines to 0.04 in the second year, 0.03 in the third year and 0.02 in the fourth year. In the fifth year and beyond the exchange ratio is 0.01. Exchange rights for 675,000 Ablaris shares were sold in fiscal 2011, and remain outstanding at June 30, 2014. The exchange rights are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the exchange rights on the date of issuance was estimated using an option pricing model and recorded on the Company&#8217;s Consolidated Balance Sheet as a derivative liability. The fair value of the exchange rights is estimated at the end of each reporting period and the change in the fair value of the exchange rights is recorded as a non-operating gain or loss as change in value of derivatives in the Company&#8217;s Consolidated Statement of Operations. During the nine months ended June 30, 2014, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $31,791.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="width:72.36%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160; 201<font style="color:#;">4</font></p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,&#160; 2013</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom"  style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5 Years</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3 Years</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the derivative liability related to these exchange rights: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,375</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,806</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,569</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,791</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,360</p></td>
<td valign="bottom"  style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:10%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The derivative assets/liabilities are estimated using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. Changes in the assumptions used could have a material impact on the resulting fair value. The primary input affecting the value of the Company&#8217;s derivatives liabilities is the Company&#8217;s stock price. Other inputs have a comparatively insignificant effect. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal 2012, contingent consideration was recorded upon the acquisitions of Roche Madison Inc. and Alvos Therapeutics, Inc., totaling $173,621. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions and experience. Estimating timing to complete the development, and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and the Company&#8217;s experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded as operating expenses as contingent consideration &#8211; fair value adjustments in the Company&#8217;s Consolidated Statement of Operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of contingent consideration fair value. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,621</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price contingent consideration</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421,652</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September 30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price contingent consideration</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of contingent consideration obligations is estimated through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&nbsp;&nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date.&nbsp;&nbsp;Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. Each of these assumptions can have a significant impact on the calculation of contingent consideration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s other financial instruments, which include accounts receivable, accounts payable, and accrued expenses approximate their respective fair values due to the relatively short-term nature of these instruments. The carrying value of the Company&#8217;s debt obligations approximates fair value based on market interest rates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2%;text-indent:-7.2%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2"></a>ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933 and Section&#160;21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; or &#8220;continue&#8221; or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Readers should carefully review the factors identified in this report under the caption &#8220;Risk Factors&#8221; as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (&#8220;SEC&#8221;), including our most recent Annual Report on Form 10-K. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary Dynamic Polyconjugate (DPC) delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead&#8217;s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is leveraging its in-house R&amp;D expertise and capabilities, as well as a broad intellectual property portfolio for RNAi therapeutics, and RNAi and peptide delivery vehicles and targeting methods to seek development partnerships with other pharmaceutical and biotech companies committed to bringing RNAi therapeutics to market, as well as continuing the preclinical and clinical development of its own clinical candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead operates a lab facility in Madison, Wisconsin, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, are based. The Company&#8217;s principal executive offices are located in Pasadena, California.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has historically financed its operations primarily through the sale of Arrowhead securities. Research and development activities have required significant capital investment and are expected to continue to require significant cash investment for the foreseeable future, particularly as clinical trials progress with ARC-520, the Company&#8217;s candidate for the treatment of hepatitis B (HBV), and as the Company expands its existing candidate pipeline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2014, the Company had $188.5 million in cash and liquid investments to fund operations. During the nine months ended June 30, 2014, the Company&#8217;s cash position increased significantly primarily due proceeds from the sale of equity securities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended June 30, 2014, cash used in operating activities was $24.5 million, which represents the on-going expenses for research and development activities, business development, and general and administrative expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities during the nine months ended June 30, 2014 was $41.0 million, of which $39.8 million related to net investments in marketable fixed income securities.&nbsp;&nbsp;Capital expenditures were $1.3 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities in the nine months ended June 30, 2014 was $184.8 million.&nbsp;&nbsp;The Company completed equity financings in October 2013 and in February 2014 with net proceeds of $172.6 million.&nbsp;&nbsp;Additionally, financing activities included cash inflow from the exercise of warrants and options of $12.4 million.&nbsp;&nbsp;Principal payments on capital leases were $0.3 million. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>

<hr style="page-break-after:always">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Financing Activity / Sources of Capital<font style="font-weight:normal;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 24, 2014, the Company sold 6,325,000 shares of common stock, at a public offering price of $18.95 per share.&nbsp;&nbsp;Net proceeds were approximately $112.6 million after underwriting commissions and discounts and other offering expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;11, 2013, the Company sold 3,071,672 shares of Common Stock, at a price of $5.86 per share, and 46,000 shares of Series&#160;C Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;), at a price of $1,000 per share. The Preferred Shares are convertible into shares of Common Stock at a conversion price of $5.86 per share. The aggregate purchase price paid by the Purchasers for the Common Stock and Preferred Shares was $64,000,000 and the Company received net proceeds of approximately $60,000,000, after advisory fees and offering expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the Company&#8217;s current cash resources and operating plan, the Company expects to have sufficient liquidity to fund operations for the next twelve months, and beyond.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management makes certain judgments and uses certain estimates and assumptions when applying accounting principles generally accepted in the United States in the preparation of our Consolidated Financial Statements. We evaluate our estimates and judgments on an ongoing basis and base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could change our reported results. We believe the following accounting policies are the most critical to us, in that they are important to the portrayal of our Consolidated Financial Statements and require our most difficult, subjective or complex judgments in the preparation of our consolidated financial statements. For further information, see <font style="font-style:italic;">Note 1, Organization and Significant Accounting Policies</font>, to our Consolidated Financial Statements which outlines our application of significant accounting policies and new accounting standards. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from product sales are recorded when persuasive evidence of an arrangement exists, title has passed and delivery has occurred, a price is fixed and determinable, and collection is reasonably assured. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may generate revenue from technology licenses, collaborative research and development arrangements, research grants and product sales. Revenue under technology licenses and collaborative agreements typically consists of non-refundable and/or guaranteed technology license fees, collaborative research funding, and various milestone and future product royalty or profit-sharing payments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with payments under collaborative agreements for research and development is recognized ratably over the relevant periods specified in the agreement, generally the period during which research and development is conducted. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Business Combinations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2011, we acquired all of the outstanding common stock of Roche Madison, Inc. and certain related intellectual property assets for a $50,000 promissory note and 1,288,158 shares of Arrowhead Common Stock, an estimated consideration value of $5.1 million on the date of the acquisition. We assigned the value of the consideration to the tangible assets and identifiable intangible assets and the liabilities assumed on the basis of their fair values on the date of acquisition. The excess of net assets over the consideration was recorded as a non-operating gain. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2012, we acquired all of the outstanding common stock of Alvos Therapeutics, Inc. in exchange for the issuance of 315,457 shares of Arrowhead Common Stock, valued at $2.0 million at the time of acquisition. The consideration was assigned to its tangible and intangible assets, and liabilities based on estimated fair values at the time of acquisition. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of value to certain items, including property and equipment, intangible assets and certain liabilities require management judgment, and is based upon the information available at the time of acquisition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>

<hr style="page-break-after:always">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Impairment of Long-lived Assets </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that our assumptions about the useful lives of these assets are no longer appropriate. If impairment is indicated, recoverability is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Impairment of Intangible assets </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets consist of in-process research and development, patents and license agreements acquired in conjunction with a business acquisition. Intangible assets are monitored for potential impairment whenever events or circumstances indicate that the carrying amount may not be recoverable, and are also reviewed annually to determine whether any impairment is necessary. Based on ASC 350, the annual review of intangible assets is performed via a two-step process. First, a qualitative assessment is performed to determine if it is more likely than not that the intangible asset is impaired. If required, a quantitative assessment is performed and, if necessary, impairment is recorded. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize stock-based compensation expense based on the grant date fair value using the Black-Scholes options pricing model, which requires us to make assumptions regarding certain variables including the risk-free interest rate, expected stock price volatility, and the expected life of the award. The assumptions used in calculating stock-based compensation expense represent management&#8217;s best estimates, but these estimates involve inherent uncertainties, and if factors change or the Company used different assumptions, its stock-based compensation expense could be materially different in the future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Derivative Assets and Liabilities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on our Consolidated Balance Sheet and no further adjustments to their valuation are made. Some of our warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on our Consolidated Balance Sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. We estimate the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. Changes in the assumptions used could have a material impact on the resulting fair value. The primary input affecting the value of our derivatives liabilities is the Company&#8217;s stock price. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview of recent research and development activity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company began a Phase 1 clinical trial in Australia in healthy volunteers to characterize the safety profile of ARC-520, its candidate for the treatment of hepatitis B (HBV). No dose-limiting toxicities and no serious adverse events have been noted to date.&nbsp;&nbsp;This trial completed anticipated enrollment in October 2013. The Company began a Phase 2a pilot efficacy study in Hong Kong for chronically infected HBV patients in March 2014. &nbsp;&nbsp;The study is ongoing.&nbsp;&nbsp;In June 2014, the Company announced its next clinical candidate, ARC-AAT, an RNAi therapeutic designed to treat liver disease associated with Alpha-1 antitrypsin deficiency (AATD).&nbsp;&nbsp;The Company continues to develop other clinical candidates for future clinical trials, focusing on intravenously-administered therapeutics targeting gene knockdown in the liver, as well as formulations for administering siRNA-based therapeutics by subcutaneous administration.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a consolidated loss attributable to Arrowhead of $11,628,919 and $36,199,748 for the three and nine months ended June 30, 2014, respectively, compared to a consolidated loss attributable to Arrowhead of $6,079,010 and $17,451,105 for the three and nine months ended June 30, 2013, respectively. Details of the results of operations are presented below. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded revenue of $43,750 and $131,250 during the three and nine months ended June 30, 2014, respectively, compared to $43,750 and $246,516 during the three and nine months ended June 30, 2013, respectively. The revenue in fiscal 2014 was related to three license agreements for a research method acquired through the acquisition of Roche Madison, Inc. The revenue in fiscal 2013 also included $115,266 in non-recurring services revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. Certain reclassifications have been made to prior period operating expense categories to conform to the current period presentation. The following tables provide details of operating expenses for the three and nine months ended June 30, 2014 and 2013. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Salaries &#8211; Three and Nine months ended June 30, 2014 compared to the three and nine months ended June 30, 2013 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company employs management, administrative, and scientific and technical staff at its corporate offices and its research facility. Salaries expense consists of salary and related benefits. Salary and benefits include two major categories: general and administrative compensation expense, and research and development compensation expense, depending on the primary activities of each employee. The following table provides detail of salary and wage expenses for the three and nine months ended June 30, 2014 as compared to the three and nine months ended June 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A - compensation-related</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D - compensation-related</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,454</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,652</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">802</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nine months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nine months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A - compensation-related</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,192</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D - compensation-related</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,131</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,634</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,006</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,628</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:3pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A compensation expense increased $54,000 from $638,000 during the three months ended June 30, 2013 to $692,000 during the current period. The majority of this change was due to salary increases and headcount changes.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A compensation expense increased $1,192,000 from $1,875,000 during the nine months ended June 30, 2013 to $3,067,000 during the current period. The majority of this change was also due to annual performance bonuses paid during the period, none were paid in the previous period.&nbsp;&nbsp;Additionally, a portion of the increase is due to salary increases.&nbsp;&nbsp;G&amp;A headcount remained fairly consistent during the past twelve months.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D compensation expense increased $748,000 from $1,014,000 during the three months ended June 30, 2013 to $1,762,000 during the current period.&nbsp;&nbsp;R&amp;D headcount, higher by 24 people at June 30, 2014 versus June 30, 2013, and salary increases accounted for the change in salary expense.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D compensation expense increased $1,436,000 from $3,131,000 during the nine months ended June 30, 2013 to $4,567,000 during the current period.&nbsp;&nbsp;Increased headcount and salary increases accounted for the change in salary expense.&nbsp;&nbsp;Annual performance bonuses were paid to certain employees during the nine months ended June 30, 2014 totaling $356,000 in expense; none were paid in the prior period.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General&#160;&amp; Administrative Expenses &#8211; Three and nine months ended June 30, 2014 compared to the three and nine months ended June 30, 2013 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides detail of G&amp;A expenses for the three and nine months ended June 30, 2014 as compared to the three and nine months ended June 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional/outside services</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">759</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and related</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business insurance</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Communication and Technology</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office expenses</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,582</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">899</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">683</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nine</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nine</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional/outside services</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,778</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">992</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and related</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business insurance</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Communication and Technology</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office expenses</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,866</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,597</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,269</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional/outside services include legal, accounting, consulting and other outside services retained by the Company. All periods include normally recurring legal and audit expenses related to SEC compliance and other corporate matters. Professional/outside services expense increased $436,000 from $323,000 during the three months ended June 30, 2013 to $759,000 during the current period. Professional/outside services expense increased $786,000 from $992,000 during the nine months ended June 30, 2013 to $1,778,000 during the current period.&nbsp;&nbsp;The increase in professional fees primarily related to professional recruiting fees for the hiring of new R&amp;D personnel to support and expand its clinical pipeline.&nbsp;&nbsp;Additionally, the Company incurred higher SEC filing fees associated with financing in February 2014 and higher NASDAQ fees based on a higher number of shares outstanding.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent expense decreased $118,000 from $257,000 during the three months ended June 30, 2013 to $139,000 during the current period.&nbsp;&nbsp;Patent expense decreased $167,000 from $707,000 during the nine months ended June 30, 2013 to $540,000 during the current period.&nbsp;&nbsp;Patent expenses related to Calando declined by $145,000 in the nine month period, and $31,000 in the three month period.&nbsp;&nbsp;Calando reduced its patent expense cost by terminating its license agreement with Caltech in August 2013, which had obligated Calando to pay certain related patent costs, and by curtailing prosecution of other non-strategic patents.&nbsp;&nbsp;Accordingly, patent expense related to Calando is expected to be negligible going forward.&nbsp;&nbsp;Additionally, during the nine months ended June 30, 2014, Arrowhead deconsolidated Calando based on the fact that Calando is now subject to the control of a bankruptcy trustee.&nbsp;&nbsp;During the three and nine months ended June 30, 2014, patent costs related to our DPC platform increased which partially offset the decrease in the Calando costs.&nbsp;&nbsp;This is due timing of patent filings.&nbsp;&nbsp;The Company continues to invest in patent protection for its DPC technology, related product candidates and other RNAi technology through patent filings in multiple countries internationally.&nbsp;&nbsp;The Company expects to extend and maintain protection for its current portfolios, as appropriate, and file new patent applications as technologies are developed and improved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities-related expense remained consistent at $41,000 during the three months ended June 30, 2013, compared to $43,000 in the current period. Facilities-related expense increased $10,000 from $127,000 during the nine months ended June 30, 2013 to $137,000 during the current period.&nbsp;&nbsp;Facilities expense increased due to routine increases in ancillary lease charges.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel expense increased $93,000 from $141,000 during the three months ended June 30, 2013 to $234,000 during the current period.&nbsp;&nbsp;Travel expense increased $140,000 from $333,000 during the nine months ended June 30, 2013 to $473,000 during the current period.&nbsp;&nbsp;Travel expense increased due to travel in support of our R&amp;D function, primarily our GMP manufacturing campaign.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business insurance expense increased $48,000 from $49,000 during the three months ended June 30, 2013 to $97,000 during the current period. Business insurance expense increased $61,000 from $148,000 during the nine months ended June 30, 2013 to $209,000 during the current period. Business insurance costs increased slightly primarily related to added coverage related to the Company&#8217;s clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Communication and technology expense increased $62,000 from $26,000 during the three months ended June 30, 2013 to $88,000 during the current period. Communication and technology expense increased $139,000 from $113,000 during the nine months ended June 30, 2013 to $252,000 during the current period. The increase was related to equipment purchases to replace outdated equipment and to outfit new employees.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office expense increased $117,000 from $22,000 during the three months ended June 30, 2013 to $139,000 during the current period. Office expense increased $212,000 from $81,000 during the nine months ended June 30, 2013 to $293,000 during the current period. The increase was related to conferences/training, office supplies, miscellaneous administrative expenses, and expenses related to an office expansion at our R&amp;D facility in Madison. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense increased $43,000 from $40,000 during the three months ended June 30, 2013 to $83,000 during the current period. Other expense increased $88,000 from $96,000 during the nine months ended June 30, 2013 to $184,000 during the current period. The increase was related to trade shows, conferences and marketing materials.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses &#8211; Three and nine months ended June 30, 2014 compared to the three and nine months ended June 30, 2013 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D expenses are related to the Company&#8217;s on-going research and development efforts, primarily its laboratory research efforts based in Madison, Wisconsin, and also include outsourced R&amp;D services. The following table provides detail of R&amp;D expenses for the three and nine months ended June 30, 2014, as compared to the three and nine months ended June 30, 2013. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies &amp; services</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In vivo studies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside labs &amp; contract services</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">329</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Toxicity/efficacy studies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,109</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug Manufacturing</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,371</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">386</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,985</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty &amp; milestones</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and related</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,392</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,756</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,636</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">264</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>

<hr style="page-break-after:always">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nine Months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nine Months</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2013</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies &amp; services</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">755</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">714</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In vivo studies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(312</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-57</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside labs &amp; contract services</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">775</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Toxicity/efficacy studies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,651</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">879</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,772</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug Manufacturing</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,630</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,309</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,321</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,978</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,495</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty &amp; milestones</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and related</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">685</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,720</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,262</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:8.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom"  BGCOLOR="#B6EAFC" style="width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies and services expense increased $394,000 from $219,000 during the three months ended June 30, 2013 to $613,000 during the current period.&nbsp;&nbsp;Laboratory supplies and services expense increased $714,000 from $755,000 during the nine months ended June 30, 2013 to $1,469,000 during the current period.&nbsp;&nbsp;The increase is a result of additional supplies necessary to support increased efforts in pre-clinical research as the Company accelerates efforts to identify new clinical candidates as well as to support ongoing clinical efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In vivo studies expense decreased $35,000 from $99,000 during the three months ended June 30, 2013 to $64,000 during the current period. In vivo studies expense decreased $312,000 from $548,000 during the nine months ended June 30, 2013 to $236,000 during the current period.&nbsp;&nbsp;The prior period expense relates to studies related to development of new clinical candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside labs and contract services expense increased $242,000 from $87,000 during the three months ended June 30, 2013 to $329,000 during the current period.&nbsp;&nbsp;Outside labs and contract services expense increased $398,000 from $377,000 during the nine months ended June 30, 2013 to $775,000 during the current period.&nbsp;&nbsp;The increase was primarily related to oligonucleotide synthesis related to development of new clinical candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Toxicity/efficacy studies expense increased $1,614,000 from $495,000 during the three months ended June 30, 2013 to $2,109,000 during the current period.&nbsp;&nbsp;Toxicity studies expense increased $2,772,000 from $879,000 during the nine months ended June 30, 2013 to $3,651,000 during the current period.&nbsp;&nbsp;This category includes IND-enabling toxicology studies as well as non-clinical toxicology studies, such as long-term toxicology studies, and other efficacy studies.&nbsp;&nbsp;The current period expense primarily relates to toxicology studies related to ARC-520, our clinical candidate for HBV, specifically toxicology studies to support our anticipated phase 2b clinical trial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug Manufacturing expense increased $1,985,000 from $386,000 during the three months ended June 30, 2013 to $2,371,000 during the current period.&nbsp;&nbsp;Drug Manufacturing expense increased $4,321,000 from $1,309,000 during the nine months ended June 30, 2013 to $5,630,000 during the current period.&nbsp;&nbsp;The current period expense relates to drug manufacturing to supply  toxicology studies for our anticipated HBV Phase 2b clinical trial, as well as to supply the Phase 2b clinical trial anticipated for 2015.&nbsp;&nbsp;The Phase 2b clinical trial will be a much larger study than previous clinical trials, and as such, the Company anticipates increased Drug Manufacturing expenses in future periods.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials expense increased $350,000 from $205,000 during the three months ended June 30, 2013 to $555,000 during the current period.&nbsp;&nbsp;Clinical trials expense increased $1,495,000 from $483,000 during the nine months ended June 30, 2013 to $1,978,000 during the current period.&nbsp;&nbsp;Clinical trial expenses are increasing as the Company advances ARC-520, its drug candidate for Hepatitis B.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting expense increased $41,000 from $61,000 during the three months ended June 30, 2013 to $102,000 during the current period.&nbsp;&nbsp;Consulting expense was consistent at $193,000 during each of the nine months ended June 30, 2013 and 2014 respectively. The majority of consulting expense during the current period relates to regulatory and clinical efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and milestones expense was consistent at $13,000 and $12,000 during the three months ended June 30, 2013 and 2014 respectively.&nbsp;&nbsp;License, royalty and milestones expense decreased $143,000 from $175,000 during the nine months ended June 30, 2013 to $32,000 during the current period.&nbsp;&nbsp;Licensing fees, royalty and milestones expenses in the prior year were primarily related to a one-time fee of $120,000 related to access to certain targeting technology.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities expense increased $28,000 from $178,000 during the three months ended June 30, 2013 to $206,000 during the current period.&nbsp;&nbsp;Facilities expense increased $143,000 from $542,000 during the nine months ended June 30, 2013 to $685,000 during the current period.&nbsp;&nbsp;Facilities expenses were higher in the current period primarily due to repairs and maintenance costs on lab equipment.&nbsp;&nbsp;Although much of our equipment is under maintenance contracts, certain additional expenses were incurred during the current quarter. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research expense increased $18,000 from $13,000 during the three months ended June 30, 2013 to $31,000 during the current period.&nbsp;&nbsp;Other research expense decreased $126,000 from $197,000 during the nine months ended June 30, 2013 to $71,000 during the current period.&nbsp;&nbsp;Other research expense in the prior period relates to work at the University of Cincinnati related to our obesity program, which studies have been completed, and no further studies are currently planned.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense, a non-cash expense, increased $1,675,000 from $364,000 during the three months ended June&#160;30, 2013 to $2,039,000 in the current period.&nbsp;&nbsp;Stock-based compensation expense increased $2,644,000 from $1,114,000 during the nine months ended June 30, 2013 to $3,758,000 during the current period.&nbsp;&nbsp;Stock-based compensation expense is based upon the valuation of stock options granted to employees, directors, and certain consultants. Many variables affect the amount expensed, including the Company&#8217;s stock price on the date of the grant, as well as other assumptions. The increase in this expense is primarily due to new options granted in 2013, including grants of restricted stock units. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Depreciation and amortization expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense, a non-cash expense, decreased $178,000 from $454,000 during the three months ended June&#160;30, 2013 to $276,000 in the current period.&nbsp;&nbsp;Depreciation and amortization expense decreased $277,000 from $1,352,000 during the nine months ended June 30, 2013 to $1,075,000 during the current period.&nbsp;&nbsp;The decrease is primarily related to amortization of capitalized patents related to Calando, which were fully written off in fiscal 2013, thus no further amortization will be recorded. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other income / expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income increased $861,000 from $212,000 during the three months ended June 30, 2013 to $1,074,000 during the current period.&nbsp;&nbsp;This increase is primarily related to the change in the value of derivative liabilities related to certain warrants with a price adjustment feature, which requires derivative accounting.&nbsp;&nbsp;Other expense increased $4,065,000 from $1,308,000 during the nine months ended June 30, 2013 to $5,373,000 during the current period, also primarily related to the change in the value of the derivative liabilities discussed above.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any off-balance sheet arrangements or relationships. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3"></a>ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4"></a>ITEM&#160;4. CONTROLS AND PROCEDURES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chief Executive Officer and our Chief Financial Officer, after evaluating our &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e)) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) as of the end of the period covered by this Quarterly Report on Form 10-Q (the &#8220;Evaluation Date&#8221;), have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer where appropriate, to allow timely decisions regarding required disclosure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.&nbsp;&nbsp;Accordingly, our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No change in the Company&#8217;s internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) occurred during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II_OTHER_INFORMATION"></a>PART II&#8212;OTHER INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_2"></a>ITEM&#160;1. LEGAL PROCEEDINGS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. We believe there is no litigation pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_2"></a>ITEM&#160;1A. Risk Factors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended September&#160;30, 2013. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended September&#160;30, 2013, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our common stock. Additional risks not currently known or currently material to us may also harm our business. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_2"></a>ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_2"></a>ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_2"></a>ITEM&#160;4. MINE SAFETY DISCLOSURES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_2"></a>ITEM&#160;5. OTHER INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_2"></a>ITEM&#160;6. EXHIBITS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:6.72%; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>Number</p></td>
<td valign="bottom"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:89.94%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Document&#160;Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.&#8224; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="top"  style="width:3.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following materials from Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, formatted in XBRL (Extensible Business Reporting Language): (1) Consolidated Balance Sheets, (2) Consolidated Statements of Operations, (3) Consolidated Statement of Stockholders&#8217; Equity, (4) Consolidated Statements of Cash Flows, and (5) Notes to Consolidated Financial Statements. *</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:10%;">
<tr>
<td valign="bottom"  style="width:100%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:-4.54%;font-size:2pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been requested with respect to certain information contained in this exhibit. Such information has been omitted and furnished separately to the SEC. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top" style="width:95.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:-4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.53%;text-indent:-4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURE"></a><font style="text-decoration:underline;">SIGNATURE </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: August 12, 2014 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="2" valign="bottom"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD RESEARCH CORPORATION</p></td>
</tr>
<tr style="height:24pt;">
<td valign="bottom"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>arwr-ex10_20140630353.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 10.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Execution </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LICENSE AGREEMENT </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This License Agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is entered into by and between ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having offices located at 300 Third Street, Cambridge MA 02142 U.S.A. (&#8220;<font style="text-decoration:underline;">ALNYLAM</font>&#8221;), and ARROWHEAD RESEARCH CORPORATION, a corporation organized under the laws of the State of Delaware having offices located at 225 South Lake Avenue, Suite 300, Pasadena, CA 91101 and ARROWHEAD MADISON INC., a corporation organized under the laws of the State of Delaware having offices located at 465 Science Drive, Madison, WI 53711 (collectively &#8220;<font style="text-decoration:underline;">ARROWHEAD</font>&#8221;). </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">INTRODUCTION </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM owns or has rights to certain intellectual property covering technology useful for the discovery, development, manufacture, characterization, or use of therapeutic products that function through RNA interference (&#8220;<font style="text-decoration:underline;">RNAi</font>&#8221;). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD desires to research and potentially develop and commercialize siRNA based products that target messenger RNAs encoded by the genome of human hepatitis B virus (&#8220;<font style="text-decoration:underline;">HBV</font>&#8221;), and for such purpose ARROWHEAD desires a license under certain of the aforementioned intellectual property of ALNYLAM to use the technology covered by such intellectual property to research, develop and commercialize any such product. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM is willing to grant ARROWHEAD a license to research, develop and commercialize products as described above under the terms and conditions of this Agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ALNYLAM and ARROWHEAD agree as follows: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I &#8211; DEFINITIONS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Affiliate</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM CRT Additional Patent Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Broad RNAi Intellectual Property</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Broad RNAi Know-How</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Broad RNAi Patent Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Intellectual Property</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Patent Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Stanford Additional Patent Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Target-Specific Patent Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.11</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calendar Quarter</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.14</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercialize or Commercialization</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.15</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Information</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.16</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Control or Controlled</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.17</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover or Covered</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Develop, Developing or Development</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dynamic Polymeric Conjugate Technology or DPC Technology</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.21</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.22</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing ALNYLAM Third Party Agreements</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.24</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Field</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Commercial Sale</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTE</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.27</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTE Rate</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.28</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAAP</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLP Toxicology Study</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IND or Investigational New Drug Application</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.31</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensed RNAi Product</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.32</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Sales</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Person</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pivotal Trial</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Authority</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research or Researching</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Collaboration Term</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">siRNA</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.41</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicensee</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.42</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Target</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.43</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Territory</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.44</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.45</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valid Claim</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II - RESEARCH AND DEVELOPMENT<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Target Selection</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Collaboration</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Collaboration FTEs</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Status Reports</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, Development, Manufacture and Commercialization following Research Collaboration Term</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III - GOVERNANCE<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JRDC</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decision Making; Limits on Authority</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV - LICENSE GRANTS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licenses</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicensing</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Retained Rights of ALNYLAM</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Patents Option</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusivity</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE V - FEES AND ROYALTIES<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTE Costs</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payments</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales Milestone Payment</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party License Fees</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VI - REPORTS, TAXES AND PAYMENTS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reports</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Withholding</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audits</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Late Payments</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VII - INTELLECTUAL PROPERTY<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prosecution and Maintenance of Patent Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Infringement of ALNYLAM Rights</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claimed Infringement of Third Party Rights, and Third Party Intellectual Property Obligations</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VIII - CONFIDENTIAL INFORMATION<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Use and Non-Disclosure of Confidential Information</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permitted Disclosures</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publicity</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IX - INDEMNIFICATION AND INSURANCE<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD Indemnification</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Indemnification</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Procedures</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE X - EXPORT<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assistance</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XI - TERM AND TERMINATION<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Material Breach</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination by ARROWHEAD</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination Due to Patent Challenge</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequences of Termination; Survival</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XII - MISCELLANEOUS<font style="font-weight:normal;"></font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representations by ARROWHEAD and ALNYLAM</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual Covenants</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dispute Resolution; Arbitration Procedures</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequential Damages</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.7</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.8</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Independent Contractors</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.9</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governing Law; Jurisdiction</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.10</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.11</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Implied Waivers</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.12</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.13</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Headings; Construction; Interpretation</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.14</p></td>
<td valign="bottom"  style="width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Counterparts</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE I - DEFINITIONS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">General</font>. When used in this Agreement, each of the following terms, whether used in the singular or plural, will have the meanings set forth in this Article I. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Act</font> means the United States Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. &#167;&#167; 301 et seq., as such may be amended from time to time, and its implementing regulations. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Affiliate</font> means with respect to a Person, any other Person which controls, is controlled by, or is under common control with the applicable Person. For purposes of this definition, &#8220;control&#8221; shall mean: (a)&#160;in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%)&#160;of the stock or shares (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person; and (b)&#160;in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%)&#160;of the equity interest or the power to direct the management and policies of such non-corporate entities. For purposes of this Agreement, Regulus Therapeutics, LLC, 3545 John Hopkins Ct., San Diego, California 92121, shall be deemed not to be an Affiliate of ALNYLAM. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM CRT Additional Patent Rights</font> means the patents and patent applications listed on Exhibit E, and all continuations, continuations-in-part, divisionals, and other substitute applications with respect thereto; any patents issued with respect to any of the foregoing; and all reissues, substitutions, confirmations, re-examinations, supplementary protection certificates, certificates of invention and patents of addition with respect to any of the foregoing; and all counterparts to any of the foregoing in any country of the Territory. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Broad RNAi Intellectual Property</font> means ALNYLAM Broad RNAi Know-How and ALNYLAM Broad RNAi Patent Rights. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Broad RNAi Know-How</font> means Know-How, Controlled by ALNYLAM as of the Effective Date or during the Research Collaboration Term to the extent that such Know-How is necessary or useful for the Research, Development, Commercialization or manufacture of Licensed RNAi Products. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Broad RNAi Patent Rights</font> means Patent Rights that are Controlled by ALNYLAM as of the Effective Date or during the Research Collaboration Term and that Cover Alnylam Broad RNAi Know-How, but specifically excluding any ALNYLAM CRT Additional Patent Rights, ALNYLAM Stanford Additional Patent Rights and ALNYLAM Target-Specific Patent Rights. The ALNYLAM Broad RNAi Patent Rights as of the Effective Date are listed in Exhibit A. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Intellectual Property</font> means the ALNYLAM Broad RNAi Intellectual Property and the ALNYLAM Target-Specific Patent Rights. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Patent Rights</font> means the ALNYLAM Broad RNAi Patent Rights and the ALNYLAM Target-Specific Patent Rights. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Stanford Additional Patent Rights</font> means the patents and patent applications listed on Exhibit F, and all continuations, continuations-in-part, divisionals, and other substitute applications with respect thereto; any patents issued with respect to any of the foregoing; and all reissues, substitutions, confirmations, re-examinations, supplementary protection certificates, certificates of invention and patents of addition with respect to any of the foregoing; and all counterparts to any of the foregoing in any country of the Territory. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Target-Specific Patent Rights</font> means such claim or claims contained in Patent Rights Controlled by ALNYLAM as of the Effective Date or during the Research Collaboration Term and that are specifically directed to particular sequences of Licensed RNAi Products against the Target. The ALNYLAM Target-Specific Patent Rights as of the Effective Date are listed in Exhibit A. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.11</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Approval</font> means, with respect to each Licensed RNAi Product Developed and Commercialized, the receipt of sufficient authorization from the appropriate Regulatory Authority to market such Licensed RNAi Product in a country, including (where legally required in a particular country prior to marketing a Licensed RNAi Product) all separate pricing and/or reimbursement approvals that may be required for marketing. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Calendar Quarter</font> means, in any calendar year, one of the following three-month calendar quarters: January&#160;1 through March&#160;31, inclusive; April&#160;1 through June&#160;30, inclusive; July&#160;1 through September&#160;30, inclusive; or October&#160;1 through December&#160;31, inclusive. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.13</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Clinical Trial</font> means any human clinical trial. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.14</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Commercialize or Commercialization</font> means any and all activities directed to manufacturing (including, without limitation, by means of contract manufacturers), marketing, promoting, distributing, importing, exporting and selling a Licensed RNAi Product, in each case for commercial purposes, and activities directed to obtaining pricing and reimbursement approvals, as applicable. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.15</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Confidential Information</font> means all proprietary, confidential information and materials, patentable or otherwise, of a Party which are disclosed by or on behalf of such Party to the other Party hereunder, including, without limitation, chemical substances, formulations, techniques, methodology, equipment, data, reports, know how, sources of supply, patent positioning, business plans, and also including without limitation proprietary and confidential information of Third Parties in possession of such Party under an obligation of confidentiality, whether or not related to making, using or selling Licensed RNAi Products. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.16</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Control or Controlled</font> means, with respect to any item of or right under an intellectual property right, the possession (whether by ownership or license, other than pursuant to this Agreement) of the ability of a Party to grant access to, or a license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense; <font style="text-decoration:underline;">provided</font> <font style="text-decoration:underline;">that</font> any intellectual property right that is licensed or acquired by a Party after the Effective Date and that would otherwise be considered to be under the Control of such Party shall not be deemed to be under the Control of such Party if the application of such definition in the context of any licenses or sublicenses granted to the other Party under this Agreement would require the granting Party to make any additional payments or royalties to a Third Party in connection with such license or sublicense grants, unless the other Party agrees to pay the additional payments or royalties to the Third Party. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.17</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Cover or Covered</font> means with respect to the applicable country, but for the license granted under a Valid Claim of a Patent Right, the manufacture, use or sale, or offer for sale in such country of the subject matter at issue would infringe such Valid Claim, or in the case of a Patent Right that is a patent application, would infringe a Valid Claim in such patent application if it were to issue as a patent. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Develop, Developing or Development</font> means with respect to a Licensed RNAi Product, preclinical and clinical drug development activities, including without limitation: test method development and stability testing, toxicology, formulations, quality assurance/quality control development, statistical analysis and report writing; clinical studies and regulatory affairs; Approval and registration. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Dynamic Polymeric Conjugate Technology</font> or <font style="text-decoration:underline;">DPC Technology</font> means an siRNA delivery system including a membrane-active polymer, a masking agent to reversibly mask the activity of the polymer in vivo, and optionally a targeting agent. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Effective Date</font> means January&#160;4, 2012. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.21</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Executive Officers</font> means the Chief Executive Officer of ALNYLAM (or a senior executive officer of ALNYLAM designated by ALNYLAM&#8217;s Chief Executive Officer) and the Chief Executive Officer of ARROWHEAD (or a senior executive officer of ARROWHEAD as designated by ARROWHEAD&#8217;s Chief Executive Officer). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.22</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Existing ALNYLAM Third Party Agreements</font> means the agreements listed on Exhibit B between ALNYLAM and the listed Third Parties. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.23</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">FDA</font> means the United States Food and Drug Administration or any successor agency thereto. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.24</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Field</font> means the prevention, treatment and prophylaxis of disease in humans. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">First Commercial Sale</font> means, with respect to each Licensed RNAi Product, the first commercial sale in a country as part of a nationwide introduction after receipt by ARROWHEAD or any of its Affiliates or Sublicensees of Approval in such country, excluding <font style="font-style:italic;">de minimis</font> named patient and compassionate use sales. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">FTE</font> means the number of full-time-equivalent person-years (each consisting of a total of 1,840 hours) of scientific, technical, regulatory, marketing or managerial work by each party&#8217;s personnel on or directly related to the applicable activity conducted hereunder. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.27</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">FTE Rate</font> means $*** U.S. Dollars per FTE, increased annually beginning on January&#160;1, 2013 and thereafter on January I of each succeeding year by the percentage increase in the CPI as of December&#160;31 of the then most recently ended calendar year over the level of the CPI on December&#160;31, 2011 e., the first such increase or decrease would occur on January&#160;1, 2013). As used in this definition, &#8220;<font style="text-decoration:underline;">CPI</font>&#8221; shall mean the Consumer Price Index &#8212; Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.28</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">GAAP</font> means generally accepted accounting principles as practiced in the United States. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">GLP Toxicology Study</font> means a toxicology study that is conducted in compliance with the then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S. to the extent applicable to the relevant toxicology study, as they may be updated from time to time) (&#8220;GLP&#8221;) and is required to meet the requirements for filing an IND. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">IND or Investigational New Drug Application</font> means a United States investigational new drug application or its equivalent or any corresponding foreign application. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.31</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Licensed RNAi Product</font> means a pharmaceutical product (a)&#160;containing, comprised or based on siRNAs or siRNA derivatives or other moieties effective in gene function modulation and designed to modulate the function of the Target through RNA interference and (b)&#160;incorporating DPC Technology. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.32</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Net Sales</font> means, with respect to Licensed RNAi Products, the gross amount invoiced by ARROWHEAD or its Affiliates or Sublicensees, as the case may be, on sales or other dispositions of such Licensed RNAi Products to Third Parties, less: (A)&#160;portions of invoiced amounts written off by ARROWHEAD, its Affiliates or Sublicensees as uncollectible, relating to specific invoices and not a general reserve for uncollectible amounts, in accordance with their normal accounting practices (provided that if any such written-off amounts are subsequently collected, such amounts shall be included in Net Sales when collected); and (B)&#160;the following deductions, to the extent standard and customary and incurred in accordance with ARROWHEAD&#8217;S usual practices, as generally applied across its business (i)&#160;rebates, quantity, trade and cash discounts, and other usual and customary discounts to customers; (ii)&#160;charge-back payments and rebates granted to managed health care organizations or to national, state or local governments, their respective agencies, purchasers or reimbursers, adjustments arising from consumer discount programs or other similar programs; (iii)&#160;retroactive price reductions, credits or allowances granted upon rejections or returns of Licensed RNAi Products, including for recalls or damaged goods; (iv)&#160;compulsory payments and rebates made or granted to government entities with respect to sales of Licensed RNAi Products; (v)&#160;freight, postage, shipping and insurance charges for delivery of Licensed RNAi Products; and (viii)&#160;sales taxes, excise taxes, use taxes, value-added taxes, import/export duties or other governmental charges with respect to Licensed RNAi Products, excluding income taxes. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Sales between ARROWHEAD and its Affiliates or Sublicensees for resale shall be excluded from the computation of Net Sales, but the subsequent resale of such Product to Third Parties shall be included within the computation of Net Sales. Sales or other dispositions of Licensed RNAi Products used for promotional or advertising purposes or used for research or development purposes (including clinical trials) or for donations, to the extent reasonable and customary and in accordance with ARROWHEAD&#8217;S usual practices, as generally applied across its business, shall be excluded from Net Sales. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the event that a Licensed RNAi Product is sold in any country in the form of a combination product containing one or more therapeutically active ingredients in addition to such Licensed RNAi Product in any year, Net Sales of such combination product will be adjusted by multiplying actual Net Sales of such combination product in such country by the fraction A/(A+B), where A is the average Net Sales prices per daily dose during such year of the Licensed RNAi Product in such country, if sold separately in such country, and B is the average Net Sales prices per daily dose of any product containing the other therapeutically active ingredients in the combination product in such country, if sold separately in such country. If, in a specific country, both the Licensed RNAi Product and the product containing the other therapeutically active ingredients in the combination product are not sold separately in such country, the fraction of actual Net Sales of the combination product that will be deemed to be Net Sales of the Licensed RNAi Product will be determined based upon the commercial values of the Licensed RNAi Product and the other therapeutically active ingredients in such combination product. If the Parties are not able to agree on any such allocation, the matter may be submitted by either Party for resolution by arbitration pursuant to Section&#160;12.3. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the event ARROWHEAD or any of its Affiliates or Sublicensees receive non-monetary consideration in exchange for the sale or other disposition of Licensed RNAi Products to Third Parties, Net Sales for such sale or other disposition shall include the fair market value of the non-cash consideration received as a result of such sale or other disposition. If such sale or other disposition occurred in a country where ARROWHEAD or such Affiliate or Sublicensee sold the same Licensed RNAi Product in commercial quantities solely for monetary consideration, the fair market value of the non-cash consideration received for such Licensed RNAi Product shall be determined on the basis of the value received in such solely monetary transactions. If ARROWHEAD or its Affiliate or Sublicensee did not have sales or other dispositions of Licensed RNAi Product in such country solely for monetary consideration, then the fair market value of such Licensed RNAi Product shall be determined on the basis of all relevant facts and circumstances. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Sales shall be determined from books and records maintained in accordance with GAAP, consistently applied throughout the organization and across all products of the entity whose sales of Licensed RNAi Product are giving rise to Net Sales. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Party</font> means either ALNYLAM or ARROWHEAD; <font style="text-decoration:underline;">Parties</font> means both ALNYLAM and ARROWHEAD. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Patent Rights</font> means patents, patent applications and/or provisional patent applications, utility models and utility model applications, design patents or registered industrial designs and design applications or applications for registration of industrial designs, and all substitutions, divisionals, continuations, continuation-in-part applications, continued prosecution applications, requests for continued examinations, reissues, reexaminations and extensions thereof, in any country of the world. For clarity, any Patent Rights shall include any future Patent Rights that claim priority to or common priority with such Patent Rights. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Person</font> shall mean any natural person, corporation, unincorporated organization, partnership, association, joint stock company, joint venture, limited liability company, trust or government, or any agency or political subdivision of any government, or any other entity. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Pivotal Trial</font> means a prospective, randomized, controlled Clinical Trial that is designed to confirm or that does confirm with statistical significance the efficacy and safety of a drug in a given patient population, the results of which are intended, either alone or with other pivotal human clinical studies, to form the basis for Approval. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Regulatory Authority</font> means the FDA in the United States or any health regulatory authority in another country that is a counterpart to the FDA and holds responsibility for allowing development of Licensed RNAi Products and/or granting Approval for a Licensed RNAi Product in such country. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Research or Researching</font> means identifying, evaluating, validating and optimizing Licensed RNAi Products. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Research Collaboration Term</font> means the period commencing on the Effective Date and ending on the date on which ARROWHEAD or its Affiliates or Sublicensees initiates the first GLP Toxicology Study for a Licensed RNAi Product. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">siRNA</font> means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a)&#160;two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b)&#160;a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.41</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Sublicensee</font> means any Third Party to whom ARROWHEAD, pursuant to a written agreement, has granted a sublicense of all or a portion of the rights granted hereunder, <font style="font-style:italic;">provided</font> that such Third Party has the responsibility for the Commercialization of such Licensed RNAi Product in a licensed territory and has the right to record sales of such Licensed RNAi Product for its account. For clarity, &#8220;Sublicensee&#8221; shall exclude any wholesaler or reseller of Licensed RNAi Product that purchases Licensed RNAi Product from ARROWHEAD, its Affiliates and Sublicensees and that is not responsible for marketing or promotion of such Licensed RNAi Product, any contract manufacturer or service provider (e.g., a clinical research organization or its equivalent) or other Third Party acting solely on behalf of ARROWHEAD or its Affiliates and not on its own behalf </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.42</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Target</font> means HBV, or a single alternative messenger RNA target selected by ARROWHEAD and designated in accordance with Section&#160;2.1. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.43</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Territory</font> means worldwide. For clarity, at any time the Territory will not include any country to which the exportation or re-exportation of materials, products and related technical data covered by this Agreement is restricted under U.S. export laws, which restriction has not been removed or waived. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.44</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Third Party</font> means any person, corporation, joint venture or other entity, other than ALNYLAM, ARROWHEAD and their respective Affiliates. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.45</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Valid Claim</font> shall mean (a)&#160;a claim of an issued and unexpired patent within the ALNYLAM Patent Rights that (i)&#160;has not been rejected, cancelled, revoked or held to be invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no appeal can be further taken, and (ii)&#160;has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable through reissue or disclaimer; or (b)&#160;a claim included in a patent application that has not been pending for more than *** (***) years from the earliest priority date for such patent application, cancelled, withdrawn or abandoned or finally determined to be unallowable by the applicable governmental authority (from which no appeal is or can be taken). </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE II - RESEARCH AND DEVELOPMENT </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Target Selection</font>. ARROWHEAD has selected HBV as the Target as of the Effective Date. At any time during the Research Collaboration Term but prior the start of the first study of a Licensed RNAi Product in a non-rodent efficacy animal model, ARROWHEAD may provide ALNYLAM written notice designating one (1)&#160;alternative target that ARROWHEAD desires to Research, Develop and Commercialize in accordance with this Agreement. Within ten (10)&#160;business days of receipt of such alternative target from ARROWHEAD, ALNYLAM shall provide ARROWHEAD written notice confirming whether such alternative target is available to be licensed by ALNYLAM to ARROWHEAD hereunder; provided that such alternative target shall be deemed available unless prior to the date of such request from ARROWHEAD (a)&#160;ALNYLAM has entered into a bona fide collaboration agreement or license agreement with a Third Party pursuant to which ALNYLAM has granted such Third Party license rights with respect to such proposed target or (b)&#160;ALNYLAM or its Affiliates have previously initiated a bona fide, active research program with respect to such proposed target and/or are in active discussions with a Third Party concerning a research or business collaboration around such target. In the event that such alternative target is available to be licensed hereunder, (i)&#160;such alternative target shall thereafter be deemed the Target (and HBV shall thereafter be deemed not to be the Target) and (ii)&#160;ARROWHEAD shall thereafter have no further right to replace the Target with an alternative target except as mutually agreed by the Parties. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Research Collaboration</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Research Collaboration Plan</font>. Within ninety (90)&#160;days after the Effective Date, the ARROWHEAD shall develop a research collaboration plan, which plan if necessary shall set forth each Party&#8217;s obligations and responsibilities during the Research Collaboration Term in connection with the Research and Development of Licensed RNAi Products (&#8220;<font style="text-decoration:underline;">Research Collaboration Plan</font>&#8221;), which shall be attached as Exhibit C. Each Party shall use commercially reasonable efforts to conduct the activities that may be allocated to such Party in the Research Collaboration Plan. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Final Authority</font>. ARROWHEAD shall have the final authority with respect to all details of the Research Collaboration Plan, except that ARROWHEAD shall not have any authority either (i)&#160;to cause ALNYLAM to conduct any activities other than with ALNYLAM&#8217;s agreement; or (ii)&#160;to materially change the scope of ALNYLAM&#8217;s obligations under the Research Collaboration Plan without ALNYLAM&#8217;s written consent. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Research Collaboration FTEs</font>. During the Research Collaboration Term, subject to Section&#160;2.2(b), the Parties shall prepare annual updates to the Research Collaboration Plan setting forth the number of FTEs each Party will commit to the activities under the Research Collaboration Plan during the next calendar year. Such annual updates will be completed and agreed upon at least thirty (30)&#160;days prior to the beginning of the next calendar year. During the Research Collaboration Term, ALNYLAM shall provide such number of FTEs as may be specified in the Research Collaboration Plan to perform the activities that may be allocated to ALNYLAM under the Research Collaboration Plan. ARROWHEAD shall reimburse ALNYLAM its FTE costs (at the FTE Rate) with respect to the FTEs provided by ALNYLAM to conduct activities under the Research Collaboration Plan (&#8220;FTE Costs&#8221;). ALNYLAM shall invoice ARROWHEAD quarterly for such FTE Costs and payment shall be due and payable within thirty (30)&#160;days after receipt of invoice. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Status Reports</font>. ARROWHEAD and ALNYLAM shall each provide the JRDC a semi-annual written report summarizing in reasonable detail such Party&#8217;s activities under the Research Collaboration Plan. Such semi-annual reports will reflect all material work done and results achieved in carrying out activities under the Research Collaboration Plan in the prior six (6)&#160;month period. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Research, Development, Manufacture and Commercialization following Research Collaboration Term</font>. Following the Research Collaboration Term, ARROWHEAD (or its Affiliates or Sublicensees, as applicable) shall be solely responsible for the Research, Development, manufacture and Commercialization of Licensed RNAi Products in the Field in the Territory, including all costs associated with such activities. ARROWHEAD shall use commercially reasonable efforts to Research, Develop, manufacture and Commercialize Licensed RNAi Products in the Field in the Territory. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE III - GOVERNANCE </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">JRDC</font>. The Parties shall establish a joint Research and Development committee (the &#8220;<font style="text-decoration:underline;">JRDC</font>&#8221;) as more fully described in this Section&#160;3.1. The JRDC shall comprise two (2)&#160;representatives from each of ALNYLAM and ARROWHEAD. Each Party may replace its representatives at any time upon written notice to the other Party. The JRDC shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. The JRDC shall perform the following functions: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">oversee, review and monitor progress of activities under the Research Collaboration Plan; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">review the Research Collaboration Plan and any amendments to such plan; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">evaluate reports submitted to the JRDC by the Parties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">discuss and attempt to resolve any deadlock issues submitted to it by the Parties; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">such other responsibilities as may be assigned to the JRDC pursuant to this Agreement or as may be mutually agreed upon by the Parties from time to time. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Decision Making; Limits on Authority</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subject to Section&#160;2.5, in the event of any disagreement as to a matter within the JRDC&#8217;s responsibilities, ARROWHEAD shall have the final decision-making authority; provided that ARROWHEAD may not exercise its final decision-making authority to: (i)&#160;impose additional obligations on ALNYLAM without ALNYLAM&#8217;s written consent; or (ii)&#160;resolve any dispute between the Parties as to their respective rights and obligations under this Agreement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The JRDC shall not have any authority beyond the specific matters set forth in this Article III, and in particular shall not have any power to amend or modify the terms of this Agreement. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE IV - LICENSE GRANTS </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Licenses</font>. Subject to the terms and conditions of this Agreement, ALNYLAM hereby grants to ARROWHEAD: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A worldwide, non-exclusive, royalty-bearing right and license under the ALNYLAM Broad RNAi Intellectual Property for the sole and exclusive purposes of Researching, Developing and Commercializing Licensed RNAi Products in the Field in the Territory. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A worldwide, exclusive, royalty-bearing right and license under the ALNYLAM Target-Specific Patent Rights for the sole and exclusive purposes of Researching, Developing, manufacturing and Commercializing Licensed RNAi Products in the Field in the Territory. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The licenses granted to ARROWHEAD under Sections 4.1(a) and (b)&#160;include the right to grant sublicenses with respect to Licensed RNAi Products which ARROWHEAD or its Affiliates have identified in good faith as clinical candidate(s) and for which they have previously commenced GLP Toxicology Studies or intend to commence GLP Toxicology Studies within the subsequent six (6)&#160;months. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Sublicensing</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the event that ARROWHEAD sublicenses the rights granted under Section&#160;4.1, ARROWHEAD will notify ALNYLAM within thirty (30)&#160;days after such sublicense becomes effective and provide a copy of the fully executed sublicense agreement to ALNYLAM within the same time frame (which copy may be redacted, provided that information relevant to ARROWHEAD&#8217;s obligations to ALNYLAM hereunder shall not be redacted), which shall be treated as Confidential Information of ARROWHEAD, provided that ALNYLAM may disclose such sublicense agreement(s) to Third Parties under confidence if and to the extent required in order to comply with ALNYLAM&#8217;s contractual obligations related to ALNYLAM Patent Rights; and provided, further, that such Third Parties are bound in writing by confidentiality obligations consistent with those set forth herein. Should this Agreement or the rights granted to ARROWHEAD hereunder terminate for any reason, any sublicense(s) granted by ARROWHEAD to an ARROWHEAD Sublicensee shall survive such termination, <font style="text-decoration:underline;">provided</font> <font style="text-decoration:underline;">that</font>, as to each such ARROWHEAD Sublicensee, the ARROWHEAD Sublicensee is not then in material breach of the sublicense, all financial obligations to ALNYLAM under this Agreement through the date of termination with respect to the, sublicensed rights have been satisfied, all obligations (including without limitation all financial obligations) to ALNYLAM under this Agreement with respect to the sublicensed rights continue to be satisfied by or on behalf of the ARROWHEAD Sublicensee and ALNYLAM shall have no responsibility for ARROWHEAD&#8217; s obligations to the ARROWHEAD Sublicensee under the sublicense. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Without limiting the foregoing, all sublicenses granted shall be subject to the following conditions: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Such sublicense shall be consistent with the requirements of this Agreement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ARROWHEAD shall be primarily liable for any failure by its sublicensees to comply with all relevant restrictions, limitations and obligations in this Agreement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any such sublicense to a Third Party shall be in writing; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the event that the Sublicensee initiates any legal action seeking a determination that any of the ALNYLAM Patent Rights in any country are invalid, unenforceable, and/or not infringed (including a request for reexamination or opposition of any such ALNYLAM Patent Rights), ARROWHEAD shall terminate the sublicense at the request of ALNYLAM. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Retained Rights of ALNYLAM</font>. Any rights of ALNYLAM not expressly granted to ARROWHEAD under this Agreement will be retained by ALNYLAM. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Additional Patents Option</font>. ALNYLAM further grants to ARROWHEAD an option (the &#8220;<font style="text-decoration:underline;">Additional Patents Option</font>&#8221;) to expand the ALNYLAM Broad RNAi Patent Rights to include either the ALNYLAM CRT Additional Patent Rights or the ALNYLAM Stanford Additional Patent Rights, or both, for the sole and exclusive purposes of Researching, Developing, manufacturing and Commercializing Licensed RNAi Products in the Field in the Territory. The Additional Patents Option shall be exercisable by ARROWHEAD by written notice to ALNYLAM of such exercise given by ARROWHEAD anytime during the Term specifying the family or families of additional patent rights to which such exercise applies. Following exercise of the Additional Patents Option, the Parties shall negotiate and enter into a supplemental agreement containing terms and conditions for such license expansion, which shall include terms that pass through ALNYLAM&#8217;s costs of granting such expansion as well as terms that ALNYLAM is required to impose on sublicensees under ALNYLAM&#8217;s applicable agreement(s) with Third Party(ies), but which terms shall not impose burdens on ARROWHEAD beyond the foregoing costs and pass-through terms and the applicable terms of this Agreement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Exclusivity</font>. During the Term, neither ALNYLAM nor any of its Affiliates shall, directly or indirectly, Develop, manufacture commercial quantities of or Commercialize, any Licensed RNAi Product in the Field in the Territory, or collaborate with or assist any Third Party with respect to any of the foregoing, except as provided in this Agreement. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE V - FEES AND ROYALTIES </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">FTE Costs</font>. ARROWHEAD shall reimburse ALNYLAM in accordance with Section&#160;2.3 its FTE Costs with respect to the FTEs provided by ALNYLAM to conduct activities under Research Collaboration Plan. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Milestone Payments</font>. Upon the achievement by ARROWHEAD, its Affiliates or Sublicensees of each of the milestone events in the table below with respect to a Licensed RNAi Product, ARROWHEAD will provide written notice to ALNYLAM of the occurrence of such milestone event within five (5)&#160;days after such event and ARROWHEAD will make the indicated milestone payment to ALNYLAM within thirty (30)&#160;days after the occurrence of such event. Milestone payments will be due only once for the first Licensed RNAi Product to achieve the relevant milestone event and not for any subsequent Licensed RNAi Product or second generation of the same. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:75%;">
<tr>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone Event</p></td>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="width:13.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initiation of first Clinical Trial</p></td>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dosing of the first patient in a Pivotal Trial</p></td>
<td valign="bottom"  style="width:1.24%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Approval granted by a Regulatory Authority</p></td>
<td valign="bottom"  style="width:1.24%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.24%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Commercial Sale of a Licensed RNAi Product</p></td>
<td valign="bottom"  style="width:1.24%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event one or more milestone events set out above are skipped for any reason, the payment for such skipped milestone events(s) will be due upon the earlier of (a)&#160;achievement of the next achieved milestone event or (b)&#160;First Commercial Sale of a Licensed RNAi Product. In addition, if a Clinical Trial becomes a Pivotal Trial after the dosing of the first patient in such Clinical Trial, the Milestone payment above for dosing of the first patient in a Pivotal Trial (if not previously paid) shall become payable when such Clinical Trial is determined to be a Pivotal Trial. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Royalties</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Royalties on worldwide Net Sales, whether such sales are made by ARROWHEAD or through its Affiliates or Sublicensees, will be due and payable by ARROWHEAD to ALNYLAM on a Licensed RNAi Product-by-Licensed RNAi Product and country-by-country basis in the Territory commencing on the First Commercial Sale of such Licensed RNAi Product until the later of (i)&#160;ten (10)&#160;years following the First Commercial Sale of such Licensed RNAi Product in such country; or (ii)&#160;the expiration of the last Valid Claim Covering such Licensed RNAi Product in the country of sale or in the country of manufacture (the &#8220;Royalty Term&#8221;). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subject to subsection (a)&#160;of this Section&#160;5.3, the following royalties will be payable by ARROWHEAD to ALNYLAM (all references are to U.S. dollars) on aggregate worldwide Net Sales that fall within the indicated ranges of Net Sales for each calendar year. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:75%;">
<tr>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty Rate for annual worldwide Net Sales of Licensed RNAi Products up to and including $***</p></td>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
<td valign="bottom"  style="width:3.78%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.78%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.78%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty Rate for annual worldwide Net Sales of Licensed RNAi Products greater than $*** up to and including $***</p></td>
<td valign="bottom"  style="width:1.42%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
<td valign="bottom"  style="width:3.78%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.78%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.78%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty Rate for annual worldwide Net Sales of Licensed RNAi Products greater than $***</p></td>
<td valign="bottom"  style="width:1.42%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
<td valign="bottom"  style="width:3.78%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.78%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If, during any period within the Royalty Term for a given Licensed RNAi Product in a given country, neither (i)&#160;any Valid Claim in such country Covers the manufacture or Commercialization of the Licensed Product in the country of sale, nor (ii)&#160;any Valid Claim Covers the manufacture of the Licensed RNAi Product in the country or countries where such Licensed RNAi Product was manufactured, then the royalty rates applicable to such Licensed RNAi Product in such country shall be reduced to *** percent (***%) of the rates set forth in Section&#160;5.3(b) for such portion of the Royalty Term during which such condition exists. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Sales Milestone Payment</font>. For the milestone listed in the table below, ARROWHEAD shall pay, or cause to be paid, to ALNYLAM the following payments concurrently with ARROWHEAD&#8217;s payment of royalties pursuant to Section&#160;6.1 for the Calendar Quarter during which the achievement of the event set forth below occurs: </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:75%;">
<tr>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone Event</p></td>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  style="width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First calendar year in which aggregate annual Net Sales of Licensed RNAi Products in the Territory exceed $***</p></td>
<td valign="bottom"  style="width:1.42%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p></td>
<td valign="bottom"  style="width:3.78%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.42%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.44%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.78%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">For the avoidance of doubt, the foregoing milestone payment set forth in this Section&#160;5.4 shall be payable no more than once. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Third Party License Fees</font>. ARROWHEAD shall be solely responsible for all licensee fees, milestone payments, royalties, sublicense income and other amounts payable (a)&#160;by ALNYLAM pursuant to the applicable Existing ALNYLAM Third Party Agreement identified on Exhibit B that become payable as a result of any license granted by ALNYLAM to ARROWHEAD hereunder with respect to Licensed RNAi Products, and (b)&#160;by ARROWHEAD and its Affiliates and Sublicensees to Third Parties for licenses or other rights under patents and intellectual property rights of Third Parties with respect to Licensed RNAi Products Researched, Developed and Commercialized hereunder. ARROWHEAD shall pay to ALNYLAM the amounts payable by ALNYLAM to third parties as described in the foregoing clause (a)&#160;within thirty (30)&#160;days after any invoice therefor from ALNYLAM to ARROWHEAD. ARROWHEAD shall be entitled to deduct from royalty payments payable hereunder for a given Licensed RNAi Product *** percent (***%) of any Third Party License Fees Payments paid by ARROWHEAD with respect to such Licensed RNAi Product during the applicable reporting period; provided that in no event shall a deduction under this Section&#160;5.5 reduce any royalty payment with respect to any such Licensed RNAi Product payable by ARROWHEAD hereunder to less than *** percent (***%) of the royalty payment amount otherwise payable pursuant to </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Section&#160;5.4. In addition, ARROWHEAD shall be entitled to deduct from milestones payable hereunder for any given Licensed RNAi Product *** percent (***%) of any milestone payment actually paid by ARROWHEAD to any Third Party for such Licensed RNAi Product pursuant to an Existing ALNYLAM Third Party Agreement as set forth in the foregoing clause (a). </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE VI- REPORTS, TAXES AND PAYMENTS </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Reports</font>. As to each Calendar Quarter commencing with the Calendar Quarter during which the First Commercial Sale occurs, within seventy five (75)&#160;days after the end of such Calendar Quarter, ARROWHEAD will deliver to ALNYLAM a written report showing, on a Licensed RNAi Product-by-Licensed RNAi Product and country-by-country basis, the Net Sales of Licensed RNAi Products calculated under GAAP and its royalty obligation for such Calendar Quarter with respect to such Net Sales under this Agreement together with wire transfer of an amount equal to such royalty obligation. In addition, if the sales milestone set forth in Section&#160;5.4 is achieved during such Calendar Quarter, ARROWHEAD shall also pay to ALNYLAM the sales milestone payment set forth in Section&#160;5.4 with such wire transfer. All Net Sales will be segmented in each such report according to sales by ARROWHEAD and each Affiliate and Sublicensee, including the rates of exchange used to convert Net Sales to United States dollars from the currency in which such sales were made. For the purposes of this Agreement, the rates of exchange to be used for converting Net Sales to United States dollars will be the simple average of the selling and buying rates of Dollars published in <font style="font-style:italic;">The Wall Street Journal East Coast Edition</font> for the last business day of the Calendar Quarter covered by the report. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Tax Withholding</font>. ARROWHEAD will use commercially reasonable efforts to reduce tax withholding with respect to payments to be made to ALNYLAM, provided that ALNYLAM will reasonably cooperate with ARROWHEAD for said purposes. Notwithstanding such efforts, if ARROWHEAD concludes that tax withholdings under the laws of any country are required with respect to payments to ALNYLAM, ARROWHEAD will, subject to Section&#160;12.6(c), make the full amount of the required payment to ALNYLAM after any tax withholding. In any such case, ARROWHEAD shall provide ALNYLAM with a written explanation of such withholding and original receipts or other evidence reasonably desirable and sufficient to allow ALNYLAM to document such tax withholdings for purposes of claiming foreign tax credits and similar benefits. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Payments</font>. Unless otherwise agreed by the Parties, all payments required to be made under this Agreement will be made in United States dollars via wire transfer to an account designated in advance by the receiving Party. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Audits</font>. At any given point in time, ARROWHEAD will have on file and will require its Affiliates and Sublicensees to have on file complete and accurate records for the last three (3)&#160;years of all Net Sales (including associated data). ALNYLAM will have the right, once during each twelve (12)&#160;month period, to retain at its own expense an independent qualified certified public accountant reasonably acceptable to ARROWHEAD to review such records upon reasonable notice, during regular business hours. If the audit demonstrates that the payments owed under this Agreement have been understated, ARROWHEAD will pay the balance to ALNYLAM together with interest on such amounts in accordance with Section&#160;6.5. If the underpayment is greater than five percent (5%)&#160;of the amount owed for any calendar year, then ARROWHEAD will reimburse ALNYLAM for its reasonable out-of-pocket costs of the audit. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Late Payments</font>. ARROWHEAD shall pay interest to ALNYLAM on the aggregate amount of any payments (except for those payments which are the subject of a reasonable, good faith dispute) that are not paid on or before the date such payments are due under this Agreement at a rate equal to the then current 30-day United States dollar LIBOR rate plus two percent per annum. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE VII- INTELLECTUAL PROPERTY </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Prosecution and Maintenance of Patent Rights</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ALNYLAM will have the sole and exclusive right to file, prosecute and maintain patent protection (or to decline to do so) in the Territory for all ALNYLAM RNAi Patent Rights in its discretion and the first right to file, prosecute and maintain patent protection (or to decline to do so) in the Territory for all ALNYLAM Target-Specific Patent Rights. ALNYLAM covenants that it will not abandon, sell or exclusively license any portion of the ALNYLAM Patent Rights in any manner that would adversely affect ARROWHEAD&#8217; s rights hereunder. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ALNYLAM shall keep ARROWHEAD informed as to material developments with respect to the filing, prosecution and maintenance of the ALNYLAM Target-Specific Patent Rights, including by providing copies of all substantive office actions or any other substantive documents that ALNYLAM receives from any patent office. ALNYLAM shall provide ARROWHEAD with reasonable opportunities to substantively comment on the filing, prosecution and maintenance of the ALNYLAM Target-Specific Patent Rights prior to taking material actions, and will in good faith consider any actions recommended by ARROWHEAD; provided that ARROWHEAD provides such comments promptly and consistent with any applicable filing deadlines. If ALNYLAM decides not to file an ALNYLAM Target-Specific Patent Right or intends to allow an ALNYLAM Target-Specific Patent Right to lapse or become abandoned without filing a substitute, ALNYLAM shall, notify and consult with ARROWHEAD regarding such decision or intention at least thirty (30)&#160;days prior to the date upon which the subject matter of such ALNYLAM Target-Specific Patent Right shall become unpatentable or such ALNYLAM Target-Specific Patent Right shall lapse or become abandoned, and ARROWHEAD shall thereupon have the right, but not the obligation, to assume responsibility for the filing, prosecution and maintenance thereof at its own expense with counsel of its own choice. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Infringement of ALNYLAM Rights</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Each Party will promptly report in writing to the other Party during the Term any known or suspected infringement by a Third Party with respect to any ALNYLAM Patent Right by the Research, Development or Commercialization by such Third Party of a product that is or would be competitive with a Licensed RNAi Product being researched, Developed or Commercialized by ARROWHEAD, its Affiliates or Sublicensees (&#8220;<font style="text-decoration:underline;">Competitive Infringement</font>&#8221;) and will provide the other Party with all available evidence supporting such Competitive Infringement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ALNYLAM shall have the sole and exclusive right to initiate and control any infringement or other appropriate suit in the Territory against any Third Party who at any time has infringed, or is suspected of infringing, any of the ALNYLAM RNAi Patent Rights in its discretion. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ARROWHEAD shall have the first right to initiate and control any infringement or other appropriate suit in the Territory with respect to a Competitive Infringement of an ALNYLAM Target-Specific Patent Right. ALNYLAM shall, at ARROWHEAD&#8217;s expense, cooperate with ARROWHEAD in any such suit and shall have the right, at its own expense, to be represented in such action by counsel of its own choice. If ARROWHEAD fails to bring any such action or proceeding within a period of ninety (90)&#160;days after first being notified of a Competitive Infringement of an ALNYLAM Target-Specific Patent Right, then ALNYLAM shall have the right to bring and control such an action with respect to such Competitive Infringement of an ALNYLAM Target-Specific Patent Right by counsel of its own choice. ARROWHEAD shall, at ALNYLAM&#8217;s expense, cooperate with ALNYLAM in any such suit and have the right to be represented in such action by counsel of its own choice at its own expense. Any recoveries resulting from such an action brought in accordance with this clause (c)&#160;shall be applied as follows: (i)&#160;first, to reimburse each Party for all out-of-pocket costs incurred in connection with such proceeding (on a pro rata basis, based on each Party&#8217;s respective litigation costs, to the extent the recovery was less than all such litigation costs); and (ii)&#160;the remainder of any such recovery shall be shared between the Parties with the Party that initiated such action retaining *** of the remainder of such recovery and the other Party receiving *** of the remainder of such recovery. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Claimed Infringement of Third Party Rights, and Third Party Intellectual Property Obligations</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the event that a Third Party at any time provides written notice of a claim to, or brings an action, suit or proceeding against, either Party, or any of their respective Affiliates or Sublicensees, claiming infringement of its patent rights based upon an assertion or claim arising out of the development, use, manufacture, distribution, importation or sale of Licensed RNAi Products (&#8220;Third Party Claim&#8221;), such Party will promptly notify the other Party of the claim or the commencement of such action, suit or proceeding, enclosing a copy of the claim and all papers served. Each Party agrees to make available to the other Party its advice and counsel regarding the technical merits of any such claim at no cost to the other Party and, if requested by the other Party, to provide reasonable assistance to the other Party at no cost to the other Party other than out-of-pocket expenses incurred in connection with such assistance. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">EACH PARTY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, OF NONINFRINGEMENT WITH RESPECT TO ANY LICENSED RNAi PRODUCT. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE VIII - CONFIDENTIAL INFORMATION </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Non-Use and Non-Disclosure of Confidential Information</font>. Each Party agrees that all Confidential Information of a Party that is disclosed by a Party to the other Party (a)&#160;will not be used by the receiving Party except in connection with the activities contemplated by this Agreement or in order to further the purposes of this Agreement, (b)&#160;will be maintained in confidence by the receiving Party and (c)&#160;will not be disclosed by the receiving Party to any Third Party who is not a consultant or advisor under an obligation of confidentiality to, the receiving Party or an Affiliate or Sublicensee of the receiving Party, without the prior written consent of the disclosing Party. The disclosing Party is liable for any breach of the non-disclosure obligation of its consultants, advisors, Affiliates and Sublicensees as applicable. Notwithstanding the foregoing, Confidential Information shall not include information which (i)&#160;was known by the receiving Party or its Affiliates prior to its date of disclosure by the disclosing Party to the receiving Party as demonstrated by legally admissible evidence available to the receiving Party or its Affiliates, (ii)&#160;either before or after the date of the disclosure such Confidential Information is lawfully disclosed to the receiving Party or its Affiliates by sources other than the disclosing Party rightfully in possession of such Confidential Information or other information and not bound by confidentiality obligations to the disclosing Party, (iii)&#160;either before or after the date of the disclosure by the disclosing Party to the receiving Party such Confidential Information becomes published or otherwise part of the public domain through no fault or omission on the part of the receiving Party or its Affiliates, or (iv)&#160;is independently developed by or for the receiving Party or its Affiliates without reference to or in reliance upon the Confidential Information as demonstrated by legally admissible evidence available to the receiving Party or its Affiliates. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Permitted Disclosures</font>. Notwithstanding the foregoing provisions of Section&#160;8.1, each Party may disclose Confidential Information belonging to the other Party to the extent: (a)&#160;reasonably necessary to Research, Develop, manufacture and Commercialize Licensed RNAi Products, including to obtain Approval of Licensed RNAi Products, (b)&#160;to its employees, consultants and advisors, and the employees, consultants and advisors of its Affiliates or Sublicensees as applicable, who have a legitimate business need to know and an obligation to maintain in confidence the Confidential Information of the disclosing Party, (c)&#160;reasonably necessary for the prosecution and maintenance of Patent Rights, (d)&#160;reasonably required in order for a Party to obtain financing or conduct discussions with Development or Commercialization partners so long as such Third Party recipients are bound by an obligation of confidentiality consistent with that set forth herein, (e)&#160;reasonably necessary in connection with prosecuting or defending litigation as permitted by this Agreement, (f)&#160;reasonably necessary to enforce its rights under this Agreement or (g)&#160;required to be disclosed by the receiving Party to comply with applicable laws or regulations or legal process, including without limitation by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or NASDAQ, provided that the receiving Party provides prior written notice of such disclosure to the disclosing Party and takes reasonable and lawful actions to avoid or minimize the extent of such disclosure. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Publicity</font>. No disclosure of the existence of, or the terms of, this Agreement may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by law or as set forth in this Section&#160;8.3. The Parties acknowledge and agree that, upon and following the Effective Date, the Parties shall jointly issue a press release announcing the execution of this Agreement in form and substance substantially as attached hereto as <font style="text-decoration:underline;">Exhibit D</font>. Either Party may issue such other press releases or otherwise make such public statements or disclosures (such as in annual reports to stockholders or filings with the Securities and Exchange Commission) as it determines, based on advice of counsel, are reasonably necessary to comply with applicable laws and regulations. In addition, following any initial press release(s) announcing this Agreement or other public disclosure approved by both Parties, either Party shall be free to disclose, without the other Party&#8217;s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance herewith. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE IX - INDEMNIFICATION AND INSURANCE </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ARROWHEAD Indemnification</font>. ARROWHEAD agrees to indemnify and hold harmless ALNYLAM and its Affiliates, and their respective agents, directors, officers and employees and their respective successors and assigns (the &#8220;<font style="text-decoration:underline;">ALNYLAM Indemnitees</font>&#8221;) from and against any and all losses, costs, damages, fees or expenses (&#8220;<font style="text-decoration:underline;">Losses</font>&#8221;) incurred by an ALNYLAM Indemnitee arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party (&#8220;<font style="text-decoration:underline;">Claim</font>&#8221;) based on (a)&#160;the development, use, manufacture, distribution or sale of any Licensed RNAi Product by ARROWHEAD or any of its Affiliates or Sublicensees, including, but not limited to, any claims made against ALNYLAM by Third Parties alleging infringement, injury, damage, death or other consequence occurring to any person claimed to result, directly or indirectly, from the possession, use or consumption of, or treatment with, any Licensed RNAi Product, whether claimed by reason of breach of warranty, negligence, product defect or otherwise, and regardless of the form or forum in which any such claim is made, (b)&#160;any breach of any representation, warranty or covenant of ARROWHEAD in this Agreement, or (c)&#160;any act or omission by ARROWHEAD or an ARROWHEAD Indemnitee, which constitutes recklessness, gross negligence, or willful misconduct on the part of ARROWHEAD or an ARROWHEAD Indemnitee in connection with this Agreement. The above indemnification shall not apply to the extent that any Losses are due to (i)&#160;a material breach of any of ALNYLAM&#8217;s representations, warranties, covenants and/or obligations under this Agreement; or (ii)&#160;any act or omission by ALNYLAM, or an ALNYLAM Indemnitee, which constitutes recklessness, gross negligence, or willful misconduct on the part of ALNYLAM, or an ALNYLAM Indemnitee. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">ALNYLAM Indemnification</font>. ALNYLAM agrees to indemnify and hold harmless ARROWHEAD and its Affiliates, and their respective agents, directors, officers and employees and their respective successors and assigns (the &#8220;<font style="text-decoration:underline;">ARROWHEAD Indemnitees</font>&#8221;) from and against any and all Losses incurred by an ARROWHEAD Indemnitee arising out of or in connection with any Claim based on (a)&#160;any breach of any representation, warranty or covenant of ALNYLAM in this Agreement, or (b)&#160;any act or omission by ALNYLAM or an ALNYLAM Indemnitee, which constitutes recklessness, gross negligence, or willful misconduct on the part of ALNYLAM or an ALNYLAM Indemnitee in connection with this Agreement. The above indemnification shall not apply to the extent that any Losses are due to (i)&#160;a material breach of any of ARROWHEAD&#8217; s representations, warranties, covenants and/or obligations under this Agreement, or (ii)&#160;any act or omission by ARROWHEAD, or an ARROWHEAD Indemnitee, which constitutes recklessness, gross negligence, or willful misconduct on the part of ARROWHEAD, or an ARROWHEAD Indemnitee. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Indemnification Procedures</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Each indemnified party shall notify the indemnifying party in writing (and in reasonable detail) of the Claim within ten (10)&#160;business days after receipt by such indemnified party of notice of a Claim or otherwise becoming aware of the existence or threatened existence thereof. Failure to give such notice shall not constitute a defense, in whole or in part, to any claim by an indemnified party hereunder except to the extent the rights of the indemnifying party are materially prejudiced by such failure to give notice. The indemnifying party shall notify the indemnified party of its intentions as to defense of the Claim or potential Claim in writing within ten (10)&#160;business days after receipt of notice of the Claim. If the indemnifying party assumes the defense of a Claim against an indemnified party, an indemnifying party shall have no obligation or liability under this Article IX as to any Claim for which settlement or compromise of such Claim or an offer of settlement or compromise of such Claim is made by an indemnified party without the prior written consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The indemnifying party shall assume exclusive control of the defense and settlement (including all decisions relating to litigation, defense and appeal) of any such Claim (so long as it has confirmed its indemnification obligation responsibility to such indemnified party under this Section&#160;9.3(b) with respect to a given Claim); <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that the indemnifying party may not settle such Claim in any manner that would require payment by the indemnified party, or would materially adversely affect the rights granted to the indemnified party hereunder, or would materially conflict with the terms of this Agreement, or adversely affect other products of the indemnified party, without first obtaining the indemnified party&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The indemnified party shall reasonably cooperate with the indemnifying party in its defense of the Claim (including making documents and records available for review and copying and making persons within its control available for pertinent testimony in accordance with the confidentiality provisions of Article VII, and neither party shall be required to divulge privileged material to the other) at the indemnifying party&#8217;s expense. If the indemnifying party assumes defense of the Claim, an indemnified party may participate in, but not control, the defense of such Claim using attorneys of its choice and at its sole cost and expense, with such cost and expense not being covered by the indemnifying party. If an indemnifying party does not agree to assume the defense of the Claim asserted against the indemnified party (or does not give notice that it is assuming such defense), or if the indemnifying party assumes the defense of the Claim in accordance with Section&#160;9.3(b) yet fails to defend or take other reasonable, timely action, in response to such Claim asserted against the indemnified party, the indemnified party shall have the right to defend or take other reasonable action to defend its interests in such proceedings, and shall have the right to litigate, settle or otherwise dispose of any such Claim; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that the indemnified party shall not have the right to settle such Claim in any manner that would adversely affect the rights granted to the other party hereunder, or would materially conflict with this Agreement, or would require a payment by the other party, or adversely affect the products of the other party, without the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE X - EXPORT </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">General</font>. The Parties acknowledge that the exportation from the United States of materials, products and related technical data (and the re-export from elsewhere of United States origin items) may be subject to compliance with United States export laws, including without limitation the United States Bureau of Export Administration&#8217;s Export Administration Regulations, the Act and regulations of the FDA issued thereunder, and the United States Department of State&#8217;s International Traffic and Arms Regulations which restrict export, re-export, and release of materials, products and their related technical data, and the direct products of such technical data. The Parties agree to comply with all applicable exports laws and to commit no act that, directly or indirectly, would violate any United States law, regulation, or treaty, or any other international treaty or agreement, relating to the export, re-export, or release of any materials, products or their related technical data to which the United States adheres or with which the United States complies. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Delays</font>. The Parties acknowledge that they cannot be responsible for any delays attributable to export controls which are beyond the reasonable control of either Party. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Assistance</font>. The Parties agree to provide assistance to one another in connection with each Party&#8217;s efforts to fulfill its obligations under this Article X. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE XI - TERM AND TERMINATION </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;"></font><font style="text-decoration:underline;">Term</font>. This Agreement will remain in effect until the end of the last-to-expire Royalty Term with respect to all Licensed RNAi Products (the &#8220;<font style="text-decoration:underline;">Term</font>&#8221;) unless terminated in accordance with this Article XI. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Material Breach</font>. Either Party (the &#8220;<font style="text-decoration:underline;">Non-Breaching Party</font>&#8221;) will have the right to terminate this Agreement, upon written notice to the other Party (the &#8220;<font style="text-decoration:underline;">Breaching Party</font>&#8221;), in the event the latter materially breaches its obligations under this Agreement and does not remedy such breach within sixty (60)&#160;days (thirty (30)&#160;days for payment breaches) after receipt of written notice from the Non-Breaching Party specifically identifying the breach and stating it intends to terminate the Agreement if the Breaching Party fails to remedy the breach within the sixty (60)-day (or thirty (30)-day for payment breaches) notice period. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Termination by ARROWHEAD</font>. ARROWHEAD will have the right to terminate this Agreement for any reason upon thirty (30)&#160;days&#8217; prior written notice to ALNYLAM. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Termination Due to Patent Challenge</font>. If ARROWHEAD or any of its Affiliates or Sublicensees initiates, or assists any Third Party in initiating, any legal action seeking a determination that any of the ALNYLAM Patent Rights in any country are invalid, unenforceable, and/or not infringed (including a request for reexamination or opposition of any such ALNYLAM Patent Rights), to the extent permitted by the applicable law of such country, ALNYLAM may terminate this Agreement upon thirty (30)&#160;days&#8217; prior written notice to ARROWHEAD, <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, <font style="text-decoration:underline;">that</font> if, prior to the end of such thirty (30)-day period ARROWHEAD is able to obtain a full and complete withdrawal of such action and ARROWHEAD shall pay all of ALNYLAM&#8217;s costs associated therewith, the termination shall not become effective and this Agreement shall remain in full force and effect. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Consequences of Termination; Survival</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the event this Agreement is terminated under Section&#160;11.2, 11.3 or 11.4, all licenses and other rights granted by ALNYLAM to ARROWHEAD under this Agreement will terminate. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination or any rights of the Parties that accrued prior to such expiration or termination. Termination of this Agreement, for whatever reason in accordance with the provisions hereof, shall not limit remedies that may be otherwise available in law or equity. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The provisions of Article VIII shall survive the expiration or termination of this Agreement for any cause and shall continue in effect as applicable for ten (10)&#160;years from the date of initial disclosure. In addition, the provisions of Articles V, VI, IX and XII (other than 12.1 and 12.2), and this Section&#160;11.5 shall survive any expiration or termination of this Agreement. </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ARTICLE XII - MISCELLANEOUS </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Representations by ARROWHEAD and ALNYLAM</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Each Party hereby represents and warrants to the other Party, as of the Effective Date, that: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Such Party is duly organized under the laws of the state or country of its formation, and has all necessary power and authority to conduct its business in the manner in which it is currently being conducted, to own and use its assets in the manner in which its assets are currently owned and used, and to enter into and perform its obligations under this Agreement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The execution, delivery and performance of this Agreement (A)&#160;has been duly authorized by all necessary action on the part of such Party and its Board of Directors (or comparable governance body) and (B)&#160;does not and will not conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which such Party is a party or by which it is bound. Further, no consent, approval, order or authorization of, or registration, declaration or filing with any Third Party or governmental authority is necessary for the execution, delivery or performance of this Agreement. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.6%;margin-left:12.4%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against it in accordance with its terms, subject to (A)&#160;laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (B)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neither such Party nor any of its Affiliates has been found in breach of any laws or regulations governing the production of medicinal products in the United States or any other jurisdiction within the Territory. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (v)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Neither such Party nor any of its Affiliates has been debarred (nor is such Party or any of its Affiliates using in any capacity in connection with its activities under this Agreement any person who has been debarred) by the FDA from working for or providing services to any pharmaceutical or biotechnology company under Section&#160;306 of the Act. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Such Party has never approved or commenced any proceeding, or made any election contemplating, the winding up or cessation of such Party&#8217;s business or affairs or the assignment of such Party&#8217;s material assets for the benefit of creditors. To such Party&#8217;s knowledge, no such proceeding is pending or threatened. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ALNYLAM represents and warrants to ARROWHEAD that as of the Effective Date: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ALNYLAM has the right to grant ARROWHEAD the licenses granted hereunder and has not granted any conflicting rights to any other person or entity. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ALNYLAM has not previously granted any right, license or interest in or to the ALNYLAM Patent Rights, or any portion thereof, that is in conflict with the rights or licenses granted to ARROWHEAD under this Agreement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:87.54%;margin-left:12.46%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ALNYLAM and its Affiliates have taken reasonable measures to protect the ALNYLAM Intellectual Property, consistent with prudent commercial practices in the biotechnology industry. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE XII, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY, INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Mutual Covenants</font>. Each Party hereby covenants to the other Party that: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Such Party shall comply with all applicable laws, rules and regulations in connection with this Agreement and the transactions contemplated hereby and will perform its activities pursuant to this Agreement in compliance in all material respects with GLP and GCP; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All employees of such Party or its Affiliates working under this Agreement will be under the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Dispute Resolution; Arbitration Procedures</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In the event of any dispute, controversy or claim arising out of or relating to this Agreement or the breach thereof, the Parties will try to settle such dispute, controversy or claim amicably between themselves, including referring such dispute, controversy or claim to the Executive Officers. In the event that after forty-five (45)&#160;days the designated officers of both Parties fail to resolve the matter, either Party may submit such dispute, controversy or claim that is not an &#8220;Excluded Claim&#8221; for resolution by binding arbitration under the Rules of Arbitration of the American Arbitration Association. Judgment on the arbitration award may be entered in any court of competent jurisdiction. The arbitration will be conducted in New York, New York and the language of all communications and proceedings relating to the arbitration will be English. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical business. Within thirty (30)&#160;days after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within thirty (30)&#160;days of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the Parties shall select two replacement arbitrators to replace the arbitrators originally selected, which replacement arbitrators shall select a third arbitrator within thirty (30)&#160;days of their appointment. The Parties agree (a)&#160;to meet with the arbitrator(s) within thirty (30)&#160;days of selection and (b)&#160;to agree at that meeting or before as to the conduct of the hearing which will result in the hearing being concluded within no more than six (6)&#160;months after selection of the arbitrator(s) and in the award being rendered within thirty (30)&#160;days of any post-hearing briefing, which briefing will be completed by both sides within thirty (30)&#160;days after the conclusion of the hearings, or within sixty (60)&#160;days of the conclusion of the hearings if there is no post-hearing briefing. In no event will the arbitrator(s), absent agreement of the Parties, allow more than three (3)&#160;days per side for the hearing or more than a total of six (6)&#160;days for the hearing. Multiple hearing days will be scheduled consecutively to the greatest extent possible. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party&#8217;s compensatory damages. The costs, expenses, attorneys&#8217; fees and arbitrators&#8217; fees and any administrative fees of arbitration of both Parties shall be borne by the Parties as determined by the arbitrators, who shall take into account the nature of the dispute and reasonableness of the Parties&#8217; positions with respect to the dispute in making such determination. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable Massachusetts statute of limitations. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending an award of the arbitrators on the ultimate merits of any dispute. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As used in this Section&#160;12.3, the term &#8220;Excluded Claim&#8221; shall mean a dispute, controversy or claim that concerns (i)&#160;the validity or infringement of a patent, trademark or copyright; or (ii)&#160;any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. Excluded Claims shall be resolved in a court of competent jurisdiction. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Force Majeure</font>. No failure or omission by the Parties in the performance of any obligation of this Agreement will be deemed a breach of this Agreement or create any liability if the same will arise from any cause or causes beyond the control of the Parties, including, but not limited to, the following: acts of God; acts or omissions of any government; any rules, regulations or orders issued by any governmental authority or by any officer, department, agency or instrumentality thereof; fire; flood; storm; earthquake; accident; war; rebellion; insurrection; riot; and invasion. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Consequential Damages</font>. NEITHER PARTY (INCLUDING ITS AFFILIATES AND SUBLICENSEES) SHALL BE LIABLE UNDER THIS AGREEMENT FOR ANY SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OR FOR LOSS OF PROFIT OR LOST REVENUE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OF A PARTY OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE VIII. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Assignment</font>. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.27%;margin-left:5.73%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This Agreement and any of its rights and obligations may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party, which consent may not be unreasonably withheld, delayed or conditioned; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that either Party may assign this Agreement, without the consent of the other Party, in connection with such Party&#8217;s merger, consolidation or transfer or sale of all or substantially all of the business or assets of such Party relating to the subject matter of this Agreement; <font style="text-decoration:underline;">provided</font> <font style="text-decoration:underline;">further</font> that the successor, surviving entity, purchaser of assets, or transferee, as applicable, expressly assumes in writing such Party&#8217;s obligations under this Agreement. Any purported assignment in contravention of this Section&#160;12.6 shall, at the option of the non-assigning Party, be null and void and of no effect. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this Agreement is assigned by a Party in connection with such Party&#8217;s merger, consolidation or transfer or sale of all or substantially all of the business or assets of such Party relating to the subject matter of this Agreement, such assignment shall not provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If ARROWHEAD assigns its rights and obligations hereunder to an Affiliate or Third Party outside the United States pursuant to this Section&#160;12.6, and if such Affiliate or Third Party shall be required by applicable Law to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings, ALNYLAM receives an amount equal to the sum it would have received had no such assignment been made. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:94.33%;margin-left:5.67%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This Agreement will be binding upon and inure to the benefit of the Parties and their permitted successors and assigns. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.7</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Notices</font>. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.73%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices to ALNYLAM will be addressed to: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alnylam Pharmaceuticals, Inc. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 Third Street </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, Massachusetts 02142 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.A. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Business Officer </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile No.: (617)&#160;551-8101 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copy to: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wilmer Cutler Pickering Hale and Don LLP </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60 State Street </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts 02109 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.A. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Steven D. Barrett, Esq. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile No.: (617)&#160;526-5000 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices to ARROWHEAD will be addressed to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Brendan Rae, Ph.D., J.D. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Arrowhead Research Corporation </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">225 South Lake Avenue, 3rd Floor </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pasadena, CA 91101 </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Telephone: (626) 304-3400 </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fax: (626) 304-3401 </p></td></tr></table></div>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copy to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Thomas Haag, Ph.D., Esq. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fanelli Haag PLLC </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">1909 K St. NW, Suite 1120 </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Washington, DC 20006 </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Telephone: 202.706.7910 </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:88.54%;margin-left:11.46%;">
<tr>
<td valign="top" style="width:11.46%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="top" style="width:88.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fax: 202.706.7920 </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Party may change its address by giving notice to the other Party in the manner provided in this Section&#160;12.7. Any notice required or provided for by the terms of this Agreement will be in writing and will be (a)&#160;sent by certified mail, return receipt requested, postage prepaid, (b)&#160;sent via a reputable national express courier service, or (c)&#160;sent by facsimile transmission, with a copy by regular mail. The effective date of the notice will be the actual date of receipt by the receiving Party. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.8</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Independent Contractors</font>. It is understood and agreed that the relationship between the Parties is that of independent contractors and that nothing in this Agreement will be construed as authorization for either Party to act as the agent for the other Party. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.9</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Governing Law; Jurisdiction</font>. This Agreement will be governed and interpreted in accordance with the substantive laws of the State of New York of the U.S.A., notwithstanding the provisions governing conflict of laws under such law of the State of New York to the contrary, provided that matters of intellectual property law will be determined in accordance with the national intellectual property laws relevant to the intellectual property in question. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.10</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Severability</font>. In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any law of the relevant jurisdiction, the validity of the remaining provisions will not be affected and the rights and obligations of the Parties will be construed and enforced as if the Agreement did not contain the particular provisions held to be unenforceable, provided that the Parties will negotiate in good faith a modification of this Agreement with a view to revising this Agreement in a manner which reflects, as closely as is reasonably practicable, the commercial terms of this Agreement as originally signed. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.11</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">No Implied Waivers</font>. The waiver by either Party of a breach or default of any provision of this Agreement by the other Party will not be construed as a waiver of any succeeding breach of the same or any other provision, nor will any delay or omission on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.12</font></p></td>
<td valign="top" style="width:94.33%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Entire Agreement</font>. This Agreement, along with that certain Confidential Disclosure Agreement by and between the Parties dated as of October&#160;28, 2011, constitutes the entire agreement between the Parties with respect to its subject matter and supersedes all previous written or oral representations, agreements and understandings between the Parties. This Agreement may be amended only in a writing signed by both Parties. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.67%;text-indent:-5.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.13</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Headings; Construction; Interpretation</font>. Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires, (a)&#160;any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b)&#160;any reference to any law, rule or regulation refers to such law, rule or regulation as from time to time enacted, repealed or amended, (c)&#160;the words &#8220;herein,&#8221; &#8220;hereof&#8217; and &#8220;hereunder,&#8221; and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, (d)&#160;the words &#8220;include,&#8221; &#8220;includes,&#8221; &#8220;including,&#8221; &#8220;exclude,&#8221; &#8220;excludes,&#8221; and &#8220;excluding,&#8221; shall be deemed to be followed by the phrase &#8220;but not limited to,&#8221; &#8220;without limitation&#8221; or words of similar import, (e)&#160;except where the context otherwise requires, the word &#8220;or&#8221; is used in the inclusive sense, and (f)&#160;all references to &#8220;dollars&#8221; or &#8220;$&#8221; herein shall mean US Dollars. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.73%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.14</font></p></td>
<td valign="top" style="width:94.27%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;">Counterparts</font>. This Agreement may be signed in counterparts, each and every one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. Facsimile signatures and signatures transmitted via portable document format (PDF) shall be treated as original signatures. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5.73%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties hereto have set their hand as of the Effective Date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="2" valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Laurence E. Reid</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: L.E. Reid</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: CBO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="2" valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD RESEARCH CORPORATION</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chris Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Chris Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:35%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President &amp; CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD MADISON INC.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:87.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chris Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Chris Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="width:12.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President &amp; CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*** Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signature Page to License Agreement</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM Patent Rights</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Our Ref. No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Application No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Patent No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40.66%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Application Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AT1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E297.463</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AT2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E418.60</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AU</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2000032713</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">778474</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AU1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005201044</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005201044</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AUD2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2008202208</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Opposed</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CA</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2,359,180</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2,359,180</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CH1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CH2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CY1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CY05/1101016</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CY2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE0</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50000414.5-08</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1144623</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50010528.6-08</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1214945</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DED1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066235.8</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066235.8</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DED2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066344.3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DED3</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066382.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DEUTM</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">20023125.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE20023125&#160;U1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RegUtilMode</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DK1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DK2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02003683.6</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1214945</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD3</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">06025389.5</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD4</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10011217.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3ES1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ES2243608</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3ES2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FI1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Finland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FI2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Finland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FR1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FR2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GB1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1214945</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GB2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GR1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Greece</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">3054579</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GR2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Greece</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 00910510</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1144623 B9</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revoked</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IE1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IE2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IT1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IT2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD10</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2009-285706</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD3</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-186341</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD4</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-186340</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD5</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-186339</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ExamReq</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD7</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2009-002825</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD9</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2009-285705</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LI1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LI2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LU1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LU2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3MC1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Monaco</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3MC2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Monaco</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3NL1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3NL2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3PT1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3PT2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3SE1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3SE2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982325</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982305</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON3</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982425</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON4</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982441</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON5</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982345</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON6</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982434</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/382395</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/383099</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD3</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/382768</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD4</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/612179</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/DE00/00244</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3ZA</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">South Africa</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ZA 20015909</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2001/5909</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.1DE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10100586.5-09</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE10100586&#160;C1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION IN CELLS, USEFUL FOR e.g., TREATING TUMORS, BY INTRODUCING DOUBLE-STRANDED COMPLEMENTARY OLIGORNA HAVING</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/894018</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4AT</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E328.075</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4AU</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002229701</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002229701</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4CH</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4CY</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4DE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50206993.7-08</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4EP</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4GB</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02710786</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4IE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4JP</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002-556740</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">4210116</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4JPD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002-556739</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">4209678</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4LI</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4LU</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4TR</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Turkey</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4US</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,339</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,829,693</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/00152</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1DE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247.4-2405/1349</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50214866.9-08</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1EP</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247.4</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1EPD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10002422.3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1EPD2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10011812.4</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1ES</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ES2204360</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1FR</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;02702247</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1GB</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247.4-2405/1349</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1HKD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11100629.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1HKD2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11111936.1</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1NL</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02702247</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/00151</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.2US</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,260</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,473,525</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.2US</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/276,270</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4AU</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005284729</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4CA</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2580560</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4EP</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05797892.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4EPD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11004902.0</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4HK</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">07114036.0</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4US</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/941663</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7767802</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4USCIP2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/229183</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7423142</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4USCON2</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/961337</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4USD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/175,938</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,868,160</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US2005/033&#160;309</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.2DE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE 10163098</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE10163098</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.3USCIP</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,512</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,348,314</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD TO INHIBIT THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.3USCON</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/959,936</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,745,418</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD TO INHIBIT THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.3USCON1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/631689</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD TO INHIBIT THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-011.2WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/11973</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF DOUBLE STRAND RIBONUCLEIC ACID FOR TREATING AN INFECTION WITH A POSTIVE-STRAND RNA-VIRUS</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.2EP</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02779511.1</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF A DOUBLE-STRANDED RIBONUCLEIC ACID FOR SPECIFICALLY INHIBITING THE EXPRESSION OF A GIVEN TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.2EPD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10011813.2</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF A DOUBLE-STRANDED RIBONUCLEIC ACID FOR SPECIFICALLY INHIBITING THE EXPRESSION OF A GIVEN TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.2WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/11969</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF A DOUBLE-STRANDED RIBONUCLEIC ACID FOR SPECIFICALLY INHIBITING THE EXPRESSION OF A GIVEN TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.3US</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,463</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,763,590</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF A MUTANT GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.3USCON1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">13/177316</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF A MUTANT GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.3USD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/817009</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7994309</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF A MUTANT GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-013.1WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/11972</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DRUG FOR TREATING A FIBROTIC DISEASE THROUGH RNA INTERFERENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-014.1WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/12221</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SMAD7 INHIBITORS FOR THE TREATMENT OF CNS DISEASES</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.2US</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/349,320</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,196,184</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RNA (dsRNA) AND METHOD FOR USE FOR INHIBITING EXPRESSION OF A FUSION GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.2USCON1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/912616</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RNA (dsRNA) AND METHOD FOR USE FOR INHIBITING EXPRESSION OF A FUSION GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.2USD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/656,349</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,846,907</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RNA (dsRNA) AND METHOD FOR USE FOR INHIBITING EXPRESSION OF A FUSION GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.3WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP03/00604</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INCREASING THE EFFICIENCY OF AN INHIBITOR OF TYROSINE KINASE ACTIVITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.1DE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10302421.2-41</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RIBONUCLEIC ACID WITH IMPROVED ACTIVITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2AT</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E367441</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2AU</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2004206255</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2004206255</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2AUD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2008203538</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2BE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2CA</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2513809</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2513809</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2CH</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2CY</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2DE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">602004007620.1- 08</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2DK</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DK/EP&#160;1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2EP</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2EPD1</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">07010839.4</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2ES</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2FR</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2GB</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2HK</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">08105048.3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2HU</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hungary</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2IE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2IT</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2LI</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2LU</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2NL</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926B1</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2PT</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2SE</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2SI</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Slovenia</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2TR</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Turkey</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2US</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/543048</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2WO</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US2004/001 461</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-017.1EPUS</p></td>
<td valign="top"  style="width:11.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14.08%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">60/479,354</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.74%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Converted</p></td>
<td valign="top"  style="width:40.6%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SiRNA WITH INCREASED STABILITY IN SERUM</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Isis&#160;Docket&#160;No.</p></td>
<td valign="bottom"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent&#160;No.</p></td>
<td valign="bottom"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0129</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATE190981T1</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0130</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497875</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0131</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690 33 495.8</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0132</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497875</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0133</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497875</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0134</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497875</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0135</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LX</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497875</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0136</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497875</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0041</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658562</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCLEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0042</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCLEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0043</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497875</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCLEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0045</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5792847</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCLEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0047</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5466786</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED NUCLEOSIDE AND NUCLEOTIDE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0046</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6476205</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0126</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0148</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4178</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-ALKYLATED GUANOSINE 3&#8217;o-PHOSPHORAMIDITES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0146</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-AMINOPYRIDINE AND 2-PYRIDONE C-NUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0113</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6447998</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2-AMINOPYRIDINE AND 2-PYRIDONE C-NUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5017</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-GUANIDINYL-SUBSTITUTED OLIGONUCLEOTIDES AND GENE EXPRESSION MODULATION THEREWITH</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4997</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-GUANIDINYL-SUBSTITUTED OLIGONUCLEOTIDES AND GENE EXPRESSION MODULATION THEREWITH</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2004</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5859221</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2826</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6005087</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4099</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6531584</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5137</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4071</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6147200</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4477</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4496</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4044</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6600032</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5036</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6673912</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2824</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6127533</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-AMINOOXY-MODIFIED OLIGONUCLEOTIDES (as amended)</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3156</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6043352</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-DIMETHYLAMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4047</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750469</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-DIMETHYLAMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4048</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-DIMETHYLAMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4049</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-DIMETHYLAMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4068</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-DIMETHYLAMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5018</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-DIMETHYLAMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1082</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5914396</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-MODIFIED NUCLEOSIDES AND PHOSPHORAMIDITES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2005</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5872232</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-O-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0780</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5457191</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-DEAZAPURINES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2044</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5587470</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-DEAZAPURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0002</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5223618</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#8217;-DESMETHYL NUCLEOSIDE ANALOG COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4260</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6320040</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#8217;-DESMETHYL NUCLEOSIDE ANALOGS, AND OLIGOMERS THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2090</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5998603</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#8217;-DESMETHYL NUCLEOSIDE ANALOGS, AND OLIGOMERS THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-221.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5912332</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AFFINITY-BASED PURIFICATION OF OLIGONUCLEOTIDES USING SOLUBLE MULTIMERIC OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1692</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679566</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1693</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2170869</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1694</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">694 33 036.1</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1698</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728139</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1699</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728139</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1700</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728139</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1702</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728139</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1710</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728139</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1711</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3484197</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1712</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2000</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1788</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5834607</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINES AND METHODS OF MAKING AND USING THE SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3508</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6576752</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY FUNCTIONALIZED OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5089</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY FUNCTIONALIZED OLIGOMERS, OLIGOMER ARRAYS AND METHODS OF USING THEM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3993</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6639062</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2829</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">740799</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2830</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2831</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2849</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2850</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399743</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2955</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6172209</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES AND METHODS FOR MAKING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3996</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">752878</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES AND METHODS FOR MAKING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3997</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES AND METHODS FOR MAKING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3998</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES AND METHODS FOR MAKING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4017</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES AND METHODS FOR MAKING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4309</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6194598</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMINOOXY-MODIFIED OLIGONUCLEOTIDES SYNTHETIC INTERMDIATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0054</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5214136</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTHRAQUINONE-DERIVATIVES OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-116.0USC1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5929226</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIOATES AND ARYLPOSPOHONOTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0718</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5386023</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGNUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH REDUCTIVE COUPLING</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0031</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5378825</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0026</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5602240</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3293</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6025482</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PERPARATION THEREOF THROUGH REDUCTIVE COUPLING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2420</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5969118</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH RADICAL COUPLING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0716</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5541307</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND SOLID PHASE SYNTHESIS THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0543</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">666121</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0545</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0550</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586570</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0551</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692&#160;31&#160;441.5</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0552</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586570</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0560</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586570</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0564</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2711180</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0565</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155574</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4293</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0567</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5610289</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0546</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586570</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES ANALOGUES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2404</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5965721</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE MODIFIED OLIGONUCLEOTIDES ANALOGUES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5061</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE-MODIFIED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1713</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5618704</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BACKBONE-MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION TH EREOF THROUGH RADICAL COUPLING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0097</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643720</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BINDING COMPETENT OLIGOMERS CONTAINING 2&#8217;, 5&#8217; LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0122</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643720</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BINDING COMPETENT OLIGOMERS CONTAINING 2&#8217;, 5&#8217; LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0123</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693&#160;22&#160;640</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BINDING COMPETENT OLIGOMERS CONTAINING 2&#8217;, 5&#8217; LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0124</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643720</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BINDING COMPETENT OLIGOMERS CONTAINING 2&#8217;, 5&#8217; LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0125</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643720</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BINDING COMPETENT OLIGOMERS CONTAINING 2&#8217;, 5&#8217; LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0099</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5434257</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BINDING COMPETENT OLIGOMERS CONTAINING UNSATURATED 3&#8217;,5&#8217; AND 2&#8217;,5&#8217; LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0AT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0AU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2604995</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0BE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0CH</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0CN</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CN</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0DE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69514351</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0FR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0GB</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0IE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0NL</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0SE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763050</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDE AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDES AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-132.0USC1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6489464</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRANCHED OLIGONUCLEOTIDES AS PATHOGEN-INHIBITORY AGENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-128.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BUILDING BLOCKS WITH CARBAMATE INTERNUCLEOSIDE LINKAGES AND NOVEL OLIGONUCLEOTIDES DERIVED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2350</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6111085</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4070</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6166188</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4507</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6322987</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4802</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5239</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2951</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6277967</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBOHYDRATE OR 2&#8217;-MODIFIED OLIGONUCLEOTIDES HAVING ALTERNATING INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3863</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6326358</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBOHYDRATE OR 2&#8217;-MODIFIED OLIGONUCLEOTIDES HAVING ALTERNATING INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3868</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBOHYDRATE OR 2&#8217;-MODIFIED OLIGONUCLEOTIDES HAVING ALTERNATING INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4847</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARBOHYDRATE OR 2&#8217;-MODIFIED OLIGONUCLEOTIDES HAVING ALTERNATING INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5300</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0060</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651569</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0062</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0063</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0079</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2580091</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0080</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5093</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR DETECTING AND MODULATION RNA ACTIVITY AND GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0979</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6358931</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR MODULATING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4919</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6610663</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR MODULATING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0707</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5514786</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS FOR INHIBITING RNA ACTIVITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1787</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6262241</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUND FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5055</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS AND OLIGOMERIC COMPOUNDS COMPRISING NOVEL NUCLEOBASES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0282</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5359051</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS USEFUL IN THE SYNTHESIS OF NUCLEIC ACIDS CAPABLE OF CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4319</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4338</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3299</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6207819</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4528</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6462184</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5039</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS, PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF MIXED BACKBONE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1715</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5608046</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONJUGATED 4&#8217;-DESMETHYL NUCLEOSIDE ANALOG COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-175.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6372427</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COOPERATIVE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-175.1US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COOPERATIVE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-175.1WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COOPERATIVE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0984</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0985</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635023</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0989</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635023</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0990</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635023</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0991</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693&#160;31&#160;543.1</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0993</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635023</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1000</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">635023</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1003</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1006</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5719271</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1007</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104965</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1304</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5543507</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0462</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5359044</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CYCLOBUTYL OLIGONUCLEOTIDE SURROGATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1450</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6001841</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CYCLOBUTYL OLIGONUCLEOTIDE SURROGATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0628</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2122030</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0646</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2823959</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0629</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724447</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0633</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724447</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0634</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692 33 046.1</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0635</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724447</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0643</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724447</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0649</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6153737</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4470</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6395492</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5024</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5060</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5109</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5166</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5425</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5426</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE AND OTHER PROPERTIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0073</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5484908</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION DIRECTED BY OLIGONUCLEOTIDES CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0077</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6235887</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION DIRECTED BY OLIGONUCLEOTIDES CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0080</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0121</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692 32 816.5</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0072</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5594121</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0076</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5645985</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0082</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0084</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5830653</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0085-CPA2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6380368</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0079</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679508</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0081</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637965</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0083</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taiwan</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116354</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0120</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637965</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0143</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0145</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0152</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637965</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0153</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637965</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0016</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXONUCLEASE-RESISTANT OLIGONUCLEOTIDES AND METHODS FOR PREPARING THE SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0029</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5264564</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORMACETAL / KETAL LINKED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0031</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653504</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORMACETAL / KETAL LINKED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0033</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498843</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORMACETAL / KETAL LINKED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0034</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69027443</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORMACETAL / KETAL LINKED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0035</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498843</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORMACETAL / KETAL LINKED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0036</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498843</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORMACETAL / KETAL LINKED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0037</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5264562</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORMACETAL / KETAL LINKED OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3811</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6593466</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FUNCTIONALIZED OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0816</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">669353</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0841</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5623065</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2002</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5955589</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2454</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5856455</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4387</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4852</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5213</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0818</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2126691</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0819</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0821</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0822</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0823</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0824</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0825</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69232032</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0827</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0831</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0834</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0835</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0838</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3131222</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4383</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0839</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2825</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188858</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217;-MODIFIED MACROMOLECULES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4288</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGOMERS HAVING SITE SPECIFIC PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2003</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5090</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GUANIDINIUM FUNCTIONALIZED OLIGOMERS AND METHODS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4406</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6534639</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GUANIDINIUM FUNCTIONALIZED OLIGOMERS AND METHODS OF SYNTHESIS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1058</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HETEROATOMIC OLIGONUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1059</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HETEROATOMIC OLIGONUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1078</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2879973</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HETEROATOMIC OLIGONUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1245</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6087482</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HETEROATOMIC OLIGONUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1960</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5623070</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HETEROATOMIC OLIGONUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2421</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5777092</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HETEROATOMIC OLIGONUCLEOSIDE LINKAGES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1959</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5677437</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HETEROATOMIC OLIGONUCLEOTIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0AT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198073</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0AU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674158</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0BE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0CH</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9500143</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0CZ</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CZ</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0DE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69329755</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0DK</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0ES</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ES</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0FR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0GB</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0IE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0IT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0NL</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0SE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650493</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5652355</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.0USD1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6143881</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDE PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.1US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6346614</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDES PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-118.1USC1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBRID OLIGONUCLEOTIDES PHOSPHOROTHIOATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-224.1US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMPROVED REAGENTS AND PROCESS FOR SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-123.0USC2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5739308</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INTEGRATED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4723</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5272</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5273</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5274</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LABELED OLIGONUCLEOTIDES, METHODS FOR MAKING SAME, AND COMPOUNDS USEFUL THEREFOR</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1164</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5554746</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LACTAM NUCLEIC ACIDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4390</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0061</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIPOPHILIC OLIGONUCLEOTIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0BE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0DE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96904686</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0DK</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0ES</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ES</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0FI</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FI</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0GR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0LU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LX</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0PT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0SE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850300</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-191.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5968909</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF MODULATING GENE EXPRESSION WITH REDUCED IMMUNOSTIMULATORY RESPONSE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-146.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5847104</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF TRITIUM LABELING OLIGONUCLEOTIDE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-146.0USD1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF TRITIUM LABELING OLIGONUCLEOTIDE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-146.0USD2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5668262</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHOD OF TRITIUM LABELING OLIGONUCLEOTIDE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-152.0CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS AND COMPOUNDS FOR THE STEREOSELECTIVE ENRICHMENT OF OLIGONUCLEOTIDE DIASTEREOMERS AND OLIGONUCLEOTIDES THEREBY PRODUCED</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-152.0EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS AND COMPOUNDS FOR THE STEREOSELECTIVE ENRICHMENT OF OLIGONUCLEOTIDE DIASTEREOMERS AND OLIGONUCLEOTIDES THEREBY PRODUCED</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-152.0JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS AND COMPOUNDS FOR THE STEREOSELECTIVE ENRICHMENT OF OLIGONUCLEOTIDE DIASTEREOMERS AND OLIGONUCLEOTIDES THEREBY PRODUCED</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-152.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5750674</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS AND COMPOUNDS FOR THE STEREOSELECTIVE ENRICHMENT OF OLIGONUCLEOTIDE DIASTEREOMERS AND OLIGONUCLEOTIDES THEREBY PRODUCED</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3073</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6335437</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4101</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4105</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0AT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0BE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0CH</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0DE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">697 20 481.2</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0DK</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0ES</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ES</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0FI</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FI</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0FR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0GB</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0GR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3043738</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0IE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0IT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0LU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LX</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0MC</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MC</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0NL</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0PT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0SE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">928335</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4853</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS OF MODULATING PHARMACOKINETICS OF OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5400</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS OF MODULATING PHARMACOKINETICS OF OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5401</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS OF MODULATING PHARMACOKINETICS OF OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5402</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS OF MODULATING PHARMACOKINETICS OF OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-226.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5886165</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MIXED BACKBONE ANTISENSE OLIGONUCLEOTIDES CONTAINING 2&#8217;-5&#8217;-RIBONUCLEOTIDE- AND 3&#8217;-5&#8217;-DEOXYRIBONUCLEOTIDES SEGMENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-259.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MIXED-BACKBONE OLIGONUCLEOTIDES CONTAINING POPS BLOCKS TO OBTAIN REDUCED PHOSPHOROTHIOATE CONTENT</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-259.0USC1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MIXED-BACKBONE OLIGONUCLEOTIDES CONTAINING POPS BLOCKS TO OBTAIN REDUCED PHOSPHOROTHIOATE CONTENT</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0095</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5817781</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED INTERNUCLEOSIDE LINKAGES (H)</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0098</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6410702</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED INTERNUCLEOSIDE LINKAGES (II)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0150</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6683166</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED INTERNUCLEOSIDE LINKAGES (II)</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0056</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5596086</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED INTERNUCLEOSIDE LINKAGES HAVING ONE NITROGEN AND TWO CARBON ATOMS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1724</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5808023</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGNUCLEOTIDES INCORPORATING THIOL-DERIVATIZED NUC LEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4289</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6653458</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5110</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.2US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6476000</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF OLIGONUCLEOTIDE CPG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5054</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC AND OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC SUGAR MOIETIES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1832</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREF ROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1850</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3072127</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREF ROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1833</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739351</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1837</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739351</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1838</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739351</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1839</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">695&#160;26&#160;331.5</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1841</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739351</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1849</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739351</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5046</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM AND PROCESSES FOR PREPARING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0284</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5212295</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONOMERS FOR PREPARATION OF OLIGONUCLEOTIDES WITH CHIRALPHOSPHORUS LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1051</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5459255</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N2 SUBSTITUTED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1767</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">731807</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N2 SUBSTITUTED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1784</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N-2 SUBSTITUTED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3151</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6166199</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N-2 SUBSTITUTED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2407</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5808027</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N-2 SUBSTITUTED PURINES IN OLIGONUCLEOTIDES (as amended)</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0053</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5414077</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-NUCLEOSIDE LINKERS FOR CONVENIENT ATTACHMENT OF LABELS TO OLIGONUCLEOTIDES USING STANDARD SYNTHETIC METHODS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1085</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2140428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1086</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651759</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1090</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651759</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1091</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651759</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1092</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693 33 344.8</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1102</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651759</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4806</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1105</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3015464</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL 2&#8217;-O-ALKYL NUCLEOSIDES &amp; PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION &amp; USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0002</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5194599</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL HYDROGEN PHOSPHONODITHIOATE COMPOSITIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0003</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622930</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL HYDROGEN PHOSPHONODITHIOATE COMPOSITIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0005</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5565555</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL HYDROGEN PHOSPHONODITHIOATE COMPOSITIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2347</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6000000</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5866691</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL LACTAM NUCLEIC ACIDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3297</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6084082</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL LACTAM NUCLEIC ACIDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0134</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655937</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL NUCLEOSIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0136</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2089377</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL NUCLEOSIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0137</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544792</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL NUCLEOSIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0141</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544792</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL NUCLEOSIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0142</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69128250</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL NUCLEOSIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0143</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544792</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL NUCLEOSIDE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5052</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL PEPTIDE-CONJUGATED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5052WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL PEPTIDE-CONJUGATED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1917</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2184005</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL PHOSPHORAMIDATE AND PHOSPHOROTHIOAMIDATE OLIGOMERIC CO MPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1918</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">751948</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL PHOSPHORAMIDATE AND PHOSPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1923</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">751948</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL PHOSPHORAMIDATE AND PHOSPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0024</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5138045</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL POLYAMINE CONJUGATED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0290</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544757</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL POLYAMINE CONJUGATED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0510</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5218105</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOVEL POLYAMINE CONJUGATED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4804</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4948</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5377</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5378</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5379</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5399</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Docketed</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0311</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641565</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0314</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544824</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0318</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544824</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0319</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691 26 530.5</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0320</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544824</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0327</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544824</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0333</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5614617</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0330</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2089377</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0313</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0094</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5792608</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0128</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEOSIDE 5&#8217;-METHYLENE PHOSPHONATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0007</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEOSIDE HYDROGEN PHOSPHONODITHIOATE DIESTERS AND ACTIVATED PHOSPHONODITHIOATE ANALOGUES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4803</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3453</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6335434</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4732</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6500945</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1872</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6121433</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5214</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS THAT INCLUDE CARBOCYCLIC NUCLEOSIDES AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1720</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5792844</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3141</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6214551</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0713</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5489677</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITR OGEN ATOMS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1968</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2906</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6420549</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED DIMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5081</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED DIMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0032</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2071483</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1198</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6235886</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE AND NUCLEOTIDE AMINE ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4508</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6495671</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE AND NUCLEOTIDE AMINE ANALOGS, METHODS OF SYNTHESIS AND USE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5025</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE AND NUCLEOTIDE AMINE ANALOGS, METHODS OF SYNTHESIS AND USE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0049</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5486603</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE HAVING ENHANCED BINDING AFFINITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1014</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5783682</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE MIMICS HAVING NITROGEN-CONTAINING LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3138</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6271357</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE MIMICS HAVING NITROGEN-CONTAINING LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4729</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5023243</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHOD OF MAKING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2954</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6528631</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE-FOLATE CONJUGATES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0063</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES AND THEIR ANALOGS CAPABLE OF PASSIVE CELL MEMBRANE PERMEATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1169</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES BEARING ALKYLAMINO AND ALKYLENEGLYCOL SUBSTITUENTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3758</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6656730</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONJUGATED TO PROTEIN-BINDING DRUGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4921</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763518</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONJUGATED TO PROTEIN-BINDING DRUGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4922</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONJUGATED TO PROTEIN-BINDING DRUGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4923</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONJUGATED TO PROTEIN-BINDING DRUGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4942</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONJUGATED TO PROTEIN-BINDING DRUGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5246</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONTAINING 2&#8217;-O-MODIFIED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5426</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONTAINING 2&#8217;-O-MODIFIED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2014</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5587469</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES CONTAINING N-2 SUBSTITUTED PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3310</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6369209</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4877</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762212</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4878</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4879</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4898</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4949</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0727</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2121144</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2260</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5852188</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3306</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6239265</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5033</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5856462</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-227.1US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5067</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5067US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5067WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5068</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5068US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5068WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2012</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5587361</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CH IRAL PURITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2298A</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257972</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CH IRAL PURITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2299</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">698739</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CH IRAL PURITY</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2301</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CH IRAL PURITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2319</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CH IRAL PURITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4499</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CH IRAL PURITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4500</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CH IRAL PURITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2300</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CHIRAL PURITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3890</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6440943</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3895</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3914</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0746</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2693643</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SUBSTANTIALLY CHIRALLY PURE PHOPHORO THIOATE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0728</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655088</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SUBSTANTIALLY CHIRALLY PURE PHOSPHOROTHIOATE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0732</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655088</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SUBSTANTIALLY CHIRALLY PURE PHOSPHOROTHIOATE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0733</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655088</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SUBSTANTIALLY CHIRALLY PURE PHOSPHOROTHIOATE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0734</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692 32 699.5</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SUBSTANTIALLY CHIRALLY PURE PHOSPHOROTHIOATE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0743</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655088</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING SUBSTANTIALLY CHIRALLY PURE PHOSPHOROTHIOATE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0142</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6495672</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES INCLUDING 2-AMINOPYRIDINE AND 2-PYRIDONE C-NUCLEOSIDES UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3889</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES INCORPORATING BOTH 2-AMINOADENINE AND 5-SUBSTITUTED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4977</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES INCORPORATING BOTH 2-AMINOADENINE AND 5-SUBSTITUTED PYRIMIDINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0005</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586520</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES MODIFIED WITH AMIDE BACKBONES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0009</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586520</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES MODIFIED WITH AMIDE BACKBONES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0010</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692 30 935.7</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES MODIFIED WITH AMIDE BACKBONES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0011</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586520</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES MODIFIED WITH AMIDE BACKBONES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0019</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586520</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES MODIFIED WITH AMIDE BACKBONES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0021</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221806</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES MODIFIED WITH AMIDE BACKBONES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NVIS-0022</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES MODIFIED WITH AMIDE BACKBONES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1669</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5506212</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES WITH SUBSTANTIALLY CHIRALLY PURE PHOSPHOROT HIOATE LINKAGES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0868</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6448373</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHOSPHATE LINKED OLIGOMERS FORMED OF MONOMERIC DIOLS AND PROCESSES FOR PREPARING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1010</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5637684</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHOSPHORAMIDATE AND PHOSPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1935</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2972344</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHOSPHORAMIDATE AND PHOSPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4790</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHOSPHOROTHIOATE MONOESTER MODIFIED OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5192</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHOSPHOROTHIOATE MONOESTER MODIFIED OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2953</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6242589</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHOSPHOROTHIOATE OLIGONUCLEOTIDES HAVING MODIFIED INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4718</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PHOSPHOROTHIOATE OLIGONUCLEOTIDES HAVING MODIFIED INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5059</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">POLYALKYLENEAMINE-CONTAINING OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0019</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5399676</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREPARATION OF OLIGONUCLEOTIDES WITH INVERTED POLARITY AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0020</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5527899</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREPARATION OF OLIGONUCLEOTIDES WITH INVERTED POLARITY AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0022</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5721218</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREPARATION OF OLIGONUCLEOTIDES WITH INVERTED POLARITY AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0024</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641219</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREPARATION OF OLIGONUCLEOTIDES WITH INVERTED POLARITY AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0026</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREPARATION OF OLIGONUCLEOTIDES WITH INVERTED POLARITY AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5139</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-199.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6140482</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRIMARY PHOSPHORAMIDATEINTERNUCLEOSIDE LINKAGES AND OLIGONUCLEOTIDES CONTAINING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0105</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6005096</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES (as amended)</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0144</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES AND OLIGONUCLEOTIDES CONTAINING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0114</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6028183</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES AND OLIGONUCLEOTIDES CONTAINING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0100</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5502177</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0102</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719272</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0103</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0104</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5763588</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0116</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6007992</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0127</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6414127</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0137</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6617437</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0139</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0140</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0141</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0147</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0157</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719272</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0158</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719272</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0159</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719272</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0160</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719272</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1325</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6060592</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE NUCLEOSIDE COMPOUNDS AND OLIGONUCLEOSIDE COMPOUNDS CONTAINING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1874</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2180978</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3147</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6271358</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA-TARGETED 2&#8217;MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3972</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNA-TARGETED 2&#8217;MODIFIED OLIGONUCLEOTIDES THAT ARE CONFORMATIONALLY PREORGANIZED</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0460</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5681941</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1897</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2536</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5811534</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3152</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6232463</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4943</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3154</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6399754</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES (as amended)</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0385</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661662</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0404</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2104052</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0407</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5670633</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2042</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT &amp; MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0387</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GEN E EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0388</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2708</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6307040</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4789</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5207</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3454</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6093807</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR-MODIFIED 7 - DEAZA 7 - SUBSTITUTED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3683</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SYNTHETIC METHODS AND INTERMEDIATES FOR TRIESTER OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3103</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6300319</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TARGETED OLIGONUCLEOTIDE CONJUGATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4799</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6525031</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TARGETED OLIGONUCLEOTIDE CONJUGATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5092</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6660720</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TARGETED OLIGONUCLEOTIDE CONJUGATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0784</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5578718</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIOL-DERIVATIZED NUCLEOSIDE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1673</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1690</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3256236</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4100</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6265558</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1992</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5852182</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIOL-DERIVATIZED OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2661</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6114513</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIOL-DERIVATIZED OLIGONUCLEOSIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0025</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2071536</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRIPLE HELIX FORMATION IN OLIGONUCLEOTIDE THERAPY</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-151.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5693773</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRIPLEX-FORMING ANTISENSE OLIGONUCLEOTIDES HAVING ABASIC LINKERS THAT TARGET NUCLEIC ACIDS COMPRISING MIXED SEQUENCES OF PURINES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1163</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6000000</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5629152</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRISUBSTITUTED BATA-LACTAMS AND OLIGO BETA-LACTAMAMIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0AT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187645</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0AU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3893095</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0BE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2203652</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0CH</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0CN</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CN</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1170367</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0DE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69513998</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0DK</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0ES</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ES</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2141393</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0FR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0GB</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0GR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0IE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0IT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0LU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LX</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0MC</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MC</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0NL</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0NO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Norway</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">971905</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0PT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-178.0SE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">788366</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF 2&#8217;-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:36.84%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Isis Current Chemistry Patents (June 2007 Updates)</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Isis Docket Number</p></td>
<td valign="bottom"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Application&#160;Number</p></td>
<td valign="bottom"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0030US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/679,159</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">BACKBONE MODIFICATIONS TO MODULATE OLIOGONUCLEOTIDE TARGETING IN VIVO</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-5772</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/283,119</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A-DNA FORM AND B-DNA FORM CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:36.84%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Isis Future Chemistry Patents (as at June&#160;27, 2007)</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Isis Docket Number</p></td>
<td valign="bottom"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Application&#160;Number</p></td>
<td valign="bottom"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0019AU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2004270741</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0019CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2538174</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0019EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4788694</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0019JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2006-526330</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0019WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2004/029650</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0020AU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2004320622</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC GAPPED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0020CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TBD</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC GAPPED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0020EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4754188.3</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC GAPPED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0020JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2007-515019</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC GAPPED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0020USA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/569,941</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC GAPPED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0020WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2004/017522</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC GAPPED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0022EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4754153.7</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">POSITIONALLY MODIFIED SIRNA CONSTRUCTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0022USA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/569,939</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">POSITIONALLY MODIFIED SIRNA CONSTRUCTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0022WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2004/017485</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">POSITIONALLY MODIFIED SIRNA CONSTRUCTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0023US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/251,564</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOSITIONS AND METHODS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0026US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0026USA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/574,396</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0026WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2005/031269</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0027US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/627,964</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0027US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/747,042</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUNDS AND METHODS FOR SYNTHESIS OF BICYCLIC NUCLEIC ACID ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0027WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2007/061183</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0029US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/747,057</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5&#8217;-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Isis Docket Number</p></td>
<td valign="bottom"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Application&#160;Number</p></td>
<td valign="bottom"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0029US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXPIRED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60/747,059</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5&#8217;-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0029WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2007/68690</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5&#8217;-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0030US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60/820,431</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BICYCLIC CYCLOHEXOSE NUCLEIC ACID ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0035US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60/890,079</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5&#8217;-SUBSTITUTED-2&#8217;-F MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0036US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60/871,397</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING A MODIFIED HEMIMER MOTIF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0037US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60/895,019</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BICYCLIC CYCLOHEXITOL NUCLEIC ACID ANALOGS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0026EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4788713.8</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0026US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/936,273</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0026WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2004/029821</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0030EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4788853.2</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGONUCLEOTIDES OPTIMIZED FOR KIDNEY TARGETING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0030US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/946,498</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGONUCLEOTIDES OPTIMIZED FOR KIDNEY TARGETING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0030WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2004/030785</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGONUCLEOTIDES OPTIMIZED FOR KIDNEY TARGETING</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0051AU</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2005286738</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED ANTISENSE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0051CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2580504</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED ANTISENSE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0051EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5798891.7</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED ANTISENSE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0051JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TBD</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED ANTISENSE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0051US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/231,243</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED ANTISENSE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0051WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCT/US2005/033837</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENHANCED ANTISENSE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0070US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60/852,894</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0172</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/921,734</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PYRIMIDINE DERIVATIVES FOR LABELED BINDING PARTNERS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GLIS-0173</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABANDONED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/064,374</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-175.1CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2473906</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COOPERATIVE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-175.1EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3732025.6</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COOPERATIVE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-175.1JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABANDONED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2003-562339</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COOPERATIVE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5213US.C1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/457,703</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5213US.C2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/457,715</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5475</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GRANTED (Reissue Patent)</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/925,348</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">METHODS AND COMPOSTIONS COVERING CHIMERIC OLIOMERS (GAPMERS) HEMIMERS AND [HAVING (Sp)n-(Rp)m-(Sp)p] WHERE THE CONFIGURATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5481</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/859,825</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5553</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2003228477</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5554</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2482440</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5555</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3726231.8</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5582</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/510,667</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="top"  style="width:50.66%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Isis Current Motif and Mechanism Patents (June 2007 Updates)</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Isis Docket Number</p></td>
<td valign="bottom"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent&#160;Number</p></td>
<td valign="bottom"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0005US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0004US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CROSS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0004WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CROSS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0005US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0005WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0008US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0009US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR AND BACKBONE-SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS0002-108</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5203</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO CYTOSINE AND URACIL OR THYMINE AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5301</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5312</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5313</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-FLUORO SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5314</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5326</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0004US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CROSS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0007US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0007US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-PHOSPHOROUS-LINKED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0008US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE GUANINE AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0009US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR AND BACKBONE-SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0012US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STRUCTURAL MOTIFS, AND OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0012US.P1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STRUCTURAL MOTIFS AND OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2197</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5898031</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2483</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2484</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6107094</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5207</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0002-104</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0002-105</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0002-106</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0002-107</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS0002-503</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2465</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2465EP.D1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2465EP.D2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4313</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4313US.C2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4313US.P2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5027</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0015US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROBE DESIGN FOR THE DETECTION OF RNAs IN CELL EXTRACTS, CELLS, AND TISSUES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0016US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0016US.L2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0016US.L3</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0016WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0016US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS0003-500</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5030</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5030.D1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5030EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0522</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0522.D2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0207</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">654816</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0209</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2082044</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0210</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529008</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0214</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529008</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0215</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69131848</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0216</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529008</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0223</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529008</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0226</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2800848</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1124</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PSEUDO-HALF-KNOT FORMATION BY HYBRIDIZATION OF ANTISENSE OLIGONUCLEOTIDE TO TARGET RNA&#8217;S SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1130</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PSEUDO-HALF-KNOT FORMATION BY HYBRIDIZATION OF ANTISENSE OLIGONUCLEOTIDE TO TARGET RNA&#8217;S SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1149</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3113280</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PSEUDO-HALF-KNOT FORMATION BY HYBRIDIZATION OF ANTISENSE OLIGONUCLEOTIDE TO TARGET RNA&#8217;S SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1241</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5512438</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INHIBITING RNA EXPRESSION BY FORMING A PSEUDO-HALF-KNOT RNA AT THE TARGET&#8217;S RNA SECONDARY STRUCTURE USING ANTISENSE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1420</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5866698</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0270</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF GENE EXPRESSION THROUGH INTERFERENCE WITH RNA SECONDARY STRUCTURE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5323</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-FLUORO SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5324</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217; METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0013US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2&#8217;-SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5321</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5322</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS COMPRISING ALTERNATING 2&#8217;-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5325</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS COMPRISING ALTERNATING 2&#8217;-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0001US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF THE RNA INTERFERENCE PATHWAY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0001US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF THE RNA INTERFERENCE PATHWAY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0001WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODULATION OF THE RNA INTERFERENCE PATHWAY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0004US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISOFORM-SPECIFIC TARGETING OF SPLICE VARIANTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0004WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISOFORM-SPECIFIC TARGETING OF SPLICE VARIANTS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0027US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EFFICIENT REDUCTION OF TARGET RNA&#8217;s BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0027WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EFFICIENT REDUCTION OF TARGET RNA&#8217;s BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC COMPOUNDS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1962</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGONUCLEOTIDES FOR MODULATING GENE EXPRESSION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0328</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0332</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NZ</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332999</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0384</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6232296</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INHIBITION OF COMPLEMENT ACTIVATION AND COMPLEMENT MODULATION BY USE OF MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0760</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INHIBITION OF COMPLEMENT ACTIVATION AND COMPLEMENT MODULATION BY USE OF MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISPH-0327</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712228</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0026US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1399</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691853</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGOS WHICH INTERFERE WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1401</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691853</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGOS WHICH INTERFERE WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1403</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691853</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGOS WHICH INTERFERE WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1404</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69430740.8</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGOS WHICH INTERFERE WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1405</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691853</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGOS WHICH INTERFERE WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1415</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691853</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGOS WHICH INTERFERE WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0030US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANTISENSE OLIGONUCLEOTIDES OPTIMIZED FOR KIDNEY TARGETING DEMONSTRATE INCREASED EFFICACY IN MICE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0006US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0029US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOUBLE STRANDED COMPOSITIONS COMPRISING A PHOSPHOROTHIOATE RNA REGION AND A 3&#8217;-ENDO REGION FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CORE0029US.L2</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOUBLE STRANDED COMPOSITIONS COMPRISING AN RNA REGION AND A 3&#8217;-ENDO REGION FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4730</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5919619</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHODS OF MAKING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4502</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDE THERAPEUTIC AGENT AND METHODS OF MAKING SAME</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0002US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0014US.L</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHIMERIC OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0001US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGONUCLEOTIDES FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHEM0001WO</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MODIFIED OLIGONUCLEOTIDES FOR USE IN GENE MODULATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0816</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">669353</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0841</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5623065</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2002</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5955589</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2454</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5856455</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-3153</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6146829</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4291</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6326199</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4387</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4852</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-5213</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0818</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2126691</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0819</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0821</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0822</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0823</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0824</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0825</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69232032</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0827</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0831</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0834</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0835</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618925</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0838</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3131222</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4383</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-0839</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217; MODIFIED PHOSPHOROTHIOATE OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2825</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188858</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED 2&#8217;-MODIFIED MACROMOLECULES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-4288</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGOMERS HAVING SITE SPECIFIC PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-2003</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAPPED OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0AT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0BE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0CA</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0CH</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0DE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">696 28 864.8</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0DK</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DK</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0EP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0EPD1</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0ES</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ES</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0FI</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FI</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0FR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0GB</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0GR</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0IE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0IT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0JP</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0NL</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NL</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0PT</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PT</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0SE</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1019428</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.0US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5652356</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.1US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5973136</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HYBN-198.2US</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5773601</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INVERTED CHIMERIC AND HYBRID OLIGONUCLEOTIDES</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1203</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NZ</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256787</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1204</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668604</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1207</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">672193</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1211</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FR</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">672193</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1212</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GB</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">672193</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1223</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CH</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">672193</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1206</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2145664</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1226</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2818031</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1229</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5952490</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISIS-1213</p></td>
<td valign="top"  style="width:11.9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DE</p></td>
<td valign="top"  style="width:13.56%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:13.82%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693 32 206.3</p></td>
<td valign="top"  style="width:49.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OLIGONUCLEOTIDES HAVING A CONSERVED G4 CORE SEQUENCE</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="5" valign="top"  style="width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Isis Current Mechanism and Motif Patents (June 2007 Updates)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Isis Docket Number</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0005EP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">6/18/2004</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0005USA</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">5/5/2006</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CHEM0021EP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CHEM0021USA</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CHEM0021WO</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0005WO</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0026EP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0027EP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0036US</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0041US</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0043EP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0043USA</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0043WO</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0052US.L</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EXPIRED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0052US.L2</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EXPIRED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055AU</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055CA</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055EP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055JP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C1</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C10</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C2</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C3</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C4</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C5</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C6</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C7</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C8</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055US.C9</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055USA</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0055WO</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056AU</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056CA</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056EP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056JP</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">JP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056US.C1</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056US.C2</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056US.C3</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056US.C4</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056USA</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0056WO</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INACTIVE</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0060WO2</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0066WO</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0068WO</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">WO</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-2965EP.D1</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-2965EP.D2</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-5482</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-5586</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-5737</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AU</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-5738</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CA</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISIS-5739</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FILED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0054US.L</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EXPIRED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CORE0053US.L</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:15%;white-space:nowrap;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EXPIRED</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our&#160;Ref.&#160;No.</p></td>
<td valign="bottom"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">CaseType</p></td>
<td valign="bottom"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Application No.</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent No.</p></td>
<td valign="bottom"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2004263832</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2004263832</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PI0411219.9</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ExamReq</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Brazil</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2528510</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">200480022894.9</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abandoned</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">China (People&#8217;s Republic)</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04776661.3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Patent Convention</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DIV</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10180048.0</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Patent Convention</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DIV</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10180047.2</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Patent Convention</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">5572/DELNP/2005</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">India</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">172268</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abandoned</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Israel</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2006-533810</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ExamReq</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DIV</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2011-148461</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ORD</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US2004/019229</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Cooperation Treaty</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">200507781-3</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">117818</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DIV</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">200704437-3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/560377</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United States of America</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PRO</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">60/478,076</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United States of America</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">13/065601</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United States of America</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-006</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CON</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">13/234698</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United States of America</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005319306</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2592099</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05854816.5</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1833967</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Patent Convention</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DIV</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10010655.8</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abandoned</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">European Patent Convention</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EPP</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05854816.5</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1833967</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EPP</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05854816.5</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1833967</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-548393</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Abandoned</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ORD</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US2005/046162</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Cooperation Treaty</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EPP</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05854816.5</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1833967</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PRO</p></td>
<td valign="top"  style="width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">60/638,294</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United States of America</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.36%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NUCL-010</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Not Filed</p></td>
<td valign="top"  style="width:14%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United States of America</p></td>
<td valign="top"  style="width:34.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Ref. No.</p></td>
<td valign="bottom"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Application&#160;No.</p></td>
<td valign="bottom"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent No.</p></td>
<td valign="bottom"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Application Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AT1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E297.463</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AT2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E418.60</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2000032713</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">778474</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AU1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005201044</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005201044</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3AUD2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2008202208</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Opposed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CA</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2,359,180</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2,359,180</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CH1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CH2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CY1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CY05/1101016</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3CY2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE0</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50000414.5-08</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1144623</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50010528.6-08</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1214945</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DE2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DED1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066235.8</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066235.8</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DED2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066344.3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DED3</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10066382.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DEUTM</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">20023125.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE20023125&#160;U1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RegUtilMode</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DK1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1214945 B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3DK2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02003683.6</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1214945</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD3</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">06025389.5</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3EPD4</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10011217.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3ES1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ES2243608</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3ES2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FI1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Finland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FI2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Finland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FR1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3FR2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GB1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1214945</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GB2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GR1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Greece</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">3054579</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3GR2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Greece</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 00910510</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1144623 B9</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revoked</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IE2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IT1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3IT2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD10</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2009-285706</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD3</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-186341</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD4</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-186340</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD5</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-186339</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ExamReq</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD7</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2009-002825</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3JPD9</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2009-285705</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LI1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LI2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LU1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3LU2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3MC1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Monaco</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3MC2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Monaco</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3NL1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3NL2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3PT1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3PT2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3SE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02003683</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP&#160;1214945&#160;B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3SE2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05002454.6-2107</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1550719</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982325</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982305</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON3</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982425</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON4</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982441</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON5</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982345</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USCON6</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/982434</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/382395</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/383099</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD3</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/382768</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3USD4</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/612179</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/DE00/00244</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-001.3ZA</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">South&#160;Africa</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ZA 20015909</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2001/5909</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND MEDICAMENT FOR INHIBITION THE EXPRESSION OF A DEFINED GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.1DE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10100586.5-09</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE10100586 C1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION IN CELLS, USEFUL FOR e.g., TREATING TUMORS, BY INTRODUCING DOUBLE-STRANDED COMPLEMENTARY OLIGORNA HAVING</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/894018</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4AT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E328.075</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4AU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002229701</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002229701</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4CH</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4CY</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4DE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50206993.7-08</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4EP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4GB</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02710786</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4IE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4JP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002-556740</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">4210116</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4JPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002-556739</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">4209678</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4LI</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4LU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4TR</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Turkey</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02710786.1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1352061</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,339</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,829,693</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-002.4WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/00152</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1DE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247.4- 2405/1349</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">50214866.9-08</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1EP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247.4</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1EPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10002422.3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1EPD2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10011812.4</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1ES</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ES2204360</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1FR</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02702247</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1GB</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02702247.4- 2405/1349</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1HKD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11100629.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1HKD2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11111936.1</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1NL</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP 02702247</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1349927</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.1WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/00151</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICAMENT FOR TREATING A TUMOR DISEASE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.2US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,260</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,473,525</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.2US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/276,270</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4AU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005284729</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4CA</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2580560</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4EP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05797892.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4EPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11004902.0</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4HK</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">07114036.0</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/941663</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7767802</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4USCIP2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/229183</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7423142</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4USCON2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/961337</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4USD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/175,938</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,868,160</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-006.4WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US2005/033 309</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI- APOPTOTIC GENES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.2DE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE 10163098</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DE10163098</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INHIBITING THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.3USCIP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,512</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,348,314</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD TO INHIBIT THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.3USCON</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/959,936</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,745,418</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD TO INHIBIT THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-008.3USCON1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/631689</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD TO INHIBIT THE REPLICATION OF VIRUSES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-011.2WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/11973</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF DOUBLE STRAND RIBONUCLEIC ACID FOR TREATING AN INFECTION WITH A POSTIVE-STRAND RNA-VIRUS</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.2EP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02779511.1</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF A DOUBLE-STRANDED RIBONUCLEIC ACID FOR SPECIFICALLY INHIBITING THE EXPRESSION OF A GIVEN TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.2EPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10011813.2</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF A DOUBLE-STRANDED RIBONUCLEIC ACID FOR SPECIFICALLY INHIBITING THE EXPRESSION OF A GIVEN TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.2WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/11969</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">USE OF A DOUBLE-STRANDED RIBONUCLEIC ACID FOR SPECIFICALLY INHIBITING THE EXPRESSION OF A GIVEN TARGET GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.3US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/384,463</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,763,590</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF A MUTANT GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.3USCON1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">13/177316</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF A MUTANT GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-012.3USD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/817009</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7994309</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF A MUTANT GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-013.1WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/11972</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DRUG FOR TREATING A FIBROTIC DISEASE THROUGH RNA INTERFERENCE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-014.1WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP02/12221</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SMAD7 INHIBITORS FOR THE TREATMENT OF CNS DISEASES</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.2US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/349,320</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,196,184</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RNA (dsRNA) AND METHOD FOR USE FOR INHIBITING EXPRESSION OF A FUSION GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.2USCON1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/912616</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RNA (dsRNA) AND METHOD FOR USE FOR INHIBITING EXPRESSION OF A FUSION GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.2USD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/656,349</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,846,907</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RNA (dsRNA) AND METHOD FOR USE FOR INHIBITING EXPRESSION OF A FUSION GENE</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-015.3WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/EP03/00604</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD FOR INCREASING THE EFFICIENCY OF AN INHIBITOR OF TYROSINE KINASE ACTIVITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.1DE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10302421.2-41</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DOUBLE-STRANDED RIBONUCLEIC ACID WITH IMPROVED ACTIVITY</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2AT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">E367441</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2AU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2004206255</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2004206255</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2AUD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2008203538</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2BE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2CA</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2513809</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2513809</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2CH</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2CY</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2DE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">602004007620.1-08</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2DK</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DK/EP&#160;1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2EP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2EPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">07010839.4</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2ES</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2FR</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2GB</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2HK</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong&#160;Kong</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">08105048.3</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2HU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hungary</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2IE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2IT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2LI</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2LU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2NL</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926B1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2PT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2SE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2SI</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Slovenia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2TR</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Turkey</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04704041.5-1521</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1587926</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/543048</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-016.2WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US2004/001 461</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RIB-017.1EPUS</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">60/479,354</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Converted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SiRNA WITH INCREASED STABILITY IN SERUM</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EXHIBIT B</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">IN-LICENSES COVERING ALNYLAM PATENT RIGHTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">B.1.&#160;&#160;&#160;&#160;In-Licenses Covering Base Alnylam Patent Rights </font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Co-Exclusive License Agreement between Garching Innovation GmbH and Alnylam Pharmaceuticals, Inc., (effective December&#160;20, 2002) and Amendment (effective 8&#160;July, 2003). </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amended and Restated Strategic Collaboration and License Agreement effective as of April&#160;28, 2009, between Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">B.2.&#160;&#160;&#160;&#160;In-Licenses Covering Additional Alnylam Patent Rights Stanford </font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Co-Exclusive License Agreement between THE BOARD OF TRUSTEES OF THE LELAND Stanford JUNIOR UNIVERSITY and Alnylam Pharmaceuticals, Inc., (effective September&#160;17, 2003) </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cancer Research Technology Limited </font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Exclusive License Agreement between CANCER RESEARCH TECHNOLOGIES LIMITED and Alnylam Pharmaceuticals, Inc., (effective July&#160;18, 2003) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EXHIBIT C</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">RESEARCH COLLABORATION PLAN</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">[Reserved.]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT D </p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRESS RELEASE </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contacts:</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alnylam Pharmaceuticals, Inc.</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cynthia Clayton</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Levitan</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Investor Relations and</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Trout Group, LLC</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Communications</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646-378-2920</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617-551-8207</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ir@arrowres.com</font></p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amanda Sellers (Media)</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spectrum</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202-955-6222 x2597</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alnylam and Arrowhead Form Collaboration and Licensing Agreement</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8211; Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Toward Hepatitis B Virus (HBV) &#8211;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#8211; Alnylam Gains Access to Arrowhead&#8217;s Dynamic Polyconjugate (DPC)</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Delivery Technology for &#8220;Alnylam 5x15&#8221; Target &#8211;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, Mass. and Pasadena, Calif., January&#160;5, 2012<font style="font-weight:normal;"> &#8211; </font><font style="text-decoration:underline;font-weight:normal;">Alnylam Pharmaceuticals, Inc.</font><font style="font-weight:normal;"> (Nasdaq: ALNY), a leading RNAi therapeutics company, and </font><font style="text-decoration:underline;font-weight:normal;">Arrowhead Research Corporation</font><font style="font-weight:normal;">, (Nasdaq: ARWR) a nanomedicine company with development programs in RNAi and obesity, announced today that they have entered into a collaboration and joint licensing agreement. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alnylam has granted Arrowhead a license under its intellectual property that enables the discovery, development, and commercialization of an RNAi therapeutic targeting the hepatitis B virus (HBV). Alnylam is eligible to receive from Arrowhead milestone payments and royalties on sales of product resulting from the license. In addition, Alnylam has received a license from Arrowhead to utilize their <font style="text-decoration:underline;">Dynamic Polyconjugate</font> (DPC) delivery technology for an RNAi therapeutic product. Alnylam expects to deploy this technology for an undisclosed target in its &#8220;<font style="text-decoration:underline;">Alnylam 5x15</font>&#8221; pipeline which is focused on genetically defined targets and diseases. Arrowhead is eligible to receive from Alnylam milestone payments and royalties on sales of product resulting from the license. No additional financial details were disclosed. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We view Arrowhead&#8217;s DPC technology as a promising emerging delivery approach, with the potential to complement our existing delivery platform which currently includes lipid nanoparticles and our siRNA conjugate platform,&#8221; said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. &#8220;In addition, by granting Arrowhead a license for their HBV program, we are enabling their efforts with access to Alnylam intellectual property which we believe is critical for the development and commercialization of RNAi therapeutics. We look forward to continuing to work with Arrowhead, who is already a partner and licensee of Alnylam.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;This license from Alnylam is an important step for us as we expand our pipeline to include our first DPC-enabled candidate targeting hepatitis B,&#8221; said Christopher Anzalone, Ph.D., President and CEO of Arrowhead. &#8220;With over 350&#160;million carriers world-wide, HBV represents a large underserved medical need, and one that RNAi and DPCs are well-suited to address. We are also very pleased to grant Alnylam the first commercial license to our DPC technology for one of their genetically defined disease targets. We believe DPCs represent one of the most promising delivery approaches for the systemic delivery of RNAi therapeutics, and we look forward to a close collaboration to help Alnylam bring a DPC-enabled candidate to the clinic.&#8221; </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About RNA Interference (RNAi) </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as &#8220;a major scientific breakthrough that happens once every decade or so,&#8221; and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNAs (siRNAs), the molecules that mediate RNAi and comprise Alnylam&#8217;s RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About DPC Technology </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dynamic Polyconjugate (DPC) technology is a systemic siRNA delivery platform that enables polymer-based formulation chemistry to efficiently target gene silencing complexes to specific cells. As the DPCs attach to and enter the target cells, they respond to the environmental cues provided by the cell to disassemble and release the active siRNA molecule. This unique chemistry mimics the natural viral targeting and disassembly process. Pre-clinical studies show that DPCs are highly efficacious for delivery to the liver. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About &#8220;Alnylam 5x15&#8482;&#8221; </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The &#8220;Alnylam 5x15&#8221; strategy, launched in January 2011, establishes a path for development and commercialization of novel RNAi therapeutics to address genetically defined diseases with high unmet medical need. Products arising from this initiative share several key characteristics including: a genetically defined target and disease; the potential to have a major impact in a high unmet need population; the ability to leverage the existing Alnylam RNAi delivery platform; the opportunity to monitor an early biomarker in Phase I clinical trials for human proof of concept; and the existence of clinically relevant endpoints for the filing of a new drug application (NDA) with a focused patient database and possible accelerated paths for commercialization. This strategy leverages Alnylam&#8217;s clinical progress on siRNA delivery, including definitive human proof-of-concept data for systemic delivery. By the end of 2015, the company expects to have five such RNAi therapeutic programs in advanced clinical development. These include ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, ALN-APC for the treatment of hemophilia, and one additional program from the company&#8217;s ongoing discovery efforts that will be designated at or around the end of 2011. Alnylam intends to focus on developing and commercializing certain products arising under the &#8220;Alnylam 5x15&#8221; strategy itself in the United States and potentially certain other countries; the company will seek development and commercial partners for other core products both in the United States and in other global territories. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About Alnylam Pharmaceuticals </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia. As part of its<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top"> </sup></font>&#8220;Alnylam 5x15<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">TM</sup></font>&#8221; strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015. Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington&#8217;s disease. The company&#8217;s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam&#8217;s VaxiRNA&#8482; platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world&#8217;s top scientific journals such as <font style="font-style:italic;">Nature</font>, <font style="font-style:italic;">Nature Medicine</font>, <font style="font-style:italic;">Nature Biotechnology</font>, and <font style="font-style:italic;">Cell</font>. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit <font style="text-decoration:underline;">www.alnylam.com</font>. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About Arrowhead Research Corporation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead&#8217;s world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company&#8217;s lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and Adipotide&#8482;, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic Polyconjugate&#8482; (DPC), Liposomal Nanoparticle (LNP), and RONDEL&#8482; delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies. For more information, please visit <font style="text-decoration:underline;">www.arrowheadresearch.com</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alnylam Forward-Looking Statements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various statements in this release concerning Alnylam&#8217;s future expectations, plans and prospects, including without limitation, statements regarding Alnylam&#8217;s views with respect to the potential for RNAi therapeutics and DPC technology, and Alnylam&#8217;s expectations regarding its &#8220;Alnylam 5x15&#8221; product strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Alnylam&#8217;s ability to discover and develop novel drug candidates, successfully demonstrate the efficacy and safety of its drug candidates, including those utilizing DPC technology, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, obtaining regulatory approval for products, competition from others using technology similar to Alnylam&#8217;s and others developing products for similar uses, as well as those risks more fully discussed in the &#8220;Risk Factors&#8221; section of its most recent quarterly report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Alnylam&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam does not assume any obligation to update any forward-looking statements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Forward-Looking Statements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This news release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation&#8217;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT E </p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM CRT ADDITIONAL PATENT RIGHTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Ref. No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application&#160;No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PatNumber</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ApplicationStatus</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001AU1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">200114065&#160;B2</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">774285</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING&#160;GENE&#160;EXPRESSION&#160;WITH&#160;DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001AT1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Austria</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING&#160;GENE&#160;EXPRESSION&#160;WITH&#160;DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001BE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Belgium</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001CA1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2391622</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ExamReq</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001CY1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cyprus</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001DK1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Denmark</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001EP1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1230375B1</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001FI1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Finland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001FR1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">France</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001DE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Germany</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001DE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Greece</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001HK1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong Kong</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">03100785.6</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1050378</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001IE1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ireland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001IL1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Israel</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">149666</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001IT1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Italy</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001JP1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2001-538524</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001JPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Not Filed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001LV1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Latvia</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EP1230375B1</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001LI1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liechtenstein</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001LU1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Luxembourg</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001MX1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mexico</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PA/a/2002/005013</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001MC1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Monaco</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001NL</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Netherlands</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001NZ</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Zealand</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">519325</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">519325</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001NZ1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Norway</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">20022359</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001PL</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Poland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">P356698</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001PL1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Poland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">P388605</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001PT1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Portugal</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001SG1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Singapore</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">200203380-1</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">89569</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001ZA1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">South Africa</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002-3816</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002/3816</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001ES</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Spain</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001SE</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sweden</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001CH</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Switzerland</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001TR1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Turkey</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001GB0</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United&#160;Kingdom</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001GB1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">00976188.3</p></td>
<td valign="top"  style="width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1230375</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GrantedInOp</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001US1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/150426</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001USCON1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/933121</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CRT-001USCON2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/933,153</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12.5%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">INHIBITING GENE EXPRESSION WITH DSRNA</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT F </p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALNYLAM STANFORD ADDITIONAL PATENT RIGHTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Our Ref. No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Application No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Patent&#160;No.</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN 001.4US1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/259226</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF VIRAL GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN&#160;001.4USCON1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/368,082</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF VIRAL GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN 001.4USCON2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/576052</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF VIRAL GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.1USPRO1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">60/307,411</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR IN VIVO DELIVERY OF A NAKED RIBONUCLEIC ACID INTO A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.2USPRO1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">60/360,664</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR IN VIVO DELIVERY OF A NAKED RIBONUCLEIC ACID INTO A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3AU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2002326410</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accepted</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3AUD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2009200231</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3CA</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2,454,183</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3EP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">02761123.5</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3EPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10178509.5</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3HK</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hong&#160;Kong</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">04108019.6</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3JP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2003-515539</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3JPD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2007-511489</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3JPD2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2010-249697</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US02/22869</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-001.3US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">10/200002</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Appealed</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHOD AND COMPOSITIONS FOR RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMALS</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003AU</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2005240118</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Opposed</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003AUD1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Australia</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003CA</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2564503</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003EP</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">05749437.9</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003IL</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Israel</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">178679</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pending</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003WO</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PCT/US2005/015264</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CompletedNt</p></td>
<td valign="bottom"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003US</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/122,328</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,307,067</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Allowed</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003USCON1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">12/950672</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Published</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003USCON2</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">11/953,705</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">7,838,504</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
<tr>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">STN-003USPRO1</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">US</p></td>
<td valign="top"  style="width:14%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">60/568,358</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Converted</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>arwr-ex31_201406306.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Research Corporation, certify that: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Research Corporation; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:59%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 12, 2014</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ C<font style="font-size:7.5pt;">HRISTOPHER</font> A<font style="font-size:7.5pt;">NZALONE</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>arwr-ex31_201406307.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Research Corporation, certify that: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Quarterly Report on Form 10-Q of Arrowhead Research Corporation; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 12, 2014</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski,</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>arwr-ex32_201406308.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Research Corporation (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section&#160;1350, that (i)&#160;the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2014, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii)&#160;the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 12, 2014</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ C<font style="font-size:7.5pt;">HRISTOPHER</font> A<font style="font-size:7.5pt;">NZALONE</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of these written statements required by 18 U.S.C. Section&#160;1350 has been provided to Arrowhead Research Corporation and will be retained by Arrowhead Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>arwr-ex32_201406309.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
<body>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Research Corporation (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section&#160;1350, that (i)&#160;the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2014, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii)&#160;the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="top"  style="width:59%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 12, 2014</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kenneth A. Myszkowski</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of these written statements required by 18 U.S.C. Section&#160;1350 has been provided to Arrowhead Research Corporation and will be retained by Arrowhead Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>arwr-20140630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Instance Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2014-08-12T15:59:41.1142645+00:00 -->
<!-- Version            : 1.9.0.3 -->
<!-- Package ID         : F4AAA9047B9D167BE0DC1A89763CCCBA-0000879407-001406 -->
<!-- Copyright (c) 2014 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:arwr="http://www.arrowheadresearch.com/20140630" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="arwr-20140630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <context id="C_0000879407_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_20140811">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <instant>2014-08-11</instant>
    </period>
  </context>
  <context id="C_0000879407_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_20140401_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_20130401_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_20121001_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:NoncontrollingInterestMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtFiveDollarAndEightySixCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtFiveDollarAndEightySixCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtFiveDollarAndEightySixCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PreferredStockMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:PreferredStockIssuedAtThousandDollarsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:PreferredStockIssuedAtThousandDollarsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:PreferredStockIssuedAtThousandDollarsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedToGallowayMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedToGallowayMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedToGallowayMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:NoncontrollingInterestMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:NoncontrollingInterestMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtFiveDollarAndEightySixCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:PreferredStockIssuedAtThousandDollarsPerShareMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_20120930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_20140218">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:IssuedToGallowayMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-02-18</instant>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrRocheMadisonMember_20121021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:RocheMadisonMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-10-21</instant>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrRocheMadisonMember_20121020_20121021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:RocheMadisonMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-20</startDate>
      <endDate>2012-10-21</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FinancialInstrumentAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WarrantMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ExchangeRightsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapSummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis_us-gaapBondsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:BondsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRangeAxis_us-gaapMinimumMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRangeAxis_us-gaapMaximumMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:CommercialNotesDueWithinOneYearMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueAfterOneYearWithinThreeYearsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:CommercialNotesDueAfterOneYearWithinThreeYearsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:CommercialNotesDueWithinOneYearMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueAfterOneYearWithinThreeYearsMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:CommercialNotesDueAfterOneYearWithinThreeYearsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20111021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:BusinessAcquisitionAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:RocheMadisonMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-10-21</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:BusinessAcquisitionAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:RocheMadisonMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:BusinessAcquisitionAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:RocheMadisonMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_20111001_20111021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-21</endDate>
    </period>
  </context>
  <context id="C_0000879407_20121001_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicensingAgreementsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_us-gaapRangeAxis_us-gaapMinimumMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PatentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_us-gaapRangeAxis_us-gaapMaximumMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PatentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:LicensingAgreementsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20140401_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PatentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PatentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20130401_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PatentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20121001_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:PatentsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:CalandoPharmaceuticalsIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:CalandoPharmaceuticalsIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20101001_20110930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:AblarisTherapeuticsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20110930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:AblarisTherapeuticsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:AblarisTherapeuticsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_deiLegalEntityAxis_arwrLeonardoBiosystemsIncMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="dei:LegalEntityAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:LeonardoBiosystemsIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SeriesBPreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SeriesCPreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrPurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrPurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_20131011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <instant>2013-10-11</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20131011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SeriesCPreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-10-11</instant>
    </period>
  </context>
  <context id="C_0000879407_20131010_20131011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2013-10-10</startDate>
      <endDate>2013-10-11</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20131010_20131011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:StatementClassOfStockAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:SeriesCPreferredStockMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-10</startDate>
      <endDate>2013-10-11</endDate>
    </period>
  </context>
  <context id="C_0000879407_20140223_20140224">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <startDate>2014-02-23</startDate>
      <endDate>2014-02-24</endDate>
    </period>
  </context>
  <context id="C_0000879407_20140224">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
    </entity>
    <period>
      <instant>2014-02-24</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantOneMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantOneMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantTwoMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantTwoMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantThreeMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantThreeMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFourMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantFourMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFiveMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantFiveMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSixMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantSixMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSevenMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantSevenMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantEightMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantEightMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantOneMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantOneMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantTwoMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantTwoMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantThreeMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantThreeMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFourMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantFourMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFiveMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantFiveMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSixMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantSixMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSevenMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantSevenMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantEightMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:WarrantEightMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_arwrCorporateHeadquartersInPasadenaMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:CorporateHeadquartersInPasadenaMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_arwrResearchFacilityInMadisonMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ResearchFacilityInMadisonMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapMajorPropertyClassAxis_us-gaapAssetsHeldUnderCapitalLeasesMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:MajorPropertyClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:AssetsHeldUnderCapitalLeasesMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsStockOptionPlanMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsStockOptionPlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsFourEquityIncentivePlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsThirteenIncentivePlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsFourEquityIncentivePlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:PlanNameAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsThirteenIncentivePlanMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRangeAxis_us-gaapMinimumMember_20121001_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRangeAxis_us-gaapMaximumMember_20121001_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RangeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20140401_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20130401_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20121001_20130630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ArrowheadMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:AwardTypeAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockUnitsRSUMember</explicitMember>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ArrowheadMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ArrowheadMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ArrowheadMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel3Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueMeasurementsRecurringMember</explicitMember>
        <explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel3Member</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrUnidymIncMember_20110101_20110131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:UnidymIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrUnidymIncMember_20110131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:UnidymIncMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-01-31</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20120930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:DerivativeFinancialInstrumentsAssetsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20121001_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:DerivativeFinancialInstrumentsAssetsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:DerivativeFinancialInstrumentsAssetsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:DerivativeFinancialInstrumentsAssetsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByAssetClassAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:DerivativeFinancialInstrumentsAssetsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandTenWarrantsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandTenWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandsTwelveWarrantsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsTwelveWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandThirteenWarrantsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandThirteenWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandTenWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20121001_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandTenWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsTwelveWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20121001_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandsTwelveWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandThirteenWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20121001_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:TwoThousandThirteenWarrantsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20120930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FinancialInstrumentAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WarrantMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20121001_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FinancialInstrumentAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WarrantMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FinancialInstrumentAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WarrantMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FinancialInstrumentAxis" xmlns="http://xbrl.org/2006/xbrldi">us-gaap:WarrantMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:AblarisTherapeuticsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ExchangeRightsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20120930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ExchangeRightsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20130930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ExchangeRightsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20140630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
      <segment>
        <explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" xmlns="http://xbrl.org/2006/xbrldi">arwr:ExchangeRightsMember</explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0000879407_20131001_20140630">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0000879407_20131001_20140630">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0000879407_20131001_20140630">2014-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0000879407_20131001_20140630">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0000879407_20131001_20140630">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0000879407_20131001_20140630">ARWR</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0000879407_20131001_20140630">ARROWHEAD RESEARCH CORP</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0000879407_20131001_20140630">0000879407</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0000879407_20131001_20140630">--09-30</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0000879407_20131001_20140630">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000010" contextRef="C_0000879407_20140811" decimals="INF" unitRef="U_shares">52908567</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">138349733</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000012" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">19114444</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="F_000013" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">75000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000014" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">700063</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000015" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">532354</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000016" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">538742</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000017" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">91660</us-gaap:OtherAssetsCurrent>
  <us-gaap:MarketableSecuritiesCurrent id="F_000018" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">23834408</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent id="F_000019" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">9030261</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:AssetsCurrent id="F_000020" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">163422946</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000021" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">28843719</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000022" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">3674131</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000023" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">3513235</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000024" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">3199523</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000025" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">3240513</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:MarketableSecuritiesNoncurrent id="F_000026" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">26284862</us-gaap:MarketableSecuritiesNoncurrent>
  <us-gaap:MarketableSecuritiesNoncurrent id="F_000027" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">1702153</us-gaap:MarketableSecuritiesNoncurrent>
  <us-gaap:OtherAssetsMiscellaneousNoncurrent id="F_000028" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">41414</us-gaap:OtherAssetsMiscellaneousNoncurrent>
  <us-gaap:OtherAssetsMiscellaneousNoncurrent id="F_000029" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">30011</us-gaap:OtherAssetsMiscellaneousNoncurrent>
  <us-gaap:Assets id="F_000030" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">196622876</us-gaap:Assets>
  <us-gaap:Assets id="F_000031" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">37329631</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000032" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">2158133</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000033" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">1199632</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000034" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">1068667</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000035" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">638884</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000036" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">611092</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000037" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">905771</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000038" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">71875</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000039" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">103125</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DerivativeLiabilities id="F_000040" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">4018719</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="F_000041" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">4096363</us-gaap:DerivativeLiabilities>
  <us-gaap:CapitalLeaseObligationsCurrent id="F_000042" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">213110</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent id="F_000043" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">221345</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:NotesPayableCurrent id="F_000044" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">50000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent id="F_000045" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">971557</us-gaap:NotesPayableCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000046" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">58500</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000047" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">588343</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000048" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">8250096</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000049" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">8725020</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermNotesPayable id="F_000050" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">50000</us-gaap:LongTermNotesPayable>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="F_000051" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">812169</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="F_000052" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">1061113</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000053" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">1752822</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000054" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">1758709</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="F_000055" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">2564991</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="F_000056" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">2869822</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:CommitmentsAndContingencies id="F_000057" xsi:nil="true" contextRef="C_0000879407_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000058" xsi:nil="true" contextRef="C_0000879407_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000059" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">21</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000060" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">10</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue id="F_000061" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">145278</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000062" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">124859</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000063" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">388558305</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000064" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">193514766</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000065" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">-202340717</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000066" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">-166140969</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000067" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">186362887</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000068" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">27498666</us-gaap:StockholdersEquity>
  <us-gaap:MinorityInterest id="F_000069" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">-555098</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterest id="F_000070" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">-1763877</us-gaap:MinorityInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000071" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">185807789</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000072" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">25734789</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000073" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">196622876</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000074" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">37329631</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000075" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000076" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000077" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000078" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000079" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">21291</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000080" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_shares">9900</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000081" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">21291</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000082" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_shares">9900</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000083" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000084" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000085" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">145000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000086" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_shares">145000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000087" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">52908567</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000088" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_shares">32489444</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000089" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">52908567</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000090" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_shares">32489444</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Revenues id="F_000091" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">43750</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000092" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">43750</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000093" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">131250</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000094" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">246516</us-gaap:Revenues>
  <us-gaap:LaborAndRelatedExpense id="F_000095" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">2454449</us-gaap:LaborAndRelatedExpense>
  <us-gaap:LaborAndRelatedExpense id="F_000096" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">1651729</us-gaap:LaborAndRelatedExpense>
  <us-gaap:LaborAndRelatedExpense id="F_000097" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">7634142</us-gaap:LaborAndRelatedExpense>
  <us-gaap:LaborAndRelatedExpense id="F_000098" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">5006328</us-gaap:LaborAndRelatedExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000099" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">1582465</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000100" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">899633</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000101" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">3865845</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000102" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">2597279</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000103" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">6392200</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000104" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">1756527</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000105" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">14719739</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000106" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">5458212</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensation id="F_000107" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">2038682</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000108" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">363593</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000109" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">3758264</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000110" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">1114375</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000111" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">276054</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000112" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">454086</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000113" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">1075238</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000114" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">1352448</us-gaap:DepreciationDepletionAndAmortization>
  <arwr:ImpairmentOfIntangibleAssets id="F_000115" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">1308047</arwr:ImpairmentOfIntangibleAssets>
  <arwr:ImpairmentOfIntangibleAssets id="F_000116" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">1308047</arwr:ImpairmentOfIntangibleAssets>
  <us-gaap:OperatingExpenses id="F_000117" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">12743850</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000118" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">6433615</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000119" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">31053228</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000120" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">16836689</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000121" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">-12700100</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000122" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-6389865</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000123" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-30921978</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000124" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-16590173</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="F_000125" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">78702</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="F_000126" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-159530</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="F_000127" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-69350</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="F_000128" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-380699</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000129" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-39949</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000130" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-58878</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000131" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-76388</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:InterestIncomeExpenseNet id="F_000132" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">226424</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet id="F_000133" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-48252</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet id="F_000134" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">386392</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet id="F_000135" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-68403</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:UnrealizedGainLossOnDerivatives id="F_000136" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">758469</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives id="F_000137" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">200747</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives id="F_000138" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-5712335</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives id="F_000139" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">215620</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000140" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">10054</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000141" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">259221</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000142" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">81269</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000143" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-997976</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000144" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">1073649</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000145" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">212237</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000146" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-5372902</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000147" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-1307846</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000148" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">-11626451</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000149" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-6177628</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000150" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-36294880</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000151" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-17898019</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000152" xsi:nil="true" contextRef="C_0000879407_20140401_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="F_000153" xsi:nil="true" contextRef="C_0000879407_20130401_20130630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="F_000154" xsi:nil="true" contextRef="C_0000879407_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="F_000155" xsi:nil="true" contextRef="C_0000879407_20121001_20130630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000156" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">-11626451</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000157" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-6177628</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000158" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-36294880</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="F_000159" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-17898019</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="F_000160" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-354</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:ProfitLoss id="F_000161" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">-11626451</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000162" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-6177628</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000163" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-36294880</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000164" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-17898373</us-gaap:ProfitLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000165" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">2468</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000166" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-98618</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000167" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-95132</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="F_000168" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-447268</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLoss id="F_000169" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">-11628919</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000170" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">-6079010</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000171" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-36199748</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000172" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-17451105</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000173" contextRef="C_0000879407_20140401_20140630" decimals="2" unitRef="U_iso4217USD_shares">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000174" contextRef="C_0000879407_20130401_20130630" decimals="2" unitRef="U_iso4217USD_shares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000175" contextRef="C_0000879407_20131001_20140630" decimals="2" unitRef="U_iso4217USD_shares">-0.81</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000176" contextRef="C_0000879407_20121001_20130630" decimals="2" unitRef="U_iso4217USD_shares">-0.92</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000177" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_shares">51931989</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000178" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_shares">26134183</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000179" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_shares">44565008</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000180" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_shares">18893197</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000181" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130930" decimals="0" unitRef="U_iso4217USD">124859</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000182" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130930" decimals="0" unitRef="U_iso4217USD">10</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000183" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130930" decimals="0" unitRef="U_iso4217USD">193514766</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000184" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20130930" decimals="0" unitRef="U_iso4217USD">-166140969</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000185" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20130930" decimals="0" unitRef="U_iso4217USD">-1763877</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesIssued id="F_000186" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130930" decimals="INF" unitRef="U_shares">32489444</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="F_000187" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20130930" decimals="INF" unitRef="U_shares">9900</us-gaap:SharesIssued>
  <arwr:WarrantsExercisedDuringPeriodShares id="F_000188" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">2875727</arwr:WarrantsExercisedDuringPeriodShares>
  <arwr:WarrantsExercisedDuringPeriodValue id="F_000189" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">2875</arwr:WarrantsExercisedDuringPeriodValue>
  <arwr:WarrantsExercisedDuringPeriodValue id="F_000190" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">10001918</arwr:WarrantsExercisedDuringPeriodValue>
  <arwr:WarrantsExercisedDuringPeriodValue id="F_000191" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">10004793</arwr:WarrantsExercisedDuringPeriodValue>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000192" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">377112</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000193" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">377</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000194" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">2368885</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000195" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">2369262</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000196" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">3758264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000197" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">3758264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000198" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">3071672</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000199" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">3072</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000200" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">14057040</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000201" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">14060112</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000202" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000203" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">6325</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000204" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">112575234</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000205" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">112581559</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000206" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">46000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000207" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">46</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000208" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">45999954</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000209" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">46000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000210" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">131579</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000211" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">132</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000212" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">499868</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000213" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax id="F_000214" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">5789979</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax id="F_000215" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">5789979</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits id="F_000216" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">7638033</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits id="F_000217" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20131001_20140630" decimals="INF" unitRef="U_shares">-34609</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits id="F_000218" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">7638</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits id="F_000219" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-35</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits id="F_000220" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-7603</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="F_000221" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">1303911</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="F_000222" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">1303911</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:ProfitLoss id="F_000223" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-36199748</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000224" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-95132</us-gaap:ProfitLoss>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000225" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140630" decimals="0" unitRef="U_iso4217USD">145278</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000226" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20140630" decimals="0" unitRef="U_iso4217USD">21</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000227" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20140630" decimals="0" unitRef="U_iso4217USD">388558305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000228" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20140630" decimals="0" unitRef="U_iso4217USD">-202340717</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="F_000229" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20140630" decimals="0" unitRef="U_iso4217USD">-555098</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesIssued id="F_000230" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20140630" decimals="INF" unitRef="U_shares">52908567</us-gaap:SharesIssued>
  <us-gaap:SharesIssued id="F_000231" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20140630" decimals="INF" unitRef="U_shares">21291</us-gaap:SharesIssued>
  <us-gaap:SharesIssuedPricePerShare id="F_000232" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtFiveDollarAndEightySixCentsPerShareMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">5.86</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000233" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">18.95</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000234" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrPreferredStockIssuedAtThousandDollarsPerShareMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">1000</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="F_000235" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-354</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:AmortizationOfDebtDiscountPremium id="F_000236" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">416292</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium id="F_000237" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">82341</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:GainLossOnSaleOfEquityInvestments id="F_000238" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">87197</us-gaap:GainLossOnSaleOfEquityInvestments>
  <us-gaap:AssetImpairmentCharges id="F_000239" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">2315721</us-gaap:AssetImpairmentCharges>
  <us-gaap:IncreaseDecreaseInReceivables id="F_000240" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-75000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables id="F_000241" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-9375</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInOtherReceivables id="F_000242" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">517986</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncreaseDecreaseInOtherReceivables id="F_000243" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-1080</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="F_000244" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">127248</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="F_000245" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">441373</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000246" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">11402</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000247" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">1813</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000248" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">990929</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000249" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">183959</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000250" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">459690</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000251" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">95132</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities id="F_000252" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-4480</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities id="F_000253" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-313354</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000254" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-24496567</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000255" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-13639360</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000256" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">1251987</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000257" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">191656</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000258" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">89505</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000259" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">46365528</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000260" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">4058003</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000261" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">6590824</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000262" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">1160181</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000263" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">-41026691</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000264" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-2999973</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="F_000265" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">257178</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="F_000266" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">160495</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000267" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">172641720</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000268" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">42448824</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <arwr:ProceedsFromExerciseOfWarrantsAndStockOptions id="F_000269" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">12374005</arwr:ProceedsFromExerciseOfWarrantsAndStockOptions>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000270" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">184758547</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000271" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">42288329</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="F_000272" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-354</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="F_000273" xsi:nil="true" contextRef="C_0000879407_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations id="F_000274" xsi:nil="true" contextRef="C_0000879407_20121001_20130630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations id="F_000275" xsi:nil="true" contextRef="C_0000879407_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations id="F_000276" xsi:nil="true" contextRef="C_0000879407_20121001_20130630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations id="F_000277" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">-354</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000278" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">119235289</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000279" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">25648642</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000280" contextRef="C_0000879407_20120930" decimals="0" unitRef="U_iso4217USD">3377288</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000281" contextRef="C_0000879407_20130630" decimals="0" unitRef="U_iso4217USD">29025930</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaid id="F_000282" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">21478</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="F_000283" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">32139</us-gaap:InterestPaid>
  <us-gaap:CommonStockSharesIssued id="F_000284" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_20140218" decimals="INF" unitRef="U_shares">131579</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue id="F_000285" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_arwrIssuedToGallowayMember_20140218" decimals="0" unitRef="U_iso4217USD">500000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockSharesIssued id="F_000286" contextRef="C_0000879407_deiLegalEntityAxis_arwrRocheMadisonMember_20121021" decimals="INF" unitRef="U_shares">239894</us-gaap:CommonStockSharesIssued>
  <us-gaap:OtherPaymentsToAcquireBusinesses id="F_000287" contextRef="C_0000879407_deiLegalEntityAxis_arwrRocheMadisonMember_20121020_20121021" decimals="0" unitRef="U_iso4217USD">986049</us-gaap:OtherPaymentsToAcquireBusinesses>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="F_000288" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 1. &lt;font style="font-style:italic;"&gt;ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Nature of Business &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary Dynamic Polyconjugate (DPC) delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead&amp;#8217;s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Historically, the Company&amp;#8217;s primary source of financing has been through the sale of equity securities.&amp;nbsp;&amp;nbsp;Research and development activities have required significant capital investment since the Company&amp;#8217;s inception and the Company expects its operations to continue to require cash investment in fiscal 2014 and beyond as the Company advances its research and development efforts, including clinical trials, and related drug manufacturing costs.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At June 30, 201&lt;font style="color:#;"&gt;4&lt;/font&gt;, the Company had $138.3 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 27 months.&amp;nbsp;&amp;nbsp;These bonds provide a source of liquidity, though the Company plans to hold them until maturity.&amp;nbsp;&amp;nbsp;At June 30, 2014, the Company had invested $50.1 million in bonds.&amp;nbsp;&amp;nbsp;During the nine months ended June 30, 2014, the Company&amp;#8217;s cash position increased by $119.2 million, which was the result of the receipt of cash from the issuance of equity of $172.6 million and cash from the exercise of warrants and options of $12.4 million, partially offset by net cash invested in fixed income investments of $39.8 million, cash outflows of $24.5 million related to continuing operating activities and capital expenditures of $&lt;font style="color:#;"&gt;1.3&lt;/font&gt; million. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&amp;#8212;The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries.&amp;nbsp;&amp;nbsp;Arrowhead&amp;#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&amp;#8217;s research and development facilities are located.&amp;nbsp;&amp;nbsp;All significant intercompany accounts and transactions are eliminated in consolidation, and non-controlling interests are accounted for in the Company&amp;#8217;s financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&amp;#8212;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form&amp;#160;10-Q and Article&amp;#160;8 of Regulation S-X.&amp;nbsp;&amp;nbsp;Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year.&amp;nbsp;&amp;nbsp;The September 30, 2013 Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K for the year ended September&amp;#160;30, 2013.&amp;nbsp;&amp;nbsp;Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&amp;#8212;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&amp;#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&amp;nbsp;&amp;nbsp;The Company had no restricted cash at June 30, 2014 and September 30, 2013.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&amp;#8212;The Company maintains several checking accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&amp;#8212;The Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments &amp;#8211; Debt and Equity Securities.&amp;#160;This statement requires certain securities to be classified into three categories: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity&amp;#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trading Securities&amp;#8212;Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-Sale&amp;#8212;Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&amp;#8217; equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At &lt;font style="color:#;"&gt;June 30, 2014&lt;/font&gt;, the Company classified all of its investments as held-to-maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity investments are measured and recorded at amortized cost on the Company&amp;#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.&amp;nbsp;&amp;nbsp;See further information regarding the Company&amp;#8217;s short and long term investments in Note 2 &amp;#8211; Investments.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See further information regarding fair market value of marketable debt securities in Note 10 &amp;#8211; Fair Value Measurements, such fair market data is obtained from independent pricing services. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&amp;#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets Subject to Amortization&amp;#8212;Intangible assets subject to amortization included certain license agreements acquired through business combinations. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-Process Research&amp;#160;&amp;amp; Development (IPR&amp;amp;D)&amp;#8212;IPR&amp;amp;D assets represent capitalized on-going research projects that Arrowhead acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&amp;amp;D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets are impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration - The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event.&amp;nbsp;&amp;nbsp;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&amp;nbsp;&amp;nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within our consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minority Equity Investments&amp;#8212;The Company had a minority equity investment in Leonardo, a privately held biotechnology company.&amp;nbsp;&amp;nbsp;Based on the status of the development of Leonardo&amp;#8217;s program, this investment has been fully impaired and the net book value at June 30, 2014 is $0.&amp;nbsp;&amp;nbsp;The operations of Leonardo ceased in December 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-controlling Interests in Majority-Owned Subsidiaries&amp;#8212;Operating losses applicable to majority-owned Calando, Ablaris and, prior to its disposal, Unidym have periodically exceeded the non-controlling interests in the equity capital of either Subsidiary. Such excess losses applicable to the non-controlling interests have been and are borne by the Company as there is no obligation of the non-controlling interests to fund any losses in excess of their original investment. There is also no obligation or commitment on the part of the Company to fund operating losses of any Subsidiary whether wholly-owned or majority-owned. The Company allocates the non-controlling interests&amp;#8217; share of net loss in excess of the non-controlling interests&amp;#8217; initial investment in accordance with FASB ASC 810-10. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When there is a change in the Company&amp;#8217;s proportionate ownership share of a development-stage Subsidiary resulting from additional equity transactions in the Subsidiary, the change is accounted for as an equity transaction in consolidation. To the extent that the increase in the calculated value of the Company&amp;#8217;s interest in the equity of the Subsidiary exceeds the Company&amp;#8217;s investment in the transaction, that increase in value is referred to as the Company&amp;#8217;s &amp;#8220;increase in its proportionate share of the Subsidiary&amp;#8217;s equity&amp;#8221; and the amount is recorded as an increase in the Company&amp;#8217;s Additional Paid-in Capital. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&amp;#8212;Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. The Company may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments under collaborative research and development agreements are recognized ratably over the relevant periods specified in the agreement, generally the period during which research and development is conducted. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance for Doubtful Accounts&amp;#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development&amp;#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings (Loss) per Share&amp;#8212;Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options issued to employees and consultants and warrants to purchase Common Stock of the Company.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&amp;#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative Assets and Liabilities &amp;#8211; The Company accounts for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on the Company&amp;#8217;s Consolidated Balance Sheet and no further adjustments to their valuation are made. Some of the Company&amp;#8217;s warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on the Company&amp;#8217;s Consolidated Balance Sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&amp;#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2014, the FASB issued ASU 2014-10, &lt;font style="font-style:italic;"&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance&lt;/font&gt;, which eliminates the distinction and separate requirements for development stage entities and other reporting entities under U.S. GAAP.&amp;nbsp;&amp;nbsp;Specifically the amendment eliminates the requirement for development stage entities to 1) present inception-to-date information in the statements of income, cash flow and shareholders&amp;#8217; equity, 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.&amp;nbsp;&amp;nbsp;ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 with early adoption permitted.&amp;nbsp;&amp;nbsp;The Company has adopted ASU 2014-10 effectively with the filing of this Form 10-Q.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU No. 2014-09 &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;, which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and will become effective for the Company in the first quarter of 2018. The Company is evaluating the potential effects of the adoption of this update on its financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2013, the FASB issued ASU 2013-11, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists&lt;/font&gt;, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity&amp;#8217;s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. The Company is evaluating the impact, if any, of the adoption of ASU 2013-11 on its Consolidated Balance Sheet.&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock id="F_000289" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 2. &lt;font style="font-style:italic;"&gt;INVESTMENTS&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash balances in short-term and long-term debt securities.&amp;nbsp;&amp;nbsp;Investments at June 30, 2014 consisted of corporate bonds with maturities remaining of less than three years at the time of purchase.&amp;nbsp;&amp;nbsp;The Company may also invest excess cash balances in certificates of deposit, money market accounts, US Treasuries, US government agency obligations, corporate debt securities, and/or commercial paper.&amp;nbsp;&amp;nbsp;The Company accounts for its investments in accordance with FASB ASC 320, Investments &amp;#8211; Debt and Equity Securities.&amp;nbsp;&amp;nbsp;At &lt;font style="color:#;"&gt;June 30, 2014&lt;/font&gt;, all investments were classified as held-to-maturity securities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&amp;#8217;s short and long-term investments as of June 30, 2014, and September 30, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,834,408&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,850&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(237,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,599,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due after one year within three years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,284,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(152,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,136,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,119,270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,749&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(389,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,735,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,030,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,998,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due after one year within three years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,702,153&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,362&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699,791&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,732,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,698,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000290" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 3. &lt;font style="font-style:italic;"&gt;FIXED ASSETS&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and other fixed assets are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers, office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323,376&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,248,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,452,013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,955,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,749,409&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross fixed assets &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,607,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,594,421&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&amp;nbsp;&amp;nbsp; Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,933,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,081,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,674,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,513,235&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock id="F_000291" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"&gt;NOTE 4. &lt;font style="font-style:italic;"&gt;ACQUISITIONS &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Roche Madison &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&amp;#160;21, 2011, the Company entered into a Stock and Asset Purchase Agreement (the &amp;#8220;RNAi Purchase Agreement&amp;#8221;) with Hoffmann-La Roche Inc. and F Hoffmann-La Roche Ltd (collectively, &amp;#8220;Roche&amp;#8221;), pursuant to which the Company purchased from Roche (i)&amp;#160;all of the outstanding common stock of Roche Madison Inc. (&amp;#8220;Roche Madison&amp;#8221;, now &amp;#8220;Arrowhead Madison&amp;#8221;) and (ii)&amp;#160;the intellectual property rights then held by Roche related to its RNAi business and identified in the RNAi Purchase Agreement (the &amp;#8220;Transaction&amp;#8221;). In consideration for the purchase of Roche Madison and the Roche RNAi assets, the Company issued to Roche a promissory note with a principal value of $50,000 and 1,288,158 shares of Common Stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the RNAi Purchase Agreement, Roche has a right of first negotiation on certain product candidates developed by the Company and its affiliates relating to the purchased assets. If the Company proposes to out-license or enters into substantive negotiations to out-license, any Clinical Candidate or Existing Candidate (as such terms are defined in the RNAi Purchase Agreement), the Company must give notice of the Candidate it proposes to out-license and negotiate exclusively and in good faith with Roche for 90 days regarding the applicable out-license. This right of first negotiation applies to all Existing Candidates (as defined in the RNAi Purchase Agreement) and the first five Clinical Candidates for which the Company delivers notice to Roche and subsequently enters into an out-license. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the consideration paid by the Company as per the closing terms, the Company is obligated to make certain royalty and milestone payments to Roche upon the occurrence of certain events. For certain product candidates that are developed by the Company that are covered by a valid claim by the patent rights transferred in the Transaction for which the Company and Roche do not enter into a licensing arrangement, the Company will be obligated to pay a 3% royalty on Net Sales (as defined in the RNAi Purchase Agreement), provided that the royalty rate may be reduced or offset in certain circumstances. The obligation to pay royalties on such candidates will last until the later of (i)&amp;#160;the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii)&amp;#160;ten years after the first commercial sale of such product candidate. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will also be obligated to make cash payments to Roche upon the achievement of various milestones for certain clinical candidates, for which the Company and Roche do not enter into a licensing arrangement, including the first regulatory approval in certain jurisdictions, and upon certain annual sales milestones for candidates that receive regulatory approval. The potential payments range from $2,500,000 to $6,000,000 per milestone. At the time of acquisition, the Company&amp;#8217;s estimate of future payments for potential royalties and milestones had a net present value of $84,935 which was recorded as contingent consideration as a part of other non-current liabilities.&amp;nbsp;&amp;nbsp;Contingent consideration is calculated by modeling research and development activities for clinical candidates, forecasting timelines to market, and using &amp;#8220;peak sales&amp;#8221; estimate modeling, cash flows and potential milestone and royalty payments are calculated.&amp;nbsp;&amp;nbsp;The modeling assumes certain success rates, and discount factors related to riskiness of projects and the time value of money to calculate a net present value of future consideration payments to Roche.&amp;nbsp;&amp;nbsp;These estimates are based on many unknown variables that are difficult to estimate, and due to the extended process of drug development prior to marketing of drug candidates, the models must extend many years into the future.&amp;nbsp;&amp;nbsp;Such predictions are inherently uncertain.&amp;nbsp;&amp;nbsp;On a quarterly basis, the Company re-evaluates its contingent consideration, and if material, makes adjustments to the recorded liability.&amp;nbsp;&amp;nbsp;Any adjustment to the contingent consideration liability is reflected in the Company&amp;#8217;s Statement of Operations.&amp;nbsp;&amp;nbsp;During fiscal 2013, the contingent consideration liability was increased by $1.4 million, which is recorded as a part of other non-current liabilities on the Company&amp;#8217;s Consolidated Balance Sheet. There have been no changes to the liability during the nine months ended June 30, 2014.&amp;nbsp;&amp;nbsp;For additional information related to our valuation of this obligation, see &lt;font style="font-style:italic;"&gt;Note 10, Fair Value Measurements&lt;/font&gt;.&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:IntangibleAssetsDisclosureTextBlock id="F_000292" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 5. &lt;font style="font-style:italic;"&gt;INTANGIBLE ASSETS&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets consist of in-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) not subject to amortization, and other intangible assets subject to amortization, which were capitalized as a part of a business combination. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IPR&amp;amp;D represents projects that have not yet received regulatory approval and are required to be classified as indefinite assets until the successful completion or the abandonment of the associated R&amp;amp;D efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in one or more jurisdictions which, individually or combined, are expected to generate a significant portion of the total revenue expected to be earned by an IPR&amp;amp;D project. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&amp;amp;D and begin amortization. If the associated R&amp;amp;D effort is abandoned the related IPR&amp;amp;D assets will likely be written off and we would record an impairment loss. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets subject to amortization include patents capitalized as part of a business combination as well as license agreements capitalized as part of a business combination from the acquisition of Roche Madison.&amp;nbsp;&amp;nbsp; The license agreements are being amortized over the estimated life remaining at the time of acquisition which was 4 years, and the accumulated amortization of the assets is approximately $147,800. Patents have been amortized over a period of three years to twenty years, however the patent assets were fully impaired as of September 30, 2013. Amortization expense for the three and nine months ended June 30, 2014 was approximately $13,663 and $40,990, respectively.&amp;nbsp;&amp;nbsp;Amortization expense for the three and nine months ended June 30, 2013 was approximately $74,115 and $222,345, respectively. Amortization of license agreements is expected to be approximately $14,000 for the remainder of fiscal year 201&lt;font style="color:#;"&gt;4, $55,000 in &lt;/font&gt;201&lt;font style="color:#;"&gt;5&lt;/font&gt;, $14,000 in 2016, and zero thereafter. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We review amounts capitalized as IPR&amp;amp;D for impairment at least annually in the fourth quarter, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In the event the carrying value of the assets is not expected to be recovered, the assets are written down to their estimated fair values. We continue to test our indefinite-lived IPR&amp;amp;D assets for potential impairment until the projects are completed or abandoned. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides details on our intangible asset balances: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&amp;#160;assets&lt;font style="font-weight:normal;"&gt;&lt;br /&gt;&lt;/font&gt;not subject to&lt;br /&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&amp;#160;assets&lt;br /&gt;subject to&lt;br /&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;br /&gt;Intangible&amp;#160;assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September&amp;#160;30, 2012&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,117,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,667,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,784,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,308,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,308,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(236,009 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(236,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td valign="bottom" style="width:46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,117,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,191&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,240,513&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,990&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,990&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,117,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,199,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock id="F_000293" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 6. &lt;font style="font-style:italic;"&gt;INVESTMENT IN SUBSIDIARIES&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to 100% ownership interest in Arrowhead Madison Inc., Arrowhead also maintains majority ownership in Calando Pharmaceuticals, Ablaris Therapeutics, Inc., and a minority investment in Leonardo Biosystems, Inc. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Calando Pharmaceuticals, Inc. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Calando is a developer of polymer delivery systems for siRNA and small molecule based therapeutics.&amp;nbsp;&amp;nbsp;Calando&amp;#8217;s current cash resources preclude additional development of its platform technology and therapeutic candidates.&amp;nbsp;&amp;nbsp;Arrowhead has determined that it will not provide substantial further investment to Calando based on Arrowhead evaluation of Calando&amp;#8217;s development and business prospects and Calando has been unsuccessful in its efforts to obtain capital from other sources.&amp;nbsp;&amp;nbsp;Calando has ceased operations and terminated its technology license with the California Institute of Technology on which its siRNA therapeutic development efforts were based.&amp;nbsp;&amp;nbsp;Further, pursuant to an involuntary petition by an unpaid Noteholder, Calando is undergoing Chapter 7 bankruptcy proceedings.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2009, Calando outlicensed its small molecule program to Cerulean Pharma, Inc., a Boston, MA-based biotech company which has continued the development of the program.&amp;nbsp;&amp;nbsp;Under the license, as the development program progresses, Calando could collect partnership, milestone and royalty payments from Cerulean.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Calando has an outstanding promissory note with a balance of principal and interest totaling $1,253,000 as of June 30, 2014.&amp;nbsp;&amp;nbsp;The promissory note became due on November 26, 2013, but was not repaid due to lack of cash resources at Calando.&amp;#160;&amp;#160;The holder of the Note initiated an involuntary petition of bankruptcy against Calando.&amp;#160;&amp;#160;A trustee has been appointed and a meeting of Calando creditors has occurred.&amp;#160;&amp;#160;It is expected that the trustee will dispose of Calando assets, primarily its license agreement with Cerulean.&amp;#160;&amp;#160;The Company cannot estimate the proceeds from the disposition of Calando&amp;#8217;s assets, nor how it will be distributed amongst its various creditors, which includes Arrowhead and the holder of the Note.&amp;nbsp;&amp;nbsp;During the nine months ended June 30, 2014, Arrowhead deconsolidated Calando based on the fact that Calando is now subject to the control of the bankruptcy trustee.&amp;nbsp;&amp;nbsp;The deconsolidation of Calando resulted in an approximately $87,000 gain to the Company&amp;#8217;s Consolidated Statement of Operations.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014, Calando owed to Arrowhead $&lt;font style="color:#;"&gt;4.5&lt;/font&gt; million under a series of 8% simple interest notes and advances. It is unlikely these notes will be repaid in full. The balance of the notes and advances has been fully reserved.  &amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014, Arrowhead owned &lt;font style="color:#;"&gt;79&lt;/font&gt;% of the outstanding shares of Calando and &lt;font style="color:#;"&gt;76&lt;/font&gt;% on a fully diluted basis.&amp;nbsp;&amp;nbsp;As a result of the ongoing bankruptcy proceeding for Calando, we do not expect our equity ownership to result in any return of capital as part of the liquidation of Calando.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Ablaris Therapeutics, Inc. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ablaris was formed and began operations in fiscal 2011, based on the license of certain anti-obesity technology developed at the MD Anderson Cancer Center at the University of Texas. During fiscal 2011, Ablaris raised $2.9 million in cash, of which $1.3 million was invested by Arrowhead and $1.6 million was invested by outside investors, through the issuance of Ablaris Series A Preferred stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014, Arrowhead owned &lt;font style="color:#;"&gt;64&lt;/font&gt;% of the outstanding shares of Ablaris and &lt;font style="color:#;"&gt;64&lt;/font&gt;% on a fully diluted basis. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Leonardo Biosystems, Inc. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leonardo, a privately-held drug-delivery company in which Arrowhead has a 3% ownership interest, ceased operations in December 2013. Arrowhead&amp;#8217;s investment in Leonardo and its receivable from Leonardo have been fully reserved.&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000294" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 7. &lt;font style="font-style:italic;"&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At June 30, 2014, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001, and 5,000,000 shares of Preferred Stock, par value $0.001. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At June 30, 2014, &lt;font style="color:#;"&gt;52,908,567&lt;/font&gt; shares of Common Stock were outstanding.&amp;nbsp;&amp;nbsp;Additionally, 21,291 shares of Preferred Stock were outstanding, including 5,291 shares of Series B Preferred Stock, convertible into 2,891,257 shares of Common Stock, and 16,000 shares of Series C Preferred Stock, convertible into 2,730,375 shares of Common Stock, (collectively, the &amp;#8220;Outstanding Preferred Stock&amp;#8221;). At June 30, 2014, 7,182,925 shares were reserved for issuance upon vesting of restricted stock units and exercise of stock options granted under Arrowhead&amp;#8217;s 2000 Stock Option Plan, 2004 Equity Incentive Plan, and 2013 Incentive Plan, as well as for inducement grants made to new employees. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Outstanding Preferred Stock is convertible to Common Stock by each holder at its stated conversion price, subject to a 9.99% beneficial ownership limit for each holder.&amp;nbsp;&amp;nbsp;The holders of Outstanding Preferred Stock are eligible to vote with the Common Stock of the Company on an as-converted basis, but only to the extent they are eligible for conversion without exceeding the 9.99% ownership limitation. The Outstanding Preferred Stock does not carry a coupon, but is entitled to receive dividends on a pari passu basis with the Common Stock, when and if declared.&amp;nbsp;&amp;nbsp;In any liquidation or dissolution of the Company, the holders of Outstanding Preferred Stock are entitled to participate in the distribution of the assets, to the extent legally available for distribution, on a pari passu basis with the Common Stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&amp;#160;20, 2011, the Company and Lincoln Park Capital Fund, LLC, an Illinois limited liability company (&amp;#8220;LPC&amp;#8221;) entered into a $15 million purchase agreement (the &amp;#8220;Purchase Agreement&amp;#8221;), whereby LPC agreed to purchase up to $15 million of Common Stock, subject to certain limitations, from time to time during the three-year term of the Purchase Agreement. The Company has the right, in its sole discretion, over a 36-month period to sell up to $15 million of Common Stock (subject to certain limitations) to LPC, depending on certain conditions as set forth in the Purchase Agreement. As of June 30, 2014, the Company had drawn $1 million from the facility. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&amp;#160;11, 2013, the Company sold 3,071,672 shares of common stock, at a price of $5.86 per share, and 46,000 shares of Series&amp;#160;C Convertible Preferred Stock (the &amp;#8220;Preferred Shares&amp;#8221;), at a price of $1,000 per share. The Preferred Shares are convertible into shares of common stock at a conversion price of $5.86. The aggregate purchase price paid by the Purchasers for the Shares and Preferred Shares was $64,000,000 and the Company received net proceeds of approximately $60,000,000, after advisory fees and offering expenses. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 24, 2014, the Company sold 6,325,000 shares of common stock, at a public offering price of $18.95 per share.&amp;nbsp;&amp;nbsp;Net proceeds were approximately $112.6 million after underwriting commissions and discounts and other offering expense.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about warrants outstanding at June 30, 2014: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="top" style="width:58.84%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&amp;#160;of&amp;#160;&lt;br /&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;font style="font-weight:normal;"&gt;&lt;br /&gt;&lt;/font&gt;Life&amp;#160;in&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;416,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,324&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334,347 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;289,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="top" bgcolor="#CFF0FC" style="width:58.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total warrants outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,526,781 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock id="F_000295" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 8. &lt;font style="font-style:italic;"&gt;LEASES&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space for its corporate headquarters in Pasadena, California. In March 2014, the Company signed a lease addendum to expand its corporate headquarters.&amp;nbsp;&amp;nbsp;It is expected the new space will be available in September 2014.&amp;nbsp;&amp;nbsp;The leases for the expansion space and the current space will expire in August 2019.&amp;nbsp;&amp;nbsp; Rental costs, including the expansion space are approximately $22,000 per month, increasing approximately 3% annually.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s research facility in Madison, Wisconsin is leased through February&amp;#160;28, 2019. Monthly rental expense is approximately $25,000. Other monthly rental expenses include common area maintenance and real estate taxes totaling approximately $16,000 per month. Utilities costs are approximately $15,000 per month. Including monthly payments recorded under a capital lease of approximately $19,000, total monthly costs are approximately $75,000 per month. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Facility and equipment rent expense, related to continuing operations, for the three and nine months ended June 30, 2014 was $138,000 and $403,000, respectively.&amp;nbsp;&amp;nbsp;Facility and equipment rent expense, related to continuing operations, for the three and nine months ended June 30, 2013 was $126,000 and $407,000, respectively.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014, future minimum lease payments due in fiscal years under capitalized leases are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;4 (remainder of)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;5 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;6 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;7 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;8 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;9 &lt;/font&gt;and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,175&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,681 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,025,279&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(213,110 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;812,169&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014, future minimum lease payments due in fiscal years under operating leases are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;4 (remainder of)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134,164&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;5 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;580,626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;6 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;597,196&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;7 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;613,984&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;8 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;638,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;9 &lt;/font&gt;and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;432,861 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,997,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock id="F_000296" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 9. &lt;font style="font-style:italic;"&gt;STOCK-BASED COMPENSATION&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead has three plans that provide for equity-based compensation. Under the 2000 Stock Option Plan, 38,000 shares of Arrowhead&amp;#8217;s Common Stock are reserved for issuance upon exercise of non-qualified stock options. No further grants can be made under the 2000 Stock Option Plan. The 2004 Equity Incentive Plan reserves 2,734,840 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others.  The 2013 Incentive Plan reserves 4,000,000 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance awards to employees, consultant and others.&amp;nbsp;&amp;nbsp;As of June 30, 2014, there were options granted and outstanding to purchase 38,000, 2,638,652 and 736,875 shares of Common Stock under the 2000 Stock Option Plan, the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively. Also, as of June 30, 2014, there were 410,085 shares reserved for options issued outside of equity compensation plans as inducement grants to new employees. During the nine months ended June 30, 2014, no options were granted under the 2004 Equity Incentive Plan, 765,000 were issued under the 2013 Incentive Plan and 165,000 options were granted outside of equity incentive plans as inducement stock options to new employees. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize information about stock options:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&amp;#160;of&lt;br /&gt;Options&lt;br /&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;br /&gt;Per&amp;#160;Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&amp;#160;30, 201&lt;font style="color:#;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,910,794&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,509,166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(675 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&amp;#160;30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,419,285 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;930,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.05&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(148,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(377,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,823,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,271,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable At June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,532,180 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,666,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for the three and nine months ended June 30, 2014 was $1,070,631 and $2,186,653, respectively. Stock-based compensation expense for the three and nine months ended June 30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt; was $363,593 and $1,114,375, respectively. There is no income tax benefit as the Company is currently operating at a loss and an actual income tax benefit may not be realized. The loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate grant date fair value of the options granted by the Company during the three and nine months ended June 30, 2014 is estimated at $&lt;font style="color:#;"&gt;1,176,000&lt;/font&gt; and $&lt;font style="color:#;"&gt;8,295,600&lt;/font&gt;, respectively. The aggregate grant date fair value of the options granted by the Company during the three and nine months ended June 30, 2013 is estimated at $&lt;font style="color:#;"&gt;1,094,295&lt;/font&gt; and $&lt;font style="color:#;"&gt;1,197,588&lt;/font&gt;, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The intrinsic value of the options exercised during the three and nine months ended June 30, 2014 was $371,334 and $3,606,061, respectively.&amp;nbsp;&amp;nbsp;No options were exercised during the three and nine months ended June 30, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014, the pre-tax compensation expense for all unvested stock options in the amount of approximately $10,514,619 will be recognized in the Company&amp;#8217;s results of operations over a weighted average period of &lt;font style="color:#;"&gt;3.2 &lt;/font&gt;years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&amp;#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&amp;#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&amp;#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value stock options are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:36.22%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine months&amp;#160;ended&amp;#160;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;4&lt;/font&gt;&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.8% to 2.5%&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7%&amp;#160; to&amp;#160;1.3%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.25 to 9.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5 to 6.25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average grant date fair value per share of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$8.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.26&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The dividend yield is zero as the Company currently does not pay a dividend. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The risk-free interest rate is based on the U.S. Treasury bond. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility is estimated based on volatility average of the Company&amp;#8217;s Common Stock price. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units (RSUs) are granted under the Company&amp;#8217;s 2013 Incentive Plan.&amp;nbsp;&amp;nbsp;During the nine months ended June 30, 2014, the Company issued 470,000 restricted stock units to certain members of management and certain members of its Board of Directors.&amp;nbsp;&amp;nbsp;At vesting each RSU will be exchanged for one share of the Company&amp;#8217;s Common Stock. The RSUs issued to management vest in equal installments on the one and two year anniversary of the date of grant.&amp;nbsp;&amp;nbsp;The RSUs issued to the members of the Board of Directors vest upon the one year anniversary of the date of grant.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity of the Company&amp;#8217;s Restricted Stock Units:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64.68%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br /&gt;Number of&lt;br /&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.96%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Grant&lt;br /&gt;Date&lt;br /&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September&amp;#160;30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;- &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:15.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;470,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.96%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10.5%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.08%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:15.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;470,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded $968,051 and $1,571,611 of expense relating to restricted stock units during the three and nine months ended June 30, 2014 respectively, and such expense is included in stock-based compensation expense.&amp;nbsp;&amp;nbsp;There was no expense relating to restricted stock units during the three and nine months ended June 30, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014, the pre-tax compensation expense for all unvested restricted stock units in the amount of approximately $5,291,302 will be recognized in the Company&amp;#8217;s results of operations over a weighted average period of &lt;font style="color:#;"&gt;1.5 &lt;/font&gt;years. &lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000297" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 10. &lt;font style="font-style:italic;"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&amp;#160;1 provides the most reliable measure of fair value while Level&amp;#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;1&amp;#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;2&amp;#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&amp;#160;3&amp;#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&amp;#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes fair value measurements at June 30, 2014 and September&amp;#160;30, 2013 for assets and liabilities measured at fair value on a recurring basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2014: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138,349,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138,349,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,018,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,018,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations related to acquisitions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30, &lt;font style="color:#;"&gt;2013&lt;/font&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,114,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,114,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,096,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,096,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations related to acquisitions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash balances in short and long-term corporate bonds, generally with remaining maturities of less than two years.&amp;nbsp;&amp;nbsp;At June 30, 2014, the Company had short-term investments of $23,834,408, and long-term investments of $26,284,862, for a total of $50,119,270.&amp;nbsp;&amp;nbsp;The fair value of its investment at June 30, 2014 was $49,735,616.&amp;nbsp;&amp;nbsp;The Company expects to hold such investments until maturity, and thus unrealized gains and losses from the fluctuations in the fair value of the securities are not likely to be realized.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the proceeds from the sale of Unidym in January 2011, Arrowhead received a bond from Wisepower in the face amount of $2.5 million. The bond is convertible to Wisepower common stock at a price of $2.00 per share. The conversion feature is subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the conversion feature on the date of issuance was estimated using an option pricing model and recorded on the Company&amp;#8217;s Consolidated Balance Sheet as a derivative asset. The fair value of the conversion feature is estimated at the end of each reporting period and the change in the fair value of the conversion feature is recorded as a non-operating gain/loss as change in value of derivatives in Company&amp;#8217;s Consolidated Statement of Operations. During the quarter ended March&amp;#160;31, 2013, the trading of Wisepower stock was halted. Trading resumed in July 2013, but the trading price is significantly below the conversion price.&amp;nbsp;&amp;nbsp;During fiscal 2013, the Company determined that the probability of realizing value from the conversion feature was remote, and the derivative asset value was reduced to zero.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the nine months ended June 30, 2014, there was no change in the fair value of the derivative asset. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used in valuing the derivative asset were not applicable as the value has been determined to be zero at June 30, 2014 and September 30, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a reconciliation of the derivative asset: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2012&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receipt of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease &lt;font style="color:#000000;"&gt;in value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receipt of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of an equity financing in June 2010, Arrowhead issued warrants to acquire up to 329,649 shares of Common Stock (the &amp;#8220;2010 Warrants&amp;#8221;), of which 24,324 warrants were outstanding at June 30, 2014. Similarly, as part of a financing in December 2012, Arrowhead issued warrants to acquire up to 912,543 shares of Common Stock (the &amp;#8220;2012 Warrants&amp;#8221;) of which 265,161 warrants were outstanding at June 30, 2014.&amp;nbsp;&amp;nbsp;Further, as part of a financing in January 2013, Arrowhead issued warrants to acquire up to 833,530 shares of Common Stock (the &amp;#8220;2013 Warrants&amp;#8221;) of which 24,623 warrants were outstanding at June 30, 2014.&amp;nbsp;&amp;nbsp;Each of the warrants discussed above contains a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the terms of the Warrants, the Company issues Common Stock at a price lower than the exercise price for the Warrants, the exercise price would be reduced to the amount equal to the issuance price of the Common Stock.&amp;nbsp;&amp;nbsp;As a result of these features, the 2010 Warrants, the 2012 Warrants, and the 2013 Warrants are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the Warrants on the date of issuance was estimated using an option pricing model and recorded on the Company&amp;#8217;s Consolidated Balance Sheet as a derivative liability. The fair value of the Warrants is estimated at the end of each reporting period and the change in the fair value of the Warrants is recorded as a non-operating gain or loss as change in value of derivatives in the Company&amp;#8217;s Consolidated Statement of Operations. During the nine months ended June 30, 2014, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $5,680,544. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used in valuing the derivative liability were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2010 Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;June 30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;September&amp;#160;30,&amp;#160;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.11%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2012 Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;June 30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;September 30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.2&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013 Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;June 30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;September 30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.6 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.3&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a reconciliation of the derivative liability related to these warrants: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2012&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;626,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,153,819&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,066,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,754,808 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,091,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,680,544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,789,982)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,982,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:1pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:1pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:1pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In conjunction with the financing of Ablaris in fiscal 2011, Arrowhead sold exchange rights to certain investors whereby the investors have the right to exchange their shares of Ablaris for a prescribed number of Arrowhead shares based upon a predefined ratio. The exchange rights have a seven-year term. During the first year, the exchange right allows the holder to exchange one Ablaris share for 0.06 Arrowhead shares (as adjusted for a subsequent reverse stock split). This ratio declines to 0.04 in the second year, 0.03 in the third year and 0.02 in the fourth year. In the fifth year and beyond the exchange ratio is 0.01. Exchange rights for 675,000 Ablaris shares were sold in fiscal 2011, and remain outstanding at June 30, 2014. The exchange rights are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the exchange rights on the date of issuance was estimated using an option pricing model and recorded on the Company&amp;#8217;s Consolidated Balance Sheet as a derivative liability. The fair value of the exchange rights is estimated at the end of each reporting period and the change in the fair value of the exchange rights is recorded as a non-operating gain or loss as change in value of derivatives in the Company&amp;#8217;s Consolidated Statement of Operations. During the nine months ended June 30, 2014, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $31,791.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72.36%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&amp;#160; 201&lt;font style="color:#;"&gt;4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&amp;#160; 2013&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.3 Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a reconciliation of the derivative liability related to these exchange rights: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 201&lt;font style="color:#;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,806&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,791&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:4pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:4pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The derivative assets/liabilities are estimated using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. Changes in the assumptions used could have a material impact on the resulting fair value. The primary input affecting the value of the Company&amp;#8217;s derivatives liabilities is the Company&amp;#8217;s stock price. Other inputs have a comparatively insignificant effect. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During fiscal 2012, contingent consideration was recorded upon the acquisitions of Roche Madison Inc. and Alvos Therapeutics, Inc., totaling $173,621. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&amp;#8217;s own assumptions and experience. Estimating timing to complete the development, and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and the Company&amp;#8217;s experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded as operating expenses as contingent consideration &amp;#8211; fair value adjustments in the Company&amp;#8217;s Consolidated Statement of Operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a reconciliation of contingent consideration fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 201&lt;font style="color:#;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September 30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of contingent consideration obligations is estimated through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&amp;nbsp;&amp;nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date.&amp;nbsp;&amp;nbsp;Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. Each of these assumptions can have a significant impact on the calculation of contingent consideration. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&amp;#8217;s other financial instruments, which include accounts receivable, accounts payable, and accrued expenses approximate their respective fair values due to the relatively short-term nature of these instruments. The carrying value of the Company&amp;#8217;s debt obligations approximates fair value based on market interest rates. &lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock id="F_000298" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Nature of Business &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary Dynamic Polyconjugate (DPC) delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead&amp;#8217;s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:LiquidityDisclosureTextBlock id="F_000299" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Historically, the Company&amp;#8217;s primary source of financing has been through the sale of equity securities.&amp;nbsp;&amp;nbsp;Research and development activities have required significant capital investment since the Company&amp;#8217;s inception and the Company expects its operations to continue to require cash investment in fiscal 2014 and beyond as the Company advances its research and development efforts, including clinical trials, and related drug manufacturing costs.&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At June 30, 201&lt;font style="color:#;"&gt;4&lt;/font&gt;, the Company had $138.3 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 27 months.&amp;nbsp;&amp;nbsp;These bonds provide a source of liquidity, though the Company plans to hold them until maturity.&amp;nbsp;&amp;nbsp;At June 30, 2014, the Company had invested $50.1 million in bonds.&amp;nbsp;&amp;nbsp;During the nine months ended June 30, 2014, the Company&amp;#8217;s cash position increased by $119.2 million, which was the result of the receipt of cash from the issuance of equity of $172.6 million and cash from the exercise of warrants and options of $12.4 million, partially offset by net cash invested in fixed income investments of $39.8 million, cash outflows of $24.5 million related to continuing operating activities and capital expenditures of $&lt;font style="color:#;"&gt;1.3&lt;/font&gt; million. &lt;/p&gt;&lt;/div&gt;</us-gaap:LiquidityDisclosureTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000300" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Principles of Consolidation&amp;#8212;The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries.&amp;nbsp;&amp;nbsp;Arrowhead&amp;#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&amp;#8217;s research and development facilities are located.&amp;nbsp;&amp;nbsp;All significant intercompany accounts and transactions are eliminated in consolidation, and non-controlling interests are accounted for in the Company&amp;#8217;s financial statements. &lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="F_000301" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Basis of Presentation&amp;#8212;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form&amp;#160;10-Q and Article&amp;#160;8 of Regulation S-X.&amp;nbsp;&amp;nbsp;Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year.&amp;nbsp;&amp;nbsp;The September 30, 2013 Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K for the year ended September&amp;#160;30, 2013.&amp;nbsp;&amp;nbsp;Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates id="F_000302" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Use of Estimates&amp;#8212;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000303" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Cash and Cash Equivalents&amp;#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&amp;nbsp;&amp;nbsp;The Company had no restricted cash at June 30, 2014 and September 30, 2013.&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000304" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Concentration of Credit Risk&amp;#8212;The Company maintains several checking accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:InvestmentPolicyTextBlock id="F_000305" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Investments&amp;#8212;The Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments &amp;#8211; Debt and Equity Securities.&amp;#160;This statement requires certain securities to be classified into three categories: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity&amp;#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trading Securities&amp;#8212;Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-Sale&amp;#8212;Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&amp;#8217; equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At &lt;font style="color:#;"&gt;June 30, 2014&lt;/font&gt;, the Company classified all of its investments as held-to-maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity investments are measured and recorded at amortized cost on the Company&amp;#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.&amp;nbsp;&amp;nbsp;See further information regarding the Company&amp;#8217;s short and long term investments in Note 2 &amp;#8211; Investments.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See further information regarding fair market value of marketable debt securities in Note 10 &amp;#8211; Fair Value Measurements, such fair market data is obtained from independent pricing services. &lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000306" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Property and Equipment&amp;#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock id="F_000307" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Intangible Assets Subject to Amortization&amp;#8212;Intangible assets subject to amortization included certain license agreements acquired through business combinations. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:InProcessResearchAndDevelopmentPolicy id="F_000308" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In-Process Research&amp;#160;&amp;amp; Development (IPR&amp;amp;D)&amp;#8212;IPR&amp;amp;D assets represent capitalized on-going research projects that Arrowhead acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&amp;amp;D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets are impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step. &lt;/p&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
  <arwr:ContingentConsiderationPolicyTextBlock id="F_000309" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Contingent Consideration - The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event.&amp;nbsp;&amp;nbsp;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&amp;nbsp;&amp;nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within our consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&lt;/p&gt;&lt;/div&gt;</arwr:ContingentConsiderationPolicyTextBlock>
  <us-gaap:EquityAndCostMethodInvestmentsPolicy id="F_000310" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Minority Equity Investments&amp;#8212;The Company had a minority equity investment in Leonardo, a privately held biotechnology company.&amp;nbsp;&amp;nbsp;Based on the status of the development of Leonardo&amp;#8217;s program, this investment has been fully impaired and the net book value at June 30, 2014 is $0.&amp;nbsp;&amp;nbsp;The operations of Leonardo ceased in December 2013. &lt;/p&gt;&lt;/div&gt;</us-gaap:EquityAndCostMethodInvestmentsPolicy>
  <arwr:NoncontrollingInterestsPolicyTextBlock id="F_000311" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Non-controlling Interests in Majority-Owned Subsidiaries&amp;#8212;Operating losses applicable to majority-owned Calando, Ablaris and, prior to its disposal, Unidym have periodically exceeded the non-controlling interests in the equity capital of either Subsidiary. Such excess losses applicable to the non-controlling interests have been and are borne by the Company as there is no obligation of the non-controlling interests to fund any losses in excess of their original investment. There is also no obligation or commitment on the part of the Company to fund operating losses of any Subsidiary whether wholly-owned or majority-owned. The Company allocates the non-controlling interests&amp;#8217; share of net loss in excess of the non-controlling interests&amp;#8217; initial investment in accordance with FASB ASC 810-10. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When there is a change in the Company&amp;#8217;s proportionate ownership share of a development-stage Subsidiary resulting from additional equity transactions in the Subsidiary, the change is accounted for as an equity transaction in consolidation. To the extent that the increase in the calculated value of the Company&amp;#8217;s interest in the equity of the Subsidiary exceeds the Company&amp;#8217;s investment in the transaction, that increase in value is referred to as the Company&amp;#8217;s &amp;#8220;increase in its proportionate share of the Subsidiary&amp;#8217;s equity&amp;#8221; and the amount is recorded as an increase in the Company&amp;#8217;s Additional Paid-in Capital. &lt;/p&gt;&lt;/div&gt;</arwr:NoncontrollingInterestsPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000312" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenue Recognition&amp;#8212;Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. The Company may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments under collaborative research and development agreements are recognized ratably over the relevant periods specified in the agreement, generally the period during which research and development is conducted. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. &lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy id="F_000313" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Allowance for Doubtful Accounts&amp;#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. &lt;/p&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000314" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Research and Development&amp;#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. &lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000315" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Earnings (Loss) per Share&amp;#8212;Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options issued to employees and consultants and warrants to purchase Common Stock of the Company.&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000316" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Stock-Based Compensation&amp;#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate. &lt;/p&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:DerivativesPolicyTextBlock id="F_000317" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Derivative Assets and Liabilities &amp;#8211; The Company accounts for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on the Company&amp;#8217;s Consolidated Balance Sheet and no further adjustments to their valuation are made. Some of the Company&amp;#8217;s warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on the Company&amp;#8217;s Consolidated Balance Sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. &lt;/p&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000318" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Income Taxes&amp;#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period. &lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000319" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Standards &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In June 2014, the FASB issued ASU 2014-10, &lt;font style="font-style:italic;"&gt;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance&lt;/font&gt;, which eliminates the distinction and separate requirements for development stage entities and other reporting entities under U.S. GAAP.&amp;nbsp;&amp;nbsp;Specifically the amendment eliminates the requirement for development stage entities to 1) present inception-to-date information in the statements of income, cash flow and shareholders&amp;#8217; equity, 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.&amp;nbsp;&amp;nbsp;ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 with early adoption permitted.&amp;nbsp;&amp;nbsp;The Company has adopted ASU 2014-10 effectively with the filing of this Form 10-Q.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU No. 2014-09 &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;, which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and will become effective for the Company in the first quarter of 2018. The Company is evaluating the potential effects of the adoption of this update on its financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2013, the FASB issued ASU 2013-11, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists&lt;/font&gt;, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity&amp;#8217;s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. The Company is evaluating the impact, if any, of the adoption of ASU 2013-11 on its Consolidated Balance Sheet.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:HeldToMaturitySecuritiesTextBlock id="F_000320" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following tables summarize the Company&amp;#8217;s short and long-term investments as of June 30, 2014, and September 30, 2013. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,834,408&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,850&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(237,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,599,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due after one year within three years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,284,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(152,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,136,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,119,270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,749&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(389,403&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,735,616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Unrealized Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,030,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,998,480&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due after one year within three years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,702,153&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,362&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699,791&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,732,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,643&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,698,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000321" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers, office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323,376&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,248,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,452,013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,955,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,749,409&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross fixed assets &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,607,608&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,594,421&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&amp;nbsp;&amp;nbsp; Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,933,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,081,186&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,674,131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,513,235&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock id="F_000322" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table provides details on our intangible asset balances: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&amp;#160;assets&lt;font style="font-weight:normal;"&gt;&lt;br /&gt;&lt;/font&gt;not subject to&lt;br /&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&amp;#160;assets&lt;br /&gt;subject to&lt;br /&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;br /&gt;Intangible&amp;#160;assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September&amp;#160;30, 2012&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,117,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,667,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,784,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,308,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,308,047&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(236,009 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(236,009&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td valign="bottom" style="width:46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,117,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,191&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,240,513&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,990&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,990&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,117,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,199,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="F_000323" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes information about warrants outstanding at June 30, 2014: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="top" style="width:58.84%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;prices&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&amp;#160;of&amp;#160;&lt;br /&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;font style="font-weight:normal;"&gt;&lt;br /&gt;&lt;/font&gt;Life&amp;#160;in&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70.60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;416,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,324&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334,347 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:8.56%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:1.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:8.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:48.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;289,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="3" valign="top" bgcolor="#CFF0FC" style="width:58.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total warrants outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,526,781 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock id="F_000324" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;As of June 30, 2014, future minimum lease payments due in fiscal years under capitalized leases are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;4 (remainder of)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;5 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;6 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;7 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;8 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;228,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;9 &lt;/font&gt;and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,175&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,681 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,025,279&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(213,110 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;812,169&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000325" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;As of June 30, 2014, future minimum lease payments due in fiscal years under operating leases are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;4 (remainder of)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134,164&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;5 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;580,626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;6 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;597,196&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;7 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;613,984&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;8 &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;638,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;9 &lt;/font&gt;and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;432,861 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:44%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,997,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000326" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following tables summarize information about stock options:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&amp;#160;of&lt;br /&gt;Options&lt;br /&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;br /&gt;Per&amp;#160;Share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&amp;#160;30, 201&lt;font style="color:#;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,910,794&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,509,166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(675 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&amp;#160;30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,419,285 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;930,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.05&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(148,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(377,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,823,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,271,011&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable At June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,532,180 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,666,712&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock id="F_000327" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The assumptions used to value stock options are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:36.22%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine months&amp;#160;ended&amp;#160;June 30,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;4&lt;/font&gt;&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.8% to 2.5%&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7%&amp;#160; to&amp;#160;1.3%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.25 to 9.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5 to 6.25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average grant date fair value per share of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$8.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.26&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock id="F_000328" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the activity of the Company&amp;#8217;s Restricted Stock Units:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64.68%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;br /&gt;Number of&lt;br /&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.96%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Grant&lt;br /&gt;Date&lt;br /&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September&amp;#160;30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;- &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:15.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;470,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.96%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10.5%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.08%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:15.7%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:0.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;470,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000329" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes fair value measurements at June 30, 2014 and September&amp;#160;30, 2013 for assets and liabilities measured at fair value on a recurring basis: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30, 2014: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138,349,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138,349,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,018,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,018,719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations related to acquisitions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30, &lt;font style="color:#;"&gt;2013&lt;/font&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,114,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,114,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,096,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,096,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations related to acquisitions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000330" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following is a reconciliation of the derivative asset: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2012&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receipt of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease &lt;font style="color:#000000;"&gt;in value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receipt of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <arwr:FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock id="F_000331" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The assumptions used in valuing the derivative liability were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2010 Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;June 30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;September&amp;#160;30,&amp;#160;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.11%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2012 Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;June 30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;September 30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.2&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2013 Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;June 30, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;September 30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.6 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.3&amp;#160;Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:41.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:27.04%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.58%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:2.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:25.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</arwr:FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000332" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following is a reconciliation of the derivative liability related to these warrants: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2012&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;626,195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,153,819&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,066,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,754,808 &lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 2013&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,091,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,680,544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,789,982)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,982,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:1pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:1pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:1pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <arwr:FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock id="F_000333" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72.36%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:0pt;;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June 30,&amp;#160; 201&lt;font style="color:#;"&gt;4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&amp;#160;30,&amp;#160; 2013&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.88%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.39%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.5 Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.3 Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;None&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:72.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1.32%;"&gt;
&lt;p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:13.16%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</arwr:FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000334" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following is a reconciliation of the derivative liability related to these exchange rights: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 201&lt;font style="color:#;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,375&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,806&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of instruments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,791&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net settlements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:4pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-top:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:4pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock id="F_000335" contextRef="C_0000879407_20131001_20140630">&lt;div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following is a reconciliation of contingent consideration fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September&amp;#160;30, 201&lt;font style="color:#;"&gt;2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,621&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421,652&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at September 30, 201&lt;font style="color:#;"&gt;3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value at June 30, 2014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,595,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
  <us-gaap:DebtInstrumentMaturityDateDescription id="F_000336" contextRef="C_0000879407_20131001_20140630">less than 27 months</us-gaap:DebtInstrumentMaturityDateDescription>
  <us-gaap:Investments id="F_000337" contextRef="C_0000879407_us-gaapSummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis_us-gaapBondsMember_20140630" decimals="-5" unitRef="U_iso4217USD">50100000</us-gaap:Investments>
  <arwr:NetCashInvestedInFixedIncomeInvestments id="F_000338" contextRef="C_0000879407_20131001_20140630" decimals="-5" unitRef="U_iso4217USD">39800000</arwr:NetCashInvestedInFixedIncomeInvestments>
  <us-gaap:RestrictedCashAndCashEquivalents id="F_000339" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">0</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents id="F_000340" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">0</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:CashFDICInsuredAmount id="F_000341" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">250000</us-gaap:CashFDICInsuredAmount>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000342" contextRef="C_0000879407_us-gaapRangeAxis_us-gaapMinimumMember_20131001_20140630">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000343" contextRef="C_0000879407_us-gaapRangeAxis_us-gaapMaximumMember_20131001_20140630">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <arwr:CostMethodInvestmentAttributableToNoncontrollingInterest id="F_000344" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">0</arwr:CostMethodInvestmentAttributableToNoncontrollingInterest>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain id="F_000345" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20140630" decimals="0" unitRef="U_iso4217USD">1850</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain id="F_000346" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueAfterOneYearWithinThreeYearsMember_20140630" decimals="0" unitRef="U_iso4217USD">3899</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain id="F_000347" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">5749</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss id="F_000348" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20140630" decimals="0" unitRef="U_iso4217USD">237181</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss id="F_000349" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueAfterOneYearWithinThreeYearsMember_20140630" decimals="0" unitRef="U_iso4217USD">152222</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss id="F_000350" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">389403</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000351" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20140630" decimals="0" unitRef="U_iso4217USD">23599077</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000352" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueAfterOneYearWithinThreeYearsMember_20140630" decimals="0" unitRef="U_iso4217USD">26136599</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000353" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">49735616</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:MarketableSecurities id="F_000354" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">50119270</us-gaap:MarketableSecurities>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain id="F_000355" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20130930" decimals="0" unitRef="U_iso4217USD">7500</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain id="F_000356" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">7500</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss id="F_000357" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20130930" decimals="0" unitRef="U_iso4217USD">39281</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss id="F_000358" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueAfterOneYearWithinThreeYearsMember_20130930" decimals="0" unitRef="U_iso4217USD">2362</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
  <arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss id="F_000359" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">41643</arwr:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000360" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueWithinOneYearMember_20130930" decimals="0" unitRef="U_iso4217USD">8998480</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000361" contextRef="C_0000879407_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_arwrCommercialNotesDueAfterOneYearWithinThreeYearsMember_20130930" decimals="0" unitRef="U_iso4217USD">1699791</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000362" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">10698271</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:MarketableSecurities id="F_000363" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">10732414</us-gaap:MarketableSecurities>
  <us-gaap:FurnitureAndFixturesGross id="F_000364" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">334162</us-gaap:FurnitureAndFixturesGross>
  <us-gaap:FurnitureAndFixturesGross id="F_000365" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">323376</us-gaap:FurnitureAndFixturesGross>
  <arwr:ResearchEquipment id="F_000366" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">4248606</arwr:ResearchEquipment>
  <arwr:ResearchEquipment id="F_000367" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">3452013</arwr:ResearchEquipment>
  <us-gaap:CapitalizedComputerSoftwareGross id="F_000368" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">69623</us-gaap:CapitalizedComputerSoftwareGross>
  <us-gaap:CapitalizedComputerSoftwareGross id="F_000369" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">69623</us-gaap:CapitalizedComputerSoftwareGross>
  <us-gaap:LeaseholdImprovementsGross id="F_000370" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">2955217</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:LeaseholdImprovementsGross id="F_000371" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">2749409</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000372" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">7607608</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000373" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">6594421</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000374" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">3933477</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000375" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">3081186</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <arwr:BusinessCombinationConsiderationPromissoryNoteIssued id="F_000376" contextRef="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20111021" decimals="0" unitRef="U_iso4217USD">50000</arwr:BusinessCombinationConsiderationPromissoryNoteIssued>
  <arwr:BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued id="F_000377" contextRef="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20111021" decimals="INF" unitRef="U_shares">1288158</arwr:BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued>
  <arwr:ApplicableOutLicenseTerm id="F_000378" contextRef="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20131001_20140630">P90D</arwr:ApplicableOutLicenseTerm>
  <arwr:PercentageOfRoyaltyLiability id="F_000379" contextRef="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20140630" decimals="2" unitRef="U_pure">0.03</arwr:PercentageOfRoyaltyLiability>
  <arwr:ObligationToPayRoyalties id="F_000380" contextRef="C_0000879407_20131001_20140630">later of (i) the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii) ten years after the first commercial sale of such product candidate.</arwr:ObligationToPayRoyalties>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow id="F_000381" contextRef="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20140630" decimals="0" unitRef="U_iso4217USD">2500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh id="F_000382" contextRef="C_0000879407_us-gaapBusinessAcquisitionAxis_arwrRocheMadisonMember_20140630" decimals="0" unitRef="U_iso4217USD">6000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
  <arwr:PresentValueOfContingentAcquisitionConsideration id="F_000383" contextRef="C_0000879407_20111001_20111021" decimals="0" unitRef="U_iso4217USD">84935</arwr:PresentValueOfContingentAcquisitionConsideration>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 id="F_000384" contextRef="C_0000879407_20121001_20130930" decimals="-5" unitRef="U_iso4217USD">1400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="F_000385" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20131001_20140630">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="F_000386" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_us-gaapRangeAxis_us-gaapMinimumMember_20131001_20140630">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="F_000387" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_us-gaapRangeAxis_us-gaapMaximumMember_20131001_20140630">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="F_000388" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20140630" decimals="0" unitRef="U_iso4217USD">147800</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000389" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20140401_20140630" decimals="0" unitRef="U_iso4217USD">13663</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000390" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">40990</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000391" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20130401_20130630" decimals="0" unitRef="U_iso4217USD">74115</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000392" contextRef="C_0000879407_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20121001_20130630" decimals="0" unitRef="U_iso4217USD">222345</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear id="F_000393" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo id="F_000394" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">55000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree id="F_000395" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive id="F_000396" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000397" contextRef="C_0000879407_20120930" decimals="0" unitRef="U_iso4217USD">3117322</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill id="F_000398" xsi:nil="true" contextRef="C_0000879407_20121001_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <arwr:IndefiniteLivedIntangibleAssetsAmortization id="F_000399" xsi:nil="true" contextRef="C_0000879407_20121001_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000400" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">3117322</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <arwr:IndefiniteLivedIntangibleAssetsAmortization id="F_000401" xsi:nil="true" contextRef="C_0000879407_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill id="F_000402" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">3117322</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000403" contextRef="C_0000879407_20120930" decimals="0" unitRef="U_iso4217USD">1667247</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:ImpairmentOfIntangibleAssetsFinitelived id="F_000404" contextRef="C_0000879407_20121001_20130930" decimals="0" unitRef="U_iso4217USD">1308047</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000405" contextRef="C_0000879407_20121001_20130930" decimals="0" unitRef="U_iso4217USD">236009</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000406" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">123191</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000407" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">40990</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000408" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">82201</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000409" contextRef="C_0000879407_20120930" decimals="0" unitRef="U_iso4217USD">4784569</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <arwr:OwnershipPercentageInSubsidiary id="F_000410" contextRef="C_0000879407_20131001_20140630" decimals="INF" unitRef="U_pure">1.00</arwr:OwnershipPercentageInSubsidiary>
  <arwr:OutstandingBalanceOfPromissoryNote id="F_000411" contextRef="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20140630" decimals="0" unitRef="U_iso4217USD">1253000</arwr:OutstandingBalanceOfPromissoryNote>
  <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount id="F_000412" contextRef="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">87000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
  <arwr:AmountOwedBySubsidiary id="F_000413" contextRef="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20140630" decimals="-5" unitRef="U_iso4217USD">4500000</arwr:AmountOwedBySubsidiary>
  <arwr:StatedPercentageOfNotesAndAdvances id="F_000414" contextRef="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20140630" decimals="INF" unitRef="U_pure">0.08</arwr:StatedPercentageOfNotesAndAdvances>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage id="F_000415" contextRef="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20140630" decimals="INF" unitRef="U_pure">0.79</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <arwr:EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis id="F_000416" contextRef="C_0000879407_deiLegalEntityAxis_arwrCalandoPharmaceuticalsIncMember_20140630" decimals="INF" unitRef="U_pure">0.76</arwr:EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000417" contextRef="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20101001_20110930" decimals="-5" unitRef="U_iso4217USD">2900000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <arwr:InvestmentInPreferredStock id="F_000418" contextRef="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20110930" decimals="-5" unitRef="U_iso4217USD">1300000</arwr:InvestmentInPreferredStock>
  <arwr:InvestmentInPreferredStockByOutsider id="F_000419" contextRef="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20110930" decimals="-5" unitRef="U_iso4217USD">1600000</arwr:InvestmentInPreferredStockByOutsider>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage id="F_000420" contextRef="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20140630" decimals="INF" unitRef="U_pure">0.64</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <arwr:EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis id="F_000421" contextRef="C_0000879407_deiLegalEntityAxis_arwrAblarisTherapeuticsMember_20140630" decimals="INF" unitRef="U_pure">0.64</arwr:EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis>
  <arwr:OwnershipPercentageInSubsidiary id="F_000422" contextRef="C_0000879407_deiLegalEntityAxis_arwrLeonardoBiosystemsIncMember_20131001_20140630" decimals="INF" unitRef="U_pure">0.03</arwr:OwnershipPercentageInSubsidiary>
  <us-gaap:CapitalUnitsAuthorized id="F_000423" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">150000000</us-gaap:CapitalUnitsAuthorized>
  <us-gaap:CommonStockSharesOutstanding id="F_000424" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20140630" decimals="INF" unitRef="U_shares">2891257</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000425" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20140630" decimals="INF" unitRef="U_shares">2730375</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000426" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20140630" decimals="INF" unitRef="U_shares">5291</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000427" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20140630" decimals="INF" unitRef="U_shares">16000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance id="F_000428" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_20140630" decimals="INF" unitRef="U_shares">7182925</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
  <arwr:ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion id="F_000429" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_pure">0.0999</arwr:ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion>
  <arwr:MaximumEquityCommitmentAmountUnderAgreement id="F_000430" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrPurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_20140630" decimals="-6" unitRef="U_iso4217USD">15000000</arwr:MaximumEquityCommitmentAmountUnderAgreement>
  <arwr:EquityCommitmentAgreementPeriod id="F_000431" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrPurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_20131001_20140630">P3Y</arwr:EquityCommitmentAgreementPeriod>
  <arwr:CashDrawnFromFacility id="F_000432" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrPurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_20140630" decimals="-6" unitRef="U_iso4217USD">1000000</arwr:CashDrawnFromFacility>
  <us-gaap:SaleOfStockPricePerShare id="F_000433" contextRef="C_0000879407_20131011" decimals="INF" unitRef="U_iso4217USD_shares">5.86</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="F_000434" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20131011" decimals="INF" unitRef="U_iso4217USD_shares">1000</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000435" contextRef="C_0000879407_20131010_20131011" decimals="INF" unitRef="U_shares">3071672</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000436" contextRef="C_0000879407_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20131010_20131011" decimals="INF" unitRef="U_shares">46000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <arwr:ConversionPricePerShare id="F_000437" contextRef="C_0000879407_20131011" decimals="INF" unitRef="U_iso4217USD_shares">5.86</arwr:ConversionPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000438" contextRef="C_0000879407_20131010_20131011" decimals="0" unitRef="U_iso4217USD">60000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <arwr:AggregatePriceOnIssuanceOrSaleOfEquity id="F_000439" contextRef="C_0000879407_20131010_20131011" decimals="0" unitRef="U_iso4217USD">64000000</arwr:AggregatePriceOnIssuanceOrSaleOfEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000440" contextRef="C_0000879407_20140223_20140224" decimals="INF" unitRef="U_shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare id="F_000441" contextRef="C_0000879407_20140224" decimals="INF" unitRef="U_iso4217USD_shares">18.95</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000442" contextRef="C_0000879407_20140223_20140224" decimals="-5" unitRef="U_iso4217USD">112600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000443" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantOneMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">70.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000444" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantTwoMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000445" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantThreeMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">5.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000446" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFourMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000447" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFiveMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">4.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000448" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSixMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000449" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSevenMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">2.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000450" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantEightMember_20140630" decimals="INF" unitRef="U_iso4217USD_shares">1.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000451" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantOneMember_20140630" decimals="INF" unitRef="U_shares">94897</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000452" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantTwoMember_20140630" decimals="INF" unitRef="U_shares">416225</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000453" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantThreeMember_20140630" decimals="INF" unitRef="U_shares">291204</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000454" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFourMember_20140630" decimals="INF" unitRef="U_shares">24324</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000455" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFiveMember_20140630" decimals="INF" unitRef="U_shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000456" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSixMember_20140630" decimals="INF" unitRef="U_shares">334347</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000457" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSevenMember_20140630" decimals="INF" unitRef="U_shares">75000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000458" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantEightMember_20140630" decimals="INF" unitRef="U_shares">289784</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000459" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">1526781</us-gaap:ClassOfWarrantOrRightOutstanding>
  <arwr:RemainingLifeOfWarrant id="F_000460" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantOneMember_20131001_20140630">P2Y10M24D</arwr:RemainingLifeOfWarrant>
  <arwr:RemainingLifeOfWarrant id="F_000461" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantTwoMember_20131001_20140630">P1Y2M12D</arwr:RemainingLifeOfWarrant>
  <arwr:RemainingLifeOfWarrant id="F_000462" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantThreeMember_20131001_20140630">P4M24D</arwr:RemainingLifeOfWarrant>
  <arwr:RemainingLifeOfWarrant id="F_000463" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFourMember_20131001_20140630">P1Y6M</arwr:RemainingLifeOfWarrant>
  <arwr:RemainingLifeOfWarrant id="F_000464" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantFiveMember_20131001_20140630">P2Y6M</arwr:RemainingLifeOfWarrant>
  <arwr:RemainingLifeOfWarrant id="F_000465" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSixMember_20131001_20140630">P2Y1M6D</arwr:RemainingLifeOfWarrant>
  <arwr:RemainingLifeOfWarrant id="F_000466" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantSevenMember_20131001_20140630">P3Y6M</arwr:RemainingLifeOfWarrant>
  <arwr:RemainingLifeOfWarrant id="F_000467" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrWarrantEightMember_20131001_20140630">P3Y6M</arwr:RemainingLifeOfWarrant>
  <us-gaap:LeaseExpirationDate1 id="F_000468" contextRef="C_0000879407_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_arwrCorporateHeadquartersInPasadenaMember_20131001_20140630">2019-08-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseAndRentalExpense id="F_000469" contextRef="C_0000879407_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_arwrCorporateHeadquartersInPasadenaMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">22000</us-gaap:LeaseAndRentalExpense>
  <arwr:PercentageOfIncreaseInAnnualRentalCost id="F_000470" contextRef="C_0000879407_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_arwrCorporateHeadquartersInPasadenaMember_20131001_20140630" decimals="2" unitRef="U_pure">0.03</arwr:PercentageOfIncreaseInAnnualRentalCost>
  <us-gaap:LeaseExpirationDate1 id="F_000471" contextRef="C_0000879407_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_arwrResearchFacilityInMadisonMember_20131001_20140630">2019-02-28</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseAndRentalExpense id="F_000472" contextRef="C_0000879407_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_arwrResearchFacilityInMadisonMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">25000</us-gaap:LeaseAndRentalExpense>
  <arwr:OtherRentalExpenses id="F_000473" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">16000</arwr:OtherRentalExpenses>
  <us-gaap:UtilitiesCosts id="F_000474" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">15000</us-gaap:UtilitiesCosts>
  <arwr:PaymentsUnderCapitalLease id="F_000475" contextRef="C_0000879407_us-gaapMajorPropertyClassAxis_us-gaapAssetsHeldUnderCapitalLeasesMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">19000</arwr:PaymentsUnderCapitalLease>
  <arwr:IncreaseInMonthlyExpenditureDueToUtilitiesCosts id="F_000476" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">75000</arwr:IncreaseInMonthlyExpenditureDueToUtilitiesCosts>
  <arwr:FacilityAndEquipmentRentExpense id="F_000477" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">138000</arwr:FacilityAndEquipmentRentExpense>
  <arwr:FacilityAndEquipmentRentExpense id="F_000478" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">403000</arwr:FacilityAndEquipmentRentExpense>
  <arwr:FacilityAndEquipmentRentExpense id="F_000479" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">126000</arwr:FacilityAndEquipmentRentExpense>
  <arwr:FacilityAndEquipmentRentExpense id="F_000480" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">407000</arwr:FacilityAndEquipmentRentExpense>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear id="F_000481" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">57105</us-gaap:CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent id="F_000482" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">228420</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears id="F_000483" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">228420</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears id="F_000484" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">228420</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears id="F_000485" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">228420</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter id="F_000486" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">95175</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments id="F_000487" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">40681</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments id="F_000488" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">1025279</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear id="F_000489" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">134164</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000490" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">580626</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000491" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">597196</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="F_000492" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">613984</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="F_000493" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">638217</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="F_000494" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">432861</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000495" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">2997048</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000496" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsStockOptionPlanMember_20140630" decimals="INF" unitRef="U_shares">38000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000497" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">410085</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000498" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20140630" decimals="INF" unitRef="U_shares">2734840</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000499" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20140630" decimals="INF" unitRef="U_shares">4000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000500" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsStockOptionPlanMember_20140630" decimals="INF" unitRef="U_shares">38000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000501" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20140630" decimals="INF" unitRef="U_shares">2638652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000502" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20140630" decimals="INF" unitRef="U_shares">736875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000503" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20131001_20140630" decimals="INF" unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000504" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20131001_20140630" decimals="INF" unitRef="U_shares">765000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants id="F_000505" contextRef="C_0000879407_20131001_20140630" decimals="INF" unitRef="U_shares">165000</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000506" contextRef="C_0000879407_20120930" decimals="INF" unitRef="U_shares">1910794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000507" contextRef="C_0000879407_20121001_20130930" decimals="INF" unitRef="U_shares">1509166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod id="F_000508" xsi:nil="true" contextRef="C_0000879407_20121001_20130930" unitRef="U_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000509" contextRef="C_0000879407_20121001_20130930" decimals="INF" unitRef="U_shares">675</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000510" contextRef="C_0000879407_20130930" decimals="INF" unitRef="U_shares">3419285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000511" contextRef="C_0000879407_20131001_20140630" decimals="INF" unitRef="U_shares">930000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod id="F_000512" contextRef="C_0000879407_20131001_20140630" decimals="INF" unitRef="U_shares">148561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000513" contextRef="C_0000879407_20131001_20140630" decimals="INF" unitRef="U_shares">377112</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000514" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">3823612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000515" contextRef="C_0000879407_20140630" decimals="INF" unitRef="U_shares">1532180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000516" contextRef="C_0000879407_20120930" decimals="2" unitRef="U_iso4217USD_shares">6.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000517" contextRef="C_0000879407_20121001_20130930" decimals="2" unitRef="U_iso4217USD_shares">2.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice id="F_000518" xsi:nil="true" contextRef="C_0000879407_20121001_20130930" unitRef="U_iso4217USD_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000519" contextRef="C_0000879407_20121001_20130930" decimals="2" unitRef="U_iso4217USD_shares">3.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000520" contextRef="C_0000879407_20130930" decimals="2" unitRef="U_iso4217USD_shares">4.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000521" contextRef="C_0000879407_20131001_20140630" decimals="2" unitRef="U_iso4217USD_shares">14.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice id="F_000522" contextRef="C_0000879407_20131001_20140630" decimals="2" unitRef="U_iso4217USD_shares">5.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000523" contextRef="C_0000879407_20131001_20140630" decimals="2" unitRef="U_iso4217USD_shares">6.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000524" contextRef="C_0000879407_20140630" decimals="2" unitRef="U_iso4217USD_shares">6.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000525" contextRef="C_0000879407_20140630" decimals="2" unitRef="U_iso4217USD_shares">5.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000526" contextRef="C_0000879407_20131001_20140630">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000527" contextRef="C_0000879407_20131001_20140630">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000528" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">30271011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000529" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">13666712</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000530" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">1070631</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000531" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">2186653</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000532" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">363593</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000533" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">1114375</us-gaap:AllocatedShareBasedCompensationExpense>
  <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue id="F_000534" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">1176000</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
  <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue id="F_000535" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">8295600</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
  <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue id="F_000536" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">1094295</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
  <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue id="F_000537" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">1197588</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000538" contextRef="C_0000879407_20140401_20140630" decimals="0" unitRef="U_iso4217USD">371334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000539" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">3606061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000540" contextRef="C_0000879407_20130401_20130630" decimals="0" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000541" contextRef="C_0000879407_20121001_20130630" decimals="0" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000542" contextRef="C_0000879407_20131001_20140630" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000543" contextRef="C_0000879407_20121001_20130630" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000544" contextRef="C_0000879407_20131001_20140630" decimals="3" unitRef="U_pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000545" contextRef="C_0000879407_20121001_20130630" decimals="3" unitRef="U_pure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000546" contextRef="C_0000879407_20131001_20140630" decimals="3" unitRef="U_pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000547" contextRef="C_0000879407_20121001_20130630" decimals="3" unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000548" contextRef="C_0000879407_20131001_20140630" decimals="2" unitRef="U_pure">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000549" contextRef="C_0000879407_20121001_20130630" decimals="2" unitRef="U_pure">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000550" contextRef="C_0000879407_us-gaapRangeAxis_us-gaapMinimumMember_20131001_20140630">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000551" contextRef="C_0000879407_us-gaapRangeAxis_us-gaapMaximumMember_20131001_20140630">P9Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000552" contextRef="C_0000879407_us-gaapRangeAxis_us-gaapMinimumMember_20121001_20130630">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000553" contextRef="C_0000879407_us-gaapRangeAxis_us-gaapMaximumMember_20121001_20130630">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000554" contextRef="C_0000879407_20131001_20140630" decimals="2" unitRef="U_iso4217USD_shares">8.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000555" contextRef="C_0000879407_20121001_20130630" decimals="2" unitRef="U_iso4217USD_shares">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000556" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20140630" decimals="INF" unitRef="U_shares">470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000557" xsi:nil="true" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20130930" unitRef="U_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000558" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630" decimals="INF" unitRef="U_shares">470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000559" xsi:nil="true" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630" unitRef="U_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_000560" xsi:nil="true" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630" unitRef="U_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000561" xsi:nil="true" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20130930" unitRef="U_iso4217USD_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000562" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630" decimals="2" unitRef="U_iso4217USD_shares">14.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="F_000563" xsi:nil="true" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630" unitRef="U_iso4217USD_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="F_000564" xsi:nil="true" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630" unitRef="U_iso4217USD_shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000565" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20140630" decimals="2" unitRef="U_iso4217USD_shares">14.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000566" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20140401_20140630" decimals="0" unitRef="U_iso4217USD">968051</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000567" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">1571611</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000568" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20130401_20130630" decimals="0" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000569" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20121001_20130630" decimals="0" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000570" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20140630" decimals="0" unitRef="U_iso4217USD">5291302</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000571" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20131001_20140630">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000572" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20140630" decimals="0" unitRef="U_iso4217USD">10514619</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000573" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrArrowheadMember_20131001_20140630">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000574" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" decimals="0" unitRef="U_iso4217USD">138349733</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000575" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" decimals="0" unitRef="U_iso4217USD">138349733</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeAssetsNoncurrent id="F_000576" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DerivativeAssetsNoncurrent id="F_000577" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DerivativeLiabilities id="F_000578" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" decimals="0" unitRef="U_iso4217USD">4018719</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="F_000579" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" decimals="0" unitRef="U_iso4217USD">4018719</us-gaap:DerivativeLiabilities>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000580" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" decimals="0" unitRef="U_iso4217USD">1595273</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000581" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20140630" decimals="0" unitRef="U_iso4217USD">1595273</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000582" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" decimals="0" unitRef="U_iso4217USD">19114444</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000583" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" decimals="0" unitRef="U_iso4217USD">19114444</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeAssetsNoncurrent id="F_000584" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DerivativeAssetsNoncurrent id="F_000585" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DerivativeLiabilities id="F_000586" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" decimals="0" unitRef="U_iso4217USD">4096363</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="F_000587" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" decimals="0" unitRef="U_iso4217USD">4096363</us-gaap:DerivativeLiabilities>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000588" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" decimals="0" unitRef="U_iso4217USD">1595273</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000589" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20130930" decimals="0" unitRef="U_iso4217USD">1595273</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <arwr:NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds id="F_000590" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrUnidymIncMember_20110101_20110131" decimals="-5" unitRef="U_iso4217USD">2500000</arwr:NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="F_000591" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrUnidymIncMember_20110131" decimals="INF" unitRef="U_iso4217USD_shares">2.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue id="F_000592" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20120930" decimals="0" unitRef="U_iso4217USD">250250</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases id="F_000593" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20121001_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 id="F_000594" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20121001_20130930" decimals="0" unitRef="U_iso4217USD">-250250</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements id="F_000595" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20121001_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue id="F_000596" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases id="F_000597" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 id="F_000598" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements id="F_000599" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue id="F_000600" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByAssetClassAxis_us-gaapDerivativeFinancialInstrumentsAssetsMember_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <arwr:WarrantsIssuedToAcquireCommonStock id="F_000601" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandTenWarrantsMember_20140630" decimals="INF" unitRef="U_shares">329649</arwr:WarrantsIssuedToAcquireCommonStock>
  <arwr:WarrantsIssuedToAcquireCommonStock id="F_000602" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandsTwelveWarrantsMember_20140630" decimals="INF" unitRef="U_shares">912543</arwr:WarrantsIssuedToAcquireCommonStock>
  <arwr:WarrantsIssuedToAcquireCommonStock id="F_000603" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandThirteenWarrantsMember_20140630" decimals="INF" unitRef="U_shares">833530</arwr:WarrantsIssuedToAcquireCommonStock>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000604" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandTenWarrantsMember_20140630" decimals="INF" unitRef="U_shares">24324</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000605" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandsTwelveWarrantsMember_20140630" decimals="INF" unitRef="U_shares">265161</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000606" contextRef="C_0000879407_us-gaapClassOfWarrantOrRightAxis_arwrTwoThousandThirteenWarrantsMember_20140630" decimals="INF" unitRef="U_shares">24623</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000607" contextRef="C_0000879407_20131001_20140630" decimals="0" unitRef="U_iso4217USD">5680544</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000608" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20131001_20140630" decimals="4" unitRef="U_pure">0.0011</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000609" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20121001_20130930" decimals="4" unitRef="U_pure">0.0033</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000610" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20131001_20140630">P1Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000611" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20121001_20130930">P2Y2M12D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000612" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20131001_20140630" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000613" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20121001_20130930" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000614" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000615" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandTenWarrantsMember_20121001_20130930" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000616" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20131001_20140630" decimals="4" unitRef="U_pure">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000617" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20121001_20130930" decimals="4" unitRef="U_pure">0.0139</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000618" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20131001_20140630">P3Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000619" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20121001_20130930">P4Y2M12D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000620" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20131001_20140630" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000621" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20121001_20130930" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000622" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000623" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandsTwelveWarrantsMember_20121001_20130930" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000624" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20131001_20140630" decimals="4" unitRef="U_pure">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000625" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20121001_20130930" decimals="4" unitRef="U_pure">0.0139</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000626" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20131001_20140630">P3Y7M6D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000627" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20121001_20130930">P4Y3M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000628" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20131001_20140630" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000629" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20121001_20130930" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000630" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000631" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrTwoThousandThirteenWarrantsMember_20121001_20130930" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000632" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20120930" decimals="0" unitRef="U_iso4217USD">626195</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="F_000633" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20121001_20130930" decimals="0" unitRef="U_iso4217USD">2153819</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000634" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20121001_20130930" decimals="0" unitRef="U_iso4217USD">5066591</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="F_000635" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20121001_20130930" decimals="0" unitRef="U_iso4217USD">3754808</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000636" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20130930" decimals="0" unitRef="U_iso4217USD">4091797</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="F_000637" xsi:nil="true" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000638" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">5680544</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="F_000639" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">5789982</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000640" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_us-gaapWarrantMember_20140630" decimals="0" unitRef="U_iso4217USD">3982359</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000641" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">31791</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <arwr:TermOfExchangeRights id="F_000642" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630">P7Y</arwr:TermOfExchangeRights>
  <arwr:ExchangeRightConvertibleConversionRatioForFirstYear id="F_000643" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.06</arwr:ExchangeRightConvertibleConversionRatioForFirstYear>
  <arwr:ExchangeRightConvertibleConversionRatioForTwoYear id="F_000644" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.04</arwr:ExchangeRightConvertibleConversionRatioForTwoYear>
  <arwr:ExchangeRightConvertibleConversionRatioForThreeYear id="F_000645" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.03</arwr:ExchangeRightConvertibleConversionRatioForThreeYear>
  <arwr:ExchangeRightConvertibleConversionRatioForFourYear id="F_000646" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.02</arwr:ExchangeRightConvertibleConversionRatioForFourYear>
  <arwr:ExchangeRightConvertibleConversionRatioForFiveYear id="F_000647" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.01</arwr:ExchangeRightConvertibleConversionRatioForFiveYear>
  <arwr:NumberOfExchangeRightAreSold id="F_000648" contextRef="C_0000879407_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_arwrAblarisTherapeuticsMember_20131001_20140630" decimals="INF" unitRef="U_shares">675000</arwr:NumberOfExchangeRightAreSold>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000649" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630" decimals="4" unitRef="U_pure">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="F_000650" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930" decimals="4" unitRef="U_pure">0.0139</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000651" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630">P3Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="F_000652" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930">P4Y3M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000653" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="F_000654" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930" unitRef="U_pure" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000655" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000656" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930" decimals="2" unitRef="U_pure">0.69</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000657" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20120930" decimals="0" unitRef="U_iso4217USD">10375</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="F_000658" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000659" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930" decimals="0" unitRef="U_iso4217USD">-5806</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="F_000660" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20121001_20130930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000661" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20130930" decimals="0" unitRef="U_iso4217USD">4569</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="F_000662" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="F_000663" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630" decimals="0" unitRef="U_iso4217USD">31791</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements id="F_000664" xsi:nil="true" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20131001_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000665" contextRef="C_0000879407_us-gaapFairValueByLiabilityClassAxis_arwrExchangeRightsMember_20140630" decimals="0" unitRef="U_iso4217USD">36360</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000666" contextRef="C_0000879407_20120930" decimals="0" unitRef="U_iso4217USD">173621</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <arwr:BusinessCombinationPurchasePriceContingentConsiderationFairValue id="F_000667" xsi:nil="true" contextRef="C_0000879407_20120930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <arwr:BusinessCombinationContingentConsiderationPayments id="F_000668" xsi:nil="true" contextRef="C_0000879407_20120930" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <arwr:BusinessCombinationFairValueOfChangeInContingentConsideration id="F_000669" contextRef="C_0000879407_20120930" decimals="0" unitRef="U_iso4217USD">1421652</arwr:BusinessCombinationFairValueOfChangeInContingentConsideration>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000670" contextRef="C_0000879407_20130930" decimals="0" unitRef="U_iso4217USD">1595273</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <arwr:BusinessCombinationPurchasePriceContingentConsiderationFairValue id="F_000671" xsi:nil="true" contextRef="C_0000879407_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <arwr:BusinessCombinationContingentConsiderationPayments id="F_000672" xsi:nil="true" contextRef="C_0000879407_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <arwr:BusinessCombinationFairValueOfChangeInContingentConsideration id="F_000673" xsi:nil="true" contextRef="C_0000879407_20140630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000674" contextRef="C_0000879407_20140630" decimals="0" unitRef="U_iso4217USD">1595273</us-gaap:BusinessCombinationContingentConsiderationLiability>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>arwr-20140630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Schema Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2014-08-12T15:59:41.1142645+00:00 -->
<!-- Version            : 1.9.0.3 -->
<!-- Package ID         : F4AAA9047B9D167BE0DC1A89763CCCBA-0000879407-001406 -->
<!-- Copyright (c) 2014 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:arwr="http://www.arrowheadresearch.com/20140630" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20140630" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" namespace="http://fasb.org/us-types/2013-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" namespace="http://fasb.org/us-gaap/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" namespace="http://xbrl.sec.gov/country/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2012-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arrowheadresearch.com/20140630/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20140630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20140630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20140630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20140630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity" id="Role_StatementConsolidatedStatementOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statement of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementOfStockholdersEquityParenthetical">
        <link:definition>100050 - Statement - Consolidated Statement of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="Role_StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies" id="Role_DisclosureOrganizationAndSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>100090 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssets" id="Role_DisclosureFixedAssets">
        <link:definition>100100 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitions" id="Role_DisclosureAcquisitions">
        <link:definition>100110 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssets" id="Role_DisclosureIntangibleAssets">
        <link:definition>100120 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiaries" id="Role_DisclosureInvestmentInSubsidiaries">
        <link:definition>100130 - Disclosure - Investment in Subsidiaries</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100140 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100150 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100160 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100170 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies">
        <link:definition>100180 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>100190 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssetsTables" id="Role_DisclosureFixedAssetsTables">
        <link:definition>100200 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsTables" id="Role_DisclosureIntangibleAssetsTables">
        <link:definition>100210 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100220 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100230 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100240 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100250 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100260 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail" id="Role_DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail">
        <link:definition>100270 - Disclosure - Investments - Summary of Short and Long-term Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixdAssetsAdditionalInformationDetail" id="Role_DisclosureFixdAssetsAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Fixd Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail" id="Role_DisclosureSummaryOfPropertyAndEquipmentDetail">
        <link:definition>100290 - Disclosure - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetail" id="Role_DisclosureAcquisitionsAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Acquisitions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail" id="Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail">
        <link:definition>100320 - Disclosure - Intangible Assets - Schedule of Intangible Asset (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiariesAdditionalInformationDetail" id="Role_DisclosureInvestmentInSubsidiariesAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Investment in Subsidiaries - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail" id="Role_DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail">
        <link:definition>100350 - Disclosure - Stockholders&apos; Equity - Summary of Information about Warrants (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail" id="Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail">
        <link:definition>100370 - Disclosure - Leases - Future Minimum Lease Payments under Capitalized Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" id="Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
        <link:definition>100380 - Disclosure - Leases - Future Minimum Lease Payments under Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" id="Role_DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail">
        <link:definition>100400 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" id="Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail">
        <link:definition>100410 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail">
        <link:definition>100420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail" id="Role_DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Reconciliation of Derivative Asset (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail" id="Role_DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail">
        <link:definition>100460 - Disclosure - Fair Value Measurements - Assumptions Used in Valuing Derivative Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail" id="Role_DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail">
        <link:definition>100470 - Disclosure - Fair Value Measurements - Reconciliation of Derivative Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail" id="Role_DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail">
        <link:definition>100480 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration Obligations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="arwr_DocumentDocumentAndEntityInformationAbstract" name="DocumentDocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_DocumentDocumentAndEntityInformationLineItems" name="DocumentDocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_DocumentDocumentAndEntityInformationTable" name="DocumentDocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ImpairmentOfIntangibleAssets" name="ImpairmentOfIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_StatementConsolidatedStatementsOfOperationsLineItems" name="StatementConsolidatedStatementsOfOperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_StatementConsolidatedStatementsOfOperationsTable" name="StatementConsolidatedStatementsOfOperationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantsExercisedDuringPeriodShares" name="WarrantsExercisedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_WarrantsExercisedDuringPeriodValue" name="WarrantsExercisedDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" name="IssuedAtFiveDollarAndEightySixCentsPerShareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" name="IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" name="PreferredStockIssuedAtThousandDollarsPerShareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_IssuedToGallowayMember" name="IssuedToGallowayMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" name="ProceedsFromExerciseOfWarrantsAndStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" name="StatementConsolidatedStatementsOfCashFlowsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_StatementConsolidatedStatementsOfCashFlowsTable" name="StatementConsolidatedStatementsOfCashFlowsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_RocheMadisonMember" name="RocheMadisonMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_NoncontrollingInterestsPolicyTextBlock" name="NoncontrollingInterestsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" name="FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_ExchangeRightsMember" name="ExchangeRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_NetCashInvestedInFixedIncomeInvestments" name="NetCashInvestedInFixedIncomeInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" name="CostMethodInvestmentAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" name="HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" name="HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_CommercialNotesDueWithinOneYearMember" name="CommercialNotesDueWithinOneYearMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" name="CommercialNotesDueAfterOneYearWithinThreeYearsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ResearchEquipment" name="ResearchEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_BusinessCombinationConsiderationPromissoryNoteIssued" name="BusinessCombinationConsiderationPromissoryNoteIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" name="BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="arwr_ApplicableOutLicenseTerm" name="ApplicableOutLicenseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_PercentageOfRoyaltyLiability" name="PercentageOfRoyaltyLiability" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="arwr_ObligationToPayRoyalties" name="ObligationToPayRoyalties" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_PresentValueOfContingentAcquisitionConsideration" name="PresentValueOfContingentAcquisitionConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_ExpectedAmortizationExpenseLineItems" name="ExpectedAmortizationExpenseLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ExpectedAmortizationExpenseTable" name="ExpectedAmortizationExpenseTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_IndefiniteLivedIntangibleAssetsAmortization" name="IndefiniteLivedIntangibleAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_OwnershipPercentageInSubsidiary" name="OwnershipPercentageInSubsidiary" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_OutstandingBalanceOfPromissoryNote" name="OutstandingBalanceOfPromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_CalandoPharmaceuticalsIncMember" name="CalandoPharmaceuticalsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_AmountOwedBySubsidiary" name="AmountOwedBySubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_StatedPercentageOfNotesAndAdvances" name="StatedPercentageOfNotesAndAdvances" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" name="EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="arwr_InvestmentInPreferredStock" name="InvestmentInPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_InvestmentInPreferredStockByOutsider" name="InvestmentInPreferredStockByOutsider" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_AblarisTherapeuticsMember" name="AblarisTherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_LeonardoBiosystemsIncMember" name="LeonardoBiosystemsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" name="TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" name="ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="arwr_MaximumEquityCommitmentAmountUnderAgreement" name="MaximumEquityCommitmentAmountUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_EquityCommitmentAgreementPeriod" name="EquityCommitmentAgreementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_CashDrawnFromFacility" name="CashDrawnFromFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" name="PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_CommonStockExercisePrice" name="CommonStockExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_ConversionPricePerShare" name="ConversionPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="arwr_AggregatePriceOnIssuanceOrSaleOfEquity" name="AggregatePriceOnIssuanceOrSaleOfEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_RemainingLifeOfWarrant" name="RemainingLifeOfWarrant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_WarrantOneMember" name="WarrantOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantTwoMember" name="WarrantTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantThreeMember" name="WarrantThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantFourMember" name="WarrantFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantFiveMember" name="WarrantFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantSixMember" name="WarrantSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantSevenMember" name="WarrantSevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantEightMember" name="WarrantEightMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_PercentageOfIncreaseInAnnualRentalCost" name="PercentageOfIncreaseInAnnualRentalCost" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_CorporateHeadquartersInPasadenaMember" name="CorporateHeadquartersInPasadenaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_OtherRentalExpenses" name="OtherRentalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_PaymentsUnderCapitalLease" name="PaymentsUnderCapitalLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" name="IncreaseInMonthlyExpenditureDueToUtilitiesCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_ResearchFacilityInMadisonMember" name="ResearchFacilityInMadisonMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_FacilityAndEquipmentRentExpense" name="FacilityAndEquipmentRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_TwoThousandsStockOptionPlanMember" name="TwoThousandsStockOptionPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_TwoThousandsFourEquityIncentivePlanMember" name="TwoThousandsFourEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_TwoThousandsThirteenIncentivePlanMember" name="TwoThousandsThirteenIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_ArrowheadMember" name="ArrowheadMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_FairValueMeasurementsDisclosureLineItems" name="FairValueMeasurementsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_FairValueMeasurementsDisclosureTable" name="FairValueMeasurementsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" name="NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="arwr_UnidymIncMember" name="UnidymIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_WarrantsIssuedToAcquireCommonStock" name="WarrantsIssuedToAcquireCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="arwr_TwoThousandTenWarrantsMember" name="TwoThousandTenWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_TwoThousandsTwelveWarrantsMember" name="TwoThousandsTwelveWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_TwoThousandThirteenWarrantsMember" name="TwoThousandThirteenWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="arwr_TermOfExchangeRights" name="TermOfExchangeRights" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_ExchangeRightConvertibleConversionRatioForFirstYear" name="ExchangeRightConvertibleConversionRatioForFirstYear" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_ExchangeRightConvertibleConversionRatioForTwoYear" name="ExchangeRightConvertibleConversionRatioForTwoYear" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_ExchangeRightConvertibleConversionRatioForThreeYear" name="ExchangeRightConvertibleConversionRatioForThreeYear" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_ExchangeRightConvertibleConversionRatioForFourYear" name="ExchangeRightConvertibleConversionRatioForFourYear" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_ExchangeRightConvertibleConversionRatioForFiveYear" name="ExchangeRightConvertibleConversionRatioForFiveYear" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_NumberOfExchangeRightAreSold" name="NumberOfExchangeRightAreSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" name="BusinessCombinationPurchasePriceContingentConsiderationFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_BusinessCombinationContingentConsiderationPayments" name="BusinessCombinationContingentConsiderationPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" name="BusinessCombinationFairValueOfChangeInContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>arwr-20140630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2014-08-12T15:59:41.1142645+00:00 -->
<!-- Version            : 1.9.0.3 -->
<!-- Package ID         : F4AAA9047B9D167BE0DC1A89763CCCBA-0000879407-001406 -->
<!-- Copyright (c) 2014 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="arwr-20140630.xsd#TemplateLink" roleURI="http://www.arrowheadresearch.com/20140630/role/TemplateLink" />
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10230.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10260.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10300.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <loc xlink:href="arwr-20140630.xsd#arwr_ImpairmentOfIntangibleAssets" xlink:type="locator" xlink:label="arwr_ImpairmentOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_LaborAndRelatedExpense" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="arwr_ImpairmentOfIntangibleAssets" order="10210.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:type="locator" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AssetImpairmentCharges" order="10230.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10280.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10290.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10300.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="10310.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10630.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10640.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ResearchEquipment" xlink:type="locator" xlink:label="arwr_ResearchEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="arwr_ResearchEquipment" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10060.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="10070.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>arwr-20140630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2014-08-12T15:59:41.1142645+00:00 -->
<!-- Version            : 1.9.0.3 -->
<!-- Package ID         : F4AAA9047B9D167BE0DC1A89763CCCBA-0000879407-001406 -->
<!-- Copyright (c) 2014 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="arwr-20140630.xsd#TemplateLink" roleURI="http://www.arrowheadresearch.com/20140630/role/TemplateLink" />
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="arwr-20140630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationTable" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationTable" />
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="arwr_DocumentDocumentAndEntityInformationTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_DocumentDocumentAndEntityInformationTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10690.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10350.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="11250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="11970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="12050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="12130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="12210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="12290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="12370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="12430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="12510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="12590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="12670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="12750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="13070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="13150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="13230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="13310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="13390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13470.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10650.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ImpairmentOfIntangibleAssets" xlink:type="locator" xlink:label="arwr_ImpairmentOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfOperationsTable" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsTable" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="arwr_StatementConsolidatedStatementsOfOperationsTable" order="10260.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsTable" xlink:to="dei_LegalEntityAxis" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_Revenues" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="11260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="arwr_ImpairmentOfIntangibleAssets" order="11420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="11540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="11860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="12020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="12180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="12480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="12640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="12800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="12960.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="13280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="13440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_ProfitLoss" order="13540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="13700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="14020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="14180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="14340.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsExercisedDuringPeriodValue" xlink:type="locator" xlink:label="arwr_WarrantsExercisedDuringPeriodValue" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsExercisedDuringPeriodShares" xlink:type="locator" xlink:label="arwr_WarrantsExercisedDuringPeriodShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedToGallowayMember" xlink:type="locator" xlink:label="arwr_IssuedToGallowayMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" xlink:type="locator" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedToGallowayMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10410.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_WarrantsExercisedDuringPeriodShares" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_WarrantsExercisedDuringPeriodValue" order="11150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" order="13810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="14030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="14250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" order="14490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="14710.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" xlink:type="locator" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10140.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10180.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:type="locator" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfCashFlowsTable" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsTable" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="arwr_StatementConsolidatedStatementsOfCashFlowsTable" order="10360.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsTable" xlink:to="dei_LegalEntityAxis" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProfitLoss" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="10960.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="11140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="11300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="11620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="12000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="12080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="12160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="12240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="12400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" order="12480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" order="12620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="12700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="12760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" order="12840.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" order="12920.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="13060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="13260.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <loc xlink:href="arwr-20140630.xsd#arwr_RocheMadisonMember" xlink:type="locator" xlink:label="arwr_RocheMadisonMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedToGallowayMember" xlink:type="locator" xlink:label="arwr_IssuedToGallowayMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedToGallowayMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10100.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_RocheMadisonMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="10370.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies" xlink:href="arwr-20140630.xsd#Role_DisclosureOrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestments" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestments" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestments">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssets" xlink:href="arwr-20140630.xsd#Role_DisclosureFixedAssets" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitions" xlink:href="arwr-20140630.xsd#Role_DisclosureAcquisitions" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitions">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssets" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiaries" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentInSubsidiaries" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiaries">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquity" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquity">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeases" xlink:href="arwr-20140630.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeases">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurements">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="arwr-20140630.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NoncontrollingInterestsPolicyTextBlock" xlink:type="locator" xlink:label="arwr_NoncontrollingInterestsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:type="locator" xlink:label="us-gaap_EquityAndCostMethodInvestmentsPolicy" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="arwr_ContingentConsiderationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_ContingentConsiderationPolicyTextBlock" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAndCostMethodInvestmentsPolicy" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_NoncontrollingInterestsPolicyTextBlock" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="11610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="11770.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssetsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureFixedAssetsTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssetsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesTables" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10170.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10250.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightsMember" xlink:type="locator" xlink:label="arwr_ExchangeRightsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_ExchangeRightsMember" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="10720.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NetCashInvestedInFixedIncomeInvestments" xlink:type="locator" xlink:label="arwr_NetCashInvestedInFixedIncomeInvestments" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:type="locator" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Investments" xlink:type="locator" xlink:label="us-gaap_Investments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BondsMember" xlink:type="locator" xlink:label="us-gaap_BondsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfInvestmentsByTypeDomain" xlink:type="locator" xlink:label="us-gaap_SummaryOfInvestmentsByTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfInvestmentsByTypeDomain" xlink:type="locator" xlink:label="us-gaap_SummaryOfInvestmentsByTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xlink:type="locator" xlink:label="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xlink:to="us-gaap_SummaryOfInvestmentsByTypeDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xlink:to="us-gaap_SummaryOfInvestmentsByTypeDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentsByTypeDomain" xlink:to="us-gaap_BondsMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10100.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_Investments" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_NetCashInvestedInFixedIncomeInvestments" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="10580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_RangeAxis" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" order="10890.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <loc xlink:href="arwr-20140630.xsd#arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <loc xlink:href="arwr-20140630.xsd#arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="arwr_CommercialNotesDueWithinOneYearMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10120.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_MarketableSecurities" order="10760.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixdAssetsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFixdAssetsAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixdAssetsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10120.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10160.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ResearchEquipment" xlink:type="locator" xlink:label="arwr_ResearchEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10110.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="arwr_ResearchEquipment" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10630.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PresentValueOfContingentAcquisitionConsideration" xlink:type="locator" xlink:label="arwr_PresentValueOfContingentAcquisitionConsideration" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ObligationToPayRoyalties" xlink:type="locator" xlink:label="arwr_ObligationToPayRoyalties" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PercentageOfRoyaltyLiability" xlink:type="locator" xlink:label="arwr_PercentageOfRoyaltyLiability" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ApplicableOutLicenseTerm" xlink:type="locator" xlink:label="arwr_ApplicableOutLicenseTerm" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" xlink:type="locator" xlink:label="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationConsiderationPromissoryNoteIssued" xlink:type="locator" xlink:label="arwr_BusinessCombinationConsiderationPromissoryNoteIssued" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_RocheMadisonMember" xlink:type="locator" xlink:label="arwr_RocheMadisonMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="arwr_RocheMadisonMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10120.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_BusinessCombinationConsiderationPromissoryNoteIssued" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_ApplicableOutLicenseTerm" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_PercentageOfRoyaltyLiability" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_ObligationToPayRoyalties" order="10540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_PresentValueOfContingentAcquisitionConsideration" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10830.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExpectedAmortizationExpenseLineItems" xlink:type="locator" xlink:label="arwr_ExpectedAmortizationExpenseLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExpectedAmortizationExpenseTable" xlink:type="locator" xlink:label="arwr_ExpectedAmortizationExpenseTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="us-gaap_RangeAxis" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="arwr_ExpectedAmortizationExpenseTable" order="10230.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="dei_LegalEntityAxis" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="11270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="11430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="11750.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IndefiniteLivedIntangibleAssetsAmortization" xlink:type="locator" xlink:label="arwr_IndefiniteLivedIntangibleAssetsAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="arwr_IndefiniteLivedIntangibleAssetsAmortization" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11410.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiariesAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentInSubsidiariesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiariesAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_LeonardoBiosystemsIncMember" xlink:type="locator" xlink:label="arwr_LeonardoBiosystemsIncMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_InvestmentInPreferredStockByOutsider" xlink:type="locator" xlink:label="arwr_InvestmentInPreferredStockByOutsider" />
    <loc xlink:href="arwr-20140630.xsd#arwr_InvestmentInPreferredStock" xlink:type="locator" xlink:label="arwr_InvestmentInPreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AblarisTherapeuticsMember" xlink:type="locator" xlink:label="arwr_AblarisTherapeuticsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" xlink:type="locator" xlink:label="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatedPercentageOfNotesAndAdvances" xlink:type="locator" xlink:label="arwr_StatedPercentageOfNotesAndAdvances" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AmountOwedBySubsidiary" xlink:type="locator" xlink:label="arwr_AmountOwedBySubsidiary" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="locator" xlink:label="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
    <loc xlink:href="arwr-20140630.xsd#arwr_OutstandingBalanceOfPromissoryNote" xlink:type="locator" xlink:label="arwr_OutstandingBalanceOfPromissoryNote" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CalandoPharmaceuticalsIncMember" xlink:type="locator" xlink:label="arwr_CalandoPharmaceuticalsIncMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_OwnershipPercentageInSubsidiary" xlink:type="locator" xlink:label="arwr_OwnershipPercentageInSubsidiary" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_OwnershipPercentageInSubsidiary" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_CalandoPharmaceuticalsIncMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_OutstandingBalanceOfPromissoryNote" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_AmountOwedBySubsidiary" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_StatedPercentageOfNotesAndAdvances" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_AblarisTherapeuticsMember" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_InvestmentInPreferredStock" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_InvestmentInPreferredStockByOutsider" order="11030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_LeonardoBiosystemsIncMember" order="11350.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_AggregatePriceOnIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="arwr_AggregatePriceOnIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ConversionPricePerShare" xlink:type="locator" xlink:label="arwr_ConversionPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CommonStockExercisePrice" xlink:type="locator" xlink:label="arwr_CommonStockExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CashDrawnFromFacility" xlink:type="locator" xlink:label="arwr_CashDrawnFromFacility" />
    <loc xlink:href="arwr-20140630.xsd#arwr_EquityCommitmentAgreementPeriod" xlink:type="locator" xlink:label="arwr_EquityCommitmentAgreementPeriod" />
    <loc xlink:href="arwr-20140630.xsd#arwr_MaximumEquityCommitmentAmountUnderAgreement" xlink:type="locator" xlink:label="arwr_MaximumEquityCommitmentAmountUnderAgreement" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:type="locator" xlink:label="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_MaximumEquityCommitmentAmountUnderAgreement" order="10920.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_EquityCommitmentAgreementPeriod" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_CashDrawnFromFacility" order="11040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_CommonStockExercisePrice" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ConversionPricePerShare" order="11550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_AggregatePriceOnIssuanceOrSaleOfEquity" order="11710.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_RemainingLifeOfWarrant" xlink:type="locator" xlink:label="arwr_RemainingLifeOfWarrant" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantEightMember" xlink:type="locator" xlink:label="arwr_WarrantEightMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantSevenMember" xlink:type="locator" xlink:label="arwr_WarrantSevenMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantSixMember" xlink:type="locator" xlink:label="arwr_WarrantSixMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantFiveMember" xlink:type="locator" xlink:label="arwr_WarrantFiveMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantFourMember" xlink:type="locator" xlink:label="arwr_WarrantFourMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantThreeMember" xlink:type="locator" xlink:label="arwr_WarrantThreeMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantTwoMember" xlink:type="locator" xlink:label="arwr_WarrantTwoMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantOneMember" xlink:type="locator" xlink:label="arwr_WarrantOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantOneMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantTwoMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantThreeMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantFourMember" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantFiveMember" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantSixMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantSevenMember" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantEightMember" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10240.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="arwr_RemainingLifeOfWarrant" order="11020.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_FacilityAndEquipmentRentExpense" xlink:type="locator" xlink:label="arwr_FacilityAndEquipmentRentExpense" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" xlink:type="locator" xlink:label="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PaymentsUnderCapitalLease" xlink:type="locator" xlink:label="arwr_PaymentsUnderCapitalLease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UtilitiesCosts" xlink:type="locator" xlink:label="us-gaap_UtilitiesCosts" />
    <loc xlink:href="arwr-20140630.xsd#arwr_OtherRentalExpenses" xlink:type="locator" xlink:label="arwr_OtherRentalExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:type="locator" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PercentageOfIncreaseInAnnualRentalCost" xlink:type="locator" xlink:label="arwr_PercentageOfIncreaseInAnnualRentalCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:type="locator" xlink:label="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10140.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="dei_LegalEntityAxis" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_PercentageOfIncreaseInAnnualRentalCost" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="arwr_ResearchFacilityInMadisonMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_MajorPropertyClassAxis" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain_2" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_OtherRentalExpenses" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_UtilitiesCosts" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_PaymentsUnderCapitalLease" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_FacilityAndEquipmentRentExpense" order="10780.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_CapitalLeasedAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" order="10120.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="dei_LegalEntityAxis" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="10500.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10110.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="dei_LegalEntityAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10390.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ArrowheadMember" xlink:type="locator" xlink:label="arwr_ArrowheadMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="locator" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:type="locator" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsStockOptionPlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsStockOptionPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsStockOptionPlanMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10180.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" order="10880.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" order="11340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="11810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_ArrowheadMember" order="12340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12480.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13030.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10160.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10960.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11160.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10100.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10250.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeAssetsNoncurrent" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10650.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NumberOfExchangeRightAreSold" xlink:type="locator" xlink:label="arwr_NumberOfExchangeRightAreSold" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFiveYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFiveYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFourYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFourYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForThreeYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForThreeYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForTwoYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForTwoYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFirstYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFirstYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TermOfExchangeRights" xlink:type="locator" xlink:label="arwr_TermOfExchangeRights" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AblarisTherapeuticsMember" xlink:type="locator" xlink:label="arwr_AblarisTherapeuticsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsIssuedToAcquireCommonStock" xlink:type="locator" xlink:label="arwr_WarrantsIssuedToAcquireCommonStock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandThirteenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandThirteenWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsTwelveWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandsTwelveWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandTenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandTenWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" xlink:type="locator" xlink:label="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" />
    <loc xlink:href="arwr-20140630.xsd#arwr_UnidymIncMember" xlink:type="locator" xlink:label="arwr_UnidymIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueMeasurementsDisclosureTable" xlink:type="locator" xlink:label="arwr_FairValueMeasurementsDisclosureTable" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueMeasurementsDisclosureLineItems" xlink:type="locator" xlink:label="arwr_FairValueMeasurementsDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_FairValueMeasurementsDisclosureTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_MarketableSecurities" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_UnidymIncMember" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_TwoThousandTenWarrantsMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_TwoThousandsTwelveWarrantsMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_TwoThousandThirteenWarrantsMember" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_WarrantsIssuedToAcquireCommonStock" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_AblarisTherapeuticsMember" order="11100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_TermOfExchangeRights" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFirstYear" order="11280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForTwoYear" order="11340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForThreeYear" order="11400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFourYear" order="11460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFiveYear" order="11520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_NumberOfExchangeRightAreSold" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="11700.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsAssetsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsAssetsMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10100.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" order="10320.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightsMember" xlink:type="locator" xlink:label="arwr_ExchangeRightsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandThirteenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandThirteenWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsTwelveWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandsTwelveWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandTenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandTenWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_TwoThousandTenWarrantsMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_TwoThousandsTwelveWarrantsMember" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_TwoThousandThirteenWarrantsMember" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10320.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_ExchangeRightsMember" order="11370.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightsMember" xlink:type="locator" xlink:label="arwr_ExchangeRightsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10290.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_ExchangeRightsMember" order="10920.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" xlink:type="locator" xlink:label="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationContingentConsiderationPayments" xlink:type="locator" xlink:label="arwr_BusinessCombinationContingentConsiderationPayments" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" xlink:type="locator" xlink:label="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="arwr_BusinessCombinationContingentConsiderationPayments" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" order="10250.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>arwr-20140630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2014-08-12T15:59:41.1142645+00:00 -->
<!-- Version            : 1.9.0.3 -->
<!-- Package ID         : F4AAA9047B9D167BE0DC1A89763CCCBA-0000879407-001406 -->
<!-- Copyright (c) 2014 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document document and entity information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DocumentDocumentAndEntityInformationAbstract" xlink:to="arwr_DocumentDocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Document And Entity Information [Abstract]</label>
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Document And Entity Information [Abstract]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationTable" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationTable" />
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document document and entity Information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DocumentDocumentAndEntityInformationTable" xlink:to="arwr_DocumentDocumentAndEntityInformationTable_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Document And Entity Information [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Document And Entity Information [Table]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationLineItems" />
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Document And Entity Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="arwr_DocumentDocumentAndEntityInformationLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_DocumentDocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Document And Entity Information [Line Items]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Financial Position [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents and other intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Miscellaneous Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital lease obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Lease Obligations Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LONG-TERM LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes payable, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Notes Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital lease obligation, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Lease Obligations Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LONG-TERM LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrowhead Research Corporation stockholders&apos; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 5,000,000 shares authorized; 21,291 and 9,900 shares issued and outstanding as of June 30, 2014 and September 30, 2013, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, $0.001 par value; 145,000,000 shares authorized; 52,908,567 and 32,489,444 shares issued and outstanding as of June 30, 2014 and September 30, 2013, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Arrowhead Research Corporation stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ImpairmentOfIntangibleAssets" xlink:type="locator" xlink:label="arwr_ImpairmentOfIntangibleAssets" />
    <label xml:lang="en-US" xlink:label="arwr_ImpairmentOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ImpairmentOfIntangibleAssets" xlink:to="arwr_ImpairmentOfIntangibleAssets_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement [Abstract]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfOperationsTable" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsTable" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Statement consolidated statements of operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsTable" xlink:to="arwr_StatementConsolidatedStatementsOfOperationsTable_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Consolidated Statements Of Operations [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Consolidated Statements Of Operations [Table]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsLineItems" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Consolidated Statements Of Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="arwr_StatementConsolidatedStatementsOfOperationsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Consolidated Statements Of Operations [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Salaries and payroll-related costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Labor And Related Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <label xml:lang="en-US" xlink:label="arwr_ImpairmentOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment expense</label>
    <label xml:lang="en-US" xlink:label="arwr_ImpairmentOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OTHER INCOME (EXPENSE)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity in income (loss) of unconsolidated affiliates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Equity Method Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (loss) on sale of fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in value of derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Derivatives</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL OTHER INCOME (EXPENSE)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">LOSS FROM CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Discontinued Operations Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net (gain) loss attributable to non-controlling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Attributable To Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET LOSS ATTRIBUTABLE TO ARROWHEAD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHAREHOLDERS - BASIC &amp; DILUTED:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding - basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsExercisedDuringPeriodShares" xlink:type="locator" xlink:label="arwr_WarrantsExercisedDuringPeriodShares" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantsExercisedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised during period shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantsExercisedDuringPeriodShares" xlink:to="arwr_WarrantsExercisedDuringPeriodShares_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsExercisedDuringPeriodValue" xlink:type="locator" xlink:label="arwr_WarrantsExercisedDuringPeriodValue" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantsExercisedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised during period value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantsExercisedDuringPeriodValue" xlink:to="arwr_WarrantsExercisedDuringPeriodValue_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" />
    <label xml:lang="en-US" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issued at five dollar and eighty six cents per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" xlink:to="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued @ $5.86</label>
    <label xml:lang="en-US" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issued At Five Dollar And Eighty Six Cents Per Share [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" />
    <label xml:lang="en-US" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issued at eighteen dollar and ninety five cents per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" xlink:to="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued @ $18.95</label>
    <label xml:lang="en-US" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issued At Eighteen Dollar And Ninety Five Cents Per Share [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" xlink:type="locator" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" />
    <label xml:lang="en-US" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock issued at thousand dollars per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" xlink:to="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock issued @ $1,000 per share</label>
    <label xml:lang="en-US" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Issued At Thousand Dollars Per Share [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedToGallowayMember" xlink:type="locator" xlink:label="arwr_IssuedToGallowayMember" />
    <label xml:lang="en-US" xlink:label="arwr_IssuedToGallowayMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issued to galloway.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_IssuedToGallowayMember" xlink:to="arwr_IssuedToGallowayMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_IssuedToGallowayMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Issued to Galloway</label>
    <label xml:lang="en-US" xlink:label="arwr_IssuedToGallowayMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issued To Galloway [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantsExercisedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantsExercisedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised During Period Shares</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantsExercisedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, Amount</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantsExercisedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised During Period Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuances, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlements related to derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock converted to common stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Units</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock converted to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Units</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deconsolidation of Calando Pharmaceuticals, Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest Decrease From Deconsolidation</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss for the nine months ended June 30, 2014</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance Amount</label>
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued, price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:type="locator" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" />
    <label xml:lang="en-US" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of warrants and stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:to="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Cash Flows [Abstract]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfCashFlowsTable" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsTable" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Statement consolidated statements of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsTable" xlink:to="arwr_StatementConsolidatedStatementsOfCashFlowsTable_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Consolidated Statements Of Cash Flows [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Consolidated Statements Of Cash Flows [Table]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Consolidated Statements Of Cash Flows [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Consolidated Statements Of Cash Flows [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES OF CONTINUING OPERATIONS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) attributable to Arrowhead</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Income) loss from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discontinued Operation Income Loss From Discontinued Operation Before Income Tax</label>
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on disposal of fixed assets</label>
    <label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in value of derivatives</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization (accretion) of note discounts, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash gain in equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfEquityInvestments" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Equity Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash impairment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Receivables</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Receivables</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES OF CONTINUING OPERATIONS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES OF CONTINUING OPERATIONS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on capital leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Capital Lease Obligations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and preferred stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</label>
    <label xml:lang="en-US" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of warrants and stock options</label>
    <label xml:lang="en-US" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Warrants And Stock Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from discontinued operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Discontinued Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided By Used In Operating Activities Discontinued Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided By Used In Investing Activities Discontinued Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided By Used In Financing Activities Discontinued Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) discontinued operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Discontinued Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET INCREASE IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">CASH AT BEGINNING OF PERIOD</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">CASH AT END OF PERIOD</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosures:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid</label>
    <label xml:lang="en-US" xlink:label="arwr_IssuedToGallowayMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Galloway Limited</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock value</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_RocheMadisonMember" xlink:type="locator" xlink:label="arwr_RocheMadisonMember" />
    <label xml:lang="en-US" xlink:label="arwr_RocheMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Roche madison.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_RocheMadisonMember" xlink:to="arwr_RocheMadisonMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_RocheMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roche Madison Inc</label>
    <label xml:lang="en-US" xlink:label="arwr_RocheMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Roche Madison [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Payments To Acquire Businesses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost And Equity Method Investments Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets subject to amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research &amp; Development (IPR&amp;D)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development Policy</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="arwr_ContingentConsiderationPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ContingentConsiderationPolicyTextBlock" xlink:to="arwr_ContingentConsiderationPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</label>
    <label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:type="locator" xlink:label="us-gaap_EquityAndCostMethodInvestmentsPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAndCostMethodInvestmentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority Equity Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:to="us-gaap_EquityAndCostMethodInvestmentsPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAndCostMethodInvestmentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity And Cost Method Investments Policy</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_NoncontrollingInterestsPolicyTextBlock" xlink:type="locator" xlink:label="arwr_NoncontrollingInterestsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="arwr_NoncontrollingInterestsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for non-controlling interests.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NoncontrollingInterestsPolicyTextBlock" xlink:to="arwr_NoncontrollingInterestsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_NoncontrollingInterestsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interests in Majority-Owned Subsidiaries</label>
    <label xml:lang="en-US" xlink:label="arwr_NoncontrollingInterestsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interests Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Accounts Receivable Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings (Loss) per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short and Long-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets And Goodwill Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information about Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Lease Payments under Capitalized Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Lease Payments For Capital Leases Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Lease Payments under Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarize Information about Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used to Value Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Activity Related to Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Derivative Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumptions and methodology for liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" xlink:to="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used in Valuing Derivative Liabilities</label>
    <label xml:lang="en-US" xlink:label="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions And Methodology For Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightsMember" xlink:type="locator" xlink:label="arwr_ExchangeRightsMember" />
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExchangeRightsMember" xlink:to="arwr_ExchangeRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange rights</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Rights [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Fair Value of Contingent Consideration Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition Contingent Consideration [Text Block]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_NetCashInvestedInFixedIncomeInvestments" xlink:type="locator" xlink:label="arwr_NetCashInvestedInFixedIncomeInvestments" />
    <label xml:lang="en-US" xlink:label="arwr_NetCashInvestedInFixedIncomeInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net cash invested in fixed income investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NetCashInvestedInFixedIncomeInvestments" xlink:to="arwr_NetCashInvestedInFixedIncomeInvestments_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Investments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xlink:type="locator" xlink:label="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Investments, Other than Investments in Related Parties, by Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xlink:to="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Investments Other Than Investments In Related Parties By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfInvestmentsByTypeDomain" xlink:type="locator" xlink:label="us-gaap_SummaryOfInvestmentsByTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfInvestmentsByTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Investments, by Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfInvestmentsByTypeDomain" xlink:to="us-gaap_SummaryOfInvestmentsByTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfInvestmentsByTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Investments By Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BondsMember" xlink:type="locator" xlink:label="us-gaap_BondsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_BondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Bonds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BondsMember" xlink:to="us-gaap_BondsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bonds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Investments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash to fund operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date Description</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Investments" xlink:type="locator" xlink:label="us-gaap_Investments" />
    <label xml:lang="en-US" xlink:label="us-gaap_Investments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Investments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase (decrease) in cash</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash from issuance of equity</label>
    <label xml:lang="en-US" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash from exercise of warrants and options</label>
    <label xml:lang="en-US" xlink:label="arwr_NetCashInvestedInFixedIncomeInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash invested in fixed income investments</label>
    <label xml:lang="en-US" xlink:label="arwr_NetCashInvestedInFixedIncomeInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Invested In Fixed Income Investments</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash outflow related to continuing operating activities</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Capital expenditures</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount insured in FDIC per account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash F D I C Insured Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost method investment attributable to noncontrolling interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" xlink:to="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minority equity investment, book value</label>
    <label xml:lang="en-US" xlink:label="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Method Investment Attributable To Noncontrolling Interest</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accumulated unrealized gain on investments in debt securities classified as held-to-maturity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accumulated unrealized loss on investments in debt securities classified as held-to-maturity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial notes due within one year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommercialNotesDueWithinOneYearMember" xlink:to="arwr_CommercialNotesDueWithinOneYearMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Notes Due Within One Year</label>
    <label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Notes Due Within One Year [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" />
    <label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial notes due after one year through two years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" xlink:to="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Notes Due After One Year Within Three Years</label>
    <label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Notes Due After One Year Within Three Years [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross Unrealized Gains</label>
    <label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Gain</label>
    <label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</label>
    <label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Fair Value Disclosure</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial notes (due within one year), Amortized Cost</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial notes (due after one year within three years), Amortized Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ResearchEquipment" xlink:type="locator" xlink:label="arwr_ResearchEquipment" />
    <label xml:lang="en-US" xlink:label="arwr_ResearchEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchEquipment" xlink:to="arwr_ResearchEquipment_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers, office equipment and furniture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures Gross</label>
    <label xml:lang="en-US" xlink:label="arwr_ResearchEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research equipment</label>
    <label xml:lang="en-US" xlink:label="arwr_ResearchEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Computer Software Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationConsiderationPromissoryNoteIssued" xlink:type="locator" xlink:label="arwr_BusinessCombinationConsiderationPromissoryNoteIssued" />
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationConsiderationPromissoryNoteIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination consideration promissory note issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_BusinessCombinationConsiderationPromissoryNoteIssued" xlink:to="arwr_BusinessCombinationConsiderationPromissoryNoteIssued_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" xlink:type="locator" xlink:label="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" />
    <label xml:lang="en-US" xlink:label="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition equity interests issued number of shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" xlink:to="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationConsiderationPromissoryNoteIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue of promissory note to Roche</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationConsiderationPromissoryNoteIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Promissory Note Issued</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue of Common Stock</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Equity Interests Issued Number Of Shares Issued</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ApplicableOutLicenseTerm" xlink:type="locator" xlink:label="arwr_ApplicableOutLicenseTerm" />
    <label xml:lang="en-US" xlink:label="arwr_ApplicableOutLicenseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Applicable out license term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ApplicableOutLicenseTerm" xlink:to="arwr_ApplicableOutLicenseTerm_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ApplicableOutLicenseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Applicable out-license term</label>
    <label xml:lang="en-US" xlink:label="arwr_ApplicableOutLicenseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Out License Term</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_PercentageOfRoyaltyLiability" xlink:type="locator" xlink:label="arwr_PercentageOfRoyaltyLiability" />
    <label xml:lang="en-US" xlink:label="arwr_PercentageOfRoyaltyLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfRoyaltyLiability" xlink:to="arwr_PercentageOfRoyaltyLiability_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ObligationToPayRoyalties" xlink:type="locator" xlink:label="arwr_ObligationToPayRoyalties" />
    <label xml:lang="en-US" xlink:label="arwr_ObligationToPayRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to pay royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ObligationToPayRoyalties" xlink:to="arwr_ObligationToPayRoyalties_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_PercentageOfRoyaltyLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty liability</label>
    <label xml:lang="en-US" xlink:label="arwr_PercentageOfRoyaltyLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Liability</label>
    <label xml:lang="en-US" xlink:label="arwr_ObligationToPayRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to pay royalties</label>
    <label xml:lang="en-US" xlink:label="arwr_ObligationToPayRoyalties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Pay Royalties</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_PresentValueOfContingentAcquisitionConsideration" xlink:type="locator" xlink:label="arwr_PresentValueOfContingentAcquisitionConsideration" />
    <label xml:lang="en-US" xlink:label="arwr_PresentValueOfContingentAcquisitionConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Present value of contingent acquisition consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PresentValueOfContingentAcquisitionConsideration" xlink:to="arwr_PresentValueOfContingentAcquisitionConsideration_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payments to Roche, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Range Of Outcomes Value Low</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payments to Roche, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High</label>
    <label xml:lang="en-US" xlink:label="arwr_PresentValueOfContingentAcquisitionConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net present value of contingent consideration</label>
    <label xml:lang="en-US" xlink:label="arwr_PresentValueOfContingentAcquisitionConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Present Value Of Contingent Acquisition Consideration</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration - fair value adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExpectedAmortizationExpenseLineItems" xlink:type="locator" xlink:label="arwr_ExpectedAmortizationExpenseLineItems" />
    <label xml:lang="en-US" xlink:label="arwr_ExpectedAmortizationExpenseLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected amortization expense line items.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="arwr_ExpectedAmortizationExpenseLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill And Intangible Assets Disclosure [Abstract]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ExpectedAmortizationExpenseTable" xlink:type="locator" xlink:label="arwr_ExpectedAmortizationExpenseTable" />
    <label xml:lang="en-US" xlink:label="arwr_ExpectedAmortizationExpenseTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected amortization expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="arwr_ExpectedAmortizationExpenseTable_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ExpectedAmortizationExpenseTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Amortization Expense [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_ExpectedAmortizationExpenseTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Amortization Expense [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_ExpectedAmortizationExpenseLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Amortization Expense [Line Items]</label>
    <label xml:lang="en-US" xlink:label="arwr_ExpectedAmortizationExpenseLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Amortization Expense [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization of the assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements remainder of 2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements, thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_IndefiniteLivedIntangibleAssetsAmortization" xlink:type="locator" xlink:label="arwr_IndefiniteLivedIntangibleAssetsAmortization" />
    <label xml:lang="en-US" xlink:label="arwr_IndefiniteLivedIntangibleAssetsAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite Lived Intangible Assets Amortization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_IndefiniteLivedIntangibleAssetsAmortization" xlink:to="arwr_IndefiniteLivedIntangibleAssetsAmortization_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" />
    <label xml:lang="en-US" xlink:label="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived and indefinite lived intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" />
    <label xml:lang="en-US" xlink:label="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of finite lived and indefinite lived intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:to="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived And Indefinite Lived Intangible Assets [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived And Indefinite Lived Intangible Assets [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived And Indefinite Lived Intangible Assets [Line Items]</label>
    <label xml:lang="en-US" xlink:label="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived And Indefinite Lived Intangible Assets [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intangible assets not subject to amortization, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets not subject to amortization, Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Indefinitelived Excluding Goodwill</label>
    <label xml:lang="en-US" xlink:label="arwr_IndefiniteLivedIntangibleAssetsAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Amortization</label>
    <label xml:lang="en-US" xlink:label="arwr_IndefiniteLivedIntangibleAssetsAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Amortization</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intangible assets not subject to amortization, ending balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intangible assets subject to amortization, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Finitelived</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Amortization</label>
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intangible assets subject to amortization, ending balance</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Total Intangible assets, beginning balance</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Total Intangible assets, Impairment</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Total Intangible assets, Amortization</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Total Intangible assets, ending balance</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_OwnershipPercentageInSubsidiary" xlink:type="locator" xlink:label="arwr_OwnershipPercentageInSubsidiary" />
    <label xml:lang="en-US" xlink:label="arwr_OwnershipPercentageInSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership percentage in subsidiary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OwnershipPercentageInSubsidiary" xlink:to="arwr_OwnershipPercentageInSubsidiary_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments All Other Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments All Other Investments [Abstract]</label>
    <label xml:lang="en-US" xlink:label="arwr_OwnershipPercentageInSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage in subsidiary</label>
    <label xml:lang="en-US" xlink:label="arwr_OwnershipPercentageInSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage In Subsidiary</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_OutstandingBalanceOfPromissoryNote" xlink:type="locator" xlink:label="arwr_OutstandingBalanceOfPromissoryNote" />
    <label xml:lang="en-US" xlink:label="arwr_OutstandingBalanceOfPromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding balance of promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OutstandingBalanceOfPromissoryNote" xlink:to="arwr_OutstandingBalanceOfPromissoryNote_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CalandoPharmaceuticalsIncMember" xlink:type="locator" xlink:label="arwr_CalandoPharmaceuticalsIncMember" />
    <label xml:lang="en-US" xlink:label="arwr_CalandoPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Calando pharmaceuticals inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CalandoPharmaceuticalsIncMember" xlink:to="arwr_CalandoPharmaceuticalsIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_CalandoPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Calando Pharmaceuticals Inc</label>
    <label xml:lang="en-US" xlink:label="arwr_CalandoPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Calando Pharmaceuticals Inc [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_OutstandingBalanceOfPromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Balance of Promissory Note</label>
    <label xml:lang="en-US" xlink:label="arwr_OutstandingBalanceOfPromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Balance Of Promissory Note</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="locator" xlink:label="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_AmountOwedBySubsidiary" xlink:type="locator" xlink:label="arwr_AmountOwedBySubsidiary" />
    <label xml:lang="en-US" xlink:label="arwr_AmountOwedBySubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount owed by subsidiary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AmountOwedBySubsidiary" xlink:to="arwr_AmountOwedBySubsidiary_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatedPercentageOfNotesAndAdvances" xlink:type="locator" xlink:label="arwr_StatedPercentageOfNotesAndAdvances" />
    <label xml:lang="en-US" xlink:label="arwr_StatedPercentageOfNotesAndAdvances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stated percentage of notes and advances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StatedPercentageOfNotesAndAdvances" xlink:to="arwr_StatedPercentageOfNotesAndAdvances_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_AmountOwedBySubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount owed by subsidiary</label>
    <label xml:lang="en-US" xlink:label="arwr_AmountOwedBySubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Owed By Subsidiary</label>
    <label xml:lang="en-US" xlink:label="arwr_StatedPercentageOfNotesAndAdvances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stated percentage of notes and advances</label>
    <label xml:lang="en-US" xlink:label="arwr_StatedPercentageOfNotesAndAdvances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stated Percentage Of Notes And Advances</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" xlink:type="locator" xlink:label="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" />
    <label xml:lang="en-US" xlink:label="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment ownership percentage on dilutive basis.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" xlink:to="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</label>
    <label xml:lang="en-US" xlink:label="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of investment ownership</label>
    <label xml:lang="en-US" xlink:label="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage On Dilutive Basis</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_InvestmentInPreferredStock" xlink:type="locator" xlink:label="arwr_InvestmentInPreferredStock" />
    <label xml:lang="en-US" xlink:label="arwr_InvestmentInPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment in preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_InvestmentInPreferredStock" xlink:to="arwr_InvestmentInPreferredStock_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_InvestmentInPreferredStockByOutsider" xlink:type="locator" xlink:label="arwr_InvestmentInPreferredStockByOutsider" />
    <label xml:lang="en-US" xlink:label="arwr_InvestmentInPreferredStockByOutsider_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment in preferred stock by outsider.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_InvestmentInPreferredStockByOutsider" xlink:to="arwr_InvestmentInPreferredStockByOutsider_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AblarisTherapeuticsMember" xlink:type="locator" xlink:label="arwr_AblarisTherapeuticsMember" />
    <label xml:lang="en-US" xlink:label="arwr_AblarisTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ablaris Therapeutics.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AblarisTherapeuticsMember" xlink:to="arwr_AblarisTherapeuticsMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_AblarisTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ablaris Therapeutics</label>
    <label xml:lang="en-US" xlink:label="arwr_AblarisTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ablaris Therapeutics [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <label xml:lang="en-US" xlink:label="arwr_InvestmentInPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in preferred stock</label>
    <label xml:lang="en-US" xlink:label="arwr_InvestmentInPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment In Preferred Stock</label>
    <label xml:lang="en-US" xlink:label="arwr_InvestmentInPreferredStockByOutsider_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in preferred stock by outsider</label>
    <label xml:lang="en-US" xlink:label="arwr_InvestmentInPreferredStockByOutsider_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment In Preferred Stock By Outsider</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_LeonardoBiosystemsIncMember" xlink:type="locator" xlink:label="arwr_LeonardoBiosystemsIncMember" />
    <label xml:lang="en-US" xlink:label="arwr_LeonardoBiosystemsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leonardo biosystems, inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeonardoBiosystemsIncMember" xlink:to="arwr_LeonardoBiosystemsIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_LeonardoBiosystemsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leonardo Biosystems Inc</label>
    <label xml:lang="en-US" xlink:label="arwr_LeonardoBiosystemsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leonardo Biosystems Inc [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital stock authorized for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand stock option plan two thousand four equity incentive plan two thousand thirteen equity incentive plan and inducement grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:to="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2000 Stock Option Plan, 2004 Equity Incentive Plan, 2013 Equity Incentive Plan, and Inducement Grants</label>
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Stock Option Plan Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan And Inducement Grants [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share reserve for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:type="locator" xlink:label="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" />
    <label xml:lang="en-US" xlink:label="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold percentage of common stock ownership upon preferred stock conversion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:to="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold percentage of common stock ownership upon preferred stock conversion</label>
    <label xml:lang="en-US" xlink:label="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Percentage Of Common Stock Ownership Upon Preferred Stock Conversion</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_MaximumEquityCommitmentAmountUnderAgreement" xlink:type="locator" xlink:label="arwr_MaximumEquityCommitmentAmountUnderAgreement" />
    <label xml:lang="en-US" xlink:label="arwr_MaximumEquityCommitmentAmountUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum equity commitment amount under agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MaximumEquityCommitmentAmountUnderAgreement" xlink:to="arwr_MaximumEquityCommitmentAmountUnderAgreement_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_EquityCommitmentAgreementPeriod" xlink:type="locator" xlink:label="arwr_EquityCommitmentAgreementPeriod" />
    <label xml:lang="en-US" xlink:label="arwr_EquityCommitmentAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity commitment agreement period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquityCommitmentAgreementPeriod" xlink:to="arwr_EquityCommitmentAgreementPeriod_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CashDrawnFromFacility" xlink:type="locator" xlink:label="arwr_CashDrawnFromFacility" />
    <label xml:lang="en-US" xlink:label="arwr_CashDrawnFromFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash drawn from facility.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CashDrawnFromFacility" xlink:to="arwr_CashDrawnFromFacility_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" />
    <label xml:lang="en-US" xlink:label="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement with lincoln park capital fund limited liability company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" xlink:to="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement with Lincoln Park Capital Fund, LLC</label>
    <label xml:lang="en-US" xlink:label="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement With Lincoln Park Capital Fund Limited Liability Company [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_MaximumEquityCommitmentAmountUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum equity commitment amount under agreement</label>
    <label xml:lang="en-US" xlink:label="arwr_MaximumEquityCommitmentAmountUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Equity Commitment Amount Under Agreement</label>
    <label xml:lang="en-US" xlink:label="arwr_EquityCommitmentAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity commitment agreement period</label>
    <label xml:lang="en-US" xlink:label="arwr_EquityCommitmentAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Commitment Agreement Period</label>
    <label xml:lang="en-US" xlink:label="arwr_CashDrawnFromFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash drawn from facility</label>
    <label xml:lang="en-US" xlink:label="arwr_CashDrawnFromFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Drawn From Facility</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_CommonStockExercisePrice" xlink:type="locator" xlink:label="arwr_CommonStockExercisePrice" />
    <label xml:lang="en-US" xlink:label="arwr_CommonStockExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommonStockExercisePrice" xlink:to="arwr_CommonStockExercisePrice_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ConversionPricePerShare" xlink:type="locator" xlink:label="arwr_ConversionPricePerShare" />
    <label xml:lang="en-US" xlink:label="arwr_ConversionPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ConversionPricePerShare" xlink:to="arwr_ConversionPricePerShare_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AggregatePriceOnIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="arwr_AggregatePriceOnIssuanceOrSaleOfEquity" />
    <label xml:lang="en-US" xlink:label="arwr_AggregatePriceOnIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate price of issuance or Sale of equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AggregatePriceOnIssuanceOrSaleOfEquity" xlink:to="arwr_AggregatePriceOnIssuanceOrSaleOfEquity_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock, price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</label>
    <label xml:lang="en-US" xlink:label="arwr_CommonStockExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Exercise Price</label>
    <label xml:lang="en-US" xlink:label="arwr_CommonStockExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance and sold of Common Stock</label>
    <label xml:lang="en-US" xlink:label="arwr_ConversionPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</label>
    <label xml:lang="en-US" xlink:label="arwr_ConversionPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Price Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, preferred stock and warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <label xml:lang="en-US" xlink:label="arwr_AggregatePriceOnIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate price on issuance or Sale of equity</label>
    <label xml:lang="en-US" xlink:label="arwr_AggregatePriceOnIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Price On Issuance Or Sale Of Equity</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_RemainingLifeOfWarrant" xlink:type="locator" xlink:label="arwr_RemainingLifeOfWarrant" />
    <label xml:lang="en-US" xlink:label="arwr_RemainingLifeOfWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining life of warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_RemainingLifeOfWarrant" xlink:to="arwr_RemainingLifeOfWarrant_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantOneMember" xlink:type="locator" xlink:label="arwr_WarrantOneMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantOneMember" xlink:to="arwr_WarrantOneMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 1</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant One [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantTwoMember" xlink:type="locator" xlink:label="arwr_WarrantTwoMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantTwoMember" xlink:to="arwr_WarrantTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 2</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Two [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantThreeMember" xlink:type="locator" xlink:label="arwr_WarrantThreeMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant three.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantThreeMember" xlink:to="arwr_WarrantThreeMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 3</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Three [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantFourMember" xlink:type="locator" xlink:label="arwr_WarrantFourMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant four.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantFourMember" xlink:to="arwr_WarrantFourMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 4</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Four [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantFiveMember" xlink:type="locator" xlink:label="arwr_WarrantFiveMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant five.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantFiveMember" xlink:to="arwr_WarrantFiveMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 5</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Five [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantSixMember" xlink:type="locator" xlink:label="arwr_WarrantSixMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant six.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantSixMember" xlink:to="arwr_WarrantSixMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 6</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Six [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantSevenMember" xlink:type="locator" xlink:label="arwr_WarrantSevenMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant seven.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantSevenMember" xlink:to="arwr_WarrantSevenMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 7</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Seven [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantEightMember" xlink:type="locator" xlink:label="arwr_WarrantEightMember" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant eight.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantEightMember" xlink:to="arwr_WarrantEightMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant 8</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Eight [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</label>
    <label xml:lang="en-US" xlink:label="arwr_RemainingLifeOfWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Life in Years</label>
    <label xml:lang="en-US" xlink:label="arwr_RemainingLifeOfWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Life Of Warrant</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_PercentageOfIncreaseInAnnualRentalCost" xlink:type="locator" xlink:label="arwr_PercentageOfIncreaseInAnnualRentalCost" />
    <label xml:lang="en-US" xlink:label="arwr_PercentageOfIncreaseInAnnualRentalCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in annual rental cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfIncreaseInAnnualRentalCost" xlink:to="arwr_PercentageOfIncreaseInAnnualRentalCost_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Operating Leased Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Leased Assets [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Subject to or Available for Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Or Available For Operating Lease [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Subject to or Available for Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Or Available For Operating Lease [Domain]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate Headquarters in Pasadena</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CorporateHeadquartersInPasadenaMember" xlink:to="arwr_CorporateHeadquartersInPasadenaMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Headquarters In Pasadena</label>
    <label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Headquarters In Pasadena [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:type="locator" xlink:label="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Component Of Operating Other Cost And Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Component Of Operating Other Cost And Expense [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</label>
    <label xml:lang="en-US" xlink:label="arwr_PercentageOfIncreaseInAnnualRentalCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in annual rental cost</label>
    <label xml:lang="en-US" xlink:label="arwr_PercentageOfIncreaseInAnnualRentalCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Annual Rental Cost</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_OtherRentalExpenses" xlink:type="locator" xlink:label="arwr_OtherRentalExpenses" />
    <label xml:lang="en-US" xlink:label="arwr_OtherRentalExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other rental expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OtherRentalExpenses" xlink:to="arwr_OtherRentalExpenses_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PaymentsUnderCapitalLease" xlink:type="locator" xlink:label="arwr_PaymentsUnderCapitalLease" />
    <label xml:lang="en-US" xlink:label="arwr_PaymentsUnderCapitalLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments under capital lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PaymentsUnderCapitalLease" xlink:to="arwr_PaymentsUnderCapitalLease_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" xlink:type="locator" xlink:label="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" />
    <label xml:lang="en-US" xlink:label="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in monthly expenditure due to utilities costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" xlink:to="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research facility in madison.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchFacilityInMadisonMember" xlink:to="arwr_ResearchFacilityInMadisonMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Facility in Madison</label>
    <label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Facility In Madison [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorPropertyClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Property Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorPropertyClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Property Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorPropertyClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Property Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="us-gaap_MajorPropertyClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorPropertyClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Property Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:type="locator" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Held under Capital Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Held Under Capital Leases [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_OtherRentalExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rental expenses include common area maintenance and real estate taxes</label>
    <label xml:lang="en-US" xlink:label="arwr_OtherRentalExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Rental Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UtilitiesCosts" xlink:type="locator" xlink:label="us-gaap_UtilitiesCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_UtilitiesCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Utilities costs per month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UtilitiesCosts" xlink:to="us-gaap_UtilitiesCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UtilitiesCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Utilities Costs</label>
    <label xml:lang="en-US" xlink:label="arwr_PaymentsUnderCapitalLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly payments under capital lease</label>
    <label xml:lang="en-US" xlink:label="arwr_PaymentsUnderCapitalLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Under Capital Lease</label>
    <label xml:lang="en-US" xlink:label="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in total monthly expenditures</label>
    <label xml:lang="en-US" xlink:label="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Monthly Expenditure Due To Utilities Costs</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_FacilityAndEquipmentRentExpense" xlink:type="locator" xlink:label="arwr_FacilityAndEquipmentRentExpense" />
    <label xml:lang="en-US" xlink:label="arwr_FacilityAndEquipmentRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Facility and equipment rent expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_FacilityAndEquipmentRentExpense" xlink:to="arwr_FacilityAndEquipmentRentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_FacilityAndEquipmentRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility and equipment rent expense</label>
    <label xml:lang="en-US" xlink:label="arwr_FacilityAndEquipmentRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Facility And Equipment Rent Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capital Leased Asssets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capital Leased Asssets [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_CapitalLeasedAssetsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Leased Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasedAssetsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leased Assets [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 (remainder of)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Remainder Of Fiscal Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Due Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Due In Two Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Due In Three Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Due In Four Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Due Thereafter</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Interest Included In Payments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 (remainder of)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Remainder Of Fiscal Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:type="locator" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" />
    <label xml:lang="en-US" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award inducement grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:to="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsStockOptionPlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsStockOptionPlanMember" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsStockOptionPlanMember" xlink:to="arwr_TwoThousandsStockOptionPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2000 Stock Option Plan</label>
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsStockOptionPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Stock Option Plan [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands four equity incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2004 Equity Incentive Plan</label>
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Four Equity Incentive Plan [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands thirteen incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Incentive plan</label>
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Thirteen Incentive Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserve for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted and outstanding to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xml:lang="en-US" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted outside of Equity Incentive plans</label>
    <label xml:lang="en-US" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Inducement Grants</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options Outstanding, beginning balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Outstanding, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Outstanding, Exercised</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options Outstanding, ending balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Outstanding, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Share, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Share, ending balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense, options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="locator" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <label xml:lang="en-US" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grants in period fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of the options granted</label>
    <label xml:lang="en-US" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of the options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units issued under 2013 incentive plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Unvested, beginning of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares,Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Unvested, End of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, ending balance</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_ArrowheadMember" xlink:type="locator" xlink:label="arwr_ArrowheadMember" />
    <label xml:lang="en-US" xlink:label="arwr_ArrowheadMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Arrowhead.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ArrowheadMember" xlink:to="arwr_ArrowheadMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_ArrowheadMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrowhead</label>
    <label xml:lang="en-US" xlink:label="arwr_ArrowheadMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrowhead [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-tax compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period to recognize pre-tax compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosures [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsNoncurrent" xlink:to="us-gaap_DerivativeAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration obligations related to acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueMeasurementsDisclosureLineItems" xlink:type="locator" xlink:label="arwr_FairValueMeasurementsDisclosureLineItems" />
    <label xml:lang="en-US" xlink:label="arwr_FairValueMeasurementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurements disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_FairValueMeasurementsDisclosureLineItems_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueMeasurementsDisclosureTable" xlink:type="locator" xlink:label="arwr_FairValueMeasurementsDisclosureTable" />
    <label xml:lang="en-US" xlink:label="arwr_FairValueMeasurementsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurements disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="arwr_FairValueMeasurementsDisclosureTable_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_FairValueMeasurementsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Disclosure [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_FairValueMeasurementsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Disclosure [Table]</label>
    <label xml:lang="en-US" xlink:label="arwr_FairValueMeasurementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Disclosure [Line Items]</label>
    <label xml:lang="en-US" xlink:label="arwr_FairValueMeasurementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Disclosure [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total investments</label>
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of investments</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" xlink:type="locator" xlink:label="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" />
    <label xml:lang="en-US" xlink:label="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash consideration received in sale of interest in subsidiary, bonds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" xlink:to="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_UnidymIncMember" xlink:type="locator" xlink:label="arwr_UnidymIncMember" />
    <label xml:lang="en-US" xlink:label="arwr_UnidymIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unidym inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_UnidymIncMember" xlink:to="arwr_UnidymIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_UnidymIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unidym Inc</label>
    <label xml:lang="en-US" xlink:label="arwr_UnidymIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unidym Inc [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non cash consideration received in sale of interest in subsidiary, bonds</label>
    <label xml:lang="en-US" xlink:label="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Consideration Received In Sale Of Interest In Subsidiary Bonds</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bond convertible conversion price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Price1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsAssetsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeFinancialInstrumentsAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsAssetsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeFinancialInstrumentsAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Instruments Assets [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Value, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receipt of instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements</label>
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Value, Ending balance</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsIssuedToAcquireCommonStock" xlink:type="locator" xlink:label="arwr_WarrantsIssuedToAcquireCommonStock" />
    <label xml:lang="en-US" xlink:label="arwr_WarrantsIssuedToAcquireCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued to acquire common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_WarrantsIssuedToAcquireCommonStock" xlink:to="arwr_WarrantsIssuedToAcquireCommonStock_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandTenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandTenWarrantsMember" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandTenWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Ten Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandTenWarrantsMember" xlink:to="arwr_TwoThousandTenWarrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandTenWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2010 Warrants</label>
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandTenWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Ten Warrants [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsTwelveWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandsTwelveWarrantsMember" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsTwelveWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands twelve warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsTwelveWarrantsMember" xlink:to="arwr_TwoThousandsTwelveWarrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsTwelveWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Warrants</label>
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandsTwelveWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Twelve Warrants [Member]</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandThirteenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandThirteenWarrantsMember" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandThirteenWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand thirteen warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandThirteenWarrantsMember" xlink:to="arwr_TwoThousandThirteenWarrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandThirteenWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Warrants</label>
    <label xml:lang="en-US" xlink:label="arwr_TwoThousandThirteenWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Warrants [Member]</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantsIssuedToAcquireCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to acquire Common Stock</label>
    <label xml:lang="en-US" xlink:label="arwr_WarrantsIssuedToAcquireCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued To Acquire Common Stock</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash gain (loss) from change in fair value of the derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Term</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Value, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues</label>
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements</label>
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Value, Ending balance</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_TermOfExchangeRights" xlink:type="locator" xlink:label="arwr_TermOfExchangeRights" />
    <label xml:lang="en-US" xlink:label="arwr_TermOfExchangeRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of exchange rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TermOfExchangeRights" xlink:to="arwr_TermOfExchangeRights_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFirstYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFirstYear" />
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFirstYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange right convertible conversion ratio for first year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExchangeRightConvertibleConversionRatioForFirstYear" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFirstYear_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForTwoYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForTwoYear" />
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForTwoYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange right convertible conversion ratio for two year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExchangeRightConvertibleConversionRatioForTwoYear" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForTwoYear_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForThreeYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForThreeYear" />
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForThreeYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange right convertible conversion ratio for three year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExchangeRightConvertibleConversionRatioForThreeYear" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForThreeYear_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFourYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFourYear" />
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFourYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange right convertible conversion ratio for four year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExchangeRightConvertibleConversionRatioForFourYear" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFourYear_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFiveYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFiveYear" />
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFiveYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange right convertible conversion ratio for five year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExchangeRightConvertibleConversionRatioForFiveYear" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFiveYear_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NumberOfExchangeRightAreSold" xlink:type="locator" xlink:label="arwr_NumberOfExchangeRightAreSold" />
    <label xml:lang="en-US" xlink:label="arwr_NumberOfExchangeRightAreSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of exchange right are sold.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfExchangeRightAreSold" xlink:to="arwr_NumberOfExchangeRightAreSold_lbl" />
    <label xml:lang="en-US" xlink:label="arwr_TermOfExchangeRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of exchange rights</label>
    <label xml:lang="en-US" xlink:label="arwr_TermOfExchangeRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Exchange Rights</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFirstYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange right convertible conversion ratio for first year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFirstYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Right Convertible Conversion Ratio For First Year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForTwoYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange right convertible conversion ratio for second year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForTwoYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Right Convertible Conversion Ratio For Two Year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForThreeYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange right convertible conversion ratio for third year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForThreeYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Right Convertible Conversion Ratio For Three Year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFourYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange right convertible conversion ratio for fourth year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFourYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Right Convertible Conversion Ratio For Four Year</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFiveYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange right convertible conversion ratio for fifth year and beyond</label>
    <label xml:lang="en-US" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFiveYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Right Convertible Conversion Ratio For Five Year</label>
    <label xml:lang="en-US" xlink:label="arwr_NumberOfExchangeRightAreSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of exchange right sold</label>
    <label xml:lang="en-US" xlink:label="arwr_NumberOfExchangeRightAreSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Exchange Right Are Sold</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business combination, contingent consideration</label>
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" xlink:type="locator" xlink:label="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" />
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination purchase price contingent consideration fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" xlink:to="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationContingentConsiderationPayments" xlink:type="locator" xlink:label="arwr_BusinessCombinationContingentConsiderationPayments" />
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationContingentConsiderationPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_BusinessCombinationContingentConsiderationPayments" xlink:to="arwr_BusinessCombinationContingentConsiderationPayments_lbl" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" xlink:type="locator" xlink:label="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" />
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination fair value of change in contingent consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" xlink:to="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition Contingent Consideration [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition Contingent Consideration [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition Contingent Consideration [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Value, Beginning balance</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price contingent consideration</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Purchase Price Contingent Consideration Fair Value</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationContingentConsiderationPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payments</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationContingentConsiderationPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Payments</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration</label>
    <label xml:lang="en-US" xlink:label="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Fair Value Of Change In Contingent Consideration</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Value, Ending balance</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>arwr-20140630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2014-08-12T15:59:41.1142645+00:00 -->
<!-- Version            : 1.9.0.3 -->
<!-- Package ID         : F4AAA9047B9D167BE0DC1A89763CCCBA-0000879407-001406 -->
<!-- Copyright (c) 2014 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/role/TemplateLink" xlink:href="arwr-20140630.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="arwr-20140630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationTable" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationTable" />
    <loc xlink:href="arwr-20140630.xsd#arwr_DocumentDocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="arwr_DocumentDocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationAbstract" xlink:to="arwr_DocumentDocumentAndEntityInformationTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationTable" xlink:to="arwr_DocumentDocumentAndEntityInformationLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="13060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="13220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="13300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ImpairmentOfIntangibleAssets" xlink:type="locator" xlink:label="arwr_ImpairmentOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfOperationsTable" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfOperationsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="arwr_StatementConsolidatedStatementsOfOperationsTable" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsTable" xlink:to="dei_LegalEntityAxis" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsTable" xlink:to="arwr_StatementConsolidatedStatementsOfOperationsLineItems" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_Revenues" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="arwr_ImpairmentOfIntangibleAssets" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="13270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="13430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_ProfitLoss" order="13530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="13690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="14010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfOperationsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="14170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="14330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsExercisedDuringPeriodValue" xlink:type="locator" xlink:label="arwr_WarrantsExercisedDuringPeriodValue" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsExercisedDuringPeriodShares" xlink:type="locator" xlink:label="arwr_WarrantsExercisedDuringPeriodShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedToGallowayMember" xlink:type="locator" xlink:label="arwr_IssuedToGallowayMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" xlink:type="locator" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedToGallowayMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_WarrantsExercisedDuringPeriodShares" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_WarrantsExercisedDuringPeriodValue" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" order="13800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="14020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="14240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" order="14480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="14700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="14920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_li0l2" order="15200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" xlink:type="locator" xlink:label="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" xlink:type="locator" xlink:label="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtFiveDollarAndEightySixCentsPerShareMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedAtEighteenDollarAndNinetyFiveCentsPerShareMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_PreferredStockIssuedAtThousandDollarsPerShareMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:type="locator" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatementConsolidatedStatementsOfCashFlowsTable" xlink:type="locator" xlink:label="arwr_StatementConsolidatedStatementsOfCashFlowsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="arwr_StatementConsolidatedStatementsOfCashFlowsTable" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsTable" xlink:to="dei_LegalEntityAxis" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsTable" xlink:to="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProfitLoss" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_li0l2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="13050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_StatementConsolidatedStatementsOfCashFlowsLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="13250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="arwr-20140630.xsd#Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <loc xlink:href="arwr-20140630.xsd#arwr_RocheMadisonMember" xlink:type="locator" xlink:label="arwr_RocheMadisonMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IssuedToGallowayMember" xlink:type="locator" xlink:label="arwr_IssuedToGallowayMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="arwr_IssuedToGallowayMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_RocheMadisonMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies" xlink:href="arwr-20140630.xsd#Role_DisclosureOrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestments" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestments" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestments">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssets" xlink:href="arwr-20140630.xsd#Role_DisclosureFixedAssets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitions" xlink:href="arwr-20140630.xsd#Role_DisclosureAcquisitions" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitions">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssets" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiaries" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentInSubsidiaries" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiaries">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquity" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquity">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeases" xlink:href="arwr-20140630.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeases">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurements">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="arwr-20140630.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NoncontrollingInterestsPolicyTextBlock" xlink:type="locator" xlink:label="arwr_NoncontrollingInterestsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAndCostMethodInvestmentsPolicy" xlink:type="locator" xlink:label="us-gaap_EquityAndCostMethodInvestmentsPolicy" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="arwr_ContingentConsiderationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_ContingentConsiderationPolicyTextBlock" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAndCostMethodInvestmentsPolicy" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_NoncontrollingInterestsPolicyTextBlock" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssetsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureFixedAssetsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssetsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesTables" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightsMember" xlink:type="locator" xlink:label="arwr_ExchangeRightsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_ExchangeRightsMember" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NetCashInvestedInFixedIncomeInvestments" xlink:type="locator" xlink:label="arwr_NetCashInvestedInFixedIncomeInvestments" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:type="locator" xlink:label="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Investments" xlink:type="locator" xlink:label="us-gaap_Investments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BondsMember" xlink:type="locator" xlink:label="us-gaap_BondsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfInvestmentsByTypeDomain" xlink:type="locator" xlink:label="us-gaap_SummaryOfInvestmentsByTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xlink:type="locator" xlink:label="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesByTypeAxis" xlink:to="us-gaap_SummaryOfInvestmentsByTypeDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentsByTypeDomain" xlink:to="us-gaap_BondsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_Investments" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_ProceedsFromExerciseOfWarrantsAndStockOptions" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_NetCashInvestedInFixedIncomeInvestments" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_RangeAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_CostMethodInvestmentAttributableToNoncontrollingInterest" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <loc xlink:href="arwr-20140630.xsd#arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <loc xlink:href="arwr-20140630.xsd#arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="arwr_CommercialNotesDueWithinOneYearMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="arwr_CommercialNotesDueAfterOneYearWithinThreeYearsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_MarketableSecurities" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixdAssetsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFixdAssetsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixdAssetsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ResearchEquipment" xlink:type="locator" xlink:label="arwr_ResearchEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="arwr_ResearchEquipment" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PresentValueOfContingentAcquisitionConsideration" xlink:type="locator" xlink:label="arwr_PresentValueOfContingentAcquisitionConsideration" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ObligationToPayRoyalties" xlink:type="locator" xlink:label="arwr_ObligationToPayRoyalties" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PercentageOfRoyaltyLiability" xlink:type="locator" xlink:label="arwr_PercentageOfRoyaltyLiability" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ApplicableOutLicenseTerm" xlink:type="locator" xlink:label="arwr_ApplicableOutLicenseTerm" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" xlink:type="locator" xlink:label="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationConsiderationPromissoryNoteIssued" xlink:type="locator" xlink:label="arwr_BusinessCombinationConsiderationPromissoryNoteIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_RocheMadisonMember" xlink:type="locator" xlink:label="arwr_RocheMadisonMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="arwr_RocheMadisonMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_BusinessCombinationConsiderationPromissoryNoteIssued" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_ApplicableOutLicenseTerm" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_PercentageOfRoyaltyLiability" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_ObligationToPayRoyalties" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="arwr_PresentValueOfContingentAcquisitionConsideration" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExpectedAmortizationExpenseLineItems" xlink:type="locator" xlink:label="arwr_ExpectedAmortizationExpenseLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExpectedAmortizationExpenseTable" xlink:type="locator" xlink:label="arwr_ExpectedAmortizationExpenseTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="arwr_ExpectedAmortizationExpenseTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="us-gaap_RangeAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseTable" xlink:to="arwr_ExpectedAmortizationExpenseLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ExpectedAmortizationExpenseLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_li0l2" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IndefiniteLivedIntangibleAssetsAmortization" xlink:type="locator" xlink:label="arwr_IndefiniteLivedIntangibleAssetsAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTable" xlink:to="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="arwr_IndefiniteLivedIntangibleAssetsAmortization" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_li0l2" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_li0l2" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_li0l2" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets_li0l2" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_li0l2" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiariesAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureInvestmentInSubsidiariesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiariesAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_LeonardoBiosystemsIncMember" xlink:type="locator" xlink:label="arwr_LeonardoBiosystemsIncMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_InvestmentInPreferredStockByOutsider" xlink:type="locator" xlink:label="arwr_InvestmentInPreferredStockByOutsider" />
    <loc xlink:href="arwr-20140630.xsd#arwr_InvestmentInPreferredStock" xlink:type="locator" xlink:label="arwr_InvestmentInPreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AblarisTherapeuticsMember" xlink:type="locator" xlink:label="arwr_AblarisTherapeuticsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" xlink:type="locator" xlink:label="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <loc xlink:href="arwr-20140630.xsd#arwr_StatedPercentageOfNotesAndAdvances" xlink:type="locator" xlink:label="arwr_StatedPercentageOfNotesAndAdvances" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AmountOwedBySubsidiary" xlink:type="locator" xlink:label="arwr_AmountOwedBySubsidiary" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="locator" xlink:label="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
    <loc xlink:href="arwr-20140630.xsd#arwr_OutstandingBalanceOfPromissoryNote" xlink:type="locator" xlink:label="arwr_OutstandingBalanceOfPromissoryNote" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CalandoPharmaceuticalsIncMember" xlink:type="locator" xlink:label="arwr_CalandoPharmaceuticalsIncMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_OwnershipPercentageInSubsidiary" xlink:type="locator" xlink:label="arwr_OwnershipPercentageInSubsidiary" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_OwnershipPercentageInSubsidiary" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_CalandoPharmaceuticalsIncMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_OutstandingBalanceOfPromissoryNote" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_AmountOwedBySubsidiary" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_StatedPercentageOfNotesAndAdvances" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_AblarisTherapeuticsMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_InvestmentInPreferredStock" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="arwr_InvestmentInPreferredStockByOutsider" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_LeonardoBiosystemsIncMember" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_AggregatePriceOnIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="arwr_AggregatePriceOnIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ConversionPricePerShare" xlink:type="locator" xlink:label="arwr_ConversionPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CommonStockExercisePrice" xlink:type="locator" xlink:label="arwr_CommonStockExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CashDrawnFromFacility" xlink:type="locator" xlink:label="arwr_CashDrawnFromFacility" />
    <loc xlink:href="arwr-20140630.xsd#arwr_EquityCommitmentAgreementPeriod" xlink:type="locator" xlink:label="arwr_EquityCommitmentAgreementPeriod" />
    <loc xlink:href="arwr-20140630.xsd#arwr_MaximumEquityCommitmentAmountUnderAgreement" xlink:type="locator" xlink:label="arwr_MaximumEquityCommitmentAmountUnderAgreement" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" xlink:type="locator" xlink:label="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandStockOptionPlanTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10020.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_PurchaseAgreementWithLincolnParkCapitalFundLimitedLiabilityCompanyMember" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_MaximumEquityCommitmentAmountUnderAgreement" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_EquityCommitmentAgreementPeriod" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_CashDrawnFromFacility" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_CommonStockExercisePrice" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ConversionPricePerShare" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_AggregatePriceOnIssuanceOrSaleOfEquity" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_RemainingLifeOfWarrant" xlink:type="locator" xlink:label="arwr_RemainingLifeOfWarrant" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantEightMember" xlink:type="locator" xlink:label="arwr_WarrantEightMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantSevenMember" xlink:type="locator" xlink:label="arwr_WarrantSevenMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantSixMember" xlink:type="locator" xlink:label="arwr_WarrantSixMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantFiveMember" xlink:type="locator" xlink:label="arwr_WarrantFiveMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantFourMember" xlink:type="locator" xlink:label="arwr_WarrantFourMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantThreeMember" xlink:type="locator" xlink:label="arwr_WarrantThreeMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantTwoMember" xlink:type="locator" xlink:label="arwr_WarrantTwoMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantOneMember" xlink:type="locator" xlink:label="arwr_WarrantOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantOneMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantTwoMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantThreeMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantFourMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantFiveMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantSixMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantSevenMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_WarrantEightMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="arwr_RemainingLifeOfWarrant" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_FacilityAndEquipmentRentExpense" xlink:type="locator" xlink:label="arwr_FacilityAndEquipmentRentExpense" />
    <loc xlink:href="arwr-20140630.xsd#arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" xlink:type="locator" xlink:label="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PaymentsUnderCapitalLease" xlink:type="locator" xlink:label="arwr_PaymentsUnderCapitalLease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UtilitiesCosts" xlink:type="locator" xlink:label="us-gaap_UtilitiesCosts" />
    <loc xlink:href="arwr-20140630.xsd#arwr_OtherRentalExpenses" xlink:type="locator" xlink:label="arwr_OtherRentalExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:type="locator" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorPropertyClassDomain" xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorPropertyClassAxis" xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_PercentageOfIncreaseInAnnualRentalCost" xlink:type="locator" xlink:label="arwr_PercentageOfIncreaseInAnnualRentalCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:type="locator" xlink:label="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_PercentageOfIncreaseInAnnualRentalCost" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="arwr_ResearchFacilityInMadisonMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_MajorPropertyClassAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassDomain" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassDomain" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_OtherRentalExpenses" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="us-gaap_UtilitiesCosts" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_PaymentsUnderCapitalLease" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems" xlink:to="arwr_FacilityAndEquipmentRentExpense" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_CapitalLeasedAssetsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="dei_LegalEntityAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:to="us-gaap_CapitalLeasedAssetsLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalLeasedAssetsLineItems" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="dei_LegalEntityAxis" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ArrowheadMember" xlink:type="locator" xlink:label="arwr_ArrowheadMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="locator" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:type="locator" xlink:label="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsStockOptionPlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsStockOptionPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsStockOptionPlanMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10020.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_ArrowheadMember" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeAssetsNoncurrent" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NumberOfExchangeRightAreSold" xlink:type="locator" xlink:label="arwr_NumberOfExchangeRightAreSold" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFiveYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFiveYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFourYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFourYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForThreeYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForThreeYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForTwoYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForTwoYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightConvertibleConversionRatioForFirstYear" xlink:type="locator" xlink:label="arwr_ExchangeRightConvertibleConversionRatioForFirstYear" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TermOfExchangeRights" xlink:type="locator" xlink:label="arwr_TermOfExchangeRights" />
    <loc xlink:href="arwr-20140630.xsd#arwr_AblarisTherapeuticsMember" xlink:type="locator" xlink:label="arwr_AblarisTherapeuticsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="arwr-20140630.xsd#arwr_WarrantsIssuedToAcquireCommonStock" xlink:type="locator" xlink:label="arwr_WarrantsIssuedToAcquireCommonStock" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandThirteenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandThirteenWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsTwelveWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandsTwelveWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandTenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandTenWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <loc xlink:href="arwr-20140630.xsd#arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" xlink:type="locator" xlink:label="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" />
    <loc xlink:href="arwr-20140630.xsd#arwr_UnidymIncMember" xlink:type="locator" xlink:label="arwr_UnidymIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueMeasurementsDisclosureLineItems" xlink:type="locator" xlink:label="arwr_FairValueMeasurementsDisclosureLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="arwr-20140630.xsd#arwr_FairValueMeasurementsDisclosureTable" xlink:type="locator" xlink:label="arwr_FairValueMeasurementsDisclosureTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="arwr_FairValueMeasurementsDisclosureTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="arwr_FairValueMeasurementsDisclosureLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_MarketableSecurities" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_UnidymIncMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_TwoThousandTenWarrantsMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_TwoThousandsTwelveWarrantsMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="arwr_TwoThousandThirteenWarrantsMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_WarrantsIssuedToAcquireCommonStock" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="arwr_AblarisTherapeuticsMember" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_TermOfExchangeRights" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFirstYear" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForTwoYear" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForThreeYear" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFourYear" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_ExchangeRightConvertibleConversionRatioForFiveYear" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="arwr_NumberOfExchangeRightAreSold" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_FairValueMeasurementsDisclosureLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsAssetsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsAssetsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_li0l2" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightsMember" xlink:type="locator" xlink:label="arwr_ExchangeRightsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandThirteenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandThirteenWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandsTwelveWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandsTwelveWarrantsMember" />
    <loc xlink:href="arwr-20140630.xsd#arwr_TwoThousandTenWarrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandTenWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_TwoThousandTenWarrantsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_TwoThousandsTwelveWarrantsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_TwoThousandThirteenWarrantsMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_ExchangeRightsMember" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail">
    <loc xlink:href="arwr-20140630.xsd#arwr_ExchangeRightsMember" xlink:type="locator" xlink:label="arwr_ExchangeRightsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="arwr_ExchangeRightsMember" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail" xlink:href="arwr-20140630.xsd#Role_DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_li0l2" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" xlink:type="locator" xlink:label="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationContingentConsiderationPayments" xlink:type="locator" xlink:label="arwr_BusinessCombinationContingentConsiderationPayments" />
    <loc xlink:href="arwr-20140630.xsd#arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" xlink:type="locator" xlink:label="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="arwr_BusinessCombinationContingentConsiderationPayments" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="arwr_BusinessCombinationFairValueOfChangeInContingentConsideration" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_li0l2" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments under Operating Leases (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2014 (remainder of)</a></td>
        <td class="nump">$ 134,164<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump">580,626<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump">597,196<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump">613,984<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump">638,217<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2019 and thereafter</a></td>
        <td class="nump">432,861<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 2,997,048<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasedAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the remainder of the fiscal year following the latest fiscal year ended for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2RAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Derivative Liability (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in value</a></td>
        <td class="nump">$ 5,680,544<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Value, Beginning balance</a></td>
        <td class="nump">4,091,797<span></span></td>
        <td class="nump">626,195<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of instruments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,153,819<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in value</a></td>
        <td class="nump">5,680,544<span></span></td>
        <td class="nump">5,066,591<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Net settlements</a></td>
        <td class="num">(5,789,982)<span></span></td>
        <td class="num">(3,754,808)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Value, Ending balance</a></td>
        <td class="nump">3,982,359<span></span></td>
        <td class="nump">4,091,797<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Exchange rights</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Value, Beginning balance</a></td>
        <td class="nump">4,569<span></span></td>
        <td class="nump">10,375<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of instruments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in value</a></td>
        <td class="nump">31,791<span></span></td>
        <td class="num">(5,806)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Net settlements</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Value, Ending balance</a></td>
        <td class="nump">$ 36,360<span></span></td>
        <td class="nump">$ 4,569<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!NR'4D#`(``#@>```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F4MNVS`41><%N@>!T\*B
M^6F:%I8SZ&?8!FBZ`$9ZM@1+)$$RJ;W[4G(2%('KP(B!WHD%2^2[1QR<@>[B
M:COTQ3V%V#E;,5'.64&V=DUGUQ7[=?-M=LF*F(QM3.\L56Q'D5TMW[Y9W.P\
MQ2+OMK%B;4K^$^>Q;FDPL72>;'ZR<F$P*?\-:^Y-O3%KXG(^O^"ULXELFJ5Q
M!ELNOM#*W/6I^+K-M_<D@?K(BL_[A6-6Q8SW?5>;E$GYO6V>I<P>$LJ\<UH3
MV\['=QF#\8,)XY-_!SSL^Y&/)G0-%=<FI.]FR!A\V_/?+FQNG=N4QX<<H'2K
M55=3X^J[(9]`&7T@T\26*`U].5W+P73VD?M(_K0X\NDBS@PROM\T^$0."<*A
M0#@T",=[$(X+$(X/(!R7(!P?03C$'`4$Q:@"1:D"Q:D"1:H"Q:H"1:L"Q:L"
M1:P"Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P*Q:P*Q:P*Q:P*
MQ:P*Q:P*Q:P*Q:P*Q:P*Q:P*Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:
MQ:SZ?YDUY5Z.^/3[>I5-8UXHAF+:]13/_#%W/_2EY-8$:GZFD!O,LP/\/?L8
M1^[WKH/S,3>=@4X_A<<J<]P]\WD0A=314YEYJ!1\2LPMZ>F!SUI)&GO8AIH#
MV7SJ?9=_````__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R
M96QS+RYR96QS(*($`BB@``(`````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````(R2ST[#,`S&[TB\
M0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?
M'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+
MBQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J
M/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C
M`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/
M5%\```#__P,`4$L#!!0`!@`(````(0!+1T5B-P(``'T=```:``@!>&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````"\F4]KVT`4Q.^%?@>Q]WB][ZV<I$3.)11R;=,/(*RU
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ME`B'30-A')O&01QA5W6!55W855U@55=V8BE,+,].+(\3B^TZ#KJ.8T_'P>DH
M.\\5YKEGY[F'>5[.FN>QK<?0?$UC?@427V/BXC1*"/IL$`Q;QE#%CCT:!V4C
ML\KF'<U"8`T4=@T46`.5;<@*#5G954=AU?'LJN-AU?'LJN-AU6'30)ARUNR,
MZ73(K\"G-SE_CI$%LY4"A>+8GN>@YSFVYSGH><(V&8$FHW3I0.TH>ULKW->>
M_3SEX?.4L/-28%[Z65WO'>7&PR<&-@V$80MGTHV]^&BZ_@T``/__`P!02P,$
M%``&``@````A`'2!;149!```]0X```\```!X;"]W;W)K8F]O:RYX;6R4EUUO
MHS@4AN]7VO^`N-])^$@RK9J.VFZKC;2S4TVZG4OD@A.L@LUB,VGVU\\!FN0%
MDRB]2FSPZ_/QG&-S]>4MSYR?O-1"R;GK?1J[#I>Q2H1<S]U_GQ[^^.PZVC"9
ML$Q)/G>W7+M?KG__[6JCRM<7I5X=$I!Z[J;&%)>CD8Y3GC/]215<TI.5*G-F
M:%BN1[HH.4MTRKG)LY$_'D]'.1/2;14NRW,TU&HE8OZGBJN<2].*E#QCALS7
MJ2BT>WVU$AE_;CUR6%'\PW*R^RUSG8QI<Y\(PY.Y.Z&AVO#.1%D5MY7(Z.E%
M,`[<T?7>R<?22?B*59EY(O=VZA0O/_3]:?UF'8IGP3?ZL*@>.F\_A$S4IGZ5
M0KO=CP(R8-,\^B$2D]+S\7B\G_N+BW5J=I,D/P+])H*T3_/KR,:]740BRE1T
M+XTPVV@AV^@+12FLH[X@SSS7*2\%_2D7B5<;CBIW%$25B811B*);EC$9\VA9
M+]4@X8.$_P&)Z)&!2@`J3:R/&K(T9$^=;AVI5?2MX*`2@DIXTI:]2BVR-"H&
ME0FE9A^5R<=D**#[X$Y!IJ'B3)_N&,9W!BJS\XQI(D,J:,P$4_VYK_.M7#,I
M_F\*IX%F*=924'$Q::(;\&F"Z;[HRRSD3ZJA)CFX!I/KC?N+'L0;\76C=9>K
M"2;3L^"\B?^KA!9-I>->5#3[W'D6CPM)S6LM7C(^L"'FR[,@//@6"1DMJQ<M
M$L%*01WPD/()9LNS$*Q!>TU5EE`_BN[)`;/%Q=1<#[9;X/W-F>YN=H'O6X0U
MF]W2FB2Z4SDU8-VD%S:<(NB>!=<#$V7TS+**1U]I[ZILRPX%$"KO@U0AG5/$
MRCO%5?3$*'L8\RGB16VUU\40KX'%2)EO46;Q,J"`Q/D6<0,I']!`]'P+O3;S
M`\N0-G^8-AN``1T$S[?`.\+!@`X"V1Z$V/).-QDB8-\Y_8YC%IB'4M14B'G.
MRFW3QE-5FHBA3L<QBT]"8]=XHIN$K@)T;6#9[J1$G8YC%IY@PV-)5YV2CMOF
MY*4*+W+0";#@:-!#%7N:;1#J8-T%9U"+WH'.K&./Q:Y-_S).>5)1]Z13$W0"
M+$$:]/PZY*O?.FLO06?6\6L8Z&[[A#"A#K83NEOU[!FJR4,.02?`NJ1!3^>]
M+C&X^TN6[,0'>0XLGM]U'BI#/3;Z*J3(JSQJ9GNW).0YL'@^K8/]-D"@:=!S
M[,C1\1YL"%"(`-'@3)TVV*B#B0\MH(_:HW65%ZB#B0\MH(_IM/9@@$(DF@8]
MQXZUQ'8>#<+S);2(/J;3(@4ZLXX]%M''=+[S6,D8=$(DF@9G^D6WLUZ@D>C0
M(OJT/9U`(]*AA?0QH;N4[G&=JS\2'39$CYKSA#Z-8I;%],U6_]0?/0VFH]T7
MZ_4O````__\#`%!+`P04``8`"````"$`1?U2,V0'``#F'@``&````'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;)2978^CN!*&[U?:_Q!QGPZVP896IT?#QYRS
MTJZT.CJ[>TTGI(,F"1'0TS/_?LO8`5<Q2>B;Z4GR4/AU5=DO^.G3]^-A\:UL
MVJH^K3WVX'N+\K2IM]7I=>W]]?\OR\A;M%UQVA:'^E2NO1]EZWUZ_O67I_>Z
M^=KNR[);0(13N_;V77=^7*W:S;X\%NU#?2Y/\,NN;HY%!Q^;UU5[;LIBVU]T
M/*RX[\O5L:A.GHGPV,R)4>]VU:;,ZLW;L3QU)DA3'HH.QM_NJW-[B7;<S`EW
M+)JO;^?EICZ>(<1+=:BZ'WU0;W'<//[V>JJ;XN4`NK^SH-A<8O<?)N&/U::I
MVWK7/4"XE1GH5'.\BE<0Z?EI6X$"/>V+IMRMO<_L,1>^MWI^ZB?H[ZI\;YW_
M+]I]_?Z?IMK^7IU*F&W(D\[`2UU_U>AO6_T57+R:7/VES\"?S6);[HJW0_>_
M^OV_9?6Z[R#=(2C2PAZW/[*RW<",0I@''NI(F_H``X!_%\=*EP;,2/&]__M>
M;;O]VA/R(52^8(`O7LJV^U+ID-YB\]9V]?$?`S$;R@3A-@C\M4$8_W`088/`
MWR'([!$$]F(8\W#QW!&LS)3T,YP57?'\U-3O"RA;$-V>"]T$[!$"7Z;63,0P
MV=?F&B99!_FLHZP]Y2U@&ELHD&_/*GQ:?8.<;BR2_`21&$DOB,Z@#IM=OAC#
M,GQ)?B%T^8"B019DR97U\TJYC%[#>O27^R;F"X@]R.'XONF44`HCV10A0?(I
MX01!<J!>7#DZ2]!P5QK@(DM?!)RC0D5XC(E!H+`&H21MZ5TBNTODMP@D$P;B
MRKR=-0VO/9C#8>PJ)O(,$O4%&0@5^OCW],[OF?L[TZL%"9"[``]DR,:21L*@
ML^8+TS#.6T3NFQ@$[CYHIWF[2V1WB?P6@>3)C\C3,,Y;1+HZ,8CL\\:#,`@"
MDMG4)1C,N^*$R%Q"21&P@+:?2X2PHPL^M@>2!^O:_.QIF,@C-TX,8N2Q,-*%
M0PK3):(XED)@(',!$<DP"DB(W"5X&"ON=`=2IUV2LP/<;CH-$W5D:(E!C#HI
M8@YF"0\^=0FF0AERNG8B(E`L5H+D-W>1,(!99.,T(WWQ1_1IF.@+\.@3@]CB
M]&'RH_'&_;:5NH20(HS)%&4(4#!V26Z2NP1C3"]>PS"0.@;;P/ST]331-P;N
M1Y]8Q@I4T@_)X%)$0'OZT;CLV8U;CVKMV1+W5<C%V%L]DJ,@3(0\"$8$2]2;
M_.P*9<82N/L"'5YBF5OKIT6L`N%'?D"+]'Z4_&84+%*;@?DBC75`(LGP$F88
MJX"K0$1T_TH1(P,A)"/ED"%$,#\4W%DG;2[1K60DI(S&?L4ZM1F8K]-8!Z1S
MK!);KX8Q.I>,*]]GDR6'(4B**(9%<^@H6[2($7[,8=TA=\MQ(-AZ8I^IL;^Q
M5FT/YFLU9@(&,6SJSB1:K8:Y6;AWD8S=1?*;"!:I78(C<IXWU8]O9*&-R3:1
M6,8D5D7*I^LL`I8LC$-!8F08D;&@+9!C0D2^C*^5KC8,CM+;.R4S]L(MW9CZ
M',O<3*?K4I8BCJD5RFP06_]A%$UK%L4`,Q2-58USJ4W#?(7&8B"%)$4)0S8$
M]CD^V4Q<8AE$/"0Q,A0#]EOP%+AS<T0L913XUSI2NX;Y`HW'0`+'P+8C71\"
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MGJ0/?7EV7,++$5+L*0+`QS,"9!@(F:!^`0%!H+AS#YQ38HAFRIP:(T8W@X0;
MR+R<7.J6C6)G9;0%C"#I*WC:&/?]GLEP('B"@]W3>93NH1Q#3,&2#X]R0[M@
MT=J.?+QEC8EQ6Y8Y-JP?1L(-%/=O]I9P7$,RDTX`XK<R"M!WASD%'+.(57[(
M)W%C<6#A&Q[.F$^-DH5NKD@FS@TDNQ\EOXD@E?J4X..Y[*_">ZM;+2:7%C+K
M3LABP6+ZO)HBADL&KV$CFE'$!`&\#O1]TM'Z=-%YGQ1%^F;C9F\4F^-#<[AU
M+)O7,BT/AW:QJ=_TT:"`DAN^'8XM/W-]Z$.^3]@C'$5-O\_@F+/_?C5<`*>,
MY^*U_*-H7JM3NSB4.[B5_Z!@)6W,.:7YT-7G_JCMI>[@?+'_[Q[.DTLXY/(?
M`-[5=7?YH(^RAA/JYW\!``#__P,`4$L#!!0`!@`(````(0"':\#B/`,``+0*
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)2676^;,!2&[R?M/R#N
M"Y@$\J&0JDG5K=(F3=,^KATPP2I@A)VF_?<[YA`"3I?2FQ#J][QY_![7]NKV
MI<BM9U9++LK()HYG6ZR,1<++?63__O5P,[<MJ6B9T%R4++)?F;1OUY\_K8ZB
M?I(98\H"AU)&=J94M71=&6>LH-(1%2MA)!5U016\UGM75C6C25-4Y*[O>:%;
M4%[:Z+"LQWB(-.4QNQ?QH6"E0I.:Y50!O\QX)4]N13S&KJ#UTZ&ZB451@<6.
MYUR]-J:V5<3+QWTI:KK+8=XO9$KCDW?S<F%?\+@64J3*`3L702_GO'`7+CBM
M5PF'&>C8K9JED7U'EEOBV^YZU03TA[.C['VW9":.7VJ>?.,E@[2A3[H#.R&>
MM/0QT7^"8O>B^J'IP(_:2EA*#[GZ*8Y?&=]G"MH=P(STQ);)ZSV3,20*-HX?
M:*=8Y```GU;!]=*`1.A+\SSR1&61/0F=8.9-",BM'9/J@6M+VXH/4HGB+XI(
M:X4F?FL"S]8$ICRV>-(6P[,K=OQY0(+P?007I].D<T\57:]J<;1@R0&PK*A>
MP&0)SCJ6Z7]C@3QTS9TN:DI!+:&7SVM`6+G/D'_<:C:7&G^HV+ZAF'42%_@Z
M2`BI#_EVSTYP6@S=L:T>7-CY-A/8H&;:TQCXVVN*`1O\T'@V+8YL\.[8)L0S
MV%`S;V(-9L0SR7#\;?8!&4C&DVFQ)M/-]#UB_.@&AT,<]N=3WZ#>H@`^NYF=
M+094L+C&4VEQC\IL(PY?H4+!"*KP(U1:W*,Z+UI<7#A\A0H%(ZAF'Z'2XA[5
MW%A6.'R%"@4CJ/21V-LRKO\W:K&F.J^+"2$&&FH0;1&0V7GE-(%N<7P$V>(C
M9%ILDAE;U`8U2'8S]<*Y@;Y%P0@T`B?6^-0:M0DW-6)K14A'/#_P9XNA9-M*
MQO`9!\'UKA+<NX=M-=JV:45M>CZ!QIN[AB$!S?3L,M@V]$'9ST\?5!/(]!U.
M737,,3![W#A'-FZX<^*3\")%=$$%\4)"R*0+&BGQWH$G:T7W[#NM][R45LY2
M`/6<&>Q$-=XZ\$6)JCE!=T+!;:'YFL'MD,'QZCD@3H50IQ=]K^GNF^M_````
M__\#`%!+`P04``8`"````"$`DXX^D+D"``!7!P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6R4E6]OFS`0QM]/VG>P_+X!`R$0A52MJFZ3-FF:]N>U
M`R98!8QLIVF__<Y<`J1IJ_1-@/CQ\[L['\?J^JFIR:/01JHVHVSF4R+:7!6R
MW6;TS^_[JX028WE;\%JU(J//PM#K]>=/J[W2#Z82PA)P:$U&*VN[I>>9O!(-
M-S/5B1962J4;;N%1;SW3:<&+?E-3>X'OQU[#94O18:DO\5!E*7-QI_)=(UJ+
M)EK4W$+\II*=.;HU^25V#=</N^XJ5TT'%AM92_O<FU+2Y,MOVU9IOJDA[R<6
M\?SHW3^<V3<RU\JHTL[`SL-`SW-.O=0#I_6JD)"!*SO1HLSH#5O>IM1;K_KZ
M_)5B;R;WQ%1J_T7+XKML!10;CLD=P$:I!R?]5KB_8+-WMON^/X"?FA2BY+O:
M_E+[KT)N*PNG/8>$7%[+XOE.F!P*"C:S8.Z<<E5#`/!+&NDZ`PK"G_KK7A:V
MRF@8S^8+/V0@)QMA[+UTEI3D.V-5\P]%[&"%)L'!!*X'$P:W[V_V,)`^KSMN
M^7JEU9Y`KP#*=-QU'EN"BTLH>C,AR,3MN7&;^JV@-G`(C^LX6*R\1ZA<?M#<
MGFN"0>$!?(@`J-,(7B_ED>S$4#1*)N1D\.VCNT5---',!\4)&6PN)SMQ1L%[
M((?,'WR1C)JDKP@+(Q9'@^`$#+%=#G9B!W9E#GPVYH),7([[Y7GBQT'\.A,.
M]7*F$T^8HR4R<?G`3!<L'04G><8?83KQA/FRGW`9F3$+T^2-VBX^PG3B"?-E
M)^'R@1DF`1N#.LG33??)2_1^"SNQ8TX;B0UGA@5&#8*C,$CB47`"3C\"=N)3
M,//'A!",&NS@($T7?C36!,DX&W&&='PK?G"]E:TAM2CAS?!G"V@.C9,1'ZSJ
M^EFQ418F6G];P0=,P"#Q9R`NE;+'!S=[AT_B^C\```#__P,`4$L#!!0`!@`(
M````(0!Z'B8X+P@``/XO```9````>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;)R:6V_B2A:%WT>:_X!X/^#R#8B2'+4O57.D,])H-)=G`DZ"&G"$G4[WOY]=
MWH7CVB9[PW1+(8&OEEVK=I673=W__O.PG_RH3LVN/CY,U2R83JKCIM[NCB\/
MTW__2_^VG$Z:=GW<KO?UL7J8_JJ:Z>^/?_W+_4=]^MZ\5E4[`85C\S!];=NW
MN_F\V;Q6AW4SJ]^J(WSR7)\.ZQ;^/+W,F[=3M=YVC0[[>1@$Z?RPWAVGJ'!W
MND:C?G[>;:JBWKP?JF.+(J=JOV[A_)O7W5MS5CMLKI$[K$_?W]]^V]2'-Y!X
MVNUW[:].=#HY;.[^>#G6I_73'OK]4\7KS5F[^V,D?]AM3G53/[<SD)OCB8[[
MO)JOYJ#T>+_=00^L[9-3]?PP_:;N3+28SA_O.X/^LZL^FL'OD^:U_C"GW?;/
MW;$"MV&<[`@\U?5WB_ZQM6]!X_FHM>Y&X!^GR;9Z7K_OVW_6'W^K=B^O+0QW
M`CVR';O;_BJJ9@..@LPL3*S2IM[#"<#/R6%G2P,<6?_L7C]VV_;U81JELV01
M1`KPR5/5M'IG):>3S7O3UH?_(J2<%(J$3B2"LW>?PUM7-HY=8WAUC<-H%H?)
M8GG+*<#)=OV`U]M/(76-X?7<.+W]%!9.!5[/*N$L7"8J264OYS@NW3`7ZW;]
M>'^J/R8P=\#YYFUM9Z*Z`^7S^.)H]"/^U8##2%N1;U;E80KM82P;J-(?CVFX
MNI__@,K:."8;,XO41_(S8NO(ZA;G-SYUE=^D/!/G)AK?@)_]J22*',><&5OY
MX$-O!E35T(S+17[NLX5MG\]'SO"-X9%#_V3S,;%8^$@Q1HA(.2:HB!XC(3F.
M&2/Q,NG/Q7,%IMW0%5LB\9=+P-D=VP@F^W`8ED&OWXUNA@Q,S,^A\HE<)`J1
M*$5"BX3A",\KZ,S0*[Z"+/PPA9'H^Y]&U"-DTFY.Q2H(!H/4F9@C`#][D<]A
MQ$DD292BA!8)PQ&>0U`Y0X=L-45P6>*=LHVH4V0ER)!!IZ)E&*6*S)P<"3C3
M+ZT2-4I10WL:L5K!$NU7M1D2:J6"Q2KN"<\KN&#<[I5M1+TB3F3(,$[D(E$@
M@7ZOH@#^]9WHZJX4)?100B7!2J5TI>8T/*O@VG.[5;81M2KR>Y$APUDE$@42
M:)5*D[%5HH06"<,1GE4VFY-+OCP#;2-JU6?5XGJ.S+);JZ"J@S0B<S0?$E$:
M)2OB=C$$0K5,TX00Y9!02L71@DPOC00S8H8C/*M6OE7\(F5A:A$YMPP95PEJ
MD8Y*(?>(8!6'*Z)1#(DE?`PB?LV60T*IU2)9+GU"(\%YQ!&>1PI6[V$]\29U
M-'6)S/K,06XM7Z@H(J66.R+N:HUTO_";IP'\)X58<NUU_^&7%PK#(KX]-FP.
MIIM@#T;382:($I+=,H40,WJYC!0.4>'JDHDE_[&6#V!8Q/?(IM'K/<+L.O0H
MC48>(<1Z)"*%$I%21K2,&!;QO;)9=.#5=7%<88*%GY_99Y3''<1ZQB5AC)NR
M2BDC6D8,B_B>09>&G@EST-)TB2(+:*80<BMYD*@X5>2.-W<,XV=QA4PIRV@9
M,2SBNV7S*:DP.2#8IT(CUX@CF8,81W(9*2X@:4PN`N4%B%Q(M8P8%O%=LU%U
MX)I08QALO34L)A>I3''IMYMLN8P4,E+*B)81PR*^5S:K#KRZ<@W#A"NL85P,
M=IZ)2*%$I)01+2.&17S/;&@EGETQ*S'J>G5&PU2F$,*U;)4N837SXV+NB"_B
MUK"Y2A8J5:1]R;77_8>#:Y-_?,,BODTVM]YN$Z9=SZ:8WC0KA-"F>#&^X\T=
MP2QOA2A2RB+Z$D(RM+G$]*YZEH4DP%_W2*9K1:Z2,;E9RQS$&)++2"$CI8QH
M&3$LXGM&4OUU*UB(P9U?P1S$>B;>`!2R2BDC6D8,B_B>V3`]F)K\%3*T-*FO
MB*8P!^$CAR1<J2@@LS9W"&-G(:N4LHJ6$<,BOE<V9P^\NG).8CKWEK&(9K`0
M(<:07$:*"T@:D+OT\@)$,YB,&!;Q78-.#5T3*LS2I,)BTH4L1(AU2T0*6:64
M$2TCAD5\KRZD?/EK'?M-(W@FK&`(L9Z)2.$.Q:B4,J)EQ+"([]E-&3^\D/%'
MW^\XR#WJ6HZ?!SJ`L:&0-$I90\N(81'?)QN?;U^],'3[JQ=)DEF($..7&-T+
M2:-T`..YEA'#(KY?)-L+Z]:%3!^3=34+$6*ZD,M((2.EC&@9,2SB>W4AX%^Q
M;F%V%]8MA%C/1*2`YZEVB6142AG1,F)8Q//,WB<.YR-?7QU-KHNC=<M!.`_#
M110OZ1.8W"&,$86L4LHJ6D8,B_A>74CVMK7@&29R?NV*$'*>I=$R36A:=0CK
MF:A2RBI:1@R+^)[9K'[S>A_95K3.B"&9@QA#<ADI>L1N3:)/"OL/OWS^H&7$
ML(COE@W@`[>$RL*X[E563&[VLP@AUB41*6254D:TC!@6\;V"+@V]NNX^.[*M
MI)3J(-8SU&&00E8I943+B&$1WS.2[(7ZPB3NU==XM4<(5Z[8/OFBWSGGD9SH
M'<*HE+**EA'#(KY7)-%?=Y\=74KV-*DZ"'N[B-(EW:B0.X(M+SS2UR*E+*)E
MQ+"([]C_E>UAC_(5:[T8W7.GPUJ&*LZR2[MM9!$M(W;;]=<Y#RW#;=6XW_90
MG5ZJO-KOF\FF?K=;IB/XWKU_M]_._2VT.TK)^YFZR[L]T>3]0MW!#EB[C;7_
M`'9?OZU?JK^O3R^[8S/95\]PJ&"V@.EYPOW;^$=;OW6[?Y_J%O9==[^^PC[[
M"K;=!C.`G^NZ/?]A#]#OW'_\'P```/__`P!02P,$%``&``@````A`,*G%;=>
M!```V@\``!D```!X;"]W;W)K<VAE971S+W-H965T-#$N>&ULG)==CZLV$(;O
M*_4_(.X7,!\F1$F.%E;;'JF5JJKG])H0)T$+.,)DL_OO.V8<P$ZRW6PNDA!>
M3QZ_,_;@Q;>WNK)>62M*WBQMXGBVQ9J";\IFM[1__//\,+,MT>7-)J]XPY;V
M.Q/VM]6OORQ.O'T1>\8Z"R(T8FGON^XP=UU1[%F="X<?6`-WMKRM\PXNVYTK
M#BW+-_V@NG)]SZ-NG9>-C1'F[6=B\.VV+-@3+XXU:SH,TK(J[X!?[,N#.$>K
MB\^$J_/VY7AX*'A]@!#KLBJ[]SZH;=7%_/NNX6V^KF#>;R3,BW/L_N(B?%T6
M+1=\VSD0SD70RSDG;N)"I-5B4\(,I.U6R[9+^Y',,Y+8[FK1&_2S9"<Q^6Z)
M/3_]UI:;/\J&@=N0)YF!-><O4OI](W^"P>[%Z.<^`W^UUH9M\V/5_<U/O[-R
MM^\@W1',2$YLOGE_8J(`1R&,XT<R4L$K`(!WJRYE:8`C^5O_>2HWW7YI!]2)
M8B\@(+?63'3/I0QI6\51=+S^%T5$A<(@O@H"GRJ('SBA'\6S>Z($*@I\JBB$
M?CJ*B_/J;7K*NWRU:/G)@MH#<G'(9263.426_@3@,LYF<.R68>"4#/(HHRSM
MV+9@N(`LOZYH&"_<5\A,H30I:N!]T!!=D5TJ(D('C0O$`S98.<6^GLXSG11+
M.IE>B9OB#U,4?_B;7I%=48SST4C`M"F)-#"\66!G(CD(C)YX$<T\'2%%33C5
MZ(KL(X7&"$%,1IGDCUV3@Y8V&#'DBX8SG2!%#>TS'H0D\6>1KLBF"I(0+T["
M0:$Q@F?W,\I!!F-@I#)%#3(F@0>O`0!S/160R$L(O5%T]"N(<I"!&"8Z08H:
M1'P@X2RBYM)`!9@Y)".Z`0F+\'X?Y2`#,C)L2E&C((,X)L1P.D-%V%?#`XW'
M4M`2+5OKE1WGXV*4@TQ`PZ,4-:H89WY`+P`UA5&N&F/R%48YR&0T+$I1@XPD
M"GQB+OL,%5JFAVK1&`FLX/N-[$>9E,'P#[@_*E'29S)TJ+'L,^T^=<9$Z(!R
M/[\[TP2[@+;O1..>H0!1A(`D=+RQUG!-JR@H\!W/3Z:O<3XZL-SU[P?&7J$#
M&SPI01'R1,YL)%"\>%]+^XT%3N2V?S\E-@N=<OP'92N*D)(Z_@7E]'[@)&/=
MZ#[*3?]^0CG*K,RQZ2I"%)T))WN,\G%Z7ZM<G?!+W48^.%X0&AZE2C1D6E]:
MF;H-F.-./DATQB^U&W*EWT1FOU&B*02EQGZ?71&-5:V3?JGGD"M-Q^Q[J1+I
MI,:FFET1W2(UFL_'38=<Z3ITK'E5D2B:X3.0Y\?$(^.&J*H2-=-9W`(T.L__
M`%YI.?1BKT01`I*`4AI?-$8X@LG*_@@0CUAX=JA9NV,9JRIA%?PHCT\$IC_\
M.ASM'OW^<#;<@)/5(=^Q/_-V5S;"JM@6AGI.#.NJQ;,97G3\T)],UKR#,U7_
M=0]G:`;/[IX#XBWGW?E"GOZ&4_GJ/P```/__`P!02P,$%``&``@````A`)-9
M#5B.!```:10``!D```!X;"]W;W)K<VAE971S+W-H965T,S<N>&ULE)A;;Z,X
M%(#?5]K_@'B?@"&7)DHR*C'='6E66JWV\DS`25`!1Y@T[;_?<S!DL>G:S$O;
MT,_'_GQL<^+MU_>R<-Y8+7)>[5PR\UV'52G/\NJ\<__Z\^7+D^N()JFRI.`5
MV[D?3+A?]S__M+WS^E5<&&L<B%")G7MIFNO&\T1Z864B9OS**OC/B==ETL#'
M^NR):\V2K&U4%E[@^TNO3/+*E1$V]908_'3*4T9Y>BM9U<@@-2N2!L8O+OE5
M]-'*=$JX,JE?;]<O*2^O$.*8%WGST09UG3+=?#M7O$Z.!7B_DWF2]K';#Z/P
M99[67/!3,X-PGASHV'GMK3V(M-]F.1C@M#LU.^W<9[*)R=KU]MMV@O[.V5T,
M_G;$A=]_J?/L>UXQF&W($V;@R/DKHM\R?`2-O5'KES8#O]=.QD[)K6C^X/=?
M67Z^-)#N!1BAV";[H$RD,*,09A8L,%+*"Q@`_'3*')<&S$CRWOZ^YUESV;GA
M<K98^2$!W#DRT;SD&-)UTIMH>/F/A$@72@8)NB#0H@M"X)&YL2<'TGK1I$GV
MVYK?'5@LT)6X)KCTR`8"]D*R^X?B_QF"&@9YQB@[=^4Z,'@!:7G;+TFP]=Y@
M*M..B<;,:JDBAQ[!B<.XM'_P7URB-HE[`K,&2@\OF)&AU^<)ZH>/,`Z_[S>2
M#R#VPT>S.8R)U4H=&ATC6I!X3`R"*#JAJH-I"F'UFK6P$7`#BR4)U4%&DID/
MF(5*'*P$M1*QB5`\82##M$WSQ$8[%R;SD:TEF:L6D61,GE:"2N*I7=]DZ?N^
MVD=LBJ!8PD8;6IJSB+!NI^4HDHS)SDI022REW6)L9XJ@V"U_Q`YAW4X[%B+)
MF.RL!)6$M%M]8F>*H-C!(3<]=PCK=MHQ$4FFF_?P:33Q!P4(QNN.#H&Y'XXB
MQ"JP&@**&Y8I@Y>!>5TBK+L]J3LBDHPI<U:"6HG81"A^:]5OVNF"C6RGJ&1,
MGE:"6HG81"B>!%X-TQ/9TGHFUUHF.\BD:$=HAW2+?3U<B.T+/S;&4!WQS3]Y
ML1)9)RCOB$`[OZ,.,CK*.`:$VJ/$1D2UQ!)A8#EMR6(]:%VS'610.=@1:D=B
M(Z+:8ITPL#4?0$16%6I.M?HPZB"CI:DZZ>I0B2S:E^,\7/G:01<;NU$=82@_
MX(BTMC<#K8R,B(2,CE:$=E'DW@S@BZ6V/6)C-ZHCU@J#/$Y<M;+"4/.IUZOX
M;0LFQ.AJ16@7A03K-J/^S-?ZB8W]J+)8.@QD+8M6%AJJI%ZL$E,UTJ[(@QVA
M=B0V(JHEUA`#RXDIE94'[)Y!::Y-=40D9$RI%:'V*+$146VQI!C86G(J"Q`U
MIZ.#R%2E=#FU(I1(I#^(%H&V=.(.^'PR54<L)Z8[RN)#=1P=1*8*I7.T(A0N
M<'"+R^]9P2>U>@>8'.4-CKSI*%E]9@=6%,))^0UO9T+8]8^GCYNCYP`O`+3G
M$=G`M<3X.<6;)GSN/1K`1<\U.;/?DOJ<5\(IV`FZ\F<K.(YJ>54D/S3\VMZ[
M''D#5SSMGQ>XTF-PX>'/`#YQWO0?L(/')>'^7P```/__`P!02P,$%``&``@`
M```A`&KP\>43!0``P1@``!D```!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
ME)E=CZ,V%(;O*_4_(.X7L/E(B)*L9CJ:=J6N5%7M]IH0)T$#.`(RF?GW/?X(
M8!,V]EQD0O)P7I_CPXMQUE\_JM)Y)TU;T'KC(B]P'5+G=%_4QXW[[S^O7Y:N
MTW99O<]*6I.-^TE:]^OVUU_65]J\M2=".@<BU.W&/77=>>7[;7XB5=9Z]$QJ
M^.9`FRKKX+`Y^NVY(=F>GU25/@Z"Q*^RHG9%A%5C$H,>#D5.7FA^J4C=B2`-
M*;,.QM^>BG-[BU;E)N&JK'F[G+_DM#I#B%U1%MTG#^HZ5;[Z=JQID^U*R/L#
M15E^B\T/)N&K(F]H2P^=!^%\,=!ISJF?^A!IN]X7D`$KN].0P\9]0JOG*'+]
M[9H7Z$=!KNWHO=.>Z/7WIMC_6=0$J@WSQ&9@1^D;0[_MV4=PLC\Y^Y7/P%^-
MLR>'[%)V?]/K'Z0XGCJ8[A@R8HFM]I\OI,VAHA#&PS&+E-,2!@"O3E6PUH"*
M9!_\_[78=Z>-&R9>O`A"!+BS(VWW6K"0KI-?VHY6_PD(R5`B")9!X+\,@B,O
MPO%B:1#%%R/B";YD7;9=-_3J0->`9GO.6`^B%41FF850'S&./M>Y5"%'%N2)
M1=FX"]>!TUN8G_=MG.*U_PXUS27S+!AX[1G4$SZ,IA\2#&,\I/M%OBDSF"FS
MHK.A/(L/QC+#0!29T$:&P5"9T>#C-.R'+Y0%$XV9GE"4`3%/D,$;%[+JRQ:G
M41]7*`LFX85',4Z@)7I"489N,U=FL*X<]W&%LF`,<DYLE!G\J-J",5"&KC3/
MF<%ZSHF6LV!27NU%X,7I^&^8&J7P[$XPNLQ^WM,,U@<QQ!6%%XR8\C1:IHM^
MD(IN:J/+8%UWB"MT!:.4/5W>UT;@(^9)<UI73_O(0EU"BGR/*(DC9C?&%>?T
MHXZ3D(FXE84A85GJ):XWG826PEQG<K:R-"3\2I75VTQ"HL\BE&`\.(!:;RB+
M1;T9K4^VWFI(0.-Z)T$PD[J5L[%[MR:?!(-EREXS]C9D96Z<?MAKQO:&K/R-
MTWKA)[TV=KC8"X:K4)UR*U-#)JXF(=%N.$4X&!I2U;8R-F3B;!)2VVUF[8"M
MK(W3:M&30%\]2&@L/W.I82MKX_2C=I.0B;B5M6$3:Y.0N*$B+YRYG6`K=^.T
M6O/INDE"LMVB$,]T&X;"F)L;IW5IW=PD-*YX,M?L["'!0OZ>N0VM),R-A]RX
M8_D!4:XT;&5NG'[8;<;FAJW,C=-ZX75SDY#HMLA#P_=JVE;FADW,34*BVU`P
M=RO#5M;&:3WG2;--5VU),),X>_HS;S9.J_))H,M+R*#90BMKX_2C9I.0B;B5
MM84FUB8AT6PA;`[<7[V$5M;&:;7F4VN3D&BV,(S":)@5I=%#J(S%?#-:UQXB
M"W/A(55S28(95P^MO(W3JGPR6IY(>>.%6VCE;9Q^V&[&WA9:>1NGU<SC=+B$
M9>;CA1OVT,SJ);3R-D[KRL.-4BH+`Q3MMHAGS2VT,C=.Z]*3;KMC;FCF,2&R
M,C=.J_()TA\3)&3@+Y&5N7'Z4;=)R$3<RMPB$W.3T&W=MAQ6M(K!1%;FQFFU
MYE-SDY!<M\'FQW+H1U7;RMQ@"_FQN4EH7/)DTFYB)UELM%:D.9+?2%FV3DXO
M;)<8P4-\_VF_@_V$^1YT_P5L()^S(_F>-<>B;IV2'.#4P%N`NS5B"UH<=/3,
MMW%WM(.M8_[V!#\5$-@,A<TIUSE0VMT.V"9W_^/#]G\```#__P,`4$L#!!0`
M!@`(````(0`ZK[.DR`8``+<E```9````>&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;*2:6X^B2!3'WS?9[T!X;Q44`=/VI)%[=I/-9B_/-**2$3%`3\]\^SU%
ME9=3V'5TMA]:+7_\Z_*O4]3!>O[RO=IKWXJF+>O#4C=&$UTK#GF]+@_;I?[W
M7^&3HVMMEQW6V;X^%$O]1]'J7UY^_>7YHVZ^MKNBZ#10.+1+?==UQ\5XW.:[
MHLK:47TL#O#-IFZJK(./S7;<'ILB6_<75?NQ.9G,QU56'G2NL&CNT:@WFS(O
M_#I_KXI#QT6:8I]UT/YV5Q[;DUJ5WR-79<W7]^-37E='D'@K]V7WHQ?5M2I?
M)-M#W61O>^CW=V.6Y2?M_L-`OBKSIF[K33<"N3%OZ+#/[M@=@]++\[J$'K!A
MUYIBL]1?C45J&OKXY;D?H'_*XJ.]>J^UN_HC:LKU;^6A@-$&GY@#;W7]E:')
MFA7!Q>/!U6'OP!^-MBXVV?N^^[/^B(MRN^O`;@MZQ#JV6/_PBS:'$069D6DQ
MI;S>0P/@OU:5;&K`B&3?^]>/<MWMEOIT/K+LR=0`7'LKVBXLF:2NY>]M5U?_
M<JCOT5G$%"+P*D0,<V0ZEF'-'U"9"I79E<K=38#&]OV`U__1A+E0@=>?'PU;
MB+AG$=-\>$@-F`G<&#8E'G5FS%WN)XV?==G+<U-_:!")X&-[S%A<&PM6Q6FZ
M<'//$^BS^0,3AZF\,IFE#AV%J='"I/_V8MGF\_@;3-1<,-XM9HJ9U8EA\Y()
M^[R`SRY6$,@%X:G@4K6!1:,3<1*-3P672RQ;:DG"&;N/$%9Q>E4PAL$[CR#,
M<32"MP/M-%",9@-U:HMW*KANRPQW8'6+L3#C#QEI_(,;A(U%0HY`3\\V2B(1
M2<1#PK*EQB9#1JHG51%H^&&10,//)O#LT_7N9`.["MD@%ZSD`E\N".2"D!=<
MCYYES_$(1[<8R87X%N-@G>0.)KW%N&<=-(JPQ/[$*+*KX/YP-5TL9W*NH`]@
MCS/P_SREI,FP(@F?)`*2"$DB(HF8)!*22%4$L@3F,+)$O:XP>JE#U%R&V9'6
M08\ST(`+@\U:D83/B7F_Q!O6A/]AE8!4"4DB(HF8)!*22%4$,@/N_P^8P6AL
MQN!FR!&5%R3A<T)X,1-F2%[<P81D31%)Q"21D$2J(I`;L,]XP`U&2V[(D<$1
ME1LDX7/"Y9$1/$G[B4#]=4CJ1R01DT1"$JF*0!ZP?/%ZXZA>GAB-/9A+=S2/
M(RH/2,+G!(^(V_%`$B%92T02,4DD))&J".0$I!4/.,%HR0EI_^%Q1.4$2?B<
M^#0:U%^'I'Y$$C%))"21J@CD`4N='C"AQ[$+MK3I]P2CLH%&?(&(D##=B6/-
M);\#Q$S-F>/.9E)K0KJJ",F8C@L/#*2:8EHEP2KV=#*5LX=4J8)M84G;_:N4
MP7.\ZUV4+>]G!:.TA<LH$%^H<%M,PW2E.U*``->=2,T(Z69$2,(:5!'3$@F2
M,.:PV\/;BU2I@:U@&=T#5O`$\-H*RY&21,_@D&*@5S3BTTA`(R&-1#02TTA"
M(ZE`^.RR#<=TS4O2A5UA.>*U*_>ESP9/+;$[TH['$Y#2':ZC0'RA`B'2[ZS<
M$0N&J[]I\"1-BX"N.*21B$9B&DEH)%4BV"T8J(%;4[CUJ#=?!KL,WVTL1UK@
M/0$IK%C1B$\C`8V$`G%0EHE7GHB6B6DDH9%4B6![6#IY'4R$+3S[Q$%TB5/^
M^(0]N@?OE+:0B$^K!#02WD(FTHTKN@5AZV(:26@D52+8%Y98/N`+ST.Q+])S
M/,]0):N]=2L:\6DDH)%0('RY-_C:B(<\HE5B&DEH)%4BV!66:C[@"L],L2O2
M_M(S."32#F?D2N&T0H`U<B1;??&](MP"&@EI)**16"!B%01;L:<)+9$J$>P&
M2S<?<(-GI]@-.:,W.,3GY7QJLHP<]V&%D.G$-N;RDS)?($I+5+ER'XPAK1+1
M2(R:.QONAQ-:(U4BV!.6?C[@"<]6L2>7Y_WB?J)*:<6ZQ1$>1+=BA)0(#!()
M:22BD9A&$AI)E0BRQ)3S_/OVR_UET@[,E6+!$Y!8Q@V33:]!P""($S+C"T85
M,302TDA$(S&-)#22*A%LD)SQ,X/H+;(YS/PM.2?W!*08UY5`^)H]G_4.2C[[
MM$Q`(R&-1#02TTA"(^P\R^>;5&X//Z_"CQY41;,M5L5^WVIY_<[.HMBPTS^7
MGL_)O$[9S^12N6<LX)3`L#R!<S6WRCUSX=W269D+^(UWJ..;"_BI=U@>F`OX
MQ1?*Q^<&P;&98[8M?L^:;7EHM7VQ@:Y,1C;LQQM^\(9_Z.IC?]#BK>[@P$S_
M=@<'I`HX53`9`;RIZ^[T@55P/G+U\A\```#__P,`4$L#!!0`!@`(````(0"R
MYE/JUP,``)`.```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;)R7VXZ;
M,!"&[ROU'1#W!4Q"3@JI-D';5FJEJNKAFH"3H`6,;&>S^_8=>PB)2>IDNQ=+
M")__S#\SMO'\XTM5.L^4BX+5L4N\P'5HG;&\J+>Q^^OGXX>)ZPB9UGE:LIK&
M[BL5[L?%^W?S`^-/8D>I=$"A%K&[D[*9^;[(=K1*A<<:6L.3#>-5*N&6;WW1
M<)KF>E!5^F$0C/PJ+6H7%6;\'@VVV10935BVKV@M4833,I40O]@5C3BJ5=D]
M<E7*G_;-AXQ5#4BLB[*0KUK4=:IL]F5;,YZN2_#]0H9I=M36-Q?R59%Q)MA&
M>B#G8Z"7GJ?^U`>EQ3POP(%*N\/I)G8?R"PA0]=?S'6"?A?T(,X^.V+'#I]X
MD7\M:@K9ACJI"JP9>U+HEUQ]!8/]B]&/N@+?N9/33;HOY0]V^$R+[4Y"N2-P
MI(S-\M>$B@PR"C)>&"FEC)40`/QWJD*U!F0D?='70Y'+7>P.1EXT#@8$<&=-
MA7PLE*3K9'LA6?4'(=)*H4C8BL"U%2&1-PRC\>0M*H-6!:[_'\JP%8'K,931
MW:'XF!R=ZR25Z6+.V<&!!@;[HDG5="`S4#XF&5/2I?U?68=T*Y$'I1*[8]>!
MA`IHE>=%1(9S_QG*F[7,$AGX?\9$)K.Z9(A)))=$1$8=XX.KSAK4[-S:];XY
M.E"P<J#Z2%E:XA=FN./NAS2SNF1"DTBN$"<1(UKHC?NC53#TLY'+B?G32V2@
MIJ=\F\3J)I'8""-Z^)GSZ%4;36'&VW.N!L4NI.@4(9F:,2Z1L;FX0H2!J9)<
M83K"\`$K0]_'X*8/-:CG(^SU[1*9B9X;D^%TT.]\?&[QF=@(P\/H?SRH07T/
MO69>(F.)<7632)`8Z3R08:#^KE<"%I/S2M@[2<%F]&0\Z'1Q0B-CB_XFD=@(
MHP;J)>1L6;5'K^!;LQD96_0WB<1&&-%/WQ*]@LW<1V$_]\A@U2.CYKB0XG.+
MN\1&&+$3F*[WIU[3_>@O=BXE&;MMTX:3"8EZB^VJU;$YL"*F!;7)W=T]!+=$
M8QD->\O+LH4L\:VN(>%I:]6%2JY!W3PS3:BM[WX3N%&:)DX[)<Y@@I#5!"(D
MG.H5)O""7BLF5A'3@=K][G>`>Z7IH-<F2V+;4'$JM`@V6Z@GRVF%;(M@4S$M
M0*[>8$'1_<G0WY#AE5]!UB(@@A9&>HV_L&!300MX,,"7U8KR+5W1LA1.QO;J
MI9]`?;MONP/)0ZB/%-T#.`\TZ99^2_FVJ(53T@T,#;PQ[*4<3Q1X(UFC7X77
M3,))0'_<P<F/PHM@X`&\84P>;]29I3M++OX"``#__P,`4$L#!!0`!@`(````
M(0!0$D^ZT@0``&06```9````>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;)R8
MVVZK.!2&[T>:=T#<[W#.24FVFG#6C#0:S>&:$B=!#3@"VK1OOY=Q2+!)66EO
M0EA\_FVOWS;8BY_O^5%Y(V65T6*I&B-=54B1TFU6[)?JO__X/Z:J4M5)L4V.
MM"!+]8-4ZL_5[[\MSK1\J0Z$U`HH%-52/=3U::YI57H@>5*-Z(D4\&1'RSRI
MX;;<:]6I),FV*90?-5/7QUJ>9(7*%>;E(QITM\M2XM+T-2=%S45*<DQJ:']U
MR$Y5JY:GC\CE2?GR>OJ1TOP$$L_9,:L_&E%5R=-YM"]HF3P?H=_OAIVDK79S
MTY//L[2D%=W5(Y#3>$/[?9YI,PV45HMM!CU@:5=*LENJ3\8\-DQ56RV:!/V7
MD7/5^:]4!WH.RFS[1U80R#;XQ!QXIO2%H=&6A:"PUBOM-P[\52I;LDM>C_7?
M]!R2;'^HP6X'>L0Z-M]^N*1*(:,@,S(=II32(S0`?I4\8T,#,I*\-]=SMJT/
M2]4:CYR);AF`*\^DJOV,2:I*^EK5-/^?0\9%BHN8%Q&X7D0,9V2;SF3Z%17K
MH@+75F7\=17[HC*[J4"S'NR(`?GGZ6!&\*Z:^FABZ#-K@N9#X[EMK'*3.EDM
M2GI68/Q#]JI3PF:3,6=5M";QE%YM^\PUL(NI/#&9I3I1%3"D@J'VMG(L?:&]
MP?!(+\R:,_![90R1V/0)QQB+C-NO:2(A7HNP(<5:Y[>!3VL.6J(M$LJ!2`[$
MG8`&R;QF%"P5,GI_N+>)8S1+7%OQN@W<VFJ*&=C<(28BXG($6GA-M23B]8F)
M).+W$4DDZ!.R2-A'))$()>(A0D@]3,\OI)[10NKEP$8.N#S0S:MC28/8>X#Q
M'V""!YCP`29Z@(GO,3>?A!S#(O:%'#-:R+$<V,@!EP?X*LYFKR<'?#D0R(&P
M#=S&OSV;B7,DZC..?NMSLW#$+0.S4T@"K+="$MBJ:<'J.3S762G@.K/2L2RQ
M56O.0+W7F>N(Q`8E7)3P4,)'B0`E0I2(4"(>(@1+QM^RA)5:JK#`W-)MV6+"
MUYP9L@0E7)3P4,)'B0`EPCN$+BU@T1W&D@9A?(^YO88%8^"CX!MSA962C9%>
M4&O.#!F#$BY*>"CAHT2`$B%*1"@1<V+:?'X9]F2JW[[`!$?8!JO[S3>\:C%:
M=F(J31'.C)N:;7TVNU7<K*.;[G/3&NNZM!B[7<"PQF-I6?2ZSR>V84CCT>\^
MO].`H/O<-$W+E@1"#@R,I0@EXB%",``V`((!C[T^6"G9""F/:\YP(PQ;[XP`
M;@1_/M!-%R4\E/!1(D")$"4BE(B'",$0MO/YAB--,<D26QK[ZPO$/7&<OB<7
M8,@4'/%PQ,>1`$="'(EP)!Y$1&_81JN[7#TV6PR^/Q->[;;TJEM?H,_GRP48
M](97-(!XN(J/(P&.A#@2X4@\B(C>L*W9-[SA.SK1&^G;>PU'4VR]XZ\S:5)M
M+@\'DN[BB(<C/HX$.!+B2(0C[+".9>1^I[DO_#".G_#DI-R3#3D>*R6EK^R@
MS8$7]#5Z/01\LMGI@Q1WC3F<H_3C/CLTO!-?F_/U/9V-.8<M'ML_72N`,[Y3
MLB=_)N4^*RKE2';0-#C)@D_]DI\2\IN:GIKSJ6=:P^E>\_<`I[D$]H3Z".`=
MI75[PRJXG@^O?@$``/__`P!02P,$%``&``@````A`/-F.!&Z`P``/@T``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULG)==;]HP%(;O)^T_1+DOB?,%
M04!54G6;M$G3M(]KDQBPFL21;4K[[W<<AX`-34MO"('WO#SG([:9W3Y7I?-$
MN*"LGKMHY+L.J7-6T'HS=__\?KB9N(Z0N"YPR6HR=U^(<&\7GS_-]HP_BBTA
MT@&'6LS=K93-U/-$OB45%B/6D!J^63->80FW?..)AA-<M$%5Z06^GW@5IK6K
M':;\/1YLO:8YN6?YKB*UU":<E%@"O]C21AS<JOP]=A7FC[OF)F=5`Q8K6E+Y
MTIJZ3I5/OVUJQO&JA+R?483S@W=[<V9?T9PSP=9R!':>!CW/.?52#YP6LX)"
M!JKL#B?KN7N'IAF*76\Q:POTEY*].'GOB"W;?^&T^$YK`M6&/JD.K!A[5-)O
MA?H(@KVSZ(>V`S^Y4Y`UWI7R%]M_)72SE=#N&#)2B4V+EWLB<J@HV(R"%B-G
M)0#`JU-1-1I0$?S<7O>TD-NY&R:C>.R'".3.B@CY0)6EZ^0[(5GU3XN0@NI-
M@LX$KIT)BD=1$(\GU[B$G0M<#R[)NUT\G5=;IGLL\6+&V=Z!V0-RT6`UR6@*
MSH?ZZ&SZBKU6,$A2F=PIE[D[=AVHA8`N/RWB*)QY3]"9O-,LM09>>PTR%=FY
M(D9)K_&`N,>&4IYB7V[G@4Z)%9WJB<)=Z@].48+^9UI%=D$Q[B4&"13ME$05
M,(0Q'2920:`[J44<1;V_AM2:Z%1C*K(AA<$()M<SJJ"Y"X7H^Q5'L4FPU)I)
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MG+Q63+7PGW`.[S5(;Q,FG[W9=**AF>PD[QI*\+D"4*GM+ML[#=*BH6$T%(/#
M:.TU;]3OPB836XOS4ITI(8?#3IBF<7#67T-BC8">0WV,U>>SBO`-R4A9"B=G
M.W5$1;#N]I_VQ^>[H#T`]U_`Z;7!&_(#\PVMA5.2-83ZHS'\.M?G7WTC6=.>
M_E9,PKFU?;N%_RD$SD?^",1KQN3A1IVP^W\^B_\```#__P,`4$L#!!0`!@`(
M````(0`H:I@<>`0``($2```9````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
M;)2878^C-A2&[ROU/R#NE\]`/I1D-01H5]I*5=7=7A/B)&@`(TPF,_^^QQ@"
M-AF;O4D">?QRSNOC+[9?WXM<>T,UR7"YTVW#TC54IOB4E9>=_N/?^,M*UTB3
ME*<DQR7:Z1^(Z%_WO_^VO>/ZE5P1:C10*,E.OS9-M3%-DEY1D1`#5ZB$?\ZX
M+I(&+NN+2:H:):>V49&;CF7Y9I%DI<X4-O4<#7P^9RD*<7HK4-DPD1KE20/Q
MDVM6D5ZM2.?(%4G]>JN^I+BH0.*8Y5GST8KJ6I%NOEU*7"?''/)^MQ=)VFNW
M%Q/Y(DMK3/"Y,4#.9(%.<UZ;:Q.4]MM3!AE0V[4:G7?ZB[V)[85N[K>M03\S
M=">CWQJYXOL?=7;ZGI4(W(9^HCUPQ/B5HM].]!8T-B>MX[8'_JZU$SHGM[SY
M!]__1-GEVD!W>Y`136QS^@@12<%1D#$<CRJE.(<`X%,K,EH:X$CRWG[?LU-S
MW>FN;WA+R[4!UXZ(-'%&)74MO9$&%_\QR.ZDF(C3B<!W)V+#SYF-W:XQ?'>-
MG5^/8-&)0,Q]!&O#67FVY_]"'GZG`M]]**YA+ZP9&B;SM>VF,&F2_;;&=PUJ
M'YPC54)'DKT!W;Y_F)N/'ONLPZ"GJ,@+5=GI2UV#OB!096][SUMNS3>HC+1C
M@BEC\\2A)V@94-F0W8#/0=;V^491S_2-XO[&T&AXC@E9/U*'&ABG_KPD^PPI
M3#/L'Q/T-X;'.'QD!T:,HQ>(<$IXWII7B::,H!++""YA*.'Y"5.82UB\<6`W
MQOEYWHJ//GS"^!;/1#.8^!GS2;?"6)N?)85A3AE5V&(E5%C`&/@<JI#/X*`D
M0B41*8E81G#]#+/,?`<HO-.AAH;L?*'"`L;8SKH=VH/O[2@]L'\AND&!]R=4
M$I&2B/D8+,-R'P_ADH=);)P\G=!<6+;DHYLV$DT8]-LT`\9(TCPP8L5,<CS7
MLH12#Y4:D9*(903G!$S'HA,+<%'N!&TD.K%X.,V<8(S,"4;XK1.KY=0'I4*D
M)&(9P?E`]Y*C)4Z>/X7%_#TA?\;(\F<$RW_A0?Z32E!J1$HBEA&<`VO>@7EC
M@C82G1"G1L;(G&!$/W7`L!57"*5$I"1B&<$98<-,,+\66EJT8+*MH9([7>9!
MIS.8L!06^;`C)"+11,07AF4L%>%MH'NDV4/"9CLJ?HD0NC'H($D&APX9V2"4
M4Z@6B28B4QM8N,\CX6V@.Z>1#?/&!3T[3`:&T*%!!ST/@BV;:B3L$#:/..LG
M\TBD5HFE"&\(W6:-#)%/E3;;E'%UL116O*"#I$8P'0D2=BK,")LNK.*$&JD?
M%$L1W@@(9FS$S,J@K83Y8BGLE@(X;2OG"R42=BK=7L-_:HA2A9[\/X^%&<).
M]NS(6*#Z@@XHSXF6XAL]M;NPPC_N/MXHO+CTF"3<#^P-'/">W'<V0<N;CP;P
M`J!*+NBOI+YD)=%R=(9'6<82-B\U>X7`+AI<M0?8(V[@Z-_^O,*K'@1'1\L`
M^(QQTU_`@\W'RZ/]_P```/__`P!02P,$%``&``@````A`+`M$.RZ`P``K`P`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULE)=1;Z,X%(7?5]K_@'@O
M8`@0HB2C)IWNCC0KK58[L\\$G,0J8(2=IOWW>R\&BDU+,WD(`8X/G\\UMK/^
M\E(6UC-M!./5QB:.9UNTRGC.JM/&_O'OX]W2MH1,JSPM>$4W]BL5]I?M[[^M
MK[QY$F=*I04.E=C89RGKE>N*[$S+5#B\IA7<.?*F3"6<-B=7U`U-\[916;B^
MYT5NF;+*5@ZKYA8/?CRRC#[P[%+22BJ3AA:I!'YQ9K7HW<KL%KLR;9XN]5W&
MRQHL#JQ@\K4UM:TR6WT[5;Q)#P7T^X4LTJSW;D\F]B7+&B[X43I@YRK0:9\3
M-W'!:;O.&?0`8[<:>MS8]V2U)PO;W:[;@'XR>A6CWY8X\^L?#<N_LXI"VE`G
MK,"!\R>4?LOQ$C1V)ZT?VPK\W5@Y/::70O[#KW]2=CI+*'<(/<*.K?+7!RHR
M2!1L'#]$IXP7``#?5LEP:$`BZ4M[O+)<GC=V$#EA[`4$Y-:!"OG(T-*VLHN0
MO/Q/B4AGI4S\S@2.G8D?.`L_C)>_XA)T+G#L7$CD^,N0A-'G+*[J5QO30RK3
M[;KA5PO&'I"+.L613%;@C/D$D++JS9#81X%!4FARCRX;.[8M:"Z@RL_;*`K7
M[C-4)NLTNZF&Z(I]K\""`M[`"+F-&=^O78^"8D3!6B+;3ET`[X'--YX[5<3Q
M(-%((*$Q"::U^'`T]438"%(=`81+;_!7D$JS&&MTQ7Y.H3&"R9AQ/BT4;VP(
M8`@G"-_ZKMB4AOA)6UB#?/_178T),KJ="<4Z4Q1%>AH[I>F9B!,G^N?KG5ED
MO47L>/J'?+T+AF=H[-&OL*/89#?S5)J>W7?""8G)KK<@CJ]W-AGW5F.'-_+V
MW%&LLP>1\8KNE*9G]YPH&4)K!\M^1J"1X0+[SKPS/UJQD4EH3C-*H\;JTDG,
M*,>W(<BW<:71)3K=/!6*=:I%8L2R4QIX5X;WS.#>SRDT-@+3LQG=YY-0V^JS
M6:@3S6'.2G1.G,Y')9X/D:C)7YN)(J-XNTXTYHNBI3$"WQ6]U4-GQ*G_=D:U
M4(P90V_"J$1C1K/49$ZB\^&L/^*[;<$A:JV`[[?1-EEQ.M$LY\UK#FSA-,Y/
M:HUJ_8T)IK56HC%?%)N+3_M<6(-'/1T/")6EVARJ74])FQ/=TZ(05L8ON/'S
M854;K@Z;TGL?-Q#&]1UN5O&Z.]R`O6*=GNA?:7-BE;`*>@1+SXEAM6G4;E.=
M2%ZW>ZT#E[!+;'^>X5\!A0V*YX#XR+GL3_`!P_^,[?\```#__P,`4$L#!!0`
M!@`(````(0`%+.&&,0,``%4*```9````>&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;)Q676_:0!!\K]3_8-U[_`$&`P*BI%':2*U45?UX/NPS/L7V67='2/Y]
M=[U@;$-2ISP`-G,SLW/+GI?7ST7N/`EMI"I7+'!]YH@R5HDLMROVZ^?]U8PY
MQO(RX;DJQ8J]",.NUQ\_+/=*/YI,".L`0VE6++.V6GB>B3-1<..J2I3P2ZIT
MP2U<ZJUG*BUX4B\J<F_D^U.OX+)DQ+#00SA4FLI8W*EX5XC2$HD6.;?@WV2R
M,D>V(AY"5W#]N*NN8E540+&1N;0O-2ESBGCQL"V5YIL<ZGX.0AX?N>N+,_I"
MQEH9E5H7Z#PR>E[SW)M[P+1>)A(JP-@=+=(5NPD6MT'(O/6R#NBW%'O3^NZ8
M3.T_:YE\E:6`M&&?<`<V2CTB]"'!6[#8.UM]7^_`=^TD(N6[W/Y0^R]";C,+
MVSV!BK"P1?)R)TP,B0*-.YH@4ZQR,`#O3B&Q-2`1_EQ_[F5BLQ4;3]U)Y(\#
M@#L;8>R]1$KFQ#MC5?&'0,&!BDA&!Q+X/)`$$S<<3:+9`!:/'-4%WG'+UTNM
M]@YT#6B:BF,/!@M@QLK&D`_Y:&I]K52H$4END&7%(N;`<@/[\[2>1L'2>X),
MXP/FEC#PWF!."`_<-);`1MO2Y9"/R@A&90P=K=S2C;;,J#'2D1F_1P;!*P;<
MC?EI>+)/RH0)6YC)966`M`O$S,-7N^E8*"Z"O6FSS_R&GQP09H`#4&L[>#MB
M!/=JCTZ9DC)A.LK3QEPG]NE[I!'<EQXWO"1-F&G==6'DPZL!=(2A.X?7C."^
M<-CPDC!AAM2,YT#K3_9VW`CN2Y\:B:0),T1Z_AYI!/>E3]M(TH3Y=]P!3)%V
MT<?)\G;Q]:J^A:@7_`$TI/P`ITXK^H$N:%9U_N[1K.^"0/.Z\8+0G9SZH]-W
M`4ZD]UN@.=:U,.];(-"@('KC;F`0%^;>V=0)+@R^4]=TLP"K_Y$%KNHUQ:P_
M?>'\1]#KVT&G.QU^A=!;\4GDN7%BM<.3.X!M;.XV3Q4WH_JYH/D!#O6*;\4W
MKK>R-$XN4ECJNQ&,/TV/!71A554?K1MEX3BOOV;P^";@@/)=`*=*V>,%/G@T
M#X3KOP```/__`P!02P,$%``&``@````A`,?/G?0M!```1A$``!D```!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&ULE)A1;Z-&$,??*_4[(-[/>`W&8-D^G8W2
MGM23JJIW?<:PME&`M=A-G'S[SK"$[L+>0O,0F^0WX_G/##.L=Y_?JM)YI0TO
M6+UWR6+I.K3.6%[4U[W[_>^G3Y'K<)'6>5JRFN[==\K=SX=??]D]6//,;Y0*
M!SS4?._>A+AO/8]G-UJE?,'NM(;_7%A3I0(NFZO'[PU-\]:H*KW5<AEZ55K4
MKO2P;>;X8)=+D=&$92\5K85TTM`R%1`_OQ5W_N&MRN:XJ]+F^>7^*6/5'5R<
MB[(0[ZU3UZFR[==KS9KT7(+N-Q*DV8?O]F+DOBJRAG%V$0MPY\E`QYIC+_;`
MTV&7%Z``T^XT]+)WOY!M0B+7.^S:!/THZ(,K[QU^8X_?FB+_HZ@I9!OJA!4X
M,_:,Z-<<_P3&WLCZJ:W`GXV3TTOZ4HJ_V.-W6EQO`LJ]!D4H;)N_)Y1GD%%P
MLUBMT5/&2@@`?CM5@:T!&4G?VM='D8O;WO7#Q7JS]`G@SIER\52@2]?)7KA@
MU3\2(ITKZ635.8'7S@F!MS.-_<XX4(P7JVA-UN%T")Z4TV8G245ZV#7LX4#+
M0<#\GF(#DRUXQK2$D%QS6B`?:/,%C5I3H#G4\O401JN=]PKYSSKF.&8&Q,E`
M;'0GR1@)HG7/>*"A%P*)'`H)?EK?#R%H!)5T'46(W_MOQ1XE`[GIF?\B:(G3
M))'8"$T%A**JL)<!X;T+OOO(@D%H1XE$;8V")8DV)-;EG70B#OUPD(!$$N8$
M:,$#H@:/O>1/]A(:Z2+\.-!C/$HF;%60=;Q>;08QGB:)1",V?K@B_8=H(J!G
M5!'V"B"L!Q]&P^`E`Q_?5VE0I-,DD=@(+?I0CQY+,'T7H-'472`9FXI)(K$1
MFHJ-KL)>`X3U&JP&/7Z42-<_?N0'\<8?=I#&Q(0$\--W2'N?)Q(QYT"+'Q\:
ME*%JCQ]A/7X_'@1WE(SVR:$>W&D:20Q([T2+/_X_\2.LQS^:0A*1^3=/(9TP
M32%):"DP!T]@Y*C9GS>&6BM=QG@.=9!M$$TC28?,D8+[3VFDF5+DUE3W0JAL
M3;G5B(3,0<BU-HTD5D1K*7S0&4J9GDRMU=1HZB"K%-L"EC>WU8LN!1>B4A7[
M[4WD^E2K,9I/'6,?4#IDGE`=8TZ%+@(85<3,UD(K_2X)H\$D.A()F8/H6FL2
M2:Q>="FX'95ZS%MZ^/`/4J`Z_5X.H^'<[2"K%-MN[EK+ANA2<$4J4B9:2RY4
MM;7&JX,8MNZ@8J<93&)B?C*`<4_.%R&WJBIBM#^(NIS-"V2`F#9(AYB+J9<!
M-Z6B8.;-(?>KJL2P0B0DG\C-S[)P#,;.M"!X4D;$)D6>A.59[YY>Z;>TN18U
M=TIZ@89?+C;0E(T\!\L+P>[MF>[,!)Q?V[<W^+Z"PH%ON0#XPICXN,"3=O\-
MR.%?````__\#`%!+`P04``8`"````"$`FX-R4_@.``"@E0``#0```'AL+W-T
M>6QE<RYX;6SD7?MOV\@1_KU`_P=":8L>4%MO6_)9/L2*V09(T\,E10OTBH*2
M*)L7/E222NPK^K]WAL]9\;%+<JG-H35ZD2AQYMMO7KO#%7G[W;-C:Y]-/[`\
M=S487XX&FNENO9WE/JX&?_VH7RP&6A`:[LZP/==<#5[,8/#=W:]_=1N$+[;Y
MX<DT0PU$N,%J\!2&AYOA,-@^F8X17'H'TX5/]I[O&"&\]1^'P<$WC5V`)SGV
M<#(:70T=PW('L80;9RLBQ#'\3\?#Q=9S#D9H;2S;"E\B60/-V=Z\?70]W]C8
M`/5Y/#.VJ>SH34&\8VU]+_#VX26(&WK[O;4UBRB7P^40)-W=ND='=\)`VWI'
M-UP-)MDA+?[D[6XUN!IH\9#7W@Y`_.[?1R_\]C?Q/Z_^\.K5Z%_??/N/'\S=
M/W_\??&S'[\9#%,U1";8H%[FY:A6+'P<2QXF([B[W7MN/I#I'&A"MFX^N=X7
M5\?/P!E@>/BUN]O@9^VS8<.1,<+;>K;G:R%8&<87'7$-QXR_L39L:^-;^+6]
MX5CV2WQX@@<BQTB^YUA@)CPXC#6<5\\&T:1C6B`,9DQ3/$+'Y,"0##Q8/R;C
MIY(Q,;KF?%U=^&-T1:.H'Y<T746_*'#815=F*Z+'?]RL!KH..60\&B&MU&`]
M*5NN1Z#O;,JNYF<;V52?ZM=21\;X8M%NJ'"JRZ22HU!_??WF;'3*5U8UNB0-
MGRL",.#DLFA!Z-;$][6.?^?PDS,7-*D68[PCDLPD_BC\\OSXT7+,0'MO?M%^
M\!S#17)I88N^S=1E%,_82;Z*GL5G'B8?>28ZFN1(YST57YRFG%BUV]2+>A!7
M56,'$AY$:\ECKF%?PQS./O7UR&8%7T_A\H5V(SW5PR5<CIHQUT,EZ2&VR*9I
MQ;K1WM9D.E&>M1N+/M(J1.!+$I\:F@M<C@%FZ.9UF:BMFBA2`B@7EFUGR^#I
M#!>*<.3N%E;DH>F[.KS1DM<?7PZP3'2A>8"@AO'W.-]^](V7\21:+(F=$'BV
MM4,4C^MH<9IXW?KJ05\_1'H),E$4%4)U?7W=@]"'^^5:/M+U<BE;Z$2'/\E"
M7\_Q3[)0'?ZWEL9ID@FBT!I*\*9,GA9:V$P:75XOE\O%^&JQ6"QGT_%L%I&\
M23S:<G?FLXG])6DT%1',`<%RNEA>30#(:+:(5)T5P10`7,_GB_EX.9G!_Z.$
MV3\"V9Q"/TVQ50D"158E"!19->IG2(Q5:.TJMBI!H,BJ!($BJU[+*A-)_KM6
M;E6"0)%5"0)%5HV60!)C%2Z9*(Y5@D"150D"15:5-OE,8G6IW*H$@2*K$@3G
MMFJZK((NL!Y-K(LSL^KY<;22@[7CQO-W<+TYO8@Z7L"Z+3YV=VN;^Q!6B;[U
M^(3_AMX!_KOQPA"NSM[=[BSCT7,-&UX.TS/2?VO.A.O7<*EZ-0B?K.TG4,8L
MC&.\L8J^-&29:(8S_-GU;'0]FT^NXD64)-6.N;..3G%TF>Y27P$:D5O^P`F'
M;J8D<8>\13]$*R3F$SPC,G5D:<$3P"=2EQ`\0\88\\M5HF,D9XB-D9P@.$9R
MAN@8(73*@BME<N<=8>O$J8%U?3$:12NQQOY2+I``+_$8[CE%/KFGE##*/4>4
MTY0\R"^%V+B?X%\T8RT9*>>,XC@Y)Y2,DG.&Z!A9ORD=<=9.P/1<@N2$;^;K
M[6"`HOC$4CQ)=L*^<WS%4MAY!09;%$Y&#.<W*U6"^(D*P3/:\2HHO`3.B8V+
M++4#5##T2;7K34]/XTD)YHH_'\5M(%7X>3(W@ZG>UK3M#SCY^OL^F^]!6_/N
M]GE/=K?!ED/<_H6;Y_`E7#M(7L9SN_@-Z*HZ:5)YDF8<#O;+^Z.S,7T]VH<8
MJ8B.XC6*_-U]-"G-W[^VK4?7,:/&["`6\[WOA>8VC/9)1E>(JO!,*_",$T$B
M>+KHGU7H!YZ$^>BB'QI_I48$7I3J!^<2UB_3'W!':.+48`+JU'5X9"*`]DZ*
M`(R@`@'N8$TX`/=4@0"6S2D"<-`<`<"I\8HN<0"[!S*5X`.Y2M#?ETK(,>DH
M&94]CK(J_8+^FE'J3/KM1#/)M^#H.<WPI@9`)Y55*595BB%FATC+*8`W-13H
M4'7EE+QQ5<Y71@A)NH`A9P320!TC\KR2Y%S0F0.H9^1>XCR$.`6F(M40`(X2
M",00L`%*/09%%9AZ@Z(23"$P-?B,,4&]@:F0BC``'B51D<\3H`&O'(*J#$F\
M8:(J15(,JG)D[@T352F20%"5(:DE5*5(BD%5CB2F4)4B"01@1$F&I)90E2(I
M!E4Y,C?%5%6*)!!494ABB6G/*7)(VZ9Q$Y7T3\=@A>I>*%@H7?^?&NMYS^VD
MCJM632`K/3U>/L5+1S!&M)@B:VG\T;"1-D^U)\^W?H95)OYX>`O=5-,?X(_-
M0VM+CWSQC<-'\QG6HO%%QN=]IP%R,.7ZH;L^T)HHE\Y/!RP"EN80P1UYM*KG
M=N9//(/M;G,]A`L"NSNJ,2#7"0;I+B`I1#!R5=,$55(Y!FHJQ),TG>$P,XEH
ME<VXODJ4XW)"G7((.W7*H3RJ4]YXY#47%H5-6%G_.N3W"6EK2_'>LD33R*.K
M`,%=04YJ@`Z9"(MY7(#NDYYF^KZ2K<X(B?&GIXO(NHC7H[9O(WRXFX?.90IS
M"0U_L1/3`"XVK)O33"IQ\ZAE@0L3S34[*;I-P)77?M8;6D*FOA'MBVHV<R.A
MS/,,,5_@4H@:DX+<A,*O@:QJO#`H"7'4A#OIANN2DDF<`J[N$PKJU#(3"B&-
MP8F7@5C[]9XR./I%,H8P1DIGBQQ!W9X#FXU2%0#9+#:&A,T:ED78,NER`U6L
M3A3`B5B])62)/G`6BKOBK=J)4`QUUB-:^6S:PN'Z!83//BU^E0AAG5#GLV=#
MB&"%EHF5$]<F?.#E-C%UK,&D**],<<!!G2WD*%>Z,*QRP\J1URP,X=84"FU8
M-1+>8D$XH)JX,PD>-E\6>4TFUG6\D@D63QJSQ$R+Q:ELH?I40-J\/%7&1S&]
MERX&*W`"LDVT>$XV1+,A*@*S*S`T;YK(95\<:.)F$Z*\E6=T[853(HB7,A82
MK[F"?LJ1+N(`PD$OZ*D5/+`VX66B-%Q/^T."M/"4B?!2!8'C)]U8XMB3+?A*
M+`<(V23#8F)9$THN\;J6QGJ#SAB=+)U8O;"HJ$.:<]G.Q0K*U+L8O3@WJ9P2
M%.;8(L!SMAI$0ZNU`;FJSL0&QPTK'8^Z66FA!<%I/1O#AHJ]T+R?]2PYRF6O
M`FAB:F6*2A>"#^I2PMF<I3H7<+Q%,&DU\1WIZZBOM2O9L8UVDK,;&4K8L=H:
M[BS@:%QV)!/8VU2O!@23%,73O#1_#>N41CMV*@.5US&5YWTBG!71]%:G6S@A
MS;S2G5!JL>(DF,K23:-"*J#QUU(]E;:LP"RE,ZTB._+"#G6FG0L,09DSO3)W
MZ5+!94\&Y51$3C`)3JLH5TGNZ4(5Z;VP];LWM%PR*Q(\!YY(@F]/,1<T#8^S
M<\I;FM&JS:&1G?:T(*Q5NB>,`9%R9V5R@Z0G>$TL*!U"5Y/UX5)=<IKL\M0%
M2^]M@"[@9!-%:U/J5%WP_;_4<9E[E6BN9S(%-CBE-)ZXM;"B@'/0B!1PX>DL
M]<06*[1J$F$0YR$1%&7S;5(>V5S+LRE;OX79:VMA'C@1$[>$+-'@)Z,HM/SK
MIDCGIK@`[I=!,9L*P+W/$U-"B:F`1H128;OWYZ><]*X^KEBCPP:$K\CH!31?
MJ]'[(;$WKP2X=59FG;)1.['#O)+V7]EDWQ]<;DD%U67UGK$W!UZO_.'5W;3_
M5SD?*0`4":,.3L!E%5<0OSS4U!?.L4;CTD@`X4NAWF\C;Y2!H+A=3+@J-U%/
MLP>0L>GY$B*O,W1F.`TV&TU)FA`C"L9:>1/8QL(X>VVX)J<;@O`6%6)>+Y+P
MA"*CQ:I5'"6[A.D-#[%9'W66;T*2M^B2G@-&Q(8MBE8;BW9EL":B*"%BX<F)
M*,XD,LL<\</AZG[`VSQS-("6-B:YWE,QXZGG2L1W?JGQ1@TLS"()P5[-VB:Z
M^IQ;-=\,1)C"EV63K#%L\&374[U,<>`)M.7Z`1>KOD4AZ43,Y.R;3'%6F2XA
MJLQ2H*4\"U3&?5DJBNY:!?>I(G?]9^_YG]W52L,GT:\&D]%OM0OM]18C$\I&
M;"?<E+LY6C8\NPU_\X)W'-L>`WA$T7U\,+E%5)VLK,6(=]"@LL!)FLH""3&N
M"3@RE07KM*:RLIU`F%:(+'@@0F-96>]L"J^H+.@+-<65M9*F+/=S0>YG97:,
M[J9)[`A#%L%%9>5V!.;(&''(367E=@3#45DPY*:R<CL"0B)K!DJ:RLKM"%:@
MLL#=FLK*[#@#PQ%9<T'NKTKMR/HJSMA%<%%9N1U97YT*^BJ5E=N1]54<<E-<
MN1U!*N%K!A\TE97;D<T3,\$\0<>8VY'E?B[(_6E&93T>"Y+(Z&(IN>W@%>$(
M%R3B4G*KL5X^%?3R&$MN+]:_9X+^'4O)+07RR(AF\('XB#(;35EV9X+LWAN[
MM+*P#H-U1@3&VK"W1]O`I]&D@O!'=V1`>"-?(4E/YO:3MH8G]62"V'C`,BHB
MZ.'Y8!NN$7K^BX9W<\S$L4:?"XK[H^=E'+$2\+>@(H#^9!H[RWW4@)>DB#,$
MX9W\FHC)8H&E!Z>X3<3`V3$:UO^P+=9$#)P=BV&3*LZ?1,2\=0_'S$)L+L72
M+2+BG>5^,G>LY[!9`G^6)B+IO7D,?2/S/S:D)H+$O,?G.V4RV!01/:[I=,[X
M'A[GE)*(O3,2.SB'%@'^EV-(:,2SB!#L5X@(^6B%\,C%Q)IL#",L(1$>W&$U
M$W&2401E_,WP78P6)G1/?+1B1/D-:V'VOWO.G_45\1X:\$C)Z"E@V7H`B-J9
M>^-HAQ^S#U>#_/6?HX>9@C,EW_K>^NR%D8C5('_]#I\2"U$,/2-(-^\">/(H
M_*L=?6LU^,_#_?7RS8,^N5B,[A<7LZDYOUC.[]]<S&?K^S=O].5H,EK_%RAS
M;#>X>1[/5H.G,#S<#(?!]LETC.#2L;:^%WC[\'(+#Y_U]GMK:PZ#@P]))7@R
MS="QAY/1:#E<#ATC>NXC"+D);/B6GPPV`?\A/[8:D#<Q_.C1D``;;A&7#F(8
MX"/3/J"2N_\!``#__P,`4$L#!!0`!@`(````(0`-6US4!&@``"Q1`0`4````
M>&PO<VAA<F5D4W1R:6YG<RYX;6SLG=MN)%>6GN\-^!T"A1J+`DB*ASKVJ&N<
MQ4.),R6RFLF2NFWX(ID9)%-*9N;DH4KLJX;A-[!O#-B`,-=^"OE-]"3^_K7V
MWK$C(I/%:K@UOK#1X^YB1NS#.O[KL'=\_0\_W8Z*#^5L/IR,?_]H=WOG45&.
M^Y/!<'S]^T?O+XZW7CPJYHO>>-`;3<;E[Q_=E?-'__#JW_Z;K^?S1<&[X_GO
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M.N<'WQ0'9^?OUHQV@+#-V/T)`O13\4_E7?.Y+W;X?R^>OWRR\[SYT\%R-I.L
MY@1<1^TOMK9V7F[M[S3'")LZ'H[*67$`FZXGL_8:NK>]D1XX+Z>3V4)T.YC<
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M*2@F5TF(3?_;&UFWX8>^[WL=3\9;45L^N=\';4:&:.@JY1J/N\;^`#Q6<.V+
M7W[^Y>>6\,UFDX\W8`J,WQP7U;_!]LT@@S$4Q(*)NYF,!@";+TSK%G>_:XZ!
MG0A298]O%H]WMG=V=F'\K,#T+,N_+YYN8N;U?\7<K65ON<`R#/]<#OZ^V-O=
MW'NY:QMXN?FR>F8XGTONI>^3RKBBP.(8Z*-,Z,.>P60"%"XQ20&4[&\BYO-I
MV9<\CUK&/%CQM6O>?7+OJI_NL=87FT^?/;?9]_<VG[QXN?GDR9.XQ;_Q\CN#
M`<HY&:.'LM);PW'1=[UL\@<#L;Q=CLS[##`+_6'+8EY,I,^=SQ>&YERGDG&D
M4)9(CA3#6\*$]H1F\;L79P?_],W9V\.C\^[__I=?__/_^O6__$MQ](?W)Q=_
M:@[L5B!3[*)S>EA\Q@#W.N%WN'"0;KD8@M6^7.>46X*>)+RYVM:3+;%_Z!LN
M10]].M.3YBMU<5^[\OICGUSVRL=7KWGEH_<N.$--W07B:]A!RG\&$C`#M18_
M[3\X=-EO$BI-A25<O8*SV@KN"U+.C[X[.GU_U)SB[-W1>>?BY/1-<?3'=T>G
MW38HZ((29QAQLRW!LV_-2E?B_F3>=NUO</F"VC*7O<'M<&PPWESY.N203+[>
M&8`(1A,#5<WE&M#=NL39#P@T;X4&5_K[PW(*FARZZ[!UW`I/_WGEPR<@[.',
MHJ^PON:TKO*?IE7UQ-NS;@M>G5U\<W1>G)P>G'U[5&P$>K?P]A&`$FR)$1T2
MM=^6Q<9H,I]_*6%;\H=,#GI75\`BI+&%8M\0B:?WQL4<U*WWKX8_R8L9/%X#
M.]U&IJD#/;Y<^?3!#4BVU$K-MVH&O'-`;:TU.?*(>XH#KZ'T@R@E&A?'YV??
M$O>=(L/O)<:!!6>GW>+UT?'9^5$D^$7GCVWA!LI_&"I14I!ZB+M>]'YJD_03
MDS7W<7IT$2?>T*M?^D(/3[IAK4>'V5)7O;U*@D[+1;%Q#7._+"0416^QF`TO
MEPN!]6(Q*0S7K?!Y+69H>;:CSL7%^<GK]Q>=UV^/BHNS(@75ZY948#"*[C<=
M"/O@=^WQX%R+K>)UIWMR4/R[WNWT[XO#D[?O+XX.6TCN^W)X?:,@M4<FJX>4
M!?N?66E&PA`,^V9G!L/1DL>;JUYM-R6I9DD2G@Q*MR8$-DS2'MI";P-M14!8
M_[YX_'3[Q;,'/KK[8OOET^:S#7^=C;QKJ!5_X[1HOAB<FNVK.''`BDB\(:$P
M^=A;ASGM\>90U1I6_ISAO7<![X6PI#E0CO<(^%;AO29,.UD#TUZ3#1J/!>1B
MVJ)SJ[0B.E#<FZ)HO]@-P/\3+Q[]5,[Z0X655\7'WDR)J)8>K7IFL_"5-8GA
MG)E,!97GQ-`^>DMDUSQV_ZB2/^5RYC$)M'KR]%CKYW*Q&`54$WT[PE.9\Q2$
MMP2I$I:Y0C3<,KF+F527`7!@RD_9+^N6]N`!FHL^+"MW*!,.GPZ4TAI,BG>P
M^+;7+Y<&HZ'*R;B_W7Q?UM3,J&P_D+M`O,J"]2K13#Z6+=1BN^;[I`!7R^.]
M^>C&6Y4PWOO6YQJRAX41P68XX]R&;1;3V;!?%O?8F0R")(1JD;#E^XXQ-VO!
M\$&G^TUQ_/;L^^"X*\#4.;@X^<ZR4L79\6J'WG(2D8%-QNCO$6@X>&HZRA1?
M-E_=0%``7<&_7LTFM\6`M+EE,Y0"4.;/\7[K38&N\!["R%O3"<!+4IGCKN9K
MV(H$3(N-'ADV0K\)`_'>F*R53X^A0XC'[02CF4]E5X4*!,64CS3X&%.<S0G3
M&\-/PEX'>',-&_:-^77X:$XW2QVU>'.>DKDMH^E(L,KVKGD@&[VU!^"+B=+[
M+CCJY#1"*?#?`^2H.5I3*$].OSOJ6DST@,%:&W^W)'5%@&(:,5V9*FXN`!3:
M+\O!O#!Y6X766V^$220EM[W9CZ5#P'E)5F]EHG3U%`]Z55C12/3N_.R[DT,(
M_OI/RDL8Y;^$^I]!K>8^FJ0_/CGMG!X(Q_]5I)^A]<,I2D><&D+TE(OR''%+
MUNJ$B0Y2=,U]EP>_S>SB"GVL#R>G$AV]AHPPPH9SJQOP0),P*XG^6=1ICFC&
M^<J,\WUFK27/(<.!YEL5QT9HCNWE"CG#]<\<#\<@E/N?D>&V$::*R^2`+^^*
MC:6B?=G6-9:XM>00?)T?=;H*_TQZFTLVR>M<$"2^.3D]M<CQ6+'-R=GAND>/
M2//AFU8_U%U.IXZ@>K,[6RF>9TG"L;6ZB'`M6=J:*P_PUWO7A[GWX_*2TO>+
MU:7O&!@4;X=D[MNATUE_L:V$N(KJ>\UEGD_H#"B^I;0[Q]?A,YL/U)"%I0>:
M3[P-59V[@FI=`)_-9\YFU[UQR-J8SG2'U^,A<82*P@07"@`D4>^H:;8+#3,:
M#=30\+OY%"CX^T=3N%'./I2/7IV>71P5N]N%S\=S^L\[_K_+KUY]/>3_YG]6
M3H/NB9U'_*L_&3E"O&647?UE=@PB\$<NAK?8^M/R8W$^N>V-]>M5[W8XN@LC
MZ`]?V>"+5V?G;SJG)_^!A-O9J6>-3]Z<GAR?''140STX.'NO/,:;XMW9VY.#
M5*!C75DKQ&EO@5C)FKQ>S@&L\Y9)2^!F=25E2-Z@N!Q.IC6,;.DT"LTQ^R:R
M+GJSZU)(_ORT,Q1"GO6F!JGGV\4%_(?)4[W"B"-R=L3I>HMB'QAR`HS$*Z$+
MAW=CZ-$7D^X`4C\L*=&1U3I\=X!&ER,J(CPT)9^H[@\%#2'_5TT_F"VOYPKV
M!<#&!M59$2:!;-4527T5L6]+O"Z91D:X(20LR8TA$>,%?)A3<U=L)*U4G7"K
MWQ/EK@O*4R5;2?3Z]2__G:4/IRR*0`!?,EH.>(W6@JVG>SN6(NK?S"9C-G-#
M09JF%7;^NO@PG"U!9WJL@T51-&&[BO,),DV4C&3Y'X>+FZ(S@O9;JC,QQ.QN
MRF+8M"^X?[=IDDY:?$$:->0ZH>?UK'?K4.RRG`OB*:TY`:V.)M=WK=CF+7TW
M0\HRK7#M&Y*QE+OZI`6820XJ<-$W/QN""2#9!(`1<H;1;`-JBLNR%/UGD^7U
MC;T<P4J`G14`V5:-;UU:M^BI$F9`I;@APU/,]+ZJP?-,P4,1"49$+,O/XG5S
MU?JCA=5&D^Q7JU3WD4?)9`7=/3*5Z5A:VBS,[JXGFPVV7'G/C!IC;/#+\FZB
MM/8\7P19[@\6?=L\LC)6OFSDLB638'TDQ25+$MA'TL2+@CP>/3[.^AB`2^Q!
M=^/E%>0"U^EYY=N-M$U3V5G4@]4:;R'RH'B\N_]B>[_`-(T4+;,Y<[4HW-52
MHI0BFVT,.EORHIYH)>K9LVS-!(.%YE269#C9X&#Y$ZH6GF>.C)Q(,%T>@E5*
M?;#I2T@Y9X=A<SP]TJLH\+C8>QXB<=OMQ0U$#<\';(`1JZ1T%,5="TO"&>T3
MQH6,"QM1OD\KOR65OAB.PM2+.YOCTQ1,>WS\=&=[-Z>D[<1&.71&B3R?2"?4
M:&C:Y]!G@G8[@X@%S>9=WL&\W9?;>W'*S>+CS9`"^<<@A_!E.5K()VA>BZRF
M]D\;T>">?LC1;5!87GF\^WQO^UD<VJ2\_MI:!!MS63;(WO:3.`8Y!*P7',;X
M3JZN\._"<:#E7,,0%1CNH3$*H4I')2L6/#W>?[G]HAK3%D7^US&LYMQ[LOTT
M_LZNO20%FT.X+H7)XM;*Y$@QHW&Q0@2B+J@F`C[>K72D956[RULSCSSW64AD
M\>J=AR;(MR8Y2"@/1O_ZE_]V`7-8=-6:=>5@&1V95^5&-QMN_D@4"/S8:,E_
M&>^DK-WEY1SK;W4[E^U83Z]9^8HX\_B".?-JP(#PHKS)T4_ZYLC@7?KQ>\N0
M8)OU'/[8I#!W*VM-(I:-$I8Z>PKJWG%P7S(-1+DW,&^/F$R%.-+VQ4KU",[E
M4917U3#X;ZJ.<9D587G`+>S:.HF]'@9'0.7*V:AT)]_.*NZT9.4UM0ECSSOM
MGJXOK2_P6C/81B2BRW%OB0`R7;52S;U*!,Q9FA.>JB5.'I/U:;C9P'KY#%^$
M#6AP4)A"8LF=T`YE6722W]6A8N]J;^_'-KV%&Z3N?OW+_WC3Z;S[]2__\\M`
M`7#6\#9;T;#JU'69:Z_![,V8_LUE8`QZ>0S`^^5G];_:6QUL1']4_O+S"^D$
M[9[J#(%(17?KCRX"MB^V$:'*2IH,5/=:0`>#:P4[U'`^/PS$O6A,"0J/08>$
M-;!)VJ?C.O@Q`NMFFZPTSQRB!IQ,<=<,QOCX9<I2WOBG*7N#'Y:AIS!W\&,M
M8,2<:K<20Z#];&FN7MPFQA4/QR3+YG,!+TE<K[BB'@WK*KEQE&2,#_L<:%'.
M%Y[#^KOHBQ)Q-,4@0W+4**S:Z%AT?#+,LF3==V`5(_8%^VLW+F6FBG7&THMU
MC)KW8?V,C;0J4QKE>!6;-@OJE,5@`@.:W%)8'X+E%G,4:*!&U8BYZ,UQ]3CT
M2[D\``Z:`$U_H$IN'#=5$-<^K5:5<$3J:C"]FZM]9SR&<PBJ>O,4B"1Y_B?C
MFYX7.4/M(!'SEY]C&Y@1^H#JB)*UR,2(R,#"62UXGC'Y5D@)C4%]$0B0F1J\
M*R)4HAF@K.1<_].V&]I@PUO33(QL_J\;O?7O05;(QM%\`?9'08*-XCT,C"L/
M/Z^<W"FNR160&,%76)G5YBBHH?!?U"3MX+;W(P8\KL74%B(M;T/9S(([&A]H
MI;/-]JP(**464RJ3ICF3A5VU=L(^0+6IIFL/_A19&@P9>^;B#)*$-&DM*XEW
M$%N<[7\<$<60-\#:1RH&^3$9E+*CI2B=PU5BODO9+1E)SU9.0UHWQ(F]!%#=
MHLW*5)Y2C&E8>2+Q-V@D1!<F3PH=IQ?^'T^@$G,-^^9K;.&-H,'(G>0V=2^V
M?-L!<2>;K*3C`"LV7!3GP_F/07SBS#H4(G&?D^91BF!4D#GJ_QA,H6,8F:-&
MA$8(O_A(9)*<H,@$2C-%D5%0/!`$RRT?#X#A+&,H+3@NH3:ST0DD0(VQY&=S
MD7E7Z<;QX0EI""U@.97X/=Y[ZMVA:$\<?QNDDT3T$G#!1NKQ'Q9*1@TLB<0`
M2"8UY`*,%W%F$*<8>,2I%59[LQ4&OZ)?!KYF#@B8=,1MRR8Y[N<AMA\>\^W?
ME*-!BT\G*7)NRJ-#;96AJVCMTL\#6)(!TSI;;.%?L.IX3DX*7?N_LI*!B6\6
M\4/C&*A+J^]<Z#E4A/GH8_3<TD$Z_AW7OJDHK[SC<14Q(L7GF\7U!&D92RVV
M**0!C<5;_E7.L(ELOIIWDWF\3SA&B*SX*SB*!8B1YI3$U<S$)EKT-)4Q7])7
M11\B=+;/:BK](*'+P=9QI_N:\P\'Q?X>)Y!R$OSZE_^*^*'BHJ!,`S:RFRHT
MZ*BYMF3+T4Y+@A`[!P^138Q(2<^#PS`[QY_(Q&`2!,@Y30*(;N6:OT$JMA:3
M+8^Q%W<HIZTH'UGI,DD=Q-4*%<SKGRZ4X`8!;_59L`GOP[^3@'LH+7NMZ%WI
M*(!WLL(,B65689.E*FG1$DT=^9`1J`@2UZ:)1`G&;"Y3<UPJO/?E2.;E(N&5
ML(ZTV%:^1!P0$<1L7L;F7_ME+._L0MU8K2$NRU,3PRA'MQR#*4:V?I5643)3
M`WKG)"D&-0UQ,**Z4N:M#78^](8C-69ML:ZM+E[A_@W*@&3\A0LEZU"W3Q(9
MLHYU=A;:<2!D]EB3%=7FUNR-850G9VO8`R4]`Z"+F[/-5\R%&*S*T('0U2WZ
M*0D1O=5:$[JJ"#4#'UNTN4"^HH-(>X:N-2TT.Y2I8</<U//!2I$YC_K#&4WF
M:)6E?*>.?M0E)-$`XIA<1$>K->OO%?'`!0VG6,O3U%CDD49SU7"NR:<6`9IZ
MB4A5IE/LNR7S8^Y,8@=2Q.3`E)9:"85J_8&8%MWCG*M$0@VQ;Q>'BM27RAMH
M7(AS.X16TF>X6;5Q:L@FN;6J2J=YPP)R`(74@>S-5Z&ELY#A=F++>]0)?+==
MG$ZL5P$OD(2.353[SW@1;$I00Y9-RHZEN:UACP.-T6.E2J/*4'G@9&JLHL2`
M@`YH.H9RK/<2SO/V;$OY19P98CLCY#*LU,6,7BUG^IEA4-@0-<[*Z][,[)1(
MDE/9'&0P"I@Q,RK5)DQV3]6^L5?(#61NH24+GY[;]#=X2-\<5+U',R"$S;V[
M8Y,?*YK\3L=?BF]=K`QM;A;S)3G$?/!!;]$3X2:7@FS1"A!#EE/U0Z'C6-N^
MS+8*:;0)M<W>N[SC04[/^K@Q?;4?9-_MA\#B2K[E+&*Z21B")T%Q^2(#>UWP
M0;ZNT/FTV>A]<ZFK8T.J8*&"AE/G.<^[HB1Y\SB4)N$,>I"+"Y[)5PZ=DF)Z
M/4DRHA.K:EW=,I&\+0DB$-.H$EBC<`JH6,[+JZ5"`8')H"6AMP:<:I6TD+B5
MCT=^A9_'%F!2LWJKS+#Y8-IX*):'WKVZDJ9I%2H@V6$6*:K%`&D)5]#0=1:+
M`.?%83]2)[EF-L$_K103%+K'W0?JP37DT5(XVS<L/TJ.&#[K-R)+.%8T4&A+
M&"-^K9OMD+90)C%8[GYO-KO3=![QA;W`_$`SR8I<*%HNKC"X?&]+V<B9Q..7
M'=N)<J4_6#0Y4=^F((O%O$AL]FR8A#1I?#:80H^/$R"(R(URM`ZJ%KUKF.>Q
MG8F80&PLGR7APWI>*EVI'(!E=>(*/S'K_ZL4WD+5+:HX)TI1)>R7GT.S-^P.
M!SN*C9-WY_;7PR]%ZOB/R$[`1O#<(5%O2(PC7=<3"8%^LQH;PB>."+(B*%7B
M^J'4[LH$!CJ+GLA^*%Q4'MB@`R8T,Q(%EA*/(<-JY@B^7:#\+ILJ?DUU+-76
MK%$O2Y-<(@><6%`'8((,*U$@R=>@7+C4.N]EHY/(90I$FL8:']PG(D!*7EH$
MR3(OL5,3"YVD)8'*L?JHS=:*T3):@8K;Q7N@G-R"V"?KE(]\A:L-#U+LC@4%
M$"4PR+(V\L3N<%TK%$AX2HHYE.^*IJ5F=V*JMKYSL[67ZOF.H,/&S(KUN%QJ
MH0$S-N@8&-JP.@B(C)IB!R7R/*GLI>R>L@U;\T4YU1:U>V?HU7#&\_9WS'VO
MD#."LY9/U23SN91;VXQ;1X2N6)2\*-9$AY=_Y,2GQ'-L]BD9M(KYY@.B936'
MZ)PNR?%6=%86TS-(5+I*ZLWD&]QZRBW5S:=-X@FM+%<V'$\YO"K'8WBH6K%$
MH)+EZ"9:PHAM<F:MH4(TVD$9'T:$.MNAL920S)VZ`2C6"`VJX!Y9@",6.F,'
MG@F)7%'LZFR16-09\K#MI=VM]C0H:W.IRIVH:U,!0$4^59AR7Z?`2M*0L`(B
MK17E?@S)]$2,+:+.RYQ-/.=4[4T14[`85J@>GL@-4EV84`,+3NWR;HJD.@&)
MT[P`9D(.$0>0N:\>F:"H&;5;KI.X0C9'\JX00[+H>KYEMB_*I_]-JD>K0&XS
MA7+()$#(T%=SM535M>K5-*D5_QDJSK2401*Y)AP=UBT<?8-[6")5F/M4C`*(
M,!A_S*SE3QPL&K%/&AT0!;9<S7`K9":(4.LEZO5OE-(S3<9@?B";,%F*85:0
M4A;.R(VA-Z02EJW.%W0\3D+*2GHXF]SU1D#%U(#:GM+:.F#`8-G'M-@HZIX:
M!9,3@HP@+S(Z&3GJ1*[N.S"`97`^>SBM`;&IY#.&C$UO5L^.R;]8-<"(G[^M
MQMC$GG7KD0EPRRKWZ")Q.Z';2T&9JKIN@N(L-@DDN8P))MBP=C>)=Y%1B'>J
M#X@'BD?#Q0%`A3@'-L3]6H'8$KC\0G_24=@EH7!L&);\J2`5/+4#^VG`(AYZ
M+&@ULWN-S+^!2U5=DPJGT3)Z\7>);\BMDB#AKA5##]M%UE[?-E%2G@<16@N6
M;:$Q4LDV):^P,.'U*A&0THP6;.3-/O<N0PM[T#)HR609UH9B88NZ\:Y1$`R+
M5!#%Y.#_0I5H^",_E%=)L^)IM$21!\XM<KQAO(;U)&I1K9]&CRLT/\0UEHD@
MY8YU07\:>"=J7G;*^$&C6XTEZY\.X^!/9:(`2B'7'.*']IB24AA4LS;Y\K/F
M2S-%N6EI[+ZA*C'J2-UD.3!HT"VL(A^A2:$5AL^,`_%,)M@!'X?@!B%,>EGO
MVC#,H<AL<JFD@1U5#4ST%,:VM:O@7`6\BQ^6@VO;/BZ3%,UH<@?->#ZZ0?%:
M0IEY0/7`!M#B\6!E#>+?<S_DV%V&0DZJA!\"V7.2!G)M``QJK:H.*B?!;(*)
M&?ES8^,(RWHRK%3'J^Q`Z`7+'OQ6Y>;7JE%,G&E;3>O/SB47UYB8<5S;UXT"
M[K=#N@R4+C\BB<%_9<DF0JN+;%25`5EI?%YY$IZOTE8B]-N2FSQF@XG`%PB#
M.WB$7RW5?CDDHX7MLY93B?R4M9DAI=D%-H4MR]3@/]%([2C3,_TI#A\:D:RM
M51`&=F?K2+VF!"','@&AN5@-JEZRR\GDQY"RQ,C63NH);W'UBTR\ME]9NWP%
ME%ELU>R9DX1^7PM]GOLMX+/NB*I63&GP!R/^UME'.36R":GS"N*?(4YX/V0V
MY-<16W(#\;SV;7QY8B\?^.E%HJM+W;F`[1J#@6$"<HH=%<[$+%+;Z(TVU;0S
MN+OUG@$76F_J-21)\1.,+T*MN07%UJX'@@S$=CB942\[I)V0L^TJ2@ZEPI4;
MN7^JJFM)6B>'=3F9X11HP-&+4>85+UK[&#NG6)VAFR!*ZS<#=:R)5;H2%@AO
MPHK];4)U&$5`*15-V78S;"Q(Q!9L;LSK142_V"B*MY!G%.ZX]#A_D+2*W\RM
M-57$5(><=LE_<S'-W99S7NZQ)@MU-$:P:FUW1J#U/%7%9:X*C)8G%?'8HT&(
M^]\/"9",1)+RM47/%W1S[>ZT5.9[!?R)F4!8\T(:*6-X-`%39=TP.F141(W9
M_&8XK?:AK$)*&Q&BZS*`C)R..:1AWH)4W444))M\;-4=&!90O>_14UP>0M#,
MT0!KV@-I(X*^?I4>:X==GNDH?[)B:1;E>Q-OW'J_-U+0HB20@\D@VD&0C"1$
MFB7;(M9S<H7YPY/5VH.FNU#4!XC%I#A$1@3M&'L)2+;N8CWA*T$%T@$WY-FU
M,2JG+8S&P/PUV2-P1,:^)'SB<K50>]EW05-A,N+!-=J\L0`@FU=;6U->UE\^
MT!+"<\$@BA[GCHXE8YCD^%<3EYBGO2J%%%&<%*4K12V'R[GZN?`]F6P*("'Z
M1"%T'X#W_\$&SE2`9TE!@&[ENA1QRQ^J>.MUDJRWBR"6T-FS&RJGF/$)1X0Q
MCQ'HR$=X3-G'4!"E*[UGM.K-499+W**P"`/5;84R`-Z$A3Z%R_5<-P)B]9B3
MY5:N/)"!/6BN'M89I\6FD4)/L\IN9VJ8;Y^7]&MZE"Y_4OK;4-VIS]D"K-V*
MR>RU^GQ9NGQQ-PW^3(HF`IM1FU"6EZ4W#\J\ZO.X7M*GAL[(Y;7V5(BU:_>E
MH60[M(,83B;<;7^-28H0K\?XGFDA)Q<;;DGF-42,(%MB^"Z&EDZ)^HX3V5H4
MSBH'02Y#A`=OC/NINI/R@0X#R/40!]%L`SV"!4ETI:\F=0%+L_P-NI)L"YY2
M6[LDA`]>*&TAF8O\-3U:3K?X;^!SKE!9"D9JK7JS)SV<B+'I.PM>41WD33@J
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M)])X:9=,(JAHB-VSHO$1@>R.RJ#:E;*K"<3N2KIG?@FXE.ZO78`9,\TB)S(E
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M-=7AF&T_,[:LM&<,<5.:-QO)]N1[ER&2KU4&`-?Q84+<H--2,N,>W:<GX-P5
M<3MHT/*E+5MZ2&HJW*;<\;8'#1&/X,L3JTMIK9@F_=!;OG!`71RQ:F16DW;L
M9<=\ADQ"C%\0+IO[J^QFE^#H4YE'=ACOPN!0HI^\NU_29\[-$G;51-O%]X;%
MD8S426CF/LS:]-7Q7&M/EX34+JN-\7T07`M:#E*0!QMJO73&`[(%L6NLG<(.
MO0$NW5J&#G602]%)1V19$I=/E6C\D>`@10%,ZRH'FN%R:[LW7&H:=A>WK",^
M^-7+4D?;;7BP5B2:N4:%!?@&'1.5.>$_Z<"29F`UK#>=]#2)6TO:C/<Y*S]#
M.&Q)0?F(D:8Z:(*RN6DTL`'K75#9;&T2B3@!G?5#AH1C3L;[.+8(V\R-BH?8
MT7ZD$[+:BXN.*;GE-INIXG9-)QPKMM)5):)LA45'VEI8B.)2>0VMQDH0(?=6
M+@F`/5OA9;GXJ%/WWGXKVD28G\B`JD5KTC?I$B=EWA&W7*>C=7%[G,WAXHC@
MK%!0QQ_!7$LNM(10RS,V:G/)(4BJU0=`M*R^O:8Z![E/L@YS<SH%?HKD+M#B
MB^'YCS1RLSHM,&7W30^BC:RLXZ9MW@SG:'C%GF"ESEX0H=!(EY(KDKB6G3SQ
M@\@7N@'T/K\-,!2A[:90F(Y"F#Y'0>4\@S7^K?3,#4],I.+!0S5F%'VM/`XI
M&ZT-B\"5V?<*.LLP2(-14(K"S:3WAAB'JOPK<WA[=Y2S=+XFKP\R"R-R$=ER
MIHZT]V%_H-*XK16+9EI7F%2*C,MM+8_)0UBMXW*V7#]WY:N/$J^MZET)EST4
M+$*3+/HWSV*_*D]4:4OLR0(IF`*'D+?DI22UY5@^AU&8;=3[R$[XU<H8Q#DD
MJ44-Q(6_U]+W6F!41O:4SN:$4V2^&]?]X,FQM+$AI_>3Y3"<Z]O6GQM<18SY
MG*`H+0\.*1Q3"[!@*I[OU/T=.M-%1"Z'L5:,W+S'AI,D//SY4K;4^]3<4B2O
M8;)62:12*/0U8:ETD_T41P*D=S,BX@`2;3.1XX'&@3%9]O>>53:YV@Y<FH#[
MG`C5+G@YP2C`O1"-RCYUP?8#`=;Z.]RDL^9&H).Q5Y!TT8<RI!P@T[F>$$!T
MNN_MVT*DNC?;EP;]#2\,RL)>[8G4]Q&AE)V7W[C@-'*_>+G[],O?%4?AQ+M`
M`#;V(!P@.D[J?5Y:FA;2G`LZT(LG!MJ]F!@$\[AC^E_1"BN^(AO?$5L94T]B
M.CI-_8:K9924<.+J[J1P?=+?Z-JD:$;3N7Z7/&IAE-;ZGIV1PD8<$8"%;=$$
M.4]=HDZ0D=V':P=XT9UG93+2CV[9WV]WM^VDN!44NYY<(Q(@\I2@\&VB0+7&
M^K)E?&H5T'N7!(#K%3ZJ[_?9Z.B609,\3`BFFWUD]]"[JI+GU+%.=2FX"5,^
MH'4<ARN]N*>RQTE&6W]E-+,A<;5^_!5IJE5@9!8C_3`&^WXK&PD,"($1FO=G
M0X_L@JMODQY3&^_^J1E-HSI)&^*&\35S`,#@S9-L`E';.S+MF/6:MP'E.JZ(
M2UZ_<#9G-1"%5CA5=T.TUJE`?BFT%8C<6KV)0&8.;+EV'%G1HNQ?N#'(A[0.
M5FNG[]'[1NH/DV4YF]VG?BN;'\C""RJ=/X@H2Z=62)$-4@4[(%PK+MAC,G>5
M45)SKS)XU,G",6PG%6<0K#/&RNO'.B.NRQ=LU*2[Z6JQ>XWCMX0/ZVWCZ82K
MXK"<6SLO?U/S6,M!@_PI<_5Q2W:`[V!)5$Y/#NDUMY3/=IZ%R_9_.XMES='S
M)?Z0>I#:%IS18%DK&HD],:F<P\+K8&`#M'S#+14D6^%W3FCSU6B<RS(175"@
M,-"?4^;740/2;55`8(*5[6XY13O@F.UD`+;*"E68(CX-%TB'&BA4])NV0]!V
MI6*46V#ET:H^4-ZL(%!8C*,-GC:P87\DUROUHCCO16$'#3(@K<4(E&`/EE,S
M@E:@#T85;%15>M4KA@52]H/:U=+"O()Z,G\@>+#%X].]3TPVA?RX.TA2*9BI
MR`']E.RGP!<G@F"0%3@B282S7<KR_K6\XRDV,#&`QJOBNO0#:^*7`&83MTBA
MZ0X-N^%+'L`3S]#-#V.)1]0,^.(#<5!:15LJK&+@H4)(OZB%ACWR(9Q4`V$L
M(CC/C-=_239(2S3IO238)M1)%L:,G,Q+M$G!5+IAIC6<:QCLJ!$&X44]_I1I
M#[$==-4856[8QS>8KQ_2.LR-5#(`OK%VZP1L*I\5@CF4^V$F[1^7&$L6N;\6
M[^UOZ;N1R5)&E/,WQ'LG6?P9[=;S)SL@O'>.#3Q$D%,>$Y=EPG,!#']-;8^2
M9&'=%SWNI%S$[]-`;E4AN!^=4U0H'`&X===W40JU4.MM/;`I,>O9/\.5#OD;
MQ9%5NEL$^>U@'XD%S)<WK>&[!26(?=R"($UM&ND8=PI(%:I<!AIY6<JZ9.I-
M.YB`.HWF@49Z&RMCUI+S(OPK7.R0OR`\T/L03GYGX9EDFE>RD$^4UB`Q=C+K
M^M$N(6$;RM.9/<"VF4I;$5!\]Y?")7&N_Q)B1#6$EBQP'*!IDR"6F(H!L=MV
MM].6[*SGLV0`I+`167P^N-DW.V<)%VZ/BH%R:%!V=&DH:;LXJN,?IN7I`(%J
M&2PMJ&Y!O-NRBD[-7M3M1P!*1J)@/]9G"3_+BISJ'MF]W_X>6;]S^UN^O-E-
MRIB,WN+51<TZJQ>(4B;_%_KAS,<%9EL?X-K+/AIGP`TX9MVE:GJO]UT:()@K
ME0(?2-).U4FB=C]=]&BP+-P7H716=2",AW5$54A&^5CEZ1P_A_).\]A^"Q>G
M8R_>V;=VI_+[*ZXA67L+R?MN<:$V*?HCE`+AG]6]))3%R?"`(-)7)WFBVG.#
M=N;T5]Y*$KM4HS\-67#WX6);U:UHW%I;"MS_[`M(?OFYT^`@RP0MY#-:.2+6
M&6`LD6'S>@,=TH)"2DNT,JJ2Q2NZ$28?A:64RH+SY'!5N@6BRBZ&C9L-JA^K
M]RMG\M4HU=WXY*+#J6[KFXNMI73:[[KV5-^9[J1+2]1BT/SU#1!J;FXWG.W4
M)Q\:*:;%J]93<JSM#TH=IU/YS6F@1[RW9FPWUFWHUJ!XL(.^6>E&"&6JI3]N
M#K.QM_]\<_?%;O/OK3=7S^<!J\YN:+HX?::<K7$V=OD2Y=Y>Z[+PC7U]CG)G
MO[D0YT=B7'5-6O/!C?V7FWOMC9"@;SVYM[G_K+V`)[N;SYZTYC^VSZ%UK,Q4
M'VA]*&P6?_^WM_C')W_D>POYEWUSG*O[185B%F1DE-X+5RO@P3VUE7^`)&7I
MXXTB___&!5R1CEW'6,]EG,CK7^_&A;HX+E[%TK.9O^:/LI]TZLR$WG7M.<%:
M308H47/&G&"X^>(Y:7P[19^>;S[1Y<@FL4+KS=773S3?]F^Y7IO5S$6P^=Q;
M?/_OY`:5PL\^$`M\?>@W'#?V-U_N[V\^>=[Z>#N_[+S8Q1"V/LO6J2[]:!CQ
M3^C_D]]<_U=_QJ!S\(?W)UT^FJ2O'3I1ZU:A]IF&)M7/Q@7?>)CPF>)??@[?
M>2#:S1RR$DKT(BA;@S+T_)-YANG-9A;Q2S=%)_:J%AMZG39Q^V!`^W>[4M9@
MX#=(*A<_CK?>]OAN`E<"<FJIOVV#'Q?M']\N!L5&;"!4EG/39M&+&I-#,DMU
M:M.`RDJK)%1`%JFG*^18?,*-X9>__"RT`Z#0LO.NN7[HIXN]7S5"^E)U36[M
MSRR$3S21>>>'3KH>(5R2;#M72+4QU+2:3X&1-7:K4$XRS^PWE6J.*%MV;1P.
M7=T%`M'F"Y:F2.DG@8S$Z0X1B]:J=L>0DUG#AL2F"^Q>N#E9"]3E(THM93F]
M%%IG'QRJ[=I8INWX7VU&3VW59:EJQ?,'[2X)<I!S%5C'NBG)Y,+.G(6/^%CG
MA;C#=>OV[4-MDB]TOWBQN?OTA7>I&:03@"&PZXI;+=2'%";)L'7J6Q9MT=P,
M&U#[?L^YH*D]JS7F?CU.)UJEB8E"]E!,LT/<M)T.J(BI0!P*!K");EM-%T70
M&`1CJX^V$O_`4$/%?G8$&29=J*RL$S#=2!#'D)"0)[5L*M+*I2%^RPR9!%-5
MA0=R6YQ!L^.45"2RE3=?$VZ^*PZH$:C1GM10V(02$Y;HT=*JOVY`&,L?8!.X
M,DQE;:JY>9/U&FE#.W-"W))<MO.,XKJ<55"_:B8R6.MV*BK&+:D/@FX&G<Y0
M\81?D'JED-6+R`U^)D\N;)+BESL<_+Q3U'E-\LO(#GNR@GY&T9!W-EU<+07V
MGG-")J1-+\H.$.R!%$I*Y.)VI5I2FS$>$;:M6_B(BMU!*H(B`D''H(F$`?>.
M?$"D7$J(M/,=-[T#EB!FV#6@.%BW#.J>:PFY)6[\85)E1F1)2UT"2.*$F-FM
MF5T>$W4J'K`0/U.7?SI<4>TM=0S6+X:(P^CPB4ZA',/Y^+<5ZFI)-Q=E.V/6
MUMOTA-TIY;_WU+;*[HF*26P%19^B__B?:+]E65-'AE$D,[:62VLS4GMVS@W\
M3G/C5W2_KNVBJ34\QLO'<]T*"?LZ>4DP8M'V_ZZ(I,6"*37<M:LG/D-*=10U
M?);+J**9XYB6YE$6QEI*U)%B?6[AZP\H9F1"[7(3+P]4"12Q5\NM#HBP5C,Z
MF8FU38YZ6)$E1?R1T5:>T8H.YM2U,`I/0Q85&B+T%WN%">P7DL49O]P4NS3:
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M)T`%M5X\(9!Z&C"TY%WU$T\5V/$O`1;9N;HS,-`T#0>C/>=@A[55Q+1387ZQ
MBQ*$BO,.***N'`?7`!:))V2QK-9H*INGA:[\JE+63J+MISLP&@))9S2$8R`1
M&:%UWTT6DFNG@Y"8OP*\3\O>CRX>@.*J)3\N)6NR`09!V8KBB<;V]V@;DV3(
MT53;2TGL.+!@'U>$0(+0OH51H)M3V0F@I2]2I6Z=&8MGL*"+;)]%!6IRU<8,
M$V/!_&(\K5"Z8\*5(+7?NHU0IO6LDXC0J5GG=]I2M!]Q,W,L;Q!0QXBIQY)H
M[PZ+_2,1DDX<>W.9I?P7#B:Y>5\7.J$*U3F(L&G2G_Q1N[#SU0/VR_Z,-LBL
M7:B4=^IX4P]O.'O%]?A8+A4:SVA/7ZM`J8_-2RS4#;?!:3,\IFBVR:[N0D!O
MHH6QQ0_'NKC`,%9J+K"GSX!1NC5.17$`&-08-M#0K-P*)2TXKW0_E%ZI'$X+
MNC"E_;IIA*H%'TN`S*F3WR"^UIN4-K8/AT]<L;/JZ4C3=1.FWF-KRN+<K1H_
M(#VV5G,$?V-&J1N;T43H,R)9\[RN[(?88SA0?4EMWXW:`Z:5_<$#V$%U`YM\
MG2G[RI0C*&Q&VN[#[=#GG?8P8X_V5IW4=)G%WHX@FHG4\3BMB$3O5_IF`VV"
M4*]6,#,9$4:-6+NGX@MV#!X+NF3:K1N=0NF3'R"S-755V(FK(BF;.8P'*.@_
M^J+EW[!9X511NSIBJU)&[8+AUEK^1GT"`26QV:P&>E)=UV?9JL_+\#W]S3-\
MKTY.+SJG;TY>OSVZ)\V?[<IS!.Z',5X(Q'"\%:WB6F^IK%6Z;-624F.N9B)(
M7'6OK5L<=^>80N7(=:`XS+SV)5=+KQOF%Z%BJ0">?GE*=O<R:#A>?]O`NXM7
M::EHPM2QBC6O97>^FDIJ$W?$-`&OZ3J"%F`SGRP7'%K(S&<"D>NUS>Q:SK!/
MO&V(,H(_UM%M%LU59AY>^*&,QK6K4GX&B%>MGOM=M_$65B"?'2?&,"J7F?6Z
MU_P89IYTAE?B-*"UP<'I)D#$ZX;%&O@7-=@8C1Y4NW4IG&^!G`7QFRR,`O!P
MPS?&/-[/INM*:^#942"]%>E`#RY,&,LX9C=8\$I^H"!=/,'%G=F7/&D#R".Q
MQ83+<6&#7Q"1O\^J07EV`8!2.D7%_X!G`E967P`XCL9PY0U)P,1;,[RBS!DX
M,<F._YBE#/31X87`[M"[K>*?\B#2GVHR8:;+%9?/AOM/U_+5NG\N>1N2.NJ*
M!CP;VX^U>13KE\.RZ_S$O&;7OD(OD."W:.&78%E[OMJ0VKKR4`V52]4IH!`"
M"W)/J^N*T:][=11)8W60G/^."<CJ3H7/',NB)%.5JA8C5GA,&G+GYB2M#6C%
M?%+H<+UR$O=T,T:$HCI&=27%CS<02W[0)\/$=7W*(I\GC@+="OHBJ^I44*Y:
MAB'H(.IEJO:3Q6FHS./=)\\W7^SLZ,())8G"O0?6:%XIJ:T:"^E*;V);-<((
M8WSDU8!,-_G^RD?TQTU/2&5$$P`25:LH$U?WIEE,D$KMU9>=:G>>FRKKVG(%
M4D8?:\61/'X"QUAFI+GI_<UGS_;-ZCY^LK/Y\B5(`1,>[N$8!43J3',RRA+\
M-=/OKYK^^9/-W=VG/OW>'GT!3VBYK\U?WSL$7R%>\+)AGYJ[?&(!?:28B]C`
MDU'948#0//_XZ5-['*M+TQX+0C2R/SQS6?MS.;-H!]RKS%%+T[^7*.MF_=#<
MW-+@RMIH79GA0.[K5V!C"XS35\!+<N8A4O%EJ$729,R3J6;YJW;F6B+/7(2^
M0\1@0;>L*U+`/\6<V#`34<*6E7?UJ_HDJ;/I['^UQS`U=`L*:^3H&NQ1*(!>
MR#EES\I*1!,[4`#JF%U'GD.T:E6#ZC9W2.SQ20@]>0PWH=.JEM*OKFRO2!W4
M3Q2O,@(9[2L<$7P99H)E!22!O^#%`")6W(9R`6$:?52*@74KE<H,>'/=3JR<
MOA99QVJ$G7P!F7"Y]7VH"D]2"EW1"+-X58>'7S>NGLRM8/,W)7J:?ZLP8_.7
MU.%`8CJV<J6.H%9'SXG=$"Y?V!QGJ_F'C=W-_9T7FSM/6IT!G<SVM-[:VU>V
M[F7S[_<NL]5AM.%V[YY!:M%@\[F3=$VAU+2;72U9?Y+(9\VQ1FM7>O:O$<Q\
M=]2]4(-J<7):=-^_[IX<GG3.3XZZOO)FK);B7RGF[L[.WV4W`2+-Z#/Z!PU:
M=76KQ>>?([#$=_71P7BK8FT\JIKHPV!2O.-\W&VO7W)1#7FP>77Q)MHVXY-Q
M^CM_56N"F\3L\M2J*U$+B]>:%J^'D_D=';`J>NF].J<6K]9.?=_#0A0HN9>H
MK,XQG8S(X',E%+E,S!V?2O-)S77/AY1BS?/-^?CLB"07F9LED9LGX["+:7.&
MK<*:+)-CYTZ4WU69`+)C3S`<2G@Y9LP2%7FH@O=4[HHOK2\P@'R+M+J(3?`A
MFY*18X[=)J]82NV[PO%Z!T]"+3B%-,'<64G3ZML$$?'ZC8P;2%`D<DH^5I/$
M]G'/H>0[S[>C-:?>"N8UU`(3^',<6ZLU!+?D+J'TP0Q$P3JMKZ`"]&`MX?A.
MO&#5$*^'U(&V.0OL@%_?[Z4-QQ(H8MB\*`$7]UJN5S-D!(ZPQ0K>4%I+'#+_
M>-A#!/%O?#;3R@47%5/8?LB>,9;+2\ZCG!:<`+"]6$!O%+45'PLPE+-ZZXW"
ME#%7,>#K]#7C*1&R!7YD\OEI.;:B\2EY(S^4NIFHB83;85O_O,O!36_*?HOG
M2.SXQ]ERNJ#/&C;H>PM`BE6Q#WAJYV4U'B%=(`OY2FVQK@B,Q55!]LG<@_+_
MD'>FN7%=69[?2B"A;-$`13,XL[K+0(A#)JLD4R72-A*-_L!)$C-EDL4@;:M0
M'VH/M0&OQ4OIE?3O?\Z=WKWO100M.ZN`3M@I.=Y[=SCWW#,/]UP-5N?$(-WV
MT4LB@&]OED>O)Z%`T[F7/S:.+1NQ`U!X$$4%U_E*X)D8K\P4F\\`]TU1+L+B
M-R`MLH,KGL)NN*EX<87V)S9].0`BZN$!H/=9"(<R=2U432TJ[AG.-!X(P[ZX
M8UO-$'W2M@`*<%0LB:"N3?0%[`3A0FH;AO<0NZ.;D@BWZ?L:X1G1.YO$XZVN
M:LM\T&%_MIY3X%!/=([SAA0T14&#MU\CWUD.[1KBLN=OJ;6T;,4WR(,8BA29
M$!JMJN:4)JK(&90E`#--ZABI=W44PE$V`/;:C1O":]XN,/3,.D5VAYZ0=?D(
M/_#"H*[RW=W1Q$B6=$$)ED)+`$&'P=()R[^@&GM&$$*(@Z<#'T$42Z4DRMMQ
M&C>'6)EHN_1Q2!?OY,./9=-T+R+M2!J\A\UT4$1'LN>%ST2\!>0H-1NL."YO
MA)*T>;Q4WCZTI;)Q&90LEPZ;"/PYYTL^__TU9RG(X*!Z+Y[/&F-A3D^W`BBQ
M'@#()CO&M!`+!%&=7WN:=M#!%Z$WYFBTI4QQB4X1B_VRM@C1Q%TTW#O\D,R<
M$4NGI&C`+/+:PD0J[F]3T&&!/>$`$T*6L\:Z#D%N@2_C*&,IL!M0LU))=[;M
MA@D9HXLG')]Q^+UR+[,<-WT"_*2]MIDN89(`^O112]&/SS96-N5Y_J@-&($'
MWZ=8.#@TT'WGC_`>&5(SK0"[>&87XY(F1\@>A,$9RC_>I%Y*^()UUWG1L!W<
M";>>'<ORX;[Y@C#9@3<CV^6R*^GF$L!*N5X5-UUXZWFK7LA[>Q?1M8TGG8;"
MC/F&:X?;6[PL!Z%/?QGJ,H)7U^XZ`]K$(GHV8!SUQEED@3CA_HF$P*DC>IIM
M%!G7KJM523+=4*'>2GM.A;8YKS"#(9.JA!$K;AZF*+-`6:--4(#T[N7)\E42
MTO]5Z8>34,C^M!`Y^^7B^*;(.+NP3AF`""NLN%#R*`KCLR>1>.7.)8S4#%A=
M!!\Z,<'7+PARMJ310F@*O%:D1O>6UIBD5X@S3SF1/2$>D$2_Y(_P`@7WD;1M
M',8_I<\0J-DX-UE2W`J-(!7,^6QM93?=`98O5J1(_2`_X-)<3X_=X:F,/3Y$
M:,KH)7SAU:W!5\6I,08`('UN5#+VX-'V%'\;<TCC`D_\(DZ47/S.BU#Q94\,
M;>^MSVMSU-_:F(/Z<5IMQ5X>0OT:BQ96KN*+2%3B<]Z[XH7UKE"0P(ND+<GH
M(A&.XW`I+F_&!!^%R^4K$@49(C\:T9P1]F-1#PDC."@B]3-J6R@FO!H7:`1.
MO`VU*E;9->Z97LB>YHHV]9$FBWP.=5Z>AS8@72#.,1%L__U-!">GQWO__.?C
M5_L';T^`U.C@7[XY.OV+K[IK'I@T.8I"Z"B1>#"3NY2X5&./%3<.F*ENI&2&
MWJ.S1[*/E7Z(T0^"&:^&LC>MU'@0QL98C&/`5AZ*>5.P.=)4:IM,OY'556Z_
ML+OONWS'[+3:3QM30;MO\NMVL65M;FT/1+_CF<&D6`CM)DU,4JD,.1O)]5C;
M'1<#5"MKQI`#,$;A;5;?!A+RLB`A87O`$G+Y8!YC+M#M:&UY9U?R_]#:'71C
M"Y(K5A=FV%MH!FHQ+Z]O;Q:?=X^KRB$1'N$0/RZ4G`H8GA;1GH0R*SF,M325
M`3X*$!VT\NA#$>6`5[R%G&NA-(Z/C^@9+O/$(I%B#_XLEC*VRK8@K`M171J#
MZKL:LG..[TS??H-]2\K1ZD9N"J1B:8IE]&="4]$K&:FZ#[)[SRZ'"KY[;SRO
M[(_U'B[#>=[@?P@=F@;R?F?`5=)QB2&,5YZ4>)]5ZPMR/"Q8($(5%6/T#Z>2
M*:'R%[B!"R'[;+2[LHL4YH4>R!]#UD["CLJD$3O'I2]&3Q)WH*`"_JRERVJ/
MV<V#(5CX#](5L_&EH`]1%(RT2L(>_TQ?A*V+R7M$F#18+]M0Q+F98(+EI)Q/
M:R_VKVFY[GA!@FW$9!F'0+5M$]A<,IZUN\M;Q.H;=#QSOL!(L3;<R0ZB)4KS
M!(OH<V&"OG,O:6[6'>/2/!`6Y'$-943B\.WU`T=:'"'20D2"VM!V*$022EX=
MZ6<Z^5PCK!+S8-H/MDYE"ZFH.&#DB`HFX+Z>IQQ?L0F)ME0UE1-5\H"&39IH
M,5547#EPO1(:O7Q$/I6G-=?\T`&5WR/JL1LQB@5@TO"`XS))#P<J5[9*TA/\
M7D&@;S]BPB*<%>'U3M[\T2&D8GGTZM6>".OH"!WLYI;SLRO`\>5PM8L@#"DV
MZ-6;/8L*,LF7MXQRGR%Y9C4NIBGEYM8IGZQ-J])@=M#W5UQI1O>O#'O20(]W
MHB?E'!QO20XZ%QS)7+$KOA%##@P";GH@),0T7OU9Q-180N\+2V.7%34B3[M:
MOQWQMDH2U%%;2H>8H-,@C.DZ8*P1PD2.%S;'`:]OO4`NP(<:'/CL:*HPB;F;
M&RT5U*MG<U]H2T".,*$K_.-FB@.EXIL0`TQ%K`0.`H6\,O+&,@(J]VVR5YPO
MKA-Z,0:T^S/\I,_&2>%(UAU,'5:&?":R"DW=.%<.S/V]'&$`W"8A?WNM8-/@
MH*0JXWG@ZX,+\!?(,DK_6]G9$EC]?9<3-OKE!&++P9PL>53L/&-JTGA.3#5W
M/*WF'9L4F29V["A&=*7>G;AY2KLR65XL=^8;*\BWL:^T1Y_@[#WIM.]%C=(%
M\=?*C*MXK%@(17`$8]^(T=-FC=(KGVU9J('M242C/)=`R)5<9\EW;L\#]I5I
M:<O2%TPJ#F%I=$NYMAQ.;Z'$N.3\H%=BC`CA'*VU'J)V>'5^3U0T!;@V#$_X
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M+)%]1$;JIG^X.KL,L3<Z?!CY%"G[YLQLJ\&7AQU4[2;)$19AK2^,]U0^L_`>
MHATO^?KRT1Q<7$.3L08GM'O1N!64.XSUVA8<K:Q9RF&-*4S#EI.$Z+#A2)5L
M=A/5?:A(>:*?N9B`5RE,K.U/'M\_8OQGF[LV[N@M\@@BC15'+-51T8QF!L:H
M[C3A7U*11,F-1]L0RBK0?>Z^B^''$\0(4*OQLCA7L^U(W;/SB!Q1:P]!B\NC
M[T07L"<@-B!UN>$H6N0B^:/R`NU;;)^CUY(>$"651\)>V98%P_%Q=X7/G"BN
MC([9?=A0\YGE35B09^`_<"D\3<A-!"":'5`'P6],9%J5RLJ!I\E55\T9U/($
M0:K"6R\2&?*]9*788/V14^_B(Y3-D,YGY\"R4R81+,CSS(S82N\(<JR!3CRR
M'GW7^9";?N)X@XO9KA=3G^YA$&N,C*>**'8<\3`40/C15%!$,@X7?O!H2CU;
M3))H8,=>1490GN-I,L_EL_$Z,4KRB_(!X9+F)*WB%67Y^R]:I$=8/AOC<BT6
M:7ZFGD76D.V5-T->&3$-U]]#J/R4$S;(?<O-*2(H0X!`1`NSW@5:8Z@G04AE
MQMH@-U'+T5(9F=F4KM(---#K2GG49;T)%:EA22@07)CZH0*]MMH*56^B/[Q^
MWP:+)#!$Q]?O+*U1FG0\7JU_IQWQG"]_4W@'WPN$<C%HF_FOIPU6=QMSV/GN
MWY^=FSWZQ<O)"76V]HY?OSGX^F2BRCJ^;M9;)!<E\YMY$/VF$_J$"F8>8.1+
MV4.,S[N_K:?%5^ZK<04#Z#?@!9J0Q=\T<?#D9E.T68EFV!]+RZ)2<Y$V"!)2
M:[R.G7&%R(<45!4,?OC\L::YW<^)L]AN_YI=A1DV/$)`I_*Q3C$';Z]O+.]L
MK$8M,$H,-JOH?6=AF`"L&(^80*H*Y<46C`)U+:JA6YF(*:399&G,G!A/KQ^^
M-&@6_<R2#=/M_SC63<[6MR;,3^.>&F-IWDS6K,)9_1TVDSNR]>[`R%G8@#A'
M+U$P<A<,_F8YGGH+-=#"]E_H&G"\I(\Z7B*X+&_QUZW--7M[FY#9G4'C>[!<
M#Z..:X`S4$<K\L^;DZB8T&A"+V_4P[Y@A6++&R0OKNXD$W[G]D2[NYQ#0$-:
MEZXT:!D\Z,A5$M#<.NF7G_F(#Z_,Y<"M:RF//F-M98YHH'I2J9FA*:M=-T``
MYJ"1?WO+A1[[-.RDO,$-'.T<Q^&K"(+.Q"T@L#W*)HQGH0\*G4LL2U87&%VN
MX*5K*[T8HU8J%]KJQ9WQ&_TWZ[?U1.XHJ93,AZ\*RWC]Q7>Q_6;]8((!D%JP
M]<]1]ZY_1RB(K5-R]<XWJL)V(H-2_3K6+"LX#[VN'YUBS*Q_FT3K4?W@B&&H
M5GI]43_XEFY;S:PQSGVR4#C^L]9Z\"=9*ZXNZ\DLLH*J9\V#"*WFP=+6]F8]
M"A74ZI]F+GB]?GMIO"$W:E,;=6E]&\_>N,DW*$;O&%SJ<7>(Y;#2`?6#L+TS
MY<\"TYF#;`\-<B(.V"-*1/7$!`[1A*?J'AADD5_7J2`N[6--Q1*AZNLU5?W-
MYP]JQ?K6^O+F[KK/3JE&C!LX<>O93R6:2Y>&)LK?(5M_4=`=XJNM1[L+[P4I
M&24SR[!FX;4J[MJJG'$7#ZJ_US-@)TL)88EP`9<$[',5);!(-2412@?,'<QL
MX8@1^A4=1I'[6$3Q;=EZS8^4(AC16BQ3+_$>O"167BHTP,.YY`V@>XT1V53L
M0I/E!U/]+.0QB5L))I&01^;!'"6H:D^)G<,<SF2>P)0Z!50)[1UO%]KA#H$"
MF\M;U+N1E)23_BR/\[]LW>M]ZU[=W=!B$_KM;B]O4F.PN^[Z0H.-'&X@J3G'
MK01W%+D5C&P&<3U\XM5<QU.ROK[A:R.A<A40;^%:Z<!4XAUB>SQFX]>?-?EZ
M@VU#TB.V]*L7NH8=<2C:KB0%*P'ET6+2:EU#ET,@(=;WD8R3'@O/ZO(FM&`+
MW3Q:(&4E>G]CRG_X.ESX:)#CWIG45X0,!@==;)^-K];XM30#I=<S[_K*FI/M
M9M\ZYNZ%LL"!4NIP5:*+6+BRM#.[CXSOMS-W\N[M32P+O4B&E:1Q2M/[GO(I
M7>JT-\U\E*,9!?)'PF.!#G8*92!K3"VFNPUDBDO)M2[U1WITZ?&B%GP6(U9`
M-5.NDL-#YA:G6@QB5>[$UGS%,0_?%QCH3W?F%H`R<5J;"1;4I4UVJ@YL<V#(
ME]X`U@3]F)*NJ`-:R]MBY4;S4H]4NTJ]TC]0816>((3]>/63W:S@@)4,FRH3
MK=!.Q;OI:L(2RZ*ZU550,07P^04B'"P%S`+X%XBNN0H"<T8>@8]6Y<%2A[7Z
M,,2;SL/LC%AVABV6ZOVJRPU+4X_5@9@NMIKL'GY`"Z)FP!&*'2&Z*N/$0$U+
MP1M`YZI8:E$5BB0%Y(CM)]5Y/5HZ%*6L@`*D&]G4^2/T'X\LJ(L"BN7IAV+O
M!2RW"&Y;\(!G%9?W$"22"7K8#OAUKL7SR\^X1ZXN?_DY"F(U>=\/$2VC3]=7
M'QN9]&U_.]EZD/$*`>ZH/&LKFW_L"]M<7=GF=][XY6>"@/]8?_YM:OA=/SF(
M76^MK,$2YVA"9V/6W%HA0(T%[*YL-R+M)I'Y/-(K]?!1TTF4LE^Z@'ZZ[4:'
M')E/D#'J(4]%#3LP%<&T1/=*<,M26XI$PBHL*2I\WHLBJGW6T^!7DW0BQ*V7
M8VCI03DN8B>:X3+8NS0]C?-#.I<$H$#H2BK!W_%)A+`\(U[-3&\#906C3;2F
MM00WHP9=_UNCI;<GWTR_,)R/<EU6[<N%8-NNH_S,J;:?A9(YPE[7-Q_L"!NH
M##);1O;`)OPV>C0CJ!4C5+ZW="WCRIG<&-WM>4.DX>4M9%M(M8\_\$*Q[+9@
M]*;(DXR'`(`D%\1N<A[1JXHV9HB+Y*>$1WDPSK0$2<[:##VLNUBDYC-6*G,I
M?\%5]O&CJ"6[<4ZDJ<PP]>.M74+^P_,$%-P0T*(C!B1':36KN$P!*?UG"P<#
M@`>4Z@5-;F%-"TU:(Y;N9&5KR:86UZ9"<<6TDQ*._7@Y8((!%/7TVG_]VY]D
M-:A_W$?1JG_[)DJ4J![)$9WJ!33Z_K><8VMS.+R]?T>3O/9!.7KD$/+2;M3+
M$`@#3+@(P8'Y;'<+7]YFT*;'RYN*=J(]%]@0!6-S(YI@9MDW7>.U7Z!?I3-P
M&9.JY7%2Y"9_2--"#5%TY1969)_?UQGVA(BJL%4%$*%W_[[K_]W4C@$:!0AT
MBP;U#PMVIWK$6B(S.N/?7OT8PXJ-@3<<XC`U">JIK!>MAW-\:6/J#CG>\J+^
M^3O$QAQ.CMZ.OIV\^N9@])HPF6_>'BS4K"P(C6`I!#;W)3:3">(=4G&,6E7<
M`5<_BY64^LYV#_`\5EX/TH5K#^:=\[I:Y\H9M.*^)DY:J*;,02J"HDHL%FP'
M,X@J#@)(G/L3!9Y7KE9HM?,3P>0V\A>Z3GRN"`;5^;2O1#SA$N=75&XBT-F+
MD2H0V,.-Q438@C`P[-L2O\4L2"+JI&SHG4AFV%M9P"Y*X(I"PS#U*!$8.*D6
MSWO+<?$MM=`+<V($*\'(/MBT^(KQ+A6@RDK+1^6G"[1%&*I=H$+G"J`QW03Q
MQ,3U<,^2XKI"'A0C(?5&!<*YS?=DW+.YH$@4&D0^9J5KH5V$[]='7G!.$=BI
M,6RA<I6L/+9?!5%2\]`AQ`*(155`7[YJ!>'F(.K7RKA"08,$@(%.4H(!1U!S
MM:Q<A="($RQV41RXBR#%LP_7F">(\K*JJP4:.ZMNPQLB+&F')5.^:=X<-WM(
M$NOCC5=]9='_^DBV`EY1.2'$#60`E=[KV"GEB80H@L?`422>`"!^B\BO$LXU
M%PPK6)NQ@NZTFB2VU>R=HET8<=;W[>+CJNUB:\LW)"Z$'6D23^XKS\(1T\!S
M2V>$^Q^DM'*5R:-`G;DT@1-LXEM5/93XV1,(%M%OQH8#@!DGH;W7[""G`<#;
M@@/*.L:$W^S<<-MB,\OKLRM=[B)@E"Q;LJ\5V-/!K*,;&D.)7ECIWN(VF+)_
M+K3EWU1._$>EK_>1*2>9P:RD_42;4B*7$3U0U`9(6HTTI[H1%K%C@[GM(#KZ
MP,-,S8LM&<7L2&0&FAX)T!!YX'Z'`6O2QWV6'4,*J)9DF3F-.-N9O'EJB#%J
MW$K^<Z."^\^-L+J/]8C45=U*WT`-.KD$62&75$%H1;>>7`U8A_X1'F#,K2@7
MVDC</:!K=J6C2NS'!&_GT#/[B=K!?*2*@S=QS+&NU@QTN:#<ECJ5:S-BP$(S
M53-)45/:1=K-0%0+&E92!CM'T=51E<!0=#7-2;@VYK.U]>4=@D\VR*6LEMF\
MN46_(<)4MM:\K0'M=RV,F96I*]%X3&?"[=4H*)=8*T[`W<L#ZF9TENR!?QN[
M!,+@*1EOI5$BK"5M6ZOU6ZMG@7*&+)\'5$2<2M,&@)'::8KHAT<]4&BGF<FM
M)DG8I<K(1-,CM^_CHYQ?;BL-/+JX=FQ`7"OW]C2B*0(;ZS!83_<X4<,5)MVJ
M`2GH/N613,_@Y,R"U>/RT_=L;/1/9S>>%&!93BG829=2;1BXL&:R\2T07WMU
M!^\5I0[\E1"?+,R3=[\9DU><R0KS9-/ATD`X/3452IH'NBBR4'1<ED7.H#KM
M-=)[BUP"\V/Y0!;=_.[*^LUK^"*=!VDP764*_NJ\H"S(I'>H)!<4.V%/;K69
MG.R-=L:;2'YE86`=0'LD/=,&621:&F3,L"A?Z6V1Q#.5!SRKH(*)IF)26I`[
M$H0]0-JC<,.``16-7^Q!:V[I>V-D)7K$3SY0O48[DILS;U9B="/9!(SJ63Y0
MRZL,'`0+K0!OIA[*>ZB$,$L-3AO'=+.WJ]M&PH#:]=D_5]JEK5OA<-E#K/OR
MI7N(P10SOFMX<3U#A+Q+$Y\&`73R`)Q,HF<3QRS;+UHJ&:&C#2'_");2R%]+
MZL.&T<F<DFM`^V:0C*=N:-/9?CA3'1@@'5X#K6@A8=I]T=]>J9N:+PYFPHFA
M:L<]<7Z%+&LO%F"S=XTT!8-A+K]!@(!&C>0J^GZ8WL0;/>/6GWOO#[,A.;'0
M?AR>B184$\:;I.W!%1!7(V%#%ZE0+`SCKWK7(2ZTS,H-.7JBN1-94J-B\\@X
MH`VUM[%>4S/S*9_!R)-;*NI$I2!5#^(Q>2;-WMV1WF3B$>O1$AQTRDZTVC4E
MV(TBNU6]9C:Z,8G9YP+`M6RAQ6:QC'MI(A$AQZ3\&08+$[6*>L6-U/"MW1@N
M<YHUV><:2>BM"/P=BK?4)]R-X##J<7=MPV8."G"`6#@]_8/"S-'7<>#^_?D_
M_N'P$-LU__L#.4+WA\A3@NH__N&4S-$IW;%^I`(U9F`]?7=&_:)/_GBL'[XT
M`\K#5Y$HI$F+`.&E-80#_NWN@'PK:"64D?SIG@T^?#4#9#U28MAT=QW1*%0,
MUA$ZZA5-,I?&?A%B&X/IA6O*X/8YQD\B.3)'#M;RE,W%K3,IDVOC":_K:[OT
M7-Z-P;T<+&0B.T1BHU"-.XJ99IZ$R:NNMI$:N+ZVP34,F6\6US`K_6UE=$(L
M#FGD*G/!]9"I12A%@257^7U#9;T6Q+HG;&IW3$.GC?4%-K76V906$?9$;.5X
M:_R435G:QV,HMCB\JT)V@BX_85,[],W=7$]AV#-.:GUH4\1HK"F6:^&#TIX.
MZ#06B4GZ5&:L1X0'1+USM%N):DKV%AGZGNJ59S?74TMJ<WN&$2)%)_Q-G$:]
M#ZW3E\A3DH#83W0S68$MJ54!S;-H2VX=)0A0.\`0??V@KH5Q<1$]N]S.;L"T
MB]6%R"BKD/)RN50:,(;CA&7*-J&?NT-7+Q6&RL3:]%$0<=D$%II@"4C;=3"P
M:;U97CECX=SVJJ`85#,PW*GOKW,CTT\9GS,SYLV,$:8<_.Z2;X17M+W]=Y%W
MD_EC2.9-"__=)-URAGGRK<Q;BXNX`9/N*,G1Z@&+B+E/<B_GM2-\W;RPPIVV
MUBPK)J%\IC"6SD3W^!D:]@[A9!L;GRN>Y6&-'T&0APRSG9M4\]VN4$0>*)>I
M?D=A)NBZV.!CWIFU@JM?ZT2#U`_E6_I+7SKVVLK:0*(V"6:-OY7E91)0S[$^
M-,?&X!P=VM&.M]6_YHV5]8$UGT+MGBJVYI,L;&4@.R3QQ\#*&J'V*"K6X-2@
MI$J5[X2B)JS7&Z0G_?8F5J75G?K)$84];F_^2A,Y4]!35:$LP##Q)%151#C+
MRAA:8V;Z5C\AQD2,8D_:')+A1B35EZ4&CY5FT27/OUHLFWZR3\5DTF#\BI(]
M]=H7Q6+$TF0O27:-''%7K,L_<\>$\6K[)'HY3$=V$IKF"XNW%:EV*$V#<BF7
MCC;MS57E2'6VU1U"@:ADAQI?#%6ERFW)Y17A:ILS`S(UW;9*L/KRE[CTR:'B
M^X;SA3;+Z*P8E\`A5]*G:&\/=%8__0#EM_VA.:E))7H&\S/!AH1LP1IQ1`8J
MWP`/UN,#.KT1#Z/?S8['H[7X*/3MT#.K#Z!QWEV_PW^07C^_^J1A]21#1*J<
M#`",-5ZA?;5$*^PH`=C:$VD7%M_3`0KXHB!\0Z\:^]Q\I!3SL@!=8_7L/UZY
M/7YWZ2%OGQ!0;+/_S8QFB1X-"1'U^G\W6:)GHLR6)4*V)K/_#T4*#'7;N^-&
MGHCJ-I&=<+DF9*AF_'JIX?PPNGX.>*K[G;QF(,`"YIF$5Y"FC]$G!#F`1E4'
MW;"[I4V8U%;-I+2(VOPS_3).8Z$97.=LT'6S<Y_-V5P[F(]Y/3FK1:ARQ[DF
MHAJ6HS<BAW9/;3(9Q3LMMNOF*JD(9@WHBQ`7H7,O"QKG#RFN4Z$=<KWPHT78
M&FGKCS!=&3FO-V.P%M98^KQ:?^!?,3K;FC)=8)UPTB^SK2<,99'6J0#Z'!Y9
M5:K%E1LBNJ.6:K)%U%)+0W0^'-5[2[V71?"UQ/)5YU+,<D'4B5<4"2[RL.(+
M58<3XR)B0\LHW="TA@!*S0UH#,586:3(L^[69^FVVUC[XRX`I'19:H>=AG"C
M(QJK&"N<?/SA=BI73&IH$OLWI$(FS\;;Y,VLP>5XK33?%F[E",/!19:.58!8
MF%P=MX,GUT]IVDS%!A8=.ET#!3Q[82FPT+2@=[+.NZLF.')*\_J+E-\2<MFL
M7`HV%E]-N5MV4$A@G4"#</;31WH4T+/8\C$08#!8ZJ)A#0_A`2DP-*VW1BRJ
M3W;N@NZ0;A6UWTD81N;PP`/#9<^@0QP2LM%6$P,,9U6TPW"C0VBE8AL#]W5J
M^!>PC<C/RJG$#M+)1`%9$6F)W9EQM053D'F7$53"%%J$!%$;"V`3^>%DPSRN
M2'L^LUZS`/+#6[7E9$/[5)4F5DM%3"!!3G"6#O<GQ&7SU++O(;I-*U(PY$B3
MR\S$I\'HU/A*FN]L5&!$YQ\K;!H:SY"]@^5+]7C^#:B=/8@GO`^9+S',)K<F
MEP0-P$R=ECA-!`D"G;7YL;I(H4"/,MG9$YV%'AXOC:8'(;*D'N6!<KUD3!J(
MVTC]6SUV:T3-<TSVA*N9(5S66HZ<Z)&2$Y2D)B#F#>[G(BZ&(Q2F.%)B_D4*
MCYV!8KR7,"/DFIA;K(:Z81/T#S81>Z<S)#LI";E0P/E.09@\O4L';6Q$YLQ"
M#7!'9>7/=3';>$4Y_"(L(CNV!TF)3D/]$\$&%]?`?%#FT^@]Q)M:N=R]6WR%
M%<,J3BSL<7""D@SJI$JA,'M0PS*03<S5WD_V_^]__&>)*[DK>6*D)9[ME:[G
M(9-3GY@R5U8:W&L&2\/?8O%%*(9LSD-#U.MA$_VPB%6/F@^2%2$O1GBXZ(3?
M-AZXY/>KI^+REL<Q8Q*N'[6/C=09U<UB'JFMMX_O/YA_TDEA3!R[TDV&F4CA
MCO%FNK<5Q3-J6VPNPB7+AK$53'EY=`'%\KR6GHAIG(,8(._,968SCQLZ"/,3
M`GE&!S4+P@63"U[KO/4.D4S"BLM8#^J<%2+W\'01(*;@K!P]!PG(="_$+YQ[
MTT5,)8J0$#\Q$_QO<_N4Z>="HQ/R2%B`L`7O4A=.`B7,-,@D)6DO+QL?Z"3B
M_AU2B&N&>NDN1N*#U\)Y-0BB:VXBLMUW:M!"S'7G4\]K,UY%IMIAY@N,GB2>
MP*G".(0V243,//#ZWPS5VA7+X0[*096O87(Z:4DP>?FBB\6B%"D$W@`\_"#5
M^BHTC>XD67$L2C9P5"%B]:7A*:LH1Z@AU",?(!V)FS@YKEB13CX:PW+T1J5/
M$+M+PS^_A#/N<D/91`92TU4_],3Y2GKLDDTP2B(_%*;0F$H<$DTX`(M[4BQ'
M;'6!?!9_Y!(JM,$E-GZ]5[&=S$#N`)RW41:68G<$Q4*"2W'C$/V(S0F8;#JN
M*RM%!""-\T#/#-%BP2X?IUW/4*K.)7MDXF>2@Z\.),WW/XG$05;N&._;Z.GC
M>UK<!#0V`>^D.%9%@SUZU-@;8J\N)(@MQ;\U^9YO<&!2R1Q$UD[A-R%>BS2$
MFN"_5-UYO?7&"9WA2OW2-^`>KT2:605DJ)GE](,MV?YR0+5VH">:6@_$4E0D
M*$C(6ILU.!O)PU&_^^9>H@11]KI/&O-.E[=^ZPB_\(V7X)\HV*P3=@?F$BWF
ME*']\`4S$/P^';V%Q%O]SO]Q]OW=_Z2/2VZ_MY3Z^C9`9B^1C0O"!,O[MNJ)
M7E-OG3C63[D#@[()C>74K^)QN6!4^H)!4MZC&Z`8\*Z1W]=G?[5A7AS3Q8`0
MGL$NL*K,BYC'37CK64KR(-0S36(]$9-9]V\?SQ](Y;>@0]"L.;<$(9U%`9]Z
MV(,SNDW2L&VT](K6]%]8G.2)C.7UB_LY@"L<FT9^E6T4]0='7NGE5-5)VV<)
MHJ.E4]&1:7-:)Q92;L%G)S1]P82B^5)8\I&%,_<>RN'U3\`[K'*!X7\MW@X.
M??'AZE)=6[DN-;;7D#A19:#0_R`V`%H$)$=-G>GO@N>KGN&5`JPXWP$P'SX:
M?07GK9JGO4T5XR!A>8AK:$Q@4<D^7#W)(J.$4$JN2?\8!HJ>^I.#2W<,D>K<
M0L,&(WI35ZE!/U`CQ?1!*4V\_=9$[IF?=3!26M0$7]\/(A1OLWF6BQ>30GVP
MWM3P0S$=G_)UJ4T/GM+`^])?^Z]C3#M$D'KP##N?#AD,*A,R)8R7U&<I(M2-
M&JSO_I.^B"3B4_W57E*2"FB(PPR0Z=%Q9N'U6`==/UC]N#EPU&N!0S2[V%Q<
M*KRZ'B'<KOKG)XL`+XH$P0[:+NU;*_@O1DO?G.R/GK7D\.IN)2J!313F2:0X
MQZ(XF;;^[U>JG'&DIM;_IUZZ<7Y$KW?<<<+*8YAS_=IK3^J0R*VX=[M0]3O/
M<Z['VK87ZFX`J`!*9!P/]US"DVI_L_1+:0SUD+8ZLW2E`"E0P\._AM]-<5B\
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M^\X7=\SB_L(H,]:2OYF\0ZP=Q4_B$*<?%."D01J`(X$E`6PNQ:N7$-$I8-,$
M\I2P:32+HA4'F\:0T)B_GG>>KU`N_D$R]2-&&'.XDC*-^AL"Z#78+`UE<H'2
M0Y]1R1RCN?L>HO3CT6LHR(?IZ$#))35TB.::]?@8KYX:!<HYW60SOI2%3/I3
ML="9$,T<5THZ*O_(&Y/WD+'G@M>]1-ZE:QH?88Z`H%UGO5&_?#PC;Y6![`E&
M1%GNR1M73`?V`0<XC\V:>%?[=!@3249.1[11*UX6:)U&/M5/HK&(-SJEI6LM
M`M.YW930\48O>J@1I#T2C)C+UC]I8V?Q+C2HG\G"R(Z=XK<NTOKL"LF&3[("
M"JX45HC"R%</H"`V4RN`3J>C.U`S1^O@!Z)4P,9$TOJE24Y4@9V]B+UX.<Z&
MU#_?7<4@^JFY\&_P:P$2*I()`V+W^NC!;D4_\=QDQHV+7\:49UI(O4#CM'VO
M][.)6N?ZC+OXQE"TV>XKO`><'WQ]0LNG_I20@VAE#<3?;7KZ59Z>672L\X'[
M?@35ZVPX.3/#20VFYVNK_?SQ^4;_[R6A.RLL+YI-EZ5_FL[RN,K:3[V4SCN,
M%G$J=:NW#+$S7)5.,_KB;188`R[+EYN_8G;_L@F0F3^G12@BNXHEUO/V(5X2
MS8%"_7RN?''(?<"G_@JK*/P4NG8$P##>YA_K(:<S,:MXV\^6P`#RFA[/_XI#
M0)3YK,`"),&K]]<4Q0+-@TMDQH87&>^(@)1K.H3/-`HN,E!Y3)^Y)C(XG[3!
MWQ)8@V,]!5"#@SP-2(/#S`;0J275-WBU`.X,?CF\^<%/9FUU\*/9&\LZ@W3"
MD\)X^^LENSTY%B]O1V\PL'Y//S$B/_#W3+G5%S46$VR8U/U&CHN1O:=%^%0]
M0.I'_O+Z=OH)W9:TJ)YY9)N^GWZXOI.V&%DX&P8=D$^N"6"K!RX*[8]B+CFT
M[4V62+Y&V:B_(G4/B<>3T!'2EC%"_9`B_?C\K:P?,I-GN"^/_L1/P3!M.M1C
M2S@X>7ZE43"?4H%V>-D6>X`_+^^266],+3*Q_O('I=TWG+XKV)0YC%,+*:_W
MV7T_6P]R*^/ZBS(Q`5WCG1<<GUK/E)D'D2$E#*T^;69)5J&>EP4Y;4T>D?I#
MDQAK`_6OUFU61[.4%YJKH;R$OI+U0DRSB<U)ZX<IL"/)8Z8PPSDQXPSVUZU'
M.5&,&U4LZX[E`^\UG<WK]_H[[4@W(W=`6BFF8^XD_%!1"6]"ZV]R\P:>"5&1
M`!Y#6V^KN=A@K'EON)FR:R/U2SQST9-D#J4*B/V.7G["]G&&"=O?"_;^T02C
MV>5,"2):JQP_SQZIA'QOA@U9HJ.IKH:#3X5C3`V$S'\U]*9L"CA_Z37;O:A2
MV%!??-;<'MM""BK,ES:F/`ZH3+V.8%:*6:0:]-K\>C$S\]'DT22DUM^'8RF_
MB^*_UDN,5OV%:2Z7UI#7C)GO0JNZ^KV34%'%-KC,959X$D-ZND[]=B(90@A+
MZ8"6<=:#&AZ*9P")#UT/"/'VQK&-Q;4$O-;5I4^:/]I9:7ESU9BV4E.3L"7.
M,!Z]@CKBMJ_L+M2K&B`]A9FG]?L$.SW^KCGV]#V,$=/1,<4YW$X\.K['J2U+
MQ"S5S-O22#^*$]6+CL,U3/O@)U@/E6\<$LVU?1N;LYJA5$2ZU[+V/-2['Y%]
MSW'+3$2F?9]*'A?2.`N>CTT;'*W%`3`IS1I@O=XBZN1B4V\T7X:IMP:<!''-
MC4:7MCWORT:C2U_2#UOP&FW-W.QVL^1@HN8[WW3]0EQSDQ$8'*^_FE=RH8F8
M$K4&2[/SU$/]94<VC7`1@T)HPAIT=04G6"E9"\:2P0QUEDC<Z]D=1NM]UVU$
M1:T,0O6+<#CW^H#3#Z8NV&OD)-B"0OQ9_=7A_*:>]2<3#R?Y,W7?0VVFR*WZ
M'<ZOA0\L(UF6G/Q?E.U+ZSGV4N??/Y>=?X]RY]_ZBWQR'ZW4"9N.9E&%%M:O
M=\^J?OJF([YRC@FRWOMV%'K0JIEJ_2U.)&SU1*<ET'(@H>EM_6["W44<^P'*
M17C`?.H;8&SS)%?!+,K[I!5EF(?/YG&#ZH.%5F3LJ2]>X5??>).39!F;+RB%
MR(9%FO[59YMY6!RD4.E0NE3)N_4[Q'=CR?J@+X@5-M*JM9.KIW5PG9M<BE21
MY=)`EJ@3VA^M<9@#])A,=LGP8MQ\/1/6",+I:)@68H"KKZ*3N!'6$)!OR:H^
M:QZ\F=$JIYZ\:<'@@J&,:SB2O`:UY*C!WCOU@-%'.I=?<[][(D]"NX%ZU(P$
M8%O\S*1/2*>5/Y2K(=)193J*:P1-1>=;#SAS]M&_YUSL^L-^):GGK0&5J7V3
MM<)S9JQUQLUUX7*!F**Y)"Y#.%Z=SC6;:UN=\_V>S!5]_?CF?!?%T`;)YWPW
MVUHVY^,PJ0+]ZN-*]R4T8R2E/<C)Q,2B!,'Q7%5=P*3XA+$&J-P31A@\@">,
M$??:',83QIA],$\8Z"F'E+455$O\L=Z+[[3/8[@3?+#DC;F^,M[IE\!#E\Y1
M1(3A.98CDO0A5`P24:+:S`FS;IH9AL7(U2@Z^.+,=<P@,@BJB\0?SB4Q`]V,
M!OVHP^_W.U*?;U5G5T/F>6A_,*@</=\-(^RDP]CM/?T9T"KT_8;)I`C,+.`U
M[U@`9F"#1"/U1]>9,9>G(0ZL)#:(#\[#Z]V[N+8\0$K"T]&W%E@V\.WH<*B3
M2?P\K^@`8\O@6M(]IY>9>MJ&SG72,(K8@G);`RZ]10<:V/6BG_=#9=&O!Z&V
MZ`"SB:9)G!XNVXG.?5$&TG:>_!9QN'.O>[&LH.I.0(DB:#7'_!Z74;YZBT0%
MQ,\R['>FG2M/M1P'M1A(^6W"*#5&+_`)8N!`G?6G?-S8H_+'G;7^>C\=%1EQ
MO@T$486BUTB8PQ#HKF,_=_B8I>&ZHS*[C!H3H>U37C,+LIGQ(H?M8:WRN<FI
MXPX`$,"+<:/W3X/!648?:0`R.&;G&72B+XY2P97!O.XUN+.I/=AW(93])NM@
M)</VY'J%8@T4+8<+8I;A.GTF=9.\(?GJ:["S6R\VIP+0HR65G/NBS*W4UMXU
M.B10B06^!\.4*(?AD(/L5@57ZD5T`]"'@&3#F0,DE[SZW)&*XE.?.U0N5_6Y
M(Q75K3Y[J+ZB6/6@6?_HGI-Y1^J74Q@D9HASZLLJ:G"XSDG]]3"U@33.29PH
M2/Q^QC\<$5</0Y))_=Z,Y?P63$%<SW'^-&=.SZ):QB:7:;DZ)U0HO(<0,R/<
M9ABVC<C,I=:0&JP`4<D,HTA80RQY!.8Y0&+8W%S+2S+1Q.2'`2=#&G">:C(,
MAYDX%G=/GZLYWJ_A"?8^(RMG[K3IYI4!R-(@.48Y.OAKP:_ZT>[+Z?3AJ_\G
M`````/__`P!02P,$%``&``@````A`*//[_G:`@``TP@``!@```!X;"]W;W)K
M<VAE971S+W-H965T,RYX;6R4EEMOFS`4Q]\G[3L@OY=;@(0HI"KINE7JI&G:
MY=D!$ZP"1K;3M-]^QW8N0"Y+\@`X_I\_/Q\?V\SNW^O*>B-<4-8DR+-=9)$F
M8SEM5@GZ_>OI;H(L(7&3XXHU)$$?1*#[^>=/LPWCKZ(D1%K@T(@$E5*V4\<1
M64EJ+&S6D@9Z"L9K+*')5XYH.<&Y#JHKQW?=R*DQ;9!QF/)K/%A1T(P\LFQ=
MDT8:$TXJ+(%?E+05.[<ZN\:NQOQUW=YEK&[!8DDK*C^T*;+J;/J\:AC'RPK&
M_>X%.-MYZ\:1?4TSS@0KI`UVC@$]'G/LQ`XXS6<YA1&HM%N<%`EZ\*:+&#GS
MF<[/'THVHO-LB9)MOG*:O]"&0+)AFM0$+!E[5=+G7/T%P<Y1]).>@!_<RDF!
MUY7\R3;?"%V5$F8[A`&I<4WSCT<B,D@HV-A^J)PR5@$`7*V:JLJ`A.!W?=_0
M7)8)&D5V.'9''LBM)1'RB2I+9&5K(5G]UXB\K94Q\;<F<-^:>/!X9?!H&PSW
M?;#M3T(OC/Z/X)CAZ.P\8HGG,\XV%E0<`(L6J_KUIN"LTC*"Y)Y."^1#Q3RH
M(!T*:@%3^3:/HIGS!NG/MI+T6.+W%8L3BO%>X@#>GA%RU&6\S*;$"8+K@>U@
MJ_%3(XDUN/?E;K1_J^Y>G.WN04&RKH=2X@'4I/_6U$@B#16Z^M=7+"XI>FC!
M+6A*/$"+^R].C<2@^9X?>_W^1;<_CEUWW]VC@F5R?<*4N$\U/MB:6322\U3=
M_O-4T2U42CR@&N0B-9*SM76VNY>J\2U02CR`&BRUU$A,JKS@='5=UO3PU)'8
MV3,NKT<E'N`-%EQJ)-O2]V-W$D:#);OH2D9^,(F#(#A=9O$M<$H\@#O8FC(S
MDHMP7<D9.',NF9VWQ2OR'?,5;815D0+V*=<>0[5R<RJ9AF2MWF&73,)IHA]+
M^'@@L/VZ-H@+QN2NH<Z]_>?(_!\```#__P,`4$L#!!0`!@`(````(0!\^M`F
M;@8``!8;```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE)G;;MLX$(;O
M%]AW,'1?FV=*09RB4M'=`EM@L=C#M6++L5#;,B2E:=]^AR)K<JC8D5H@B9//
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M(`"^+HZU:0W(2/E]^/Y2;_O].N%J*37A%/#%8]7UGVH3,EELGKN^.?YG(>I"
MV2#,!8'O+@AELX-P%P2^^R`LE52JMZ6L[+*&+'TL^_+AOFU>%M!Z(+P[EZ:1
MZ1U$?CTMD`_#?C#P\!98<0>U_/;`U/WJ&Z1_XY#\%003Q2N$OB`KD'71!NF:
MKLW`4)QDX;6EE["#_-PB(D`D)HI;!)(&GS-=FH'7"<3VTC+\P;E%TB&GE*=<
M9)ISS!2(R2@5\.^"('6PQ.GJ#(S5<7():Q-GD5N)LX0:]&M)B(^`A,&6F2[,
MP)$P&@FSB/M8^%05YRP$)&=<7LF8FB/,P)$P%@FSB!4F>:I%!!0AD%&EKB1,
MS]%EX$A7E(_<(E87,WTF2+1+BA#)""=,^:RC8AJ+G#PZ#!QI\Z6P7681JXTJ
M+AC+1#1>BI!A:2JXIGXK(779''4&CM1%HR&WB%7'E1:4^[0,^@M$2&JZ[=(5
M2!H%%PLS9SR)P^_>&+[F79'(*#WY$'F=.)4TRR2+.J#`"!,$E%Z1.<\;[%P/
MIQSW<]U6F%K&M9]BJ4A5O#$00S5A5%[39Z;UY`:D=K8C?5'KYXZQ^@2%_Y?,
MV!(C@!-"?0_@"L_R!SHV".Z[VJ7.,E8:S91B+-51^0L7R)5?<Y:IH$NQ0C.Q
MIR?/SG?0<+$PX2>64V@9^'IA?/^[]-U"L+Q93F$.=-'6$+XR3EYH!=!4*1T9
MK`OC<@R[1W'?G5C>++^@8\.(_2!WC/MLHE*EHMU3($3Q%,;?I3VQNEFN0<>V
M(?R.<\D+34%12C*?&%?:D,B(U-H7`(N;91MT[!O!H<>)"TU!TU2/VBX$Z'!T
MOY*X6:9!QZXAHH_.'6/+*@B("_S*92[T#4&@Z8)3#$H=BWSCME\,-/:+V$YS
MQUAY#"R-1KNZP`0@P1*QN%ENP<9N(:)^SQUCQ9DSY4A;:">9IE+Z$%C;+*=@
M8Z<0L5,XQFE+0=VEHVQ5(P!.6GY/86VSK(*-K4+$5N$8JRUEH"V+C0(C&ACF
M%X#EF9$]V2>8'?"A3T@?V&Y7Q]SRB9L(EC?+)\QU<N03TH\I)\\R-^6%5H(;
M$XN+7&+:.8^-W4)&TS9WC"LQ951%35`@@A*8V=>.>6R66PPTGBK!^<RE,/0"
MJB5+6;2`PH6Q"P`DU<2O`"=QEE^PL5\$EWQ.7F@'3"J195$3%"Z,E<=2E84K
MP/)F608;6X:,+<,QJ`%'^]?&N<(@@>;"(MS`TYIP>!>^G1(,5YM'QR`1T12\
MB6"9D7T8F1KVV6V/XV,;D?&H=HRP]ZOB2J._!NZ'Q47^,5'<V$>D;W*70\NX
M?2`DTY'\@B."B32(@47.,A(^-I+@'H039QDK#LZ;4J:<1.U:N$!N!1F75&CE
M^Q5+A%X)>_&-XAH:CYK@5H23:!G[Z>\885P03?TQ8*`*CBBXVT+-.<O7`HLT
MTSUPO(D;QGH"%.MR]1-?VN8\]`V:PD$/;F&,M(80TR*#*X%KZ8S\Y8UTCGTE
M.&BZ=%K&I5-*2;)1/R*$:K@0T7X-.).SG(5;UT`9]!<X3A]REE2F1.O4U]%5
M.X28U%R$#%88F<O$6H]-1D7;(H=G&J9YW1W=*]?K".*O7Z_;)QOVGOVY?*J^
ME.U3?>H6AVH'G4:69DBV]KF&?=$WY^$>_6/3P_.(X<<]/'^JX`8^60*\:YK^
MYPOSY.3R1.OA?P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,`
M``!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;
MK4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V
M2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MW
MAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+
M/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8
MO,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*
MUM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<
MG@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^
MUI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']
M?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]
MB.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/C
MA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>_
M_/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E
M)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG
M&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=
MD#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I
M!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.K
ML$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S
M7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([
M-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$
MRI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;
M:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$
M5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WP
MNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<
MR\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO
M^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[
MF8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"
MFZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQ
MO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5
M<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6
M*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0
M.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\I
MQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"
MW>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-
MJF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]
MX*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^X
MT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4
M%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04
M``8`"````"$`5-P;J-L"``"]"```&0```'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6R,EEV/HC`4AN\WV?]`>C]\"J@1)^.0V=UD-]EL]N.Z0I%F@)*VCC/_
M?D^I,A89]$9!G_/ZON<<P-7]:UU9+X0+RIH$>;:++-)D+*?-+D%_?C_=S9$E
M)&YR7+&&).B-"'2__OQI=6#\692$2`L4&I&@4LIVZ3@B*TF-A<U:TL`W!>,U
MEG#*=XYH.<%Y5U17CN^ZD5-CVB"ML.2W:+"BH!E)6;:O22.U""<5EN!?E+05
M)[4ZNT6NQOQYW]YEK&Y!8DLK*M\Z4635V?+;KF$<;RO(_>K-<';2[DXNY&N:
M<298(6V0<[31R\P+9^&`TGJ54TB@VFYQ4B3HP5NF,7+6JZX_?RDYB+-C2Y3L
M\(73_#MM"#0;QJ0&L&7L6:'?<O41%#L7U4_=`'YR*R<%WE?R%SM\)7172IAV
M"(%4KF7^EA*104-!QO9#I92Q"@S`JU53M1G0$/S:O1]H+LL$!9$=QF[@`6YM
MB9!/5$DB*]L+R>I_&O*.4EK$/XK`^U'$@\,;BX-C\>RLV/;GH1=&URTX.D[7
MG11+O%YQ=K!@X\"P:+':7V\)RJHMLP_;`OU0-0^JJ"L%6L`H7]:Q%Z^<%^A_
M=F0VEXQO$H\CQ$`DO41F\["7<2!#'P0:.0P2P):,S_<41!7!))%U%F3>ZW=A
M-YJ!WO3,NX..>+Q*I%.$D0*LG*>8=J_@!(%V[RQV%P/WFIEW0_+"1>C'@4D\
M7B52@XB#R/=Z"<,\].C<O-JEZR-016:(63!8@XUFC!%$O04]@Q'$)-(1XEW$
MR`'[?YYC>@@*'OH?KI!F)OV/(`/_(\0'_B/3_VUS4$7#',-ETLQDCA%DD$,3
MD=[(F>]%X?N-P1A#;,:8'H."3?NQYYJ_O-',U+5PE8!'E/J=H\;8M:"?0/H>
MV^(=^8'YCC;"JD@!UX-KQS!'KI\_^D2RMKN7;IF$YT9W6,+?!`(W6M<&N&!,
MGD[4$Z[_X['^#P``__\#`%!+`P04``8`"````"$`AI,J3!X$``#?#@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R45UUOHSH0?5_I_@?$>P,.WU&2
M54O5NROM2E=7]^.9@).@`D;8:=I_OV.&$&Q2EKR0D!P?CL^,9YCUU_>R,-YH
MPW-6;4RRL$V#5BG+\NJP,?_]Y^4A-`TNDBI+"E;1C?E!N?EU^\>7]9DUK_Q(
MJ3"`H>(;\RA$O;(LGAYIF?`%JVD%_^Q94R8";IN#Q>N&)EF[J"RLI6W[5IGD
ME8D,JV8.!]OO\Y0^L_14TDH@24.+1(!^?LQK?F$KTSET9=*\GNJ'E)4U4.SR
M(A<?+:EIE.GJ^Z%B3;(K8-_OQ$W2"W=[,Z(O\[1AG.W%`N@L%#K><V1%%C!M
MUUD..Y"V&PW=;\Q'LHI):%K;=6O0?SD]\\%W@Q_9^<\FSW[D%06W(4XR`CO&
M7B7T>R9_@L76:/5+&X&_&B.C^^14B+_9^1O-#T<!X?9@1W)CJ^SCF?(4'`6:
MQ=*33"DK0`!<C3*7J0&.)._MYSG/Q'%C.O[""VR'`-S842Y><DEI&NF)"U;^
MCR#242')LB.!SXZ$>`MWZ07A/2Q.QP*?%Q9_-HN%^VIM>DY$LETW[&Q`[H%R
M7B<RD\D*F*4_#KB,N^D=^\PP<$J2/$J6C1F8!BSG$.6W;4#\M?4&D4D[S!-B
MX-ICB(J(QPAOP&*!XEXV6#F4?3N<%W42+-7)\$JY3_C#4,I2DW(#$?0010F8
M-E0B#?3!P&E%<A$8/?`BL,.>'T4BQAU@/!413R$4C4`RU#BM38(W)AC0Q\E=
MZK%$3-A&VO-#VW-=31LBX-JS7-4KVN`8S=<FP9JVT%&?_(28VT]NG8VG$(HV
M7]4V+[9RT>]BBY@IC5,(12,<NOG^2;#J7V!'FG^(\=O8NG9$@NB:^>C?$.$O
M?1)]$EK91`>U93KM)%B5!A52DX88Q38M,V.$H/HE\9R07/>G^!;=(TZ"=7':
MDY\0@T^^?284A.W[7G2M@(HV`@5DOG,M6E-GZ]9U()3W`*TGBD*]Z*D8)_#<
M<%"55(6R5L^.+<'*/JPI`;&UX'8@5.B`.L>[A@X33X'HN:GJDP5\OCXL]T-]
M;GB-#=9C@B`E^]0MQ),059^LW0-]\TH+P8H/U[ZJCOM&!YK4.;MS$*`9ZIP^
MPRU:S<1Q?>E`&&?7\T=!EH^$)MH6(&)#&O8NJQ;>U3GD2]_H"%^9NQ#?Z`S:
M,8\[(L7>*T95J/6/WYB')5])PE'C)0CJ#@G49BU+8P7PX(7V9]KNZAMDW#C<
M<8E!T"?.="=X$J.Z=U?[@"%"C^^-$H,@?&]Q?,?7:I`<120+`I3<1&DX9^`+
M=$F;`XUI47`C92<Y0Q!(V?[7?KYY7+832O\'C!=U<J`_D^:05]PHZ!Z6VHL`
M<J_!`05O!*O;U_,=$S!8M%^/,$A2>(&U%P#>,R8N-W($ZD?3[2\```#__P,`
M4$L#!!0`!@`(````(0#!:T.4H@0``'`4```9````>&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;)18T8ZB2!1]WV3_@?#>0(&"&G72VM.[D\PFF\W.[#-BJ:2!
M,A3==O_]WN("5A5,-?B@HJ>.I^Z]A]-=ZR_O>6:]T9*GK-C8Q/%LBQ8).Z;%
M>6/_^/?Y86%;O(J+8YRQ@F[L#\KM+]O??UO?6/G"+Y16%C`4?&-?JNJZ<EV>
M7&@><X==:0'?G%B9QQ5<EF>77TL:'^M%>>;ZGA>Z>9P6-C*LRC$<['1*$_K$
MDM><%A62E#2+*]#/+^F5MVQY,H8NC\N7U^M#PO(K4!S2+*T^:E+;RI/5MW/!
MROB0P;[?R2Q.6N[ZHD>?ITG).#M5#M"Y*+2_YZ6[=(%INSZFL`-1=JNDIXW]
M2%9[/[3=[;HNT,^4WKCTWN(7=ONC3(_?TX)"M:%/H@,'QEX$]-M1?`2+W=[J
MY[H#?Y?6D9[BUZSZA]W^I.GY4D&[Y[`CL;'5\>.)\@0J"C2./Q=,"<M``#Q;
M>2I&`RH2O]>OM_18739V$#KSR`L(P*T#Y=5S*BAM*WGE%<O_0Q!IJ)#$;TC@
MM2'Q?6?FSZ/%%):@88'7EB48S>+BONHR/<55O%V7[&;![(%R?HW%)),5,(OZ
M!%!EW$U7L5\5#"HE2!X%R\:.;`N6<^CRVS8B9.V^06>2!K-###QW&`VQ[R/F
M).Q87%#<R892RK*'V]FJ$V"A3K17R-WA![(4O_N9&K$?0$0=1%$"11NO1(`W
M-I!W-9CUZH28F829=[^,XDP(11N0R-I$<T-HKKE:8A$,@?3[D;=0%>P08])H
M0B@:P4:R1K,V`=;K%VC:$$/\93V'Q"&>\B!?'[05>W5%X`0R1!$;3A$KP+K8
MF286,7(A0T_#[/N8B-SG5=$'#AQ?3`%6]07S^Y"C4Q`CZYO?'8G3:(0HZD2H
M2O<:<ZL%6%,7:C>,'6+:5GM.N%3+NS<`%&7+*<H$6%4V([I!$*/439-F0BC:
M"#A6+MLX%]>K/K-Q`S+)-$)4G>+V/;J]!&_VZJU0,^:N`;4-7C@+Q<K>7#8J
M3J.VA#C!8JD\OC[\PCM$W//'Z\>$4/5KSMW5E!M;KF](/&T0!D`1N5="K;&X
M]8_7B$$A:^P[G`RDB6YQ,T95")N=H%"@52\%/9<3!+53,&!S$T)5-REMQ!^*
MFKJ9K]^#&I#<8SVOC1!5GQ8P([V."6&.;-*/D9Y.$T35.2EH2#]I9M*$8](T
MH+;+H[R.O.V2*5Z?%$6DGT4STO,Z@N0YB'30OF%20?<VJ#6>%$JDGTH#7A\(
MG9[7C1A%H:\EDSG0:_1G7F]`;4L'O&Y"J.HFY9$_D$<+W>L-2&[?O7F8/T:(
MJD_+FW%>]S%WS%YO0$:=R#,,476*@!B=.3[&B9PY?:\WH+;+8[RN+9G@=1_V
M.$&_0*M3VO=Z3?E9K@^`(G(?%[7&DW))'#UH&OM>;T!*@W6OFS&J0BV9/O$Z
M)HD\!?U<AW,?L8UV"H:\;D"@.CSXP1.-G)9GNJ=9QJV$O8I#'0+_`G:?=@=.
MCWY]9-1]`><]U_A,_XK+<UIP*Z,G6.HY$52YQ!,CO*C8M3XO.;`*3GKJMQ<X
MV:-PHN`Y`#XQ5K47XDRJ.RO<_@\``/__`P!02P,$%``&``@````A``JOJB7[
M`@``/0D``!D```!X;"]W;W)K<VAE971S+W-H965T-#8N>&ULE)9=CZ(P%(;O
M-]G_T/1^^%)$C3@9G<SN)+O)9K,?U[44:`8H:>LX\^_WE"H"SA)-C`B^?7WZ
MG@/'U?U;6:!7)A4758Q]Q\.(550DO,IB_/O7T]T<(Z5)E9!"5"S&[TSA^_7G
M3ZN#D"\J9TPC<*A4C'.MZZ7K*IJSDBA'U*R";U(A2Z+A5&:NJB4C2;.H+-S`
M\V9N27B%K<-27N,ATI13]BCHOF25MB:2%40#O\IYK4YN);W&KB3R95_?45'6
M8+'C!=?OC2E&)5T^9Y609%?`OM_\*:$G[^;DPK[D5`HE4NV`G6M!+_>\<!<N
M.*U7"8<=F-B19&F,'_SE=H'=]:K)YP]G!]7YC%0N#E\D3[[QBD'84"93@)T0
M+T;ZG)A+L-B]6/W4%."'1`E+R;[0/\7A*^-9KJ':(6S([&N9O#\R12%0L'&"
MT#A140``O*.2F\Z`0,A;<SSP1.<QGLR<,/(F/LC1CBG]Q(TE1G2OM"C_6I%_
MM+(FP=$$CD<3/W2F01C-;W&9'%W@>'*97>WBVGTU,3T23=8K*0X(6@_(54U,
M(_M+<#;Y3"!ENYLVL?\%!DD9DP?C$N,((UBNH,BOZ\B;K=Q7J`P]:C96`^^M
MQN\KMI>*T#^[N$#<8D.47>R/RWFB,V)#9\IK<#?V0A<E&*!\H(A:28\$0KN>
MQ(AC#.9M!I%W]K5P5C/M:,+VEQO%=DS18P.3+ILI[@R*.YZ6601-T/G]R)OW
M"396,\8XIN@QPFW491QG,^)A?HL!F]7TV,Y-9`.TDGG3J$'HP:OUZ+'-;F$S
MXC[;U!NTU<9J1ME&)3TZN-VN3\Z(AW3#SK.:43HKF37)W8U%9^9GY[DR7E8C
M'L(-FGYC-:-PHY)>=(M;Z(RX3Q?YYX:Q-ZW5C-*-2BR='6/V^5PRF;$M*PJ%
MJ-B;$>5#ZNW5=GH^!,T`;+^`Z563C'TG,N.50@5+8:GG1-#STLX_>Z)%W3S]
M=T+#W&H^YO`WA<'ST7-`G`JA3R=FPK9_?-;_````__\#`%!+`P04``8`"```
M`"$`(1^0Q74&``![(@``&0```'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RD
MFEN/HS84@-\K]3\@WC=@[D23J98[4BM552_/#"$3M"%$P.SL_OL>8P+8F?5)
MVGU()MZ/`_Y\,#YQGG[YUIR4KU77U^UYIY*-KBK5N6SW]?EUI_[U9_+)4Y5^
M*,[[XM2>JYWZO>K57YY__NGIO>V^],>J&A2(<.YWZG$8+EM-Z\MCU13]IKU4
M9_B?0]LUQ0`?NU>MOW15L1\/:DZ:H>N.UA3U6641MMT],=K#H2ZKJ"W?FNH\
ML"!==2H&N/[^6%_Z:[2FO"=<4W1?WBZ?RK:Y0(B7^E0/W\>@JM*4V_SUW';%
MRPGZ_8U817F-/7ZX"=_49=?V[6'80#B-7>AMGWW-UR#2\].^AAY0[4I7'7;J
M9[+-#:)JST^CH+_KZKU?_:WTQ_8][>K]K_6Y`MLP3G0$7MKV"T7S/6V"@[6;
MHY-Q!'[OE'UU*-Y.PQ_M>U;5K\<!AMN&'M&.;???HZHOP2B$V1@VC52V)[@`
M>%6:FJ8&&"F^C>_O]7XX[E33V=BN;A+`E9>J'Y*:AE25\JT?VN8?!HT]FH,8
M4Q!XGX(0>V,9MNL]$L6<HEA+%&-C>#:QG0>N!:YZ[)"[1#$W+M%]T[V_0W!W
MC$'@_7]TR)^BP/LUBG]WAS0V4..X1\50/#]U[;L"-Q,,17\IZ*U)MA#YXX&&
M$:;L9PKO5'`!8]A#=GY]=CSW2?L*&55.3,`8>)T9PA/AE:#I0\-&8D/,&MPQ
MP2B1B`VIV)!=8RRGA9'F3YS?,LNE:>!CE@*9=[\4"E,IU^X$UX;E4@S^0L(/
M"$%C=(M8GM"?F#'0JUFU<*($)5*4R&X)Q_/X#N6WS'(EG%FX*^\W2V'.K-@0
MB@V1V!"SAK4CBRRC/N9?\A$C]##]@#&$.-DMXWB^8.J6L1U]9CA7,'.M7=&Y
MV(0977Z+TH.`6^6$XR_QQ_X&C('7.6^$S`I1(D*)&"42E$A1(D.)7$9POF%"
M7_N6>Z;P3H6\GQV:YCR,3#-#O'&>-$S/M"Q=R*IPC?BZJ1N.D%,1(Z`/\WF$
ML8I1(D&)%"4RE,AE!.?9><0SA07/PE09,,1AGAW#LSQGF7W&H0C7"'%U@]C"
M8$6,D'E&B00E4I3(4"*7$9QG>$[?G\\4YCT[OI"+`6.8:%LGQ#=<86H)UPC1
M7=.PB,7?%A%#9*91(D&)%"4RE,AE!&>:EC]W+Z(H+)H6\C5@##-M^:YI.\3A
M-89KA.B.[QFN,%X10V2F42)!B10E,I3(901G&I:H:]/W/1/I0:)QX?X/&"-Q
M%:)$A!(Q2B0HD:)$QHAI0K1U^H]/GEP6@_--8,'QN/#Q*-&X,`\$$R13CB,1
MCL0XDN!(BB/9A$Q/?$&Y]'C>.:U35M/)?4E.6'6S7I$XOK!6""9(ZIS%D2`1
M'B6>$):#IN$[EK`03CC"A\K>$F[)E",\T[1-(8TS_$)R*<)KIT7,2KM\_4=8
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MF.X)DCU*<23"D1A'$AQ)<23#D7Q"V++1<>EW!7/AP`O_3S6I<5N3NKI8DTX0
MJYJ)[=N&*]P*(8Y$/.*:CK@[$T^$9(`3'$EQ),,1NH?_XW4;$\_VZ-E>;5-U
MKU58G4Z]4K9O=/_=AF^[Y];YMP&?3;H+*;3'9`O;I;?M@;$-/N)#8PO[:K=\
M9&QA>PW:M?D$L/5_*5ZKWXKNM3[WRJDZP*7I&[HUWK$?#[`/0WL9=YI?V@$V
M_<<_C_`CCPJV=O4-P(>V':X?Z`GFGXT\_PL``/__`P!02P,$%``&``@````A
M`%Q'S3^/`P``7`P``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R4E]N.
MFS`0AN\K]1V0[QLP.4<AU8;5MI5:J>KQV@$GL18PM9W-[MMWC`G!)JS8FW#Z
M^.?WV&,FZX_/>>8]42$9+R*$1P'R:)'PE!6'"/W^]?!A@3RI2)&2C!<T0B]4
MHH^;]^_69RX>Y9%2Y8%"(2-T5*I<^;Y,CC0G<L1+6L"3/1<Y47`I#KXL!25I
M]5*>^6$0S/R<L`(9A948HL'W>Y;0>YZ<<EHH(R)H1A3XET=6RHM:G@R1RXEX
M/)4?$IZ7(+%C&5,OE2CR\F3UY5!P0789C/L93TART:XN.O(Y2P27?*]&(.<;
MH]TQ+_VE#TJ;=<I@!#KMGJ#["-WA58PGR-^LJP3]8?0L6^>>//+S)\'2KZR@
MD&V8)T5V/VE&$T53F#GDZ1G9<?ZH7_T"MP(((BM`!Y'_+F'N0AW%;\*TSR\A
M'ZII^RZ\E.[)*5,_^/DS98>C@DA32(/.QBI]N:<R@6F`6*-PJE43GH$$_'HY
MT^L)TDB>C3N6JF.$QK/1=!Z,,>#>CDKUP+0D\I*35#S_:R!<2QF1L!:!X]D\
M#Q>C23B=+]ZB,JY5X%BKX'"PBF_&5:7LGBBR60M^]F#!@G-9$KW\\0J4;^<%
M$J+9.PU':`XS%R$)D_.T"=;^$Z0_J8FM(>"W(;!-Q!="SR!X:(Q`<H8;T;`V
MHB=,.]N:&^VXH1.W2XP;PC("66@;T2MF#(OU]<SHEX!KC7O2J!N'AIBTB*E-
MQ*\1ED,0:3M\W9F&(P2C;V9D9L?=&J+M;&X3<9>X>K><04T,=Z9AV]G"CKLU
M1-O9TB;B+M'C;/869QJVG6%WH1MD6A7!!"]"YWELGK>M]QB#:AJ>,@T[QISZ
MVAJD'1B[I=!%>KSI3^?@S4'#CK=KA9D:,(CES2F3N(OT>%N^Q9N&'6]76>/-
M()8WIU#B+G(5L<H`PWXQ/'$5[;AS*G!;,Y8]IUKB&TR?/[T)#YY8;+;L]A:"
MG3K<UDS;7Z<D;C!]_O1F/=R?V=K;_D*W*K!A+']N6=Q@^OSIK7JX/[.Q6_[<
MRL#=S3]T2^,&T^</QMGV-^P;!LV;6R7A-8"IDIIIY]%!=`^H96;5UC@-E\%B
M.KLN9U,GIG<SC4A.Q8'&-,NDE_"3[L4PO-K<;9K+NNMK'D";5I(#_4;$@172
MR^@>7@U&<_@D"-/HF0O%RZK-V7$%#5IU>H0NGD+;$(P`WG.N+A>Z*6G^%VS^
M`P``__\#`%!+`P04``8`"````"$`[7JE6P\#``#]"```&0```'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6R4EEUOFS`4AN\G[3\@WQ<PGR%*4C6INDW:I&G:
MQ[4#)E@%C&RG:?_]CG%*,.FZ1(H").]Y><YK8[.X?6YJYXD*R7B[1-CUD4/;
MG!>LW2W1KY\/-S/D2$7:@M2\I4OT0B6Z77W\L#AP\2@K2I4##JU<HDJI;NYY
M,J]H0Z3+.]K"/R47#5%P*7:>[`0E15_4U%[@^XG7$-8BXS`7EWCPLF0YO>?Y
MOJ&M,B:"UD0!OZQ8)U_=FOP2NX:(QWUWD_.F`XLMJYEZZ4V1T^3S+[N6"[*M
MH>]G')'\U;N_.+-O6"ZXY*5RP<XSH.<]9U[F@=-J43#H0,?N"%HNT1V>;S+D
MK19]/K\9/<C1N2,K?O@D6/&5M13"AF'2`[#E_%%+OQ3Z)RCVSJH?^@'X+IR"
MEF1?JQ_\\)FR7:5@M&-H2/<U+U[NJ<PA4+!Q@U@[Y;P&`/AV&J9G!@1"GOOC
M@16J6J(P<>/4#S'(G2V5ZH%I2^3D>ZEX\\>(\-'*F`1'$S@>33"<7E@<'HOA
M.!2[P2S&<?)_!,^TTZ=S3Q19+00_.##C`%AV1,]?/`=G'4L(X;X="^2A:^YT
M45\*:@E#^;2*<;#PGB#__*A9GVLFBLT;BG0P\8!O@(20KH?41=`,<D:0>/#O
M&UD;3336V(K->PJ+$6YT/:,N6B*XQ\`8A)E-L#::61]S&$8XF>9H"8(P3)/!
MP2*$-L>$[P^Q%D_((G_P->D93=*314$T2_S3G7O%9JP(HSCP<3AX6&SP#%W.
MIL53MNG(&HUA2[(D.-W7D/W[?XLKN89+BZ=<D\%:&XWA"K(X#O!ISALR2Y%&
M6>2?9H3%EE[#IL53MDDF:Z,Q;&GBPV<VC)9A&RN2.(NBX)2[Q:9WS:N7%5UD
M,\:C^=(3K(W&,-Z$&3P0Z31`6^+/,)Z=YJ5%F=F4[S\16FS3A;$=S]I(CH]J
MDD8X/,5C`K04T%TP\C!H9@<S:W1'=O0;$3O62J>F)2P2OIO"S!5F_S(7BG?]
M6KSE"O:=_K2"UPP*"[7O@KCD7+U>Z!UR>'%9_04``/__`P!02P,$%``&``@`
M```A`'+=1@H-!```H`X``!D```!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MG)==;ZLX$(;O5]K_@+A/L,UWE.3H0-7=(^U*J]5^7!-P$E3`$7:;]M_O&%."
M34KI]B)`>6=X/./QV-MOKW5EO="6EZS9V7B-;(LV.2O*YK2S__[K<179%A=9
M4V05:^C.?J/<_K;_^:?ME;5/_$RIL,!#PW?V68C+QG%X?J9UQM?L0AMX<V1M
MG0EX;$\.O[0T*SJCNG((0H%39V5C*P^;=HD/=CR6.7U@^7--&Z&<M+3*!/#S
M<WGA[][J?(F[.FN?GB^KG-47<'$HJU*\=4YMJ\XW/TX-:[-#!>-^Q5Z6O_ON
M'B;NZS)O&6='L09WC@*=CCEV8@<\[;=%"2.08;=:>MS9W_$FQ9'M[+==@/XI
MZ96/[BU^9M=?VK+XK6PH1!OR)#-P8.Q)2G\4\E]@[$RL'[L,_-%:!3UFSY7X
MDUU_I>7I+"#=/HQ(#FQ3O#U0GD-$P<V:^-)3SBH`@%^K+N74@(ADK]WU6A;B
MO+/=8.V'R,4@MPZ4B\=2NK2M_)D+5O^K1+AWI9R0W@E<>R<8;A<:N[TQ7`?C
M-8E\[`>?(SAJ.%UT'C*1[;<MNUHPY0"87S(Y@?$&/,NPN!#<^V&!>$B;[]*H
M,P4UAUR^['WD;YT7B'_>:Y*IANB*](XB'"0.\`V0$*0QY#R<%,,@;&N`\Z)@
M\-L-(%$:;Z0Q\-,YA<8&'UK.)L4[&WP/;(0@@TUI(A76T(OUU^GX=>BCF[5&
M!4-;3B7%)A76/YLH3=!1K=PH]I"K*U)-X>'`NPDT-"B7Y6A2;*(9\RA1&H7F
MQ:'K!]C(=SJ68!3$$0EO`]3H`IUN63U((YW21P9"HC2*DKB1ZWDH,B(XEL3(
M123X`#+\/Y#2R(2\U9NJ"Z7I(0,20>48T4['$APB@OT/\BP[YVAEF2]:*=;A
M,#+AE$;!^0CCF(2WV=_QIV,).'")A[TAR%J>8YUN69ZED4[IFTE,E`:*82AQ
M<VF94VB,&!;BY2'LU)\M?+UH#F]6HO,9S6,^Q5BM]_.+7R]22<:1;R98>__Q
M\B?;ZA<BIQ9[G>Q6>JHT.I<[6Y&MB!OBR)"DNL2-R4BA!^Y+30/?ZQI&62:]
MJ"]=UX]C%!H%E&J:*(ZAO&_QU0'E8CXJWF7E@54+&,?11T;_2GK1[`Q4?NY+
M=,XO-1.YWX/ZA7`.M3G=&O2B^Q]7J\RL1.<SVLDG%3+M(]/M`1YW"6C$1GS3
M_OU]?AW.:".?P$W[!R%&!21XW!U6V"?P-ZR_??`T"7%'#4:G^U+_@*.#N31/
M/IWT(K6U@N;J!E`F)IYRI#0XB.,PO@U2`:HSAMI%7[(3_3UK3V7#K8H>85ZA
M=0C3K%4G#/4@V*7;+1^8@)-!=WN&DR"%K31:@_C(F'A_D&>8X6RY_P\``/__
M`P!02P,$%``&``@````A`*5D/DT6!@``K!8``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3$N>&ULK%C;CJ,X$'U?:?\!\3[A9DB"DHPZX2K-2JO5[.XS34B"
M.L01T)?Y^RW?`-OI3%8::31T#J>.J\IE4_;JZT=S-MZJMJOQ96TZ,]LTJDN)
M]_7EN#;__IY\69A&UQ>7?7'&EVIM_J@Z\^OF]]]6[[A]Z4Y5U1N@<.G6YJGO
MKZ%E=>6I:HINAJ_5!=X<<-L4/?QLCU9W;:MB3XV:L^7:=F`U17TQF4+8/J*!
M#X>ZK")<OC;5I6<B;74N>O"_.]773J@UY2-R3=&^O%Z_E+BY@L1S?:[['U34
M-)HRS(\7W!;/9XC[PT%%*;3I#TV^J<L6=_C0ST#.8H[J,2^MI05*F]6^A@A(
MVHVV.JS-)R?,G<"T-BN:H'_JZKV;_&UT)_R>MO7^6WVI(-LP3V0&GC%^(=1\
M3R`PMC3KA,[`GZVQKP[%Z[G_"[]G57T\]3#=/D1$`@OW/Z*J*R&C(#-S?:)4
MXC,X`/\;34U*`S)2?-#G>[WO3_"7:QK/5=<G-9$RC?*UZW'S+W_))9@Q,*DQ
M/+FQ%\S\N>TY,-:C(AX7@2<7"6;NPG?\@(C<&1UQ0WAR0S>8+7P?!8OY?4MX
M2_V&)[>\SP\X'YYBI.7,0?;//)QS.WC^O]!@=5('X2D&?#"T);>$Y[W0+%8&
MM*JBHB\VJQ:_&[!48<*[:T$6OA."AB@G-@U#@7U67U!81.2)J*Q-"!M*J(-%
M\;9Q/7]EO4$AEYRSU3F.S-@)!JE:(ANI0*P"B0JD*I"I0#X!+$C"D`DHZE^0
M":)",B%BV`I@DAHE;,$0)I$*Q"J0J$"J`ID*Y!-`"AN6X2\(FZA`"<&RNE,!
MC.3!^AU(2I'L!LJ0#`V)-231D%1#,@W)IXB4$G!PFI+;6ZLH?4*FD0N/MPSQ
MY%P$RJ0/)&$6:4BL(8F&I!J2:4@^1:1`P<5IH&3Q>PORW>#;\,/KGPC)26"(
M!SOH,->N-U>2,)"&)&A(K"&)AJ0:DFE(/D6D)("+TR3<GVU"E@-E"`0J8MAI
M2*0AL88D&I)J2*8A^121HH*]^/&H"%F.BB/N&!5#/-A&)A.ZD"<T&D@B&;&&
M)!J2:DBF(3E'%L0A*5#2V$X^8/>GCY#E0!GB+<=`&>+[]#.&G(5K*T$.A"%(
M+D*=HU^NA"&(]G(420<K\G5$CH^4Q9`-!"&;3V6EF.%#_7C,A"S'S!`7]K_)
M5"[E*'>,A*3Y=I%,BCC)H[GR/.0$KLR(!QD153*,+I!TX$S\48?*Y*%<SYLK
M6VH^R("PE"X'NNS'\T79<L($)"4#*76Q$RPTU%+$(818,;EH$=B*V[%NE@@S
MUL"35BC569E@,7$/^:[M>'+Z<\E,3@KI@QY>.`[KFN`#+V9MRR&YC)#6TS%#
MJ"-A&'%#Q*HF6`:NXG4L&*-1(J!QGTT%-+(R`7TJG0L&-9(30CJDQQ-"V$J5
M<$BN$F5![,AQ"PS1V")&`EJPSGGI^ZZC[`XQYSAC<27";)R35$"C>"8@+CY'
M2V0K:SV7Q.6DD";I\:2PEDJJ$@8I5:),^,YA+#1NPQ&'?)LF91[8\$_YW,3"
M;*R`1$#3.M'$,UD\\)<(N4KEYD+I1J60AFJ2%-(WP5&4]$WW/S\P>UK1<$@N
M&F6?W7%#J6B8H0_K:]S%D=)/QV)$((\L5]F"$B$_K20F/QDQXRQE1$4K_]F(
M<GF1KDS)I.//R'&^/]7ERQ:#UQ#AC;22)<X/GZRUDZJ.0?XTJ^J!=$=.*[`2
M?2B/26Z4U$>"Q7?98(X<3RF5F',FFUS"(:A[L>^E0NGN>)E@\?%\Q]..TKDT
MGIQ0TA#>2>AW?/TLH5"^0T996PG#".>W<*=%DS6NJYT.13H4ZU"B0ZD.93I$
M+M9&)UC<[**,76DT57NL=M7YW!DE?B678+"Q;58#S&[HMD$(;3,$IN(.O(`1
M]#>[>0@=Z0U\$4:TYU.4TD4(W9S.A[O!)[J;*/PMN3.\P=^Z(1S;;^AXX=--
M1[=>"*=:W6"+0C@$WL#]$,Y%@%N#1W!7>"V.U1]%>ZPOG7&N#I!&FZ[(EMTV
MLA\]+Z1GW,-M(:VI$]P*5]"KV#-86`>,>_&####<,V_^`P``__\#`%!+`P04
M``8`"````"$`UW;P_;X"``"$!P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6R4E=MNVS`,AN\'[!T$W==RG#@'(TF1KNA68`.&88=K199MH99E2$K3
MOOU(V_'B)FVS&Q]HZO](BJ*7UT^Z)(_2.F6J%1T%(26R$B955;ZBOW[>7<TI
M<9Y7*2]-)5?T63IZO?[X8;DW]L$54GH""I5;T<+[.F',B4)J[@)3RPJ^9,9J
M[N'5YLS55O*T6:1+%H7AE&FN*MHJ)/82#9-E2LA;(W9:5KX5L;+D'N)WA:K=
M04V+2^0TMP^[^DH878/$5I7*/S>BE&B1W.>5L7Q;0MY/HPD7!^WFY41>*V&-
M,YD/0(ZU@9[FO&`+!DKK9:H@`RP[L3);T<THN5E0MEXV]?FMY-X=/1-7F/UG
MJ]*OJI)0;-@FW("M,0_H>I^B"1:SD]5WS09\MR25&=^5_H?9?Y$J+SSL=@P)
M85Y)^GPKG8""@DP0Q:@D3`D!P)5HA9T!!>%/S7VO4E_`TRB8Q_%D.I^!S%8Z
M?Z=0DQ*Q<][H/YU7I]6J1)T*W#N5\32(9^%X!-!W1%@;49/@+?=\O;1F3Z!I
M`.EJCBTX2D#X?$:0"OINT'E%9Y1`K`YVX7$=369+]@BE$YW/3>L#U]YGU'LP
M@/9DH%U.1F<D8VTQE)O6<(R)SF/&_X-!9Z@$E+./_C3#UFERY!.?1X/+Y1FB
M<X/N4^PLT*U'P<S/HR#BRU'H/$2UEGBXLXOSJ.D0A6<A&C>-_T[WX,(AMK/`
M7O[+,`[/8R&VXPP;[`2VXNV.Q55#9F<9,E]I41S?1X>C84[G`53K;2JN&U([
MRY#Z2L<N3JF3<!%`L=ZFXKHAM;,,J>,7]6VG7CL4M+2Y_"3+TA%A=CC1(CCF
MO;4?MIL(3^)+^SC9-$.8]1]@"-8\E]^XS57E2"DSD`P#''JV':/MBS<U1`Y#
MS'B8?LUC`7\["2<]Q')GQOC#"X!9__]<_P4``/__`P!02P,$%``&``@````A
M`">=FLD="```8B0``!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULK)IM
M;^(X$,??GW3?`?%^@200(&I[*I#G1#J=]NY>IY"6J$!0DFYWO_V-8SM^F"Q-
M3_NFT%_&,_;?,XGM</?']_-I]"VOZJ*\W(^-R6P\RB_[\E!<7N['?W_UOJS&
MH[K)+H?L5%[R^_&/O![_\?#[;W?O9?5:'_.\&8&'2WT_/C;-U9E.Z_TQ/V?U
MI+SF%[CR7%;GK(%_JY=I?:WR[-`V.I^FYFQF3\]9<1E3#TXUQ$?Y_%SL\UVY
M?SOGEX8ZJ?)3UD#_ZV-QK;FW\WZ(NW-6O;Y=O^S+\Q5</!6GHOG1.AV/SGLG
M?+F45?9T@G%_-^;9GOMN_T'NS\6^*NORN9F`NRGM*![S>KJ>@J>'NT,!(R"R
MCZK\^7[\:#BI.1M/'^Y:@?XI\O=:^CZJC^6[7Q6'I+CDH#;,$YF!I[)\):;A
M@2!H/$6MO78&_JQ&A_PY>SLU?Y7O05Z\'!N8[@6,B`S,.?S8Y?4>%`4W$W-!
M/.W+$W0`_H[.!4D-4"3[WGZ^%X?F"-_LB;E:&`L;[$=/>=UX!?$Y'NW?ZJ8\
M_\NLF"_JQ61>X)-YL>S)8CFS#.+D1D.+-81/UG`I1;_1<,X:PB>/:$Z,^:SM
M]8UVT)UVO/#)VPWKJ<T:+KN&`WL*E=9&A$\><3Y(FS5K")^LH3UDA`;D$)U2
MDDQTM@;.AM%E`WQA30>.TN`I0+[PJ,/&:?`D(%\&C'1*4[BMB%W69`]W5?D^
M@ML,=+J^9N2F93C$%Z\%F@Y==?RL.*`JB)='XN9^#/,,:5]#17][,!?SN^DW
MJ,(]L]E@&T.UV'(+4G+$[4X'K@X\'?@Z"'00ZB#20:R#1`>I!*:@9"<G3.2O
MD).X(7)R(38<2/IJVG$+WF2G`U<'G@Y\'00Z"'40Z2#60:*#5`**=I!]OT([
MX@:R&6Y6-W*1&EEP)^R,%IJ@G4FG*"(N(AXB/B(!(B$B$2(Q(@DBJ4P4;6&@
MBK;]CSI>S<2ZE9`/?4.)I8JJ*]89\68[1%Q$/$1\1`)$0D0B1&)$$D12F2B*
MP5`_H1BQ5A6CQ()'8)=AYL+6<JPSZA1#Q$7$0\1')$`D1"1")$8D0225B:(8
M#%51C#Q*K!590K'5S."G"?&DJDF)IN924[,SZM1$Q$7$0\1')$`D1"1")$8D
M0225B:(F/$M_D9K$DZHF)9J:*TW-SJA3$Q$7$0\1'Y$`D1"1")$8D0215":*
MFF3KIB]SS,7D\ZE)'*EB4J*)N=;$[(PZ,1%Q$?$0\1$)$`D1B1")$4D0266B
MB`F+:T7,VP\38JTJ1HFJF#W3%.N,.L40<1'Q$/$1"1`)$8D0B1%)$$EEHBA&
M]A>*9'29/5E"`MY6KVVIRL>0)9:'6XQV&+D8>1CY&`48A1A%&,48)1BE"E)U
M(^MLN6X_$(LNRV'MQY-F0[9GD'[VND-;AI8P)^+1;&M[D9VPXKY<CLS.ER?<
MR[ZTG8_/&]Z,&`@K'C'D2$2,1$1N%7,KV;TQTYZ.B;#B#5..6O>J\&21_@GA
MZ9I>$9XB17BV\I?[:=JF6O@[LAF&&8/IX?UT.1(R>`Q)[GUNI;K7%JF!L.+N
M0XZ$^PB[C[F5ZEY+FT18<?<I1STJD_6ZK+)T6VB.Q?YU4T*&0@;WI+T%NVRV
M]Z:K?D5\BB1UMF1S3V0%;U+66[KXG17OOLL;"G4\AB3W/K>ZZ3X05MQ]R)%P
M'V'W,;>RNJ1(,$HYZE&:K/-EI7L4A85J)RG=%BB2,@1/14D_?4%O,"MX$@@K
M4[L?[)@5G'&2DQ++,):6J96!RVSF0A>/(5M4AC\H7J#&,VQ[:<ZUVT.(XT4X
M7CPH7J+&FR]7\X6MK8A2)9YZ[R$[C$_,%3'7GI`4V6HR:B/>PNRV#87".X9L
MN`6)Z;.UE;'+&\Z[9/0X$KY\C()^]YHR(6\(J20Z86J9%G$K$3'&*!D4,>4-
M?Q91G1ZR9?G$]-`=#H3@);\Q*%HH*B_U!2"SLD7)[SA2^HFGA[I7*H<B4_CR
MN2^!`HX4]TOM#A\R*W!_<WI0Q)B[%Q$3CFY&3#^*J$X/V0-]8GKHEDF9'HIL
M*`^1?TOM_K0U6$-5!G2G8[[L6W<ZYDDNI\XY3QI_4+R`6=DTGF%:QAK-'PH7
M"=\\7"R0)()^(T_4<)8YGRT,[9&:<D_M\-2I(CNL3TP5W9`I4T711Y5$K91*
M8DA)/%Q)U$JI)(J42D+N`Z//_5)3)F16'U42BAAS]W(E#8F8?A11G1ZRG9.G
MY_^MSNBF4)DUBM3'TU(KG:W!K"!=11GJ&;CC5JM;!<:Z(!<80_)28DB\0(VW
M,LT9JB\4+6*-8)\GZFM(M$2-!L6\7IA:%J7<.:XO6%_=GL"OY?5GRVMI,=BZ
M41<8#,$1!A_0%J,=1BY&'D8^1@%&(4811C%&"4;D=3M9"]$!T2J@K\_IR\)S
M7KWDV_QTJD?[\HV\&C=)PG68OK??K!PX-`)%=+YVX&BDAQLSAVS^>ZZ8<`7Z
MA*_`GA7:M(6O18%?#3RVBR&-;TB#'D\;$T+T\$<+_/2%WE@.O&#!7=K,'7B-
MT,,7#AR6]W#;@6/?'KYTX``3<S@^<,CA0-\5$Z[T#0+V8W"EK[=PIN"031?V
M!D<+#ME[X2MPPN"0\X.^*R9<Z>L!;-G@2I\W.)-Q-KU7X&C&(0<O.,[6,.%*
M7QS8V,*5OCAP7N.0W2OV!L<V#MG$PI5IERWP"X]K]I*G6?527.K1*7^&-)^U
M1W05_8T(_:=A-XVGLH&?=K3WCR/\EB>']]4S<J#\7)8-_X<$Z'X=]/`?````
M__\#`%!+`P04``8`"````"$`9M>J.4D#``##"@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6R45MN.FS`0?:_4?T"\+[=<(%&25;:K;2NU4E7U\NR`
M"=8"1K:SV?W[SAA",9#+OB1A,G/.S/%XF-7]:Y%;+U1(QLNU[3N>;=$RY@DK
M]VO[]Z^GN\BVI")E0G)>TK7]1J5]O_GX877DXEEFE"H+$$JYMC.EJJ7KRCBC
M!9$.KV@)_Z1<%$3!H]B[LA*4)#JHR-W`\^9N05AIUPA+<0L&3U,6TT<>'PI:
MJAI$T)PHR%]FK)(GM"*^!:X@XOE0W<6\J`!BQW*FWC2H;17Q\NN^Y(+L<JC[
MU9^2^(2M'P;P!8L%ESQ5#L"Y=:+#FA?NP@6DS2IA4`'*;@F:KNVMOWSPY[:[
M66F!_C!ZE)W?ELSX\;-@R3=64E`;S@E/8,?Y,[I^3=`$P>X@^DF?P`]A)30E
MAUS]Y,<OE.TS!<<]@XJPL&7R]DAE#(H"C!/,$"GF.20`GU;!L#5`$?*JOX\L
M4=G:#J9.-)M-YU$(,#LJU1-#3-N*#U+QXF_MY3=8-4K0H,!W@S*9.[/0F_A`
M>@7$K3/2!3X2138KP8\6=`U0RHI@#_I+`!ZO"$I!WRTZK^W0MB!7"<?PL@G"
MV<I]`>GBQN>A]H'/UL=O/5P@;9F![79F=$9FU!93>:@-79I@G&;R'AIT!B5`
MSC;[886UT[3C\U\#HT)PZ5:(71.`>)<UQB"=0EMJ8X&N[20U'Z\6,N]3AB$V
MY156C#-9&POHW&$-QUGG)NOE`M'9I&HLQF&&T3@5Z-<O,)C"B5SFQ"B3L[&8
MY2W&.7&,=^Z(OOU>X.#5O4R+@29M8S%H(V^<=C&DG7CS&V@QT*1M+";MF7OI
M0Z/UR[VIAW2@R7LRF<1G;JJ/HZ.G\P*2N:RQCNJQ(A"83-;)N,KHU66]PH;>
M/;;&9+1O-#W#UAM'NI>"Z(8;ZK>SJ1T,)Y-9YYEAY(],HPGTQ95ZA^-(`PW4
M/3./<)2^0]WA&-(`P&:J>V8.P0Y@L*&ZM[7N<"AIK$&9_:E4KPSU&[6@8D\_
MT3R75LP/N`X$\(YLK>VJL@WP-=:W3Y;;>H5QVW]@A:C(GGXG8L]*:>4T!4Q/
M#P!1+R'U@^(5)`HK`%>P.^B?&2R+%-Z3G@.2IIRKTP,PN^WZN?D'``#__P,`
M4$L#!!0`!@`(````(0"-6H&2#`D``!\I```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;*R:77/B.A*&[[=J_P/%_0G8YLNN)*<2P,;8QO;6V=UK0IR$
M&L`IS$QF_OUI66I_Z&4(J3HW`WEHO9*ZU5);X]L_?^YWG1_9L=CFA[NN<=/O
M=K+#)G_>'E[ONO_]R_UCTNT4I_7A>;W+#]E=]U=6=/^\__>_;C_RX[?B+<M.
M'5(X%'?=M]/IW>GUBLU;ME\7-_E[=J!?7O+C?GVB/X^OO>+]F*V?RT;[7<_L
M]T>]_7I[Z$H%YWB-1O[RLMUDLWSS?9\=3E+DF.W6)QI_\;9]+UAMO[E&;K\^
M?OO^_L<FW[^3Q--VMSW]*D6[G?W&\5\/^7']M*-Y_S0&ZPUKEW^`_'Z[.>9%
M_G*Z(;F>'"C.V>[9/5*ZOWW>T@R$VSO'[.6N^V`XJ6%W>_>WI8/^M\T^BL;W
M3O&6?WC'[7.X/63D;8J3B,!3GG\3IOZS0-2X!ZW=,@+)L?.<O:R_[T[_R3\6
MV?;U[43A'M*,Q,2<YU^SK-B01TGFQAP*I4V^HP'0OYW]5BP-\LCZ9_GYL7T^
MO=$WL]MYRHJ3NQ52W<[F>W'*]_]7/RH)V9@LR\;TJ1I;HYOAN&\9U->U(I82
MH4\E,KH9F,/QI!2YT/M`-:1/[KU_74L:7#GN4=V2IG"AJ[%J0)]?&R.E6=D3
M?:J&!FE<Z,E6#0RQ$J3/K<MC,ZH0TI>OC4Z$6D:_CJ"(W(7Q&1PN\47U-KS.
MZP8'3'RY<FX<*;&DOS@W"JZ<6R/*5ZX/$2/9M@[X^2CT9#J5V3E;G];WM\?\
MHT-;'L6B>%^+#=1PA!SGI71ME:F_2U3*4*'R(&3NNM2><K&@W>7'O36^[?V@
M#6&C3![1Q&A;3-E"9+]0G>E@K@-7!YX.%CKP=;#40:"#4`>1#E8ZB'60Z"!M
M@!X%HXH(+?%_(B)"1D2$G?G(H`Z1J?F?+;C)3`=S';@Z\'2PT(&O@Z4.`AV$
M.HATL-)!K(-$!VD#M/Q/^\4_X7\A0TE%^\'O4T+:6+3-5#9#+2:52144(',@
M+A`/R`*(#V0))``2`HF`K(#$0!(@:9.T0D0.:X7H?!'!>Y.P+B/!+GR4Q&K&
MQC1TSU=&W&P&9`[$!>(!60#Q@2R!!$!"(!&0%9`82`(D;9*6Y\EE+<^+X\(<
MWA#^XH$AA-I!D<2B4[!*!M,8:>E0&55!`3('X@+Q@"R`^$"60`(@(9`(R`I(
M#"0!DC9)*RCDLE90+J>#L&Y[7A+-\]KQ/:V,*L\#F0-Q@7A`%D!\($L@`9`0
M2`1D!20&D@!)FZ3E>2IX6IZ7U=/-F$)U.0BB83L(DECU@3T%,@,R!^("\8`L
M@/A`ED`"("&0",@*2`PD`9(V2<OCXCZ@6:]>=K.P;KM9D5%5%TTE$65S8]^9
MM/>=667$JW\.Q`7B`5D`\8$L@01`0B`1D!60&$@"))7$*!W4\CP]\7W!\\*Z
M[7E%&IZ7Q*)CON%Y6_-\951Y7@G5F>("\:I6#6FSWY9>5$8L[8/0$DA0M6I*
M:X\R867$TA$(K8#$5:NFM%:E)Y412Z=*"$,F'LZ_$+/2O!TT1K0JZAB95MN1
M4[:B@32L!FVKF;(R^^7SH6E-K,&@KR7:G(V,*D%=1-Y5'2ZXH>S0F`RU!>"S
M0=W9$E%P56<A-VSM(Z965$9LU5KSIE;EK-BJ'E=\U2`2;L@N'MIV?ZR=Y"D;
M#82+6RDNKFA:ZZ4N[R[OLV5#;>7(YUMQ3=-8$]I8IJJA6>\*,T9CN4Q&YF0P
M&6E),%=&Y13*NP(7B,="M?:"D=2V)K:VV_B@L@02L$BM&S)JIXFVMB-E)6ZS
M&BZ!X$O'U5.+6;WN,&'$3C*L$<6ZG7`I&V&<Q;-O\Q1MU"VGM^WFVV-.`Z1Q
MG(FZ16%1=SY"10NZ0DT_&'T(NK0R/]DNI)4EU_*P;QBV.=8R>"Y\26,PZTQQ
M$7F,+G:X4%;<X7B@^=-GF;JS):*`T<7.0NZ,G-Q8"UJ/$6M]LEV`$V)N>'$0
M"0]"NGA@CZWA2'_D2EGJS'8A'M!A&='-.LU)K**_\O??K2+:%JIE)%2T9211
MLQ@6U[ADU4`S1'-$+B(/T0*1CVB)*$`4(HH0K1#%B!)$:0NUMV_QV-Z,QYGT
M;3I>/N73%157$H_BQEO$HMYII@JUZV-+R\-9;<5:<T0N(@_1`I&/:(DH0!0B
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M6\1,_!\>;22F+`R-<9\NMK7'M;FRJ2M,%XC'.K7T@E%K+5M:@OD@M002L%(M
M'C)JBVLCCY25*$DNQ5_ZH)Y?S.IUAPDCY:B1;8]M;;FE;"/RN;TQT#`AU,:P
MO/C[0@$M5+1-7Z&F&\X4T-+JLP):6JEZEE0L<V!H#^5S0TG5.>PB\AA]LF&T
M.CRW84!G2U:N^P\87>PL5%96JX"VM.E%K/7)A@'CBKGAQ4$D/`BY81C]D3TQ
MQ["*E/J9'8/4+RZC*RMH(:.M(XGH3I^/HBF]W2.L&FB&:([(1>0A6B#R$2T1
M!8A"1!&B%:(848)(O.=4>T+FM7QO2;X9L<^.K]DTV^V*SB;_+MY)HI/D_K;"
M\H6IQZ&3E@>]SD=.6GI=YV,G+<LOG1L6O7E5UFKPB\WO9&F_3(VA,Y/'A?8+
MU7".J-`HZMHO5'XYX=E?J')R1%V$;>BEL`?S#'\4+XN=XZ:3GK-_L)P'<CIV
M\$AS/SOU@9.6Z:)-8CIQZ,H:=::V,SNG[]D.W?*B?6`[=$6+/+8=NE]%3D]!
MY"*9P-60Z/6T]_5K%JV/K]M#T=EE+[14^N49<)0ON,D_3NHQ^"D_T0MJE*?T
ME@V]B)C1&RY]\:S\DN<G_H.Z[E6O-M[_#0``__\#`%!+`P04``8`"````"$`
MTZ7H0A8%``#$%@``&````'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;)2878^K
M-A"&[ROU/R#N3\!VOHB2'.UVM>V1>J2J:L^Y9HF3H`4<`=GL_ON.!\+BK\2]
MB9*)9]Z9\?``7G]]+XO@C==-+JI-2"9Q&/`J$[N\.FS"?_]Y_K(,@Z9-JUU:
MB(IOP@_>A%^WO_ZROHCZM3ERW@80H6HVX;%M3ZLH:K(C+]-F(DZ\@G_VHB[3
M%G[6AZ@YU3S=H5-91#2.YU&9YE7815C5/C'$?I]G_$EDYY)7;1>DYD7:0O[-
M,3\UUVAEYA.N3.O7\^E+)LH3A'C)B[S]P*!A4&:K;X=*U.E+`76_DVF:76/C
M#R-\F6>U:,2^G4"XJ$O4K#F)D@@B;=>['"J0;0]JOM^$#V3U.*5AM%UC@W[D
M_-*,O@?-45Q^K_/=GWG%H=NP3W('7H1XE4N_[:0)G"/#^QEWX*\ZV/%]>B[:
MO\7E#YX?CBUL]PPJDH6M=A]/O,F@HQ!F0F<R4B8*2``^@S*7HP$=2=\W(07A
M?-<>-R&;3V:+F!%8'KSPIGW.9<@PR,Y-*\J?W2*"276Q,+6GM$VWZUI<`MAO
M6-V<4CD]9`6!KSEU$88L74E"=C+(@XRR"1=A`/H-=/9M2Q;S=?0&W<CZ-8_=
M&OC\7#.LB"";(25(8YR2O3U79;E8*LMVR50>.\-8AMIEV/^1D8NA1=#GS^R-
M"KM%T]&:F5T:EHPKE$VGT+S;E4HG3&$HM;?`((Z26M@E(?.QY&TIN5B5ZBWC
MMI+%TBXU5Z5PI.8PJ?<*E'ZJ:F^!+1T5F-A5H7_C`KM!GBSNJDH_5;6W,+QN
MQH,I03RZ5F[W4"Y6X_86I8?+V%Y-HDIA-5/PO*TIO53-WJ)T<$GLF@0&:5P?
MCN5LYM%#]%2%KR95V7$I$JALK'R[2ERMJ<D`8%)[RQQU2D2,]K$;%>93I_34
ME'N36N?4H:PQ1RJSV<)'>0#0</63WJ0J.XA#+,@A,?51-KF#P:`-JO(G[Q6:
M2V;JW5XLY!WNSC"CH]9L&<L0=A"/V#A$ES[*)HDPF*'L`""QLLAKP$P:83!#
MV0%!HB%*#MB,^.RRB2N,I0LG#EX1"[#FT_O,1S\0Z9YW\`9^-2G3E3B812W,
M2L!VFR#HI:I>3:JJ@U=4XY5LL]=,HZ,FW*-+%7:@B\(J_6(B,Y_)0D]-608#
MDZKL0!>UH,MG@]%/T[6!*W&`BUK`1>.IQTBCIZ;<LTRMV`$N22BCUV1V?Z;1
M41.V@2MQ@(M:P#6-DPF8[XRUR2V,9>RQ@UOR&52OV$_8Q!;&,H0=V*(6;!&O
M5IO8PEB:,+SHVF_(U((M.H7YO--H\T$+(QFR#FHQ"[5(`E-Y6Q;=0&,$RZMI
M/-$T=F"+6;#E=RVAIZ9LX1:-'=QBD)\^6<3GG0`=-6$9R^BT`UO,@JW[]P?T
MTE0MT**Q`UK,`BT?6**?IFM!%HT=R&(V9'G='M!34[8PB\8.9C$+LSQ'RX06
M!C-VV`$M9H$66S*/QSSTU&KN0:9>3@YJ,0NUZ)+X*)O8PF!ZS<2!+:9AZPXV
M3%IA`%`##@UOUI0X:#6UT(J1Y/Z-$!W5!E]-2H.)@U?RA5>G!DW@@KA=+[II
MLC98$0>LX`S0E/5Z#T9/3=E&*Z+3JCLS[`[F2EX?^&^\*)H@$V=Y'DCA1&VP
M#F>5#WA4J=O9ZJ$[PXR&?^`,\90>^/>T/N15$Q1\#S%C?(*JNU/([D<K3I`[
MG"2*%DX/\>L13HLYG*K%<K/W0K37'_`6&@WGS]O_````__\#`%!+`P04``8`
M"````"$`1Z'L::H"``"]!@``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;)257V_:,!3%WR?M.UA^;YP`(8`(54O5;=(F3=/^/!O'2:S&<62;TG[[7=M@
M2LLTRD,2A^-?SCUV;I;73[)#CUP;H?H29TF*$>^9JD3?E/C7S_NK&4;&TKZB
MG>IYB9^YP=>KCQ^6.Z4?3,NY14#H38E;:X<%(8:U7%*3J('W\$^MM*06AKHA
M9M"<5GZ2[,@H3:=$4M'C0%CH2QBJK@7C=XIM)>]M@&C>40O^32L&<Z!)=@E.
M4OVP':Z8D@,@-J(3]ME#,9)L\:7IE::;#NI^RB:4'=A^\`8O!=/*J-HF@"/!
MZ-N:YV1.@+1:5@(J<+$CS>L2WV2+=8[):NGS^2WXSKRX1J95NT]:5%]%SR%L
M6":W`!NE'IST2^5NP63R9O:]7X#O&E6\IMO._E"[SUPTK875SJ$@5]>B>K[C
MAD&@@$E&W@93'1B`(Y+"[0P(A#[Y\TY4MBWQ>)KD13K.0(XVW-A[X9`8L:VQ
M2OX)HLR9BI#1'@+G/21[/V2\A\#Y`"F269Y/IK/BOU9(*,NG=$<M72VUVB'8
M>6#<#-3MXVP!Y$,\H9@8V+_R@AH=Y,912EQ@!%$86./'53:=+\DC+`S;:VZ#
M!HY'39&>:M;G-*.H(>`Y&H<L7QH_OYX'?T[L_+E%<89OPXU3,UE\D->LSVG&
M47-B!I*[W(P3EQCH,8CBB`WV@F0:DAQG>?$JS/5+P6@\G\TGYXU-WF/,B4^-
M9<61&YP%S<P[RU/WBP\.J04!'&-U>52<9`9[]O+,G/BUM2,W6`N:\T\.WH(B
MF)_/INGD&&NP%MI(>$$DUPU?\ZXSB*FM:Q$95!WOQNYU,_(-*/X!W6.@#?]&
M=2-Z@SI>P]0T<>^H#OTG#*P:_.NW41;ZAK]LX3/!87NF"8AKI>QAX#I<_/"L
M_@(``/__`P!02P,$%``&``@````A`&`8%G!Y!P``W!\``!@```!X;"]W;W)K
M<VAE971S+W-H965T-RYX;6R<6=MNXS80?2_0?S#TGEB\Z!;$6:RTV+9`"Q1%
M+\^*+<?"VI8A*9O=O^]00TN<L:S(FX<DM@_'AV<X<TCQ\<.WPW[QM:B;LCJN
M/''O>XOBN*XVY?%EY?WS]^>[V%LT;7[<Y/OJ6*R\[T7C?7CZ^:?'MZK^TNR*
MHEU`A&.S\G9M>WI8+IOUKCCDS7UU*H[PR;:J#WD++^N797.JBWS3#3KLE]+W
MP^4A+X\>1GBHY\2HMMMR77RJUJ^'XMABD+K8YRWP;W;EJ3E'.ZSGA#OD]9?7
MT]VZ.IP@Q'.Y+]OO75!O<5@__/9RK.K\>0_S_B9TOC['[EY<A#^4Z[IJJFU[
M#^&62/1RSLDR64*DI\=-"3,PLB_J8KOR/HJ'3`?>\NFQ$^C?LGAKG/\7S:YZ
M^Z4N-[^7QP+4ACR9##Q7U1<#_6UCWH+!RXO1G[L,_%DO-L4V?]VW?U5OOQ;E
MRZZ%=`<P(S.QA\WW3T6S!D4AS+WL:*RK/1"`WXM#:98&*))_Z_Z^E9MVM_)4
M>!]$OA(`7SP73?NY-"&]Q?JU::O#?P@2AE0?1-H@"MC;S^7<($LDU,WO4][F
M3X]U];:`10-?V9QRLP3%`P0^3PQI]%.]-E-@9X)\-%%67N0M8!(-I.?KDU#Z
M<?D5)%U;3#J"H8CLC#"9`'H]1YBXRW%<]#,5`S94C'*&6XIO0.R>FV3?>XF(
MHAY"F(!"+A.C%BR[*\O@S,@,@H0[!(0*^OA($C':P3!$-H4@'"&(RW%:+0->
M>2!`+XY0(>.&F+A+ZYT*9:+CV*>8C&!$%">QBE2/(?Q`+Y>?T5!!04[S-(,8
M3U_T\5%#Q(0=SR00BJ?9_5SK2(9Q'X`0#'^$H!G$"*IA$2%!Q"!!$%(D2:0'
M#ATF(Q@1Z4`(?U@*A">4V^U"FD&<)^.0(@92VB^*@0&R/"-,I:M@J'3"SYB?
MTUJF$VS`G%?2YP?U0PSJ%\1QQ'AG[N=1J.+A<\(KN867`5->R;"ND19"+*U(
M2,6K.W,1=U($H1SJAU`34`CS->O0E%P\Y`+)60RR4U$0RY!!,@(10FB`]<I3
M>J9#STZIP'[N-I=X"&SI(0;I"3\*I!JRUD$R&\9"5""U4S24GFGD#KUYK45@
M^W=I"CWDQ_)$$)+0`IH@[RXV#")BJ?30GBA)T\@=DM-E(;#M4W)#9$L.0?C5
M=W$D$M9Y,AMFO*0I/=/)Y]/#OD_I,652@:#Q+[<Y1@C.0"H11'*8).7'[.,=
M^2Y](^3E:_9Q4.)6O3'CH(@IZQ`_Y!W=*+9#T!<TT1DF59R"4!69=[RCXHAI
M:-9%4H$@E#$*?)^54$8`R?4><Y-MB!'?T!=-QC6&NT!$2<SV.)F-@^R%[^QO
MJ&XW>8>X-`\U+&M;N\0;A(RDT]UL<1"(UN+JUDK>9!\=FMH';[ZIQ=CB`&_P
M675G#!&+8>$2Z>1-WM&A*3>GH:)T%H/<DL1/)-LP9`0A8I4$`X*2,^U]=M>3
M:`9NU]-,EM1BD)P.DC#A]4`0M.U0;C<9AAPS#+;:4PNR604_O>!&'$4)V-(,
M]4[9F<[M*#?O2"2QW[L*"LU,*[4@RQ)L/PF#D($R"H+#BTI4.$R'<F7>,9,K
M^@,HTF^'!:_1U!SCP42FNO,DA/)D+C+=G25V?:KEL,YMK2#(:@E/'4027TA)
M,8D`N<?W@?(F^^C0M)9%,*3($D3[F!30=9@X":Z=B^1-#M*A.3O>I2WH7#"A
M"H-`\HTJ`_E![/O7FB'SD7D[57GI)R*X:#RN6X1!XL=R*%TT%!L'9R-$Z(MX
MF#!9B>9@?GMU=Z.XI(,2F'`+.DLJ?!F&R4`#F5*03.#GVF,%Q?QE7G%WH]C6
MRVEUEBH>4J;6IHTS#J&2&O-P&N9T<2N#YE+R_8T%62EE$,$#F+YPK9`8QT(@
MY3H9HE!^S&[F+4TU8CM.][`ZNJXBX`&,AE^L$60V$C+5YK#G+F!*%>1VI9Q)
MU8SBDK)>F"H$(0LXTD?:=]J-U10Q\+LWAFN:_I#Q*/04TM@#EMC4@BS16,,)
M/^!.FA&0EC*.E;-7HIHR[YFI*5H'\4AGKV73CZ!QO:RD4Q#*\R8+4F@=1$IG
MEV#YO6]!-HZVST*=3D')W>1`:N0,$[).F%H0$6]P9ZL>!KJ"H0R9`;W3A4:,
M)^3&HQ!TY=LMPTD,8:A'K,?8P333;A0K[HL3OP41IJQ?]A#SA//NZNY7,]-Y
MAQSZ"%V%S)S3+N3Y<800B80G7C';SF4$)(-0QZ%S`J$ZFLX_VV^T07/]AJZ&
MA6)!MN<D<"J$'RX@!D*,4E$$3:>'4(+,<-[1<,1H0E8(J29&HV*E8=O`-B`9
M`<G$ET&B!C.B%&&IW*"A0;,]!3^WI!I!DVMP"D+Y,7]Y1\(17W'N0FR.$82W
M/A(.9T/VL)3-O1?,$@%*"C6L4>2&EZEXV7@HZI<B*_;[9K&N7LU%J806VK_;
M7^)^E.;>CKV?PN5N=Q.Z[#^`N]53_E+\D=<OY;%9[(LMA/3O(^!4X^TLOFBK
M4W?%^5RU<*O:_;N#6_0"[@7]>P!OJZH]OS"WCOV]_-/_````__\#`%!+`P04
M``8`"````"$`&=I$B'`"``!]!@``&````'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;)15VX[;(!!]K]1_0+ROL>/<%7NU491VI59:5;T\$XQC%&,L()?]^PXF
M5Z<;N2\VQ&?.F3/#D-GS099HQ[41JDIP%(08\8JI3%3K!/_ZN7P:8V0LK3):
MJHHG^)T;_)Q^_C3;*[TQ!><6`4-E$EQ86T\),:S@DII`U;R"+[G2DEK8ZC4Q
MM>8T:X)D27IA."22B@I[AJGNPJ'R7#"^4&PK>64]B>8EM9"_*41M3FR2=:&3
M5&^V]1-3L@:*E2B%?6](,9)L^KJNE*:K$GP?HCYE)^YF<T<O!=/*J-P&0$=\
MHO>>)V1"@"F=90(<N+(CS?,$OT33^0B3=-;4Y[?@>W.U1J90^R]:9-]$Q:'8
MT";7@)52&P=]S=Q/$$SNHI=-`]XTRGA.MZ7]H?9?N5@7%KH]`$/.US1[7W##
MH*!`$_0&CHFI$A*`)Y+"G0PH"#TT[[W(;)'@>!@,1F$<`1RMN+%+X2@Q8EMC
ME?SC0=&1RI/TCB3P/I)$L'P<3'PBC:\%M32=:;5'<%9`RM34G;QH"BS.4/]#
M0^#$Q;RXH"84T`::L$NCN#<C.Z@<.V+F]Y@+@H#X.0-0O<[@WZ4\*3MP@N%Y
M40['+66/Z5]A!F?$C7+\/\H.W%*.XS-O4Y>YQTR:B@R"\?#\^486,NMNV(%;
MLN'DS.ME/::#86AL=V4';BG?&?88;S@:!Y,/"CV\U76'+(;9>]QJ%]32C\*6
M<X_IX'QTF\%C90=N*=\Y]YBQ/_QA>$G,M]K?('[2:KKFWZE>B\J@DN=@/@Q&
M4#GM[P^_L:IN)FJE+,Q]LRS@FN<P;F$`X%PI>]JX&^K\QY'^!0``__\#`%!+
M`P04``8`"````"$`[\X"O7()``!A.@``&````'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;)R;V7+B.A>%[T_5>0>*^P3+QA.5Y%0SV$QF,/]P38B34`TX!:33
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MEG-KNX8E"*\\)KM]L)22U<KB?;=/U_]7D,BDE(B9B=`Q$Q'FU2)6)D+'3,0D
MDU[8@GI6F8YY9?_BRM310PSHF%7^1@R<3(2.N0B%X\+FNUEE.F:51?W6]&QA
M.U<,`X7KT`\ZYD&X/((4KD-E.N:5+X^@(-\J&TD#9SZZO/OBZ$+Z<`J`9]MU
MQW,O]Z'(C2@_Y,VXWLXBMZ+\D`>#G'7A8(K<C/)#7OWR@9!GKXKER8_F%4.1
M&U%\<N(W8I!;4IP\:5TQHKD7*??E,1#^K:@;UQA:Y*:4'_)(FK>7^J*F<MTA
M=;;G^_G#W3;]J-#UB%RV>YO+JYMH2.D\::H4=TRC7V512I]2Y8>4N:]2?"A!
M[BCU_WH0AG-7^T7I>I$QS2+&U9E6$>/I3+N(\76F4\`(0V>"(D;H3%C$F#K3
M50S]?^J[8$SO`J9_`3-0C!9G8>GM&1;I,"8JTJGK.J,B'<:,+V`F%S#3"YA8
M,7K?;;W-LR+FY,,:F?[H?#J#SYQO4<XNGB[D1I>UI-'E]$$ZO\D+6KR@S0LZ
MO"#@!2$OZ*H"ZMW)8P8[+WI%##LO^@6,8)X?\!\?%E5B)U/$*XT**O$6CXL8
MUN))`<//Y&D1PWH5*^8T<+-/!9HOZ$+W#5_(6O=5TCP-D&#)K:D8[Y`>3=NU
MZJ['>MM2"%TLCS+,X6U(="`10")4A&JJ,.N>S1K:A1(]2/0A,=":P2PWA-4C
MK;IOV:+N.J=L<#A_1U!E#(D))*:0B!6A(GXC'(?F![[#HC[3(=>Q//=D,LW%
M9*%ON%C6XBYF:::IF!*+MB#1AD0'$@$D0D4XA_/-(A/[]3J[?G6A2`\2?4@,
M/C?$]PUN9"@006($B3$D)I"80B*&Q*R,T"Q,<W[-PN479DESZ[+3IZD8:L!7
MV;4%B38D.I`((!$J0EG7I/L^USR=YX>\U84:/4CT(3&`Q!`2$21&D!A#8@*)
M*21B2,S*",V\=,=YA7DES<QKLBS15(RRA#`,H^[Z;%;?4DB)O]N0Z$`B@$2H
MB)-[]4EZ%PKT(-&'Q``20TA$BCC%7/B"70Y'4&0,B0DDII"((3$K(S3OTBW6
M%=Z5-/<NFWPW%:/B:+FNX/?'+064.1<2'4@$D`@5\75#NU"B!XD^)`:0&$(B
M@L0($F-(3"`QA40,B5D9H5F7'K%=85U)<^NR)S=-Q62YS')\TV%$2Q%EWH5$
M!Q(!),*<D$_?Z"1C23?_]LNY3P\2?4@,(#&$1*2(8\0]SV/WP".H,8;$!!)3
M2,20F)41FG'IT>L5QI6T;ER/W=DT%9)G,MLS'4:T%%'F6TAT(!%`(H1$%Q(]
M2/0A,8#$$!*1(DJB/H(:8TA,(#&%1`R)61FA>5<N>5UAW@.NNU>8;"K;S*`2
M=[8PTL9(!R,!1D*,=#,D\X;A"L=E5Y*>ACB6:=,T7T_C?0T1EK!==I,[P$T9
M:B)UY^Q7(JPQPL@8(Q.,3#$28V16BNANEFL(GY?$RI\[R`5;EHOI@:D^:LT,
M*G6STE'VD(N#QMDLN9W)9`QM2_"$S9_,=C3H,+AGXQMHC'09]UF(6]S51"SC
MW,V?>R3=K`>E?_R)PW*AQ4Z&P?'K+V<LPR,B%>KLR6YT_/9+@5&&'(-.NSWJ
M[(P;ZPP%W;5-BPWP1(/JMD__;,9,=<;W/8?=2\8946*362FB^U@N<'SVL5S:
MQ0M<<K_`F9_9T#4S2,7-IF4,GZ>A5H:4]*6-D0Y&`HR$&.EBI(>1/D8&&!EB
M),J0D@$8894Q1B88F6(DQLBL%-&-+5=!OF%LM7BB+=&9+&<TY387<G^):UL8
M:6.D@Y$`(V&&*!O(Y2##8A.I+E;I8:2/D8'6EAN+KCQL9C+$(A%&1A@98V2"
MD2E&8HS,2A'=U^2Z[_A:5N/3:7;WWY3[KY"O(=+&*AV,!!@),^3D:WWJT,42
M/8ST,3(X(G*&<6.QZ^#P^/674XPH0U17;ES'8"?H"&N,,3+!R!0C,49FI8CN
M9[E8\HT\K=98]#S-9DI-N3.0_*RB*BS#\ODVEE:&D*N_6NUK8Z2#D0`C(4:Z
M&.EAI(^1`4:&&(DP,L+(&",3C$PQ$F-DEB'%EM*-+5=2OF%LM0"C&YM=(YMR
MJ^K1V#>68_IUSV.W)*T,*K5VV6K/806Y@U4"C(08Z6*DAY$^1@88&6(DPL@(
M(V.,3#`RQ4B<(=D%QG($W8S56;Z<Z9!OBT^WV[JWY5++9V^#IQ]J94;SM,7L
MVI3[ILG3V6XRS_8,]WSG6P:5>KIL&2CS-$0"_$.AWN"Z;;HLGETLTL-('R,#
MK2DF6U<=8H%($[!H+<7V+(/-8T989XR1"4:F&(DS)-L)9QKTL(4>EK()[4RG
M;-LV_-,8Z8Z6:S!7.%HMV>B.9G%ORJW\:#H-D396Z6`DP$B8(2I%V*9O>+;#
M`MK%,CV,]#$RT!IC"M-GP1UBC0@C(XR,,3+!R!0C,4;DBW%?.TKY6;WXIM[>
M6"?;EZ25K%:[RB)]ER^UT8/!A[MCL7KC+A0-VDI.6]59^4`T:)?W>7DD&K21
M^[P\%@W:/WU>/J,W^HK*Z4V_'T7E3=&@_?+G.BW1H&WSY^5MT:#=\^?E'=&@
M3?3GY8%HT%YZ*J\=.TPO^+W-7Y)HOGU9;G:55?),L3)NY9M46_6*H/ICG[X=
M7H9Y3/?T:M_AXRN]RIG0%G_CEN#G--WG?\@?.+X<^O`O````__\#`%!+`P04
M``8`"````"$`05>KK:P"``!=!P``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6R45<MNVS`0O!?H/Q"\1Y1L*W[`<I`T2!N@`8JBCS--41(1411(.D[^
MOKNBK5A.FC@7/6=G9X;4:GGQJ&OR(*U3ILEH$L64R$:87#5E1G__NCF;4>(\
M;W)>FT9F]$DZ>K'Z_&FY-?;>55)Z`@R-RVCE?;M@S(E*:NXBT\H&WA3&:N[A
MUI;,M5;RO"O2-1O%\3G37#4T,"SL*1RF*)20UT9LM&Q\(+&RYA[TNTJU;L^F
MQ2ETFMO[37LFC&Z!8JUJY9\Z4DJT6-R6C;%\78/OQV3"Q9Z[NWE!KY6PQIG"
M1T#'@M"7GN=LSH!IM<P5.,#8B95%1B^3Q=6,LM6RR^>/DEMW<$U<9;9?K<J_
MJT9"V+!,N`!K8^X1>IOC(RAF+ZION@7X84DN"[ZI_4^S_29567E8[10,H:]%
M_G0MG8!`@28:I<@D3`T"X$BTPIT!@?#'[KQ5N:\R.CZ/TFD\3@!.UM+Y&X64
ME(B-\T;_#:!D1Q5(1CL2..](DC2:C-+I[`06%A1U!J^YYZNE-5L"FP9ZNI;C
M%DP6P+QW%G3T7O]G%3PBR26R9'1*";APL#P/JS2)E^P!,A4[S%7`P+'')#V"
M@9I>$L@XE/1ZR/O.",;.&#I*N0H/#MN,7F\S_D@;!&<4N'OQD_F\YPV=`V9R
M@$E[Q,`@0`X-8N9CV)-O&\4BP!VR)\\!!@4!<X("V'4?5X!%PPS2^'B1`V:@
M('Y6.4CA?*CA;?<(/N[]O*[!?<`,>K^>/^S3C[O'HO?R#Y@3%.!_X>BK>W\'
M8-%Q!L?Y!\Q`03P^2B&,N3`%M+2E_"+KVA%A-CC"$OA\^Z?]=+T<=0.R?P'3
MK>6EO..V5(TCM2R@-(ZFL/XVS,=PXTW;S9BU\3#7NLL*?F,2OM0X`G!AC-_?
MX`3N?XRK?P```/__`P!02P,$%``&``@````A`$"E>6G*"````R8``!D```!X
M;"]W;W)K<VAE971S+W-H965T,34N>&ULK)I=;Z/($H;O5]K_8/E^L0%_8)1D
M-0Z?AI6.CG;/N79L$J.QC67(9.;?;S7=U5_%.LEJYF(</U17P\O;376;N]^_
MGXZC;]6UK9OS_=AUIN-1==XU^_K\<C_^Z\_DMV`\:KOM>;\]-N?J?ORC:L>_
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M2Q@JO43PB2T_UB5HT#>$3]%P[LR\^3)PF;0W+M(%&_"[POS`!?_@9;KRAL(?
MHJD+]U[>T5O=XFUTU7V\W>V$NZDW9[3MM@]WU^9M!",>.F\O6S9_N"'+AK;D
MO4NC_I-/P:`LRQ>6YGX,MPP<V,+@^O;@!:N[R3<8$#L1LZ8QKAGQB!',_2QM
M9(/8!HD-4AMD-LAML+%!88-2`Q,03JH'@OT,]5@:IAY>]QJ!)J<E%49@D\@&
ML0T2&Z0VR&R0VV!C@\(&I08,J6`&^1E2L33@51B6-YS&@WR8@F30W-)/AD@!
M"8D)20A)"<D(R0G9$%(04NK$4!(NRU!R^`F"(Y-%]X+AA:XY\0T)5U-+'QF$
MS2)"8D(20E)",D)R0C:$%(24.C'T@0O[A#XLVM2'$Q\>7-(]WLJ>JF20U(>0
MF)"$D)20C)"<D`TA!2&E3@Q]X,(,?=B4[P>LZA"/N@_/^BR3J1TGEG:>Y2T9
M)+4C)"8D(20E)",D)V1#2$%(J1-#.WC"_23M6"93.TXL[7Q+.QDDM2,D)B0A
M)"4D(R0G9$-(04BI$T,[MI*Q2XU_YSN6R=2.$TN[F:6=#)+:$1(3DA"2$I(1
MDA.R(:0@I-2)H1U4ID0[;^Y\?LBR1*9TG%C2V8]+&22E(R0F)"$D)20C)"=D
M0TA!2*D30SI6HQO:W7Y>]N&F0@)9$BTL=ZDHJ1%%,44)12E%&44Y11N*"HI*
M`YEBL4I7'Z3OB,4+8RC'\)K7;%T##K/$6MIBR2AL&*F&B&**$HI2BC**<HHV
M%!44E08RQ6*UKBX67SPY;('[CFZ\2C9TX\A7JX!'MAYC4BH44113E%"44I11
ME%.TH:B@J#20*1*K8W61WE&&E[V&,AP%RF2/+D$113$BI5\BT!+F!*VXLU:J
MJ8I"*V:(/.GT7*`%S#PJU\)ZZ&RPH=ZC/[7*R4)%88^E0$'`>C0E9:6O+JGF
MN^Y0[[ZN&S@A&&$#4ONP.!=+=EY`&TIS%$#YHZYH%=AC5T;AN48N03$B77P>
MM80SD^G]J;7R2$5#B,+T&2)=?)X+Q,>H#4:9Z:WBLU!1V+`4:$AI5D3K2@\H
M"G6SE)2%6\\.@>#)+J_9\RR3/,)-8`V7BW[K9#EUYBO]GQ4>B7#/EQ<?JPQX
M60DB=0=21$'?SVH6K*R).<,(I6LN4-#O;_;>V6"42ETHU._^.-:8*O%XG]BT
M,ZNV/R$R+\XA'U[IVN6(K6!NB<RC`K>_>*O"B40.F,@P;2P0-$"4"+1042DB
M?N]F[L+SK-P9)E*M<D3J%FXPD8HJ%&*BNHYEYA*S]$U,45D9_@E1>=5NB"K0
M.\[E4<*Y<V=JW??(Y0&&5V4;I:M`RE"I:+CD7H45N#>UQD&&(;I9>2+#K"1W
M@0V7O16FCI6XQ.,#9F4E^B=TY16]H2M'[YF51PFSNHYOS<*1*S(KM\0"&7[E
M489?!>)^]6:^/1MEF$>ESA'I=B6I"Q$%O7&[6N.@Q"P#=F7E^R=DY=6^(:M`
M<%:WY@`>)>PZ<URKBH]<'F#85;91=A5(MZM`W*[NU'ZN92+S4C<K;V.8E60N
ML"$WJ^<05443:E;O<TN?/MQ\?`GTCEE%E#"K#UM)9LD086;EJ%BUD:H*I)L5
M$3>K[\_\F?W$PD0J=XY(<RLF4E&%0OR)9=5D)6:A;O78ZN7C;NW#+5U9!D"W
MW2H:"K=ZCFO-_Y$(T-VJVBA=>6=+S:T8Q=VZG%.[8H1F5X%TNV*42ETHQ&3U
MB5WQ^(!=[?74[6K+HXLH@=ZS*V\HY];`VF2+,+,R2RR0/K=B9WV!WM=%*2(Q
M5*&\"JQ'2X:)5.X<D6Y7?HK:4"A$E)A<!W055S5@5WL)]J_6"V`RN[@5*(`)
M2,ZY_M12\U%%H2,CBF)$_4_PO9J)0)ZR8"J0/^5/F+FW@!]IS<DF$S$S76&Q
M7M1*6$RN1"\$TL9):>0R"BQX5\"<`VQ1_VPN,,`'%V'@3UPR]&FLN8$O;6`'
M!?5Z%%$:BBB**4HH2BG**,HIVE!44,3>H6`VX:?*%>/O1/"?G4_5]:5ZK(['
M=K1K7MG[#AZ;VR7F+V.LW6G(=JE``'($WM.`+9FA(QX<Z6^ZW<:;X;L=]A$X
MT!O.YO,0?C\9Z&,1PF\#`WP9PK[W``]"V-,=X*L0-BPIASV%,(?E*#T"^P@A
MVR48.C*#(T-M8`L!%!DZLO;\D`U"F@U>@_DRJ"&3?2!^#:(/Q7_Q(<]@UW!.
M0QVOX639)@X]I;4[@R-#N6"')V0;#;0-;/2$;!MGZ,@,C@RU@3V>D&TU0)N)
M]`.\@G/9OE1_;*\O];D=':MGL.RTW^*[\I=X^)=.C/:GIH-W;_J!?X"7K2IX
MBP%6\^/1<]-T^(5U(%_?>O@;``#__P,`4$L#!!0`!@`(````(0`[5%BQ>!,`
M`/%D```9````>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*R=6W,;MY+'W[=J
MOX-*[T<B9W@OVZ<BSOT^6^?L/LLR;:LBB2Y)B9-OOXT!>H#&?PXEII*'2/JA
MT0"Z<>OF</SAGW\\/ES\?GA^N3\^?;R<7\TN+PY/=\<O]T_?/E[^^U_)/S:7
M%R^OMT]?;A^.3X>/EW\>7B[_^>F__^O#S^/SKR_?#X?7"]+P]/+Q\OOKZX_=
M]?7+W??#X^W+U?''X8E*OAZ?'V]?Z<_G;]<O/YX/MU^&2H\/U\%LMKI^O+U_
MNM0:=L_OT7'\^O7^[A`=[WY[/#R]:B7/AX?;5^K_R_?['R^L[?'N/>H>;Y]_
M_>W'/^Z.CS](Q>?[A_O7/P>EEQ>/=[O\V]/Q^?;S`XW[C_GB]HYU#W^`^L?[
MN^?CR_'KZQ6IN]8=Q3%OK[?7I.G3AR_W-`)E]HOGP]>/E[_,=_UR<WG]Z<-@
MH/^]/_Q\<7Z_>/E^_)D^WW^I[I\.9&WRD_+`Y^/Q5R6:?U&(*E]#[63P0/=\
M\>7P]?:WA]?_.?[,#O??OK^2NY<T(C6PW9<_H\/+'5F4U%P%2Z7I[OA`':#_
M7SS>JZE!%KG]8_CY\_[+Z_>/E\'R:KF>A7,2O_A\>'E-[I7*RXN[WUY>CX__
MIX7F1I56$A@E]-,H"5=G*PF-$OK)2H*K^6*V4ATYT?C"U*.?7,]I_$1%4CL,
MG7Z:BNN3#:V,//T\KR%2.S1$/TU%6GTG.D:E@SS]-/+SC37GB8I;4W&NII%V
MU.IJ$2S7F\&;)VK.QWE`O_#HWF7^.3M?_6)J!J<-.6=7JU_.:XR=K:;XF2-D
M]\T=_\W>9=8Y.U#]\I[^7NM%-JS9Z/;U]M.'Y^//"]H(R;@O/V[5MCK?*66\
M6K5GQO7[GY8OK5NEY1>EYN,EU:>5^4)[SN^?POGVP_7OM$_<&9D;E)E+B3U+
MJ$U!J8U\$/L@\4'J@\P'N0\*'Y0^J'Q0^Z#Q0>N#S@>]`Z[)&Z-+:-;^'2Y1
M:I1+V)@W#*R/`L_^+,%5(A_$/DA\D/H@\T'N@\('I0\J']0^:'S0^J#S0>\`
M87_:`OX.^RLUM*IH6SBQ)K102)O(*+3TG#**C%X!$@-)@*1`,B`YD`)(":0"
M4@-I@+1`.B"]2X2/R&#"1].7"]Z=E/3@"C;AC2:A<$XP\RP_"G&U"$@,)`&2
M`LF`Y$`*("60"D@-I`'2`NF`]"X1EB>3"<NK`R/<J*N<N4"\^\Q0FJ17-`GI
M.!Q70QCXA\0H-'H%2`PD`9("R8#D0`H@)9`*2`VD`=("Z8#T+A%>(9,)KYQ>
M#TI:6EX3S_+^\3`*C98'$@-)@*1`,B`YD`)(":0"4@-I@+1`.B"]2X3EZ<XC
M+*\O4%=K<M5I)ZB*T@F:A/;(W@.)@,1`$B`ID`Q(#J0`4@*I@-1`&B`MD`Y(
M[Q)A<94H<*^LI\VLI*69-5EMQYO17I,UQ2C.OA/*TR`:A7CVQX8$HZ($5*=C
M+5?U2JK.1B%6G8/J8E1M%06KA514CHJL4!AXK56C$+=60VO->UIK1T5.:Z%G
MMFX4XM9Z339#"D(XEH+%,QRKI*5C-7$=JXGG6,]HT2C$/8P-<1P+JM.QEC/X
M8"W]D8U"K#H'U06H+L=:)U17HQ"KKD%U`ZK;L9:C.O0,THU"K+K79,)E*JX_
MPV>#N'2:0:[7#/+<YMV+(RO%W8P9.8Y#]2E+R>6^\5QGI5A]SLBJ+U!]R5)"
M_<R[Q516BM77C*SZ!M6W+"74AYYQ.BO%ZGN#IIRH(M'W[Z@J,^.M/(.$$[44
MA3;<@\A(.2@V:&W'G*"NE*7$F`,OOY!9*6XQ9V35%ZB^9"FA/@2/F7A]R'X.
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M^PI1;9!CG`91BZA#U`LD7:WR`F>X6J<12!]W_49]^*,.83+CN"3#A7=*[HW4
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M.Z$^H5]>;;QIE]OV>0(55C.C$E%ET,8>(#7J:K!BBZ@SB$S%+?9"EW`I!3GG
MN'00EPDH@^2"A`/82+D'L$'>`>RMDIA;%`<@N)2E[&1/+3KE4B-%:TFY='45
M^"YE-79E%8QL8R6BRFIF-]0L974UC*RN%E&'NGJ6PE4:J$2+NTK_4KYCT.)Y
M6BG^>"D7[\*+D?:F8N`$U`:%.J`.-T&XFGM7J-C(..=/PIILR)E:=-*INJ/F
M>%W1ATERH\^QL<)J9G>5!FUM^Q4CV@B<ZZ`7Q]6HOD'U+>LZ>57H6&HQ3-!P
M%JSGL[EW2^U%@W)]T_T3)P,]3D<#4+FO?QU_D)/-'^]*A`5*HS<Q-/*V`&\E
M[;GBS&YRT<CFP_#F2_J\>N,?RRPDM@#_FI.PE-6>,G+OX'@9,U)F"Z!=W9\L
M9L`GFR^XK=-WL5'*]K(:F=O-<.$=BC6+N9N'Z9F[>1A$1K8S%,;<L;*9L7NX
M6JW6_IKL66IBCU%9,]AC<%J=3MJI6[(_E31R/\0U4@Z*$,6($D0IH@Q1CJA`
M5"*J$-6(&D0MH@Y1+Y!<YC0YP1_JN=^SGRH)E"9O>6LDGVY8>JMT;RJ2%&^@
M$:(848(H190ARA$5B$I$%:(:48.H1=0AZ@62;E+)'G?9O+$^E+CG"XT\7WCG
MP5X]3405A2\`Q2B5($H198AR1`6B$E&%J$;4(&H1=8AZ@:0O5#;D#%^8Y(E-
M)-P$&GF^\"XV>RMEU\58D5&,4@FB%%&&*$=4("H158AJ1`VB%E&'J!=(^D*E
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MMJ%8Q$B%TN-7>)9>;B2V4GS^)`+)$:E0SEWASJQZ_W,KH0D(G7N+06)$6DJ,
M2*/E=HC,@]G<VZ5C5),P&NO8`U@.S0\?WU@E&">&&LE<U-)+Q.R-U'QF4SB1
M891JM9X*X"/>L:;U<?)633E$/R)[8X@8=JEOM=`I*+,J2R\[L3=2\YEU<&38
MAFSD3$8OH1`;*6<:)),55S;2DR-4$84[/]\8H0Y`Q-+22#IQY0<SZELF9`?I
M1&;Z0[S9U0I&QQ*N`YE-U))#.R\V4$>HZJ%UP8U!TGDK/S;@BL)Y6IETWLHN
MI&$+BDU-X;S)BG;5RA'Z-^[AED?Y;S+1&W[$RS>=56K\GA_]FX21DGXTRF;Z
M0:?-U=8S43S6<OTH:\VOG,\#Y"C5K=&=HLX6^L8H]7U3N-1<0>WG*OL04(0H
M1I0@2A%EB')$!:(2486H1M0@:A%UB'J!I`_4;='UP1N&UY=+8?CQONEL9_ZS
M6?MPE.*S-4(4(TH0I8@R1#FB`E&)J$)4(VH0M8@Z1+U`PA<+_Z)ZVA>#N-S7
M#%+;CSU:5OZY:Z5&7R"*$26(4D09HAQ1@:A$5"&J$36(6D0=HEX@Z0O_POJ&
M+_!FNM#(\X5_0;!2UA=C148Q2B6(4D09HAQ1@:A$5"&J$36(6D0=HEX@Z0O_
MJOV&+_!.K1XYH"/0\X5W*=E;*39\A"A&E"!*$66(<D0%HA)1A:A&U"!J$76(
M>H&D+_S88+B9_)6/,A88-A@DW;2V%UP=WUDIZR:MBRHRBE$J090BRA#EB`I$
M):(*48VH0=0BZA#U`DDWG1??+#"^,<CSA7_[MU)L^`A1C"A!E"+*$.6("D0E
MH@I1C:A!U"+J$/4"25^HN,:]8KW[FKLP$9$3N1CDYI\018AB1`FB%%&&*$=4
M("H158AJ1`VB%E&'J!=(^D!%7ZX/WCA"=+#F7G,7&KE?)S)H/AN^[#EL3M$$
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M('IJ]H3ZG"M:]04CJ[Y$5#&:F*4G@ITSSC`,?)8:>9/73^$8*7H8@.=@9!!]
M-JV^0S"]$6C=8N9JY*R"E'6_L2/KBN;I=OIF$>X-T%IA57.W2T250;J;<B+[
MX<UP<SCW@=\E1CT&N>$FH@A1C"A!E"+*$.6("D0EH@I1C:A!U"+J$/4"27^H
M&..,:XF)C)SX::F13+_XS][OK13/FPA1C"A!E"+*$.6("D0EH@I1C:A!U"+J
M$/4"25^<%Z_19[;^I\4&>;[P4V%6ROI"ZW+3DBB5($H198AR1`6B$E&%J$;4
M(&H1=8C4^[=-MITLH7VAWZ>MW\W[>'C^=M@?'AY>+NZ.OZEW9=/;5SY]&+%^
MD??-<DUO\AX^S862#;_CVR]9T-N_Z7,$:A9*`BH9#C4H":EDN.Q`R8)*AB,.
M2I94,JQ6OV2YHKX-:6B_)*!>TW$_T;=@2R7#B>77"6<[]5#51)V0M-&GNE,E
MI(T^8YPH69`V^L1KHH1,/6GI@&RCCT"_9P'9AIZDG]`5D&WH.86I$K(-/64\
M54(=H&=>L80R6;N"PC\LH>S53@6&6$*O@/]ETM,T.2;G!DV-*?E?PMTO-)6Q
M@1NRRO2$(?M.R9-%)@U"]I@R!Z4"=RK1ARU3UHM*I@Q%*1XJF>HMY3.H9&I"
M4-B^4T$YMD,YQ9V*S;&DIWFGPRQO1M`S=COUN!Q6N2%E-Y/*]E2B,J989T\#
MC28'2JDR*ID:Z)X&JK(^$]IHH"J[@264F]VI'`>6)%2B4AU84F]VZBU+6-!L
M=NI=2UC0;G;TIL`)OMW1Z^@F^'RV4R\YFRJ94\F4E>F53E0RU7J^V>63!<5F
MIUX]A:V4FQV]1W&";W?T9KX)3OU5[WR;*IE3R51_Z0U75#+5>KS9J7=PH;)D
MLU-OXL*"E.;^5']3FOE3_:67Y.VRR?[2R]BH9*J_],(O*IEJ_6:S4R\;PV[M
M::9.=6M/\W2J6WOJEGKQWX0FZI9ZP=Q424`E0^O7XXJD?W#BQ^VW0WW[_.W^
MZ>7BX?"5#MG9\-;69_U/5N@_7LW72S\?7^F?FJ#\";TAG_YID0.]G)[>U']Y
M\?5X?.4_J.GK\1\K^?3_`@```/__`P!02P,$%``&``@````A`&IG$@)?!@``
MV!@``!D```!X;"]W;W)K<VAE971S+W-H965T,C0N>&ULK%G;CMLV$'TOT'\0
M]!Y+I.Z&[6!M*VV`%"B*M'W6RK(MK&49DC:;_'V''%(F*<:QB[Q$\=',<&Z:
M,^`NWG]M3LZ7JNOK]KQTR<QWG>I<MKOZ?%BZ?W_^\"YUG7XHSKOBU)ZKI?NM
MZMWWJU]_6;RUW4M_K*K!`0OG?ND>A^$R][R^/%9-T<_:2W6&-_NV:XH!?G8'
MK[]T5;'C2LW)H[X?>TU1GUVT,._NL='N]W59;=ORM:G.`QKIJE,Q@/_]L;[T
MTEI3WF.N*;J7U\N[LFTN8.*Y/M7#-V[4=9IR_O%P;KOB^01Q?R5A44K;_,?$
M?%.77=NW^V$&YCQT=!ISYF4>6%HM=C5$P-+N=-5^Z3Z1>4X3UULM>(+^J:NW
M7OF_TQ_;M]^Z>O>I/E>0;:@3J\!SV[XPT8\[!H&R-]'^P"OP9^?LJGWQ>AK^
M:M]^K^K#<8!R1Q`1"VR^^[:M^A(R"F9F-&*6RO8$#L"_3E.SUH",%%_Y\ZW>
M#<>E&\2S*/$#`N+.<]4/'VIFTG7*UWYHFW]1B`A3:(0*(_"T&+FA&`A%>`K%
M:)9&41BG"9Q^0S$4BO`4BC2:T30B4<S\OJ$);WG`\)1'VN0]S!-/^[88BM6B
M:]\<Z&7(1'\IV)=!YF!#YAM/'"OPO0)`YIF1)V9EZ2:N`[GMH6N^K,(X6WA?
MH-*ED%E/98@NL9$2K*S,[-8$<@7P((`Q"JC43XB"66%1R//7$KB&10V7I814
MV9I`K@":R]`C/\%E9@5*!Y6[9C[Q=2?7*!1`<XU"D2ZR&47&0"9(KB):*&#8
M#`7:%WQZL(N8'1Z,=&*-2!`KG@>^T5B;44BJ;2=(KB*:[^"EZ3N)9NQSM8\<
MV?%,3_<5D>#:/IL)LIT@N8IHCD',JF.WO6'"NC>(1-!]8\T#8C3&!H4H%'84
MHC346V.+0DG*/^LH(;[1.SD*A)0/=O6KA'EP?PA,6`\!D3CB!U.?&.=NA`8_
M%^>%T(A1@Z8A-2+.A4XX\94M$,H<O)UN)JS[B@BDF\T^\#76D[C!]Y#IL4<1
M$6FE-E]1PI+7[!%?F;#N*R+7O":&KT)#R:O0N)%7H3/-*X$5X/[$<FG=6P%=
M4YL:[@H!-;<"NI5<(6+)+F$D<W<K<&G#8V0I2/#ULPK(A.Q0BBAI%K9BS',6
MD<1H^5R>9LDSXYG[O496`MZ0_;@&1UBC&!/#Y#LA%2N-+"$8L>,4"4B@5RD7
M4I#OJQ2EU\]$FWV$4<W]P2`Q:<$@9)3`F&P;?@S43BV!4,02$)]&-#'X)I=J
MEB(PFKG?;R0ES6^$C"(87;`A**4504#P4(IP32^?C[E0O+,(C)J48'`UY-0X
M'.OR9=W"2=#$EE$9P!@4BR'RFQ8C0D9MS"$$&JP=,Q@?8T!3;I)2A,_=E%!B
MKIVY$('0H=7U+F/$=2/`S^WE>P'"4CY&B/2G18@0K"WRZ]J0";2=0KD&Z;XR
MXIKX^O"&103_07+'K(:),9K60NKFPGB5D3%NIU"N07I`C-V,@/[7TDB0)K7\
M(Z2OC63"&Z/4-8()E`OS6$L]`L9Y1@1WK8Y$D*4Z?!%2ET<AI4#;*91KD.8>
M?8AXN;1.8Q*"G(R],ETAA=0/=D@A)0B9!"&)C6&<"Q$+(=.'")E+&Y$@U?*/
MEF]GYD"5.@H1"$AP<93ZL4)6.$VEUG2RT(?(F$L;'@M^QJ7;LD\*'77I$9!<
MU+.$9.;\%R*V'#_$N*S:QE(IH&N.S8$N==0<:V0;DR!+)UTA3K+DF#&>\OE9
M:$B9TA3Y49T2$AIS;`X((:#E&,V(',=!2HD19RZT;#EFE':_QTB`FL<(05CJ
M%VE,[PU[S9A33;103#A-A@%-8T,K%UH6FJ0_H,F[]@!NQ.AQ09SJ?"&^D<Z-
M4,R@#\8I--T#I%3(`Z19EOBA4<Y<R-@*8R77ZZ9SWR(`UZ*3CP(A=1$04@JT
MG4+LBI794ED'KTSQ[JZIND.UJ4ZGWBG;5W8="COI:C'"\JXVF3^!):`WXPTP
M_)QQL^U-"F]2ZYL,WF2V-Q2L6<^!V^(GWH:3\\&4U1(8LN!/P?P)=B.+N\$<
MKJ4L>#B'*Q\+'LWAQL6"DQ@\XB=XHZ]PKWPI#M4?17>HS[USJO:0:)^W18<W
MT_AC$'OB<SO`C3+4`JY1X2\(%=Q@^NP6;-^V@_P!1WOCWR16_P$``/__`P!0
M2P,$%``&``@````A`)+O.PM[$```7E```!D```!X;"]W;W)K<VAE971S+W-H
M965T,C4N>&ULK)Q9<QLW$L??MVJ_@TKOH<@9WF4Y9<[%.7AM97>?:8FV69%$
M%4G'R;??Q@`]`/H_H<1-\A!:OVG\<32N!L'Y\//OST\WO^V.I_WAY?ZVU^G>
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M37]X>_?Q0]U`_]GO?IR<?]^<OAU^9,?]8[5_V5%KDY^4!SX?#K\JT_Q1(4I\
M!ZG3V@/KX\WC[LOV^]/Y7X<?\]W^Z[<SN7M`-5(5FS[^$>].#]2B)-,)!DKI
MX?!$!:#_WSSO5=>@%MG^?G\;4,;[Q_.W^]MPV!F,NF&/S&\^[T[G=*\D;V\>
MOI_.A^?_:J.>D=(B?2-"GT:DU^N,>MU).'J_"%G6):%/(T)E>F<!AB8M?=H"
M!.-!;S"\HAHCHT*?7`+;%!>J3V.I+CE]FG14C@OV$V/?4]XV[=D9#P;]X?B*
M]NI1\]39JG\8F='5K=YCWZE.\Q<*PQ[H61>,WUN8.]TGZRX>;\_;CQ^.AQ\W
M-&]0KSN];M4LU)OVR"O<N77;-MW]SWH[=7.E\DG)W-]2>NK()QJBOWWLCX(/
M=[_1L'HP-C.TZ?D6$5NH,:1D8PD2"5(),@GF$N02%!*4$E02+"182K"28"W!
MQ@%WY(W&)=37_@Z7*!GE$F[,&0/K(^&AB"TX22Q!(D$J02;!7()<@D*"4H)*
M@H4$2PE6$JPEV#C`:__P[VE_)4.CBL:\,R9"O\?/M%%(,T1C-/!-HL:D\0J0
M!$@*)`,R!Y(#*8"40"H@"R!+("L@:R`;EW@^H@;SQDC[6LRSD[*N7<%-.-,D
MI)FT:?<PD,.A,>)D,9`$2`HD`S('D@,I@)1`*B`+($L@*R!K(!N7>"U/_=EK
M>;U@=-2J>MD)*J'O!$U".T5%0&(@"9`42`9D#B0'4@`I@51`%D"60%9`UD`V
M+O%:G#JIU^*7FUE9^\VLR7#2K`21)B/:&SF]7TQ-<6/$O3\Q)&B$4I#.FE2N
M]-"?TN:-$4OG(%TTTE8H&/9]H;(1LD9A('*K&B/.;0&Y+=^3VZH1<G(+1;.M
M&R/.;:/)>*R:S7,L;9>N<*RR]AVKB>M8381C1:/%C1&7,#'$<2Q(9TTJI_+!
MR/?'O#%BZ1RD"Y`NFU07I*O&B*47(+T$Z563RI$.18.L&R.6WFC2XC(5T[O;
MY<MC45G[+M/$=9DFPF5B#Q`W1ES"Q!#'92"=-:F<R@=CX;+&B*5SD"Y`NFQ2
M.=)=L9VO&B.67H#T$J1732I'.A0-LFZ,6'JC28O+*!2\PF7*VG>9)J[+-*%-
M&V<>`TDT&3G^`9W,V/C3\$3XIS'BS'*0+D"Z;%*YC2C]TQBQ]`*DER"]TL2I
M_1K(1I,69ZAXW/.&LWTX?]L__#H[T))$D5'+P`HIKC31IE+QO50+W]^Z;C)H
M%%H_(4H8.9Y"K8RMJ&1VR0R[PE?6BELT9V3E"Y0OV<J7%_O1REJQ_(*1E5^B
M_(JM;$NL$6T,:O.:"E7?/^WUE+EPCT8#BKF<]A,K=<0)[58E-BCHUH<*O4FO
M.YJ(^3LQ-GU7'/8*J;$:UH=]=3_*6)S"#*=4<E$S5J-1781A1PRC_%W9%S9[
MFQ<4LK16[.(*T<*@P/ISB6B%:(UHXR%O>Z(.O:[QNHZG*>#EHL]J!1J4M+5U
MVE>L0)&QH@].&'/"H?;ZH#OI#45G23@912J-.#1HRE:NUTU!W>X2AN!U;34,
MZB($G6XP<?\3E<@YGXNE*=C*G?*AS*6UX@:I$"T8V69;(EHA6B/:>,CO!"H$
MOV+HZXC=ZP0:B:$OEKFHIZV<+AT;1./.<7`H)L7$6-'@Y\9*#?)&>B-OM5I\
MKJTNYYC;'*T6.+&PA;A@55HK+GV%:&&0TSA+1"M$:T0;#_FN5C'_%:[61P2>
MJS7RQWM?K)*1.@^GY6%B/18;%-`FKAG+85],M(FQ4A^.E>@0*5NY(]X4]8T1
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M=F^9#/MB7"7&RA\V\G`N-5:.?&;119\VA5#?-@XZ8]'M<IL_>Z:PRHQ*1)5!
M8[N`+%!KB0E7B-8&45-QCAM/RW>I.L.XPJ7ZR,-SJ4;^@,0%6%MY"[!&8@$6
MHR3IF1R]!1!=:JQL9\\XH;L`M\S$.J'9<@\[\JPJ9QD[L@I&-K,24660-TJ;
MNK!GEIAPA6B-6ANV:AFEZB3$=>G_=]ZASU,\3VOD#]Z^B)&BGK8*W(!:HU`'
MU.$X"(<]L85*3#)G_4E9R8:<F447QZG.SRRO0_JBR)_H<\RLL,KLF]*@B<V_
M8D09.-M!$<<M4'Z)\BO6NKA56+-5OUZVPFY`%W!Z8I>Z\3+TQC<=8K1T!KH+
M1!509U^_'%[KLZ_W'X35BOY)BT%B"A"38\0)NW:2BQO6,U%W&/3&<EEF(V\*
MD-N<E*VL>L;H\A1@K,P40+.ZZ"RL<C'[@JTN[\4:*UO*JF%N,<.^6!07;&8G
MHB4C.Q&M&%$CVQX*T]ZZ,3/M'@Z'PY$<DQNVPCDFD*=S<H[A?M5RIDI7M_A0
MM981?4F?VM'7Y#P.(V/EH!A1@BA%E"&:(\H1%8A*1!6B!:(EHA6B-:*-A_QQ
M3IVG9=+G"VOOOE05*)W:([;[]$=BGS4S5A?OD%@;=F2,*$&4(LH0S1'EB`I$
M):(*T0+1$M$*T1K1QD.^U]3AC[M4OS%<]%F1NR:K0)/\Y=\J&8CU+K)6UA=-
M0D8)6J6(,D1S1#FB`E&)J$*T0+1$M$*T1K3QD.\+=13B^L*9TMYPBTHI9C&-
MW'LF`:`848(H190AFB/*$16(2D05H@6B):(5HC6BC8=\'ZACCS_QP14[%'UX
MX@T3C0;UA8CZBYA(W2!6$:5=3V-&M`39W=U`;'`3:\4C)_607R-U#/#7:V0.
M)IQSD$`CKT8:>34R5I-Z>Q5T>V(F3U`F9=2DL6=J?M54-.Q6[8U1HH-GSRL:
M^0'%0.RFH\`D[-I]>&P8Q<O64P&<TS<IK8_3MU+Z550!VQ55-/&=ZR837U)G
M<[J4V&)&*@96,TC7IHP-&],\[:04N\+$6#G=(&U-.+2;:K^&*E2ZHH8ZLO*<
MJ)'OQ*&(4"(*!W4-72<RTR>QW<X0:L<6K@.9M:3RJD;AYC55J\W]6=P@/ZX9
MBL@UXH2N\PSSG3>T`ZF>@A)CY3JO/:$=M7X-VW;A`1UB4&^[/!A#O<MV_6B0
M\*/<27!"=S`V3'];/>Y,1!,EC87CQX;I5+V.<ZCCUU)N;=^H6K.#Y>EY%FKD
M!!`1HAA1@BA%E"&:(\H1%8A*1!6B!:(EHA6B-:*-A_R&5UM$=V[0.Z*K8XI0
M;S6IL]F9K"_/9&;&ZF),86W8MS&B!%&**$,T1Y0C*A"5B"I$"T1+1"M$:T0;
M#_E>D_O8-X8+;EZ5"R"F&,D9W5I97S0)&25HE2+*$,T1Y8@*1"6B"M$"T1+1
M"M$:T<9#OB_4'A-'T#MNKH<JI5B--')C"F/EH!A1@BA%E"&:(\H1%8A*1!6B
M!:(EHA6B-:*-AWP?J"VPZX,WQH/>,7LKHT;N/3\5;]<;-AM0Q"TL,<R]DVF0
MHY:QE;N;A3OE<VO%HRMG9`\`"RMO)UNX,%`:JY9[=]27KFHNW-77"OZU2(/H
MIZ/-J5[<PA+#O.;2&7C-I9&XORS"ACEKV9/6G)';7"!?&JNVMKDN'`@Q'##(
MJ4UDD%\;^4/&V%JQ\Q-&MC8IRF=LY?4M>:`WMU8LGS.R\@7*EP:U-9;:IU\Q
M[LRVWD9`LU`CK[$T$HTE]M6Q24A67)N$D:U-BO(96_F-)?;`<VO%\CDC*U^@
M?&E02V/U9:SB'#Z]_^"C5O$7#8/<-F0KNGO+Y8];6&*8.QA1+6,K]\PDD#]K
MFULKSC)GY#09RI<&M369#'XNS^M]C'@,\B.>D3CNB3BA,W49I,YUF]`\D'=X
M$F/E7T:`KZV,E7N'B.7=R!^^PID;*^]&!!0B?U<A"EL(MT(VZJS#U=*6BYU8
M67E"WK*KJGW%\*_-1=?549L??<--'TYHNU%LT%`?$/1'+3=].)43CS*R0AFB
M.6LWUWH&HI5R3F2E"T96ND14,:H3^FTI`[$WNGH3;[&?9GV-1%<72V9DK.B,
MG!/&!EWN98FQHAIPPA2U,D3S=\GG*%^@5HFH\A+Z37I=E-3'*,D@OWN.Y,F>
ML7+OO1BDCNDNS1XF1]N-4BZ$;>4,T=P@^CK[@GS.":U\P<C*EX@J1BV]]$*P
M<\4:AH%/7R/1><59862LW'LG!M&9FGX[1-M$H+6]GJN1,PHRUGYC1M8)S;43
MNO*'<P/D5EAI'CHEHLH@74R_(\OP1NX<WO=-/+W,1L:;!E&HP"6+$,6($D0I
MH@S1'%&.J$!4(JH0+1`M$:T0K1&IE_^8,Q)J'.T0_3(?_::3Y]WQZR[:/3V=
M;AX.W]6+>H;JIV0--F\1"H+I)SI_(PGQA+YAGZKOC=N>A/2DGJ$A39^>U.-2
M/@E)K36?3V$X_41U:<F'GJA3IK8GE`^=>;0]&="3>@<O2]`?\@N3Q!,*6*<%
M[?)0C8+4J=K_X1-Z^]*GUK:AMS+5KS`2><Q48[;I4.7I2@5F,%-U;^-4\]:*
M4[U;JQU0B5ISH)A_JB)ZS#L+1_2DOKPIJD&Q'#VI3QS@R82>U#M4^:3?G:K=
M-^9#AP=3M0G')QORE0X.A!A]03I5WW5BDAF)S5K%(GJBCD8P34055:<`;4_&
M]*2MHE$XH2=M%8VHHBJ,034ZA)FJ8`:?I/0D;7VR&$[5[QPQR7(X5;]VQ`>K
MX91^A]_"1U/ZL7<+'T_I%\4M?#*E'[>V\%YWJGY!B4]R\F/K@X)&5NN#<CBE
M-Q2@4CF:TF_>6_AX2C^L;N&3:=565OIMZ53]<A13).2*U@<I>:+U04;CI*VL
M&8V2MK)F-$;:RIK1"&DK*_W,=CIOS7E&7;KU040]NJU($?7GMB)%U)O;BA11
M7VXK4D1%BG7.=\T(I+>[O6Z_[A;;X]?]R^GF:?>%%I5N?9)\U.^'TW^<S87.
MSX<SO=>-(BIZOQ:]QV]'K[;JJEN?7PZ',_]!_KEKW@SX\7\"````__\#`%!+
M`P04``8`"````"$`^USL8)D7``":A```&0```'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6RLG=MR&SF2AN\W8M]!H?N66&3QI+`](;%./),;L[O7:IFV%6V)
M#DG=[GG[3102!63^4)'EG8Z)L?U5(E%`(H$?J"+YX1]_/WV_^.OP\OIX?/YX
MF5SU+B\.SP_'SX_/7S]>_O<_B]\FEQ>O;_?/G^^_'Y\/'R__=7B]_,>G__R/
M#S^/+W^\?CL<WB[(P_/KQ\MO;V\_;JZO7Q^^'9[N7Z^./P[/=.7+\>7I_HW^
M^?+U^O7'R^'^<UWHZ?MUO]<;73_=/SY?6@\W+^?X.'[Y\OAPR(X/?SX=GM^L
MDY?#]_LWNO_7;X\_7IVWIX=SW#W=O_SQYX_?'HY//\C%[X_?']_^53N]O'AZ
MN)E_?3Z^W/_^G=K]=Y+>/SC?]3_`_=/CP\OQ]?CE[8K<7=L;Q39/KZ?7Y.G3
MA\^/U`+3[1<OAR\?+V^3FWW22R^O/WVH>^A_'@\_7X._7[Q^._XL7QX_KQZ?
M#]3=%"@3@M^/QS^,Z?RS053X&DH7=0AV+Q>?#U_N__S^]E_'G]7A\>NW-XKW
MD)ID6G;S^5_9X?6!NI3<7/6'QM/#\3O=`/W_Q=.C&1O4)?=_?[SL4\6/G]^^
M?;P<C*Z&X]X@(?.+WP^O;\6C<7EY\?#GZ]OQZ7^M4<*NK),!.Z$_V4F2=':2
MLA/ZTSE)K]+^<#SI<BMTTW5[Z$_G971V.\9<F/YTA8>=VT&I5=\!_<E.^E>3
MX3`=3<;G]VCBXF+^XN[E%]Q06.N;27Q\Q[_@QO6J&5G_C[NA2-B[H;^PF^FY
M_7MM!VZ=!]G]V_VG#R_'GQ<TNU`'O?ZX-W-5<I-0Y%P&V/':Y,1[*4&Y8+S<
M&C<?+ZD\C?972N2_/J7CT8?KORCW'MCF#FT2:3%S%B;1C-M,@UR#0H-2@TJ#
MN08+#98:K#18:[#18*O!3H-]`*XI&DU(:+#].T)BW)B0N,Z\<\#'J*_ZWUFX
M(ID&N0:%!J4&E09S#18:+#58:;#68*/!5H.=!OL`B/ZG>?C?T?_&#645Y7R0
M$V/9XW?6:$"S=F,TE":SQJ2)"I`<2`&D!%(!F0-9`%D"60%9`]D`V0+9`=F'
M1,2(.DS$*+Y@N]G)6->A<%UX9\F`9M*FWP>3B>KYQL@5RX#D0`H@)9`*R!S(
M`L@2R`K(&L@&R!;(#L@^)*+G:3QWZ'EC+7O>$M7S4]7SC5'3\T!R(`60$D@%
M9`YD`60)9`5D#60#9`MD!V0?$M'S-%A%S]NE^LKHHO;A;PK*(##I3YK5888H
M0Y0C*A"5B"I$<T0+1$M$*T1K1!M$6T0[1'N!1`1(W[P7@;=OCP]_W!UI-J%E
M/1*.`8DB*Y6,$QD-2X9!,"P9DRL_/4U[,DFRQL@E2<[$[E2,@"K`==F4"ETK
M(58U1L[U'%POP/6R*16Z5AICU1@YUVM+!M-F+&[`];8IY5TG/;68[AHCYWK/
MI.X0$4FS@P]E;R1BM(-S(3/6,F26#$E"-`'JZTG,VO1I#?,V_50%T1J-)[5F
M3@:303H=#P;2*+=&J=TVUG%M?+NFE@UIJ:WBVJA;_"T-5(3F4-NB\>UJ6S8D
M<*3;MCJGMC74MFE\N]JV#6FI;<>UM?;D/JQ-#(AIIP%AK.6`L&1$<W'3LX.I
MBN.,BXE1HWLM8T_"2,>H:#RY/BH;XF^@KWU7Y_A>-)Z<[V5#6GROSO&]:3PY
MW]N&M/C>G?`M(IG0*5"'W*[-92P9B>Q.M2QGHQ/IS5;CUHS+V2I,<._>]53I
M44M756?5.,<:%]Z]JW'I44N-*U>CS;RTETS&B9H+UUC?QCMW]6T]:JEO=T9]
M=&I89ZCM43D\S+8[G/J-C.J/S/E>;-T.5@%SF*2RGI%*>S7'SUQ!D=(Z-S/G
M2UA!XGM?KM=*CUIZK3K+_<+[<NZ7'K6X7SGW([N0#:?#_EA-?QOOR3G?>M3B
M?-?N7(:7ND^$MWUE-R=[.J86R1W*%-*_L7)MR=@7%70H1U0@*A%5B.:(%HB6
MB%:(UH@VB+:(=HCV`LE8F.V[3K5D>,:.);$;?SH\<5UYYU"X9XFP+,+R""LB
MK(RP*L+F$;:(L&6$K2)L'6&;"-M&V"["]I+)F)B-_3LQ.7\/D]CC`1$?1I2K
M+F8S-CNQC_%6KF#ND(]_P2C8)97.2FZ3]%[&6SGW<X>\^P6Z7SHKZ5ZIY96W
M<N[7#GGW&W2_=5:A>]S3>"OG?N]0[5X&UYP=A,$],?D9<R5]+!+2!S8VYDR3
MRIV2/M;*;6VF29+2?VIGPZZ$\FF\NQ:79U58L56[UIICC0OOWM6X]*AE75J=
M5>,::]QX]Z[&K4<M->Y<C;S+B7;J7E0H!X@YV^@P0/@HQ`_DN\0BI7C42C]C
M*[,T--LAV(UDSI>P0L7CSF.:>:4\RWUUEON%]^5"L?2HY>Y79[G?>%_._=:C
M%O>[4^YE7,U!1X>XVG,1&B?NIN[,LS_*:9'XN.>Q1J<2WUJUYV'.%8K,;]R[
MVRK9JKW&BJW::YQCC0OOWM6X]*@E.BM7H]OS3$>#D4J"-=:W\<Y=?5N/6NK;
MG5'?7M0GAX<Y]@B'Q_E['GM@(D:*16H&4!/[+.&"(K=QS\.^A!7.`(TOUVOE
M6>XKMAJUNE]X7\[]TJ.6H*R<^]8]#]S[]BSGNW;G,KSF>"0,[XEEGX]<PNRW
M*-BZS!)`&:(<48&H1%0AFB-:(%HB6B%:(]H@VB+:(=H+)#J^KX^:?O'MB=I/
M+<3\<$O'ZG'D'5NU/BSV-FXL9XAR1`6B$E&%:(YH@6B):(5HC6B#:(MHAV@O
MD(R:.<<Y/UWZQERJ9$;BB"#MJ><S,V_E8V%]!7F6HU6!J$14(9HC6B!:(EHA
M6B/:(-HBVB':"R1C05.SB,79#S7[IJ0*BT4#_\[+C*T"E"'*$16(2D05HCFB
M!:(EHA6B-:(-HBVB':*]0#(&^IBF??DP6DQWO$52//;41GS&!=NU7,96O&WL
M#WOT/[5I9).T;^2K;(H^W3C1%#S&Z%LDU$W:4YO^&5O1_L:G-A=LU1JY*UB_
MTRIOW6Q[.\Q*=I<<"C-S@@T2OJ=4Z8RMJ`_]K=N"0CZG/:7H<BY(O>X7J7[?
MO^0G6]-MH]G'C28C%0A]#,M6TS`0UA>=$P;WJ35E[FJ,!,+L0CH$PFY:1"`L
M4NG@>ZI^#V#6;W8[P7V"0F8K$9L^ML;ZBF6$T9\=6L-R-="&IB-I6*E`0$9P
MP3`07%`,&+QU+A@)1#=9VT=9RT@%0KTV,&,KD1'6UZE>MU:17A]H8=@^#]7F
M<BUCI'I=#W^V"H<_HQ/#W]6(O3[0ZBA8D<\_(*Z]J!99[:."H43NC`M.:45I
M.3ER5A0`;P5#BZUB\3%*(<P*W<A_'G_0W9]Z(C@P;E0K+0H4WHRM`I0ARA$5
MB$I$%:(YH@6B):(5HC6B#:(MHAVBO4!BO1AH#?*+.ZG:3QT1/S#2L7H:?<=6
MK3LI;].LDXAR1`6B$E&%:(YH@6B):(5HC6B#:(MHAV@OD(Q:-[EE^ENGBT5R
M)Z47P1D7%!G4%'3AR=&J0%0BJA#-$2T0+1&M$*T1;1!M$>T0[062L=#Z,9C2
M3JP^*"4'%@7;IAFB#%&.J$!4(JH0S1$M$"T1K1"M$6T0;1'M$.T%DC'HIGK-
MJ-?Y8)%:)/5.B@N:?9!?_G369&S%.ZE1?Y3HMQAR-HFMD$91ABODB3%D!6BH
M@FGPH&[L@X+A@H%N=`7ML6H_&0XF^GVBG&WH42BEOXR!T9,=;ISE9R!X!Q;)
M&`0;'2O?V2I4C8RXPX>]T6@X5:'+V2;6XT9-=KAQ*SY%CUMT2C-:*Z$9+1*:
M,>TKG9S3&[KU<*69-QAU?ELCPI!V4\"UN512C&08>KXZ&P97D.XMN"FU=\W8
MBLX$ZX^F]:;)>*J;QS:1R-`SJBZ1J<U56ZSVE9&!7'`%@UQ@U/X$(W<%,1NH
M-9UN'05M[4$_&(1L8*LP&QBY;!A->D-X_,\V](=.XU0+PO;YIS97?6X\P+Y5
MSS^N8-CGMB#MO,U@^8T^0CN=3M1^-W?E(EUNE$F8Q\%"?/X&*K7Z)DQO1BHA
M]`:*K4ZL#6Q%VT#3Q@&U;S!4*CEGFUAP6K1&W<3SMD\I"@^'Z+#)Z;H9L[JG
MZZ3/&JO@53O'(@'IMBJGN"HSHM72WY2U"E"&5CFB`E&)J$(T1[1`M$2T0K1&
MM$&T1;1#M!=(K@%:0_SBIBYMQ(6?X].).A6^8RNCD)N5`++=>B(;%\C,%W,H
M1U0@*A%5B.:(%HB6B%:(UH@VB+:(=HCV`LFH=1-0*0HH1D9<-I%(![!RVX(B
M@P#EWI<+3X&H1%0AFB-:(%HB6B%:(]H@VB+:(=H+)&-A)-<[:\F)!9'%FI]'
M[U*+PDT=H@Q1CJA`5"*J$,T1+1`M$:T0K1%M$&T1[1#M!1(Q&'93LK6Y5"*,
MU,*M=@8SMCJQ<+,5JZID/!CUE:.<32+K]K";D*W-55-B0G:@I/3,%0Q$%:,3
M0M85Q$7<=)[(A/;A7YNK6[?:5D9AH.43%PR%+*,3#P/8*M;K6LJ:9?"L3YP,
MK1(-12`CN9,8*.DV8ZMPC\>(56V2]I/14(M:5U^D^[6H/=']J%Z'%LGN3]4B
M/F,K\\I-LW3@BZ-LQ=NY)/9ADYQM8O'0ZO5$6U"E#BU208`LX()A%G!!&HJ^
M>?#<@MU'#C>&W:1L;:ZRP.I6&0;,`FLELL"B4UE@K6*]'A.#YV5!(_^<!+@;
M6J0"`%E@K4066"1..O!Q*KN/!4"+HU_:W-&'&/3!'R,9EQ[,3K:@>6+IQP\<
M_+$OWMR]DQ[64RQ01B:\HSDZ;.Z&5FV(N<NB0/'-V"I`&:(<48&H1%0AFB-:
M(%HB6B%:(]H@VB+:(=H+)`3(2`N07]Q&U7[J[RIKQDXZ4>+ACHU:=U'>QB5D
MABA'5"`J$56(YH@6B):(5HC6B#:(MHAVB/8"R:!IJ?6K0;."B]+(9WRJ3Z/N
M1M:J/6J-C8\:H-Q[<E8%HA)1A6B.:(%HB6B%:(UH@VB+:(=H+Y",FE:9P?3>
MKA*,L%7/<AB%^RU$&:(<48&H1%0AFB-:(%HB6B%:(]H@VB+:(=H+)&,0D\O\
MJ='SST]'*)T9^;.?&1,S]?HI47_<+7-6_OM9<H=$P8$7L[)!W;3S"+4S(RD.
M$OUFGRM(GQPPA[J3JTE/_#?,?U-%,E?$?L=F?;B:.\9NDJL!G7^'_^6_^7V#
M;*A1MZ%R.)$RK(^#(PHCZ.#,/E%/<V;.*E31J7Y$F+%5\('1/%IPX)=`V1HC
M93NTQBK?4.^,+!)A&PSU-H&MA+!.$V65L15_&RI'ROI_MZ1LCE&^'9ICA;)H
MCD6F$YML&8Q\[]D'<B,N2.\;FU'8NQHI69ZQA0A,2R'9"JV_3PPQ%-HCBP+%
M.4.4(<H1%8A*1!6B.:(%HB6B%:(UH@VB+:(=HKU`LN.-=@^'SZ_J&;L'D'H&
M7M`:6:MV/=/8.*62^6(.Y8@*1"6B"M$<T0+1$M$*T1K1!M$6T0[17B`1M;'>
M.K2G2VTNSPL84;KXI$_UB<7,6[F.SQ#EB`I$):(*T1S1`M$2T0K1&M$&T1;1
M#M%>(!D+([8Q@\[X-@SS_0E*6S(*M26B#%&.J$!4(JH0S1$M$"T1K1"M$6T0
M;1'M$.T%DC'0^OY$/J"H'S,2V@,^ZA*SPF-,MJ*EW:R426\P5L\K<^<'#V3'
M6B6?:`G*X=H#O-BA[F#&5N%)(",A._`,C:TB!TSC;GJX-E>3DI7(0HFD\$Z*
M*QB<OS(RFX]&PJ3P=7NN(-726+W[21?S]9LBK4\$`D5O[4$'H@>!8&D<?&Z'
M"QK![N]3S\TY6\4"8?1C.".=N'4K-T-).+9(!@+>T6*K*8D\?Y]P:NFL^"/U
M0ZT;<S:(G,J:H=BE(:PV@XU'[4''`%[08BN1#-;7J62P5K$8=!.T]-P/E@*+
M9`PP&;A@F`Q<T$X_`WHE3FGYW-46F7ZT'#PQ=!K5Y_3!W=@BL3E*<=1;*]IO
MNX(9%SPUZFW!2(]/M"8*SGC./U^HO<A9B9$,!!SA.RL:$2W)X*QL,M!W2XS\
MX8+=_+D;P-A,6H1&AP/\VHUJ(0L1>HCHPC%S9O2!.L<RR<0*/#'KY_ES3FVN
M;L*NP.$&CJT"E"'*$16(2D05HCFB!:(EHA6B-:(-HBVB':*]0++CM6#XQ0W<
MQ"H)L8).U+G2'1NU[M^\C1\WUC<5<RA'JP)1B:A"-$>T0+1$M$*T1K1!M$6T
M0[072`9-2Z5?#9H53'+7#4\1)M:J/6J-C0M1YHLYE",J$)6(*D1S1`M$2T0K
M1&M$&T1;1#M$>X%DU+I)P@E*0D9RUYVH)6#FK5S'9XAR1`6B$E&%:(YH@6B)
M:(5HC6B#:(MHAV@OD(R%UKC!:M^N628H=QF%NVY$&:(<48&H1%0AFB-:(%HB
M6B%:(]H@VB+:(=H+)&-@U&^'-=^*Y7"?,6$DOE`N391>G35F?@')&F:^SIU^
MEBB9]%4>Y8V)5YE%P[RKLF$T,AKMEB;O/`V9&'G=H=4LT(--2>U!;TK@L0];
M)?3U7WX:8&?-,YQ$/`GJ)?`H*&_<^._A+QKF79<-8VEZ-0A]R;@;#=ZA!ZQD
M%W%G^4\S9-#A^GG0A`O:G6$MCS/'S-<`!475KCIOS/RWEA:.!>Y*9O+@(/&O
M-(MV3_4.HWVBJ<VEQF4D-D?XY,@5#"//3.Q'X6E2WI0,@MVP(-BGO,EFZWW'
MB6;CJ>;4(K&#PB=,;$7?)^H'O&/O/G7*G05]-ZY+DZ)AWE/I6,R3;&ZWG0R]
MA:9W[HQH)^?N:.:L1$BY9'#LD#N[@!415HHJY.WK_<"):%EI'B:G^8X&<RRM
M)F7]SEICYCLY:]C[DW)C$L;+U>A=E8V=<S5,_;-3V6(MID^TN-',+CIW4XM$
M6J8P(;.5F)`;=O:S^;PI$N8HWU,P/,K&SKKN\+Q^VDVGUN9JGK+2521L"L_K
M74&1L"QZU?RLGA7GKBA];Y*+0N%8X*YD)N?G8*&7`T%KPA,#`87@U"(Q$"+S
M,Q<,HI5QR5/SLRL9QMZQ<'ZV[%UOLMG=9)@YKE5/G1B)<$?F9R?6?,PRYRPV
MJ]KS+&<AYF?T5#J[F"?9W&[Z:XKZBY&8G]DJF'<S5S)@>805$5:**N3M=Q-/
M4Q1/#LGY67]<9-:8A>%RBLI-JBB:FV+A_.R*>5=E8^=<O3L_DT;MI!>MO9R0
M'!.9B5.T,Q-SM(?G3]*^3)"I'@:IZF'G>3KI=5-6UEYW3$1;X53=%`TFUZR!
M<K+N^XV/36%OY^-?-##P2#]EPW<CCA'[_AA1I$+2ZR:UK+UNOU518F#@E-T4
M#>=L!]^=9EWS6:C1IU>:Q<J5#4<:-=]:ONM0-;^;5*,'R3!S.W9BZG9F0ELW
M,#;ENJ8[91;,!DTY&7FVC#E3S>ZFU\RK<7K!<BQX,C"+,!KAMFQ@1S_*!(P&
M,S`*)C#Z$29@])-+P.@WEX#1CRX!HY]8`D8_J02,?E,)&/VH$C#Z"25@]0^M
MF_ZS?6!#87\XW?Y@]-/AY>MA=OC^_?7BX?BG^5%T^J#AIP\-MC_93D?_-^9`
MFQ)`7;F=I#>WIF*\=$>7S'EJ[,J0KM1G(LK=W61$5^J'3OH*5=+\;KR^-NK=
MF+?VL:;;47)S2^^_X15ZNY[*U`<$X*U/5^I'JG!E0E=BWFY'TYM;>DP3JV=*
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MY_'EC]=OA\/;I_\3````__\#`%!+`P04``8`"````"$`].&U>6H%``!X&```
M&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R<F5UOHS@4AN]7VO^`N)^`
M^4@@2C(J']T=:59:K?;CFA(G00TX`MIT_OT><PC%#K7I]&+2P..#WW..S5O/
MYNM;>39>:=T4K-J:9&&;!JURMB^JX];\Y^_'+X%I-&U6[;,SJ^C6_$$;\^ON
MUU\V5U8_-R=*6P,B5,W6/+7M96U937ZB9=8LV(56<.?`ZC)KX6M]M)I+3;-]
M-Z@\6XYM+ZTR*RH3(ZSK.3'8X5#D-&'Y2TFK%H/4])RU,/_F5%R:6[0RGQ.N
MS.KGE\N7G)47"/%4G(OV1Q?4-,I\_>U8L3I[.H/N-^)E^2UV]^4N?%GD-6O8
MH5U`.`LG>J\YM$(+(NTV^P(4\+0;-3ULS0>R3AW7M':;+D'_%O3:C'XWFA.[
M_E87^^]%12';4"=>@2?&GCGZ;<\OP6#K;O1C5X$_:V-/#]G+N?V+77^GQ?'4
M0KE]4,2%K?<_$MKDD%$(LW!\'BEG9Y@`_&N4!6\-R$CVUGU>BWU[VIKN<N&O
M;)<`;CS1IGTL>$C3R%^:EI7_(43Z4!C$Z8/`9Q^$A`OBV<M/Q'#[&/!YBP'A
M9D[`ZP?#E(?!"R?PB3]C"A:FI,MPDK79;E.SJP%M"Z*;2\87`5E#9)Y:%PJ$
MB1B2_5&N(<D\R`./LC57I@'#&VB0UYT7>!OK%8J:]TQTSQ"1B&\$KR`/F^`%
MK`._D(XN6"!@4`%9'*N8;HS;9#G,)WM[3(07(/8P>T>:V3VQ6HE(<H\X$I+>
M(U[@#V$$0=`A\P5Q&,HVFK\7+(>X72HC9*"'!HWO3^Z(6$LD6B)5$8(^F,A\
M?1S>FI"]8>Y>(.4V0B;H>H^X@>N%*]<5<Q"/&2>T'3]T;1%)Q@@)"?'@1T32
M,>*ZJY43!`,A:(3E-%\CAV6-[W&QALC`\T=Y"(=G8Q7O&:G.B99(582@</D9
MA1R6%(92^B-DEEA%$CJN[P2RPC'C^$MH=4]:K@DBXT1)24A5A"`1]K3Y1>2P
M+%':Y")D>HDK9^F1E2.E(1XSGN-Y0>!(79@@HI*H(@2)W"9-O`+4FR@?)$N5
MRA`ATTMUW)5GVU(=8D04,A(MD:H(06CX,T+Y(%FHM+%$R*!0-PQL_B.M2T14
M0K5$JB($H03>X)\O:3=*EBKU7=1#J!5:,USZ2VDOC@6&N$LW=)=2/I*>420D
M52*B7NX+1BVL;EV"+D)XGX128T8]=&M>GX3R*R<6D9!`)L2B)SVA%(F3F49$
MD=P^S!>)9D,4*<TO(@AYW7XK52@>;KZ_;J0D)0/"'9\T/AUN3HT7E7';,%\9
MF@Q1F=2"$4&H;U-_8D'VQ'3BNW=IHD=2)2**A">-1=Z<MJ97^2AY3<J^@"#T
M01EO-Z?*T.O4(NGPB*DHHD[N'N87$[V&6$SIC1_QO_4@"3#+P?A(G1CKD42/
MI$I$5,D-Q'R5:#>@)P<!]PZ=J#P)FCL]DNB15(F(*KF'&*F<V;/H/,8UA04H
M;HT1F;`GMN25XBE(C)/HD52)B'JYE1CIU:Q--!ZB3MD#$94[Z:NJ11)]E%2)
MB"JYCYBO$EV'IG=5UJ17J442HD52)2*H='[*`W6CQ/WVOG=[2-B/;,D3QE.0
MU+MZ)%4BHMY/>2#GW@/YMNSU>DC0*4J(]4BB1U(E(JJ$U3:_=QU.ZTY&>DBI
M$N,HD$0?)54BHDKN7F:O4#AZE3V"*_NAGL'S$=\F4W^B](Q2)3Y*@?"#X(]?
MUJ@2#WKQ&+*D]9'&]'QNC)R]\$-<!]SH<'4X8'YP^'F==#TB:S@TA.O6<`/.
M?2_9D?Z1U<>B:HPS/4!(>[$""U'CR3%^:=FE._Q\8BV<^':_GN"$G\(IH[T`
M^,!8>_O"'S#\G\'N?P```/__`P!02P,$%``&``@````A`"@$<VBG!@``;AH`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULK%G?;^)&$'ZOU/_!\OMA
M[QH;C(!3`%][4BM5U;5]=HP!*Q@CV[G<_?>=W1F;_>$01\I+"!\SXV^^V9U9
MEN7G'^79^9[735%=5BZ;^*Z37[)J7UR.*_>?;U\^S5VG:=/+/CU7EWSE_LP;
M]_/ZUU^6+U7]U)SRO'4@PJ59N:>VO2X\K\E.>9DVD^J:7^"30U67:0MOZZ/7
M7.L\W4NG\NQQWX^\,BTN+D98U&-B5(=#D>6[*GLN\TN+0>K\G+;`OSD5UZ:+
M5F9CPI5I_?1\_915Y15"/!;GHOTI@[I.F2V^'B]5G3Z>(>\?;)IF76SYQ@I?
M%EE=-=6AG4`X#XG:.<=>[$&D]7)?0`9"=J?.#ROW@2T2'KO>>BD%^K?(7QKE
M?Z<Y52^_U<7^C^*2@]I0)U&!QZIZ$J9?]P("9\_R_B(K\%?M[/-#^GQN_ZY>
M?L^+XZF%<H>0D4ALL?^YRYL,%(4P$QZ*2%EU!@+PURD+L31`D?2'?'TI]NUI
MY4:3>1A.H_D,HCSF3?NE$"%=)WMNVJK\#XT8A<(@G(+`*P4)HDDX\P,&S[SG
M&)`CO)+C;,+G(0NC-QRGY`BOW1/9.$\@)!.&5_*,)FSJO_)`#^62ZN_2-ETO
MZ^K%@24-@C375&P0MH!0G>PH4E^(U^H`!1!!'D24E3MS'9"X@<7S?1WXTZ7W
M'0J>D<W&MF&ZQ;:S$-4587<FD"B`!PGT64#!/B`+$45DT3U_TP&WM+A!N;/H
M7'8FD"B`1AF6R@=0%E&@=%"Y.\JC40!KK#<*C3QZDSX1"TE41$L%`JNI#&_9
M;JD(8\FX>](&D4#/P238&W5N.PM)5$0C"*%5@F*11\%$-(9WKG,12">/2!`I
MV@9^9*C;&_7D+211$8T\A/X8\B*03AX1@_S,(-\;]>0M)%$1C3RT!)-\")OX
MG;*+*#IS1`SF<X-Y;]0SMY!$133FXF!A-$8>3J!*[^0NXNC<$3&XQP;WWJCG
M;B&)BFC<8YL["^5ZO[\WA9_.%9'@UA.W%K*SD$1%-&(,S@6JJO?I2&N=#T$A
M=-6^EP7,-\0C*PX=J[?BW!A(.[*:S>7`"F?,-YI.0A93+H\NZL!A8A(IR^.-
M1'!N09ONJKF1`:`-A?+AW&?&L[=DP.2S:1QBF"A"'SZ?<B/SI/.:VHS%(!K/
M&,>6QA@AD%[,=V!L=CF@*I8/J-YEN2.().:#C-%K2&,Q<,8SQO&D,4;HIK'9
MVACYJ!J3SSV-R6M`8S&!QC/&>:4Q1NBFL=G2&!IH&B-T5V,T&=)8C)WQC'%(
M:8P1`HUO6RU@ULF.'%6AR1&%CD,V,W9``H^1[6A`9S%OQK/&Z:2Q1LAH(^;A
MCJ%5I"YH@D#0OK,$+-#[3T*.H/?-BO/;?M%[HAA!XY/!@:4E@Y!1`J/;;1DY
MJB4@1RP!\WG(9\8<2CJW@2*(\3.>-PXKC3="1A&,5;!E:*45@2"]"#=Y9;=,
MR'%D$<3(4I+![T%R9+:G(GO:5%!N:+\#?3Z`?DC?@G#N:3DB9-3&ZD-H%<-T
M[%?5P+PB*R8;\)QQ%EG5(@9VM;@Q>46"KYQG9,+?JNMK"<-7VBYC&56?T`3I
MQQMF]K&;53\K;"C1(&W3<&/^*O4:*)'*V![%,M;*50\Y-K2SH42#='IBJ"G+
MZ0U..`+5=<,)@I7>KPC[G$-6;YQSR(H&!`NF+#*:0T(F`P-"Q'Y')C0:E8..
M#"#66G=L,#<X&:@''8+HH!/.X5;#W-V=U\!*%\-NO/8X&C7M"<)SX<!!AZ,!
M4+@M7H2ZLV0\8['%&$V&-!:#;CQC&HNJQ@C=-#8;#'PB1ZG2_`DBC2,6Q'-K
M59#7@,9B#(YGC$-3TYB@7F.K0:"!IC%"I'$4S#DS\DPXF@QI+&;=>,8T+%6-
M$1*R*3O2/.APM(I5H<EQ)C?`-.#SR/!*R`L.=["@]$8B1IU"6^ESX^<2QWFI
MZ4^0VE^8;\BY)<<8=G6?LSV7.JLI[O`XGOE3HYP)V0P51HRL.QF.'$0T^-2"
M(02#J-NE6[C`%MM`@78V)*ZY;U98#;RVQHO3,J^/^38_GQLGJY[%E334;;WL
M8;POW\0+^!H,3S9Q[L-%NKP+MSX15^SR0MKZ!(+AY;OQ"=S*/\BE9N`;"#4<
M"0(-L'H((,X@W6`!]WX#:4P7<-TV@(<+N,D:P*,%7!(-X+,%7,$,X/,%7&\`
M[O69P6W_-3WF?Z;UL;@TSCD_@/2^/*+5^'L!OFGIY/)8M7#/+P\Q)_A=)X<+
M95_<WQRJJNW>B`?TOQ2M_P<``/__`P!02P,$%``&``@````A`,:3/()+!P``
M#AP``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULK)E=DZ)&%(;O4Y7_
M8'F_R(<"4N.D1E%!2%4JM4FN&<61&A4+F)W=?Y_3].EO,A^IW8MU?#S]0K^\
MW73#W6_?+^?1M[)IJ_JZ&#N6/1Z5UWU]J*Y/B_%?7S=?PO&H[8KKH3C7UW(Q
M_E&VX]_N?_WE[K5NGMM3678C4+BVB_&IZV[19-+N3^6E:*WZ5E[AEV/=7(H.
MOC9/D_;6E,6A;W0Y3US;]B>7HKJ.J4+4?$2C/AZK?1G7^Y=+>>VH2%.>BP[.
MOSU5MY:I7?8?D;L4S?/+[<N^OMQ`XK$Z5]V/7G0\NNRC].E:-\7C&?K]W9D6
M>Z;=?S'D+]6^J=OZV%D@-Z$G:O9Y/IE/0.G^[E!!#XCMHZ8\+L8/3I0[P7AR
M?]<;]'=5OK;2WZ/V5+]NF^J05]<2W(;K1*[`8UT_D]+T0!`TGABM-_T5^*,9
M'<IC\7+N_JQ?D[)Z.G5PN6?0(]*QZ/`C+ML].`HRECLC2OOZ#"<`_X\N%8D&
M.%)\[S]?JT-W6HP]WYH%MN=`^>BQ;+M-123'H_U+V]67?VB1@U)4Q$41^$21
MJ>6&,V?F$Y$W&GK8$#ZQH6\Y4_N]9E-L!I_8S'&MP+'G7O#V\0)L")_8,+#"
MV6SJAZ3A!WL[1Q'X9$?_O(C#C8<_4,;[J/$3>A'[3,1%5]S?-?7K"`8::+6W
M@@Q;)W+@:K`TT$O`\_%?\8!<$)4'(K,8@TEPY5O(]+?[J1_<3;Y!#O=8LS1K
M'+5BQ2I(Z(ALK(.U#C8ZV.H@T4&J@YT.,AWD$IB`<=P],.QGN$=DB'NLWTL&
MA)VN9A6K8$UB':QUL-'!5@>)#E(=['20Z2"7@&(5#-B?8161@:S"V).2%JKF
M+&F1!X.=%\W4DA4OX08:9&V0C4&V!DD,DAID9Y#,(+E,%">A6XJ3PQ,W&YFD
MNC>,=71)B>=+[KAS;;"N>!%K%AMD;9"-0;8&20R2&F1GD,P@N4P4?R`;BC]T
M2K/(?/VV5:2A:A4EGAB9*X/$!ED;9&.0K4$2@Z0&V1DD,T@N$\47N."*+V^;
M0:I5,R@)Z9J`3,\K@\0&62,1%FXH"6#APD>G.Y^KXW/+BUC^$B0NGR532GRX
MJPHA?ZH*[;B0*/)L[<:3\2)VM)R2,"1'4UR$>YSBHI2N[E3MGY<UG`S<+P;<
M]>#&2&^71$0UEY(0#BOZ,M?FM14O8J<9&V2-1/*;D@#.B4M[MJW:M.5%3#I!
M(OE-"?C-:G:\E2RMW:HR7L2:Y90,F$OV&/)J9,!$6!\R%TFUZB(2^.!==5TM
M$2M:%/C],B6PK=E<_J=5Q[3:]7BGU[P]Z\\&B?!\BR3LCS&?AOK\FF"!\#*E
M).P7[WU*=H9LQ@E98;F6-FAR650)+0R13_A*JE5?*2%+\S=\I46AT_=9N]_&
MJ"G2M.;EW$9*?%&S14(OU=3Q75?335!%M$F1B`NV,W0S3HB/CJ4E-I=%%1\=
MF+0^861?KCK)$%RJ-ZS$*LSHS+*U*QUC@1Q+T88;RI`43(9H,MVYX]I:XA-6
M(F43D1Q.5B6T,X&(K;:E">?L]UY8]94LL#\^\,E62$LHHG<BBE684<?RM!DV
M9LHB3VO11OA*CR\G%:M\&E5WZNG33L)TA'3*D)15IB.J,H%H6K4AD#.5OHEJ
M*UF,?\)6NG:'Q37KZ9)L"8G3[\05%_TX3BW'5^\N,<HH<>5MV,$V6!6(2&T9
MHG%U;/V^E;`".:Q460DK'DPH9ZQAT$]7KF6XBDT&PDI6YI]PE2[D%5<I>B^L
MM`K#ZL'3&-U55!9963N\C7"5(B6LB.CU\KRI-]76_PD3$MHI0W):#>T,J^!P
M]!ZE+;5RIC*05K*B_X2O=`.@^(KHG;32*IQ<7<O1IO_8H05*6GD;X2LBD:DM
M-@QH6H/90%RQD1Q7BI2X&M(9DZ9QA><^:A9R]OM`7,F&X!.VTOV#8BM%[\65
M5O&Y-?344XQ!LI]+1*36B*"-L!4/UJ^\^W70%JM<'*JPF`JU6TO"A(1VRI`<
M5ZHM#84,JS"N`[YBKP;B2K8(LJ__:R?@T(T&G`9S8(DHA%4(7R)XMN;F2E2Q
MAK&)U@Q-N?P&D2LBN$7DV?V8=6:N'X3:N$VP9BH[C)LD:<G*Q(7I&2)I5L\5
M+?6.1;8&;YGZM;[![6AP>P7Y9#L#>'YN+!`H@L<>S*\55DDH-M':1!L3;4V4
MF"@UT<Y$F8G("P'2(7JJU#'Z@)\^S+V4S5.Y*L_G=K2O7\C#>V<.9G!,WRPL
MIQ$\-8'NZWP6P5.#`>X$[%6$UB+UH[2?]S2^\R/82YM*NR"";:#)<S^"S:#)
M80Q$),[F+_!VY*&/H';D)7EK,E"_="-X)#F@XT4/8*KYP]*+X-';`(<S&CJA
M91#!+MRL7_L1[,5-OO$C>+@QP(,(-N$F3_P(MN+`)[S'\#;F5CR5OQ?-4W5M
M1^?R"!?<[A]P-?1]#OW2X5AYK#MX#],/FQ.\=ROAT0WL>L>C8UUW[`LY`'^3
M=_\O````__\#`%!+`P04``8`"````"$`1P>MK)@%``"/%```&0```'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6RL6%V/FS@4?5]I_P/BO2&`(0E*4DW"I]25
M5JON[C-#G`1-B"-@.NV_W^LOP';:9E:5JC*<7!_['A_;%Z\_?FTNUA?<=C6Y
M;FQW-K<M?*W(H;Z>-O;?G],/2]OJ^O)Z*"_DBC?V-]S9'[>__[9^(^U+=\:X
MMX#AVFWL<]_?(L?IJC-NRFY&;O@*OQQ)VY0]O+8GI[NUN#RP1LW%\>;ST&G*
M^FISAJA]A(,<CW6%8U*]-OC:<Y(67\H>QM^=ZULGV9KJ$;JF;%]>;Q\JTMR`
MXKF^U/TW1FI;3145IRMIR^<+Y/W5164EN=F+0=_454LZ<NQG0.?P@9HYKYR5
M`TS;]:&&#*CL5HN/&_O)C0H7V<YVS03ZI\9OW>1OJSN3MZRM#Y_J*P:U89[H
M##P3\D)#BP.%H+%CM$[9#/S96@=\+%\O_5_D+<?UZ=S#=`>0$4TL.GR+<5>!
MHD`S\P+*5)$+#`#^MYJ:6@,4*;^RYUM]Z,\;VT<SY`6+I0OQUC/N^K2FG+95
MO78]:?[E4:[@XBR>8(&G9`EGP6+NOX?$%R3P%"1`]^``D&@+3]%V^?XL(%^F
M!3P%B?ON)!:"`Y[O3@+6).L?GO\_B94@@>=[DW"X-YC5XK(OM^N6O%FP?F'R
MNUM)=P,W`E[I,6Z(P77?,QVXC9(\49:-#<*`G3I8*5^V*/37SA=P=R5B=F:,
MJT;L902U,J6-=2#1@50',AW(=:"8``Z(,"@!COP%2E`6JH3,82>!41I/2UM&
MR":Q#B0ZD.I`I@.Y#A030$D;EN0O2)NR@(5@>4T<@-1$=SS(AX4\!`5JR'X(
M&<0PD,1`4@/)#"0WD&***)+``*>2W-]OI?5I,,M<CGC'$3\</+`WD-A`$@-)
M#20SD-Q`BBFB9`5S\WA6-%C-2B#>F!5'?##6,)V>OU0G-!Z"I#R)@:0&DAE(
M;B"%0)9T0$JBX7L2I<%JHASQ5V.B'`D"OK&Y2V^N)3D$#$D*$C8XMI>E'$'L
MR&=(-K1B^Z4;H(5*FP\!DK:8TBHYP];[^.328#5GCGBP(B93N5*'L^=!2)EO
M3UOCL0CRF5:^C]Q0V^Z2@49FE0Z]2R0;8B;CT;O*U:X\WU^$ZHB+@0:(%;EH
MB3PY]7Z\PFFP*I=`%"609HJ]"&(%(C_..((0]Y&'EN%<&W%B-$I%(U[@T5,Q
M,V)RA=A'@3=WM=.WF#92I(!#_W$I:+`J!4=4YR#]8.=!X!PYP;%`N$W"5>AI
MXTV,)JE`QFTU,V+RG]$6TR:*#"Z4YX_KP*)5(22DFD(S_UY$H;%`B"6T9+;P
M5D'@N=I.D$CRT4RI;#8QAH1&\EQ"@GR!5FBNK>M"(5=%H;72P^O$Y945%`%R
MFG<"TNRAS?5>1*%QRXT%%,R9*(MP#O^THR61S49;I1*:F$1"(WFNDH?!"B%/
MLVPAFS%R5128X:DHM&3V0OH)]ITO,UDIN+2A9AH!J:;1]M2]:*B8AC<,0/)Q
MQT9:-97('J$F&*,\;<]))?TX;YF$IDZZVZ/&5?RL1U5)6H%-[,4_/F8+4+(_
MU]7+CL"H(<,[VS/=.-BF^N3R,DYQ'8>"J:J^ILU>M`N4,T\_8V(9Q?=L/UP@
MU]>LDHB8R?:6"@A\+Y=")IE^V%\NHT1_@>M[^L@+I3]54%K\_4#0S^3V/4'!
MOH.BO(14%.50,*ZK/=Q\4#=/H-B$$A-*32@SH=R$Z%W+V"//F]^=\`_:!K<G
MO,>72V=5Y)7>B\#&MET/,+^TV0<1U)(P*SH>1C'+3L.S,((ZS(R'RY\GMC=H
M\3MZ*70G?N=%\`EVA\>/GB`Q\X>='\$7RAT<15#CW\%=^($S.<.8X#KH5I[P
M'V5[JJ^==<%'D&7.5EC++Y3X2R^,\4QZN`=B'CG#Q1^&<F,^@^5X)*27+]"U
M,UPE;O\#``#__P,`4$L#!!0`!@`(````(0!Q9U[Q[1<``,*$```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;*R=:W/;.+*&OV_5_@>7OX\MBM3-E60K
M$2^Z7T[M.>>SQU$2U\16RO),9O[]-H@&@>X7IL2IG=I:SSQL-`@TT'@!2N*[
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M7__G^'-V>/SZ[97B/:`FF9;=??XK/YP>J$O)S4U_8#P]'+_3#=#_7ST]FK%!
M77+_9_WWY^/GUV_OK_O939+UAF1]]>OA]%H^&H_75P^_GUZ/3_]O;1+V9'WT
MV0?]91_I\&8PZJ5)!R<I.Z&_[D9&-UE_,!K77EJJS[@D_7759S?]\2`9U(UH
M*4E-K!M/?UW)X,9;"@ZY(/UU-YO<C)+>)!V1KY:"(RY(?[O52!.VOE7ZRP6'
M%U4XX7*)&5D<X,MN-6F&!OT+%[VP7Q,W(LR_<-%D?-'])FX<)#Z<_0MOV(73
MC/^.-^P"F@01[5]VPRZDB8]I^PW?VBE8S^C\_O7^P[N7X\\KRI/4SZ<?]R;K
M)G?&FYO+=CPUL_NMR4VSVGCY:-R\OZ;R-'%/E)+^^)".^^]N_Z`L\L`VG]`F
MD1939V%2AG&;:U!H4&I0:3#38*[!0H.E!BL-UAIL--AJL--@'X!;BD83$AJ_
M_XV0&#<F)*XS/SG@8Z0B-'46KDBN0:%!J4&EP4R#N08+#98:K#18:[#18*O!
M3H-]`$3_4S;X;_2_<4.SBO)"RYRP1BGEG<9HH"9%8])$!4@!I`12`9D!F0-9
M`%D"60%9`]D`V0+9`=F'1,2(.DS$*"X]7'8RUG4H7!=^LB25P4E5SS=&KE@.
MI`!2`JF`S(#,@2R`+(&L@*R!;(!L@>R`[$,B>IZZ3/2\63#Z@QO"'9<,XT@&
MQ9*4EL-F,J3C3`6E,6J"`J0`4@*I@,R`S($L@"R!K("L@6R`;('L@.Q#(H)"
M72:"TCX=C+7L>4M4S^M$U!@U/0^D`%("J8#,@,R!+(`L@:R`K(%L@&R![(#L
M0R)ZGB1/AYXWUK+G+5$]/U1COC%J>AY(`:0$4@&9`9D#60!9`ED!60/9`-D"
MV0'9AT3TO#E.")5K^Y@WUK+G+5$]/U(]WQ@U/0^D`%("J8#,@,R!+(`L@:R`
MK(%L@&R![(#L0R)ZGO9W'7K>6,N>MT3U_%CU?&/4]#R0`D@)I`(R`S('L@"R
M!+("L@:R`;(%L@.R#XGH>;.C[M#UM;GL>T:J\R>J\[U5T_N("D0EH@K1#-$<
MT0+1$M$*T1K1!M$6T0X1':35PY?ZBWI"QL+LW\($9+?.-^8TICT7F5,.-24<
MZH^;_=HTPO((*R*LC+`JPF81-H^P180M(VP58>L(VT38-L)V$;:73,;$[.G>
MB,GKM\>'WSX=25I2]T<"E-*Q!1]FV)TA;=W<Z/]D#I4H9(,P/+Q_)&]>KDYZ
M<B;E7'!D3R_-H4;AD'=?HOO*64GWZL1DYJW<K<X=\NX7Z'[IK*1[=2"P\E;.
M_9I1.FDZ9X/NM[Z@[YRDIU;7G;=R[O<.U7<O8VLV@V%L(S&DL]\FB';O*()H
MT8`"UT2L#ZG/&O7ICS?JJUU(;HX,:3R,QO595Y*.TVPR2M4&LF"KS`>_9$3N
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MSZ2&YN%C;*$/%PF[KR?7[H8_F:<Q-`A4!E#Y?\I6YS(`^SJ3`?@F^LU-5!>Y
MG[E;;76_\+Y<&Y<>M01EY=P/[1HWF`SZ(Y4)-]Z3<[[UJ,7YKMVY#*\Y`@C#
M>V;AMR<&(J86R4W/!*9_8^7:DILG8C08K/JOQ6&!J$14(9HAFB-:(%HB6B%:
M(]H@VB+:(=H+)&-A#@7"6%R^Z;''"2(LC,2F!UF>("LBK(RP*L)F$3:/L$6$
M+2-L%6'K"-M$V#;"=A&VETS&Q!P7O!&3#IL>>^@@XL.(-EQN1DP3RV@_XV=W
MBKN>QLH5+%Q!GVI+1L&FJG)6TCWL>L#]W!7T[A?H?NFLI'LEHE?>RMW]VB'O
M?H/NM\XJ=!_9]<#=[UW!VKT(;K_;B4]M+D]\&`GI`[L>-CHC?=C*[7HF29+1
M/W+'6[!1J'R\=]>AE4=^'*'&=152&F[D>%]+Z#G6N/#N78U+CP)?6E6O+JIQ
MC35NO'M7X]:CEAIWKD;>]$0[=2\JE`.$!IN8_>VK8]^8JP%BD5(\:J6?NH)"
M;.CNR]GJS)['^W)]57G4TE>SB]POO"_G?NE1B_O51>XWWI=SO_6HQ?WNG'L9
M5^KH+G$UYBJN%HF)#WN>OC4Z-_&M5?L.I&!?8N8W[EU?51?5.&.K]AKG6./"
MNW<U+CUJB<[*U>CV/)-A.E238(WU;;QS5]_6HY;Z=A?4MQ?UR>%A#J#THM^_
M9,]C0JU'BD4J`ZC$/G4%*:0^&6,&8%_"2J?LTOMRO59YU.)^QE;M"6;A?3GW
M2X]:W*^<^[8]C_?DG&\]:G&^:W<NPZM/LO[VQRSZ>,C%2&V']$-G;^6:F2,J
M$)6(*D0S1'-$"T1+1"M$:T0;1%M$.T1[@628S)&.GH7IN#YYZ/AQ&'-8H:>E
M12I.ZA!]R@6#/6J.J$!4(JH0S1#-$2T0+1&M$*T1;1!M$>T0[062<3)'+&&<
MSH@D/I'Q:O]3WR(5"_W0VEOY.=,4=*A`JQ)1A6B&:(YH@6B):(5HC6B#:(MH
MAV@OD(R%.5/I$`M[!!/N2_O-J8S/MNE$G4].O97K^!Q1@:A$5"&:(9HC6B!:
M(EHA6B/:(-HBVB':"R1C84Y6.L2"#V+">6&1F!=93ST%G=()CTEN(D<!*M"J
M1%0AFB&:(UH@6B):(5HCVB#:(MHAV@LD8V&.!<)87'RTUK<'"F**6)3ZCW]/
MV2I`.:("48FH0C1#-$>T0+1$M$*T1K1!M$6T0[072,0@[7;:4IO+31<CN>GJ
MJ0.L*5L90=@BI=F*CUOZ@Q[]3QVVL$E6/SN03>EV+I#BN0`CL2O(>NJP;.H*
M^J<7N2O8N@4H7,'ZBVKRULVF,9P)[:MU:LQ5%"Q245"[N2D7I"@T*P0CL>W,
M>FHG5+`5]7H8/B^@96O,AJA#:^S^*9S,*6^I2`XVHR7KZ<<7;#4)`V$+FIS3
M%(3CLX(+TA-9Z@9YZWH7<B80N-4PWVR@V*A`^)ZJGZE,V>K<=+"^1&PBK;%6
ML1FAQ?J9UJ`@-]\7H-:<FQ%<,`P$%Q0#1F^*"W8?"T0W_6I68STC+%*!T'L)
M+BAFA"UXKM>M5:S7N\D]6I[@UBU2O0[#WUJ)X6_1N>'/-4:&OY$HX<P-5N3+
M'ZRD5NB("6V1"H;>3'#!"4UB/WOAO,59T8+OK7!HV1IC\8G)C@&M!K!_K9O\
M[^,/2K7GGJO3I\,@BJQ(:*`T]YGUM&CG@J%01%0@*A%5B&:(YH@6B):(5HC6
MB#:(MHAVB/8"B:R<=1,IM;E<'AF9V>YCD2AM,?56S?*(J$!4(JH0S1#-$2T0
M+1&M$*T1;1!M$>T0[062L=`J*T@1[<L+G9+K*<(H4.A31#FB`E&)J$(T0S1'
MM$"T1+1"M$:T0;1%M$.T%TC&P(B],$V?Z7BK#<-\;(2<62_%QWFR1*OVQJQ>
M*NPWE!MF/GGZQX<L&??5/"H:$Z\SRX9Y5U7#Y+3T@ENVVFB[#JVV4E"TVB*Y
M"B5:)&=<D#X3XM.`8_S,\B;IB7^2XA?EIFC<^,\-EPWSKJN&6=?I31KZDCU@
ME%Z''K#"4/2`15)9)$KM3S,N:'49AYV9>2X;I%`E2@I7E)[\N<XK'0O<5<S$
M4XTL\3)9MMN(R0[M9CD:'-ID%HG(IP,M!MDJ$9&W)84:S!)5LFA*AL'FVPB\
M56SWIC?9;",Q.S3;F*MESR(1[G0(LYP+!O'),V;T/,[,\M[-4`F7PEG0AY-]
MI-%3Y>QBGF1SC2SMT%Q6L6&4+1K7/^9B-UH96P5!R!T+1'\1866$5<QL%?+V
MM78^DY11)&>,5%+6*KDQ\YDT;UA+4G;>PW@YYEU5X&J0^=$N6ZR%])D6HT3.
M+!+3,L.$S`5%#!VS67-\,Q;YN#<(DV@]%`JN+*&/'OD!Z]R$"=DQE^O3\43\
M4_SRQ@HUZ*93:W,Y81F)"9M!?G8%PPGKF,K/>M8V9C[BI6.!NXJ9S,_!0B\&
M@MD\=9BYM;EJM]6&8B!@?G8%PX'`[,V,:F/?E`QBW[`@]N>\R69WDV&F<2H_
M,Q+AQOSL"@;QR1V+955NLI-XP7QWI0)/E6,Q3[*Y1@-=GI\'+)F"_,PHS,_.
M*LC%>805$59&6,4LDI\'1L!TN'W6.^'M.UE$/>LE4%\OIW5%1EO[*98W[.W\
MW)B$\7(U>E=58^=<O9F?!T:`=&@QZY6PQ1:9(>(;#/FYKL<TV$^DO&&7Y^>F
M2#A'(QJJL>N>GXT\Z=`AK&;"#K%(3-A(?D89E`^8R?S<]RL)SUIGYB->NJ+!
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M49U,IVP5JDA&W.&#WG`XF*C0%6P3Z_%N:G&(:I&1['%XALU6X4,\1N(A7M;W
M>W"[?+@:J>)&FO6#?I%AZ*8$S3WK\1-3@CT(`Q>D%2*X*76\F+-[4D+U`7)O
MDHPFT#SK*189HY`ZS`465,$R-[1(1@;G@E-BS6E![@J&<AB?Q[.556LR#$;1
M=+AU%D#AK5MT;C98*S$;+'*S83CN#>![3$-K$^MSHTLZW#C+F/#&+9)]CK.!
M"X;YQR+Z1)\9++_0+Q5/)OJ'5HLAEXLD("-6PCL/%N++GV@/K>0)3](9R4CT
M]%D=6YU;&UA1V0F14OO2@3ZX84^1X(Q:M$:')]BU&RD\'**/&3NI-V7F!6K>
M6-6_&&2SDV,8$/,]2@B(.7:!I^_MIXFU'W6[=@57\E6'A`N&#]P1%8A*1!6B
M&:(YH@6B):(5HC6B#:(MHAVBO4`B48VTW@AFS9FPH/2HG=%'8?TV;HHH1U0@
M*A%5B&:(YH@6B):(5HC6B#:(MHAVB/8"R1AHZ13$X/+,-4)%Q2CX$O+4H7#=
MSO179G-GY7\2JG!(%$S]\V#9HFZ::H2:BI%,NG`>Y0K2-\C-FG'!LX'<%;$O
M$>`<QO6SF^3FXN<`Y@?11(X[,V=8-?DL^ZGVH#]W!\\!G%6H1S*MSG.V"N)=
M1`NF7AW+L'437",47(Q$V/#TB*W:3XIRYUY$RE;Y9DG9'*-R0D5P)CA6%(5+
MOZF'Y+'0,G@JQ%;)FR=`.5N(P'!ML4*R%4;Q=&@%"Z1PB%DD5TO],;HI"4;3
M5K%:`BK0JD14(9HAFB-:(%HB6B%:(]H@VB+:(=H+)&-AY%L8BR!3GQE<5OB)
MP6616"T!Y2-`!:(2485HAFB.:(%HB6B%:(UH@VB+:(=H+Y"(`3WPD3%H[_C:
M7*I'AT0RA<.>F!7\BD/.5K03-`M0TJ,7ELB3EL+Y08$\U@+Y3$NLZ`V'4.U!
M?P0=]K=L%6X2&8D\BOM;MHKL1,9:-IZY==2*M0>56K/@5,.>]K`5?4[";4MR
M5U!$#WZ>T!6\Z-!DK`78F=:@TJH]Z$#`II>MZ"S*M\;Z,F<\_AQ%Y^:""\8"
M8:1+F)'.W#HKG6!U&%LDUCAZ7Y$<Q5.VFM"JY>]3/S#(G9658]D`/DK$!I$3
MDW$W)56;JVEMQ970'GCPR07%9+`%STT&:Q6+03?9-$;9Q$C&`"<#%PPG@T6<
M?E(Z7O/2SFI;5ULD_1@%TF'HL&`)AXY%LL=QU%LK,>H9G1GUUBK6XT:8A+<>
MK,.7[YC&5MZ(A&J1#`2<]7!!<XK6-AG8EYT,](,;0[];XMCP#41B8U;]M@9>
M]EV%L14/HH6,Z)C-):&I,Z,O-CN62R96X(E>@4WO_ZWW9-2>Y"QFI,2J.EB>
M>JOFAA$5B$I$%:(9HCFB!:(EHA6B-:(-HBVB':*]0#),6EZ8,/V-\[<)Z@Y&
M*DA*^4R]E0^2]15L,@JT*A%5B&:(YH@6B):(5HC6B#:(MHAVB/8"R2!U$U+T
M]$@_KV&D8J'7;V_E8V%]B5@`*K%@A6B&:(YH@6B):(5HC6B#:(MHAV@OD(R%
MEH'!JM(NJ\SWV-1C-$;A[@Y1CJA`5"*J$,T0S1$M$"T1K1"M$6T0;1'M$.T%
MDC'HIF<GJ&<9*5&B9-&4K<X\KF$K.A"H=W>C=*@_`UBP242D3+HIVMI<K856
M<DHUDJH'J%-7,)"%C,S3>B]08%?A"J+\F'13M+6YNG4K3&444OV$A@N&8IS1
M&3'.5K%>-Z)1*Z>+?CS,[&WT)+9(!4`]L)MR04HL/K?:@OPL,\GZR7"@/P#H
MZHMTO]&%81O.9!^6D8$RGU@DNS]3^G/*5N87.OTP@4T=6_%#_"3V6\D%V\3B
MH97LF;:@8IU8I((`LX`+AD'@@F=F`1?$,-`WOSK%P=K+>>"8C`1,!&<6S@3'
MSDP%9Q;I^Z07DX`7309;5+?%JC<5"3T=7-%P/C@F/NJ"!T[.+'(^D/2,-@DG
M1;`Z7[[GLVYTNZSLD3&"79\K:GYBI66Z.#/Z^9)ZT8C.%V<4#5I,AKSUPVL=
M'OO3X20D.,>D>LST:AF8-2DNPNBM2;:*0%/2:Y.`T7N3@-&+DX#1FY.`T:N3
M@-&[DX#1RY.`T=N3@-'KDX#1^Y.`T0N4@-$;E$(FA(QY2[D<K^V)S]KK@6GE
MC8J.6DBFKFC0ZWF$470:=RZ*%!U@%!U@%!U@%!U@%!U@%!U@%!U@%!U@%!U@
M%!U@%!U@]8OB_2,M&QW[XG?[FNBGP\O7P_3P_?OIZN'XNWFI.WU7]<.[!MM7
MSG^B()N7SM>'MG@M,]?JM4-?&XWOS*,DZFJX,J$K]>??]95)[\[LZ"-E)@E=
MJ;]J"V7Z=*5>]N`*W3A)[8BWC.JA;_['KE`]]'WTR)4!W35]#CIR94C>Z-.Y
MD2LC\D8?/HE=H;NFCT1$KO0'=^;G#F-7AG2E/J/2+>V/Z$I]H@57*`JTZL2\
M47LHET>NI'2%?J,B<H4N1'E"/4"O4XN42*@'[(_,ZSM+Z)[M%VG@"MTS?18A
MXJU/PXU^LA.O?$SN/D9[TU0?L?]$W1^S_YC>?7QC/--@BH\E&C"Q&BB,T2A2
M$*,QI.Z(1I`Z(]87TZ1_9UY!AGU![Q>[,V\/PROT:K`[\^(OO$)O];HS[^S"
M*_1:`*HG%G7Z17^J)W:%?HR?ZHE=H=_1IWKJ*[=-V$\?WOVX_WI8W[]\?7P^
M77T_?*%<U*O?MO?R^-7H'/L?K_P#-;\>7U^/3[16T#OM#_>?#_3FM9YY2_&7
MX_'5_0<UY/;G\>6WT[?#X?7#?P0```#__P,`4$L#!!0`!@`(````(0`B>KB]
M&@<``%8B```9````>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)2:VV[C-A"&
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MSXO+V.+#U?!U5;1-U^SZ"0P7R42O-2^B100C;5;;"A3@M`=MN5N'3VSY9<K"
M:+,2$_1O57YTQM]!=V@^?FVK[>_5J839ACIA!5Z:YA5-OVVQ"9RC*^]G48$_
MVV!;[O*W8_]7\_%;6>T//90[`T4H;+G]\;7L"IA1&&:29#A2T1PA`?@9U!4N
M#9B1_/LZ3"!PM>T/ZS"=3K)9G#(P#U[*KG^N<,@P*-ZZOJG_DT9"423'$JE]
MS?M\LVJ;CP#J#=;=.<?5PY8P\"4G.<*0Y:TD(3L<Y`E'68>S,(#X'<SL^X;S
M=!6]PVP4RN:+M(&?@PT;+"+(9D@)TC!3<D_/)3(:8V2<+DSEBVPPPR3N,.DC
M8=`8I@CF66<_FP\#R]#2B!LVV6!!%(*)OT(T%J$'B:K%U,B,9$@HR-@,)>H[
MA64S5E'THU%5"\RO,04+M\"I(VHVF8U&13\:5;6D8F>9JP06FRGL_BI!8[M\
M\WC(799/&GF4#X%L[)G[H=&82E(MI'Q&,J1\"QI*E(^#Y_V8Z$5CJA92O/F-
M_<>`;*8^#)ID/N43GC3PI8E&OK$E&2@S(]]7*:RMJG+.K:HJ*X^R,D2'45?)
MPM1CV0I/2S<.!DU4MTZ.5)D]Q")A?:5;HT:N9F7EHQMY8NE.LYF/;O2T=*LF
MJELG1W4C4XS((_4>F*0)Q/G4KK>T\M'MHE2<^.B^YA13352W3H[J?@A>S$$O
MSF>V;F]\,8M?N,YG,[QSC&!%.%KE5C"CLG5N5+9%LY%R#Q0SRVV?N4Q:>90[
M<6"-)7,/W<*3ZKXT4=TZ.:([>0AKPMK:WJF>477+P2'7H8]L2-'<8_Y42]#3
MDJV:J.P;EX#$HAI&SIC']A*.5F!U`2.!%_H$I_.-##*P@H&G?/S.DZ"?%5<U
MT;@W#D[<07;<!:RZ^^M<>%E1%>EHU!N'9N+`F-=V%HY68!?%%OHF3Z?9HM@#
M*VL@VG"G3503E7SCO$P<!/,JL**5_'8EORZX`+:X<5XE#P%,6(OY-0&F-XO:
MR=X`2QT`2V+NL:&$)ZWTI8G.]XWS*GT(8,+:UIWIO2IU*RL/@J60H[VM&,O&
M][-PM&3C6-!$96NZD@6>6@"[OX^%]95LC0HE6X+,1S:BQZ(8CQ<3V*(CB2AF
M&:L\54U4]HWC*K4P-A)-L0I^`6;5E_],LTK)EE8^LATX\Y.MV&7*=N),[T!:
M;0MG([('A)FR-2F5;&GE(]N!-+]%?LVTU,$T>-8W7!BI[(>8EDI:D0<A/-.8
M5K*]F<9=3..P1^[/OG"C._O29"[Q)-;;CXC&K]#VWF(+<!T)*V]=H'XXM\1(
M%E"26"]_&A8BF&%'HJ'U%5#TT23GFDLKCR6&TVI&Q_/:[_P0GM9T2XX1D":Q
M7O]4-^+'0AGS>0K%T=$*K)I`]L`;4.%>W/PAE`GKJPG79Z*:<&^4<0?*QN^#
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M!_(EK7P36I?MOORE/!Z[H&C>\`4L/(#:K(9F]7:8+Y9/@&:86;LG8]"3.'M2
MZ.'.G@QZILZ>V?))OH:VXZ3@DSI]4O"!6[\CMQ2RACNJHX<GT./,C4,<N(6X
M?"`.G-2.'@8]\'S8U0,9P.-21T\"\P:/<EP]X`-/*!P]*?C`]WI7#\PU?,]U
M]&`85SLX.%6B%&=P!B/!\>0*`6,Q=W"83'@Y`#[14$]XJW_.]^4?>;NO3EUP
M+'>PZ&+Q(*>5_Q<@/_3-&18WO-MO>GB?+_X\P/]OE/">.T8:[)JFOWS``,-_
MA&S^!P``__\#`%!+`P04``8`"````"$`F])U@AD'```>'0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6RL66V/HD@0_G[)_0?C]U4!!27C;,8W0""Y
M7/;N/C.((QD5`\S.[K^_:OJ%[BZ6<9+](OI8]53W4U5--SQ\_7$Y#[YG9947
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ME?DARJ\9J`UY(AEX+HI78AH<"`3.8^2]:S+P5SDX9,?D[5S_7;S[6?YRJB'=
M,Y@1F9A[^+G)JA04!9J1V0PC+<XP`/@<7')2&J!(\J.YON>'^K0<FO;(,28+
MRP&6YZRJ=SFA'`[2MZHN+O]1(X,,2I"8C`2NG&0VFCD3RX"8]Y)8C`2NG*3E
MZ`D^97YP97[&9#2?S:;VG$RAQ]-FGG#EGI+CG7-W&`E<Q;"GYLR9-W/OB0X=
MV"@/5QZ]7^4%<X`K=V@%NG.TAL@W?/G<>`V>9?*%#Z!_Q`;/*?G"7>X=\YA6
M:E/XFZ1.'A_*XGT`JPG$K&X)69L,EQ#SDJ=:BR;X50]`W1*6)T*S'$+:H+PK
M:-SOCU-[]C#^#LV6,IL5MC%4BS6W(.U`:#<ZL-6!G0YX.N#K0*`#>QT(=2#2
M@5@"QJ"DD!.R^3OD)#1$3B[$B@.MOJ:F';?@+AL=V.K`3@<\'?!U(-"!O0Z$
M.A#I0"P!BG90?;]#.T(#U0RKE52+MJK6BAI9L,P)(ZU<U\)$*(J0+4)V"/$0
MXB,D0,@>(2%"(H3$,J)H"Q-5M.V^H_%N)M:-A'SJ*XI8L+@+O4Q[HHJZ%D;<
M;8.0+4)V"/$0XB,D0,@>(2%"(H3$,J(H!O6C*$87QA&Y"_:+1QQ5\2ABM>V\
M1L@&(5N$[!#B(<1'2("0/4)"A$0(B65$40J*0E&J7QYBK<I#$7LA5KLU11S8
MOTG5IMTL-L*(5]N6(:8@V@EJF6BJEJTGB&0C+9HOC'BT`$7;BVC<)A1>+;4Q
M<=3XD3#B;K%,K4@--]A/2$VL5:DI(DM-$4UJ[=ZR$49\A%N&2%(C:D]XM9,W
M]4V!+XPX=8"H]X@Z%%XRM9:R2!AQZEBF5G0E!SB\"VJ:O3[EZ>NJ@$*$>WY'
M:5NPVZ%[($*BRDT166Z*.$`E5;:E%L1&&/&!;QDBR8VH/>'50^T+(TX=(.H]
MH@Z9C24:*T)(+/,HVL(.6]&V0T,XV'`1B;4J(D.`7Y),NY^OF1%<6B-3:_0-
M-3(GS?[4,@S',K5*WU*3J20T1>SFX-CDV:.(`9=?Q_*I$8MEV+9C3K6^#ZB)
M%&M/$2E62)'^6)$2:^K,IS-[H994+,=2LF/`(ON)]#3F:GX89*LUK4UVS1U;
M93?<$?:#K9#V7!WYECM.1?'M.-1R>1CRN^DU80+N"/N`=A"F5EY[;M5&##$4
MW14QYHZ_BJBFAQPTY)6IOWO(B51K'P;-%)4=?>O&K.RVQ3<<4L:)TT,C2E6\
M8XYFR^5QKA;R.:30.]H:'C`KH.]-#QV$%#'D]&W$B$.]$>./(JKI(6>93Z2'
MF&O=0R$;=E=M_3G:LK0F3PF((UQ:*[2^,2O;[EG@.)/<3H*<WQ0\;M4;SU?C
M&:9E+%#^&'<;;M]R\W!A"_5,+U+#6>9T,C.T6V?,F9IX:JK(V>@3J:)'*?JT
ML5GW5^3Q""3AHTZB5DHG,4@I/-Q)U$KI)`I)=>VQ04CT/H<4>D=3)F!6'W42
MBAAR>KF3NB:D1XP_BJBF!T:OI$<Z;]V_!3,(B]9@%%)O3XZV-5@S1QMVB'T-
MQKCF?0W&AM!6_(Z/2MI#W!7/YU8TWMPT)ZB_4+0]CA9RGM[91=R*SVZQF)E:
M%<6<O*._R/E0[B\]@=^*&V2F<P\M[?_(<QL]@^SD:8L=P)I9P?,(OH9L,+3%
MT`Y#'H9\#`48VF,HQ%"$(?(*@\R1CIYV`7TE09_,7K+R)5MGYW,U2(LW\KH!
M%H#'!P'3=R&Q[<*>&Z:OX?".Y*G9IFCXBKP[Z;!?F2X\D>O@L=PG&"C^8V6Y
M\)RI`Y^Z\#2E`Y^Y\.R@`S?@C\X(GNW">1M[>(X+Y\4.?.["P0;C@>W"\0;C
M>]N%0P[&0]N%PW@'[KAPF.S`YRX<A#"^LMU5%[ZV77AJ@>W7C@M'[`Y\[L)9
M$.-;VX43(<9WMKMK\+'(/;R=NB4O69R4+_FU&IRS(Y33I#G8EO3]%OU1L^9\
M+FIX+]7TZ0G>0V;P$'XR@G(]%D7-?T#@L7BS^?@_````__\#`%!+`P04``8`
M"````"$`B6]717((``#=)```&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6RLFEMSXK@2Q]^W:K\#Q?N"+QB#*\E6N/F.[5-[SGDFX"2N`4QA9S+S[;=E
M2;YTLPY3M2\#^='Z2^IN26V-'_[\<3H.OJ?7(LO/CT-UI`P'Z7F?'[+SV^/P
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MB47@)<^_,5/WP!`T'I/6FRH"\75P2%]W'\?R/_FGDV9O[R6$VX`9L8E9AY^K
MM-B#1T%FI!E,:9\?80#P[^"4L=0`C^Q^/`XUZ#@[E.^/0WTZ,DQ%5\%\\)(6
MY29CDL/!_J,H\]/_N9$JI+B(+D3@4XAH(W6B3)E$3[.):`:?HID*HYP9JO%5
M2U.TA$_1TKBG0TCZ:K+P*3O41Z:JS'6S?Z2J=!/[(IK"J'OFIH)#J[[8%]F9
M<=_L5.E/]D6V_>6@L"S@(X`OM<K,,";3&9ONG;%5IU(&O@B96>.T?I4QS[8J
M>5>[<O?T<,T_![`C@!N+RX[M+ZH%RV,@TY9[M$[D?\IC2&"F\LQD'H?0'E*T
M@,7W_6DR51_&WV'![(7-@MH@BZ6T8*N#R:XP6&.PP<#&P,'`Q<##P,<@P"#$
M8(M!A$&,0=("8XA&'1+(TW\C)$R&A40Z<R%!$R.M&Z&EM)!-5ABL,=A@8&/@
M8.!BX&'@8Q!@$&*PQ2#"(,8@:8&._V&M_QO^9S*PJF"!M]8$\OB"&^FPA=5&
M!@I*;5)'A9`U(1M";$(<0EQ"/$)\0@)"0D*VA$2$Q(0D;=*)$3BL$Z/;IZS<
MG9AU%0KIP@4G.NRDM=\UU42>KXUDLQ4A:T(VA-B$.(2XA'B$^(0$A(2$;`F)
M"(D)2=JDXWG(YX[G^8$Q8@=9?Q!8PVX0.-&;+6I)R(J0-2$;0FQ"'$)<0CQ"
M?$("0D)"MH1$A,2$)&W2\3@D:<?C_6YFUETW"S*M3X(E)SIL@*WLGW6S?U4;
MR>Q?$[(AQ";$(<0EQ"/$)R0@)"1D2TA$2$Q(P@G45S#3CN>AGOD%SS/KKN<%
M:7F>$QWVM9;GY\CSM5'M>2'4K)0-(7;=JB6M*5UIIS:2TBX1\@CQZU9M:52\
M!;61E`Z)T):0J&[5ED:G9%P;2>E$"-&0L<?I=CW;OUB8=3=D@L!'$R!-[WIQ
M*8SF':-)UVC%C32EJH8U?:9/)@I:8VMAPQ_B6,6[(<2^IS.GTYDZ,U#<72+K
M$>+?TU$@FG6V#@V5+*$PZF2Y-NWZ9TL&$-TS@%@TDVXUYG/%1`=W(FPF9$%#
MQ#K9P0XOS1C!UMN?)ZQ=-T\X8<_5K3Q!XU@*HV;]KP0Q>5),M=ED-D79ON8V
MU>"KIZ`-!C;1=3JZ^FR.MA072W@8^$0S$`2<V9HBRN"0&[%GZY81#C7N+"*=
MQ8)(QZCZ%"+;S9A$V)"HJG!90\*J&E5-4KYG^V^+'`8'CULW@JQ#),0C+%/I
M!KD2!M1V@:K@*`LK#8;7\@'>#H25SA/74%1UKIEHF:ZE5&M#H,B6J+=#!W5H
M3I`[72G3=.91Y$O4VUD@.P,GMWR`>@RE5O_&(*V:<442]0XBEH/@+I[,3=V8
MJB@7$RE%-P=VI433""[A8$XLB_[*+_^41;`/U&G$'^OAN4\>5HM*&.[SFN-[
M2=&*HC5%&XILBAR*7(H\BGR*`HI"BK84113%%"4=U*F^V*;2B<>-Y=MV/#-'
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M&$LD'#6=S\TY2K=$VM`"FMV`X%#_>@$M[E':E8]`;3?<**"YU5<%-+<2!32H
MZ-I$157VFOTG&>2>UJR5#46V1+T;E".L1(>W-@S2F2>5F_Y]B7H["V1GG0):
M1],+I=87&P895R0;]@XBEH/@&X:J3.<SS219)-1O[!CL5J8OC>ZLH,7E3CN/
MQ`U0D_!+]I^5$&FXPI<GWXJB-44;BFR*'(I<BCR*?(H"BD**MA1%%,44L;<:
M&D_P"IJ_I<#_H_>47M_297H\%H-]_L'>0%#G\+128_YZQ,*PDLKAF*OLO8DJ
MG<DOIGRC`OVR5'5K!64(!`;]`C69Q2HN^@N44U9P\Q>HA"Q6Y]`V\$K'LW:#
M+]B0;W'-2F[9/^O6,SB1=K#0K>16QXN)E53ICZ:WG%IPO4QUEJ:UNJ5OFQ;<
MR%)[W[3@.I7RR+3@+I1R>*H!%U53&]=#@I=++KNW--Q=W[)S,3BFKQ!ZI;H4
MN?+74_@?I7BL?<E+>*T$L@->`H#7B%*XC538L^]KGI?R#^AZ7+^8]/0W````
M__\#`%!+`P04``8`"````"$`24A3MS(!``!``@``$0`(`61O8U!R;W!S+V-O
M<F4N>&UL(*($`2B@``$`````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
MG)%!3\,@&(;O)OZ'AGL+;8TNI&6)FIU<8N*,BS>$;RNQ4`)HMW\OZ[HZHR>/
MY'UY>+Z/:K[3;?()SJO.U"C/"$K`B$XJLZW1\VJ1SE#B`S>2MYV!&NW!HSF[
MO*B$I:)S\.@Z"RXH\$DD&4^%K5$3@J48>]&`YCZ+#1/#3><T#_'HMMAR\<ZW
M@`M"KK&&P"4/'!^`J9V(:$1*,2'MAVL'@!086M!@@L=YEN/O;@"G_9\7AN2L
MJ578VSC3J'O.EN(83NV=5U.Q[_NL+P>-Z)_C]?+A:1@U5>:P*P&('?;3<A^6
M<94;!?)VSW9OKDV\;RK\.ZND&.RH<,`#R"2^1X]VI^2EO+M?+1`K2'Z5DEF:
M%ZN"4%+2XN:UPJ?6>)]-0#T*_)MX`K#!^^>?LR\```#__P,`4$L#!!0`!@`(
M````(0!JXITX.P,```$,```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````)Q634_C,!"]K[3_H<H=
M4MAJM:`TJ!0JD$!4F\(>+>-,6XO$SMI.U?+KF<2D2:D3*+?$GC?SYM,37*S3
MI+<"I;D40^_DN._U0#`9<[$8>H^SR=$?KZ<-%3%-I("AMP'M780_?P13)3-0
MAH/NH0JAA][2F.S<]S5;0DKU,5X+O)E+E5*#OVKAR_F<,[B2+$]!&/^TW__M
MP]J`B"$^RK8*/:OQ?&6^JS26K."GGV:;#`F'P2C+$LZH02_#>\Z4U')N>M=K
M!DG@-R\#9!<!RQ4WF[`?^,W?(&(T@3$J#N<TT1#X]4%P`[0(VI1RI<-@9<Y7
MP(Q4/<U?,6RG7N^9:BCH#+T559P*@[0*,?M3?B>9-BK\)]6+7@(8'?@H8`_+
MSZ9L\YL/PL%9*8%?NY*%!LL$+W8YSKA)0#_,IU09!^7!69-SR<(RMH2J+!*L
M#7(M#,:+W`J;;2Z;S+<^C*70,N$Q-1"32YI0P8!$>YY^19Y,Z><F(H.6BDK3
M1,[)0X8)V^HN0F\=V6&UA12(R$CV#<C)`9B2V9CN9/H39A7$;>9!+:C@KV6E
MEZF)^$)P;#LL.#)R,KL5*]"FC)/S?L+7F*^1UA\J<LMSQ/[G7/.BN=R.W`J<
M(`O^G$"7FIH'X8)$^;/F,<?N`+?2(CLO2YG$.+S(-3(P&R?].\#&ZU!QB=<Q
M&<L4YY4NX^94,\'&)D\TR8'<H\9<V<IRRG8GP9VXVGM-9A1#Y:;<3$:7W%[(
MNX0=H>P2MQ'MDB@5[@>V"](2WRY(=YA/G:EIACG*TY2J3=GJ2ZD,H4X(AKPJ
M?S**X[+.:5(-.R>DH?G]G=S8.8EEFJ5.2+.)]LTX(?LY;M+[(B3"YSK.L3-Q
MX+5`JO'PL2T+FDZ(JYYJ:E^&U%%T0M[+L%9<I:081&Y?WB&3W&#_DGLN>)JG
MI#QM>U&Z(>Y>;BM_2]7I3!O$QN`@"$[J/,T.@E@K;F?:&M.>.\VT03K\;X/\
M!28%.\Q*N__=5@[S?[S$-VUGI=C9M3YL5W=<O.C';":O<">IUL?=PR!:4@4Q
M+E;5?7T0W.#FJ))"B;4;5S+[%\6R^V0W^O!D<-S_U<<]MG$6^/7N'KX!``#_
M_P,`4$L!`BT`%``&``@````A`&[(=20,`@``.!X``!,`````````````````
M`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4`
M``!,`@``"P````````````````!%!```7W)E;',O+G)E;'-02P$"+0`4``8`
M"````"$`2T=%8C<"``!]'0``&@````````````````!K!P``>&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`=(%M%1D$``#U#@``
M#P````````````````#B"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@`
M```A`$7]4C-D!P``YAX``!@`````````````````*`\``'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+`0(M`!0`!@`(````(0"':\#B/`,``+0*```9````
M`````````````,(6``!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!`BT`
M%``&``@````A`)../I"Y`@``5P<``!D`````````````````-1H``'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6Q02P$"+0`4``8`"````"$`>AXF."\(``#^
M+P``&0`````````````````E'0``>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;%!+`0(M`!0`!@`(````(0#"IQ6W7@0``-H/```9`````````````````(LE
M``!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L!`BT`%``&``@````A`)-9
M#5B.!```:10``!D`````````````````("H``'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6Q02P$"+0`4``8`"````"$`:O#QY1,%``#!&```&0``````````
M``````#E+@``>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(
M````(0`ZK[.DR`8``+<E```9`````````````````"\T``!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L!`BT`%``&``@````A`++F4^K7`P``D`X``!D`
M````````````````+CL``'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M+0`4``8`"````"$`4!)/NM($``!D%@``&0`````````````````\/P``>&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0#S9C@1N@,`
M`#X-```9`````````````````$5$``!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L!`BT`%``&``@````A`"AJF!QX!```@1(``!D`````````````````
M-D@``'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"+0`4``8`"````"$`
ML"T0[+H#``"L#```&0````````````````#E3```>&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+`0(M`!0`!@`(````(0`%+.&&,0,``%4*```9````````
M`````````-90``!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L!`BT`%``&
M``@````A`,?/G?0M!```1A$``!D`````````````````/E0``'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"+0`4``8`"````"$`FX-R4_@.``"@E0``
M#0````````````````"B6```>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````
M(0`-6US4!&@``"Q1`0`4`````````````````,5G``!X;"]S:&%R9613=')I
M;F=S+GAM;%!+`0(M`!0`!@`(````(0"CS^_YV@(``-,(```8````````````
M`````/O/``!X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"+0`4``8`"```
M`"$`?/K0)FX&```6&P``&``````````````````+TP``>&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``IQL``!,`````
M````````````K]D``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"```
M`"$`5-P;J-L"``"]"```&0````````````````!TX```>&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+`0(M`!0`!@`(````(0"&DRI,'@0``-\.```9````
M`````````````(;C``!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!`BT`
M%``&``@````A`,%K0Y2B!```<!0``!D`````````````````V^<``'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6Q02P$"+0`4``8`"````"$`"J^J)?L"```]
M"0``&0````````````````"T[```>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+`0(M`!0`!@`(````(0`A'Y#%=08``'LB```9`````````````````.;O
M``!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!`BT`%``&``@````A`%Q'
MS3^/`P``7`P``!@`````````````````DO8``'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+`0(M`!0`!@`(````(0#M>J5;#P,``/T(```9````````````
M`````%?Z``!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL4$L!`BT`%``&``@`
M```A`'+=1@H-!```H`X``!D`````````````````G?T``'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"+0`4``8`"````"$`I60^318&``"L%@``&0``
M``````````````#A`0$`>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M
M`!0`!@`(````(0#7=O#]O@(``(0'```9`````````````````"X(`0!X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&``@````A`">=FLD="```
M8B0``!D`````````````````(PL!`'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"+0`4``8`"````"$`9M>J.4D#``##"@``&0````````````````!W
M$P$`>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0"-
M6H&2#`D``!\I```9`````````````````/<6`0!X;"]W;W)K<VAE971S+W-H
M965T,3`N>&UL4$L!`BT`%``&``@````A`-.EZ$(6!0``Q!8``!@`````````
M````````.B`!`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(
M````(0!'H>QIJ@(``+T&```8`````````````````(8E`0!X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"+0`4``8`"````"$`8!@6<'D'``#<'P``&```
M``````````````!F*`$`>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!`BT`
M%``&``@````A`!G:1(AP`@``?08``!@`````````````````%3`!`'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+`0(M`!0`!@`(````(0#OS@*]<@D``&$Z
M```8`````````````````+LR`0!X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"+0`4``8`"````"$`05>KK:P"``!=!P``&0````````````````!C/`$`
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`!@`(````(0!`I7EI
MR@@```,F```9`````````````````$8_`0!X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L!`BT`%``&``@````A`#M46+%X$P``\60``!D`````````````
M````1T@!`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"```
M`"$`:F<2`E\&``#8&```&0````````````````#V6P$`>&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0"2[SL+>Q```%Y0```9````
M`````````````(QB`0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!`BT`
M%``&``@````A`/M<[&"9%P``FH0``!D`````````````````/G,!`'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`].&U>6H%``!X
M&```&0`````````````````.BP$`>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;%!+`0(M`!0`!@`(````(0`H!'-HIP8``&X:```9`````````````````*^0
M`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@````A`,:3
M/()+!P``#AP``!D`````````````````C9<!`'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"+0`4``8`"````"$`1P>MK)@%``"/%```&0``````````
M```````/GP$`>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(M`!0`!@`(
M````(0!Q9U[Q[1<``,*$```9`````````````````-ZD`0!X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L!`BT`%``&``@````A`")ZN+T:!P``5B(``!D`
M`````````````````KT!`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M+0`4``8`"````"$`F])U@AD'```>'0``&0````````````````!3Q`$`>&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0");U=%<@@`
M`-TD```9`````````````````*/+`0!X;"]W;W)K<VAE971S+W-H965T,C`N
M>&UL4$L!`BT`%``&``@````A`$E(4[<R`0``0`(``!$`````````````````
M3-0!`&1O8U!R;W!S+V-O<F4N>&UL4$L!`BT`%``&``@````A`&KBG3@[`P``
M`0P``!``````````````````M=8!`&1O8U!R;W!S+V%P<"YX;6Q02P4&````
/`#H`.@#(#P``)ML!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EINAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Derivative Asset (Detail) (Derivative asset, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Derivative asset</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Value, Beginning balance</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 250,250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Receipt of instruments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Decrease in value</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(250,250)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Net settlements</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Value, Ending balance</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized in the income statement for financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Asset (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived And Indefinite Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets not subject to amortization, beginning balance</a></td>
        <td class="nump">$ 3,117,322<span></span></td>
        <td class="nump">$ 3,117,322<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible assets not subject to amortization, Impairment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_IndefiniteLivedIntangibleAssetsAmortization', window );">Intangible assets not subject to amortization, Amortization</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets not subject to amortization, ending balance</a></td>
        <td class="nump">3,117,322<span></span></td>
        <td class="nump">3,117,322<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, beginning balance</a></td>
        <td class="nump">123,191<span></span></td>
        <td class="nump">1,667,247<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets subject to amortization, Impairment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,308,047)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets subject to amortization, Amortization</a></td>
        <td class="num">(40,990)<span></span></td>
        <td class="num">(236,009)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, ending balance</a></td>
        <td class="nump">82,201<span></span></td>
        <td class="nump">123,191<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total Intangible assets, beginning balance</a></td>
        <td class="nump">3,240,513<span></span></td>
        <td class="nump">4,784,569<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Total Intangible assets, Impairment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,308,047)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Total Intangible assets, Amortization</a></td>
        <td class="num">(40,990)<span></span></td>
        <td class="num">(236,009)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total Intangible assets, ending balance</a></td>
        <td class="nump">$ 3,199,523<span></span></td>
        <td class="nump">$ 3,240,513<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IndefiniteLivedIntangibleAssetsAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indefinite Lived Intangible Assets Amortization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_IndefiniteLivedIntangibleAssetsAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfIntangibleAssetsFinitelived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph ((a)(1),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarize Information about Stock Options</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following tables summarize information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of<br />Options<br />Outstanding</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br />Average<br />Exercise<br />Price<br />Per&#160;Share</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate<br />Intrinsic<br />Value</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,794</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,509,166</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(675 </p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)<font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.93</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419,285 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">930,000</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.05</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148,561</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(377,112</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.28</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,823,612</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,271,011</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At June 30, 2014</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532,180 </p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.80</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3 years</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,666,712</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:36.22%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months&#160;ended&#160;June 30,</p></td>
</tr>
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4</font><font style="font-weight:normal;"> </font></p></td>
<td valign="bottom" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">3</font><font style="font-weight:normal;"> </font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8% to 2.5%&nbsp;&nbsp;</p></td>
<td valign="bottom" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7%&#160; to&#160;1.3%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25 to 9.72</p></td>
<td valign="bottom" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 to 6.25</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value per share of options granted</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.26</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to Restricted Stock Units</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the activity of the Company&#8217;s Restricted Stock Units:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:64.68%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br />Number of<br />RSUs</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br />Average<br />Grant<br />Date<br />Fair Value</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:15.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,000</p></td>
<td valign="bottom" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td valign="bottom" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:15.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2JAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
        <td class="nump">1.80%<span></span></td>
        <td class="nump">0.70%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
        <td class="nump">2.50%<span></span></td>
        <td class="nump">1.30%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">69.00%<span></span></td>
        <td class="nump">69.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of options granted</a></td>
        <td class="nump">$ 8.92<span></span></td>
        <td class="nump">$ 1.26<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">5 years 6 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
        <td class="text">9 years 8 months 19 days<span></span></td>
        <td class="text">6 years 3 months<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6NAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems', window );"><strong>Component Of Operating Other Cost And Expense [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OtherRentalExpenses', window );">Rental expenses include common area maintenance and real estate taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UtilitiesCosts', window );">Utilities costs per month</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts', window );">Increase in total monthly expenditures</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FacilityAndEquipmentRentExpense', window );">Facility and equipment rent expense</a></td>
        <td class="nump">138,000<span></span></td>
        <td class="nump">126,000<span></span></td>
        <td class="nump">403,000<span></span></td>
        <td class="nump">407,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Assets Held under Capital Leases</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems', window );"><strong>Component Of Operating Other Cost And Expense [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsUnderCapitalLease', window );">Monthly payments under capital lease</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Corporate Headquarters In Pasadena</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems', window );"><strong>Component Of Operating Other Cost And Expense [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Aug. 31,
				 2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfIncreaseInAnnualRentalCost', window );">Percentage of increase in annual rental cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research Facility in Madison</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems', window );"><strong>Component Of Operating Other Cost And Expense [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Feb. 28,
				 2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FacilityAndEquipmentRentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Facility and equipment rent expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_FacilityAndEquipmentRentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in monthly expenditure due to utilities costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_IncreaseInMonthlyExpenditureDueToUtilitiesCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OtherRentalExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other rental expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_OtherRentalExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsUnderCapitalLease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payments under capital lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_PaymentsUnderCapitalLease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfIncreaseInAnnualRentalCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of increase in annual rental cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_PercentageOfIncreaseInAnnualRentalCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComponentOfOperatingOtherCostAndExpenseLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseAndRentalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UtilitiesCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Utilities costs incurred during the reporting period for services, such as water, sewer, gas, electricity and telephone required to operate a building.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UtilitiesCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001564590-14-003557-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-14-003557-xbrl.zip
M4$L#!!0````(`"F`#$5<$Q$0.?T``%DA#P`1`!P`87)W<BTR,#$T,#8S,"YX
M;6Q55`D``XURZE.-<NI3=7@+``$$)0X```0Y`0``[%U9;^,XMGZ_P/T/OGFX
MF,&%8^U+4%4#9^LV)E7).*GIF:<&(S$VIV7)0\E)/+_^DO)&V;(ERI0M62XT
MT%4617YGX5FX''WYR^?(:[U#'*+`_WHA7TH7+>@[@8O\P=>+2=@&H8/012N,
M@.\"+_#AUXLI#"_^\NV__^O+_[3;K7[_MM5U(O0.;U'H>$$XP?!/S]__W/K'
M=?^AU?/IBPYLW0;.9`3]J-5N#:-H?-7I?'Q\7+XAGSQ%P+O$V+UT@E&GU6XO
M>K[!$$0$5>L61+`5_[EJ*9*LM26K+2LOLGZEVU>:?"G+FF)H^O])TI4D,1W\
M?495B_ESU9(O[4OI4F6:/0'G#S"`K=XMT^Q>ZW:[MJ29U_:M;)C7=]+MC=RU
M;--0;VYNKKMMB?RQ3%N33/)769,,%GDPGF(T&$:M/SE_CB&W^I?TO]O`]Z'G
MP6GK?UO/@1^2EJ,Q\*>7K:[GM?KTE;#5AR'$[]"]G/?X^8J]%I&2'UY-(OSU
M@N$??709X$%'D22[0YY>S!NB,-`4V=S:6.W,6\Q?V-5P+L)%UP!_)$$`C(./
M(00N)L`!=H:Q()68*:JT>(UVZNT8QD/^'Z\@7`[S27](M/]0X]:R;=N=^.FB
MJ4^X.AFE]^U&N!--Q[!#&K5)*XB1LWPO^Z7D"[2!&RW?80G0.[.'BZ9DY@P`
M&"_;OH'P-6X[?T#YH[8EN:W*S"MTT##UG?A)RDM.,/$C/$UB"J%S.0C>._.'
M::]-,";3?-M[\Z?T127YH@M1^COD0<HX\-,9IK>G3U)>0/X[#*/T5V;/4EX*
MHS%.?X4^H2_(:R\@9TM[Y*0T]P%RPO07XD?L*V3&MEKQG/6N0F<(1Z`/WUJQ
MOEY1(7Z]"-%H[%$]CW\C$P8''LPW,^(WAAB^?;V@T["]F&27GZ%;8.+DGY.=
M&5D3'T4MY'Z]^/E[.`1DOL_()4]&$%#+_VWV\Y?.XM_Q:QWZWD8/<POT\_EV
MHY?YHRORC+.K=5PN>D<NG/]K_M(/.JM!%.#ESWF&CEMUTM^/N[V%?C`B#FU+
MQVF<6?6Y^?*7#H-]"]UCTM$&\^B/V[GF!'X$/V<=W/R^\F*_TVDE$U?V^])R
M+SHF;AM%TQ5@`HK\\H8@;L4:GE3>Q<RXZ?WUXMNJ_R^=U6M+"A,]?QD36QNX
MJW&(W\$1=?[?XBDO2V2*?>FL?ETVA+Z[:$:"`Z.M2K1KEVGTI<-T_J4S9T(V
M1S3)DN6C,V+F@J-OR^"'L&'QV[[T54'02?IF\A-#GRK9U:*/>"Y;('V:I%5V
MQA)1:H>?L>J"(VKU.*+FXX@JEB/*PJI7D"-*/JLNDB/S`/PY(OW0C/3NWQ."
MEB9B)+GUH[#[B<)%(_+K*/"?H\#YXSL<O4)\.)M".04'%"`;3,#/L8<<%,W0
MM%Q$&LPR]SGBJYUTK6=[;+AGS#(8=/%MT=4&]83_B?&9&":)]4@&D4>T3R2*
MAB3-<9LJW30&G)*`NZZ+Z/(1\)X`<GO^#1BC"'@-E/1.3IR2R/LP`LB'[AW`
M/O('80-EG<Z"4Q+RC\"G_>#`\PB!/=(C2:NC!HIZ%R-.2>#I0=AAERHJ(.[R
MHK%CK[.(]>J-4XS#N/>J*<F-!\+P\2V>#[&"T`7Q7AA.H-N-[NEV)+&+`'=]
M]XYNJTV?T><-Y>\3Q,]T)7:N,6=#5*(AXD.V+M%\J*C8K[CE?IX6XJ;%V20+
M,LGGZ5+7Z5)#)3^K3]GJ$W,$0G_)HA\D,8^FE&OG2.34(Q$^X9\GB.`)<HY)
MZAJ3G">.\(E30W4_*U*IBI3<^UMP[&483$)`(,0<V\?\;MU<K9D:'GB7]6!S
MI(#\SQ-$Y`0YQR=UBT_.4Z:$*5-#13^K4-GQ[4OP"_"\X`-,SRLC)[<RLB[<
MLX*?(X<3CQS.BK]5\6NHKF=%*/7T=<VTH>+'L.ND$IGG.ANG&@<YX%DG%=EQ
MOKMQRE'R0>\ZJ45JSM<813C(+2V1UW)%Q`F-D>ZA;FD=2\"9Z6QC)'WP6UK'
M$OEV+]X861_NEM:QA)P5S3=&U(>^I56FP,6=EJV)^&MY2+8*RL!_0JDY&G&D
M@TG'5(N">\.GKQ/'W!(NK^J24K6J2XK8JDO5**23O)I]##N?MI^C28ILG?2<
M+7D;)SDME;9L"1&K"]$#'`#O+AY\*<A^0,3P';@H#/R5$!692+%R0B0D7*W1
MP"&V34K+$%E<T$H14Y^/6V3267;[+73/I"=E+70OA2QNH?M^40F;5LS&<:EL
M-IW^#6!,M*EV&QY;R.)+H1/$G]H.QSU`^._`F\#KZ0,"K\BCZPW4.2WG^]VG
M,P3^`,[*@]=/!781R&$#TMAP:LKP/!F-`)X^OO7B4M>4@/`Q&D+\0DAG?NOY
M?>B1(=TG`A#!\'KZ,AU#UF!<![Y;GY75O<GF,R@,<ZJ>32W6S*GFL_+]CGPT
MFHQJ9PV6A/!)+$'NJ<WZ3>&"ST8)ER7WU(3['?PKP-1,D6SS%KY&=!4XWE1X
MALX$(VK&EIZ>;N5#3,.E'T$$P]L)_`U%0^0_^O"?$."ZF/.<)'/X_ER,J8DI
MWT\ANF\1Q'.R9SQX&6(8_[,V[OX0^I'-IT:HRQ;[4>T:F2=D/TJHF7D(^W'6
MC^/8CQ+4Y7H2(A^2;-LA+`KC$T89*XER)1<0E[E;.CW56$QD1"D+7`@N+,J:
MY`V5EFE%\@A^X9]E7K60;F9<9S/R,%:62[GE?,HM"]S]4!*?IZG"J8'-_:!<
MGZ>Q16\+(!]%\`&]0[?G$[T;H%</=L,01N'U-`Z`5IL$\U<>D$,GF3_H#DBD
M$B^8ULX3<)#-M\:TE3FGYB<**,X3&7FE+.<59XX5Y^,J=4)P9T7.J\CGU?6S
M(E=;D7>Z\FIK:8T]>+D+N7O;,^7@G_NLG`X<P$X<X:NE`A6D)JZLS@I2*T>R
MJ2"'_3QN,Q7DX%_Y%:@@!_Y:<!,5Y`@?/=YRE/P&>,!W@Z<AP"/@P$F$'."%
M/=^I>K2YWW'R#+*K'E`6%V;%PX-Z2/78T<`6\7=?/8!1^#*$&(QCZAFK+BVW
M'2JYL[^?X+=27H[(I;S;).(V!8J(_"SI/4VV+/`P1A$!GJ*-/J@`#^!S'V#@
M`^P&UR@(IV$$1PWRMSMH/QE?FWD9>M&`=`W#ZYJ7*RMV*7K9S78>5'UV\XGY
MYBSF=![41,Q/)$_X`49P:<5?/H)%R8V8FL<Q/8Y$FS%/[H,)GATS)6:.PG^'
M:RU>A@C3PBXIK;J^V_/=B1/S_Q=ZF[7RCGZY(,)PB\,[')&G-5%#YB[C](7`
M#X%#611>3]DGJQHZ$^P,00B7VU_T6/(#\IW`\TG+/^;U`N\GOON`1HB\O[IN
M&XS&P)_61>/R,X:GTHX@]IV5*TNY*A[T-DO+CAU`S_1!/OY)U\0M"[J&(_1H
M_KZ1XV%XU*S(4:28YR*2JJ//FQ-;SJQ;L^3(P3/CG8I_0*XV8`8<6S%F->`4
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M1`&><$!>CJ;/D]=_02=Z"1YQ]QT@#[QZ\#[`C^0AB)`_>(#T`-ZJ!#(>!^0!
M_!4"]]\3@AGBL.<_@1`0\8':Z0HW%[C*(.?@U5FMXI*K,(0`.\-[X,2G-WM^
M78OOEJE0&5PZ-56*ZTXL^+E1:F-6G>)7Z+D_?1?B^5'@F*WUJ^"33BK?:;AL
MAIR:@NRZ>12N79.IRU[$_O>#TBFOR6[$3I%NN=_4(-'NY,`IB'AQ0:VI`MY!
M_RF(-W,&U\1?UV8JU\%39\SYYJC$(29_110BNQYZ32KG5?<+G$>HBY>[1OB)
M"[?\+W`>3[C=#X#=]>\C]V$88>1$\SM8/WT4A?WGGW4)W!(T\<EZ)^4U"=F*
MB;3:7[6KDTA+^$Y=09'6(]2JO&PK$F05-=6UJ(I?+R4X7AW\HL:]%H7-ZZ4$
MQRME7DP):A*EUTL):A6Y%RM_U,4X^!A"X)[C_WV^#U5*2:4UV9QNAB),=<]!
M<5-TN")A^ZE;VUKI1*7J"M;7.M5*YA6Q`_<`X;\#;P*OI\N__DI$08^`31_@
M._18;[ALTO/'DRB,G\M)7\AT^!V"<(+C&ESW&/Y[`GUGFMH;TS#L0V>",?('
M=;$T.0CF\Y1YV+*?P\PG](*H-U6C)G;RK+E'U=S**D-!NZB>[6*%M*M2=E%M
MV%0H/T2H]C[A>2H<(T0H8<?SK+EU#1'*58;*A@AG[:JI72PQ1"AA*G`N,?WT
MD3L=)3Z[1FN*S[]V*:O5+2I>RA+3&CO*66*2VY*<[Q.8<EL56F]>B'*<=:*,
MCV7.1%V*2XQO"FY<J+PE7;\#>NS\'OG`=Q#P>F1T/(DM]>QV(7,VH"[>*TDL
MG_7/SY(RE$`I-2X2H@2K`R)G;2A#&PJ>'!'VI>1RU.:L+:7;CG)S*B%*4(^-
MR_IJ0_5V,46HS5E;2K<=!R\RS'Z@%/KS1K61N8AR4[LX<&HB#E\^H/<.&R[F
M5"Z<FJ@7%YH;+NMT-M1$V(Q+6WU<=>G#\YCO^D5ZFX16S997+[@KJ!SU6T*H
MF7)48M4@6SFV1@7-M1[EA@AUM"!;E:2Y5N2`2E(32[(]Z&RN*2DY`JVC+=FN
M)LTU)H=4DR-:D\TU-78]<DY\;;8ZTZGA6W!,T%R7O4Q>,=9D6E=7GC6=OV=Y
M[S]_R]A/Y!1CQ8.V6HBQ`E=87SV`4?@RA!B,X21"3OT"]'(NLVYC3/.B]+M/
M9T@K+\;+[LT-S-/8<'*^O+@RG'6@XO%Y8=&>IW?50[?"HJVV8Z^;:`N$<RY$
M5[>!$P>HM%I0+./[6,:2=-&:M^W#MS7)IT1GQ&?\[4MGO</5,%WRDQO?&O+`
M@!U'YAOG#7@AG`V4Z'*3H*>8[+N9=V)'5/A&9%F[M?_-X>]1Z`#OGQ#@>_)+
MR`)0^0$DAU[K>]O@,X0;PVM\P_]-31N<Z7LU/(E_7>0/GJ>CU\!CA]3YANSV
M?^O/!DWTN!KH+IX4?3A`)+\BNDYK[;/C&;SC]1]_^_6N>]OJWSW?=?LWO[9N
M'OM/,PAI8ZTCN2%\P33=<^'G7^&4A6+R06%-V=;^5\/?3#!.*$2*OEM\"-H+
M%[&K_W4&W"./?F4J@H,`)\BW^09_'@&/]-3JPW&`Z:?16C?!:`S\*<N-Q&`;
MH@A&H\"/:Y<]#P&&X>,DHO:0JA$#3,ZP;YIDR<0TN=!!!!(Q]+T?]Q>MB8]F
MS7_^'L:=7WS3%5NR=",IKAT89GB7AXM`..SZ+OT?_?['._`@/=09W9#D?TI:
MQPZ(A9UA+F=L9&!+"=`H##1%-G\^WQ*+K5JJ9ILJF=Y<:/8D(,OZQN%>/@)L
M6=;(G[WP=QTGF,PNGT+RPJL'?\!HKO4L["R;G1^VJ9,W5YAW`4A"?<)P#)![
M]SDFH0I,P9AAV#ETPZ0VE%&,U*$YT67Y@/P<U%5%U34N=(_1$.+96>D4:!GN
M@H-QNFJ9FK*"MCDN#ZXLWY&?9;9L&%)^6-\!_@-&5!F?Z:5L%"&8AB_#LW#P
M3:'&B-C<%<0=$`IAS7)$'+R45$DQY`)0MPE:R71&^:VZH6J*8FL&8V&VRWDK
MH*RH/#^W%,O25%.V<^%9?/62?NLH(I:<6O$Q#3J)363A93@1#GZIAJG)JLP:
MD^T0BH$5YSI47::FKPC8GD_BCP$B.CIC/VE`$E-O0D.27X+`_4`>&[$KXGR)
M*MNVKC#.)`^4_<"+<S6JHDF$Z?N`3[,./P+?V9QTXMR08BB69AG*;ANU0E$4
ML3@')9O$Z.AJ,<",._M.,A7HD>D`@\D6T.*\EB9KLI;J5;?`V`>V.`>FTCRB
M..Q94P::*M!]V8:A*):YX;ZR((AS6*JI*K;!NH14!/.P_0E,J8YNNE!5G(\B
M$\.2V3PM?7!>@.+\DDQ,O*$JW`#Q!+J+M=74J$T5YX9DR;`,FJ9GCE\`ICB'
M8Z@6"9BX4=Z-QEXPA7"^Y[P;K3@_8\BR9#-RSX2Q!VJ!R9"DFZ9<&/4M?(/D
M9[</WZ$_29M9XCR,*5LF$^^E#\T+3YPGD8GA5;CQ+>XS,XQFX&GBO(E&4M1$
MZI$Z-B<\<9Y&DXC59)=9<L"[`6,4`>\!@A`^OGIH`.+3)IM2UD3Z'Y7,<W:9
M;1>&HGC%N2.%`-;T8GA_!!'<[C,U<?Z(K@(R/$T9EPN8.`]DF[*NFQS(XOAQ
MI^W6!"ZP6;JTOI"59;!S`!3G7'3+4C65$^%N<.+<B:40[ME,<+T?,'&.Q#()
M,D7B`!;X@Q>(1ZQV,M#TK.UK#H$F)VK:P+E,7FI6IXO;S[%D13;L3*NW+:OC
M0BUP$T<B,:2L%H:]/KW2\6;X%IXTPM052UE?X4\%4`1HUMX\SX**;IF2S0\T
M$V.&J^$)+'1#LVTY==87AI>U]\^S=&W8"5GG@$>W?E$T*\WCNS<$"/('T'>2
M0:1._,UGB*Y\Y'V]B$B"EXNEZ3!G)Y&N2'>)`U(?ZN(\DMSYQ_>'9WJ$"K1G
M9X,<,EZG$&Z+"_><UV7B?L+SE"/>;5_?;=8S/!17$)S8<%P?E`>5(<XYL6%Y
M)BKF6,(&)('G"C1=,9F-O/51\V,2Z&44S=+MO)BZKHNHTP'>$T!NSY^[).8E
M%J4XWZ):EJY;JL2D+ME0]H$NT-O8JBYKIF$4A]Z'$4`^=.\`]HGM";N.,QE-
MXA696_A&STJRT,4YH;8B*2IY369RGFPL^V`7YZ':LF'(=!G!+HX]%L4P\%R(
M0[I_&+'GMXR,Q(C'+EB&:BB6Q;!Y<V@>:%GGVC@<O:G9EL$J;Q:R[\@/,/FU
M1\;',$R(5YS/:>NZ+MGLH8BU87.#,L6YG+9L&JIEFGE1;;*RY\\W3)_H&;_`
M[T811J^3>+/O):"1%4&*`\\C3=)H$>BK+-V23-.R=TF^"-RR62#.-2JZJ6JE
M<X")G$EXN7->FP*3M<W=Q"P@Q6&+<Z:;.Y!\J).!X!/`C_@YHO8_CG6>((X/
MI;+8>;WI^F'8%?KEN5CI4I*VALS;,.U+!Z]G/08=LQ/!W4DT)$;S/]!E\?-Z
MVZV'DB4IN6JU&T)1N+P>^&!P>V$X24+E=<K;H"JR8F]5!W;P`B`M7B>]#:1M
M9S$S+\;TP_,6KP?>@YM;C\YSP.7UEL7YNOV@_RKMR6'(+%X?R&_(<@#:BP)>
M=WA8"G98-6M?9[B`*VL;=FT'@D)0]_5WI4#=M&O"W-KRKDW&X-P(17DR5=$L
M.WDGI1#"+89,E!?+P<@\EFP75EN4,\O!TJU8Y^=0V"5L.]-W:>R-M'P'.513
ME]@5F-FHV5@R'9.VJ'%1/A:^6ZDYKYC)2C$P&=Z#*?Z1?P%?,W39R`+S`%X#
M3'*L^5FP^9TB%EJF>^#7'T73B8(S*7@Z"EZDF=Z!7[MDPD-3$8Z4[Y)LOI-S
MAJK)[%4L,4@S'$41Q=3I)H)B\2']!?H0`X^TZKHCY,=WD^G!L13(F4Z#7V%E
MW:+3:04Y`TY![')F%8("*FS1L\IJ^=#Y"AODW"`R=$L[`-LS_%(A\ZO;IF+:
M!;'W80CIIUM)ZUOZV=4@ON64@CPS<>)7=D.U%45*N+$=8`KBSDR7"MAJ4S=T
MQ2P7-U]EAYP;R*9LFZI=+O`,YUC(D&O$+,I*(=QQ('L-0NC2@@?D>7SLB06<
MF405B#LD8E$L!G`Z"EZDF<D4ORZKAJK;JFB@?,4I<J[=$QTP-,%(LZI5%-%6
M699IKL"']!:.,>D[?D+^[L%X.XB8\!'=&?K/!NX2DBW%-"3V]G\>2/L144:6
MIFN291R2B#+2.\G4%=4Z)!4EY(6RJBN:5HB*N+Y7;S0&"%/#_OBV?CN8A9YY
M0K^`AU<E2]*(A\\$4@!O"0Z2%^_RZ.H8TMC0'\Q=9P)G"7Y15DQ-M=B5BPT$
M'`!+<(>&IJJ&K(O!5X87)(&AJK`Y[1X`LZIC%-)$PU(-@SWUD!=@SW>"$7P(
MP@3$$OQ<FVAAG`*G8%R!X$)9@B-K&ZIE6T::*A8$68*C:JN2K9"<(DT?"Z(L
MP1&U94.W)=E4.5"N?K_'P6AV&.0[C(:!V_/?83@[T,WB+F'UTK1,B<DA<D':
MDXH25C;;LF[KJG18.DI8]VP;MJH?F(P2%D7;JB49MKT7';\`Y-,7'OUGX,''
MMT2UG&6I'):0S`MM!?1*M6UV:3\?J#T)R:K(44BQ=,MB+>AA",EPK(54BYY?
MW9.0Q2G'F5;.0X9$W2<YNP!(@=Q7,31%8R=%.@Q^L)FWKPMHOF8INE(&6+X*
MMGF7UE6[%+`9'K>0!AN6)JF\8'_Z&`*/'N!8:?RJX@!KT+,KA!2($G1+8Z\I
M9*`I##WS)O?_L_>N36X;N<+P]U-U_@/+)SGE5'$4D=35V:1J/+:SLX]OCV>\
M>?;]LL6A6B/&%*GP,F/MKW^![B;9E$B)E"B)HCKG9*.1>`'0`!I`XU*=D77,
M[AT>'O1JC7I+*NTA6-1BR[A#`;]EZ]SIR$CK#\2:\$J@TW+7CY[K94WH]9.`
M[?U&=@@@=#,ARLVP[`KWUD8D.W!Z?ZSKJZW!:@>\6@/VLL7O@]5:Y]KAWK)'
M[J3)Q^/A6*Q/J`)Y*:"W=BS9A;N'QD"T:>N$]P!A4EW3=6-X&'"K=9HOJ;.-
MH3X67>HZ`=ZR/^X6N#"ZPY'8<K8DP%F?CA6=1W`+#WO@%"TR]7S"KKLWOY/@
M[??0-SU_8KNFO[P-R3S85BRE;>^?LDMP3AN`+=[7BAS46I$Y"=4.X0L/M.%P
M((:%6T:TK6UG=@I>#O1Q;S0JC.F</]4.X>1KP]%XU-4*(T@'IQH\@"N]U\0E
M4SN#L5ZQ_T=60QVRH48)X(V*34"RBN+$P/>J`;\BL"<&OE\)^%6Y.3SPFX1K
MOY)G;5M?GZ/MXOL70Q^>5@<(@NRR=Y\#J0X1=-EEQSX'6AT@QK/3/ETWK=[8
M@<5>0R;I6SZ2\-,4U+%`@6V=FW8[Z>KWBI#?#-AJ/:P'N\7*.?7VODZU:,WT
MW65@.D@:PJIVJ@;209(.UK1`-9@.DF*`TF8,C>TP`9.EO%A146SOSK1+C=1`
M6-W*T-6(W"&2#\:C@=80]`Z1DS#&P37-0.\0N0J]WE`_%'>*L!^@DHLJ\]%8
MW'\SKR\'V?;V4KNH].YPW!4;'.X"V`&JL$"Q:^/QL%>TX"4A.T"-%:AWV)8U
ML8'@!LCB!G%QLX379F!;6*IB.U$HEL=KVULR%3&>OJVGPU6W(W98W0+3S@CL
M7%Y5"@'C\`CL7&=5!H&1=G@$=DXG+X/`>%<6^H/@5&XRN7X"X_J1?(QP&O>G
M*;U1Z"JP`:^:TL^3S@S:V-#&8F+R;B#6C69-2>Q)XY^!9O2TD=$T-&O*A8_1
M[/7Z@WY7'&O9"#2W-9HJN_<D[6-&(^3:8;UHUMTU4=O8MHJ_E381HE6:](U8
M">>YM"OV=SN(+Q(:D'P@B!FCU<[MB,^AYZ2VL8M6%>IE^V;M1L#NN1%ODP55
MA7@%795WH^)ZT^;S(.8F:ZX*,5=;)>]$Q;P>S.=!QDTV914RYK]I1V*N-A<^
M""ESNX!I&]NIU;\_E&]X5=PXK`B335;I071UN9:)ZXC02M`_3-\WX<UOOQ/?
ML@,R>1/YN+[$M[T)NT=$;I,MNO\R%9IXA4TL1\/^4(^K6DO@4A;SE8$(VL;V
M;P=$?$-0EDXG+(G)KFAO["17[]ZY4Q$\@HC!VT.3X0"A+`2^-\3&&I6`S^AF
M)LWK7$Y__+2@)U;)`T5\ZK(G:Q)C8SC4Q.8MU9$K11Q*QJVTJ<M<K$W2C;4]
MN0IJ-5*F+MOO(,I`-P:CT:C?#$H=H#43X#?6!]N%I"Q^UY,_(UZZ>>\5K`@5
MN(?5MC1?"*QM8(?DCOA/MD78>[\0RWMTZ5/6U&==QMU!&&>M;="A*7.Z=3C`
M^>*)J;=QI_A(GNE/H@6[L8OD*B_>.&80?)K2EU`^Q*V:O>TZ?&<_D3?@ZIC8
M+_(MQMR6=_;W&T0\CG]SQCS%CMH=:H-AV2TU(51Y%9A+VRI&<O-INX'INR5(
MFR737I35-S;C;`!E#V/>][K]8;>W&F\\,*6K!*IKHO3N]!ETR]C-.]"G4('J
M&QN45B(0I0DA;D*DC[9+PB72K2%:=&#@T.;M#%BG%M4W]E$]4P(7,S&2^+@"
M7L6+.15Y#Z-/-;V/70-[QZ5WE5!WG?3>@THCK;]V1GAHM5K%1\HE4S9>'!/M
M?N9%@>E.&-'VX<G">'1EM=H;'%^I5HG*GPEYBWFXMWJL>&`1W]NG.C1Q#Z)/
M>_TQ_-,_LCK=V\?:A=8[\V&7_G-<5;JQ8W.%'>?>^]UT'._97)[.`H5;^L/M
M6U&MNG)CY^B&TF_#?FX<UU7?V++Z6-0[C+X;CT=BJOTQB%F3+[1&S!U)T-]?
MG=$N,[AJ/ID1-P#CE26);^FP=.W;`3Q??,MZD9R^L4GWR1FH/QQASYV5CCNU
MTN*8M#[`(<_1*;1Q/[GQW"?B!\`&GZ9?`>",9!XV8:?R1HFY2UUQME`US.JB
MRL&3?RH3YLH`*ZRL!;$;7:BZVTB6$Z4-%0L:LDLY-7XHDM254%2GWWAEE(S%
M'8@H&]O-GWS[NAH.NML53!GZY"=*OB$6*/6`T.IS`A<$GF-/5N9PZ!O[W5>A
MT=;4T9V,[:XQUH22ILJ8UDBH`_0ZK!N_O.IS?6,;_BHKO"''NI[:RRI%]?K&
MOOVG9MS5,NDBS.K.!-<W3@78>VNL=)K8UX>K>V+#\^CUC=,(ZMA%JR1H:>=&
MO+J,U:V[;:5FX*-^?V1T5PV1QA.S+A.W6&E746=Z5S?@S=JAJSEJ)V-=9O&V
M3:)24]A^OSL^M&K,K2;1-TZ3J'][*#^TOFI=C+YQG,1!5'5AT8BFC[6JF'SV
M648B_4Y$J[9TF$KY0EN1S2G6[W?$L8>%R.U`@U-EK.Q("&W4&:\.WZR)$GLG
ME^QX.K<3&;I%]6$;J)#;%JU$Y[25_JXBS0XQI2/3V*TFF%?RMH61E)^F;\A#
M2)\1N2$LX=R.YB**!VA5WM,&NMA[8RL\>X!_@,;E(Y`5;6?H5^<&Q;MPSH@L
M_1"S/4;#3,N%K>"LT![G;*8C.&]`RAXSQUX'F>B!)\FBCY(/Q5JO1AK(B`,:
MM^X78A'[">T:$>!M@SQV"[=E<R\WPK(CV(?H?CW.3';>"VIZ^E,`^@&B6WUM
M.!9-A.T`[8/`(49Z:-W11HZI"C\H'Y"/R=HL!WW;;(^=@HOZ4.^--H&?!6=W
MX`^PX_9Z6J:WY;[`TY5*9G"NCDC6#S'\0X.+]:W<LP+3OG@<8&O51MK&A=@%
MC6N+;L;!9W.)@B-B<(#M=3SNCO7Q)AQ6X-D#_`-LM=K(&/=K!M\'P_2];3[8
MCAW:&45ZB,$7O?YX,-ZH2==!V@^)`^S$*R'].G#(BDX!*@?8F:]ZO1(;6QY@
MM6!TB*W:T(S5[MN[X?21A#=F,/OL>T_VA$Q>+[\&9`)W)PK."NTG>M^-M][/
M7$3S`'OZ%5@*XT$F<K8?O(?"_1!.N&8,C+$QZ!X&=]"=<96Q!?Z63S+#8S&&
MMC[45M\VRF(WNZVOC4?""I>'K`Z,#F%!C#7@V1H0\CV+D`F-L.0,^"W"Z`!]
MHD?COGBD5`&P+4OTP?2_$1KGOR-6Y*^ISIJZ6F:SZHU!OY]IN%\&JOT0.<3X
MA5ZW/^J**36[X+&RDK!T'\P0+UU^FF[#Z0!M?0;]<7<DSHFN#&"-^!V@S[6F
M#;";9VWX%>P(+'9690<[R!R)G@8/'HBG1?O!>RC<#S&O0L?J)M&EKQ/U+V3!
M9?W3]+WG/MX3?\[3!MZC]??IP;$?U_$\1%^=_E`3\UXJ0%8+2CLWY]X@HX-N
M3SS@VADE4;;Q9`C'CWWRQ1BWB,D!NLMH0^!M^)]NOK[)AVD?'`Y@>O3`!1@5
M;@F;4*"-X<2+XU9.GZ9QNSC0MF*O)Q&5`U@>FFX,>]UNW'>P$FBE5-\[VP5B
M5%%]6\=?[(+FJ#?LC_J][4Y;27@/A?L!@B8]71^-#'U\&-1+.G_YL[=$S`\Q
MP2,3CM@+TNU(YVR:VY&N./SSB/,S:T.QVHC08T[9+"D#VU&L-DCTU*NX$XJ#
MQJYB@3+;CM(A9K=G%$XER-;7#79;_`^:#T]@2+!<*=N;K(9519P.<'*C:6/=
MZ.OB$)4JT-6#UR&R)_J#WFC0TP^'UC4LO^\O0=)6VC;J6T>&E._Q;AC#(>SO
MV[!8@65/\+=%62JLPA@C:D9W+_CC_%O,51?!/,"QC:[UAID#_?3-Y6`ZP,&+
MH6O&N`Q,0L9P04IOI6$0%:OS>ZQJM'J'C`*P"W%;8]>:^E650FI#+@Z^M9N+
M5IY,;E^K37&&";'?DT?3>0L;3;A,$/GBP6[ZP9P`7&Z*!#`=UB"6R+,VQJ-Q
MK^+*T$._M3CPZRBP71($F?#FQDD+E5'JYN*VX71YA%&6E4K]#8"OH.D_FB[/
M=[P1ZP-!F7T&TL!#>"XD-\!,)V$Z:H`Y7A#Y&&R]LQ]=>VI;>&S!L@IH&8)C
M6V"JW0-M7CM`<)%LU;;]W_[7"7^9V$__^QC^\M__A7\LE"!<.N37%W/3?[3=
MJP<O#+WYJ^XB_(5_$WH+^B>^`VRQ"0#]JOOC+U-XZ]4S'4_UZL%S)NR+P/X/
M>:7AY?3/J3FWG>6K>WL.B_V1/"M?O+GI\DOQO:]<SX?%80\/?=,-IO`%?.L2
M=M63Z=M`C5<*O_`%@O[QT_U;1>LHB`!>%>,@/!?C8;;%+O_TY??KC[?_W_7]
M[:>/RO7'-\K=[>\?;]_=WEQ_O%>N;VX^??UX?_OQ=^7SI_>W-[=O[_"Q/^.S
M\&;ZDI\752DV**!8!KJJ)./DWHUF&,<GBC=58C:N";->I]_[<4]4]F6(:]_W
MGF?$G"A?0-Q,WYHI-YZ_\'Q>1QPHIO)@>PO05'/3(E$((N:`X,P7IKL$#?%$
M'&\!HJ:$F#>+0]Z^?+RV%=0"YH)>'G24^QE1;O@M\$2'T)EL>!<6OB]\;^';
M!!ZP5-XL74#=4D!RER"=?T:/(.W*RS>?;WZ"ESDVW+A4%HX9(FY*Z,40I*^?
M^-%CH-"NV@H@`(`@1(J-&_P4]GAPAY0YL6:@=P)XPLP,%3*=HIIP0V>I!+:#
MEP0*Z$:T6:\L$Q?]47DDL/(=):'7_YKSQ2__,P(]^`N@8"\`.!<V4%H!!;=?
M?[FYZNM=!>!4K)GON8#4C"R`JB%0X+7R9/M1H-++KJ_OZ644N_B]"NRH'N@[
M1.G9#F?*M0-K<*4I)FIR?[D`H`!Y!KBU5.'[B;(P_=`E_A7#'NCZZ)MSV"M<
MQ7L@`<9X\2HLPW*\QV7G0%RL;^%BRG>4?.Y#L/AE-RBT4=/4Q'L;MKH)$KD]
MVN'O=A!Z/HJ\`RP6IF*<Y7X?S`20R\"+?(LJRFD<+E%F)@@C(2B(OA<]SNA#
M`O!/\#+"#AZ"Y%"T([!%\BE13,B\7-YIKH29Q&+@-4]$\0DU-B8@Q(DQH%CL
MA`>$("Y#@)]1"11A@S_26#U]GW"50KXOB(5YJ_"OEX9'0`O%L0G\S*&`%P<S
M\:T@A5.P6``4-"KHPQ_(TH/_`(G$UYB3)Y.J('R/7X0\*"W/#T&%V''1I6*!
M"J+J.82E=`*F$WSBF+%>5(!-HBF0C3;J`*B#,)_D.[(P%?VF\?!UJ/PC`M5L
M=%6D_*KE@[K0?_4_[-I>QH#)<#RPV$3Y03-&'4,!T!VZ.[ILE6'5IQ%JUH0I
M.LHM\`\O",??<2WIM;"@5$R"U:<'G%E@K<AW"ZT,SD$B$X%"GQ#<?N=XS@1+
M_0`,%,"Z\B6%JQV\%?8U5]&'"G@:X2Q_C6%3AFV&W;]@X3;8ZU,9=F)]AH`F
MHAO#"WLP8WTL`,9?Y@K:W`X')5SFOG-E+7KK%$YH\$._V]%$2E-(<Y_*^L[0
M1[FX"3.D%0(\.-GPOHS44UHOO(`MF,TC5R"B2UAT;=S18U!4Y7EF@SP^<ZF%
M]8R<$`G&_K*(O:!_TB=.?6].?[#Y`:>@]N#3#]I0[PP2+%%>L[<1?IZ(%S_S
M$T6VB?.33OH0O=-+P4,CP$:%#;]-`Q(B"BX)17V$+C%JH^_T`];U"3S&GFF,
M.Z/TF?1>+PJGX,FSWW40[03N6,>DFA#7PXO/B41%S5!D*AGUJ0L<%N%T/7SH
M1MG4.D;6O>!O[^RJK!IG0=Q%<[J/`BD$=U9)_5DE=FA;9&)\!MFU[(7#6"`3
M!$@$5$=EI:0-A(#5IG$\`!"/`P*Q]4TEQ^2U!?C4U,E!]D-5?!<]!*#<`*`"
MHZ/`SN>63LK:0?P@ZMFD+^+!E5A;H-?C62:7O.3'/^BQ!M@C>!TX)X7JJ=`,
M@-T\SE3'&FS^DGR4'"=C&5&7*/;D$G)1HP<7#X46-0P^%IR;.1"<@Y_IY,2L
M#%CD*Z&Y`WLV*!1V.W\X+AOX.;9;B&;>JNXLWTTT1G#<.&5),;JUPN=(+4H:
M)&3DFF#<(>FVLS\U@JFQO<`B,Y^M%C[.G]"]ASJ29JI.%JGLH7OKTUT#?@?[
ME]V+ZX2-V^`O&G<+E)<QL'KWE]^OKS\G?VJ__,17%U;>G@L0VBY2QDQ,ZAR8
MZ`[I!J$?68E-_0YN8D_7!MU?M.[5_Z5W7\/N9CDD_66$Y/Q"'B.'O>+NZO_E
MLS]])Z`=NS*Y-)QXL%YAHDF`(O'6OHH&7$:"U.>`71;IP1Q^6#^'A/FOH*8A
M/A#C)O@P>#YPF_E(?U;I*\UT>IAHX#-.0B,C\GVVL5I^1$U]JD8F!"%Q"5J/
MJ)$0%A-4A.TC1R3\)C`*QW."0+%U8_8,DUND1/PT$!"X>@*J`UNK(M#QE?PM
M$<"]!"559&PJ=\A6&&N.S3%#4/<`]VO3H1QQ-R-@KJ!]-<%6KLCM:`[%<I!'
M4U5YB$)8.UB0U=6;)%'B]<7"R)0=%+!J`$:O@SX:W&;&>N_/R*4<FK+M=K%,
MF26F]B85>.VZL*+`T`MP[S""M28'_X=2'.]'<G,S-R%N>FE,Y=P%N2$^-EA"
M7L+#&[HG,-%+F6..O@9((J@)>.&"GNGFH\@,OS@F1\D"'(K[$[]+9+]<>%JD
MX[\R<_UM$(*Q`,N^HMZ9;F8\EH9*5@V9F)[H*%!>RU'0^9J<,WD@*!5<E+GY
M#?;Q&";*E+#NT9S[$300:DZGQ`J9^31GYH!/^3!EV<SFE*_>KJTPHEJ*J0>+
MBM'$AF?[L6/C!0(L;><'/)6G]*8?A//Y%<:(W>!8E0=4?S$W'%3A0\BW2,8B
M"_#39]1%9;MZXGBS_<HGB1^,H64:$_!0F5%7CJ1`%*IKT2MW,:P%[[8M:HE0
MA%9<>8KANHK?,<C<S(7T8'L"&S>1W1O82^Q0^6('WPK6<@XZ%O5LH`3TT,-1
MK!FQOO&]FXD8M9JR(44@;OCL938FD)8PXK$E%KI)37:?6D\1W]E03-^1"7W;
M&T)C&K"[P\]T=Q5/=UZ^>W-[P\RV:('\\8/>[ZK=;A?5=OS\#K@KB2)Y`$\`
M$,D&+&VVZX([[P4L"I`)P#(B^4`D9<)"I%GK*XFZ<$-KPF#VT*42T$8-Q)RI
MD*+/+V/HSX@S:96C('3-*6`M%K$),L'"!V9"45J!_>+#"PGLR2B:CN<^LK_F
M2342TRI"^%T1>P?-3:Z+`A;/`HN!F0G,58_IKZ*>(4O^V(0K5>71`XYW\5E7
MP0*M).1/@F8F[%:P@.E[T7QE7!D')`'BGYDA'0<Z%R;P9/8H<4V"LM%V`<]`
MJ`M;]S[>7=^]5J[O;A1#!ZTEDB`AO?:+@MV8*"5YN<3=RJD%M;FH/9ELANE>
M;'%S2P"$JV-N?=$=EHH&:FXD\J.'P8E7>X1Z^)\.F<8\G1ON.MGA$L@LP'H5
M;UP"G[_)\B6S3F@\E.:QT&@Y_LE4QQ.A7J?+EH?5QR_3V+27;HVH*A*+!@T>
MUF^+>M=!N*L".0-:W_LF]2!3IEVE-I)N[3R.FX4^BF4$X-"K4-?R2!@ZA;$S
M`@8)ZG]4#0&)HT`L*(]N"E-$*_2GKND3)G*I3!2C9*"'\DBW3::Z6,J3X#T1
MWA:VQ4MV_63:#FJO*[CZ"LNBRBT9;L6"5@%)(3:F8XC7S%9$#VW$D+.(<%GQ
M<A6L%IJ:;+%@5V*+12W^>+GXB63\1$PN"9@W1`^U6)M3RD&8&<=[RPKN,4>W
M53M]QO2/URU8V<^"E0UM9>/.YKO@"2\_:;%]*YJS(H`@=L(5KDO!_:+2&GL2
ML?TEV@/7X5JJ6.90)N,";#@\%1F2A=16\3/7N;)5R[RZVV61]S$IR60F/),1
M-%'R-JEXD?-B1\7AM(X2-Y)DC+%@[22I%0+RQX4Z,<"SS$5#^`D0>)B==*RF
MAX<_$]Y;#0T^QEJH[+/L!*OYT5M3$U[F='M-]7#EPDZ6X6%L!P]P6Z=!QPFQ
M>-J5J)MLC!PB"-A`G-M9'JK`*SP6!R-XCK:FGW]$?0?FUS3RJ<84PX$^>31I
M^+B0^M3@3FQM1H,5"?[H@:+3,V:E8&YVE#8Q_'9"TB7C;D/"@!N47$Q`K9NA
MX#M\#,M?_\!DB,>$@PB<1?$E(!@F<H?WP)K+L\T):88'T31<Z=L6VP3])]LB
M[3I\BIN[)%X,/4(4K(K,!23I2<-D,55(J(;B@TUT$N%*<-#65Y.;?Q;?6Q8%
M3[=X4#XOPFXJ#W'.+;V.10HZ&-<`B.PD$E/P;#M(`6=IG%0C`<60KE=4=\Q)
M./,FJ>X"Q89I7NA51`&91@Y-S`QB=6:RWH5`<YK`R@.:Z+1AW(,\$9>&Y8%S
M:%,!ZH+8<TRP(:FN3[5I\EH,T<%'_A:6:D:AYB!,B>+%`&)4"5_NT$Q15#3P
M-O3O'7I<PD`4#XZ*2$\7]LDFS_'1;-('%\^C70Q9*8A22'5VUIK@AT$D=<XL
M7FW$@\<<ER"A&?(*6J</C)TP'@9BWBH1NW5#9`S47KS)Y5WT\"<-JGN*V-U9
MD#KA'DZH(+W'%.Y)/:`XG."`CL*-UWP$!N3L%8M3G'"9"!!LU0]XB!_GIY5]
MJ^22^KGDBC:-@$6)DUO3$!+]A/^"DDOS/%[>?OZ2_/+F)Y%]Q!\2]41B8Y\G
M6S%EXUX]>DCZ))T$%,.?-*>5+H^0)U.2B^YPB^7O9&%HFR>?I>8L77;;%Q4X
M[L1$,-EXC4!\Z"3"3(,/1`B8<R:D^9*8`(_I"5SQV:L\K8I,+;!MR$KRN6')
MC^OI5@(/?@`EZ=&X)<TL$(C+<V[7<O-I^(-1LJ-\7>#A<63A\J+J%I\^A0V-
M7Z@*U'ZV'8<=T)F)Y<IE+XCCY?"O*ZC^S+X0)RADL><IQH\8\13D6:AAH'2(
M7<T56O)%79%W6$S<=/#9>$S-4BD8AYAX9`%201:((F+/%G5J^P$ZC_`]K29!
M8\$.618!OB0(XB/*Q&A7;/0/\7*`&[9&^QMQEBRG%35#HDI2H)4,T)03*="8
MV9"BFYZL^<0A3W@ZP?76NK-,7\+.+H5C4=M=1'!YQ,\Y4HB9WVVO>%)K#`EZ
ME_U20(587?+WER/"JB(7T5=IB,7"-/-X"<`20"6%S!OGIM%5P=`J`PC98A?T
M$NSR=7P.J'AX02:,!<5@("`I<)U#1^@)MEQ\&"T\'>MXOC.N`R"R:RGBD5#5
M7+#"(Z!V-E:!&Y#I!)X"/,(TQ\-R`?`R`H)FY\4VK.V/,@$R6U@ZQ`55H':K
M-BW6UN81U^.&RQ'345=*G)V9?H=JPXLR.A\MZ#!-.8+UCFA=7=R4*XTU6^F;
MH@4/=W@6RRAA&=0FRW*V(L?DID>N+_\.H"#?3=2_*J8+`UL#CND;YT@?-#0R
MX3/3FN$99[P!(#&\")F/IICAL21E'>!4:N]P-+"F)4A?$E=?>$O3`;M[PRMI
M808\;Q(!L[&G8(&<LU(WQW@?154@3Y;H7M+`C-*?NK_"Q0D,V4AN@G5V=\Z^
M/4T<6=<$)>`)DET"[V*_SKT)(`FRB8?%3)W&;XDWU(?X+`<CPD78)(2,%TI,
M:V'YAO'I(FJD^!V3>(]6_,(DE+?)M2GM8*DG/)26.)6QK<5($A)KYMI_1>R,
M#S0AU?&A\&:!?ER)\X-;):"Y;XS^-Z#J'UG88YWH*%RE"!\[[X\N-:?07L%Z
M0'9[&BT4DH_PZ4(ART8P>`;<=C`LTXU+):C+;/&G`H50)(%=Y_`;9C#Q/59T
M7X5TR%C+QFO`5D]-GK>R,_@8Y:;%"-/4I\[4':S:<K$D"DG6I9[.ZC9H?01%
MD#\G8"HL/<CF5MCZ,Y%K:5*7H'W$%PCUMO1'4=6L/&M%=&)O,:D/$XV>?"C$
M)ZQ2*$<1QBDI`G/,A5`<,^)C.<WFH%-["@T:[P&#;FPN`0.&!9,Z-%D_1/,$
M0/\SFCS&H1T"BMU;,G,@WN+C&(^PNU.W1?0R4^V01G56?1.D#2I1`NM!D_P)
M"'22S]A1,MG$`A'%QS/KD>93TO0LXM-4'M"H5A+&3TV80C&*H^MASFZ`;X0_
M'VV,.W'86F1S?+#A+^1!GG.Q/2L&L]6`V/%]_'@TFQCRGGBNZ4\\E7IC]A.L
M#)AO]%C[P?:H^J8%TG&9>^[>\%HT&5![1D%Z?I)**7P5OVZEDH069Z/E:6<2
M5Y*"64RH7B9V?%*,BJ5<#Y[W+=T_LFEX\+0?NH5)?4*.F0`9:`B*#=#F#;%8
M`A]-WFN3_?IQI43E-BE1H14Y?U*&N?KTC+:(6!XD,%K2^3`^O@(MXX`B0YU%
MTTSX0SSZD!O<TY'+KA_`3+6IOE5Y,C6O"(5=;.&!S:=BE<5D.6?*@LDQJ[KF
M'A+ABU]89L-5)N?WN,(.=SUV^)]@M.1!&YXVEHO(YE>E">(TW88FA_C`@CSU
M,,G.HK:B3UAZH&B<<C$I?D-<3XN/29(_8HC9W;#/`*V!X3*EW70?8J^D'MS*
M>UE"F<T$C8LN.A(Q1#'H*_6\Z7KS;3@E)@9`*7V?9X!%O/)HS61X825OS6%E
M6L%F,HAY#S0?`E^/XL_<X16"E'L.C\^M*,3"A+B1UKW2NJU2`W_,:#."F$OX
MWKVI(@,-"3;/&`T#7$\_F-F+=$U,4>,#;"8\3V`19O8FAT5F,B8\EM9,N1T'
M)+V?!2=B,(/U,"A8UNL/6JO3`Q;T^-$23943XD=QZ\#XN,Y!OQI?D#'S\WLE
M)(D`HOKA=P@TB.,\Q0\2^9'&.U-<5!ZV$0!-#OKC.;'4U2I^OE"U)CXF;C^3
M+F^RJ%D$,@]C6`J5;\GFS*TY,53%%FB5R+F5/REC8!LZ$!J%MR=OE0!^0>\#
M%N\+<TI7#L/B7ZFHQ,=;4T*"["DTGCOA/AE$9H#N-<'V!7%P"(^L\'R6.5'D
MNQV@.QG:(>QN:%YA,(]IZ?B87]C3?,P$X(%3S`:@7,9*Y5GM+0_//S@\#FB!
MOB56W"T)5]G#7ZG?%/FKNA^#BZR4)Z2G:BFRF1"0J@AF*"<#39-V'/.!AC)H
MOY.BQB@I^DD7$'[I(VTAT%%B.D>(;=[+$MS2]PFGC.%RP>T3GB%.MR%8>9!'
M>"0U)'@.]V-DXCLQ5+K^&KJTA7CAHZC_[TZ2Z$X:QJ,N&H\A<MK%X38L5_.]
MJ0V,"O),0S0\@-,J48K[[/%5+,L=PF%Q-C@$=U+.%7(A^#$),TD#!5,CXFQU
MIO'BAZE"A1JUJUCAWX3UYF`G#84@V>@LN[B$*"\9'1`MKN"_>`B0X9@T^A$'
MXP4&L,D::I@&:_IHG&5BO=G#.1ITR'\PETI:E#JEN4.<`$*Z2$K8CI(L#>T(
M\L1+L5EG'U8\FV@_?&BL";*I-O1E;'OC%[2*?:]I8U`D"%HR;[SH(<0SS7@J
M9(&'3VN>Z>HH9N8!D_@!25U(LM1I^!I('[FQRD8MQ0D;H/MBPMZ[_`]M6Y4T
MOA+T.ZY__&@_F9ZKL$YVM"D+=04P_=;S@TZ"2.9B6.!G<`SP),2;3ME&ABFQ
MPC9BAIBB&'M:4Q,XLEW%39F.7D*6@[#B-U[`(Y0\_!6?R,*RT[(9>`"&1Q"G
M)-%]PX9(+6C_D9\S\(@:S2&@YTJY70D2-VAHM,X->AMGY+_$B>T_T8(_VHY6
M6`-L5F&EN?LOG>1*9B53K3U?1.E!""I$!B>97)FTRR,XIA$-*-$0)[:^97<'
MV$\(P[ITAY^D+9SB".L;VZ%/+GX_.RO<'0#*)?@65-X+#]TBFS6WK`CEIOO3
M0AFAEB[`[K])#R>;=2E&QF01[<3Z<M%S3'H^)0V@,&D[3MIG[825._;$C*O6
M^M9N%.DK%HE%G$&H\QJJY-8+TN7AG3(MX=Z,\;Q9*V@C-3%L>)T?M2#2DX\D
MES_>ZAD/IB^+-1%UY;$_CP`5-UD5$]9]$M<+KFUID_4TJAC?*.`0O79,H-.=
M-?-HFR76W7#E)';M_#5[T(>><I9K>?B`GI;`!=2Q8.\O];H,R>@Q$#OEI>E:
M/"LF[4[@I6$)>D,"5P:F'/2%C9QF?Z?;M)B3OHI[<E3(/,`G#WO+.'$#U<P5
M\)`IH6>)]"BR59O$&T)/1W`U>#8KHB].1Q;S\`M%+=NXCA)_DCXY6^0>MS=(
MR];BF)+/<X9^=H3W,W%(LD1PCP?K"QX>8.?AV()_LH/XR(.>YZ4OZBCQG*[5
MFCGVUE5[7`C>+7B,)HFU[U*7PYO#)(42ZR?=7`C35%SLRM)1[KSYQLA<0O-G
MC'2NE</`1\=FF5CTE),?&V1:P<!UV/PXSMV/B4C-,`QC\.-\>@0I`)["G30O
MI%)42&J!%\2EK<`L%*2X[VI24"BT1S&#..&,]ED67B*N[XXK&.>WKN?4Q+HQ
M:?X8'YB`TX'7,46^<L*\G@K"TU1I!DQ&1ORT020-9X%2`@KP4EI:=E>8N_%`
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M2VU\+PH(.Y7,)PNW5E`Y)>BD$A^GVV-N&BHA'K(CKA`D(ZY)Z8EO<\QG]DB:
M[D`3@"@U6$.IM1/D6*&(?5LRV##]Q1<,SV]XGK7YG6<!(0$[M+2/;W]QO(??
M&V"XT@9%2=D)Z)*TOE-9)^Y)9)%-;,0AY<<V(BP/:?DITW;)#KC&Y2JFJX,<
MJ&G519"L$!CQ9KS+"F'1V(Q,3Q\K,'N.&UIS"]P332?Y0K"_$KC*?&Z/T/GV
M#GUPZ@>UI_7MK<MR=]+.U-2WY.&`Z[NO])<KK:N6G=<B5@S=T7/HMYC5CTSS
M\MY;V)8RUOH_O5+>\GZN<1\KGB"8#-GA[0>1\%^8@N9G2;=I3J:K7,.7D]CD
M^R=BB)P>Y]6DK_X]LJG_O-(?@"F%I+5L$.=UPFNMI,MF8LWY`APLW"O@RL[<
M2?S"U'1,E5WR(]N3OG;N.JP'9&X1.#OFL)+3##-!=05>`:QM4`&1M)^27.%D
MS``V!:!6GNB0VFE>69J5RS2#FJ::,@IM;)6A*OI/H+@?B%.\J]%S<]ZZQ2S"
M`)YD_!1WTV2%2H'EVXMLYZ[56X7.WYEM@#V2)G&ZC^8C/USM"2\(D](AVN6R
MX&YPG;#8GO@;`(^S!WCJ%=M8[9"F"O*M/Q_Z_#:RJ5A2\.F>15T3K`5@`Q[8
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M_1)?0HC2I.U_%?/!BUC,TJ43O50.O!HGV:,*BER>+<_2F))SV60R`\WPQW3.
M)*$K)@G-X*:L(-8NB-GN<?+Z6NI]\H,:-V9E1;RIPT!?Y+%,3WYBA:43M)$%
MJT)RILA09@+%.E=0\YD[N"RV1ILV@S?C>\DA-N8N>A,6G,G^DJ@H>A:!+WL@
MU%3-ZD`QD3+QI5"/_Q69?LC.80"BT=I8,,(=]-BT30Y4V//37/T8CEB9<1[P
M6#Y7;E/:=FFT?T0.56E&H=5H7&E:::M1=/%CM37L=<%.%+O4\]2JKZ[`EG"+
M\IJX9`H:A"96FH![J*1YTGBXJ-`IM(`:GF-@6M4=B!L6[N'=>('*FOG@G[RC
MJGB'\I8F<&TS'B<X/2U@R?Z@P]#PL`2W:QV12$2$.M,<$78D3S-MLPG`K*Q5
M0"3@B%#G&"^@>%"GGN$AWD!S-^.>;H)[RCU%P>6-PPRQ[TB5ZS,M)A%+J$"U
MI0D0U'2C-WEQCQ2!%;AKC:&P.#UGA2`TN!@'!)AJ9VHZ$P;-QB9I<=U>)I#!
M"_18Z_DX8,!KU)CBY\U4WF:M)%;&S`VE+8J$%=RD7GJ.&A%)Q=7(AEY:J3*A
MG_A44&$&ZI&GFJX.P0U"N)55S'R@42FA;"9]?.Y0U"TSPUL\%%4O/13U]N,_
MW][=?WC[\?X@\TZ;L,=D!(KW&;9WZ36\VF`XS]L0&^ZNE3/QI`D,1D[7N@13
MBYLWU$,7,VV/@?/+DCEHK#T3TT@%O0^W.EM)4P!&CD)*%'1)+FR2_/5.N?=I
MP@#M@PQ_IFV3%?!!76LIUM&*G9)7:*L6-DW>AMN&/LH'[)>\/AINYTZ3Z#2)
M,-,SS^PAXUK'4Y$IVV,<XK)./;0*V$S>!\S`".A<,?3ZBHXWLZT+K]9:%[)"
MV951>@4-_W=4@T5[0KF9L@<@I="1:06AS(['6A4^X)&I3P>E6\1Q`K`X8`&2
MOQ?HD?*_82-Y=(&Y"5H]+V+:L`=<T13N14!>Q1]^`9&;A+-78_U'!A9_JR]\
MIH4Z]*&,M,E#V:T]+7-KLAR4'/3&5PR87[8ND-@R&?_.KAA^L;:/"ZN(IPV%
MPW_IIW"200N(`)0$O+3>B\TX`HI\#6+HJ=6E=#O#_B)4_J=+_SDA&;)4.*0U
M<[TNJYNIO(VP9\@[/V?DX[)D19>B4EI4DC:<Z#3M)R4Q31'QAA%T'[:Z4+1W
MD:9"$DAQ8^C][F.,[&LZ-.!W[`8N^4^B+<7NF&+WGC:SD`PHT99R=T"Y2^<2
M2/\K!UV`ZX7R\$B#?+^^^)^;=^^Z[VY*NF.5D-7TCMY?1?@J^?:T`;N;-%C+
M9@2_G/#I2GBN[[*P]4_5&&@+47=58UN)?F)2_E`OE;K[:WL?T=LNF2>FFVZH
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M=7K12B9TZ9)%6P6Y%*[3"]=+734:W6WIO)Q>*;A2<(]E<`[&8W4X+AF:DKTK
M#E"%<38^J^Q=<>;ALXLIQM*ZZM#0U5[589UG6X\E<9%J1*J1LSA@;Z/4M0D7
MJ4&D!JDO,-(##ZLG6U?(UA5224DEU5#:@K<T&(]4?5@E"G2V<G>DUA4;*TFR
M*WWXUA4B<G_[.0JN'DUS\0HKG:_=R=N_(CM<?B#AS)O<ND\D".>`2/#&#BS'
M"R*?W,/[7SN>]>VW__XO1?E;?/MGWUL0/UQ^=@`&_IP%WIISIV)/?GWQ[M\@
M,OH8VV(`]/#3%S+]]<4-?ML=#<>][O#?V*)`ZW8U_-#K#HSNB]\0]AW6952P
M+OD%0.7$;H]5^?CI_JUB=!1$`*^*<1">:X<@7Q8O&+K]?V_?*-=W=V_O[^CB
MX77)2BZJ$F.P0HQ>I]_[\<1:)V8?52$QXRBF.U&\<$9\96I_)Q/%#`(2!@KH
M"<4G%JH3^"X$]@E"57F>V=9,F9M+?(#I*%,LL@*DOY$0555$%)H[0Q3+#`BV
MQ5CP-]+7""^UX*,/3X;+@3'_C%PKM#V79M\HIO(0!;9+@H!=%]CX6T=Y0Q8`
MD6W2*XN?;0<IX/B<1PI0`$1"4EXY\&1E3B5/\9X`;?S5)\&"``A/!&XAT\A1
M'/A,&WO@SYPF0.9'?-[4]^8\0RCTE(`\$9>E"G64]P00GP&C*_8<X'LB5*XI
M-<VDW4'R6@=PQ.0C]A;R'6&@4',0ID##&,"Y:;OX<@??H(3$GW=V8\PB[7GB
M-(&F-/X9#G9H_,-?FY;WQ5]\H81B5D[RY3VN0O:KU^E2,3#Z==3>=5>/-5++
MY[1[996BV$%A46S]5&]\=Q9J`+[Z'V&=#EU'^]H$6\-"'0AZ:J<SWH,L$^Q$
M(;E"\4>\GGUS<5!Q.>T:'*KKTEFIK1W)?F+M55S2?U#M=:;M`8XO6O^(P!SD
MG=HJGEQ*]79,]7;D!3A,^5"KED/JN#-9T*0WI;)72TJIZ!IGQQ5&A,_*LCNM
M0WKCS1<1"'N@@H,SM<'5R0;'II'OVF'D5^PCM#U87Q?KGY9\]9\2E:1+]3.?
MTQ+*,'JJ5C5COY%<U-A6$XT`7XKU98FU;JC&L.0$@D9SD0PU-<,@^4("8OK6
M++5#=C+76Z:0:BLT:JD>ZJEZ;Z0.NA4UD626JLT_*Z%^#<`Y9X2P7/Y+T!6&
MVNOKZMZC2>IBEDP@IME,(X,SQUV4.V\:/ILR]E*OGKM<;VTP5@=Z[;4!DIL.
M'-%INADE640JG'-4."VUO/:ULU*CZFB=$YMH?.4G,^_G,Y0YF[]L75E8-54#
MR<Y->^KJN-]7=6UX.*83I5@RWG&;#)V)=2=UF-1A^^BP86^L]KKC\])A+34-
M95"NIJ9DRB,=;)@I&JS;S=F:Z7G96K:.BON6*MVA.NCBOZ.F>M[MY#@9ZI-:
M2VJMW8.%:G_<4WMZ[5.+I%$HXX7'B!<&P2MA<9)/RK5E1?/(,;&[P41LXX`)
M]KPQ`OU".N;2,3\6#5\:ZM@PU-Y01A?;U%?_3.Q(J;ND[MI+=W5'FJJ-]DSW
MO<RHXB8==MI@8J$E>;CY!X/.:&W\00.,R<^YW;U4Q27A\>.,9?I2UJJ<UUKF
M55B'/8C>T):?+57BACH8]E3-J-W=+ZL[&EUDUM#&PXU"4RHLJ;".JK#ZFJ'J
M1E\JK--U.18EK1JP:]V(J[03SC8B?LT[M-YX\P?;I:&[+2V(M9I;$,<]=M=I
M>")]M+)6="D^8@OB7ND6Q-<W__?K[=WM_>VGCW?,R,4+D_7;NP=Q<4-F$90\
MDA10KV)ALV?-B/+!G-B!YRKUH-2$MLJ?7.63%7H/Q$];V>H:[;0$_XOM>[''
MC.DN%=I5BK8]#CW%5.Y"%!)T<*XQ@4+Y'/G6#-O[7C_ZA&;;*B_Q]O_E@W3U
M[B]?/E[;.=<E5VB__,2Z*/_=FTX!7_?JO:DPPM^Z5H>^[%W.C^]!;[_$7KBL
M#;*S5#-OQ6O$=ZC*(O*#"$B!+9!96V@1T06'<,*:);-WO+1_2@ED.D[<^-B+
MPB`$P+"]L>7-Y\`<`:4,_)[E&8K"RU7`XI\%`,%/])Y%#*Y]WWN>$7.2<_%/
ME"HO;1$\A`M6B5""8*OKI-LTW:D#!-Q59L29*`]+#J5/V`D'4,2&*^A2I:VL
MX14VLJP]M5GC:WQ%P7*N+?L]\J))FV2+@'>`(JA6`WBRSTY4IKQC=+P"ZT1$
M2.B[Z;<4`I:_D^55.P@BA@R[T$02S.%;SU\"=4,2=^M>^+9KV0N@$6L!#B_\
MH=]50;W35VFJ/AJI6G^D!#/8Q6E3[1NVRI3_.SMJ`DUOH"KX+$C%AO55.4WA
M6R`@Y2@DR]3V@U!QR:,7QFW.87F!ZTQ@%Z#^)+)"Q4))F0"C!<J$@*0"6U(>
M%->.,AOV'9].;<>FUU+FI-W0O0Q_Q,E;P$K3K`@#PWL!W`DW@(1>P=9`W(!V
M)*=J+&!:+(@>4'AI[W0!\M7;5`6?>>/8KFT!I]S$2.#CWGZW`PI:^NU+($P0
MH5(A_ISU3Y^0*4C2-LGY*<O$\P@(^DAA`\@L$JN<]$UV6(@I4C%&"=NS6PX(
M,^I&1E]7>?2\"?;`!S&@LL`6%25PW%4FYA*I_FCZD[@)O;E8P+-I'W/A/1WE
M?H9-ZXNY@-['X$.UN4ZO@!*L)(42!<!>-$7JK"],0/%8U^P3@JWQ8?4Y05/]
M`$]%9B!_1?`69YGA$M/-8MPBD0<-C'%<NE!<MK(:>6':ZP(:*`L^!`"-9LH@
MR.FK*ECQ'L"7BG>5N?F-)/K`]Y:FP^.C@"N!+=,%L3:7;.1`LB[1PF/\X%E6
MY(,;Q:0@?@Q.+T#I?P>KO4'5A#,SY&)8H'.2*RR<;\!^-ZDO.`$<37L>W["`
M!X*&C/=12F?B^RGC"IM=`1,BS@R[B8>,R'@M-JL8ER%-31]G-G"5*S[@V08Y
M>B!9\@+MX&[CQX2T\/Z/8);=F4XU"5.1@D\V3J"@5*$3'/@S?=0E.$'C`0T&
M(#,.A,`9$%.T`.U4WUNV;T5SU*T6"5!')-!R3D-PV5-1-Z#1A`I36#.*I&."
MC$>@GQTV<L(,V<2)EZO6#OF^L/UDN`:[-J`;&?TENVZBK4-?N\8R#/-G<^L*
MY]A>\3P-V+]"+B5,5Z%U2'S+!D45F`[EX_RWMTK#W*\RKND$WAKW,N5@!K--
M.L"T9C9AA7Q(/'R=%P6I_F!:/V'!>%=(F4JM4R+!;G2B9'=D2PP[)B8*H9$)
MVQZ($;Q>D(H_(]\.)C9EG4"EKZ7(Q;^#4Q-Q[EA':T6=^<0BN/GEO)+)V\)#
MCD=N2TA*H6=.S0\ZSBJE=BX@^<,`/]&_4+,GK^XHUTP!A,`H2'-AIDU&)\5V
MO3;\)5#@7GM.S2.P!R+L/IJ"@*BDD*4:(+,1!&!;@FE'C\L68'7C@J?F^:BG
MCHT^7T:4T7343T##-+`F>$=V(Z/&ZL+T*>NPF4'`N5=L5PEAD<T'L#81EDY>
M%MA-T7-AFP,FLWA^&.P2<P^M#&`+/VZ%AKCQG8</$`*#D[Z*K6P!HQ*0!V;T
M`O%Q\D_`)`4'%G'FH5PI>%H+8GYC[",X6NEZQ*"I3-2FCO?,*)^N2+H9X_>Q
MWD^6CVZ1";JYE$+>2V@`YGF$*B;F<%!X%CJ4/L.24L8.+`]T/-BB%K!Q(&IG
M$)=OS`-E(Y/^!'\V2$Q`RI0)7X!/1I9X4P)?$0=QGEPU=%;T3A%RL%G&!&7T
M>*"."#QBCKHD<K^!]^Y2[83&LFA]V-BB-W+8OL2?P8D0D=C^`NU*7.1FP-?B
MJ$_\Z#'#0N"VHJL<LP.2.KY,Y*(P7HN`.1/LV0Q0MDE1'4<5&"5*+M)W;)<B
ML>:BR-@NB!"SE2.7+V_NW9]`]I2_(I`\XL/%0"U[Q5+TR17!Q:$41<^O2(@9
MK6Q8:S0$@%U5NG$`0),_(SZ&+B9CHA1BR5[F0G>-ZC^Y6["!\Z4]>1B;U#5U
MV-`K;AGD*<.[$&"-MZQ/"_Z@?"7S!O8''-$%$@&BB(%EM2PXJ`=A1_()9490
M0S]HG1Y*LT/IQI2EG=65)?6AXA5C!VJ1GC-1@8VG[=S-"`GI)N1CE``VJ0<"
M5I$+HCG#'2A9HQ3\"<,<OW3IC#/`>`8["16$S)B+7,*A_1_[,73+1<N$D4C0
M)E[D*XS/$CLQ=5(HF0)"RH:[/V(020.@WN$8N7]2W?(!J`]"E'8:B"/@G6V'
M&>6.)++'&+=NB#/=0,?0`&S>`$;Q#$,_RAC%,@<_50W2/:Q/>H;1+WV&<?OQ
M_OKC[[>OW[_-FZ78HJA_RCMQ^2-5+`'5!@!WO/<4VC!B'/OV\Q?Z%_[[)A.:
M1ELZB!YPVZ;Q'R%97A6&-]IKT!3>Q*T^0NV0!5V[_ZQJ,V$&HY7*4ZN\J@S)
M896XC1.D1A*U.JCRQ458DL1CF.1Z*;26@8[-Y,,M0^JD6>!&!RSH3S<8&D.P
MPV2=4M^<6W8X^Q&(OG`(4[+,`38?X/F>&V^#?"REAX44\&01%3(%]#&D<VWA
M1@6;`I[F"-M#Q@H"(\";"([VA'L=JVY*D`!,75"DR(,XU)*AD;ILN"N@0<.V
M=K2&`1&XFF1=.,:-Z`J"IK0GX+N!@8,6/>4Z,E$I29/1F$!2V,.)STS3P'YT
M@;(6!MP7"$@:NPAIC;*/T:TH>S]`#?+H\@"5JV3Y@"\^]]HP=@.<"#)#&-H3
M@F$ZW%[Q)9E!G<*H4!49A2W[,OT6(Z!X6?:%R#4/Y!%=5T%*DVC\QC5&*G.^
M(!-NLK&M>N4=PL(Y]C>,8`,5GGT[Q%"+-YU2*!!'+W(FW,!!VMA@KM@^9138
M%H-VR7]9C<G#%'$`+%C5FIMU)E[Q3#!H$RC)P4(<*:SZ+#YYEHC2N7;`EVO>
MT7A&SONI]T6HG[D^GS9VL":,Q=,AM&9A2$.(*?28?Z0FSJ8I5(%E")P=LXM,
MC6KD.WVW@W9X;ZB.NMV.\IFO0&H1KT!MQ@J-/A(G]#(?#:WE9[AU&<,T\YY)
MC"8/;,92@ALCB#6\F+$_6QEXX/H<)5`3(AZH9I"^\1DL@X`>(VVVR"F]5I$V
MU,'`H'?_T.NJXW%7%>84.P6^6!W@&'G@8*:JUF?@Z+JN&KW^"CQ96@"]<M@-
MUG9%%Z\M-0VA33-SCR<L9,V=.EQ!!'/5((UK"W@[=.6'?I\^RW:SN33;;NUG
MKE83F.`Y<.N`\?-_B$\=,/`6<>MLE6;\`^G^9,,K0+JB'"V5W5UPK82-`G0#
MSJ@.>2@6Q8@YOU-P'L-9',=@9'R>P6Z.<LB.H>C.SQW<U2,0:B)8R<D"FS+N
M^TO41TE<RG3Y7HLG+-Q&P>T,7H&1))HO037;$PU5Y#XCJXIH+#O+LOR!:)P(
MUZ(FC;?4"8:OF(<.GFVJ1NF\=/HBV$O_B*,2/'!%T'6(?,%$O'*HL9F[F6>C
MP`+]4WLRC?;14!VU*-EI4V(TM(IO[RF3.8[W3"U=>L[.#^+PZ`ZL48=&8AB1
ML[N_\L`B+\&K'2E2Y+4S:NC'IT9ZGK:*T"G&JH]Z.XQ59[?V!OEM10K'-:Y4
M.:VO5Y4I@4=,9L];L;S\ZLJ#-SO#O!*TU0HTX>^U7E9%I8):(T9JINMPZ`F.
MJ=,@9#)2A9P;'LM*](MX01]\Y>=D<6-#(QOH$2^KKT'"(=M.G'0D=PFIV84V
M;58Q4MF<M[*)M8/4&5)G2+/DLC4%[<@IBO]FU2&5067^+M,6`O#=6NQ8Y,Q4
M(B)U)S-4O&)?G=;_CI,7S#`-E:;$Y<'%V@<@;RW8/<,6.2<H:VY'?;*F#55#
M;\.0[099/7MU?2VV>L[!II'J2*JCG<FFJ8/!4-5[%?L+-E(=G:YMM%0@4H%<
MJ`+IJ<-13^T/*HX..7,%4MK5JM^QRO=.,TT+3Y>OE!SQGL"%/]9.L2;G]8AQ
M,]I.7NVW<(T6VOT8;\L>WRQ@FT;9EDG)2TTUNB.U6]5L/I2X-(,J>[;=EK(G
M94_*WN';1<>8S1@`FH8M##.)3Y7-=31LCS96I/!DH1DV\/7.I]J5>U">Q/4^
MUF"EJCB>JSZK:''OQR1GTZCTH)@WVM*06N`2M<!+W<#F+..#S0TXEC9H!CDK
MNB)2M4C5TGK5(C7+&3A:,A%+3,0R3A"D:0:;53R-;'7$9\>4*7DVT4Q@F\YN
M4O2$]"`=A&]<<?B3%+QF`MMT9I.")^YY>J^+HXQ:+'KR7$*>2S1$Y<NP@3R7
MD.<24@M(+;`:/&1MO2Y(%\C3B(9(FU0H4J%(A;+O(40N7?-+$PXZF/I<2AB$
M<XE,^\O]_/!:)C9?<&CG8/0[5S5:TYE(@X=:'X!H=;74J4%1MJMB5*J[UJJ[
MTQ)RI*N\%7(K=5RM)S]2*TFM="E:J1D$Q;/QL=K7]SRD:X6"RKB=/]..S<EU
M-0Z8J@/LM;%<)49L96=RO?TKLL/E!Q+.O,FM^T3X4+HMH[F,HXSF&A50[I2C
MN0851G/]\^W=_8>W'^^5VX_*W=?7=[=O;J^_W+YM\8RNS&QN8((?%>_9)7XP
MLQ?8`Y[XV'7?=I5KW_>>9\2<Q%-4E%O7ZJC"]W3H+DZCP*E&`7SZT_-Q[I[X
M/.4&(QP33_D\,P$*BT0ACB4-X#D/#@`8T(E^YH)^#]^R=]#!4<K<=MD#[83I
M\8GOB>>:/CSRM>T%RR`D<W[?KIW[BW@XPR_[+5NU12JDV1Y8-I$98SQQODTR
M1IT.-EEXSG(.'W'BZQ/QEPI?:#KD(;"_?+RF/!+`HQQE[CG$BIQX:&HH,%3^
MV%WVVO\59T[&(RKI#%L0`2_R<<+&`L=6X:0C81"D."P,!]OA@#3'#!%A)236
MS`5KX7$9S_B)01%&J.;/J4G$:D;'JO.I6GQ>NAVF0\;X``=LC8Z#0.BTBRD.
M$J%#[Q))`>F.Z9L,DTU?0C(S*_,HDADNC".YXO%+\'XZXX;-S(W?@5#3^4.1
M*TQM`W%%^O`!;'1>Y@,;I,WFI[#Y36Q@'Z?YIB6C;['8.%(O&7O*2$WI16>*
MX!N%A8B'[CS;(9_0#0(-\+BV"0(5A'88L0%O]^D]R=@F?!;C-W$M1=K$N-$I
M2932^=-$V0JIRB+R@\AD"X0#Q=PGSXE`A0*3+TC(-#.;PQ:Y"Q/,7AP*.H-]
M%&\6)";"(4"/'@[VN)F9"YQ6-X3WN]_\:!%:2S;IEV"7X*"SHV)LXDB36YPY
MU!VGI/"BD*\P6_D5G0!D>/3-.14'XL,W0%BF5Y/-1GGMX71J5?EP?<5$Y<'V
MD('HB!@Z8Y[RPBP9!1[QX7(KJH"/F,'WY?+`5SJW*4SGCJDX.VAM`"&'F/X7
MY`AG+L?(6G0<'8X2P0;G.!N-;[7JMB';5-!B"N1"UR(F$=6%B>-M0M24*`M(
MU;D=!#BGTL5INU0KF/&P&S82W'8M>\'G5R8F$9V?B$_X05/UOD$'8+$I:-M'
M"=\SQLB\^(%8YIS0(=T@\1^])S9(31^H?$CS0Q32L6.H\WU"50&?Z.V88.K#
MBU<V*]@G..(=(8B1?$(@F!Z)>96.&\:Y2FR<8I$V@JL%O6(^HK6W^56@+?T(
M-FR2;@OF8N$A+2>Q<4>2">,)<^,T<#JM'>_R++HG3W)?<!MF!Z?%\Z_BU[+1
ME':P\`(BOH)U_%9QC8&';1S%%>9,(61<D966'&K&L\9A:Z=#L?A4JU@/H/H-
MT@F%#!Q[TYX;@P>\C//XDFW_@=X=^C;P!!L5"%H]I+`C_WM1D!(OF<O-9C0&
MHL'.QPZN<\&FR>$EYF>+7L&$6.+\[C4;A`X^,RT^3%38T%Q`6!@X&<\H]STG
MAE3@0K[0A=(F0I$E.`I,Y/`!ZZ:[.FYO-*22C4P>0[%U1GF5<>PMU[S7ZQI1
MV*J?V<2XE%E^6'74LR,+.]G)@_'H>6;[X+A;XM-9\E-E]".8:3C/+578J&69
M;6A.GN@DLX["]$;D\IFO;(HONS`6-*YJ8?EQY"6=."_N#E0:UIZ<ZCDV)Q,G
M)_M/.$U.N<0%3Q<88P&3M7!,9I6'X\PB_QA36=RU`[#8V$(GFMS=]MC!ZF-!
MUOGR3&R'*E)02G:!.X8N*=,4"3PNL[9S;6SJF'+8Z'!D`#$=E$@'[!$:QA.B
M(V&LBY@F0JX)(]]E.SMSCX0!N,QLA&>L:;3\\;9M"884QXE:%`F)D41[#Z_G
M9M(#>43S-?5T42NQF:\@:)J:W55C,P;YA_C4S<;PP)7W0`+D/,$GCH,MDWAP
M\8<WRC4J58SSW:!*`VZF<V#B"[ZZ&(BASZ&N\G<3U"FW$#(@Q:CXIHVP_:!W
MQHG>IHY_,%/Q$<Q*^4'K&,G/SW0</$8PV"SRK.4"EPX*+T5E@4$1]ATU@\*9
M[T6/S.4'PSN*-7@,X!W;/*Z5SSZ9$C0U@7T\ZUNK)H#NKYX'O2KJ.2;N5O6\
M_M@B]=P:359WX+J)BBS&$<,JX&0]4:OZ:D8<<`S\Z/$J">C&H14[CK1E`Z"F
M8N0=3*@YT3]XPAMB<>^9C2"/'Y4QV0M.$:B3#XZ4#\\`>/$PE+ILR07I:/45
MVV[+MIM_^E?^,"]["'B'JHDY;@%[!OIM6\X`>T<Y`RPZ/3WE&>"P]!G@W?VG
MF__S]T_OW[S]<B?PB_+V_WZ]O?]76\\!K\/534'P=('E,41#(UZHU+5^%YUB
MZABGJCZV4>FFJ9@1<+1/YZ'3\>=\PU61`4&+Q[$>K=?/>12\=P[ZG_*XBA8O
MGSW^0[<#',K.`_/N2W?N@EO;M9>OK=G&';:OJ^/N2.T/AEDFSB<[.[\0-O5\
MMR@Y!G.6`(2FZF.M>#W6GJGRJ!0R0W_E7FZ.O5Y?5.`@V#)".IH<-@)/T=71
M&(.PPT(60H;1!BO<PM]P4^H-0Z"R,>P7ON$E#\+#;H:D0.F)M8?>_>638!RM
MO"VY2OOE)]BJUM9TJ&HC6#D]>34E8KSI9(1+B18`$.XA7+IPB_1M&A)E4AFY
M-C^G(]^);]G,.V"_>0NV?SX"_^$=+*B2OW?J2$FVII_H;<IG<#T1Y&Y/8=L1
M6C(@*4`/_AN^%3>9]1\0)X<ZMQ0;=Q)9+'Q&0<%,@@F-<[L@362^<+PE(;O;
M@4T490PJ;>`1#%*)/(F'5Z*L@L-#3#R18H%<DX6"@Y!&(]F-`2X26&"H@H6H
MJJF,.^/QCV#/N&1J6WAVG%I9CCVW0[HFPM,+0ZS<&*$QSPVH``\K8/0]QH@\
M):<N?,=)T>*>1;P+>2P^&UQQ4L0>`3L:\5P,X+$(+=">'GG/R#+[/L1%H`>^
M%M017!^';?!N1I$5,E#CDD7_-F$W\0@[H;%,'ZQ:$T_H%GB6B"#B$04P?NBP
ML">S,#&4C^?W[B1@/@_L63;\#\@T0R^?.!C6QV,4M%:G&-X&/ZO`!KUET:1,
ML,C'`X3``[^*QXX$0JO"H4"YY120PO"4C<=E]"@I/NA@1Q7"J^*3C>R".>01
M=Q+%?#)MQXP73+Q?K4*C-IUS?W*53U;H9?K4Z6R3T++&&K+$>]A7/0>TLNE_
M4VZX8?8.-+JJO']_@[I8N74<V_7L@+$W+)YCFP^V@YH[]L5>"CO8^\\WXDZE
MT&`0/32A6N0'K9_$8A:1;X'/)IZ?O5S9#S_'EUS'EX@/I[SM$]!J\%;V%,9;
M\5T1#9:*[US;CP4=%P>_4CD&QF/'<+!NE`5M>O*:'&^%,WCEU9*`]8AY)#'3
MKD/-%$)J)K/3>YI&K,;)+B!E5`8LGW`.?J*'%<;@BIZ@*>"ZVAY%,,!M<"MR
MRLO-R/V$WP/E5%`+"\+$%NZ-KP3]QXPV/%^$5U(-'\YB:<U#,C=JM.H@3'SS
MV06X$["3D\ZI:5'&VKYE)^*W+J`%`GFR].L\@4119(?U(G&``2:*H7:'FCH8
MZJ+'Q!8UX#9JR&(D+"KY0[\S&B!KL.N9^=3+-V%3`&[P(#(Q$U9U]9H4IK_3
M)V9E<`4>C;XZ`8AQ_NH3Z':P9CWG8\Q>L&J=)+BS%YB/P(6/N)DDPL\NHX=R
M#\L,R_K,@,2O8G"`:&LP8JSXAT$O\1_C8_!XO?B^/`%[,TS/[0&NE:/A0>(%
M`[&F-#8^>;)I1L>4\)=[4W@W"B`>_+A!&;/UO&3@'7GP(TP/T7MYBH'R_D`U
M]/YJM""']Z,'Q[92D@F\-^J,^P+OY5DY'\7%HC[2RG)IFBX<&+`%HS[.LV]3
MAPE!`J,H22%$G>U%+G>86%+BZGJVR<1`>9N"%^L]TWV0VE]!-,?$F/\0C)?B
M0YC]:#YX-!O)9PZ:&/M?+5U_M:.?5A1%9.31CT^>O$(PAE`F1LKHQHIJ?GW1
M?0'[KN-@V0P0)_E[@?G#_&]>GV-1BRJIS^%5.1A5,!<!>15_^$5AE3O#;'?F
ME58+<#6\$IYJO-C0=J$_ZHQZ!=TKM'VKSK:W7%@+"@L+/-I41W,$4+*0'#(\
M_98'8E+VHGHO*%?5M;ZH6L<8;>U&R9AM>Z7;`1<Q#ZN$;?47175K7'(X2)TA
MO"+^Z@L%(OO=/4<D_OMUBBHGU[`SVE$$CD//XW'BQRC;!MV;9E7>@Z_\C-?]
MP=7^/G6'G5[O8--H*U*LB5T>"LE3R'/%Q=.[\MS1RZM+4NXT2F(HM01#[PO!
M$C\@4^YY:E:87L1K&*N.S,G3>WLJ['JVFW[^%S']_=2+H1])O>S<<+AX.]_6
M;ZPS+MC@ZVD8?%HGI&2;@#*$&G7Z!2-,JI?\GY@JPVYG4&_7NMZHHV^W$YM/
M'4&O[,$JI8SF^GO6'+2]XVE0:I!)M8U`@TZO8)<XUY8@XYXZ&E><3+R5C=`4
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M0H;14XW><"^JM,-<;:%Q>O:F:-NE3^]H,AXKX[$R'EM66BIFD\MXK(S'MLV`
M;6XPY[04&O9E(%8&8F4@]AQEUY`!V+T"L+DMY+J=87\1*G01%J8/\BKMY?Q`
M[3[D.RM#D9Y7=D;&_@'=BR'9[H'?XY+HA`'B38B6[&%Y%KM4G1F]QZ-90R)=
MH[$Z'.V?]EM6J,YK[Z\7]W,WY7,,]TO0I=L50_V8-D,Y5#;_<XS]=BJ&34Y!
MX32&+<Y1_GR&B1?AA`F]<RD^PSV=.YLW;*2^X'NN?50OI9L2C,A@BL#EFC2;
M2+'77)"F6(85#]++A7@.1M9SW3`TM:\/P)[4:B9WGIE5**XE=Y+SD>`JR)^[
MC5DJ7'P1BCO7[-QOW<\&]SS+\3SE/6,H_DRGA27790:)[3<FK0ZP.3A_^SD*
MKAY-<_&*CI'D@X'9E.^/7DC>V('E>$'DDWL`Y+4#U_SVW_^E*'^+;WM/S(`$
MGZ;O21"0O,L5>_+KBW?_ALU/'_=?X$Q(1.D+F?[ZX@:_[8Z&XUYW^&^<K:EU
MNQI^Z'4'1O?%;PCH#F0;%9`M?Z9*.:MWCVWRXZ?[M\J(S8;$JV(<A.?B"%_;
M8I>_?WM]]_:.KA%>@5_M.&5OL$*'ILPAC.='.I1U<.PBSH*D(LV&Q(<X$=U?
M>#[.!L7Y]']%IA_B"%`;QQX')J!CJLH-$`VN=VVSH]RZR@?3MV9Y8RI!&9&)
M8K+W*>8$YW%'<QRD2[XOZ)#MPA?FS]QFT[Z_+XB%LY7Q73B]GB'P;#N.\D"$
M,=<`\QU9A`0'<%'P"J>L<X+$<TXI='1Z*GMT/,O4BGQ4A>(+X5+;IZ^ZCAZC
M(,3WC'/?HWR!6\'ELKP`9W3;KN5$R73TM3>N3]K4]616+)UP3!_A`^!T/F3F
M6N-'`-F-<.IW1]F1AQL[3)-SU__RL;K:\)=`\4E`*!/&0Y%Q03Z8$SO`T=!_
MX,A1H*Z+W$.7&I?3]Z+'63)I-75A])'*%E'Y@&1V<'0M73@^G!0?LKHT-/>B
MHWRBTTSGN;<%?,5)/*05EMA4<.I3"#+E<BZ#[^`.\,1!'$+S.]P5HI^^OL0_
M:(,L.W24KR&B;I.`L5@>#VG]U9MN$S:,P5Z82YQ/C42UT#*8L'FN.%68CSQG
MXKP^NE<;L[&]%.3D>87`#->`:1&GOHL9$5>5P*Z^H"/;J?K@'*'"7XX9LBGL
MN#O;;D2GB@-%DH'J7"/1V>GT6:[M$D8OT(0N+D]F,"R;PZP9HV0(\P^]KL'6
M!:0$-:?]!.3/55$G`MK@0.L#$>AA2:!;Q#2Y$^&G40A6G3*W77L.FR<3OD1(
M)Q'=?*:@XD#FECCBC<LKEU;`91+O;U0(`SZ..)`SA`\R0[B_<89PU13=.@9Z
M-C0"#>R]:IG'X376?T)YZ=.QB!,Z(ORGC&5>KR.\(Y&;$0TLF?U3EA;==M68
M](>JUJTYO:YT;ET#@B%;](_4-ES;])4]]$LMVJ0I9SC[H-XRY:&#,]C3]YF.
MU"9=(6V50NTQV$=[',@Z.4]]<F'FR4X:1MHGEZ=AAM(^D?:)M$^D?;*3]AA)
M^T3:)](^D?;)P33,.*MA^)&Y3\QI2'QIK4AK!5BDKVK#O4H=6J0X2A@KEU[6
MC)EM"N9'^"0(Z]Z!=JU`/!O%4W-N>/?RBC9?]KKJH/8D^]IKM<Z$FC])BZL:
MP3[[MFO9"].1UI.TGFBC?;VOZL.*(Y*E`77A!E2<M+SP?,S/DW;4J<-#%V=&
MZ9JA:EI7VE'-MJ,NO2+^H^?NI2NWL&=;BKTKIAMN4W^M+]8>:;JJ#?:TVF21
MYB6F\/.B"O=1)O!3.6E2`G^9_B=MCDZ<?_;^66VC%W;LK!D]V#0K]LN[@&/G
M]6:;EZQC9,Z^C).N%_R,NNI`KSBYN)V*0IHGA:I#)NS+A+C=U,MXJ&KC>@>C
MMT;A2/4BL_6E95)$E(%FJ./]FH"W15%(RZ10=<A4?6F9[*9>C)&J:T-IF92R
M3"X]-^2$^?PR9:32"6GK$T1ZAJZ.!E7S;$^=#=)X`^K2\SGHA(.Z=T.9U+%;
MEEOKTSQT=3P>JMW>Z)@<=YYZ[<SZ<V]MM)WMRYU>\&EZ-X.U>8T-9[%K+7$#
MVB+S&F>N/!*:_?%ZF5[SF66$7#^;_B2WB_?@8KMXCTMW\;Z[_W3S?ZY>7]^]
M?:/<?/KP^>W'N^O[VT\?,]9LB_IZ`S-YS]@Y6YF9`6^YNG#@9OALALK"]Y[L
M"6OO36AS^:L'V@#9$ABRHWRE:1K8M%7'%JRT);WR:8$_*I_A::K".\H&R*TT
MQREY<:83\PUK;LP>@.E*V)K9?X(7T@;C01#17L?1`BXBWXEOV:R5,&!Y]5>$
M?<5MN#:@MWOT_4%'^>@IT\BGS94?V;@BRW2QU_?<!-2B+;!WE'OV6T]A[?6Q
MZ3$LG_U$Z.\QB(&BJT.CIXYZ"9IQ)UOZ5@0S`YC*_\2^QL2R*2D5NFD%M&]M
MZ-NT3SF_"L4ZH-UM%\3'I664<.WP9_JZ^`ILCSY?.-Z2$'@.=JZ.G)!BC?=Z
M2`:@"4=*,PJQZ=$&NL*B'0&;+2B(&.3U\LW-GJ-NI_*,_\-!91A@:WE\7#JY
M"M^[B'QKAOEUC&'A(2H&1@9]G5X]-`;J:-@7^#C#L=MX28U_*^*EN%5\SLJL
M]#)6KIW`4S&=;R/*/0W6<)0`G!&GF!PH5H11`F4=GL=$/2/D7"N86%([B2RZ
M_<3B!'3#1OK)FG64-Y$?]Z;?TG%:!=E-(*$@QZN3(68!P51E.&!]P.FM'!/Q
MSG4.1QIK_*[<%Z\3PDZ>D$>%C!SD$&.WW:*1^:FH-5CZ*%U>-,0")8CF`#>`
M!$2AHDSYQ7P`.F9I\VHW2LB$TXT)IV.]3,)I?MU&041_A]%3HD??777HNXD[
MOV8%5O"XCA!<2Z9"ZB^**,<7C&/:&0)T\5=?*&[9[^XYQ>*_7Z<DVQQ[TLI[
MNMDU*A=UJ;)&=!U&AS;4(QRTDBZ4-T5T'WPV0IQMHD'FJZHS)VL]("])R_*D
M:V(T66H'J1V:H1W^H&\EDRM1`UP_$=]\).)7;[E3*'[W&5R/[!>BGJ$!%*E`
MI`*IAUA2E;1%E7RA]4?<NHB_O(''^J851NQL*/[ZGOASJ4.D#I$ZY#)TR/7C
MHT\>S3"C,&Y!-=AN8%OBE_\TG>@<S(O3=-FI`[N&Y@^\-AT:T[X.TS&BJ63S
M\.?&'"H]<^ATJ(-A).FEYU!52$BH1*YSS4;0U+'658?C-E30'I;-#L1P&]5B
ML873$/OE>*1H*H?\T/BD\]/29]#1VM`47NJ6IOI&ET648ZB8BZ3%/J2H.PE2
M@G]FX.\E2`V`OTG@[]Z:LL4AAM]9PM()HDN-L9'V0+UE]9N:VN^.56UP?JUK
M&FE%7ZQYV`+]L+/WW4I?6^]T#:D3I$Z0)#BX[7`!F#?)*9#`G@S8IONVS26M
M/#XOI:UN\/#<<:IZMZT\36K\85(S/."DDE2O/1#6.@NX,8'",S.&6JE?Y&FU
M5"SR?+9YSG:[B=*<L[:6T:))WHX$_\S`;[IC?T[DW^O0^M([C,:5G'L>;\MN
MH;);J$BXEX-A_\Q:A3:#<'0$&_X<P]TH`<`+D_4\^,I>C*EY``(U5:/6ES2P
M#Y'.+31B=,9[)A<TN/%R(R,EEZBSFD.J,^"KTRFOEM%H;D\F#FDN&]5Z0'YX
M-7*>2#5MI1HDHCMAU1ZAJCF1X]+C/?OW2S#V\`1KZ)<@(TVU]U2XM."4H?:T
ML:J/JD:H*H^!D%[6T2AZSGY7\TC65(X[^`2<5D>1>IW!H0??2(W7!/%MO,9K
M,O'.@/<N1@D>.(>AP<JK(9@W.@YU6#3/E[&E1)^W1,LN'(?JPG'R;IR'"5%?
M1+?,L4'GI.W'`(V6^[,JL&QK3XO])+(-80*MU^GVI9A),3M:/7MS+4[)V,T$
MMFF4E8S=%(=(-G,XOV8.IRBU.E<WZ*76&ZG]@5;W&K?C@.:G([+^Z3?,TTON
MZ5VP"VF.T.^,:C^[;?2>+Z7US*B_7=#*SB1K"D920J2$G/M6=,D"(AL#[&%P
MM*@QP/'J0MIX[O;2&`Y53=,/QP?MRQ.LZ(:V,COG@E+S]CTU;&RVS@%H->CH
M%1W9,U(E31,8J05.;Q.<;[J=%#PI>$U>*2EXYR1XARWDGGC1@T,4O7,I_KE0
MR/V/R"4*+]VN?99XU>KAS$*<A8=_@!+JTD0XUZ"`H8YT0QU4C0I43N`O%.M&
MJ[J#8MYHJ^,H:#;5M3UX=7(E8IU?8&!8,>M8:A.I32[(^#B\;7%:!3#J&,J2
MF'X@M8#4`F>G!<[>GFB3*@%G6!]J:E>K/4VV%;JDSL2(BPN\\,0($['>+_BR
M*=22*YHMU7.[=C;9&*:IE8#G&J;1U+ZAJ]JH6^\LAB9IO</RXV%:8A_`#CM]
M3Z=3$ZBIW%1S<DBK8T#]SFC/!@]24YU<$!NOJ6HFE337SM]<.RU%A[M%OLY(
M]QTR'>(\HUI2F]1K'EV\$M$,=3`8J,.:,_7/4XMD(EP_AQBL2:Z;V$^[P"D&
MHH#O!-#TXP>A\O;@?1#J=?J]'W.9]'@XW86>]>WJP0S(1+&\^8*X@1G:GJN0
M[_B9*/`0)9P1^-<G1#'=B>+:+E'F\,19H!#`9)(-QRG/9J#\H*G=85<=&!J]
MY0>,APS40=]0%9\$"V*%]A-QEAVE]O?C<B"Z\8IL&*/!(#4&AMH?&PQ.3=6T
MGFH,^ZMPWL^(3Q0[`.(IM@N0`D3F=^6!N&1JAPH\"(&\`0Q,=XG769&/$NLL
M%6]!?,#)?51,N%!QO""@+S-=Q;3"R'3R'C@WE_"J$/X&0$!Y_(=,*!#L=@N^
M"X$U3"6TY_CDB3V=`H"N12C@D4/?9\,;E`F!7WR@$C[>#`(2J@JH$6N&4$XC
M!R"$.XC_!)<\+.$&T%416P/3<;QG3'CK*+MQ/)72IK$\4M%\?/3)(]!0><06
ME\H$/TY-VZ?8$\6;TO7T%DB'@%W$Z",N\R3RD<S5Q`.H3@)8-A,?"!SQPT:.
M!88<#I(6C`GG4F;=>.-(U<=]=;!R8PY;GXX61F5:=,<]1*LJ+8"(XZ':Y\T<
MBFC1,A:WW1!6)+"M_&4D<:GI;ES,5.=04PVCQU8`+*$N<.I`6Z&K8#HDGSYZ
M"1S/J%?W`L9HU=)=![A2&6*KE!P+GURA"B_<)4%;*Y'[!`(%!`IP7TV(#!L!
M/L*<>Q&("#S?7"Q\[SL5/-#_/VA=M0_O&6ACY=F&Q]!=Q_(>7=QWXKNYI#,K
M:*1KPU\"OM=0D/DVAZ_SG@B`HS#"H&3#W^8CH$!\VYO@Q9MWZ8ZN9"25NNFM
M6F44T*R*)2;LR.*J*>:SZ4^R*M)C*T$U--S#]'44Q!+SVC'!F+JS9IX#"/#'
M+'S;P@OFWH0X3./G7I=N^_1**N$3`B(,"SNA#!8%J%5B<.*7KNP4OHGRR1DO
MMC0F'C5F9L`("C(HW@NL`PK*8AQ#[2%0!,P>860$G@$/@D$\(2'QP=)A`')5
MMHV`0#H3S")K?;?*\#"[!\E$<@FLHG7W3$`LX+]@0$5S+E6X:_H3:M@I;H1#
MW?">&?`)X(!BZI#O%+,@>OB3Z4.%<@.@!>S\FE@FDK0(+@(/\):@`K.R3(EH
MS4P?C$>0)R"F!3B`=VE/;<ND%F=L#8;*U/?F\`(OR%T<A.V!0P%/=!])HBH$
MD&UW$849Q.$U"C(DH(++Q8B\NB0QUZKX2!`C4`!S`"F#HK>P77@B4W#DN\TX
M@_)?$#.-2RP2!$`V>!,HK2=[`HH,:.]0.BK(_/"?.3&#R"?YK&&'1=1LG5(1
MERG"#37T.!VR7(3"!NP\]=#$#U[M2(8S<M$S`0@:F^`QEU]?=%\HV,(1HRK`
M3,G?"W,RB?_FX1O63"D)W_"@#6Q>CKD(R*OX`WB6-+`S'&2:SU1)^AGH'4.O
MV-RI.+XJ9OAT5Q-\NDEZS^E/B4H%T0#/U0A:IS>HK1/6#L02*#*J&J,&I@'.
M`[2,%T4LP3F1@]09PBOBK[Y0(++?W7-$XK]?IZ@R<AF#CJX75#AJY2.T!R1H
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MQIOD4%KGDIEJ8R9IE1>U#5BP]`_'GA+EI>VRBI^2G>*E67Y!\M71^VB6CSO#
MO4HY+D1'2X[YI=^A#(.,(\WM&NCYQVJV:'XV^H+X2C`S6:K72DZZM-.E:;5#
M,>2H,ZZYI>Z%[`*2G?+82>OH@[([@JR2/(LJ29J"GCFXQ>3R_Q#?6ZW\2\O^
M)AX):`+SPL2JNOCVUF4<^_DG'T@@5M;)<^J_=NXZRKU/\[27RH/7,E*DT<)L
MR49"@Z?T@MC"X<GJ><G_\-T<;KI+:Q-VIM9HHX8XQ5D9K_P`NC#\OKIV&.R&
MW:"!K)"/G_+RR]W7X">:>1_74$8`M%_(`[1$\M;%#1+K,#X[IIM;3?<FK9G;
M4K:GKE0I!Q%<T1MVL<`T*<A)JL<B"C;X.!;Q0Q.K.`@6N=!JK[2@@U:1Y%R!
M][[VL(0)_GAC^\0*/3_(1>`Z3*J":!4/$"JI0R/?664**T$"PJ?6?QG98>5#
M2/D87<!'`![?2XN:_F*%V$%H.@[^$L1Z"U^)*(;/'HT>P1\N+(<?F*#&.!29
M>J%<%'.@P!L%>M$"KC5Z,0"CA0#,[D"T2-W2`CI:O$)9GY4"17,`&R!B6[*)
MY4NH;C>P2KZHOJK'<FFP*79NU3"]SJ"J)]'V)/FD;D0_6MV(-NC@(M8PC+<!
M*?HM3PA&Y!Y\Y6?\_#$N3A6_Q-UHKTAWD6]?%]W*DZF!K?:ZG?'10T!28:TI
M+*TSE@4"F?#ZE:@#KIDC*G[U.UJ/XA=O>!IC_/<[C,7_$V/Q4GL<K%%G]<!I
M"[1'/7IW>"S&VK$QWIZ'@,66<!L.`;_&_6O,4+DCBY"ZQREC5._Q5O.Y3G>4
M;7Y9VO;=NCBG/;385?:V$:S?&>Y(,$'1G=7TAZN*4Q^VLASN!+)Q>BEB%1O=
M6S?)AFR!-9]"[[A1G/@`M5XJ=#O]K:;46?0:OI**Y52*9:N[TGC%<BB%N[.U
MW1B.J9D>@Y,(U6%\D4OR/'ZODD)8X+1WCR`,-:;M4N.\3;8W/\G>._#2:`'>
M/?)<;J\Z.AL>PTRM$=S6V),:GN-?MJSL:]<=7[:/86_5"F^;[*'+CLW^DT9F
M#Q!0;0XS[!KA;),1U9(PPR$7_0Q,K";$!@^*0&O,,"EO!P^_G1Z#,S#<9&AK
M4U[CWO.PS\#`>^?Y4V+7$03;-4.T,<*PX11[CZS7-MN!.0J[K#PU6JF4"[?5
MH#I.OX>M6X@'U8@G#-_M@U?+[<M+E>-JJ)Z/'#/+LWV"W-U:BG(VK%E_"+*&
M8>UG;<F*::29`M@#1"^W9C<V88;\X4.@!R/#N=K/.QU&EPJ$M&)8_*Y1UQI4
MV^EWZ#+1V8/J\-.*QB$R//<AU[F9]#N<W$O%4A?RYZQ8<IV!DVF6PX>K6\'0
MLF'8>38,B]OLX"1U'UOQ_#`>C-1N7Z/M9'[0U/Y04P>:1H=7\SGN/G'X9&VO
MJ!_/).WV$\ZP[18^;4O?'WS6@HUS=I8JGTEMS9+7VCCWV7*B"9OV3E]WQ3I7
MY8V;+^IPXQ,Z-=SU#HR/T:K.8=>T_4].GZ:%3ZY"\WON$M!N2*;C`!&YJUM`
M7C[/VYQ[D1OBB\S%PO>^T^YDSE+YH:_J8TTUNGK2<0GY]=$%:DSBF_,ZY\#K
M(B<,6!=6XINL$:OW1``LY7FUERM<87NTLQ$N%M(BMW93Z_2S(^=HN^[.:DD=
MUWI_^SD*KAY-<_'JC1U8CH<#P#]-[[`]U&ODW1N!;M>^CUVD:&>GU\OTFL_F
M$K^[?C;]R3TLVVL'2/?;?_^7HOPM?C@6O--Z]_0M07*I8D]^??'NW^#HZ>/A
M"U@J%Q?_"YG^^N(&O^V.AN->=_AOY%JMV]7P0Z\[,+HO?D-4:M3?^6T%RC'T
M'MS[\=/]6P5,\+6%%1YLA[!Y6_R0\?KVB_+/Z_=?WRH?WE[???WR]L/;C_=W
MF57?3;B;V`I.W`?XB/J`=D:;VJ[I6K;IX,1V`E^@UL.1]M@AT(:+S%#H>MQ1
MWJ4=D$%93PC<C^(5<$5A6Z@]X9YG+W(F7(H)J'O::2P@(-FFRUZE@.)8F#9K
M04;QH"(;OWNIO+0[I*."HK%#]N2?4`_`[=26`IU![\+N6J".'DCX3(BKP#I\
M(]CKT@]MRP9\0XH"ZW%&\:;MUK!'64>YGDQLO!OTUW*U)1T`_E=D^PQPT%38
M-5.9))+'NLW!4QX][/151#W^SDF6C-BATJ,]U&A+,-QL)O84\$?0'`*;(Y(6
M=`9V$XG[O\$;HCGO,\U)8[N+*`Q^4J(@U9'X`JII.LI[?%)JU6@Q&FRQYAYV
MR"0(K9,0!P$2X`1[%'Y;>8ZA/!(7U"D0+292H`1@%-M3V\)6V4);NS^CR2-^
M`,;9RFCP=LN!'^$Q"3H`"78=]`GP0Z:+I^,]8T,Z2BS:Y0])D8&"=[83L!$8
M@+7C$WZ;V8"1;\V6*VS->KL%KW;<Z)NH"U;9(ME.]5_^&3,/6XZ$XI%K3OZ,
MZ/;^5^3A?ZA`TEV=MK<C7/`":@]@@UD0OW2MX3MAJ7>UFLZ`F'H)8F8IB/0*
M;``7FRGF46N=QBI>L;8.\0)0]8LOQ)Z__$9\"<@R6-JBA##U0:_U'@+B/Z$F
M`(5K@]SXH)&P]2/(."ZH&__5XK4S2JP=)[?GIWI6"8DU<^V_(L)ISW5B3-YD
M/8`P,Y"DE-3,_UE766B\HDE=I+INV8-],G5@301UFS&,'U`_QOU_444^(R!Y
M^R/;JR/TOUSZOM@/2O;I=%,NW$M;Y`AMZ>F9ORS!VAD?7=[BYC$&<YTJV0W`
M;29:5)%/?55@2WOGK6F-]"?OQYRAWJYH;0\K%4:\V&M.T9)TK._<DK2G75Z#
MKHT!VE.T]Y.]_=(-5='VR7YJ7,^T'2$^[P$K4H9.+$-[S7Z3,B1E2,J08IR!
M##7@B%-*JY36DTKKO1>:SAG(ZDD2J8O<NS9D1]^8P8R?H\`'C)H!<3"44F]6
MU5DVAJL[-;$=->J:,5*-WE@=&A4W]^T\4FOJ5:(S#ILO>-ZUZ%(PZQ3,9A0;
M"$<H4D"E@$H!E0(J!50*Z%D(J#1M#R68.S?$:;/W^X;XX._2]!R6!'""$,A9
M*0*Y+Y?A@Y,+^WZ\>OH]5PJ6%"PI6%*PI&!)P9*")05+"M91_+X+/@<5/$$A
M!UQ&BAH;*3IS/7$&$2,9RI4"*@54"J@4T'8*Z&FITE.[VD@=:F,IEE(LI5@V
MA2KM%4MY`)J7_@N_V.XCEI!;GAO8$]Z]2?$>@"*\^IXV[F)-6$SKK\@.:,,6
M>58J`V1M")#)R+,4+"E84K"D8+73HM74_KBOZL,]2U&E.$EQDN+4'G&JN9-V
M\SHY%72]0I3PIABK3,]=;(E%*8!7X!>R`]1^,0)!NC$,(,OQ*0ZR'%\V<9(M
M+:0,'4&&9!,G*4-2AMK?Q$G*D)2A9LJ0;*UTH2G%LK623+ZH&%L;JYK64WN]
MF@<Z-B#<)I.BI%Q>[MFL%%`IH%)`I8!*`94"*BW;=LFES"N6C94:FRMRYMMR
MXX1=)F%)P9*")05+"I84+"E84K"D8%VL8,E34-E8J8V!HC/7$V<0,9*17"F@
M4D"E@$H!;:>`GI8J/;4['JC&H'TC+*182K&48MDXL90'H+*QD@R0G=RN;IQ>
MD)%G*5A2L*1@2<%JIT7;EDXP4IQ.SDI2G-HC3H=NK-3K]'NG[JUT/R/*C3=?
MF.Y2L=TG$H2!8L._Y+M%@H`5?#Z8CNG"GW"!$LP\/Z2UH([G/EZ%Q)^#6^@O
M/'`*L;&1.PE4!9Q%<!(=9ZD\V^$,G,.Y:;O@0RIS,XQ\>FRJ>%/%P3>$,]-5
MPF=/61+3#SK"PB2?KD/E'Y%+%&SZI'>UG@HWI5#/S`F#B@'#D)AC=2J^XP?=
M4$=&3^UU1^H*V&M7#E1]U%-'`UU5@'2*"=YL:#KTMWY7U;0Q\'0W%T*DXM2T
M?>3IB.`=2,/T!8JY@H+R;`;*#W1`;U\=:(/"I\98DN\+8L$SP<&>>0Y@'%FS
M#`81>.E.3.`EPS6<1?B#3T#2_@/>^2,L0\"I$`2P"%/?FU-B3IW("B/NS,,R
MAVL(X3<!L>+E,WT"?!0JCOV-P#H#6`]$B5_4287J[`7D.E`6)K`\)\'"]RQ"
M)@+I`M.A!/KJVI,E<I7R#].-3'^)"ZVIRK7O>\\S`ESJ$XO83[`.)A44]H@_
M[(`LO&?BIV2WB&+./5A0QI:=O@+(.K`T'059@MYK!QB->2)^:&-',:!_^B#+
MF\\]$-70L[XAYYD`M6T1_K1N5UG`1<$,EI`]D#THP)C.E"`#$7Q\$#W\"2R'
MCYX(.?"6A9"A,`,'+WP26+[]`#A%L&2^<GUWHXRT?D>YANM\;*?@+-4";LIY
MK<=(,$%=@D(4!!%J'BHMP.GVG`:9HH"^WE6\!0U$(794NW@3XE#V!DICOX9)
M_$`N18GC-/PE@.]<VL:!/O(U4W'*W8R0$#$S,TACXC^C52DT;!%:6`"\C`!8
M<`<Q+52(H"\I#6$E;&_"A16>!<KPD10+8/Z[$FPIW,#/5]Z"!NG@!2CR/Z.T
MXX_IXY.GIEA2N=]*J+L0_D-5&MS\:<%C@4%'>0.:`=Z'4/X%W`\:%E&&.SZ8
MOC43.O=I5`,:C"M`#)%)\&$I_S+&Q36?F0Z\%"C/+P-VB^;P3!2RR%GR!SU$
M8>9AC-N1A<&^L*>V!4(-%S\0QWM>)2.]-E?[<H2F=F#!)I""'&OD"<%=Q'8Q
MZCGCBPS:X8%E!BT1):8/\2F,WHG.R%E'1!<V2B\D:L(.JRS('\,NG406"[C^
MA_A>FS2NP$E@-!`0:S><!9R;U@T!3CO7VRH]ZQ+=(JJA<@*LHOF";>)1P.0$
M*1"3<XV?G@G?QLW%P@$YP:W$#.BUC'(S^.N!$#?#[72O1ZY;-VN0<Y-VG?'7
M1NL(/?4<T"5(5AM5+BI@UP*QYP<C^>QVN`ZD1Z9`JLQ7$3I%K]/!J$JOTRVG
MD/U!>P_R_DDE&D2VH)\N2&K%'H/RT/_BDN5T\(3AWT8?_=<=J=PY+:#-VN0+
M.K,+Z@;8;A#ZT;QZ0[`6:(N\O5`>4#;R@/*4:N&D9D>&*4Y8/F.!/QR0HK[]
M8B/-.$)!R8S7)@MPV;;)KMKFPHR4E^VQ4@Y`G9\.9>KD-LGM=H9],!,H=`O3
M![74>DWWD8!N(V'HD,0FVJ+O]M!SJSRZ:1$V-2MN.-/69F?M2I]SU86UV6)E
MI5O:;.?OW)4(%=6>_7^&2DF&BMI05RG#13)<='9FC%04,ES42D61A(DR,:#+
MMC-DV$<:'.T-VC0N6".#+S+XTC#+1@9?MFJNB1=AOI'>N13-E01I,BEX=>]\
MFZA\QBJM_M#-KH2Z.-VV'\^=I[9K:?684!QCNG0P8+A4IK9KNK0@@Z;I@VX"
MO=05"V&PKH-,E&?3AQ>QHB;:-<0G2K3`OPQ]K`YZ8U:D0JNS;EA-RQTM#7B)
MZ;4Q_^G=7_#YRA_\:<GWVB\_J7@K<(DU4_2>:NB]])TT]=F+PB`T75HUL*I(
M.\J=#70T?:Q@,05$LPB"O\J2G3%]LA*28[B^WS,J(*GG(BG@..BKVD"K@F1>
MY<.[R,>\^DU8"R5.1B6D1X:A]HUN!:2-;4CWU(%N[(OS6ZS+X8G;R:,F=F!%
M`2;2FP_>$RW;"%D)G3(G6&U@!W.*XN3/*&`5($'HV]\(+T&)%KS^*"ED@C=8
MQ,>'P,.=B":'<[%)B^LZRNU4F:15$)AY'\3`Q<3(%J-0N@=96@J57PZMJV&E
MEEB+])WXEAW$8&*QX_JC5RYZ]B)GPHK\DLH3O(Q7J@$2IA-_EZ";U)UQ6!/@
M\NL\62Y]$#EQN1V\G=?'<*`RDIY\I0M?Q;4S&<ZAY8H'+VA+WM;0,K:X:_&R
MJ)0M0>!@!6SB&[:5K2G`EN4KUTK1ITSU6IF:HT3N4APH`K1<FL*<EGHED&\L
M2$K6AI4;JX-1%S:'7NLJ9RJ4**4DH2H=N("5W01U%=*LT61;+4VA\7>ZZI?A
MH$KU2\;0[FD=O7?P@X2U4>45')9]ZA0R)N'NL1>]H]5!H^XJB;H)@:KR6G44
MAIUN`0[5?<_]D#J"5[J2;$?OGJ"6IJK^%=W5'5#Q[/+UT$D=67B=_JB^(X/&
ML%%G>/:2T._H!4>G%R\)^9E>Z1])RE<)`:EUH,@Q-JF3+=(7._@&MB)!`Q&V
M?3"Z%6RD4VM`[3RWL&U(7=*FUNUHVH_U!EG;LD5MY?USW+2V(75)VUBW8QB;
M>'^/GMVMWEG>TH9AX&`[]K3B?M*"W>,X>X4Q:*#`@&I7_H6]]/;V8+80C$4J
M#DXQZ<%<JNK7.WKJ?VQC:>ESE,ZPM9_L"4;SES9Q)M+5D*Z&F`X)/TM/0WH:
M%[C=;&%]Z6@4I"%ZCAG2<SKI95S,-C$85XQ'M7-/:,$.<+GZ?C,/'\>?V-.=
M;B)9#U2L=IX[1"VNQ7$XXY!X'BR>U"PTBW>`=J%9:I>X*'W6<.?@=$E8NDS"
MNCSO`-&325C2QY`^1D5)6!^=4%8<Y/&'3+EJA+/2$L'M=D8CF7(E#T(N<=/2
M.D9MH;%+VEEDRM6%IEP9QTJY.HJ"D=[*I2K^GDRXD@E7#3"V+LG1D`E7TL^X
MT.U&)ES)A*LF^AA-E!69<"7=BW;SL$RX.I>$JW8EL\@4K#:A*5.P+E7#-=Q=
M.%T*EB%3L"[/7T#T9`J6]#JDUU%1$F0*EDS!:J[9=TE;F$S!DD<CE[IIR10L
MF8+55'>GH2E8`YF");V5LU?\O8XA4[!D"M;)C:U+<C1D"I;T,RYTNY$I6#(%
MJXD^1A-E1:9@2?>BW3Q\"2-+Z>0[.D>,CK)D(P<MS[5`G=,#H8W#V7SBT$%R
M;-!AD,Z*K&LF6;?20+(CY5HPA$XQWFR0#<CL/S3\P!;)Z8>!Y\_QH5,RZ_5Q
M=J3E:?5?_6._Z]DWFC'2>Z`/5&W<KYM/SF=,=Q47I\W:Y%:85VR[0>A'.#1U
MK]CZ6:J+75.K6ZTE=%7K&^I(&^_'#JW1"A=L==QDQS)+`^-0Q1AMTR%]M3L8
MJ/VQ)FV-LK8&=[9BF.E0<Z7;&?87H4+IOC!]4`P'U#49UCF9SOE(0B4@8>B0
MQ";!BV-4.9!=^D^:`5I+/O/F1<B\\S*TUIJ.VI4^YZK'7AKJL-]31]V1<CC&
M$J7[!/KM`&3[29I>1PCX&'5OKC&3(IG:HOKJCPCM1*5S58`]M3O6U.%X*`TY
M&32202,9--I(E)&NZ7M:X*W1"Q=LN\BPD0P;[1@V&HRZ:K_7D];&^82-&A<N
M.KR7?D$:2(:`^NIP-%;'(WU35..\0T`GLX!6:#+Q(DP[TCN7HKV2*,]Z@XX#
MQ'4.0N6+"^]LHF8;%:"!ND\U^A7S`>ICR]8HQ-,X@)70.6C()H&G3H!61/:`
MXG@X',[)06EIWOBMJUB>^V?D6C1)_-D.9S1-?&J[IHM9SQCVO'YPX-X`(QM3
M.[!,![=K356N?=][GA%SHL".,5'(=XM%0"AC!9A-;A$_-.$VVWTB0>CY@0+7
M^^1A25^2?CLSGPC]BMZ*=R8/@V]M7PEFH!0#$1C`3C&5!7QK^?8#F2AN1/L;
MX24I7.RV!S.`"Z(%8$AOF1#`#[ZAO9(Z"B;/KP)/(3+!QWHB[M62F+X2$G_>
M4=Y$/E*%T<@/0@5_4^G?V4<H)F;C!_27&9`'0!/1@F5)4*%04H2ZG>Y@'?R7
M9J"8DS^C`'/T&=Y!]!"0OR)@(\4'$/V```]ZUC<E6#AV^!/B!`^F^"D38F$C
M*+H@\((>KB-"%6"!P(0C`#\8\0_AS/;9]XKIHB'0U>.?IE[D`XO@;QWEEG]G
M3_E7]/('LL3'9BE"`0&(X%E:1WF[0FS$:3#LJZ"TLD0!?@%V8>RURGWX+I_,
MD;V\*`Q"^!M79M6JS%]>)#C0\$]B46X3JB),R_(B-Z2/"D3^HAVUE.N[&V6D
M]3O*-5SGXQN=)5O^J0E\2B-_<:W%ZDL]1J^)&;+3A/ADX1E>!()@SVD11A30
M=P-6"RJ3"]^F@CCW)L3A6..KX5+^P!MOOC#=91*,'OX2P'<N->/H(U^;#GW1
MW8R0$-$R<^M`&*FVXV&+X`*]Z34`%UQ.3&L&\"T\GU)P`6_Q)A1HO,A*(J3E
M"(8L'.-*H09M=N7!0TWZ]$>Z]K[B>$&`OUO9`"P^-44SB%^[E5IW(?P'PRKX
M@$_L;?![1O9=$"A8$3><!8@ZW)5A.E5\DX`#1<`R@QF#>>I[\Q7"K!,EMV('
M?OO!P!-*K9/N8,>KT"G<1$]74S,<5*FIR1@B0[UC5&T[NV*6KA-Y6['<B3JG
M[AD0X^O$L>L,`:+XJR\4G^QW]YQ*\=^O4S)Q&]#H:$7A7*V\*5MS2^"UM:'T
M'Y4R-'=?FEB#I$N$N@11SLD$Y'D*=.GJ2`+L&/JQ):"Z:T\7I`X'1++QX=@X
M/W,KR]2;<KAJC+5N4.QM"*,>H^$HY^QCU9$W(_9WB!Z=EZ%?)3<=L>MER]5;
M75TO+Y+IZAG>>QE*2W)+KV-LY19IES6@+>-%<N<!.AE>AF*3S'2\WH`MUVFU
M]`:\2(;;M\'>9:@JR2>RB5W-3>Q63A-/T\NN72=E@P.WQ3Q]1FIQW?'&@QB]
MMH.8LRSTJ9B/VNIJ'JVK&L.*W>;.-R]NOT!`+?JDH19S+87#LBSP<LL"=RXN
MOM3"P#9KD[V*BR]89[1:0[SLJZ/NH!FF1C,H<J063*AI9`GR'B7(E<NDVM*8
MZ8"VSZ65*!_0/KJXHN6+L:/V#?24GIM>H33^@AO/;2QJ;+T&ZZG]@>PW+B-%
M,E(D(T4-M81:HU\N1IO(2)&,%*VG`]-:46EJR.".#.XT3_7(X(X,[AS3])']
MY_;O/U<YF+-K`[6&Z[R#!WPNKO'<0#4&W7J8<9N`MU?%'4-U]2JA4U&'U*P?
M$H#KA/@43>CJQJ%FOV87&"\EMUOLLA6`=Q'\'&=OVX2UY%KM@I77`@M;JL'6
MC9>SOFZ\"Q8@BW5WD>E@.R7?M$)X'3S/"N*T\7BJ.?:,$N*L\0,P7,+2S+$/
ME(H=I9Z)X]#.4T$0S2DLK%D9B4N3GY*R&#7]$NN56:,N._AVM=Z@H:.P&$W2
MDDI\?(0H65[D3.(>=$@0H*BCV'/@T3`&%QX7.;0/5MHSBG7P`G(!.RSAZ8L(
M"#6=`EAQXZI,:ZF\5EABQRQQ>>R@\!;6>0X7"0#X!%?Y[-5)%ST+;_+I0QT$
M*P!YM*>V!8NA$`I>9\?D_$;R.N\3EG:KTU7LLHAK@%W%X&-@3WA;,=K\+6D0
M1EL44HZP_HKLP&8L`:OUQ;/@VP_FQ`[@BEO7ZE`&NW:>O`#7')06B9#75?JC
MJH1>"&H/H/A!&QKJ0-?6FKO-B1E$?M+HC+8A*P+2>P`5RMJ@(2-,"#9#I"T4
MF9R^)["RBL&7/:^/7-E')R)M*H`K;<6'\H`MTZ:.]\R[X/$>><!SW@.O_^!K
M2+!1(/`;D'`!OYK6C$$C8FMG.D)&KO<0$/^)%E]PO@VB!;:P@TL>EB`%&`=!
MI>%Z((S^-^RA!Q+UA%4G&164)QS>LYN1;UPVU!2^35R4E[=,Y5'YM.?T/QX5
M&`>(S*M=@+C>`D%G70^]!]I4DR((!$;RPJ=)9+&6>1-["K(%ND&-&^^!JD1U
M:;OX$0@0N;PQ)Y-L-WY%0E1\%A`=-"I3A4%DS5`/LC?C95\[=QWEG<>;^[WQ
MHT?E>@+@@\;E"_ORW9OKGQB\5"7XY#$"9>F!8HHA#V@/R9B;8A4E+"JBEG,?
M?2K0:$Y\"Q4C@&>1`'C_F2@1JN/_T"Z+6#[T:-(FC4H`M'5,7X'_Q9ZCX/9A
M9\^0]^##-I\^/LB+?'B2BCSD1/1&T"L1X+0$=01?D"!I9IBWV.+"WM,BI'R!
M0Y''UI*X&+'L9'XVJ;9=9G<Y46UR1G4]$%Z1?2EHC$D[REWT@'TQ0Z31G]'D
M,>9^`MSE+:FHK%&?TAAT.:R["S3EJB'(;E)FLJ<*BHHUMD3RT"T2.T$*;4I9
M*\B5OIE6N@^*CR^S_9ESU`T;50NNA@N0/Q.N8>E[W*7R"!N1FT"TLAFO=V`L
MI;MPI<1FE6F;2@X&:U%9]*B$C;1?1`A8VU?&$WOWKVS1%ENJ5+"0V*+!M!M1
M+KPH\#C)&AV]G^.#\V\;$D$\0;U@*S,]ZI]HT::8(+?A97+'$<-_#=8^G\%*
MG8%5R'SNPGU.IG[(U(\]3E);JRTNWGJY*3*,%^92II[*U--FY&FT1M^<,KNL
MR5JH8.C%8<P9F7(F!YQF7"JUIVOJH*\?CJU:F6EQP74ZZT$?Y=`E@^6S&2^X
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M\P%:K)7P?&6.Q6:+I$1&+)$0D]39])6$'HR2F41_,7G?CVM>`-:D?([FRT_L
M,/)ISGS@638ET;,=SI+BE$Q13(FG)Q5$O.(C*9BA-4!I+8G]'TJ1]6<B!V%F
MOS6SX=4LO5Y\`=85"$"EA2;KV*^P,:_%42S'=FVL&..5*;3()1\*\0FK%,JI
ME^DH;[$:([>4`U>>5UIDZDLRQ18`E84/W9)8W[H2`PM$=4E9G+)4L*EPDE4Y
M36T7I):6JZ05IJH"&Q8L`!,9+)JQV.-\8A&;ENZHZ9>@6/@W+O*;Y4>Q4-`B
M$ES3[XE.M+&P*D#)09622C]H4=0['B\5=>+BRV#F^4`$XL\5UT012[E"`)C5
MS"78ER@:?0BSU3`IE(&HDQ+-S.OH,G6QF1(5<;O\V\]1</5HFHM7[^!1U'Q^
M`PK&\;!@*KB'97WM>-:WW_[[OQ3E;_&EKU$1@S)_0P++MRFW7[N3:T9EP.HS
M6'*6+=RNV)-?7[S[-QAK^GCT@C(Y_/2%3']]<8/?=D?#<:\[_#?.K]>Z70T_
M]+H#H_OB-P1VAZU]L,+V214)Y5H;*SBM/:6@8MNGA"5BZNTHT8,8TE.([[HF
MH<A=^[[W/"/F1/D"[&[Z()`WL14`'$F+B!YL;S$SX2D6+:?%6G+&[F*)9`AX
M$M2W7SY>V[2^,JZ^97+#)02?Z-#"PD=:I(2B34OK2(C5V6^6+A##4H`/E\!K
M?T:/*-(OWWR^^0E>YH"XPD4+$%S$%B690Y"^?N)'CT&V`A4@8C(UQ4I/"XL.
M<0NQ@SFKFB=8&FH#85`5P`X%EV#!*)`C(%>6R6R71ZS\ZR@)O3*BOK`7`)Q+
M8F46*-=?;J[Z>I=6_5E@T\$FILS(`J@:`@5>*T^V'X$*Q,NNK^_I912[^+UK
M.]BU`VMPI2E8N1CZRT5`RQ09X-:2Z45P!$(7/06*/=#UT3?G=)_T'L!\Q'T1
M*T]=]#@>EYW=N7CCMK1SH5>^=JNLLK(:[SU8F#883LM4.>8JM_%1E)LV:IIV
M2^C3(J7V=QN,3!\U%=;3%NW/<4<(5M^,^IW;*2#M,Q-T""%NXH_A0P+3H9<1
MH!C0*R!6Y-,^$+D^2*)/4>9$(YB7R6/9-+4Q?7R>CXZ68&I:Y@*9`63WB3`W
M`GY&W56$#?[(&H.LU&)S'R*@NM9+*E]913U*$#.).!3,)Q#>BF<-2<^&'GWX
M`UEZ[H278R>O,2=/)M6<-K7A"I`'70NV5L932DS\$"N:`Z;*XL&5J,[!+G*C
M*9"-M9"PO"#,)WF;+.WK;"1T8S)=+Y-,E^%X8+&)\H-FC#H&>E\.W=1=MLJP
MZM,(-P2A'/H6^&<R8:7K\#NN);T6%C1N`Y!]>L"9A9KC-$[`.4AD(MB')D1L
M3O``#!1@%3M;4KC:P5MA.W85?:C,`959_AJS#@+L?G3D[`GUTA(9=F)]AH`F
MHAO#"Z8#8_V9YU`IF2NXBS@<E'"9^\Z5M>BM4SBAP0_];D<3*4TAS7TJ[XB"
MCW+1=F!(*^#FPW.*WY>1>DKKA<=[#8!,^83N_0]+6'1MW-%C4&)OZYE++8]K
M</>%NER+,(T)8#2`]@\2NK!SM0>??M"&>F>08$E]\LQMY#NN<T!O2QH,4=MC
MD71O^4'3.[T4/+1=;%38\-LT`"\(4'!)*.HCUIMA:G]/^YFD/,:>:8P[H_29
M]%XO"EF(`W_70;03N(7AN%P3LO9*<8\"05$S%)E*SH1B\*$;95/K9%-=X[=O
M=^LV62Y9&R?M=``/IO;0,L?&,;K=HSEP3;,(/H.H61BIHRN6H9=PJGG/(H-I
MUX@T<!'$_2.")&#!.GU820PD=:5H-!6^Q%8CL((`8H&-4.!-<,,DY<0@?A#U
MG](7\=Y'22@%?"O/,KF@)#_^@7%'%\P'O`[[WA1ID\)=&S9?L2,9?TD^2HZS
MTI,%'*_87TS(16T47$Z4L;A3"+A0<R`X!]\2%XD9!;#L5\C`ON<X;-M@@1)V
M.W\X8:U6-C0&R5O5[>*X2<A6@BQF8`>?II]9M-OD'LM=2I12\1:CJQW')=$;
M**^4A"A4(A%7)!77FRXNLD+DFF!-TK986P686MW4NE_X!`_/6`\<VH.';G;4
MX3:314*!C+4'A@%\NDW![UCQ,(DY[:MK)XUF`N5E#*S>_>7WZ^O/R9_:+S]Q
M_L0./O-,;!1I928V?`Y,K*4?1B2MQ(A_!S>E*2U:]^K_LBYHL)U:#DE_&=&6
M:2P.CJ^XN_I_^0(L]B*BIR=Y-)QXM,U2$KQUG-B66$4#+B-!ZN3`MH[T8(&1
MN*-7OD3>,L)B?(G'V('_S$?"FWYA%\+TD$7T*!AOH543^3[;R2T_HKY%')H'
M2%R"YBKJ5(3%9!'9A<!O`J-P/"<(%%LW9D`QS8.4B)]FTV9^$Y!S&GRFO;K8
ME?PM$<"]!#5;9-VN%](8V59&K_D9V!T]`T.#CK8G1&Y'^RN6@SR:JLI#%,+:
MD6!M]29I['AML3""9P<%K!K,:&.J![0BS5AS_QFY%NOD%[/M=K%,F26F]B8E
M?NVZV-7R"\&>=!CI6Y.#_T,ICO<CN;E=7=R:QL@_2>3G4,!+CAD$5($ST4N9
M8X[.#4@BJ`EX(>N@E8\BLS3CV"4E"W!HV@DLPWZY\&R-ENVQ]V1WL:\!^32-
M3W8#<5_2+W=?^LI\FH0L*UL2VT^2(\$"\S'F`?2FJ'SD;"KYNP\7S$!0A,A(
M<_-;VB:6"9)XFLE:P]*6HL)1,&VWQ_HYQ@>IXH::KY*OK3"BFI6I--:3#GLK
MXBD?\_Z\0(!E)Q[.<MZ*JP,N'3`T_N<MT.+)=!"P+_!"W\:#\OS?F;DF\K!Q
MN3R,M*$\0C\(5%IAYCB^$6^9`=TG6'R%'6Z*_8(7O*B*'U>8242%V078[Y<'
M./"H@P9[/-PTJ(].4B`*MT4QW.)BO#)><O:(U<Q!BN'Z5MK9:N;OP6!K7CGV
MFV/JX(L=?+N!+=4.\9/(B;T+YD210M0QIQ12D$0%S#C'!JWP;Y"T)[5FQ/K&
MC3RFUZAYG0UV8_K0L[>2B&"'$8]ZLJ!BZIW2OK!H"U$3"'7C.S*A;WM#:+0-
MS$#XF9IAXG'IRW=O;F^8?1\MD,%_T/M=%=83]_?X^1WPS!/M_0!.+\&VTF)$
MT6;F&?D.[V+QJ<S1`",2]M$6\QE2W))X(+?()PQFCW:_3M%&M<_B!BS5@5_&
MT)\19U+*)RYB\:PLW"9QN@WAJ?[E2D)*GR(MS"*=02;(SK/AZ$H*.2RH^1S/
M?61_L:02VC"3*FWAV$H17@O7<54?A'$"%K-V6<PLY@X5U3A9ICV?F<RHRJ,'
M\NCBLZZ"!1K[*#VTWR88,,!>Z7O1"V,R$P?R`>*?F3\8'Q`L3)"8;.;`FGQG
M3ZD$/--7Y3G1[Z[O7BO7=S>*H7?5#`D2TFN_@*`#K9"2;UG8^V[EM(^Z#M0M
M2NRCU#R+L]<$0/ANQYT(:G11P<6-$8G\Z&&4\-4>I[!BDC]CK>)FK"<XT/H[
M:!2`]2JV"P0^?Y/E2V:PTG,$3'9@ITPT1Y`JMB<V.<!ERQ-G_"5G.EYJ>;#V
MP]S(11MX#A\!_PD]0]PU,>\,:'WOFS00DC+M*K5IQ_75<VQAB`2>G+&K<"?@
M(6F,;<0^-=A[N#O1E&,2AV/9819ZVTP1K=`_S7E3F2A&KD\PO11^?J2;.E-=
M0;`2!(`G8B_NG=LUG\&273^9MH/:ZPJNOKHSX]#=MB5#0T'0*B`IQ*9)E\(U
MLQ71HTFZG$6$RXJ7JV"UT))GBP6[$ELLZ@3&R\5/\N,G8BY9P!QD>A@,NP1O
MR!W,X-THON!E"%$>CF[K,F@3SRI>MV!E/PM6-K25C3N;WH:9$?R$TO:M:([=
M[=$HB+/MN2X%=YI*:^RHQ=:A:`]<A\K&P\SUVJS\I`.1(5ED>!4_<YTK6[7,
MJ[M=%GD_&7PPX3(2]\A?W:0V3=$HC@IWE#>\UH`Q!K#"W`;.H%%*<Z468I6Y
MZ%E:`@0F@<3YR.S0_>=XA``:?(RU4-EGV0E6\Z.WIB:\3%;(FNKARH5E9"2C
M'@+<UFGL?$(LGF4IZJ;L[!5F9]&\\RM,)P$C>(ZVII^?VG$'YM<T\OE\GC2J
MG0[)*!SP@P9W8FLS&JQ(\$</%)V>,2L%<[.CM(GAMQ.2+AEW&Q(&W*#D8@)J
MW0P%,=M=8=6B'X3I('P>B_@2.NW$C@>TQ)L3T@P3.&C4G<_0PEDAME4FU[[0
MD<WZNY]]##Z$R\\.AMS="3H1BRWN[^!RW=^87(G#16DE&$"9"TA\P<I\D9!J
MS#@9`OU9N!)\R77&L^,*'K8-+@J>;O%CL+PS+5-YB*L!A'$O'0P0`43IO(V"
M9]OB@*L@UC,X)P@I?475W)R$,V^2JEFAIB4*R#1R:,IX.G6&CH]38!5H:CT/
MQZ-_B0$DK)^B!V'`Y.\Q28QZ2_8<<^A(NBVEBC]Y+09KX2-_2U*1EH`PI:5P
M#,`YGX3DT!QVU(GP-@Q%./2`DH$H'M46D9XN[)--GN-T#E#`MD]_>YX1%V-_
M<4D8!@XRA@\_?B6I'[E2LI0I^B(\]H&&]`-C)PPL@D;:K@W*BGE6.?SN>9-G
MVW'@AELWQ.6"EUU32#:HA^'EJH>42@HC$V96_4F/LSSEFG'L:H:(<`]?Y""]
MQQ3N21W-.&H#2T#M&_,1A(>+1JP*XGSP1/C!(GK`I*4X?;;L6\^$P\OSZFK`
M%V0#(Y5Q&CP\X$V:4;9^('><XK*&LO<5)U92A"7TJ,%/^*\BD$]Y>?OY2_++
MFY]$OA=_2/:$9+`:3V)E&MZ]>O209Y*\/]#&?]):`<I70D)C2?:_8R/QZ#O9
M(8K-DWI3=R?D%9IK0]*$.DT6^(W/J468:7"*",<]7'IH'CK60V$6%M]M[%5A
M5$5I%.0MQ/-JFD2&C@?/2J+[-SSX`78FSXU'AXG$Y;4,:Z5:O)SY3SK"\RN6
M4O,2>MPOQ:=/V6!!O%`5J(WRQL[TS<2SX4HCJ26'?UUAO\ULQG$>5A9[7KKQ
MB!%Q01$))6V4#G$H8H66?%%7%!4L)N[T^&S,QF$98XQ#3#QP`SDA"T01L><3
M,&T_P.`"?$^+"]%"L\-T`&X0Q%D-B5.GV!@_P,L!;K!'[&]8M$MK!5"E)3HP
M!5K)`$TYD0*-"5PINNG!MD\<\D0'KPI5YAF-2U_"TAV$3`H^<##BIW0IQ/E=
M!]88$C8,]DL!%6(]S]]?C@BK.Y"(ODI#<!:6[\1+``8,JBUDWCB)F*X*AMX9
M0,@6NZ"78)>_.>6`BH=;9,)84`P6`Y("UV$P(6-`VZO3#UE9YW?&=0!$=BU%
M/!*J"B,>L[$LW#E-)_`4X!&F.1Z6"X"7$1!T/:^]1";'@B4@LX65I%Q0!6J7
M\2Y+[)ILHS7]9_]5VH_R1FPYL,&*/%*98Q.W6:%Y9X9:RI42)_X+TQ!!T7E1
M9I="1RM,<T&!0R-:&)[T/$E.3X16$,GP8L]BJ7ZLEL9D]2[8/X);>;G1J7=T
MK+:).X8J3&E-WCA'BJ%-EPD(9]IQ3)-^+WFS9G&'XVA@=6.0Z=!!(Y/>TG3`
M/=OP2EJB%[<@84_!"F]GI?";26M`)U]O;;Y"Z5_8RB9[-K$^'9HUALF\/<V.
M6]==I9K!R,8\51OS;)XAB\)5:8;LHTL-0+2PL*"=W9[&OX4,2WRZ4-(HFP')
M9D#;FP'=;YQ,+4=.US!R.LS9#?*&3Q=9215,GFPP@J7P8-:F%X0?:%15.(=9
MBT5HQZF3;*21],&&WU%H>-K3]L0TS,<%[HCOXQD*V=RL]\1S37_BJ=3AM9^`
ME<!"IIDE#[9']QO:DB1N+).[F;T6;1Q4]U&0'F&F:@6^BE^W4E5)VZ&@<6]G
M<L>27@]8FK-,7*6DCP)6(3]XWK=TP\LF&L/3?N@6IBT+2:@"9*#2*#9`FS?$
M8BG*-#UYJXM0AI<%#^$C=GM)*B9OXX+)8@]!N^"JPX\K]:4)N5@Y[9^4PZ\^
M/:.U)];V"I+Q*:G9Y4?>H,>!U'17H*EI_"$>?<@-6DTH%M</X`C8=$=3>1T1
M[[X`=L+"`ZM:Q0+#R7+.U#'3E*S#"?>:">?6PAI9OBEQ`8VKV=&N8`E#"49+
M'LCCJ::YB&Q^55H;15/T:$*9#S+#DZF3C$YJC?N$)3R+YC^7Z^(WQ+TK\#%)
MPE@,,;L;=G*@-3!<IHT*W>G9*ZE7O_)>EH1J,\W`=0VZ:BN-WE9[9Z3KS0V=
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ML@5:)7)NT6O*&)]->P)"`UL(U>/%AD,%,R!K-7]!+RLB7YCOO3FNJ%UP32BG
MDR(02C`(XE^I8,<GRU-"@FSR"A[YXJX>1&:`X1:"C8WB8"&>%F-:!W.JR7<[
MP/!":(>P%Z/UBN%HMJ?$B4S"#NQCKA,/_;.!9[24^SNW<),#IJ2[J@5,0JRX
M_2/RI(>_4C\Z\E=W*@R/L_K5D!YHI\AF0H*J(ECYG`RT$,1QS`<:VJ*=T(I:
MIJ7H)_W!^*6/M+E01XGI'"&V>2]+<$O?)QSPA\L%MZ9X#0S=-($70'O`(ZG9
MPZM4'B,3WXG!_O77T*4MQ`L?1>-![B2)]J5A7>JR\Y@RIUT<?L6Z<M^;VL"Z
MH'UHR(X']%JU\WZ.HY1L%<MRAY"GD0T6PIV4<X44*G[0QPSH0,&,JK@>A^GG
M^&&J4)9-K4!6H3]A7;O865DA2#8&3UQ<0I27C`Z(%E?P7SS&RG!,&@V+CY,$
M!K#)&FJ8Z&_Z:$IF8O_9XV4:A,I_,)=*VCUB2K,C.0&$++.4L!TE61K6GIGW
M3&$]_UB7BT3[X4-C39#-T*,O8YLQOV"[P[MU&\KN6ECZ0L`]_H0&'&]V$'Q)
M6DJO!WLNN!+\&KR,9[J`:">^\:*'$+,(8JH5!'Q8]VUJLYB9!TSB!R25>@EK
MIL<OP"J1&V\QJ%4Y(P3H')I@V2S_0QMP)BT\A?TH$!J"IUW"%=9*F+:7HXX6
M%D1X?M!)$,E<#`SY#&X7GN1YTRG;>+%(0=CVS!"3QF,_=FJ"!)4HABW%>:LF
M5MXQ[UL6+UUGU0LN%<]T4Q5H)?`H!L28CDOZPK.L#6!46GH)#\#X'CXZ*9;:
M8')0C\I_Y"=[/(9-\XSH26YN@Z;$+1X:JVYQD7;;R@$KL6Q>6_69^'?HB&RP
MR2^XGCJFDO+RO1<$/]'R>THN@5^P58Z5UJJ]=)(KF8=']_#Y(DJ/27%[9)"3
MR95)FY@3Q8UH])8>@,SGM"&223M#1B$>^E![;Y*V^HS/7][8#GUR\?M9)L'N
M`%".QK?@5K[PT*6W6>_VBE!NNC\M#!5JQT%U`R?&O3ZQAR@7(G;>E=CB+D8]
MDMZ@2:-0+%**B]1NV-ONV!,S889M+8`+XN>;Y2<K;/0*>NZ`[P21I'&23W$3
M\EO:_0#(@_G?.>=(%US101?LBAW9B+0KMBG2VG[*6KR)O27<FW$#-VM?;:0F
M)CJOR:>V<'JFF]3=Q48KDY_T9;'&IR$T;&HI0,6=+\4$GIW$M?UKQLYD/:4U
MQC<*.$2O'1/H=&?-/-J;E'7P7LDQ6<LLR:8P8(0J*W$\;$?/@>$"ZB*S]Y=Z
M789D](";Y:_0U%F>H9@VE_+2<""](8$K`U,.^H*)1RNU4@-.K!];Q3U)@F"Q
MC"</VQDZ\6R#S!7PD"FA61(TR6+[9KR#N&?UQ1M"#S>Q*F?#OGS!E1PI@>)*
M#ERU]S9+U4`W5RSU*]00V9[2E&<FZ9-SQPT)E?%Q"-KG::<_.\+[F10G:7MH
M`H([`0\/<)9)[$(_V4%\I$L3+-(7=90_8N!6RO+96U<=8B'6O^`AW>1H;I?2
M7]Y&,:G%7$\]XKHC+4/!_H4=Y<Z;;PSD)S1_QH.1M8I;^.C8+)F7IIWP4\9,
MTT2X#L>IQ#5W,1&IE8YQ1)Y?17-"!,!3N).^XE3X"TDM\(*XM!68A8(4CT1(
M>A8(3?G,(,Y9II-;A)>(Z[OC"L8E$NM)CK%*3_JRQ^>KX$7C=6S_64GY6<_-
MXY4.-"4Q(R-^VKN=QI-!EP(%>+<.6ME?F$SW0,)G%F^F9R48HN0Q-I'=8P5/
MN[>S%^`N6SY94ZQJR@@NLY#YEA87]O(<S;2OB1@KP^SZ)WL2T29B63'G<I#P
M/&W8F]*)/R`5HPE-&S=1.+`M;3:'<\KQI)M2NF&IZ9>T;H,:)';P[6J*-9N9
M(6#;MZ[BG6>U+@LI?V]^W[`_770I%F5,H,]:;\_\-E3L^A"OCX\>9JG66?(:
MWEQC=,7X3"*CZ3.3"@YL,B"P>MR#)[5TV*D!WH)>%95[BP7;>*HDE8#U?L:)
M'.=U*L6WP!-]`@]'"^XKQP]K4#A:.4"OAZIC<-?`PSX.#'):F$RI0'N)LI]C
MC1+?B\++$BSRR<(-0%L<.)AJH[B:#!.944'R>#YQA0@Z<4U*3WR;8SZS1])4
M,YHM2JG!6JRN)</$RDYLJI?!ANE6OF!X%,W+B,SO/&44"=BAG0WXUAP'5_F]
M`9YEV*#$*3L!79(&UBH;X#.)++*)C3BD_`1:A.4A[;[!-'&R.Z]QN8K56"`'
M:EI4&"0KQ*<TIDVB&(UCRSQ-I*C`[#E1B>UE-/E*+JL*0;4(S9!]SX6/%A'2
MZ#:HR!-/"^-J\,%S)I55Z!['<QC,IE/R;EE()R4?MKUW)]09;L\8L5N797JF
M(WAH@(''LZ[OOM)?KK2NNM8U20"&SW3C[D\:8+ZC24!OL<P.V?SEO;>P+66L
M]7]ZI;SEDS#BMJ@\__U=HM:^)&KM"]M2^-'X;5IRX"K7\.4D-J#_B3BC;,;)
M'^FK?X]L&D19:>C$U%@RE".(RQ;@M5;2W3^QC7T!#G8:).#*$IY(_,+4$$_5
M<_(CVT6_=NXZK/=\;M<>=FIK)8>S9H+J"KP"6-N@`B)I/R6E,,D\->SB1&UF
M,2IAIUG(:=$)TV5J6DG!*+2QMYFJZ#_!5O-`G.)]F"8M\5Y[9A$&\"3CI[B+
M/ZL<3N8EYJ5)LUN%$4>9C8L]DM8HN(_F(\\5Z0DO")-:7MI=O^!N<$2Q.Q+Q
M-P`>IV[QO%=F"M@A32SGQDH^]/GC*U*QI.#3798Z>ECJQB;9L5?06FA:;V%.
M02321&RMSS.[J=?#3HW,2>Q9H-L;%DV_R2;&!^RVK+)(07*6:;WXU'9XF0RU
MKW"8@8*S/+8T4#_[C(];3*Q>;E"Q'[T.HUQW7%;+9M(ML%[$IQWR**UOH@!(
M@S7?7.$.NH.?<A4?K<(/(LS)(A/6U=*AB;DL`8OU36`O$BWY1ZY,N1YCXS-6
M$>&#ZV+'U(TE(3&:DT=30P^$@1$4X89[Y]0]?_30WA23OC`6F^#'HRC,V./Q
MC*G#NSNLEKO"G6OB&\^-9/8A_=+A[3B_<TN.V7FH#M:`X3-#H@6K1L)4Z\3[
M$6)>Z=@1Q7SP(A:X9D.X50Z\&M>0H0I"$XUNABR'-$DS24;0T0(VS*5/LFEC
MDE"+C;*"6)HG%G/%M5EKE67)#VH\7(%UU4A='/HBCZ79\^-AK`RDG<=8D:TS
M188R$RC6N8(:_#Q<P"*5=%@,^%^^E^3D8.*X-V&AKNPOB8JBAVGXL@="C>NL
M#A2SV!/O#_7X7Y'IA^P@$2`:K8UM)CS<$1OCR8D@>WY:BA;#$2LSS@,>2Z;-
M'2S1+HWVC\BA*LTHM!J-*TTK;36*08E8;0U[7;`3Q3$O/%/TJRNP)=RBO"8N
MF8(&H5GM)N`>*FF1"IZ.*S?8G@%0P\,LS!*]`W'#NG2\&R]06?=%_),WZ!?O
M4-[2?-1MQN,$IUL'K#0,=!@:'I;@**XC$HF(4/>?(\(R=FB90[;Z@O69$!`)
M."+4G<<+*!XT#,'P$&^@B?-Q$U[!H>:^K>"DQX&1V-NERO69UDJ*%<*@VM+\
M*&JZT9N\N%.<P`H\&("!Q3C;<(4@-%0;AS"8:F=J.A-4SD9Z:>WX7B:0P>O/
MV<BK.,3!2["9XN<MY=YFK2365X0;2EL4":LG3>,*.6I$)!57(QN:GVX+#U1U
M_+-A`^SL>N]]X'U=TP[;>7$"_8(K27'1IQX*`%UHE!3LAC;'=)'_%,^@S+95
MO5IKJ\I*GE?&XQ;,>MDQ%M$MFM%>:KS]`;84H1O8"D(99F%M5!_PK,7_]06R
M'G&<`(0+%B#Y>X'&%_\;MIA']]<7&-0A_HN8-NP!5S3Y>A&05_&'7T#P)^'L
MU5CG*\S?Z@N?:4$0?2@C;?)0=FM/R]R:+`<E![WQ%0/FEZT+)+9SQ[^S*X9?
MK$7*A%7$P%I*VKRI5.$D@Q80`2@)>&$2YD8<`46^!C'T5$\IW<ZPOPB5_^G2
M?TY(ABP5#ADOO%Z7U<U4WD;8,^2=GS/R<5FRHDM1*2TJ2=]=3&/>3TIBFB+B
M#2/H/FQUH6CO(DV%))#BQM#[W4=W\&LZT.1WG%0@^4^B+<7NF&+WGC;-D`PH
MT99R=T"Y2V>F2/\K!UV`ZX7R\$A'7?WZXG]NWKWKOKLIZ8Y50E;3.WI_%>&K
MY-O3'ES<I-,W70]#]B\G?/(;'F&Y+-3[4S4&VD+47=785J*?F)0_U$NE[O[:
MWD?TMDOFB>FF&^K(Z*F][JAN-MN)BU:(L=_^W0X8I;A*<4WHIJFC?O<2I>`<
M8)22*B4UH=M+W1BJVDAKA""<F!:UF[!2&TAM<%;:`,SL_GBL=H?#<@0LXQ\?
M7PY*>_9K?ORFL!`EXL+TP3._2'^?)8+%[GZ:ZX4UJ337JZ+ZK.O`][@*M5`Q
M[!%)/!/=,%#U44\=#?3#K?/>,G;`M6XKY%*V3B];ACH:CR5SM@ER*5:G%ZN7
M6E]7=;W)&]9YN;Q2=*7H'LW:U(P!>J,5/-$S8<\Z3YY74,1.RPY1],YE>:SW
M7F@Z1X^,;:*]C)Y5BI[M2LJSTVO]KJII8U4?UGX\=E!-<**@=)MPD6I$JI'Z
MU(@Z[%4,&%RFU+4)%ZE!I`:I+S9BC,9JKVN<E>"=5[1$:BFII:26VHNVO;$Z
M-/KJ0!M4"`.=K=QE`D,_TZX-R74[=/_`/V6["MFN0D1+MJO8N5U%TD<F9>.X
MH<Q^9Q%GR$FR>844'-F\0E;S'E6:9#6O;%XAQ4Z*7>/%3C:OD&A+N9/-*V3S
MBM-'$&7SBG,.=+<BB#U6NT97U0?-*+(]\K'0.<`HI55*:T*WH=KORMX5#851
M2JJ45"&%9:SJLG4%@BM;5TAE<-G*8*2.QR.U-RJY=<O.%9?C[,O.%9==2ZBI
MPZZN:OT]TS0:6DUXL9!+T3J]:"43NG3)HJV"7`K7Z87KI:X:C>ZV=%Y.KQ1<
M*;C',C@'X[$Z')<,3<G>%0>HPC@;GU7VKCCS\-G%%&-I775HZ&JOZK#.LZW'
MDKA(-2+5R%D<L+=1ZMJ$B]0@4H/4%QCI@8?5DZTK9.L*J:2DDFHH;<%;&HQ'
MJCZL$@4Z6[D[4NN*C94DV94^?.L*$;F__1P%5X^FN7CU=^),[KT/9ACY=KB\
M(Q;^UR;!/;SOM>-9WW[[[_]2E+_%EW_VO07QP^5G!]YY[4[>_A79BSG@G%RO
MV)-?7[S[-PB&H6LO%`M@A)^^D.FO+V[PV^YH..YUA__&1@1:MZOAAUYW8'1?
M_(80UMXXY&3'C$UI'#(<[-`XA+\V+0^*O_A""<6T9/+E/:Y"]JO7Z5(Q,/IU
MU.YT5\.BJ>8\K:Q5*:H;%!;5U4_UQG=WH!O(J_\1UNG0=7BO3=!=%E%,;).R
MTQG109;I>6:'Y`K%'_%Z]LW%0<7EM&MPJ*XM9Z6V=B3[B;57<4GP0;77F987
M'U^T_A&Y1.&=GBJ>?$CU=DSU=N0%.$SY0:N60^JX,UG0I+>=LE=+.ZGH&F?'
M%4:4SLJR.ZU#>N/-%Q$(>Z""@S.UP=4A<91&,=V),HU\UPXCOV(?DNW!OKI8
M_[3DJS_*7)(NU6/&IR648?14K6K&;R.YJ+&EZHT`7XKU98FU;JC&L&0'\T9S
MD0PU-<,@^4("8OK6++5#=C+76Z:0:BM4:*D>ZJEZ;Z0.NA4UD626JLT#*Z%^
M#<`Y9X2P7/Y+T!6&VNOKZMZC#>IBEDP@IME,(X,SQUV4.V\:/ILR]E*OGKM<
M;VTP5@=Z[;G%DIL.'-%INADE640JG'-4."VUO/:ULU*CZFB=UYIH?+TG9D!F
MGC-1[/G"]YX(QJ)JFGRQZ6S^LG5E8=5%#20[-^VIJ^-^7]6UX>&83I1BR7C'
M;5)R)M:=U&%2A^VCPX8]',8^/B\=UE+34`;E:FIJI#S2P6A3^SN9*&80D#!0
MZG9SMF9Z7K:6K:-BMZ5*=Z@.NOCOJ*F>=SLY3H;ZI-:26FOW8*':'_?4GE[[
MU!-I%,IXX3'BA4'P2EB<Y)-R;5G1/'+,$&S%"5GXQ++-T/9<FF!OLCGR]`OI
MF$O'_%@T?&FH8\-0>T,976Q37^XSL2.E[I*Z:R_=U1UIJC;:,]WW,J.*FW38
M:8.)A9;DX?JG#SJCM?;I#3`FX]99U$1,*B%4Q27A\>.,9?K:U:J<Q3KEJNNP
M!]$;VC*PI4K<4`?#GJH9M;O[975'HXO,&MJXM%%H2H4E%=91%59?,U3=Z$N%
M=;HNJ:*D50-VK9OI]O:DV7:F=]:,3"*'?)K>NJ'I/MJ`XC4]^H6;?_>\R;/M
M./>(>&Y_4_TH_4TU/=$K)^AH*JY8K]/O\1.Q^QE1II[C>,]@\"NLE2FF5-H3
M@&5"0M-V`L5S%2_R%3NA+3M75QY8"\;@E6#XUL%)C#[Z4>F3<FAC.KZ.>CMT
M?.6#K@;Y)YZ%G:16'+#U]:K2P.B(^VQAA^1]>X)UAGG>\:ISO"G-IBB*H36B
MVU>Z#H=N+I6JY'2Q6%X.HHWWQ9CG2/2+>$$??.7G9''Q0OS#]>#>Z.%/8L%V
M[(F7U7=V<\@3L9-V"RTA-;O0ILTJ1BJ;\U8VL7:0.D/J#&F67+:F2":@QN*_
M675(95"9OVN;VEO@S%0B(G4G5T?Q9NEXBADCR12#4$FZX:;$Y6UQ:^_->)@F
MTJ>-`9X@XMJ.T*FF#55#;T/_SP99/7LEI!=;/>=@TTAU)-71SF33U,%@J.J]
MBJF/C51'IZMHD0I$*I`+52`]=3CJJ?U!Q:KF,U<@I5VM^AVK?.]T?8;%*;RK
MV_G"M/W].Q4W9Z'+I!_7(\;-R(B]VF_A&BVT^S'>ECV^6<`VC;(MDY*7FFIT
M1VJWJME\*'%I!E7VK`B2LB=E3\K>X2M98LQF#`!-P^S*3.)397,=#=NC53P7
MGBPTPP:^WOE4NW)Z[$E<[V/U?*B*X[GJLXH6]WY,<C8YU`?%O-&6AM0"EZ@%
M7NK&0.UVQP<K:92%O5*U2-5RR:I%:I8S<+1D(I:8B+7G7*HS9K.*IY&MCOCL
MF#(ESR::"6S3V4V*GI`>I(/PC2OVI9""UTQ@F\YL4O#$/4_O=;'+0HM%3YY+
MR'.)AJA\&3:0YQ+R7$)J`:D%5H.'8(6,Q]T+T@7R-*(ATB85BE0H4J$<I&]Q
M?FG"T3H-=U<=I6YSW"3A7.(?D4L4?A+1V\\/KZ69Y`6'=@Y&OW-5HS6=B32X
MW^8!B%972YT:%&6[*D:ENFNMNCLM(4>Z"IMO:W5<K2<_4BM)K70I6JD9!,6S
M\;':U_<\I&N%@CI2T_,ZP%YK?[Y#._.B?NAW(?PX`P5)_`"[J(?+CUY(_C!]
M6,<P^.33%H)!;E=T0W9%%[NB!]$<P`88`\5V\;%\4.2#%X7*,R>H`G\$L&38
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M#RLL)0QNAM(.%GACD#1JVP^;@E+[9%COU-PC@-K"YR7`NV7/2<,XERPM,H/[
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MO>%>5&F'N=I"X_3L3=&V2Y_>V:O_99O-3!F/E?'8=6FIF$TNX[$R'MLV`[:Y
MP9S34FC8EX%8&8B5@=ASE%U#!F#W"L">?@[J^=C+.=;Q/N0[*T.1GE=V1OOT
M-.<V\\60;/?`[W%)=,(`\?'&W)VG#9ZW:U_::$!]-%:'H_W3?FN>!7@V<E8%
M]W,WY7,,]TO0I=L50_V8-D,Y5#;_<XS]=BJ&34Y!X32&+<Y1_GR&PTT$;:C/
M<.^%II,[;*2^X'NN?50OI9L2C,A@&AY]"E=3+,.*!^GE0CQR.-=:SFU?'X`]
MJ=5,[CPSZSQ'=AT:^7.W,4N%BR]"<>>:G?NM^]G@GF<YGJ>\MV-$7\4)>T6#
M^MY%8>23#[9KSZ/Y>V(&Y+.YG`,>P3O/OS$7-EA^].L@._A/G-C7N]R)?==@
M#4^SX_9494IIJLP9414'R:<L.%F52404VU6F=F"!4;W$02M*!`_V%8N1&[";
ML)L"!<1),0,^%#"0D_P.,LFOOW&27]5$F3K&:C74#^0SJ/&"&*W8R&55H,I+
MGPXG0F[VIC_1Q<6K$X56VW:T(Y&;89-7G$"\C1;==F5Z]H>JUJWYD+OT"7<#
M3)(M^D=J&ZYM^LH>^J46;=*42,H^J+=,>>CZ2.WI^\PH:).ND+9*H?88[*,]
M#F2=G*<^N3#S9"<-(^V3R],P0VF?2/M$VB?2/ME)>XRD?2+M$VF?2/OD8!IF
MG-4PICM1PAGQB3D-B2^M%6FM`(OT56VX5\)ABQ1'"6/ETHN+WI,@4&P\?"-!
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MA&?#8)8,Y:M`":(YP`U`*K:+CZ4D5<P'+T)3%XGG,=*^2I=>YL_4EC\SULOD
MS^2G_A8$*';H(2X:*-U5^Z2;6"=\(1X\9U)Y`SF"KY",]]!?%%&.+QC'M#,$
MZ.*O:*?DE>_N.<7BOU^G)-ML2FOE-^[L&I4S(JNL$5V'4:F]:H\4[&C^`)YN
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M:'P.W6GI,^AH;>@K+'5+4WVCRR+*,53,1=)B'U+4G=,AP3\S\/<2I`;`WR3P
M=^]NUN(0P^\XH9E,3A!=:HR-M`?J+2M'T=1^=ZQJ@_.KQ&^D%7VQYF$+],/.
MWG<K?6V]TS6D3I`Z09+@X+;#!6#>)*=``GLR8)ONVS:7M/+XO)2VNL'#<\>I
MZMVV\C2I\8=)S?"`&9E&NJ;7'@AKG07<F$#AF1E#K=0O\K1:*A9Y/ML\9[O=
M1&G.65O+:-$D;T>"?V;@-]VQ/R?R[W5H?>D-T^)*SCV/MV7S,]G\3"3<R\&P
M?V:=SYI!.#I1!G^.X6Z4`."%R7H>?&4OQM0\`(&:JE'K2QK8ATCG%AHQ.N,]
MDPL:W$>RD9&22]19S2'5&?#5Z917RV@TMR<3AS27C6H](#^\&CE/I)JV4@T2
MT9VP:H]0U9S(<>GQGOW[)1A[>((U]$N0D:;:>RI<6G#*4'O:6-5'52-4E;M:
M2R_K:!0]9[^K>21K*L<=O*%_JZ-(O<[@T'W\I<9K@O@V7N,UF7AGP'L7HP0/
MG,/08.75$,P;'8<Z+)KGR]A2HL];HF47CD-UX3AY-\[#A*@OHEOFV.BJ@--^
M#-!HN3^K`LNV]K383R+;$";0>IUN7XJ9%+.CU;,WU^*4C-U,8)M&6<G837&(
M9#.'\VOF<(I2JW-U@UYJO9':'VAUKW$[#FA^.B+KGW[#/+WDGMX%NY#F"/W.
MJ/:SVT;O^5):SXSZVP6M[$RRIF`D)41*R+EO19<L(+(QP!X&1XL:`QRO+J2-
MYVXOC>%0U33]<'S0OCS!BFYH*[-S+B@U;]]3P\9FZQR`5H..7M&1/2-5TC2!
MD5K@]#;!^:;;2<&3@M?DE9*"=TZ"=]A"[HD7/3A$T3N7XI\+A=S_B%RB\-+M
MVF>)5ZT>SBS$67CX!RBA+DV$<PT*&.I(-]1!U:A`Y03^0K%NM*H[*.:-MCJ.
M@F937=N#5R=7(M;Y!0:&%;..I3:1VN2"C(_#VQ:G50"CCJ$LB>D'4@M(+7!V
M6N#L[8DVJ1)PAO6AIG:UVM-D6Z%+ZDR,N+C`"T^,,!'K_8(OFT(MN:+94CVW
M:V>3C6&:6@EXKF$:3>T;NJJ-NO7.8FB2UCLL/QZF)?8![+#3]W0Z-8&:RDTU
M)X>T.@;4[XSV;/`@-=7)!;'QFJIF4DES[?S-M=-2=+A;Y.N,=-\ATR'.,ZHE
MM4F]YM'%*Q'-4`>#@3JL.5/_/+5()L+U<XC!FN2ZB?VT"YQB(`KXKC:P.3A_
M^SD*KAY-<_'JSIJ12>203].[&9#ZM1F0R8TW7Q`W,$/;<^]"S_KV:8$?@VLK
MM)_L<'F/&-X#A*\=^/&W__XO1?G;IN=]-I=S0.3ZV?0G;^<+QUL20I_[.?*M
M&5SQV3'=?YI.1-]X'031G+TP^R+%GOSZXMV_080,??A"L0!O^.D+F?[ZX@:_
M[8Z&XUYW^&^]JQE:MZOAAUYW8'1?_(:X[[`2-`)XL@"@R`.]3K_'"_KN9T0Q
M4QHI$5!8"3T4M8@`6D@IC_\&*P#7*E//<;SGX)40F*F#(1E1]*,2I=`H9`AE
M%IE*(M<PO[[H`LL0QT$=8KN/R=\+<S*)_^;*BI4.)\J*JR@+B&@N`O(J_O"+
MPM38<)`IM:P2XA[H'4.O6,I<;$V(\>SN:CB[FP2S3^\3E=HR`,_5_:+3&]16
M][T#L02*C*I:9,`TP'F`EO&BB"4X)W*0.D-X1?S5%PI$]KM[CDC\]^L4548N
M8]#1]8)\7JV\/7)`@F;IN9T7=V>^C[9+E#G\/`M2/B0`VR3],SY<.<19EA3T
M2Q'T(PFW!F[\2`HW16_;$#%V4HH_QXLF7IICG]"[E+6[=G5SJG/SWJ)?W3&D
M:R8Y_;PY?7U<7JV<7F-5S88-L0UY&V_`409H)LK2)D[)KA9T']R6%'2"G;$!
M67=,!1P-[6;D4S`[:J1K>LW4O)#]2#+5SDQU"#^G#6K]BQU\NYKZA"@VL@4)
M0L4W0W).?L[13YLN4LRTSNA'#,KJG?Z/`AEK(>B%J&_)1;^`I_1C&DT!?DK_
MT#K&C])2KX'&__0<,[0=.UQ**UT:5#M4DHXWR:&TSB4SU<9,TBHO*I)9$"LD
M$\6QIT1Y:;LLOZUD7T1IEE^0?'7T/IKEX\YPK\2E"]'1DF-^Z7<HPR#C2'.[
M!GK^09\&NMI\(K[Y2)1''+6J3,R0*%/3]GD:TX+X2H`)9(HW3;*9'JM,995V
MNC2M,JF_H\ZXY@92%[(+2';*8R>MHP_*[@@MR`FN*8=W>[*PF'S\A02A;Z-I
M3U_UU;7#@$*0GXDL)@B/+CM!F&7\VNZCPI)@83D`;(`Q4$+,'^;TP]T5_T:B
MF^XR.1P:_A(H*?$52GV%DO]5RCPRA;@1*<2]SJ"J^FU[9F&2;*L?+=E6&W1P
M$6N8U]&`O,:69U$A<@^^\C-^_AC-'\#7\*;BEU_NONY5'5EH$-5%M_)D:F`U
M;K<S/KK=+!76FL+2.F.959F)25R).N":Q2?$KW['^(/XQ1N>^Q'__0X#&&@$
ME\P(D=JC3O*T67O4HW>'QV*LPW2'VQ8Y+;:$VQ`Y_>H^@4>&D=-0N2.+D*#A
MDC(&[PJ':.,S2J:'UQ@,ZXZR]?$GF;[7(*VUC6#]SG!'@E5O%M",F-E5Q<9P
M6UD.=P+96ZD4L8J-[JV;9$.VP)I#]W)</4#9Z;=C8/V55"RG4BQ;W97&*Y9#
M*=R=K>W&<$S-]!BT=81WRSV/WZOD710X[=TC"$.-N4[4.&^3[=T;=E7P)_8.
MO#1:@'>//)?;JX[.AL<P4VL$MS7VI(;'Z9<M*_O:=<>7[6/86[7"VR9[Z+)C
ML_^DD=D#!%2;PPR[1CC;9$2U),QPR$4_`Q.K";'!@R+0&C-,RMO!PV^GQ^`,
M##<9VMJ4UW@)<]C>>?Z4V'4$P7;-$&V,,&PXQ=XCZ[7-=F".PBXK3XU6*N7"
M;36HCM/O8>L6XD$UX@G#=_O@U7+[\E+EN!JJYR/'S/)LGR!WMY:BG`UKUA^"
MO/2)PF(:Z1[CA.M)!VW"F*G#AT`/1H9SM9]W.HPN%0AIQ3RI7:.NK1A55R8Z
M*P?X5@H%7])0WQU.[J5BJ0OY<U8LN<[`R33+X</5K6#HMG59V:/Y25%G%:Q)
MI26IUT%`X`GNY+UM/F##6YL$'X@91#Z9?(*W69'OV^XCP&%O&+PXEGU5"OJJ
M"-W+YHRLV#`G6/.S%-.=;"C@,^`=/@YX)'BOBTTMD^6*'TR=-^%]GJN8BA^O
MH/*`2[CKL$=*^N)6+2?P6#/4.]P,RRW=,$[1%F:L[]P6IJ==7I'TQDWR%"T6
M9'\%BMY[\D0<1=LG`MVXNO4=(3[OSH!2ADXL0WM.6Y<R)&7HXF7(.`,9.K*%
M74]C'BFM4EIKE-9[+S2=,Y#5DQQF%[EW;3BAOC&#&8U\6/B!_!790!P,I=0;
MV3[+XORZCX?:42>@&2/5Z(W5H5%Q<]_.([6&OQ.=<=@SF_.N!Y""6:=@-B/A
MXW\/-<I8"J@44"F@4D"E@$H!E:;MF0GFSD6);?9^WQ`?_-W0?B(\">`$(9"S
M4@1R7R[#!R<7]OUX]?1[KA0L*5A2L*1@2<&2@B4%2PJ6%*RC^'T7?`XJ>()"
M#KB,%#4V4G3F>N(,(D8RE"L%5`JH%%`IH.T4T--2I:=VM9$ZU,92+*582K%L
M"E7:*Y;R`#0O_1=^L=U'@`<KS0-[0GQ:#Z]X#T`1^C%0?.*8V,0J]!33^BNR
M`YM^+P-D,D#6@@"9C#Q+P9*")05+"E8[+5I-[8_[JC[<LQ15BI,4)RE.[1&G
MFKN9-:^34T'7*T0);XJQBJT>>@^VQ*(4P"OP"]D!:K\8@2#=&`:0Y?@4!UF.
M+YLXR9864H:.($.RB9.4(2E#[6_B)&5(RE`S94BV5KK0E&+96DDF7U2,K8U5
M3>NIO5[-0S4:$&Z325%2+B_W;%8*J!10*:!20*6`2@&5EFV[Y%+F%<O&2HW-
M%3GS;;EQPBZ3L*1@2<&2@B4%2PJ6%"PI6%*P+E:PY"FH;*S4QD#1F>N),X@8
MR4BN%%`IH%)`I8"V4T!/2Y6>VAT/5&/0OA$64BRE6$JQ;)Q8R@-0V5A)!LA.
M;E<W3B_(R+,4+"E84K"D8+73HFU+)Q@I3B=G)2E.[1&GFALKX9]YG83J$"P.
MSM]^CH*K1]-<O+JS9F02.>33])UI^_\TG8A<T_35:W?R/CV]_$#,(/+)Y)/[
MA5B1[X.C]]H,[.`>D;T'8%\[GO7MM__^+T7Y6_SHE0<6/>*KZST$Q'_")]VZ
MBRB$GSW7@A=3GS%YN&)/?GWQ[M_=;M<PL`$2H`T_?2'37U_<X+?=T7#<ZP[_
MC1V=M&Y7PP^][@"N_0U1W[7#U<F<:I$%>IU^C\O\_8PH4\]QO&<@H&('B@E.
MM4@PQ9LJ(5PT64E(/EQCJR,'&M+N7JL(G:*%UF!4I876EN!6?]#>^!!5!8H9
M*@5MVD!<*[:ND;'DBSN#U?M=%?YM=$2Y;@-XYVASF[4)&`G$7H2XV=EN$/K1
MO'J?B19HB[R]4,:]&AGW.J5:.*G9D6&*$V9E6CYX(*2H':S8G\EVD8(1H63&
M:Y,%N&S;9%=M<V%&RLOV6"D'H,Y/AS)U<GNO=3O#/I@)%+J%Z8-::KVF^TA`
MMY$P=$AB$VW1=WOHN54>W;0(FWK@-9QI:[.S=J7/N>K"VFRQLM(M;;;S=^Y*
MA(IJ3RH[0Z4D0T5M2->7X2(9+CH[,T8J"ADN:J6B2,)$F1C09=L9,NPC#8[V
M!FT:%ZR1P1<9?&F892.#+ULUU\2+,-]([UR*YDJ"-/^(7*+PL$SMS4XW4?F,
M55K]H9M="75QNFT_GCM/;7=F2<DU9PZSM&33?_8S3X[F"UI\>NU./I!PYDV`
M+1Z7[SQ?R'O.YC>+*<C:AA1DCL<[VS4!'-.Y34).U]_M(/[Y#],'9@H_T`#W
M):0MFRG-E2@@D]C'QD3FE8SEN''64GDF/M[)<YZ#NK*8&6@"E;8E,A>R\.E2
MCX>#*JG'&2W7TSIZ[^!1G+7Q8Q5VBWV21+M:5^'2M8]'I7>T.FC47251-R%0
M55ZKCL*PTRW`H?K&OQ]21S`)G&RF`[U[`GL":T3P*@)(?<>&9]#+U^W6.E(@
M.OU1??&:QK!19WCVDM#OZ`5QZXN7A/QC]O2/Y+R]A(#4VB3T&)O4R1;IBQU\
M4Z8^P;,&V/9)$"JP//4>.)SG%K8-J4O:U+H=3?NQ7@^W+5O45MX_QTUK&U*7
MM(UU.X:QB??WZ,/5ZIWE[?<%L;#-EF-/*^XG+=@]CK-7&(,&"@RH=N5?Q/3W
M.D>DV\,6@NTRIWP'BDD/YE)5O][14_]C&TM+GZ-T>I/]9`,T$V5I$V<B70WI
M:HBY*/"S]#2DIW&!V\T6UI>.1D$.B.>8(3VGDU[&Q6P3@W'%>%0[]X06[`"7
MJ^\W\_!Q_(D]W>DFDO5`E0+GN4/4XEH<AS,.B>?!XDG-0K-X!V@7FJ5VB8O2
M9PUW#DZ7A*7+)*S+\PX0/9F$)7T,Z6-4E(0D"4O)M#B1*5<RY:H!9M\E;6'=
MSF@D4Z[D0<@E;EI:QZ@M-'9).XM,N;K0E"OC6"E71U$PTENY5,7?DPE7,N&J
M`<;6)3D:,N%*^AD7NMW(A"N9<-5$'Z.)LB(3KJ1[T6X>E@E7YY)PU:YD%IF"
MU28T90K6I6JXAKL+ITO!,F0*UN7Y"XB>3,&27H?T.BI*@DS!DBE8S37[+FD+
MDRE8\FCD4C<MF8(E4[":ZNXT-`5K(%.PI+=R]HJ_US%D"I9,P3JYL75)CH9,
MP9)^QH5N-S(%2Z9@-='':**LR!0LZ5ZTFX?/<5Y<#2/=V&RXM<%SPO7[3I\3
MA\;I&X;&7<``.#;##<>]V8%B*GZ&8(HW+9X"YQ/8=,E$"3V\)B#*,T]KJ&L>
M7,R?Y8;!'2G/A2%TBM%R@VPP;/]IN0>V!D\_!3=_AA(>(NOU^I<[TO*T>T_]
M\V[KV;.;,<MVH`]4;=ROFT_.9SYM%?>RS=KD%DP8T[4([H5V,C1VKW.-LU07
MNZ:UMUI+Z*K6-]21-MZ/'5JC%2[8ZKB9F>XCB><GUQS`OBB-<6&61E_M#@9J
M?ZQ)6Z.LK<&=K1CFP'/LB=+M#/N+4*%T7Y@^*(8#ZIH,ZYQ,YWPDH1*0,'1(
M8I/@Q3&J',@N_2?-OJTEEWSS(F3>>1E::TU'[4J?<]5C+PUUV.^IH^Y(.1QC
MB=)]`OUV`++])$VO(P1\C+HWUYA)D4QM47WU1X1VHM*Y*L">VAUKZG`\E(:<
M#!K)H)$,&FTDRDC7]#TM\-;HA0NV76382(:-=@P;#49=M=_K26OC?,)&C0L7
M'=Y+OR`-)$-`?74X&JOCD;XIJG'>(:"364`K-)EX$:8=Z9U+T5Y)E&>].<H!
MXCH'H?+%A7<V4;.-"M!`W:<:_8KY`/6Q96L4XFD<P$KH'#1DD\!3)T`K(GM`
M<3P<#N?DH)Q)SOXA4^U9,G\-50%BSKZQ(6>?(Y.\[/4R?N3RQC&#X/J['?P;
MX7G[W:*QER_(T8`GGAO5F/&_7S9[X<J=+O]\.*B2?YX1VJ'>,:JVQUQ1X>M$
M3HMZ,COY$3LZKA43U>$]\H7BZ'6&\-SX*\JI*]_=<S+%?[].Z<05IM'1BF(?
M6GF]7W/OTK7%H@LR*J65=S?/8L\A72+T(1#EG+09?JA'EZZ.C)F.H1].!.JJ
M:Z,+4L=N+=GX<&R<G^:09>I-"0\U!B8V:/8VQ!R.T1F1<_:Q"EZ;X2@?HIG@
M9>A7R4U';,_7<O565WN^BV2Z>J:,7H;2DMS2ZQA;N47:90WH'W>1W'F`EFN7
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M_EH#U1ATZV'&;0+>7A5W#-75JX1.11U2LWY(`*X3XE/TVJH;AYK]FEU@/,>L
M_,/WTXK?<&?-R"1RR*?IZRBP71($U]9?D1W8M`C@]5+XZP90@9<!TO`IL($O
MB[/T^W(F]L8\>RNA)7Y,B:E,8<59:*DC,^IWR:@_SDE'1^_G;&#\VX:8WR=(
MMF_E,8D<<[TQ(7]HJ`-=CIX\INW<8.WS.?*MF1D09>';%BG<Y^2YB3PWV2,,
MV5IM<?'6RTV!PE`6YE+F;<B\C68<<K1&WYSR:+;)6BC)\DC]\4UN>ZWQY$L_
MK[WXTUE-[>F:.NCKAV.K5AY37'"2ZWK01SETOKV<<%V/R751.?F:VA_W57U8
M^S3UUBBQBU%9,E(D(T4R4B2-'1DC:I(6D3$B:9$T*$;43/TCHT,-,G,N+3I4
MFRDDXT,R=_^T([)E-O_!@T>7EM]_L`!3^Y+^SRP7NL9,Y6P*]!OR$-XFC2$^
MF&'DV^'RC1F2-R2P?)OV0Q>3FP?5DIL=`%4)P694]*$RAQMG08I5J9=GX;UU
MGT@04D=7A&JXO3'Z732'U5M^F@J/^!3.B'\/T`G?W;I?6+OOSZ:/*>>OE_?+
M!:'=T_F37GON1.B;SC!5)L2R01*#7U]<]5\HD6LS4+[^VPZ\GJX-O]Z]>?%;
MOZM1M9/20'BS,.SY(PEOS&#&?B236_>=_1W_8WES4D""4:6%*0>N,1YQ<*M`
ME5VQ+_"U;^.<-+SWVJ7_>0OL"FIH%8?Q9AS60.\60BY0>!L`.X/;ZVXA>7=\
M<'#QQW=O;F]`C+`NXGKN1>"!"3!JM9%4[V<Y-_?56>@^^]Z"^.'RLP-[%:""
M:"R01[X&9!HY[^TI$6'5MTOQ%_0^16'\8+OV/)H7CS'X;/PKA;D$0'MA4&*T
M^CH&YO<M&`QWP8!*[(T7A&R212J?UR'PUT-$-\![[Z/G(L2^YSBP:]S&<UH%
MG#8-G:@LE'M!)2#V=^),[KUXR[C#8B!:('1M6=$\HOK[JXNE)X\N[+F3OWL.
M%F+\;MKB9M;;5*F3K,Z?GH\[0/!IBOL5)WGFG?%DC1MO/B>^99O.1R\DP9N(
M_&&',]O]Y!(<7K=ARRBFF3;JQV3;'>?:";?)"JB%<-=36').-T;$^YE/Z)^;
MMMYB.AJC\;AY=-QDMU3#KS_L-0"_]UZ0V2$W&24-$3#=&&HC;2_2(=:UDVZ3
M+=1,$=/Z.OS3.$KVMYAIU91(KVO4A&&.!Y"4O+ZQ`\OQT*X2$=EDRS5&FOKC
M<7<XS'5P<M#;E10E3,6&28<^T(Q!'S>APU)FDPE:#>+>>&CT!]I@-X@_F/XW
M0LVYE-XBG/69E>!4:V-]*+@F>>^N>^_NG\IXK.!6#OO=YAF/_6TAI'/#;W6_
M*1&,.C5C&&.]@39/_^#F8CFM7H&0NC%HH,6S)8Y6`;^>-NB=S.`9;++<&B))
MX%:.>J/\@&Y]N_K@X*9?[9*A#<;CX5@[-&$V&8(5`>X.QB-]N"/$6\R=P1:S
MK!*<0T/O:;TRYD[22R?RX6$`-##%._L[?@I^][-:8U"?1688H#=TH95/T>MW
M@');=YT*FZ!N&,-!:2BI#OQ"`I`(:Y:$7470MA@V54QOO3<:=`=<\:Z]M"Q`
M6\)+56C5Z^,-FP%*3P86=F@ZN`F`HEE$H%GNO&GX;/ID;3FW'%M5H-E@/-`-
M\7AB,Q"[@US?[KH7R.^)&9`9;+*W\X7O/;%VNJO`#NL+?NCC?A\^I^`6`[`+
MH%L.JJK89,,>W#6N#FCAV<H:L%MVG0I4'0ZZ\/^C$@<\>P%<W_8SZ(][\,=N
M``NFXANR`%N1=06#SP[!#W#[]=SS0_L_]/O"1XNHU;AMC6'C$F-7=8%[>"+4
MN"MV1YHV&AR*"'3_B)-80,L]V*[)TU;29!5XQMP.`L]?HGF*0TS(1,2VQ/%3
M3IY,8OU^\:P9^6!.`&TWM6TUK:MK92-.:5+$+KCDD$*`DUGM\:%GP&[Y&"&<
MGZ9W,]@-@G62E`@ZU$"2VX_O,D0)*#1@D^JCD=8?K9!D%YP$TEPO%HYMH5G[
M*0K?VQ9Q`W)/_+F(=HF(076TUP[@Q]TW'+4BF`2P/X-C!>QN/I)/TR_>TG3"
M9=S!<BF"7N*`ISKH:]I.SZS7`FS:%[]U.\DAQB9@!9P^/3CV(\LC\SZ;2W9E
MUL,9;<N&6<T,`X7B8^7`2_LG)9P1A7Q?V'[2)!*_<<P@5$*/_4*4!=P!6H^F
M9"H^2]+"GX/(FBFPL4\B*U0LTYW8$_@)L\Y"Y=D,6(;BE/@^2HQ+GWR/7YD6
M?1G<`#`@$,15ENCO*B8ZP_3"J>T'6-$0N\M*8#JTWB'_I1U.UB)Z93>"?-61
ME[UW[?N8-D(-%YI`\FD*_(=Y5P%KD>H]BTM1(EI0`VMM2Q42@B*U8GHH(OX=
M&$ND8HDSIH-2<=`]&!4155%E@?J%2^E/GZ;I,[-II4*QH4"E+9:E%HM]A>UU
MU!L;_5A!502M#N9@-4ZW+DMI$]^:N251E)I(CRWFJ![38\TDVY"'"5Q3!R=4
MQFLE/&,#=.2]_80YGR$\RH9M\#H(2'XRW*C$`5GQ(X/72QK0O(%-(!#3Y=BF
M"V!?/_J$X;5AY^X)J7-EX-\/XQ)VZ0X8?Z;[7HQE/8F0AZ=%"8/T<+38FE*I
M=P]$#/$T1'2+1-*4,%KK%HPJ:3R]X4C4-=5Q77%WA5\P^S[[")$N)2SBO5F&
MTJ)7D`J_@2C&8"!$ZC;CM"/^XQ+'777@7UP*L"$@W1V/NX?&OX396@O^\?H;
M%<)T/4WK'QK_$@9G'?@+)DAYBU[7C=Z.!-BD0(3'O/V^0&_Z"YF;6%+E?YJ^
MLP/+=/`(4J12?0E.U*PJI^A*PKD/XGC__;,GHEICCE1_#U0Y9'LCAP?*(GI;
M@I;'6LD$MGT0I.?G^*1W<(.(9'V'@CLCF(%M]:!]0J;%#WO[W7(BFBCE>9-G
MVW%$S+:<+NH58LZ:-C1T73QYKP;6"E+SA6G[:`&MJZ;TR0X^>2."8*=]#^Q7
MKNW\^B+T(U+-L\O'5?D^=]S@%3SWUQ>S,%R\^OGGY^?GSK/1\?S'GW5XQ,__
M[\-[K/><FU<XLAO'=[]0?A:\]2W$*;`ZQ^/&8;,_$X+8UW?P40\3[KY$8)54
M6J)5.ZZI2U3?86G->F*#%L4IM0(*6VR."JI.&PR&>F]82I4#$.45V[M4J8F0
M[QR.VN0+=4==$8628.UF%O>Z6\R$75#0C4%7S!"HR9Q=X9KZ$ITUW=#$7+HJ
M3%.>T-O2A8[K-Y:G<WTY1",=KM]1-M<OV*@5MV0155`IO>&HUQ]D"DNV@R(>
M[CV[Q`]F]B(]#+QU[Z*'P)[8IB^<6?:T:F=\&PZ.V4&DUDF.T;<`(8(;A;A)
M3>CL/P=WJT_3["&["/&FF,*$V._)H^F\=4,[7*;)L?C4B?=Y9OISTR)1:(-W
M!X:CM5LX3>\;:;;`=N!7^W-@-S5L;D-EY@O!AFM<?+Z0$#Q0(A118SG#)Q\S
MKE<;`?2T3;OP[H3812>,AAEG;3\4Q7P!=JSQ3":OE_GLNVD;KY$9-ISD].*3
MT0T0"RC=A;03B7!(3_.U,>5F\H3<(^IO;=->7R-Z^;+<[73C_(_M4&>9G"6'
MK'8$R-$((K*;K((C(#L4]&UI^(65+7W/)_>-[0"H3X1..A5)L,F^.`8)XOSD
M77%92V:T")D$[T`=8BY0K!P)2]VX"SWK&[`0^X+`C_0;D1Z;[)<">EP_.*9O
M!_<SXIL+2@XA4-I-SJXKG-7JXY6SVMWPRCB3,4EOW>QM(O*;C*!=D*^"LV:(
M6JT8WE)(O5[B)HFGT2)ZF\RE@Z,W*(=>"OG^^DW?9&KM@G!IL1[T3J[9]!VL
MMOJ0KT&G5;2K]1V,L_?$<TU_XKVVO6`9A&1>UC`KW+Z-*J;X2LW"5WA><!T!
MM7PL7Q!QJWI>4YACRDRG;`NJO)>O`.C-YYY+Y9/EF0HFN`CF)N.)/XO:-<@&
M](SMTY2I;N&H[8[XV#$NJQ4J<&&,JCX:@]L@1%@V(;$;NB62<TJB>[,_ND,#
M4]AW03?[[HT8ETC..=H"]_5QIH)B(Q([8URF*^*QUICNH3NB_(9?BT51Q`U6
M\]JP7/46;GNR)Y'I"+R#96K^$YF\\_QW$9;SQ>:72*02R3A8RO#1G)-$]]X_
M>_<S+PH`6/JB3[13)5XF_/+.B_PX[1W5*.P0*U?<SVP_),3-N0H,0D`IL@@K
MI#$W)_,4$7VHC?2QWA=][9HI*6QW>(0:8)65Z/@)STBVE:\+;\5PNO%@A_6#
M[&F(7K4;9.'&-DY:?]4"HX`S3S1C"XC/L5DS.^K7?\7L@"092\#,*)'H(S0A
M70K9ZL'KI?A+PI'Q0*'D=;B4[VW7\AP7KOS&=\IWD3MY;P.49))D>2(OF.YR
M4SQCL*'G4[PG5Z7'FL4H7!Y?`ZMD>Z(Q891($3HAY7)3+LN@*+9L-(/9&]]\
M=M%??&=:*W4C/:-,E\PS89X,[^0BGMT([DQL@4S%\3,.S@+BT:U#),^V2D?P
MZC>6-*4`IKMU1ZR'*P*B.JCUF9R%^_,NZ&J9G;HDNO@[J^!Z$_FP@S.^9AO[
M1_),?Q)=/&-;Q2)&7TIA$(-M=(?:8"@<#I>#:5\\ZC,K-RYB-5KTLM96%4KP
M#JWQ9E?(O-L/"W>4LTT`E(D8"MNY"._V_M@%--Y:H+,UUB=`)!Y7/(*Z?03.
MH!A^<I/K?29R;,L04=C6>&`7%'H9'5P.ICU%9EO?[%Y7UXWX0Z\,NP\,O;\S
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MN`7UX@.F"FB6"%4=P!))]*4VT+<JAEKPK,L6K6I8)%(^UO1N[QB8UF5;5K03
M$D1[AGX4/.LR%2ON^ODAN,.A69?95VT+3_9MHV?TCJ*(ZC+BJN[(B8_8/]*"
MUF635=U?A<R%X>@H$KKOZ6":5J(/AB.M*LB\#RK6`&.3:WN:V@<"E&4Z6%??
MZ->[6?Q+ZW[0>V^2]JQY8%6"NRX#);-SK\&M_4O_H.DU@EV;P9'=B-?;RM1+
M[;KLA^RNFD/NP8?Z@*[-%,ALD3F\72?0=>WKF0TO3QX_#&KDC]JVZ>SVE7-<
M72>MZ]IT5_:B7:&.]3OM!OPV:3:(XV8U$>PR"4&\Q^E=]/`GL<)[[Y-__63:
M#O:%?.?YGQ:TDQ9`@:\2FN[["P]^('\GYN2OR/1#X@>W[F<S,"?$-8LQA$_C
MJ^[HRA!VJ3PL<O"\=B=?,,_%X:T`1$1+A"F.BVC)3B094RH7RX)NG+>NY>/E
MM^ZUZT:FP^[!:90"639VS#XU62IT\RQ&MI(X;.S+O1<YXB;R<:K'K;NU$2L3
M!/U*']4I"!N[>1\9Q?+M-<N+`)URG?E1#,EM;0V^`X`\V;/H[=GE^1HB;3#_
M`7@S`]F6VO6=(,N2+OMN46V82]I!C>:L\?PG2F<1OK(3P&+F66O-Q,IS<:[.
MVGOV[->EC=,5*,0E4XX3:XL/@-',6=*UFM!Q&&\B<N\5KU*UB?"EYWJEY3:5
M(!-PBJ5.;$*.C)BC`;;.8=VE8]PH16(+*+L!O?/$]TWE^L:!@=XZ/*-Z;S:6
MBG!`H+>UMMZEH1K<6A'HE:(7IB58-C;O_1D+^I86:KV-_:$K]A4;:ETQQ+X;
M;%41!+F_B7P_FU6]L5]S51MSU-/7ZXQ*0;0#+K=8%$`G;8GHU-?G;B=T4J!V
MPRB9'B;B5%]#NUUQ2L#:"2L,L*PA55\;NQV12J#:`2>LER2LW[V`4GU-Z\9]
M;5A)061@JHI0/&`"C`8GFF#?B/@7$;OZIJ[#I9G0\1X`5D4UVQC](PE7?A<1
MKJ]!CM;5^[K8^V!_0+.(9SVI'?>WJF<#FZPXG("9HKLS>-6QS-WD-O8(KKAU
MC[H#?5`-M:)MKN2]N1O=QK:_%5$:#[5Q=92*MKKRM^=M=AO;^5;#:Z`9XU%%
M+MRXW95^0-Z&5V,'WH$QRHR4JP[73GCE;GHU=MOM&?IHH%5&JVC?*WF[B$N-
M-LEX/`256AF9PK)TOF.P7/PR);H;6^C&\;D-);K!2HWN+ID*H^SY?55L:B1&
M5>.E.#L*;LNON3\Z3GO68`<%I=:[M2(`+Z4A2UWF@&836>+Z\GV)DM0(U404
M>O%K4!Y%=>BOE^DE7*5</YO^A,FPV"B`C9!+B=;?V!#X),JB=FR/2,PRAS]'
M$DPP%09]O1UD+7/@=`S!'AJ#D>B=-YRFK`\&N,RTF&]EQFU_8Y/F6IBU?$^E
MF,`UJH$<Y(]*W1+I/OOP;'7:#@?]6O5L(8%93\M=G[[:QD6DZ?8:^(HTT0;"
MR5EM(!]1,VX)/*YU12XDQ%CKPEUM46W;1FT4MD#?T$QMK`T&9Z2>TA2/Y"TB
MA6J;U<$I5,_8A(UUZ(*E&<251AF<MK4(K[SJ@\QF7QFVX^F!K8W&RV)L]+2Q
M/FJ+B;.QF_E.&\;8Z!YG$SV.&MC8Y7RW';4WZHNAO`/`7Z/*V-CA?"?\C>%0
MT\HVU3FUUJ@:P2WVX'5CH)V/L\EIC<F(ZT2I&@HN-AD,71O5J"O6H#X8I_Q!
M,(6<3*Z?B&\^DDQ9KTBJJM:G7A`U3S?<CG:82-`FC"J2,:BDTLN2<F>+=2M-
M=9KO?`+T:J9KSDY0EK@'&$Q7L]V[/W$8ZI5)L[/-O)7OC,ZX3KZKA.&I->/&
M;O0[4;/7&8PN4C-N[&U?H?@CKZ-%K].MXNJT4#5N[*2_'W7[G5$5CJT9QX;H
MUVW=_/>@[Z"CUTO?<]*O53V7$M0\T,'.\<@H^`=ER5C5URDC](?Q>"J2\6'[
M2Q\JKUU2+7L#-/--*XQ,YY[X<UTD:;7RGM\^C_YE?-!&;U:(=ESXZR5@\:H5
M`:")!*PV5?.WS\.Z";@#_`?3A[?P'O`:;(NF`XMDJB]'V>CJ0^R`>Q#UET7@
M8(R6?4V&G^I,;AX,!L.U.-=!,%B92>LXGH6-Z/-79JT$J[]Q9,*N%7K=(5PL
ML$DYJ/;%9&?[?T..IC8:#/K&L3'99FOO4,MG#(S^^.B(;!OOO4-]GZ9IO<Q,
MHRJ8['=\G^N]O3-M?U7G;AQ`L*M0:4.A&O-`.!R72CMG:113::2/^X-V46GK
ML/,="GN[XYZ.S=';0Z7R8?$*$C<>]D>C8U"I9C\H]<WOO=!T"FW#;;,;=M%3
MQE`SC!KS@\J@=%HB;I\>49V(@R[\7ZVGXPVGXK;9%;NHN?H##`VFWQ;K=Q<%
M>)[T2U3K=1!$\R0F3"PP$=_@!#[B3KZ`O2@2KZ;@=M(WJ@[*E<7CA&3;V;QO
M-]F^V,&W=SXA<4TZOH[7\8G4V[D+DY%//:V.<[^*^)R>BEN<B&(>+*!B=]A^
M*K)ADB(5=^XU54!%O8XSDHKXG)Z*.SLA11)=)2^B^52,U?`_/<>DO<66JQO*
MSIVW\C>4P?C`&TH6DY.2KGQ^SIF0;I=H^:87KIX?E1F9\@5?*#86Y`I[0]/<
MP;^,#S7$_;=B<@J*E1D2O$8QIE8V4&S\K]$';5S'N5PCB59FK/!6-EL1W]\^
M]VEOYG92K$2]Z78V6Z/8"06SMK#ARC$S_1$;\^:%1#>.E-DOHVC4&=>8PU\1
MQ<;0=V?/8WN^84<_6`7AL>@;%WP'H1_1M#+:K_A^9KH<K(\XB3@`2-8J*\I,
MSZ'ON%\N,DK@"SS/MU$2:<',5R!R\.7NZRZ=.;"):!WAB*ID:`#UA^63X/=:
MC$.7B!Z,=EF!$DE7HM_.CK2J7%]V/`[.DN-8B_!/RKUYBS`^%O^NK,GY,?([
MSY\2.Y^,.&%)DK&:+JUB/N`DJ!.IV9,5)]6D8BJ1N83[5;=*+E-/TJ_CB+QN
MNIU&=U=:3N/T6NG\Q(?K^0A@K43LGB3VL7:#$B-/:G)YFJ.=RE-JSSS4,G/>
M=J5N]0RI\6#4[1\[.[K,T+BZ]\$-J77]H3;0CDZ#P[EG^V4G'0?[$EU/=\-^
MS]RB7;!_.U\XWI*0.^(_V1;)OS/1+Q2M@*8<B;_C7*./7O@O`@!:WJ-K_X>C
MR/630+PRP^MV(%YRD8/X?S;]<'D/RB\P+0K`ZZ7X2]+]#W2O]SPCYF2#EM_0
MRUT?PT()\=NCT/)(R\>S:SV??X77B6<+9:;NG7(="T;+GH9N)Q:Y,@=GQQ0<
M#1LA#;3QA4I.F5.Y^OG?B"=9-T$$;LQ@=NU.\#]HW#Z9#IJUB97ZQ@XLQPO`
MS1+I5J*_:_*$U\ODX]]ML(5]:[9\3YZ((ZJBY));=Q&%`?U=RRHBX8$?B(D0
MH0'^SB=_1<2UEKE/$RX,@`21CTW(=A,48V3TQD-#R%XJ3;D:"%["E6H+?=X`
MSSZ9V/273;P$OK=61]OT<9!D13=^?X8TCL60^32N)TA0CKS5S\O.G1KO;?.!
MSP85"5'"O3HCQBHWIDP;#46+()=&%<E8PD\[/ZQ?1X'MDB"`7?C!=ODF[.*T
M&X`'/@7VA+"N/?$CE@)--@X*;2=K:?UQ7Q\*6\0.%*QU"4IX3FVCV"[FQ\9I
MJ6=D[ZUUGMM`^+&F]>"?DYA[&\>YMHL\I<R14?5#FW/0G)M.L8]I[>%0VM-;
M>T>E1KZ9LG&4[?DQ5CF[9SPP!D:MUM[&F;EGB_6>ID9+'(DJ>T33K+W3."$G
MH1AM[P'*'K?CS'4`(`$NG]RZ=[!#?YJF,Z;OH@>XS#;]Y6O/G8CRO'&.\&YA
MTJ^N/5G.;UTKI9/6U5B85,.0J4BPJWYQ,RL<893TQMD+X54=]Q"FQ_PW&'OU
M0_O!(>QC`$^F[1?%</+&X<1UTBE+GM5LV?PVZ%U1V97$+4N2/(;_PPYG7UWO
M`4<YLD9NJ(LPVNQ:P([Q"C"9>&T&=D#MD-54D8WCC]=%DS[CQC&#0!3(5(>_
M`UF!]V,SAB11@]D_P@%O>;$$)H/_3^E7-R$.1N;/$>P<9I#9G,?5L\WJIGR9
M%O,U67PU$O-WTW;?>T$`PNA$$U0H;TT?^V$&&1U0[6CD$/0LP])7!^3I#80Z
MV.+<D3!TV!8L+L9>CLT%\_J:?M[KN*4.0IX7_7(5[UYG*K70L$Q*:O.(65+Q
M5IAS(LF[7756KSB2Y,Q1G8-N]9JCF@EY0/I1K^L/TV<E&730V[UW;?T5V3XX
M$\G<=Y$<)7PDBN^G*7_N)_\+9E+GS0F^)V[\\EU&K^OC06_,7<?M2.R,<0G?
MIC3&P?TS<9[('EB/-;W?,PZ/=8DCC/+KS,=![X'VR##Z1K<BVLG91AZ@0I]W
M$>\2]O^1^%OO&;IX0+,%B=U1+I&<=$0&UP=]36PS>CB\2YP6')/%]=Y`-W;%
MNYX=,(E"%MML(@&K3;LHEPF.A2CBN>31$"N@YY8.92(YJAT1)""EYD$9]5%,
MU%Y!\T"QIJ4L6OL3HUJP?D=B%(=.BH@A)CC61PRQV8Y`A(V3K0_%$:OY^=O@
MW1V[:MDW]2SQ;Y_UU>SK^A#,[RD[P$'3N[L`-<GY*C?7[#A5H,9>`>B:!/WX
MU"CJ<CC8.(CZ"&I_>Z_$75L>[D:.:JGNM2O^XY)CRRZX<<CT+L0H-*^KFP7B
M@,NCF04;1T772I#*IH%F;.&1>DV#NHW%LIR!Y4O',0_JM@#++O5OGWM'-Q'T
MO:*$-<I]8\P$O7HOH<,(?H-,A8T#BX^T'33,7-@X8_A(&T*C3(:-TX%WLI\*
M(U/_?WG7^](X$$3_))O&W4W@.#A$P0^BW/G%C]6+M%"H;&WUSS?))5X:DV%F
M]F?BMX*HG9>=V;?[)O,FPAE`HU^[B$1.&D!_7J=KHV(-ZD8ZV5+[0=JFB.C'
M71&'GAVO>^)@)'O;S/YXF(.1=&TS_2.B#J`GKJ]M(3+N`+KK^MH8/&!"5#[V
M(])'O[,!M/1MX?O:G]!M9&B`8G7EEKM9D@MSH0<,UZE(5LO/74$,]!;F(LKH
M#ETF(LV2H25H,_#P`B3H:>P1;[&04N1#,EL@T=+.OQWL+).@1;)'T%,ESK/%
MT('$>O2>ZS*&Y1,!IKU;EZA<S:LP,WIWJ0A/KMV16&LQ%]:&F$VR0<1IK<7<
MH?L`765YGBWG5VM!BV<FP!1/[1+45%@@:N%J+:IX@$[0S1>C#NI[W*[T9G^_
M+O3JI3B\;IY01UC@692[7C@*5_>U5C=*M\^7[T_K:HYUW?!W@J*#Z9,$%'_>
MJ8>F`7?HBW;B./G!X/NIORNLKG;Z:J/WKP_%2G?#=##5D;=81BRA98,"(TP6
M2/=ONSY$B(-/4(C.R1`U0?(`6NNBZ$.$.*8$A2BE0]2&R4NUW4'W,4*<-()B
MM*1G6A,ELQH=ORPCA!H1%**$48R._57TSW"M5]%_Z>+/;ONW"P;B#.`'C+$>
M>JFJ@1+M.`D@*F-5$C0W1E\^GVZADY-F,7[%?!`B5V,QUL/65H"WMBV,-["U
M1QI"<14N^I>Q>1R-R"J,1O(9)G)$NBKHF.NPC$<FI6+L;5T4\NFJI\)*F\HH
M8H2A8XM4S4M&%2YZ8ABU:1;W]L(I3V7-+A+90GZ/^WN&8>V\5S*VNDJWW)J@
MAHK!S6BZQ56Z>)F107^C69(FQ55:Z5ZGL\=850R_Q=7G$68**QE=7)V>>2B+
M5:;2P@Q#0G4UFD`L0<]6(FM7J5QV$M5L4O#`;[<C[.I)L"-_ZA/P;HR$5IG_
M(3L;3H7'I;'Y/:D0A(-$F%@^G\#M\T6=3==CX77#@B@]<1F6GZ1H91:C+V@S
MT4!K4QJ!LSR3VV*F*<(;DA[&P!EEFB*PRC"QL#)-$>Z*_7`#P[R"^@9H>[>E
MO/IQ]OZHM^6'#U!+`P04````"``I@`Q%T:>6C@<.``!9VP``%0`<`&%R=W(M
M,C`Q-#`V,S!?8V%L+GAM;%54"0`#C7+J4XURZE-U>`L``00E#@``!#D!``#M
M76UOVS@2_G[`_0>=%SCLXN"W)$V;H+F%8R>%@:0.G+2W]ZE@)-HF*HD^2DKL
M_?5'RB^2';V0E"B9SA8%FCK6<)Z';S/#&?'S[PO'-EX@\1!VKQK=5J=A0-?$
M%G*G5XW`:P+/1*CQ^[___K?/_V@VC?%X8/1,'[W``?),&WL!@;\^WO]F_'$]
MOC/ND/OS&7C0&&`S<*#K&TUCYOOSRW;[]?6U-4$N<$T$[!8A5LO$3MMH-C>2
M^P0"GRIA#(`/C?#/I7'2Z9XU.Y^:W9.G[H?+#Q>79]U6MWMV<G[VX5^=SF6G
M$Q/P?07"B/VY-+JMBU:G=1K[V@,P?X(I-(:#V-=NSWJ]WD7G[./UQ:![_O'Z
MIC/H=WN?+CZ>G_;[_>M>LT/_?/IX<=;Y2'_LGG7.XYKC^9*@Z<PW?C5_"U4V
MQBWV=X!=%]HV7!K_-!ZQZ]%O.G/@+EM&S[:-,7O$,\;0@^0%6JVU1'O#(>T8
MU[MJQ/A;/!.[A<FT?=+IG+8W7VRLOGFY\-#.MU]/-]_MMO^XOWLT9]`!3>1Z
M/NV$Z"DF)NFY[L7%13O\+?VJARZ]\/D[;(:]Q*&7D?H-]K_FYFM-]A'MX.9I
MM[7PK`;EP#`^$VS#,9P8H0*7_G(.KQH><N8V4SS\;$;@Y*H!R"MIGH0]<MIA
MS__R!.FWZ!"Z"S5G<KZ-ASOJ`D+PZPP"BU#J`3%GX5#<"&FS1]J[4MJ[2DD(
M]<$"N]A9KJ0_^E0TFQ]].BJPC2SZ7^L:V*QC'F<0^EX>RC$5\X-?S"Z!:S@F
ML,W`#KN3P=SY*ESXT+6@M1'`U%:*-U2)*F5C<P?ZNLEP`$V`]QR.(KHN30&8
ML^9.V]#VO<TGC*339J>['DR_K#_^<0_(3^B#9QL^0C,@R$?0ZP>$4)5V*;+9
M^,9D\Z$-GJ$=KH/Y8MIJ(8S\&20]SZ-D26B>]+1BA1\(G`-DW2SFT/6@A,XI
M`A2KW3--'+B^-X8F1"^LK[]"7T+[;#F*0?2!-^NY%OOGYG\!;=ZFK7H]OT^G
M[9)N[=^!'4`1-)P"JYL#]]3\H'LK<"$.O*_8-0O-B51IB@$E+2AR8/(D*08R
M=*E5,46T^16A=*S?+$P[8';D%XRM5V3;(G#XY"E?P?`<$G_Y0`>&3T<_&_ES
MMHU1;<06LBPYJM<SV2VCVMUBU9JX?M6L.7<(/"-;UFQ(%:%8]:_8A]X#6+)5
M04+MQ,>5;UQSY`/[#E+/8/1LHVEHGLJ0GB=),9`!)'279(YRK.-%]$\1H%SM
M":0$66/X`MU`9M2D25"L^`UU;?`24O^,N6U6L0G+(4R]%4J"HC`RA%1D1,LO
M/FD2*E[M"UB6*5+J64#E<'`(4PSG#KO3)TB<^%XD@B#Y><5*CZDACEQHW0#B
M4GO5HV,Y<()P*:&K(S*14"?P2%,]G2T+L9X']@-UR(?N>ESTL>-@]]''YD^A
MJ<TA3?4LB=H2=X7?/*L^D++:4N7T37Q<M5^+7$Q]T"5UXR"!GI@G^^99Q<J&
MO,RP;4'B,=?,7XJHF_1TY0H/W;5O_(`)FUH]WR?H.0CC`4^8K=?8]0FVJ2I3
MF3XIJT75NT71C;N>/;N8E5>#>1=KLN=:Q>9/OJPMF-B!18^8.VT`8F[DTQ_?
MG%;LGC^MO]'V`L<)I361#YW-\Q."'1'UUFK@[![!A#YSU>AV.MU.J]-I&'."
MPF7NJG'2,`*/ZHOGJUVQ8;Q"=C88'L=V],8?GT41!2='3T%9"V;$V:E6G)6\
M164R&V?I["^64HRHB*,/FG.4A#?1R(T@GQ\AY+=^2(3WXQ'BY7$;(P8^'2$#
M/)&`B($+K1C(-MUQ7D1G"YL"/TK8'*&XB`-M3<QL#K+"JA%X;8W+?=\OOO:E
M1,,CU'J9A]RHT\XO(N!Z67Q\P#G.GR("]#+G^`A(.T2,4.MET?&B3CSRC4#K
M9=;Q@<X[IX_0ZV72\:%/S+&((&MKPV5`3LV&V<(^T<N&VTM=PON_20"HEX&6
M#C`[LRW"JY=-EHZ7+RTQPJV759:..R^[-$*LESF6CI@G.3A"K9<-EIP2NK,G
M<V5[1_CULL9R\6?G[D>P];+'<F&G%%Q$>/6RP'+Q)A7%1&#ULKURP6;6+FU1
MGTJ:7I_;>]5D553,;3_T1I,1M4-6GL,&O'CI7+:\0ZRA2]$X[?3_+1GLDQ]#
MATY[PL2,)OL6#L]1/H<0Y6G+<P)-%,*G/]LPG'NNU7/8,=J?X><B20E\\E2G
M^<P`@=?4+;98W3!=DH5AI$E0GO^X&LZ4L`%\@38.78+UMB*6^I@I2#&,+]"E
M,\IFW6XYR$6>3\+@C`207%&J$W;`,R:T]75`40)!F@35^=BK1<V=KAL4*J%(
M>%CYR`_CE4):1L]4D=M._1>\H67HTOU&9CCG25(,Y)M+(+#1G]#Z`I![ASUO
MY$:Q4R'R<T6IKYL,\S-V"!0L+TR7H7J!W%+V2#W$T60G&K0-!0FMDYP2E?<*
M8Y(I<DN-[-6!_#WT9]@:NG14^*'%)=9%7`*5UP.6,/?KF_:CW689FU*[0?SQ
M2@;2$UBL.;JF=L!$K/PC542E<X`Z'92Z@+(7N1G7<(()W.H'O9L%-6NH*XE<
M0)9#ZIAXQ3//E:I1*87LA4DK]:$5:4_7Z=&$JBW/29[<VL>)ZN($51JH7HVA
M'VE>-B<2PM6_3($N6Z*+=ORI*OM#FNN:PX#)('`RH;K6).2"E!C]4L4)S0,@
M(V%>8?5KHZYU"2)LY6VLNE8=*-ZQA49?`>--UX*&JNE/<!VD"B,.8;&KPBG!
M.2ZCKE46%7.7$2?0M4HC/WZ2NO:EAGQTK=<0XH(WK*=K%8?@P$@+U^I:P"$$
M/S?BKFLEAQ`+>2<HNA9V9,5H=RK9-F=>NA9R<`)-.(*4JMPX!.,K_2PV7IZ7
M<DZL:^4&%^C<XWU=2SBXT.=D:>A:P,&%/2W#1M<2#B[0?-E1NI9S9%+`D>I6
MN,JC]EQ*EO=]:^/7DE(IWX@[]$S*2&'E1V>$E;T-X.K?H1N:A=L!*/GF6"&Q
MZD\']W1Y6]1;#%N2O#I`Q>NS"R/:%58YG-WQ(OYJ;EZ)E0/;K7`H!FE?5CV]
M%)6HE-%#.](J!U0:EBIAO+-C_'#J1@90G]J_4['N2I-0<;+BYGU;4OE\',)4
M]T/,UAY-!O#9#X\KZ;Y!UR4'!8Y0E^0+^ZN`XQT5<!Q1@O71YB@G9B=P)##L
M'?()3:JRFM0MDTM91IP)H17RQH8279[N@<]*,Y>C25*YIF#BG*APU7#!,MP:
MGW#/I+.$P,(0^016W(M["T+\I1A%^B]3;-4]5PY"`:FI`%,J6N/LW2P@,9%'
M&?P/(`2P%QFLW^([FB<4^&:4N`I*K7#@#3TO8)=ICDC<'I4=;VG2E!?/S==#
M8C39O.4QY>U0(LB$Q%9P+R-E^@59T+I>?J-VW="]7=V*[$[#>Y7#12LY\U`$
M=,&&:J!AY3Q50(-`0S70$,7(%-,@T)!Z<RU)P>*P!077`S-A5B;EYI6`F[NE
M>HA(F)>*B.!NJ1XB$F:F(B*X6ZI@(7S[OJD'2!#+EMR-[HJN>_QR:SUUEJ(`
ME]?#NM8"*>*->XG0]5(31;QQ[S&Z%A`IXBW-)M&UQDC.IL.EF:RZ%@<IX4W`
MX]'URA0EO`DXS+H6!97DE&#)<(M4)=`AY$*7SQM/`$[;8J'2V)*)PVI;552.
MGXSE0NY2Q4@'/#6+T"9R%J-M^9+ZT99\/B=5ZO0^!AK'H:VN]5,EQ;[27OJA
M[P4YY1-36MJ&5`W7`<_4`IR*5S0+^`7'29E`X>]Q.`,%N#JVLC(%B]I1UZ"5
MSQ='BJ^NUQ.I7]T3TKNE[C8ZSL4J+:%?UVN0%)NF@B]8T^Q&I?+)RRGOD;J$
MZ3@G(D]1E]2=3>^%KOV2/JF;GMX+6<DEG5*71;T7RMY4]NIZVU1%9+TI["Y\
M3]41\Y51Y!_1=J"OI&"^B(V]@(6;MD;V(R.6+$>3QQGU7:AOMSE.C'UG`'V`
M[`U!F>^I**F-FE]>412%VD2^O'M"X[QDI^[E25*<D9AY6UXQ%/T:(135O>9E
M-!.2\%V'YWJYI47`)]Y:>R[I65:W&6S7M4UX/7[4*K7T"T@\F(6>1V?%U\<Q
M"V.&;6OHS*D)LWI/TA<B6%V;)45Y@GF8@,0.'UA`/?`A><03_Q40*`PC7Y9H
MM>+F!7I"991I3RIF\C8@+O+IJ*2#\!8MV$_B(R%#B.K79IAFX`3AJREY3A!*
M*70MKTWU%:7)+0MW<)ZDNH`(WJR7+:?NBRSR(6+^'M&U_D.4A_(FH\XWQO!,
M<\RU7NM:Q\%/0MI&JVMIAGCWYUL\NI9;B'.19<06+IZHSK,*87BW`9O*]\A%
M3N"$'VUR-K]11X;$^GWU?2F7JXRF#L87*P2F$A\G0<.-<K&;)^S`8@'HS6\D
M_!_)=JIQ]#*4&P3P:4;5`Q.J9+FX]T0?`M2A>XL#\E\ZPDONXWW9AP'VB;8)
M5:&-"S\0N*]8&=BMZ$.`*A%Z%Y-;.\@Q=`!BF\=H<DMW&V`S]LO%F])$[=`?
MV!;L^M^!'<#1A/IM>[\OEX7\UFJN+R^-KK<6O/C@T#4L4!>-\35%WU=#U,9=
M?-_1-;)0+WTQ&T77`$6M!,9,6EV#&C7R%W=_='V51%WT97G-4J^7:!YP:"G*
M4U,<6,IL2*^P4C(4M=;[7IOE1E0DA"MV5C@UDHRJR$@_%,!RD14I\0<#62*Z
M(B'\,.!*1%A$)1\`T,)1E@*-'`!\VAL*.OA0[FOD!)YT.^_["8PH9NL8XA_J
M*3J&,$<E+!U!-*,*GHX@:*&>IE)C$TGN].<V4^V9ZD#_\W]02P,$%`````@`
M*8`,1:YV+,)B1```!5@%`!4`'`!A<G=R+3(P,30P-C,P7V1E9BYX;6Q55`D`
M`XURZE.-<NI3=7@+``$$)0X```0Y`0``[7UK;^0XDN#W`_8_^&J!PRX.566[
M7*_&]"[2KV[C7)6&[>K>^=20):934TK1HX?MG%]_I)0I*C/U8%`B%5)J<+==
M5;:"$<%@,!C/O_WWZ\([>"9!Z%+_US='[P[?'!#?IH[K/_[Z)@[?6J'MNF_^
M^[_^[7_][7^_?7MP>WM^,+$C]YF<NZ'MT3`.R'_<??O/@_\YO;T^N';]GP]6
M2`[.J1TOB!\=O#V81]'3+^_?O[R\O)NYON7;KN6]"P+GG4T7[P_>OEU#/@N(
M%3$D#LZMB!PD__OEX/CPZ.3MX9>W1\?W1Q]_^?CUEY.C=T=')\>?3C[^W\/#
M7PX/<P#^2(DXR/WOEX.C=U_?';[[D/NU&\O^:3V2@ZOSW*]=GDPFDZ^')Y]/
MOYX???I\>G%X?G8T^?+U\Z</9V=GIY.WA^Q_7SY_/3G\S/YX='+X*8\Y?5H&
M[N,\.O@/^S\3E`]NW_'_=TY]GW@>61[\GX,[ZH?L-Q=/EK]\=S#QO(-;_DEX
M<$M"$CP3Y]T*HK?F(=L8/_SU38Y_KP^!]XX&C^^/#P\_O%__XIOT-W]Y#=V-
MWW[YL/[=H_?_\^WZSIZ3A?76]<.(;8+XBH,I^N[HZ]>O[Y.?9K_*EG>B['?S
MV'Q\G_Z0_6KH_A(F2UU3.]E0"1(.2G^#_^WM^M?>\G]BLO#VP]&[U]!YP]AU
M</`W*[`#ZI%;,CM(T/TE6CZ17]^$[N+)XV0F_S8/R*P4D37V'/Y'#OG?+<][
M<[`"_./V:I=FUX_>.^[B_>IWWB<?O->'$%N+^%R\WSID9L5>!$.OX',SR-*%
MY?K*N*Z^UHEJLL3;!5D\D`"(Y^:G&I&<,Q"!'3^0MQEO8*@6`E@A+(NM%;P$
M;X\3W??A,$'KGK#?8LKZ.M$1V\APLJP@H"]S8CD!4W(,F7FB]-=`WB>X;4+9
M0DH!:&2]4I\NEBGT]46T_N_$=R[\R(V65_Z,!HM$0=71><L`_04!M,G$%4GL
MX+F^RW^-4[KQF^0U(KY#G/7W''/-)"<X,:P\:A?)9"))(;'?/=+G]PYQ^5H?
M^!\X9SZ\/3Q:J>!_9__T5PJ=W6T+ZM]%U/YY-[<8HM,XXE<-MR0V&>/QBX$&
MZW_TK`?B_?I&%M+[]E&_=#T2G#$9?*3!$H;KUJ>M(G<6!P';OTMF:%G>W]F^
M7_@.-XYD,2S_7@,/S]A*@>5=,3E^_7\$R,6=CS4@>$L>W9"MXD??K84T#XN_
M;16]^\#BDGVW7#Q03Q:OK8]:16BM.%+!N2&!2YU+]F^A+'(5`#0BRB6\`9JY
MS[4@F;(!>(1+/FX5P0E;P$GXX%G2FGKK(RT<NV<X0!F5?J-!?9RO;%&(VDB_
M^>L8&4(MHW--'BTOA3]Y=:5/W\YGI4CM6F3\7Z0LLGOKP9.2(2A$'<@RNY!<
M160AQ4(5J!G2PA:=!/;&8LRX7"^T>CQ(OGW3;V8!7:CAMD*"PK>"!@X)?GUS
MQ%Y+A^\.#]\</#%=&;!?_?4-.WEQR"B@3_SW+8YF\K3ZQ:9^Q*SN"X]PX,Q6
M)X_\#^+G'@V)\^N;*(B)-KX5OLJ4^+@IYK3D@`E&?:IGE"::"QP1>8JK]`DM
M5JV"JL\8J-K0RDI$(2%IT[O1WO'>O:T%N5^'2>Z6L931>R2AL/I(;XG5FM%]
M?#1LNG<>%(+R@1_H@A=?1ON'#\.D?>LI+N@=J#8K=HED9)\,5*F5>*HRNC\.
M5*F5>Q$%Z0/5:H4NWHSJ3P/59S).>,$$:27WM_>;$9"6`SUW$=LA3NL9]4/J
MN0[[JW-J>3S6?3<G),KHK`SSR(/I-L@C@:>,CV=FA0^)A,7AVT?+>DH=/<2+
MPO6_;'M\5O_\U[5K/;@>(Y6$3+H2.9E3CTE%>/'/F`F"C`]#'I:4PTJ=F-TE
MKWS;B[FLW]`@.;51%+@/<<0?VO?T._6Y!X'M!$/E\<J/"-NS"$)R6RMJ9LPW
MUT^.M0J)N]\:W\5F.Z(=X5L2,35.G`LK\-FNAA.;J>N8!\.=<Z9(;!?$;QEH
MF@F:.(Z;:OT;RW6N_#/KR8TL+W>70`B2@::9H-Q:?UA>+.5*+O]6,[(W#!9A
MQIJCAF_AY\:/[.2!ORKLALI40.G%S=$.T<U6-G"2W(A;+/R.9U9+Q+`@OLWN
M?.BA*@6CF82<F<*9F;Z+%.V</`#-:$^C.0D:XUX%1;?HI'K_FE@AF3YX[F/R
M?E&D0P*8;C&B_N,]"1;?:43"&VLI&Z*L_KX+V5=16S6`S)%QUNC\GG5T>!6P
M+@6A&?6\?"J@7?AY-YI&`?LZ2)H).2>!^VSQ,HW<QD/P+P&@'>W4`KTES\2/
M5:2F#()FQ"\63QY=$G)+DO=6LP,K`4SW.\ZV@[@I&15`]*-/8V8AJBN?,@C&
MKZ>&5^P.%',$%'KR&I)3`U.W6(7ACO^W1HQ67Y@P$M*UOKFA33S/\@F-FUCZ
M-=!TNQVMX"=)WJUWA*W9X-E2!TDS(>R9;?F/+EL^9>AW$EV\KE[IOU'JO+B>
M5,HW#)YV/Q-](D&TO&&"D826V#%\XD]RA@W,X50%Q\AA5KD:-C_LX"0H(%T)
MQIQV4GV]F.7Y34">+->Y>'TB?JAB/90`,&3UW!*;,-N=[34[1PULGV(XVE]@
MX9P[]MA_N#IXMKS$U1>=64&P9$H.[H67`VA2VZ@8024`C*"MCB\0T;$`0F^H
M8I4R(%T44?:E*42O(04155^;*GR0H("6LU5D#@ZMD*%&!&L+%CZ@*%AH-;7_
M`\J<.9@`;RMYY*FO-;?:#F$[MZW(<46]>=7&!@7;1B+/$V5J+YCL:@,7>7XG
MF-J2QXA"!B=J,HO>B1F-GX=Q7BM?\1FQ7P9R2DOV\FL/CF7U>:SR>JW)/#I$
M64X@3Z:<IU*0VP,M!#V:>3]S1NA1#U21I)XMC0YDQ![W0!75ZZ`<03AKV&!6
MNWP\+2/[!+4R`@<=BYE1:NX?G:!63A)!XP+C=SNRG1&+LYA+F=BR%(2,WD^H
M=12,7HG,D8SNSZA5&8SNLJR?C-@O?5%@4L06IF8)6@>DK>K2Z#*BOPY(:Q5F
M/JXI/9;I<M,72DM34S-JCP:DI2H)Q=D3HV43JRCC6W"@+WJK(@$^3W9AFGY&
M+6[_/YA:B;**C/23OIQI.=*K*F,RFG%VAU`7[CIR^W*6P=JLL@`MH_\3ZM,M
M&YYNM\`P8\YGU!:,IHK.2L86,.D+:B4).S.%E<49I5]1JT:X=MBL^19DHE:)
M,#)E*O/7A'_`V<10C7"9'@L9X3C;^ZD17M0=(R/TN&>ZJFV%OMOI)&/-AYXI
M-_UWG5J?&\%0Y&JTC0A,CESY3*/.^VO=6/P1,">1:UM97F3#9EN%,+%WWMI$
MVEB#&J6I*W)PS'7921>_"L-8[)<2_FL0IE&?Q-&<G=1_-40_#\8<"4QRIT$B
MX$YBOMZ0($%'D91R<$8[(34Z&+6@.B`%?CRJH'1`@-HAJ8-DE)`VCHHLQ+%X
M9@>CL7AF+)XI+IX9W!20IL4S.*9][,%<#)@`RRI_Y-,QFA"]>X6+T1B#V^%-
MHTM,A$#N)%0EM+A=^!#R9Z4>.*)4#+D#$$AQQ9'%G26K2.G.><6='JM(94EO
M?VG5U(7O,?O'<#J;,A,J33A1]SM6PT/H<RQ!6._SXD_B/L[9XI-GMN`C^1YS
M69S.$C'*2=&I%;KVQ'?.72^.8*]\U14TOZNJT,J?'Y5F&7#8NML9KL*;Z_NL
MP7;6@M+=A91$5SX[6N2:AJ"G\-:')M%L>]B$`G#]+<1F;@3=DOQ7VANWK?EU
MR2[8<S>TDTPO9@L(5<O8.IW=6Z\0$F!PC1*9YK+%3`P$*KK'H.C"P`CCV!:M
MJNI/B<],`07*"T!TON>G9$8#DN%'PHM7=NLPJ]#UK6"9&)4F-KX!&MH;6_LT
M19,ORO%;[2%()Y<#,=&/KQ4:ZB!I)N2''Q#+XZ_0W]B[B,O2U!?%4:";I1:4
M_CZAB>QN,!#83K,<AF;D!<ON+(],9QL=#K+V!A!29"$:U95I;LXW$LVI<^4S
MJ4BSP-6U7BG`KO27RMM%`IAN?;:Y/-2H+/S<%,HK7JDA+#XN17?7`9+,A[Q:
M/%ENP*5M.MMNU"&#B@00[9,"G@)BNXFIP/[LD<0V])W)@IN)_TK^'<)4.7BZ
M8[>K!S)QSNB"[RV8C#((FA&_7?FP^+N>/!./)OI9P:*H`:3[(F,V>&!Y?-N=
MA>LG\XWY_:]`2"THW8WXK0<:L-57G0`4*"B#8%HUJEQ*%4"TGX2D`P%(H8MO
MQD2?'8SD$WU*[CJ`[UPZMT<1L$;4=^,]+:)_;3X9J#G]5'F;1&Q>(G.F5ZE$
MS0Y$;:;1<8>Q44V91L=?,(9[6SD=N]>/2-,X'#S5%2:"R&CH,'.N/M9?;RG1
M>FM.!/N/!T-KK>TM^L*B/-U*1->\G$3[U)/!D%SVV!6]-E&J,25:Y?P3HO%F
M_S67A(])-&@<CO(J\.Z)UHPHSZZ>:SGOC14]"U$>Z%89(.%/%YW^4)]R^3`#
M!4=(1#<\U"=?B06RP2_1(P^U%:,H!F6Q3-%`;7@[7QN%%BW4AK?E=<D$HK<6
MRENP$>TR9'\9_MVG-2E(-&)">6MJ8&1!<IGH3812>QJ6IH:M:/;`-PA+5Q5=
M:U"JZ%8YD\]%SNC>@P>:0BYYQIY]>+YM5@UDI.-\JK5*>FVEQYH9)S@?;:TR
M`U[2DW$']W-.N0Y*DCE5)5X9BSY(Z]E.*Q,9206]W:H#_Q(%BE5@,=<I%N*]
MYW5&Q7?F.;$#WDD],;J(G3$3F`VH`%Q[=QHF`&E-]7D<<,N;L".<%L\SF6'Z
M@,?PI[,?3%R!C6M`@+LA,U62.N@LA6RBEH1'WP(RY_D7SZNW>8TG:Q*X(<,]
M3X%*,9V.U3L\`-_)2_*3U@0_![!+@6^3KAV(F@F;./^(5U&'>UK2]CK!Z6$[
M#GU+V`47NA&Y(\&S:Y,4_UNF<!_3NWC5(%R>)?IQZ5#XDY]-$^LMO'@E@>V&
ML$)S!>!='@I=]%9"AR:@_LFL/XN)6P9BA[/2Z:8RH%I%+V5$._BM89FH_U#H
M[FFTGV=;';V!DM["BF-V_0Y&G;71W'6>-.U.*5OZEIR2>_J;Y7GTQ5I^V_!U
MU!>]E7P.16.S95H*=1+=SVD<6KYSSD37"C)/&A!')=AJ?)Q$%XDKA_@IV(GO
M?&=[$RTOF:%]QBT511I4P:N2P0%F:R2++N_<US8H`$#6W>C;L]A+*'7"R"NN
M\J__.NX=RN847'YM68TL`:03=Y2\Y,O!T5Z#MSFD!XY^&03MC\W"-QT<_QI`
M1ANEP[$O_M[<%`0XQ@4?Z^[0EMC!_(U/?:8HX+JQ$(`!C:X'<7-Z?6OY4%FW
M%P/J7QM[=-W0)3DM^FIWF+0AJA;)S(J]J(;62N&C$H<;?U/X=FE&0G%]6+U:
M+1;W[EU?-8)$U)D#TB06W_^B-3S*[!$PE34VFB!W&');9E(+.H<AO-4O'U%7
MWETJG(XK=O>A*BCML`$^\'HM?;/3.C>(H+;#`0>P>U6-6"2DUA_8"L\15??0
M]61L!X!XJ(-5<`#UN`<)#BBYR7LRR41:`'8C&8+"[KJYZ)H-)C.,I5<-?>JO
MZNJ./5T6SFOJV'."^F#*"G"[4[,/3U!?5Y),*1[(\[G'^RV?>2+ZM_1X)Z43
M@40'EQY3VR11*V/`$,;=*V3FB98G`Z!??]ZFZ`C28V4(S?P5/4"&JR2VT[@S
MFG&_/^5HUI&^+PHN!S!W$5KL(0HLAZL&RBIZ,MJ'<#(4"K<R^H<PAK.HN/[D
ML_2)1E?T><,.K,^T7>3:5N;9:+D"M'"-OI6#;A)A+MO^)DBMJ]7TWCQ+Y%/O
MMX",Z>8[&.U?NOF8YSWF>?<]SWM,FAZ3ZB`1?QP)=49BX+B3RC3'P'&GFYF(
M@>-N,*X]!MYA)IZN"/&1A.[:JPAQEQ$831%BW!F5\&#HUKM3(:.R4X<)4U%G
M5CB_].A+1FH#WT@1.,QND`U\]1JJ:T<BCSQ!S-3-[W1;T_'34ZI2+6_-F"M_
M1H-%XNE4&0<H#5+WPXRMS:P+_A_N[GJVO*2@(3ICXK1T_4=P1QA)@)V0E;KK
MK_S49[WV73>GK@RN[LI8$G%$;@+Z[#+-<+K\P2[W*[^X)2Z$2B!@`WNYC<JE
MZUN^S7LZVI'[S#0F"9N3W7"A#MB0#J`PP`;`0AVP(9O0HIL-@(4PG7VE(>IJ
M"W1#=L$I+6JNW@+]TBO!O?+4)L1)9\RLLHZFLW5F&KMS\FE)`'\\"*KV*GR!
M#7\G,$Z2:9".E"GJ&5O;$K46FO:V#D_6<F4Q7U/_\9X$BU7VU#4W`:8/GOL(
MEST06-0GKD7-`UZQ&\84W)2:5)'T2@9/-3]]3*M\LZ*8/^^GLV]6\),D*>%W
MQ.;_YL)Z;BH`UTWNZFC>TXG-M$Q`&I,H!]#P+FX-^>(N>#'G2WW_*L&:WKEV
M*`1`1:V26M35X!6[84R!.:])5TNOI)D1VSX*AAG/>,W0NW:M!]<#JS`06.,D
M3FP[8,^5UF@K@M<%433FOB=K"0WQ2P#K6`S7TW3;D\`U1..$W03,F'?%=/,F
M)&W#ZF:7;HE-W&<N)VWLT`8TXP2U1DNW9&1BOGHEJESE$*BZFP[RPRKF;)_-
MK>`1MD%E$#0COCTG=UTHFQL3+$^#!##=^Y";Y#Z=G9.'*''_L9N"::*%&R]`
M6U(/3#,Y<@/KY2F2@V>B0?OI=I4>.%^\`()FQ&LG"\M34`O*\+$O&X^M?O;+
M(.H^,47>?HD!G%LS<4&'JJTE]3\I\U,502_$_(<FT6Q["H("</U>+.3#U1KY
M!UITT8!7'&N'=C"2KQTJ"?K)IV%)Y_&KP=6'^#6DS$D=MJF<WL;44]4M$DVP
M)')%>Y4/W.@HU&8+=]@S3%>V\`>450YM'(VV+RW1;0IU643+5D%-V?KA"4KY
MT<^,!H/B#S^B;O%LB&=Y?J"N6-#'C];>IQDG/^VI:I+U<0A&[:G(U;JW1./!
M/16E,A>F8$R'];^=:BLI%[5@TYX:!A*QB8Q'7_;4$)`(1XF.H'NJA\K"CH(Q
M>WJ%08++6>=(W)T,%*+PE0S9R"`0W6917UQM\V`W(R1CQ#%JM=LV([8S?43S
M7=2:58L\[.1P"6:@-E?:9L9.DE[&AY.]4I1%Z9>B.?/^Z<OB+-N,(Y]0*TZM
MCJM&F=@9`W$^J@UXV\%9_()EJ!5SRV42>6\[H!9$-$A'K;TU,@M2&I1QZRMJ
M!6]0M(JKQ$0'>I1:R[Q4210,"I[MJ=IJ6F":,1!G&RL#5R6X.%E,3>BC/E.M
M_MX8O@JH<<^X]:&/QFP+W)+I=9`QJ9>Y#@V8I-+I0C"KCSJ_!8EJVM\D8R#.
M%[<!G5_7"B?C4"]?X)*=A/)=B9LU3,K8A?.];81=@#9;@ETH;2XC[`(T9\O8
M]06ENFJ=7<`6?AE[OJ+456UJ<U@+1\$8E':"?L;L=.[,QIGA#,^VR1'I)JT9
M3^3[&W?2QQG8QW8C]I#OMYO1>RPM`VCZ.;<]^*H6=E\Z/9L<=)4$KG9<FJ=Q
MR(YC&,*J?^MA0:N;;JD])]\LQPVI#QR]4_2I[HZH=+&@?O*\A7=KWOG6'+*;
MP[.5<-X$,58H[F"T?]/-4F&XI[]9'E-JUE)I=-;NY^-\K'$^5N&7>(>H2'!Y
MG(^%S427'A&UJZ(P#,'2-@-)PB?8JYKG^N-;,P.IPUGBNF8@H70]P02XU#8%
M3?/J$95;3B'`@">3Y)4:]+3BV9;1=-QA!X&VMJS^D:S0,$&S3X<[JYFRC@,R
M#1XM?U6?Q4.Y[J/OSER;9XFE2=&N_WA#/=?.]7:M=.DT`]VM1T<1=\T.G1PJ
MPM.4XG7#J?*C577=*FAC><())2BJH^*>L?*44?`3Y"`RCMOHB<#CB6COA=<[
METD_;/M#B7&>>V7;=_E"U63;'P[!A#)^C0CV?45GDA4T-9:TN$K;(7=O4.51
MTQT'"=<5#M'R&XGF//D@6UQ@I&3P*``?+9;18ADMEM%B&2V6`5DL"O<`9I/C
MTGTESN9H&$F3H^!++"9''C7MO;&+JRL;6ALPN*.A,1H:HZ$Q&AJCH3$@0P-V
M!6"V,9+`6.BNRB)`1D;1IUBLC`W<]"KM=4SQC"X>7#_M/-G,P)"%.)H6HVDQ
MFA:C:3&:%@,R+625/V:CXLJ/+/_19>*HY+TH^QR+<;&#GU[5O;U<0^M""MQH
M6HRFQ6A:C*;%:%H,R+20TORX[8IU,.?*OXL?0M=QK0">`EL'!H^=48*G7GVN
M)T=C3,X8K8_1^ABMC]'ZV%/K8RA9&4D9V)QZ#,-PW8H29'Z4`\!B>!1@J%N)
M;R_XG4:DH<4!`#H:'*/!,1H<H\$Q&AP#,C@`^A^SO9%T!X>Z.#8_PF)7K+#2
MJY_31::S:U[GW=2&D``VV@ZC[3#:#J/M,-H.`[(=)/0^9ILA,7T*YH/#_12E
M0+#8%"58ZM7CN98DL^)9[!,^A^,QK84^78K?6;6DF;Q8@:-DD;2^]&B_C/;+
M:+^,]LMHOPS(?FG]EL!L[5Q:;I#TY?O&K#;V]X0FH+%3"0.+K5.,I%Z5GZTI
MT%#K2E8#:#1#1C-D-$-&,V0T0P9DAM3H?,Q&!:37J(%6K$-HR6JH->MW\I);
M.V!HQ[Z=VDH)!LOT_RH9,7#8FJ_"*Y]M$[FW7AL050Y#,_+G)'"?F>@\KV1#
M#?TJ*+H-D<*G53ITEYT&QE@F&0PQWB=@A1S(4E$!KYGD"ROPF>SS`8()>@TV
MKA:49E)N5YJ.L?*</!./)BT<+EXYIPE\MZ3`:2;I/K`<WG$S:7^^TE3A+;$)
M.R',H((3)0E0^TX]$S]F5[Q-'],+KH'820"##F'Z3GUN9[.[D?WNXWIVH(I2
M`X'3?=23I!D^(I.&T4[B+ER6Y.!!>9^.ZWXDZ<0_UUD->57EO2PX[?=Z,N`]
M#(NU"ISYD@`UD_4;I<Z+ZWG)[;59C=;@1$.@:B:PM#-0`_+D86H7RO5I;61M
ME@+1C#X[T-Q@2@_TK1O^/`N(XT;\3Q`"*L'H)J%P9C$[TE'@VA%Q2H8]@[5%
MLW4T,^%'2*:SBS!R%U8$&YVZ_:5F1)GI[H;36;Y9NI:!'\W6T7_J1.OX!GJC
M&HYF(JY=)N4.=],US">MA*-;'%>M9<Y):`?N^A79E@S"@8\AGS'D,X9\QI#/
M&/(94,A'X1Y0"`/AI;_ZAA=S(P>PU=46F1@G*:&YL)/:S,(6HR8_])\5VV^H
MC+B3#D?TMB;2C=Z]@A4#4&25;HZ,TH\#T&,5'JF,SD\#4&+R?L2,[,\#4%@0
M[W!&^)<!*#-)E[^@N<=:"Q2[R2C^.@#M)1=56Y-\)/..Q$HR*#B:47PT`!TF
M$;/.Z#T>@.J23#L0-/=8=8'R1S**Y:?6XZ6X-@$HH_:DQUJK4397QH&/`]!B
M59EZ&:&?!J"^RC,J!9D#T%CP;-B,_,_2ZJN+"<^)*[K!G.?-[['D:N\BJ#=F
M\SOQG'OZS8IBOL-WQ.;_58TO2@`;XXEC/'&,)X[QQ#&>.*!XHH3>QUQ&EAMW
MK&14E'Z/Q:C81;"C!-MV4VM'LV(T*T:S8C0K1K-BF&:%C.+';%=L1S(5/195
M0+!8&"58:E;D]IPXL4>FL^WEF;"L(\H))FJS"53`CX;(:(B,ALAHB(R&R(`,
M$:6;`+-ELCMV0<DVJ0.#Q3HIQ=.4?5(\YN)/B_=WC,)I<.L^SB.UF$N#149;
M9;151EMEM%5&6V60M@KX/L!LL:3#'I2LE*)/L5@F&[B9LD8NXX@M_8W1NH@7
MM[Q6REMUE`XO:3!]2E*R_<<<;@TMDT8+ZK[8BK%,<,DA>68]N0QM33P!K3::
M;:/9-IIMH]DVFFV#--O4+X9!U>BW9#TH%/-W/`%,W1-7`PJ+S5N)JS&/7&&A
MAR@B3Y#\P3@3)E-6)G;D/J_]ADW]=.TL;<PN+IX[<\'$B"Y)NILW,=M]KJD\
MR^>]Y-/F"V$8+Y*SU8K!K`&-#EB8W_($Y[2V*-0O8#*KC4^+\6DQ/BW&I\7X
MM!CDTT+]8ACHTT*#33&H[F&M&ZT*#<>Z'5&H5A!2#PG+8ZP*55/6\;H=X<3^
M9^R&"?WAZ3+WMY*>,0W-Y!:6A<Y!N'AENH1!3$-OWS;.9^W4@^*/-5MYF7Q<
MN]:#ZR5E72M1<:;L_-MQ$#`>);WW?OCT(21!TOWCRG^*(]X*Q;?95PG?3I=K
M&,LSSPI#^9>!,63^.AX9VC(RIMBYO;[L&T\24'^DHMG@UU;7AZK'#(N<?37Q
MG;1A%O7HX_*2!CD,X<Z25I;1+`NK#`WYVZ'D0_UCK/QP1@+.NCLF#J[-!&0Z
MNW1]BPF#Y5WYS#:,4WN"(1\6_PBNL]I<UX"^'P*;]*N_W:7!^KL,A"G-G2:$
M=Z*TVUK:7*K-)N9,1"7NG5:R;MI8>/22CU[RT4L^>LE'+_D@O>2MW!&#<IBW
M;FA@<)*W<-!K;4]!9X=2(`X]F5FQ%Q5366>"4WTO,!$4Z+"M:*5J[)A)2%A4
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MF9?G5V?L`<[-GLF"*UL(JB4`='.U9MXGB-FUL'3KXE4]XSU-C*.`E&I3D$H&
M0-5,X'<2<9XR!)Z9E>><+MFMP"[$K'ASE2_,[O;4)(RYW^AI90Z"]K+I2M"<
MI=5ZZ>7.5TJ:K:?#A7+#7*3M!6EX4$23.9/$"2^927_Q2@+;Y4."U^U@N,F5
MJP.01A<(5;]-DV%S%8:QY=O,L+RS^&,D;8$#-&EJH1E0S@6SC`E[!'&9"'C-
M\SE)_PO5V?)P-1,)/":%GVE&\9P\1,)#O9YT<<Z>P^<DM`,WD6\(\I(`.Q&O
M"=-`0;!DBC'QC327JQV`8P;-#D;&,VAR/4VS<[3KUP'VR2Z"I)F04^H[@%**
MPL]T\SI>+*Q@N<&@TR6/@,'S.NM@&7ASF22G$V*2B;;W<\O/_=N5?TL\IIZ=
M&RO@UF.*)/19U\9J72@&>)I=!93.@VOU%-)VMTQD`W7HWY>+QK5X'FJ8N*VU
M\&?(=<LC)!R2"!/)W@^TY#H6='87JB_/AY4SG$K:QV_K&Y$A)A&G[V>>K)2V
MK<Z9/<*:&*:>,WN$.C`.%W+)EY^@'W>D&TR_Y(->T(];A8/IW_#&B,0\W.EH
M+4EYF=],L&%@PB[C&17$#T325?S=@@G=63+M,T$Z1M&7M%3P`6@:91*,&9IF
M`,0<!1,&HB'DX\E]2?A3NB`+D@$R>C_V(?D:Y!_*96ID5'[JL!Y!SLVSFY2R
M39)(X1%D23?MZL@Q(TL5$IKJ#V!1>E..I*V$,$$4ZH+,.J(VD_$$4;@K*56,
MZ/J,29'_C%I.@0:D>E)LQH\O^&84Y4C/7*!W<QKPS;VF_N,]"1:YWU'*_FZT
M!I9<;S4B=.<.!S])(GQWO.PCL=UA*<1%WVM/>-Y=E)^<.`B`N8)UD#H@Y*P=
M*LX,D9`3V*RL2(B\8F)3(21HYM_OQ'/NZ=HE*3@SL>UX$2<!JA]^0&SZZ+O_
M(L[OU'/X/`T:RJ<!-EG"##F_228F-%YBS&W:P6@/<YM*RXT6"^XTM#P^BS$\
MC\EDQDR;J4_^SN[//]UH[OKW#$+R5VB#6#7@S4E((:^6:8QS(33MU\\_:+#J
M2,`#.2MK/'_TX:E-TD`-I&QU2R`&\J"96M(@QW0LH^XVZ7WI4<X55'QA[.AC
MAI4)CB#A1[US!:Z\*>QVQ9!O99@/,I81*#=K*&EH$FE)^YN&AB*LTVX:VD#B
MCXV?[8-+S&KLEQ'A^8&E*M;YUT1P'O5U"">\TCVJT&FGOU3G7=N"\('HPNJ0
MA"!76M&9&\'EOCJKKKNM]4L"P<02(9-#>D\;!(W.\TZV7<F!+@-M[`I5D,L#
M0+-G7:'VO>&2N,A+#T<#_VX=3#SO<$GJ:U(M<7AWV\U)Q.V.5,Q)Q.U;5,Q)
MQ.@9!%S@A=[!NG.Y3[Y">1TU>@Y1G6>U0P!+R97W%!I[0&?IE&M*\D0H/9\!
M$+$\GF50[N@-]9W`.CA6PM%LI^9\Q.?D*2"VN_(]L.U==6F>+&@0K9HVM]*R
MLKTUNWHE_Q9(YDW*0M),R#4O59Y3S[E:/`7T.1T`#R:B"HKV'G9/;F1Y/'QQ
M1A=/<42".SJ+7JR`@,FHAP7-EKM=:2[0:2C[4C,G+^.`:6JF0)D47KJO_$]P
M2:@`,CKW.G?N(?$]#,YS.;BGG43#G?%IUWDC'UU/.]3CU-0.0<6]).A&76,)
MH[O,ANC)S#RU3:ZWWT12"^I!BFKD5UGA@G#49=0M^VVVB3]!71BO1GQ[;V;1
MI6-`BE#.EZ+0NL.84R\_/JV]O!@@5"S./5FT-3<=7TVV8[?,@^LGZY;,LIOP
MSF"/J2H^2T;_7?EI5YSIK.23;)#@$>2]8@PE^.`1ML%^E*19YA?8G`,HUI+V
MD,`!ZVY%K[0%2>AQ.IO&$>^?%B;D_.X^SO5O?OG*O6'4-7WIAD_)PM"C,'WP
MW,=TQ"6]L9:W=&EYLHTF:@"`3R5[+S/:+$Y8"F:9'7+Y$U@)!(K2Y.G)<VW^
M^F:<OG89Y)#P5B#2Z)0#@*)RNCNY-"TU6G>B"7G;2^)\C[F9PKN7L"?&ZM^D
MT6VVB"I)FZ(O!)[91PLW#&FPY#52BJ3`@(\.X<X=P@4RJ.0MK88#CII0>TZ^
M68X;4A_84*#H4_,\7#6_5!B(4@O,0+<`LP1U0@XP.[04A+%X30$&F[.T&\1M
M9&'C<=X#N4$E=A)91FE5OX`Z@:XA=T>=H$@\E4JF;9-R)'37^[ODU3&MN`0Q
M).*6!C:ES)#"D*:L)MBGK%6X=ARS5[&?^/(@G]K;JR?U[DJ<4'M0]V1H"8@C
MY1X1$0]$'>L!45OMCA+1K>'L;[D_4%`["$VGR8$KBN%1IP-TQZ4T'-"3+N0P
M90&.'@DNH$ZA,",L"H%#T;L=7XR=60B,'I==E&WWGU"`C"76#D%=<VHZ)YU<
MN\]\RM(64KG<EHO7)V[A),W=>"NW2_8!Q"76:!G=V?D@W#A:24<[?>3GEL!'
M^@O53#A?`!79MX3?#`Y_UURR$VQY'$U]3"A93G=-6@X1W@AI$TT(M760.MQ;
MD<^71[*MK2R#WAG!:NV$Y."-$>8&$>:2X"Q7`/:6^*R4`BAT#``V=@BRQ@Y!
M^],A*'74\3&BC\R\2IY;<'Y6`-%=A\<N%R64MS[L[@I..DV?>588?K<6"CD/
M0-`&4CKP$-LEJ:=+@1'T^(/`MGBG2N=U2`+J*DP)HY,J,KY'61PJ<BK'EC(=
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M'M<>H`V2!=E=L`+8*[H.$C0D<>6OM$*]:I:.3H!@=BA4`L]$"IJI@D;KZ&9"
M]88TU(%0V&.VS@Y&C;-UQ+V:4Q`3WZG9'5C4L=DB4))`:^R:GG7$J((WZK%L
MR`/:RL:)X)&$\=T__V8K1Z?6]XDV%JON^SS$Z\QH?F[4KS?!'[R/^!;YT\CN
M01X`:U,'@XQBX5T?,E]DWS3(ZQ(-GJB--ZLHM-L'MD@'(;[N`S?D/$_"R2X=
MBC?H-EV/-[_R[^*'T'5<*W!)JR69RBO@<9_"20`^LZX)`Q,X]-2EX3+D\G;E
MV\!N?)4PX!XI0?,-^T42!,2YBZC]\W0YC:.DZ!C@BI(!UAZ*+2!F8H".38@3
M7C+%Q+NB6+Z=#$K)(\'44_H/A/U0FK*F*X!;R3YX[#B$]W,26$\DCEP;4(Y0
M!P&<W)WTH/E&HCEUQ.Y.7WP2A'/W*=>UQ#]W/;;4,SFU0CD?4<,%-`N4-&(0
M&0(`!3O+(IZ_D6\CPULFA7R"@O/,955^3V1`@:4Z[;7P0IS39:;TY;LUEWVN
M60C.B4W]D'JNDUQ&M^39\N*5M7;+;R:?Y/;Q-_;W:7!-PS!%%R(935<"M_-F
M]P2SMKAI=6IY:UV6[[8EO3<RH*#HG7%`#KV96\P.L!,=9GD*EW@M'##?=L]J
MSHJ1%^A:.&-`H4%`H>T.MN+DR4<79*!T00`HJB`+R73334G*"MMN[F[#<(,!
M`%$>O?U8W"IP(9>[4I`[\4LO*BI[F0O/.^J*,.B^2MA7PK>.N@@0KK:;VL6B
M5RCJSIE`D2A[#B%/V%>D5N8]*GJ&HNZ&"3\``)>!*%D8DOI3]Q")$%N'<XX;
MW'<5?CP1)AN8N*MZ646D;"`,J76H"XJ'I.OE8AM9#/`09:%-[<FNC"UEQ,FW
M-S<6X$QV@H]I9LHW5<SMA3:58&,):L*0ASK/'Q\#]KZ-R$W@,G7H9XHQN+/X
MR4H7E'>F2X+K)&1W1A<+ZK<4G=L`!O9!4Z:+`NYU2/C$#(UDZ(*\[[GL>]U>
M/TYN.AGB/`[8JY&M[%(GG1CQG;PD/X)Y_R0APCF<;<_%*[/CW#`520"+RP#H
MYG%R4)*%P<)1#P,>+0GGYX'UXG/IO[1LV"34DJ_50L5\1]SD_LYZU:3"`HP(
M5\"!(K9JY;$#-WE#_^"%S=D2TDB"8$(1OHG9M6.%)`/QIQO-V4UF4\^_L8*?
M9]:3&UG>9>P[URY;F3A9JWJ&RI/E+X%1LO86U-W\DB1="AA.D&A6^=<&NA>V
MC;)1A.\#RP\MFULNX>DR_Q-P!U(`5.AYX87F(;>]\BZBW-60^0I^/-&M1X6X
MHZ4/2TNK:<]<2-?EYY,P;J>OGFP&!C_@5[[C/KM.;'DY[&^9U1L\$^>2!I=Q
MQ+/U5L84+)FA]<6UVZ+Y?4H-FYS?'6:)UH#23$J.GXWHJ(:CV[XB/"/T;).7
M\*Z\E6",D'#:#@DE8'2+$F]-N#)1X7=7T=?:GS[L*N$J)K\V]*JJ``*^F5[H
M_9S&(3LUZ=V0^&UN/,O/_>22QL%ZUA^_4-QGLO4;]W,WB`CQ"WXK3;F/[03A
MWYB*A32O[AY'W6J=K:[6&7KS2P-V8ENH&D,4>JPVOS-ZGS/;<AJD4<1D9IK*
M:UT68@>&RB2.YC1P_P5K(U('R9R9TL;V2($S;7FI;4PE&-TDI"_]'[X;J6)?
M`F',9]W!J+M\UD2N3JVP](G&WN7B=VZL9>+<>K$"IT'Z:^-%=;.G#K\R]':C
MF3)\:6$UXUFW[7&H,#.WL83L4R)O6V=XS/O%DC:@]YB57<S(LX(U,Z7*UA+I
MQ"BS3(QQIMR@1C&4H2L.U3V@>C+=P01S9"2H.^W3[>5;[!\1"?T=YJ[*#8,J
M=`@5$%8PS`GM\`0UVI!05G_F2YR-%(-+&$,I"PZ-4!&(0#&I0NH$U8=D\D9'
M0<@(>=LPB5A9?DNKHGFB5@EU#CN$TI+0JZ!TORWK@L"Z*.':0];4YDZ(,J\]
MY(Z&M!KD4V[T\+/--"Y18]8=`W%8*Y`,/\&U#BL5Y5XW"NF0)4PI>/]\Z;`H
M66Z69<O4(Z%=8CQD>=HN;3UK6O`$9:&J1BT,RJ,7%8_[QJ;:F@C!&MREW^VS
MIJ1Z152(HG;$:(JHEE86B:%]^V;OE9>*B7I;U`X&3:(B6=HGNB[O4:2GNHQ3
M##;<(Y:(EWIMO6W&G[U[6\H66(L)D/A:F>\6M-_%BX45+'DCAZR>??)`X^A/
M*T@\^"U5_0/7P=L!0)808%%!.H^7J6H^M'HZ6P&3R3VK_-Q,+<EJN6EPZS[.
M(]72I%I871"S859D/PQ7/P4E!ZK!'U-L=S`RG6);N'&[%X6J"%P7Y'Y*:HT5
MH`L.!E@A5/2IXO)WY)GX:LMO?*JZO/NJN+CX4'%I/O-9;>W\EZJ+TSA07#SW
MI>+BR1QPM=4W/E5=_H4J+BX^5%QZZBO2G?NP"X6E7.M9!,9`[9Q^(KHA`5IB
M5P&D"_3!M2)54+J.G4E0N)O(4K03(M\:1?);5>RK7BCK2"Z(>:$M)VB;:B0T
M2R?T5*I/6GI!"2)1AQX4B,P9`")-&7744H7(O(DER$0=85,@,V_'"BI1QX94
MJ,P]%0250U,^N<=83SK^JQ"9?^Z*'-BAJ9\-IP*&HH?2XE=)UTZ=;;!=J2I3
M*-#+2E4Y@[FZ]/2XP\B:IM)3W`,Z6A+R6E>U8$?_]#:<'<4IS)_Z9WT4DEX9
M51)Y.-(JW5B(\YI889NSF:7A80E9UB,,]'NN\Z\FOL-#H$_\>KIE___BE0?6
MY?LZU\*!.F2O?#O@Q%[YW]@E.O>6"21&-^/">4SNZ8^(+\@K5F@H%ZM3@PON
M!9PF'(1)+N0JHS39-FD4*R!H=@K">5KV)91KTVA.`BXP[().149^2PN_U<RI
M=-[][\1S=G8)T,X/`DTS0=^L?]#@)J#,5HR6R54"=\>7P3`04-")?@?(0^,(
M91"@Q_!V=1NMU3G3DI;CAA0:`:Z%`]:JN9H?H<(GOA];7GKTN>*15[&2X#1O
M?'+"V96YH;P@^UX"P`3:;#$W2"T/*R)'8*QWOA^3878P,IX,0Q=/U&>R-)U-
MF2IAN^,_)K<K/PW<M$L%;/=1(=<D$0@;/IPD>*(,,/F=V=7_C*T@(D%XY=]8
MH>40WX(.(I>#IG_D3J+3[^*'?Q`[NJ?38/+,['SNE;FD0<;)Y$@I=**%@S?1
M61<=T;A(!C?RA0,WUMAR<W$GM80;]*RL@M>U@Q5$-6VT?SW*65`7?546]3''
MH2LN(>&11(>D!I<&A=WY&!(HRJ->JC9<88/7*D4%BLKW,B(&5=C5L;$N6RYJ
MBHTASU1HX2@4OU7[DL70%@-V70P8(O^:.0#R%/4D7-S&+5GKW!/-PKK3>-J-
M\C*7JR`>?:><&K]S);$%-O0)]MXXS>E%0FW].:^-A^2(E8D^";*'K>X+8XFB
MAQUJW=[&;;\=QQ6Y+ZC%O?DU7QYS[TOZ3U,6@#,C!&,&:P3+Y;8H-,<SG#*5
M=I'\QA9<Q(ODGXH$GG?!3W^_0395LZ5P)5HITF)DXE>RXO3!<Q^3AVGXG?IV
M'`1$KK$$`)B9`6;;&)RU1LM9!X1L2LY::&ZX#/I1,E!A.OM.HJV?JQ*KNEKG
M#+GR(\*PC-C5X\7L%'-7JPY65*W3.1/XW<IN(V+-(EC6&!@T!E*O?%[8]7>F
MBEO>XVW8.(A-BO5T49L'CH3<%ZJ-V`PT!E(;7D_U<#LG,JT/8%;.=';)S"++
MX]QOE]Z2)<9$L!V,NAL\FM]%[A)MF)Y1`<Z@Q*]\N[M//J!8[\(Q'NV5H:HP
MLENQ$Z"B\IX'=NOENSZNVV&W3%UQ7=RN+J#0*]]$?8ESM\Z/O"72EU)V'4S(
MFYT]F12GBP^YMT9?:H'U<"+WQA2Q7MQ1,1V,R#L6!!_V3$]6.99Z$BENGRGU
MCD?!FL&JTB('M"![L'JS)(8@(NC29P%7A&PS-TAC?*QRH5Y%QXHIT?O(WUJS
M[.Z"O/>E06KV7TCBH19*4`".@US%<((*="P$JX44E,"C(5DAK*``'`>Y"J$%
M*&0$A#8.+S189`PP(`HP=%(`:D+NFP09ZB"9#C-(4M:@A$QBGE+/(PVME)!U
MZ&?2%6I`/6L,+O@-[B44E8)=\:0PY'"$>L"C-D84AQWV\*!4A!X^[RDW"L,/
MTM,(!\6,XA#$?NK./`>DE:;9V92[(SM;:^2J#!^+1Q5.@-ZGS`5C"%T2<D>"
M9]<FQ2-7O_-!NV'$Q)A/5PWO:5(-+7[."VR^T^CO)+HE-GWT>:%$.JWXD@:K
M?^*_!VH>9QHSS6]&;>0D$C5-#CSHZ6D((6ASM\GZ7`';N.U\IWD_;XEG17SL
M<`!Q"E5];1#A^\!B&V@G6W2ZS/\$VG(,`E6WJTEU7'0Z$_C*#Z,@3J[9I&KP
M?F[Y*RG.3L'W&-KQUR!2VN6'H>+:T>J`_V"*,[R]^P%O@EP#J&LI"<MV)/D_
M]XS`B>_<>);_W5HH-"74L;Z!5HU#9)O^YN'9TD"MNO5AUWM;QMI+RPV2[!_V
MO(D7J5KBQ=+\;)^[SZ[#3.A;=@D849CRR&!EYW2-=#JBA3>D2TS5Q.JZ\IG2
M]$/73F@TPE$0/E`[KRE6OR5S:]8H99LO;2]J6U^W3O$2HMCE64B`0F]Q68C&
M=OC*=V([^8V4R?KW='=%Y#IB4_I^"V@(NE^T+(^<9;E13P;-^/+%];=X7U`_
ML;!7>9L)@B%OZA8\$^[_2%V,5^RZM'P;-@X:#GS,Q>@^%T-5B)52&]I8#7KE
MW+_0^SF-0W;2PONY&T2$^%<^[^OH/A-N_`.=2M+PFB#*`SWKUWX[J-9`;()L
MSKG7$,D22+K[[RN_0`V_'=?+@6<`;'QG++M+_7W>(`6L\:)XDH;:XA\MDP1D
M@P*J.N`727X!77WK6U^L>:B\:L30CKY=0FLN*I$>A+JR#D!PI1&!(?NO-#.T
M1>.Q,'NTL0($M6KO>8IIB[=%31YJAWEYNL9\H]8E>HZ9PGN])WW_-:FE]MT]
MHB88M96"DY^%_L:>M"5NEZ-M^[DS)G[9(R9"(Q]K)AUU69;1+TFKBY)E+/V`
MNC,$3G4H%Y'-6(Q[F@$R%LNG$63\E>\&/["W0TFZ2L:8+QV6*\A-QBG.T('(
MD6*ZEN`1UJ:"G;(("8-:T%Y-\N)R3*Y)FA3<0ET5@TS7PW-L,SY_[4ZUX=#Y
MD,3O-=>./V"?'*:0)%_"DVT]=HR[=6!%.</Z+;!382%(VT,;WE#Y3,9CW//8
M>L;CDA(PP6Q\\YV*"P?OXL7""AA)N;K!R0.-H[P4M5AIJ;`>[LI+"$$&LK,>
MZH_00[53@-_7FYX`4-6E3BRPIK?M.NV[2[:O0,($^]K9^3^)^SCG&OF9!-8C
M2;N@,(K.*".)652QY=V38-&58,JCAYSE.6&1I.G8),N5T$.N),K%:.V4O6'/
M]"[J<^I1ZIJUI8_,,K>V,0ZWC!E^1C^Y0=J\&2&K@;AA9_9F"`P-GR%H=<UB
M>9L)BTZ61@DY:W-WB_FBJ8+%=;.+/_IX#A1QSF-F?#^FIR--ELJ_"->[Z(#X
MH0`=O7SL:&NS$E*P/'*6C:6;^U&Z.=8RCI5'$I5'R$[<KC_>=*GG6,^P5<]P
M*!'2'^L9UCM17<_098F8IGJ&0]0-<I%E?$CDYQ^B;D6-DY_5^?G'J+L6X^1H
MX<M&=/[M=TZ<&D<57L^BZ&9,BVO#_2(*(<9+1Y]/4-1&C%*KU[&=<?IDE&<#
MH1I1D3+:6-J#D*(\932_],741<K@/IID722(9!S_M*]R;3H+*N/XYWV5<3T)
M?1E?.RPF&8(D[R2:KAG[X5!:8+N>D".*37^P']W3A!1-2=S0Q7!G<$M3@S3B
M(O-L27YX;D4$U.>Z,]2PILU6U7:;2TB6P`)K=+`*]3^HQ\!X3,NB:/F_C4Z?
M6'KKAC\O`\(O-L)49-0I0XN1Z3L[OUFO?+`>*JYF./6>N>G40ES,7>/4)^8.
M99C*F`N%4N2Z3_;1PY"5(H6/)MOZ4#>:J4I20'/S0]V#W_C&*HQYRW]F`D7P
MZ$+QT9BL*)>L.*1$L0(QZ$^/]%V!WZ9HMVDXZBYP14J&EFJ\GG1"KR-J\[;!
MT.U\`.FR1Q)R/J;+KG>BIOUWAVD1FM)E9;K##S+6HO<9N-?MU<TY+T0&*.K;
MO*]L7CO@,C9_W,.N6P:\QWO9NMUHN$/T==]7?:PI-)<Q]NNH@?5'DD7"N32W
M473D6TYG6QU[)W;$#"9FD+;=C$]V*=Q9')*T('6DUS82OJ3!C+A\PDZ(([6C
M98RQ1CAJR?PC:1V**^VF?:1[NST8LZ+:1[JWVY/UWNW)SD#P[>VFK#2W4!`X
M>%^`5F]9O*F`<?!W&Z?>,G=3?>)@[C9.O67NSD0+#-S=06I,*AJ3BK`E%=5,
MX`'DG50#ZGI?FPPLTMJXM&I]S4P32P-SC+8^'/.,]C?/:$L4^I-K5"S\Q@;`
M(4]<TJI/X0/@NLR(&D+RD$2T;$P>DDP>0C']L]WDH3$=0.>S3_!Y#P?*F7->
MB%RM49PU.N!$KM:^IF"8\B,+3H_I1!U%2T1&U]@CILM08K8/8]>O3B/N8A_&
M5G>=9:6()$CI.@9CV6,9FM^(Q?^>D%O\CS28A"&)PHG/V&X]\"Q/EX2K7W$F
M4?;5U+\E=ASPYKB,M:Y:SR#SB&')3#-(N5X_\&D<LN,9ANST/;A^<OAX5S>&
M`T.>_2ETV;FP4MZFR"\A'E\E\)I=W^=,,3^S-9]);C\@1)4`,(9V*D_,Y.+2
MDOJ1%'#?A:*9@#,KG+-#P/_#E?>SY6T<&G&X(/0`@(Z1XLXCQ?FD^5*5F-.#
M[!>8@`8;:E$I:-SRPJ;8=.4_Q5%X39Z)]P$>/:X$TP$)Q^V0<-PA"4?MD'!D
MFH1",^5WE]V]S.0!J#$EP'\=[PFAYL@\7>[BD$@6-.M`%F(7^Y=IXP:'KA)>
M!T1=!N2?,?'MED1Q"UQ')TTO429/51$6#8Y4.;@>&%K@])X6%^TZ!MX^_RA0
M0)`E_9"9%7M1#;,DSD\1&ZKU&8KD'JGL)WU\0,*%>B<QY':H8<'N=8TA<0F=
M!JFTVD261(?CH<!*1,:TK1.>JK<(_IY%AIF"A"5JZJ7^F5?$EJ+'N&`"ZD"<
M%B8<[S`!]RA.+4SXL,N$[E(42E-D]3A1BUC3_.H2C!SJ9&HM]WQUMNPQ5D-8
M/5OVN!_7CJX3!XAB"9;UXY+2Q;*J0*:8Y=N/.TP_CS8"U:)E'>H$/.WL44I.
M$-F+TD^J;A.%)H[CIOA<^3,:+!*"VDOWD0"/.FFG"O\Q]:9"./B__)668TQG
M%Z_VG&?LW?)$NTE`[J@GU8Y!`@@4I0TH9SPO.8A<9E^E?^2VRRVG^I(&ETPQ
M_IW)CS2B*J`UHD_C0!?Z&6A]Z-\S.+K8GX.MD8`7J@O]-62=LA^$D3;ASV!#
M">"=,[<4@53LK>)C*`J3!\\*V)MLSK3C$XDCUP[EX\]U$#H(SO[I1O,?/GT(
M2?"<CD#E_@YF-3&#F6G]Y`:XW3*:5O?!;\Q$NZ9A>.7;7NSPI/8+*^"#?]7B
MH?J1TIW!Z%EA.)W]:?'T]&@:)"*6F]H+2ERLA045W!6H\"H,8S[<=&*SIV3`
MSN=B0?VD$EQ:@F5`@8_V"[V?TSADY-W/W2`BQ%\O`SQ?$I`:(!?>OQ#OF33'
MK010$[ZUPC(`MS0>&WBJ2"68+DB`)H94`-&>._X0B5*9PLO[)G!M`IIJ"P`*
M?E:PMXH5SC=>*>PZ(,RJ9OK^SN+-"=9MXMG?XP?V:ZX5+$\I.W;R[XYFJT")
M^N&[SG+!KBW@V=WY3GOW*L^*>+%5`$EPK_K:(,+W[&B%EIU4@)TN\S\!SWP#
M0-5,X%527+LH]0G+$U4'2?NTQ>`GB;C!=\>-.W#E3?'W'2"M5GQ3!ZD#0L[:
MH>(,1,)89`.Z.`K]EN+42N=I`H"UC.*N&[XAFM<%M3B:P^]J=%(0VT6&V]#"
MY7!!K@V#H\T'50^#'Z(,@RM+OM2-(8A'&=#60GQAL+K+)FB&Z<]3C3(&W9CJ
M.D,;0V:N'J6M\GY",7)3;IHR_*U9PI/='"C4O;\JO`*TS%&!O'M<,XNNH?<(
M><NWQ@H0X!W$,*E4KRZL\/R*7+4.+T(IU5?O`Z^C>$?EG718EE*O\F3B%FMM
M4!U@$02C-/`;$EP2Z!)$HS3LF^YR2>11)%<.RYR7C@LC;^_8^&*K#]R+7G+#
M$H$.$CK$"%W4.D3".*Y("A*3:X=E"E8D964D#_%EH)0I)SB"LC&Q*8YDJ8\9
M/SZ@;/!NC!\BDS7CR,D`U81*;K)@",J>".:4R/.VA'P<H%:MKA(0I`]+?;92
MJW3T65IC=%NKM&DO3F=;17[M52V!%D)=OR1'21_2SA-\[T@4I9'L#G+,=S'H
M1;Y^@G;Y*PJ4U&D*H_XP]B9F!]0*88EJ>M;O#]/^@`YR;W_M,1-M!Z,^MGOF
MWR<[?4_LN>_^,R;==8"NQL58__=+9@"R$\`KEK/I%RE5\$:I$*AFI:5@3Y)-
MV-$(FPKA=)E\GGAI&[0C;1D'DXU9!\@^DRU@Q=H-&K]N`^FGHNVD`VPY'D-H
M]53+Y>(NC]ORU,_NL"5'J[SU6*OZ%W_B,"J6(6$8N$]0^Q=?84>E>G,)0[M:
MK4T$I4SSEOL*ENO/X0_F-G7_C+.Z,>LWLT>U-7=,3P9V]YS9.6=A3_+*>\[P
M2B<WBHZM@]^"C8"-R"67UND=MV<,PWB13JS]$7+YX;_!Z"OLW=EBVT;U95&'
M0U7H:M)D#=J(I_AC@^ZA-7<N7I^('1'G#^HQMO!\@5LK4G;VU$'MD,!S]]EU
MF`"V2=XFS`Z)X]F5;1&5PNJ`F%LW_'D9$+*NEFICIXIACC'!,2:((R8X-LD;
MF^05GXMJ$91S968Y@$WC>/J0,1?0VUR_05"O"%`_M>48V,,2V"N2*63!/;E`
M5<4I*Z)<GV+I6]1*N[X'EBAW&*W"SK:Z0N>C4>)*):ZN7/JX.UVWCT%2&??H
M&"15#I)^P-K,0SU(BK,.$\M1K?8[8>APTR,F;GHD11^140(!S-OT48NV)&.N
M`X")VW$,T=RD'T%U8Z9><5Q+%/%+]SW"6H":<<%$$6K)8J@CK_+4[$^\M9T&
M.9W6Q!9CT2\&CG.LM+(WZ0;6)2O7""!E6UB"MK$BV1H$QJCX&!7'$15OAYDK
M'R.\&';K0\UH)NVC9R3@'+YCI]>U&?>FLZ+"DGN&?%C\(WAPM]UU=1^,W:7!
M$=PR$&-$?XSHCQ'],:(_1O3'B'Y_):_L=D,Q5$A.YFKN>*K+=D$^>DBKH4A+
MS5X,E9[[&)(_EA#",22O'I+O,&*C*R2/LK\\BJ/:KH<,15['L#A>X\H5'$=]
M-0^`XU+C%W`/ZAG`+A07,>.<(8,UR^#P:T]JOL\2(J[\[(?364DS[^F#YSZF
M-U1[>0<M+(\Z$Z$)?<#<A(*V[/E55XB4K"Z=Q-!P%6@QG7RO^1MK*9V6H`RZ
M!?37;5&2B8,E"V8<;4(,<"'-OF:EH0'R+F0E\&.PN?-@\YT])T[,YY.N=S"9
MXQ8FJCL\7>;^5K*?X&A#:TL:.C'U^"B%UI7`FW:Q->$!U;#EPDLK\0CII8.L
M[0-9ZPM#VP%5W1?6992C_JG4TIEJ-`4(>92C(8M:LLA$\`.UIT\3LVIM<<&>
M?90ER*-+A'6D76<%3HF_O>=(/3#Y97_Y_U!+`P04````"``I@`Q%`9RNQ`1S
M``"MXP8`%0`<`&%R=W(M,C`Q-#`V,S!?;&%B+GAM;%54"0`#C7+J4XURZE-U
M>`L``00E#@``!#D!``#MO7N3XS:R)_K_C=CO@.NS,6''5K>[W1[/M.?,[*I>
MMG:K2W6KU/:9<&R<8$E0B6.*T)!4/>;37SSX`"F0!$"``*O/B3GAZBHI,Y&_
MS`202"3^_7\^[R+P"),T1/%?OWK_]MU7`,8KM`[CA[]^=4C?!.DJ#+\":1;$
MZR!",?SK5R\P_>I__NV__3___O^^>0-N;\_!;)6%C_`\3%<12@\)_/KNTS?@
M/TYOK\!5&/]^'Z00G*/580?C#+P!VRS;__CMMT]/3V\W81S$JS"(WB;)^NT*
M[;X%;]X4E,\2&&18*G`>9!#0__L1?/?N_?=OWOWYS?OOEN__^.,?/_[X_?NW
M[]]__]T/W__Q?[Q[]^.[=QR!7]BH`/=_/X+W;S^^???V`_>QFV#U>_``P?R<
M^]CE][/9[..[[_]T^O'\_0]_.KUX=W[V?O;GCW_ZX</9V=GI[,T[_']__M/'
M[]_]"?_X_OMW/_"2H_U+$CYL,_#UZALJ,KA]2_YWCN(81A%\`7\`=RA.\2=W
M^R!^>0MF401NR5=2<`M3F#S"]=N<8E3H$",5IW_]BM/?\WT2O47)P[??O7OW
MX=OB@U^Q3_Y(_JWP\>>CSS]]H)]^__'CQV_I7\N/IJ'H@YCL^V__X]/5W6H+
M=\&;,"96LR(,TO#'E/[R"JTHJ!)R@=9/D'^]*3[VAOP*V\.;#^_?/J?KK[#*
M`/CW!$7P%FX`^>_GVWDKNX_?DD]\&\,';&3KJ^`>1EA<0OO';0(WXN]%25+[
M&A'A(Q'A_0]$A'\34<M>]MAUTG"WC[!"OATBY37,S`K:)&A0UAN8A&A]$1M6
MK9BL<;GOLB`QK.LVP@9E7^*X!\U*?4S2I+PH"R+#\AZ1-".OAC%DQR)*(!^1
M3Y#9,_\0(=81,RFO/$)S1.%S!N,US(,B(8M6(MDIL12NWCZ@QV_7,,1$WW\@
M/[PA/[QY]SX/KO^&?_6?%W$69B]G>#)/@FB.R3__'_A2YQN1*(^2XI=T,'_]
MJN/+WY8"DH^2609_B:Q`8/SF\YTLG?^,[AM:36"*#@F=@J35F%6V_C?&!N1\
M`&4$,*=__Y;*4I-ZEJQJO(-D5;#%/_9PSC_Q[0KA"7.?O8EX"]DD:->IOIPM
MZM7-MVV&$"1/"0$;+V0^O*-0D]_\9[%L*_X[B]>,^CS>H&1'I_+9?8H9K3(9
M$]`@JF0:RO3-F,PZYT1)?_6W<K%;_![@Q3->5E-;"BLAWKHP(WU<D;9^IX`A
M4U6%7?D#9@WR.,`Q![\5[/^O"$4_Q\B'-@,#-1=#EL%]!(T&D)RB'<NCQ,</
M'?.IA(XZG"IQ@].L]]#I>1,5P&K,,#A$Y:`H'IV!5><57MA'C./L.4QEUYM'
M7U->:38HF#<=RJ!0YF^$A]`ZQEA>MBD9=:C"#X5&TKHTM@,Z1[L@C-4V/L5W
M-/<[[.O6MCF_,?K.S$^H5]2F``]T&$FIS]PRZ2J,X3R#.ZGPIT/5SIQ;,G`Y
M[Q(A`)7"B7T/P%AE_=10]23P5%YD=$!I(+H7[)=X0++1O?X=Y<C$?]VBCQ#R
MKF*[4*NH;?@>:+!IE2+E&;"V&2:^)@PNH^!!UMP:7U+65NW[Y@VN)`\(?5<6
M)]8L:M6`#UJ,9!1H,,:5YVCDC%TUV#6^K.VS-3H6PQ_C@V>4-2TI<!T)Q;I'
MO;KQ2<_-(-FC8H.6>QFFJR#Z.PR22_P;Z7Q`Z]>UM=J@9-%^&2=`6`'*R[4%
MMV&`)#3DE[Z;=MRK:N.6S#QG@"W7"`S4+D?+OCWG,<,CBQ9A(;3I(SWYIO<6
MN^Y2N0'+7B8!J1^\>]G=HTC6FAM?4M9D[?OFK38G#QA]5W8JUBQJU8`/6HQD
M%&@L*WL+'T)R7!EGU\%.>DDK_JYFAK%.QEJVMF(#"!^W2=L6M:,^O7BDXDA5
MNV[+E.KB]E8H&7"PLT.2U!9@BOO&]N\K6T$;*?/.EG.JK0A=[R![@4`R6O),
MZ9&ZOHU-&I=A!),SS.$!)8JEC(VO:L:S&A5K,P;E`@HV;B<,L<I1CU+\46^D
MH%ES1;=HMT/Q7896O]]M`RSVXI#1FSEX8:5FMMV4=,MQ.XC:J\VE3`'E>@(8
M7\`Q=ERJ*X,84E.BM^A$K<!(X-+A))L@O:>L#NF;AR#8,T^!4986OVFZ3/[K
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MD)82?0<IXO`AY=3T!XXIF&6@8`LHWW&FBM4*'3#[6[B"6!2\$[B&6>[?2C-&
M)QV]<-9!TDY9`01)R<OI#"(#"E+1E*<`%--*S@A4G`!F5<PSHSC"30+W0;B^
M>-[#.(4:'M!"0$OS0EKF;3YG`R#CXW2.Z-8_DM*-;[J.ZFK.68QJUHML"Y/:
MPE#%ID7?UE+R,2'SUDQY@%6^-@TH,Y<6W:%ZU*\9K]0<\1JN;P)&L>)/0?([
MS,B\<`<QP&$60AUS[B2CI?`.BA92BEN49`#_9@?"^!&FV<[UPEX&%Z2@+3\Q
MR*V_X@,J1J.Z@78<-Q'";43OJCG<WY:+Y>P*>)K%Z<W>F,K:6,S6C+2*1GN8
M9"\W>-STQC+>X.Y)F,++>;7%=!<=S75>.TD;2VO&C74-*EB=@!@>`3'N*EL"
M'Z2B-$^QB!HP4$[L'GO!BVPQ1W&*>9QAC81XXF`>B?E>/*^B`RF^^0FA]5,8
M25W.4*.G!8P,:0O.$F0T!49\!=$U9EC*D2_DG7N.$HA(1Z.>`Y9[5,6PV`B0
M3$W)$Q1,G>T+KC&69K8&/"5C*].*J'D_FON[*Q"@TK,Q:"K*6P0ZMP<5L['3
M/9_"=`4CK"*(#II.(4-M:)ZBA;"M])!7::$^B,1IHDZ->0V'*(U48SBVNS`9
MU'?2@[9ZMO;.ONR9VS?+@W?)%K;'H]C951C<AQ&=$?`6A!;B;U&TQM&)[$:R
M%YT:'7F:6@J7)6^A#>=\=CJ_FB_G%W=@=GT.[I:+L__S\^+J_.+V[@__]N?O
MWO_I+^#B__L\7_[=I:TK0XIT=3L!^'*/XIC2K3;/%C"^8]<,<2(-J(?KHC(4
MGM$JXSB_\L1Q)&KD^A3EI?8%[N"H9*ZHK+@)7LC.9$!A3Y/"H(J2.C$+Y<M%
M0<F>,?*AF*<%`D$9CT@[WJD[:F@ZYS'N>=AJE1S@^MB=%0V\C8BNTL7TK)@Y
M8>5%_4X_%DA:1S[J/:JK7!#;1S'YB]T^0B\0WL*(OFPWR/0EB&E!T4O7GBO@
M@(__%M&CA'L8PTWH-MLCCQ=2UI_/V.3N4G`#.3MG?G,.-Q!S6]_"1Q@?=!9"
M;12T4!`3L]#B+^<#$L;(I2OT0(#DM..=NJ.&IG,>(UMW$CX&Y.U?SK_4C%M(
M0%/9`EHV3+M@`Z**CUL#[T(!26G(-XU'1\J^:E>VI5M?^Y"DNF&0PL5]%#[0
MMP=TECM]E#2O$'41M7'!B_(#$6$(4,G1[?TN*8B0FM:\A2.J(T%Y`8[9J*'_
M&F5P0'I'^'4MS0LHF;=^RL2'K$Z7VI&$4OQ2<<1KUT4FAQX)#]O,MI+0/Q(?
M8^-:O[7BR4JF#XYF88+1':I5U==*$%QM1H<9NC$;MV;>K67]WAY!R1T]&3UR
MLGW4-+8E5Z4[`T]8182&ZOR8IH6ZA<7U3V^6%[>?/#3S#G#$%M^F,%^!$/A!
MQ6KTH@,4/RQALN/7:TK.(/R^GNH%I"PORVFI/D";<E&S1XGK'6HG(DA&79YI
MO[!WS``0#J"V=G>9F-$K-98@9C(?8+/0N"U#XZ-?R&/8G[PQ4HH\$EZ]*1P7
M=?O":7+(%MA,G;Z0H*V-<(SB-YYOAB4*]3M4YB4.K;OBD=U@L`>8-'Z;=G^T
M0Y[&YD%ZTV!ZLS#")F&<-1/:[4)V0X_TG4-Q%L8/,%XI'M=VDM&;=]LI6E@A
M5<Q8KT*>G=/ED`0\2$%I?D(1':-`.Q)VH6"I'7CS6L(\SN\1W["U\2S+DO#^
M0*]5+A%Q5BPD*?#"'YG'V*9@JI5N,LU9LSNV22$L]!OR\N*-):-!=G%Y-0:2
M!P_1U9Y2.)!+!WCQP!*!NH"@D'#\YS),7,`S?N5NS$MVLR1!3UL8D'JU%&+W
MV^+XG^Q10O>_(.5$^4.P1^E?:!.;[.5'OUQ?S8VMN.1H[C6RD]PD>44CE46Y
MM[;PZ[H-.IN4K+1"S>LW4_9^V7]_]_;=N_=@'R3@D;#\"_CCR;MW[\C_@Y2]
MH14<LBU*PG_!]5_`=^]/OOOXGJYF/YY\K#X3IBDI2Z>=;:HGMT"0DD3@_S[$
M$'QX=P(P!-_3S]QA#X"[>[P+SW_]X01@,GNX(K5WD9.G`F4,`DG`Y1?X41-W
M]CS:>)VWN5?@U!O7'WU7>Z?!DS&CV4>8W*/:7J^84$1>]?[[3K_ZXW?8F_Y\
M\L<?_D3]X\-W)]__^>/)]]]__PH=K-4B4!]D'J$?U6`?VZEFZS5]@"V(;H)P
M/8_S!#\W5!4WDZ&F=U>ME["%%5_)$Y!NU&_"&*P86Z?7!N4!0^KZ\QJ<Z`@7
MP@]OBD!Q+,4[T2CN<PNS((SA^B)(8AQ%T]EJ==@=Z,VM<[@)5Z'2!DF&FA9"
M_82M7#`L>(`U8^+2;Q200NJ*\QJ5W&\*=J#@!WB(SL40C91.&)9&,+8UM7!8
M17X&NLD#OW('<CD#H[D"VSF"<9INAC%>G9-<),O>J1C[\7?UVCHVR-BH:(O?
M\*G*,.?DM*]FF^)1GV8\4G)NO`7Q,@<\H0.G\0^:G)X?V"IY>,W'2_:.E9P?
M)_E[C.1%*T?-:J466E9Z_UFK87H5C1M[:IPZ-.HQ6(+*IY8&C0[.EFZ"9)'0
MM[S7-%-X`Y,[DMS5/VYJIVC@$**-^`B'4F7>W)]SH%[P6H^&NO7H/5`M!TB8
M*5@D@+%EF6^`&0/*V8%S4;[IK#Q2T7>J8TH&,&H2'<&)CDZ9_'&F5K!:G4BL
M/V^!:7$:Q@S,6B$9S5'F]#AQJ),45(SAP`B.YQSL5-4WQVB`T^,4O,Z\!*+;
M&>9""$9SA$5UF#[4&VJDC"'!41W/+[@2`]^<0P18CX<<J=!?<+I]9=$.B^W:
M'1.;%RER0VL\QMNVU$M^O-BSJ``FKK:QL%L9#1Q138[[?0HW_"&;E$XR0W&Q
MOSVI.XM7>Q,9@,3.8G!78AT,D7.XV8\<#55],])*PHSN;6U#A$[@?@_2!TB7
M\0_>?5A5?H?1C[CO.!JBYJ:CFXX9[5O=;@CMWY.]AA1(79Y@9I=A'Y`.GY#?
M7P3)4T+,_?MW/WQX1XV=_.8_Y[M]$";DKNUBTWRR5\;2)8@H:;67GAF5KM'J
M0.C3NK"O_E8Q),7Y1V\\OW5AYO+P(&FU?6LW;,[C%=I!NG+?:;;;:R6A^0BU
MD)KA=Z<)#U`RZ;@.-V9T[,,"26K)/[W7'Y:65KY</"PIG:$X15&X)KO0\I?I
M8K/80U9-FBYEN^=I$E:/FZH\K,32"HL5)P5>0A1BD!"+2D'<Q59MJ-$@=4\%
MUEK#A1)37H3*[?!"9`,J*<!O5`YA_/-WP)'1L1H/-U=A#.?X]_++,CWB5NVS
MY..!C1)9`!7&R40]''^-.-30_Y2PUG7/#I@M756CSRPIM<VJOJ-YP8E]W;Q3
MW5[\<G']^<+MA;*&/E';P#W076ZD!=%Q6G0R8X\?+O+7-G7V71U$]!I#MM&S
MT)_SYN)VMIQ?_P0N_N/FXOK.;7O"?C20M)9\U'QNX2474+`9O9=Y<(^26;S.
M'W#,Q5"Q^38*>N720F(6ECE!%"2D3)HTC<@?%7V3Y(]8KE#J]E71'E"0G+Z\
M`R`W>LJ"UJ<7KX;F7$8Q^)]@C'TNPNQGZUT8A\392&\0#<OO):6%0`]5\[Z0
M,Z2N$-18>O'RM"Q@2%&%_H(3U7$AGE+G-JK#%'?`L1CG>$$6H3W9(&BX2P\A
MS75G!TT+"_GB/CSQE77%T.W*7@8?I*0S7[&(&C`0U^!XC>H7].SP-$CA^@SM
M"%N6N55PB#8*>K<_A<1L)(C0ZO<W]X017BA5G)Q>ZNV&`LEIR3NU%[D:P@)0
M'N"L0^.6GI[>)W`54H;XYPC2>\1X^MN1R[O_4K9Y.7J:SR3WD[;Q3G7%E2VA
M.'9NGZM60`[IJ-%SE"(!0"5'MJKJ@<J/*HO:26U58@'%<YT_<D='(B\VH&(%
M&"\WR;U!23U3*25;%_4]3^5)I?!,INXLI^S&M6!6JW&%4CT;YK\^3+L5)?-V
M7%GPU>+.#^L5Z%UDOTVM^*7C(QO.*W\(AY&>LX]1?7"Y%^F<MD@0TWR'O8>N
MA=.7Y<\7MV!^?;;X=`&^SL/V-RX-7QXII*PYGU')783G5GA)SF_L(YHJ"%QB
MA%@;ET\PVZ+U/'Z$*7OB1\5O)`D.J%GLH6W>?_+>4F&,_T>Q^CK"(GQ#BN0.
M<:V"+MALP@CO!MPFM=4P/:HRE=*O[_@5^X-J"@*$9]$GC'$%'-MQSH>",":R
M+.*[((*+S4U"XD#V<H-UEQ'1:*91Z9A(DJ+>@804<0N'1IAOZ60Q2#%SXFR;
M\)GX&-W9T0=QG9X<J4&)]+3J/6P1AQCULD4,"%>R'2_X`LH8E)Q'FMA88[_:
M;'X-%6\ZM-'0#']B<C9J[O/'L8H)*\_G?./<;7IA0;+Z\A""J*']QM+N^ECU
M5DS_<YS`(")7CZM(<`Z3\)&>[RJMYGI)::'00]7"'<DME@F2%1SM)D$FDW7%
MSZ4_R&*%%+7G+RZYDU2\0&WR.&_'Q=[KZ:W;/Z4T6`\E_=>[6XG:>DF].6TX
M?T*]'Z#F,^H].O,6C(C'H2-1X#:C9B239CI78^W(8SKY,Z6\F8U\V5AY,@?)
M,?;&]0'+4MU=.84;E$#VN67P#-.+YRP)4+(.XR!YH5=:AK\#8%4,`XD<HQ*9
M=V)RR@,N;Q>?P-GB>CF__DR.?O)#H,7U'3B]N%S<7A3^O9S]A]LCS3&,KC7G
M9P'*UVE@;?G%2E3^AAL3M@AA5%Q0DY?=?G/Z.$&IRCS"GL(8;M0>;6LE,<`&
MCJ@-Q.\CPR^&#R1CGX>(FP0]ABFIW,$X%:O?C,#D/A*T(W+DQ2VZ\DC[0N_!
M3,H<2<[&D^G=]@L_MB2P%'/]>`&H9SYW[['6+$IIVA[Y@2"?K4=MLO;[#:&Z
MGL_#=,4&`=?5$*YAMMC@J*H?BOKH&C"1;A867N6[6)9[>!)"OF$QY'Q^EX>1
MBW,OHX@DQ*VQ04;/$X&SS8]YWKPG8^[D'!+S'ZD5/L)+%]7J2?Y;FCW4"P+F
MYUKB-*ZK)`5J1>VC]T*%4;FMP&1'+("$6>64IM>J&L3U4HNJ?&QL"$GD^/HA
M".-O`"E#`0&_`L@0B%N>>'6Z7]2''PU6_R2@;F278<:7*'NURJMI1MM+3<!B
M;TX!L^7R=G[Z>3D[O;H`RP68W=XN?OWY8G;NC1/U.H@IX[=IV*,8[$60Q-A+
MTN+QB=,@#5?DLG88'3*U/O2]I+34W4/5SGZ#FCG>4X"[GV>W%WX:O"QR2%&7
M_J*4NTG!JWJZ!%!V[.(_8SB*[_P*PX<M9C9[Q#N7!WA]V-W#9+$Y:E6N<XU%
MG;86;JIL++0.(!Z6/Q@,WH#3V=W\#/PAV.W_@K?X5Y^7%^<_NO0R;8S14"5/
M",_<,0OF(.<.&'NRE3_NJ3_VA9DNS7!B#9C_=#D8![J=F7GW+3$/<LR/'[+`
M7GU/XS/MCR..S[ZXM(0E2#IV'PB30UW2R6L^KCHOM[1R_C5(DB#.THMGF*S"
M%*[/#PDYCX!)B-8LM,@XJCPM]>:]$F2MM(0O^`)8,`9KRAGL*>O<']VU@E?!
M#JDJL_71#1U#HN_AF;&CG)1A,Z)4W5@1+;_WU(CJN$G9$*=)R^^VE,VS<90F
M3;*V*%KCZ9-=9]39&$@2U.M;)4/;4LMQ,G]P/(L+GWZ\^**&(M+2J.^(B1\$
M4(;-KI<Q]J0A&HK)[>#9<ZB4ANTA-`PC$4UKM]XK-EXX3B<P(H=I5Y:O(!R%
MM",DL%M@;N.X1&.<YV@7A$I-^5H(Z*4'1;3LF[[3]&RG_I&4;GS3=216,_B-
M,1G'L,^J1R$_0;+U5#%JP9>'ODS)Z%A['Y3R\.0MT(:^Q0^`\OKP2;?1L5K!
M;XS!.(9[@VG!)"%O^FC9KOC[FG4SQZ3,6W#)Q;T1=^H>R2C&,SU'0A6/:]"S
M]3HD^8,@N@G"]3P^"_9A%D3JEMU#2$OUG33-VWK%#A!^;\(8Y!Q=FKT<0DA)
M:[ZB$0F!`/,2B'&=XQ9F>$D$U\5IM;I7M%'0[,,O(F;!#U:KP^[`7G`YAYMP
M=7PG:$P'Z$$!R2G(.XWGMEZP`&5)Q*@F+J[U4S?T;CJZ]]Q;25HH&6I4E;:5
M'(YI^5+@(!6->0I$5&(@@F!<CZB>\(R"-,USLMHYR&,BPU)?37H6]JR$`^G2
MY'S!WX^$*.DHUI"/6C]*-C+5%^GX,3.-_`#5TXRB;^NE#8X(O6;[[E`ZZM>)
M5PJ.>-U6!BR74VPYZ)^GZ0&N9]EE^`C/\900D.<++TCERLM=^'Q&DO%%J:K\
M>D67LGH9@#(3*U4!3`H09&!#WI=;4T%H%1>M`7H!:?@,5O1@8P\35FGBKD9`
M'W(T3.N3@5>074ZIKX4,Z/\%_OL?W_[Y!^W'8]R,*@\?N;'.,D#X`R8`+3UC
M(@`L`Z!"<'7CDHO#GB!#&4`8EX.^QINR[(7(82+2J)+7MT<U3I9C#LR%X>-.
M3.5AX<B[P*-I!LWHHP/"M""7B$/O__SVXQ^'!B(78SN*1H40?$1B<K!`938D
MU0\<"D4LM^B08O]A(NC&(RW:ZI:IP<9*)*J.5FK&B2-3ELN21R8O@M`0X-%0
MS4\(9/'YY%'X.7GW[ET%JVX@<C;*EM/!*BH5,N11R?2::(E^"J((/04O6FN>
MXZ_K3G!-2C;7+!D"#SDSUXN15OTC">WXI>NVDAA0:;U@.VR]8$?\^GI@60G;
MZF=*.<9FR:^[7EWLHL!=%B19CM8I?`CCF%T#PF-90?*TZF&D9T38+1&F=J7D
M>^U[^J\_YR3&TRWCZOS![:;*F\]LU_3BB7J+7#J[N<@HZ\:2T>Z!U>I><V8D
M,_V4"^#]`'*MEU>/2H:`<02,98=A^W2AJ@^.DY;@Y]LX9%&A+$<Z4RW7SL>F
M2/^XV-.V<:6H:H>MZM0USP-5&=FXMD,63HCQJ>[ZN3VGU487#5?NI)",>!#S
M!:4H5.;KXUR(RH-=>BL-%[:<M8NX283;^8SFJEW3B&.7E8"XWV/[5#PE./O]
ME4K@U%UGZW\<\H=4EZBE2)=&E?L`BT1N_,`XI6F/6X@WG&F8P3N8/(8KR(9T
M"U?H(:94I*_3CR>+9NFR7;$LQ8XW5!RPXN1Q6XD^DJ&AL9%[Q4:51S!.6)+!
MZJBPKT0&O,R@%!KD4A<1D)/;ERW%-7RB?U*LV92C:'[!61*WM08AIR(DPX2W
ML![DF-20D]TB-)3H/4K26P',E_U]G&ZB72LMDW[5)&A\63B>5WGH32UP2:[>
M+?J2#6AD5^DC>Q)]1Y3,H0G<XFDT?,R?3.MYZG>6X&DV?N"5IO.HB`WN^B^W
M&A7$@D/#+(L@6QXED%U]RQ#W4#6(PN`^C,),>$(YEK-;M*CF&[X6`'M5UI/'
M'/96<$V^HO^WQ"O;(!>S$:U&?CNE<]5SAN)'["AX<;_8?,:K?'-+:@%E\XNV
M(R;V2Y!6E&4>059<;:3WB^]VK&47X2WJG@RNTHORBC_Q5"J!\]6Y#5=M(VQ\
M2>B3HWKHH#T`2Z[K1W!/FV#*KO-=.:>X-NL<KO!"((7TI3:(/Y"B*%RSND,%
M!]4@;O"V=P<?\X[:8$!J,,Y(B=0:@1L<?G?!"AZR<!5$Z0E9;#FIU!R.>>_%
M_5Z=3PG?W'?;KO@7_/-'!>L2#"BO-/VZ'(XK]ZAJ&H$7ZO2-,O)T-=X)T,M-
M`,\CV38%,%[C^/2_#_@W']Z=`%)G_:KJ1"_BXL6VBZ)3?%>)J-/RP!Z)Q>MR
MZT6M-PD[_*&_4UJLM1,97(]9HS?*9;$3L"<\N^]JN*B`%>/34@XKT)N/6!1K
M*+Y0%E`^U?T1W7MK:`7AFKY(6U1`+#9%%>(L7O-U&C+6KD-5YQJ3`@-+M]28
M!(!88EDGQ%>>THNS*5].Y/*6F@[,2%_;XW7W/PO2[66$GM*!3?T%=(9VAC\B
M::^%/V$%*"__.O>W(R1NV-^B-D_1:&W/+P6)7)2N>AJ5*VQRMS'_9<J-;4D6
MDM)Q6IFN>J169&$E5E>PK#@A<&PNI"!A>T7@VA!!G$5I79C1$%U/!%*QF_$2
M@$J$IOM1.70N_+D;[U&0'S14TV'F"F^9Y_C7\DM"+=HV;;-DXX%]$ED`%<;)
MG#T8?/4`U-#^A(#6=<P.C&V]B$[8X[7[8[B&Z].7SRE<S^,%WK#C:3%^F*VR
M\#',0GHLAW]QP+_+_X@'I+.8-L51]W5P`\PMI$YF=S^#RZO%KW?@\G;Q"2QN
M+FYGR_GU3V!VMIS_,E_.+^[`XA*<+:[Q;S^3/^0?65S?.7V!U[`!(3M83=Y8
MBAP[S%BX*(0"IR^`B$7*O$O!0"49J$0#E6P]NS]'"?A:S^8\_3Y`/$R"E>O8
MDS!DY4!?$TF_`0&7I2?GSK,D04];&(QS5^@\3%<,:[@ND:X40$]_1!\YA1N4
MY)57BG6(QEAJN:<A[@,MXR.SC!@^D)D]MXVO&?5O\A,DDOM;<Z(`5'JBR]!M
MVF*0)6PF;!WUZ,TSK*)Q451(BPC9&:GX<TRTXN."$D(%]525E7=!!!<;',LQ
MG^SE!G^5/L*W)\M3*[Y!6.>>@0>%_6*/TB`BR95-^$Q:N*4IU&J048RMIW[4
MQJ#.ME@JB.<#]A0O&4Q58#S.Z>-L1\Z*_T5-9;$YA_<9-:-#G-TD<!<>=BJ1
M78*8WL6Z/KH6GCSA6(*O@]4J@>3';PA&,<H@B\P'V@0DADZO;LM#B)15ZC-<
MD0`IO"\F_$#!$.0<1_&E9G0LJC*P+[.+EBJ^)$%,"YQ>NC8"'7U+A6Q`'DC=
M._X?9*]-AB5;EPXDCQM2UJ.7&-4=J'87@3`D7I0_!\KQ'&<Z(K/X?+</PH3F
MW[9!\J!VN;"-@EXD$Q*S]-80\8^PY`7@,[EJ[;3TI0<-)*<H[S1?3!R$!:AX
M@)R)J>3!>.5W7<]6A2W/5EEQ7SQX6K19%&]R::^\FX!.[E>%JI:QR3.PD,.E
M>X"43(JHS,2QS0PM\BFN&88P=9JQU8`6Z6MX$C#F<:1@6Y4LU[*JY4.5LG4:
MMESQ%JX@WEOB:*0TH?80,H041]/&`I0C[Y<3B4#I])LC17D'@(1W=,`QUKQ$
MKND:\XAC:J8"6(.P#=]@-Y837SVD%:GNZ46H.#]1D9E.*$;NW>8F@7BYO+Y@
M>Y-A3M.D90B<.ED;#I-S*'9HGOE+"T2=WB+2F8]P2'A*`<Z%>/L\YO12'?G3
MY;R!*>:(HLF`UB!N;ZII/ZIQ/,NT`=8_TPAUYR\XTC,.5QPB!&TD=YJMV%G+
M3?`B6X.N0,P03@VZ%LZD<@9@SSCXY4%M&'4ZCU!G/N/1Y3(E/C=B?,9SEN2`
M0VZ5.!KL+T?TS$'4(&W%:P@/3U=K'6#U.8Y0<YX#T^,^%"B.J1>K-V..U$'6
MRE+!JENQ]4'4CI5/ZSEE]^I1Y#3@4EG>C>UTPZJD5?QP*"<'1>"&O!5E052<
M"EXL`;TM\/GNXAS,K]6N"DSWIH#(VTU@,UFCR&."H1L!+D,%*TT9\[*1,D>3
M5J+(W/YEH_GU+Q=W4[YLI&M`_:%$"ZO)&XM,:"D%&W+9R$J4P7OVXN6.U3\/
M80)KM>VS>%V6MZM$$A6J6@8@S\#*20C^^A:O*&F3@WW.F9:MP(*M2\?7P!3I
MJ]9O_!J/B.=LZ=,OC#$H.`/*&F#>X*(-13LNR+4"$MPOT?9!%;)Z(,ISL-'$
MEF\6E9+Z78E+,:.YH`:F:(!FIX%?U(".WM\J2J_=^V$S)GT*DM\AK6.]@ZM#
MHIP*DR1H)H"*:-N<^XBW[4J>("V9>C7S=4+8->FUJ]-;N/JGNHHIN&O%:Y0Y
M#GOWIR`C$KPL-H/]3)VXD7C9RV>L6<\_/]2&NV,2E%3WE*!MGQ#)]%=(0&9'
M=ZX[;*\]7O[)22K!8LKZYG;QR_S\XAR<_AU\G>>OOU%+/TTW^V0^Z^0LV^1C
MELEEX+@,XR!>C9G`5N9HTDH4F=M/8%_.KV?79Q-.8.L:4'\HT<)J\L8B$UI*
MP;Q+8-_"?;[366RN4/RPA,DNOWMV14[]%_=1^*"^%E$BJV4""ASL5/.'&-!]
M$(%"#-)@9I7?VHN(!$ZW$#JXH@':]1S#NJ]6?,G>@'`&A'5YZ9(R!QSWT3?Y
M\_Q-X$7"]W+0W=6W41N\UQ,3MKUO+QY,ICVR^7=`R!'2OOXZF_,^.PJHMFS>
MNY3L-8+"[7G!$"R21ML0W6;8#E[>:+=-\GJ3W-,;$QJN$,B"-P&PX$[S+NQ=
MO85XE!YNE<;;(CE9[8Z48U':%TUW6V1^.^1L&^3C]L=EN!"VZ#292.EC8-(&
MNGE92).4;Y5TMJ#U,2$BB7N_P\OH?&H8R[BWN(7LZ*D,R2IIL=94W'L@(RT3
M&,33PCV>LMC;[2-%9K%'1O4]59PC+J)+%_JWQ`!GCB\X7;+C^`J,C!F$-$_S
MCE\=DOGK^.K8]SB^HKZGBG.?XPL/2'US?,'FQX[C*S`R9A#2/,T[?K6'\]?Q
MU;'O<7Q%?4\5YS['%^[?73J^TH;(VLY]C-V<A>P=WLI1%]X72-^_@*\/!&KR
M5L;D-^Z#-^QC;=2=;]!'FZ-G\9K\AQSS/`81.7>]@4F(ULW>!JI3LCQ=[<@L
MR\).EGU^?79[,;N[('?O2<;=]82K#"0:HLV)@,;/GN3\B_[`\0:,.3CJJ#&@
M9;QXE#,<?9+D!4_4OY"7@<P,;T^EO\N").-+XF9+<'KQT_SZFI[L7(*;B]OY
MXGQ*0[J(UXT!75R?MP_%2G2\.^SW$7V=-8B*YV'G\08E.QJB=0X?I$GJO5XO
M1]W""\85X^2%KE(BE!X2Q_WM5?%#FIKT'ZOH"*:H>FP8<&S';VG/GK*X"<*U
MBA_5OZ?9NZDB82,5QZ@#TKG6;1\M@891EQH\T6;44.1-BR)ERG)(71-<+]%/
M080-/GCY!'?W,#$CYR-,[E&)>\$!7(6[,(,Z$I=S+JV>HP4[=]L`B\9&84/J
M,ZY0[P2DE!NMY#,U`(/K@]K!-E]@2!]<[(E:Q!I(+/K^W0\?WM%(1.WC%JVV
M\%.`)RX4,]N0"4:M7U5_GOZ8BAEEK='J0.,]">Y?_8VR`3O&YZV+L-2G;M2C
M$']4R]LATVO.A.PE=`.5+6$CD9R_,0[CS/2T.^'15?'30QK&,$W5+D7WT]*:
MP_K(FK>;HD7C"TAAEK&EF<O%@C1(2%5K'@.2^P9KGREJ+5`Q',53EO`Y.\6D
M?]?98`J^K*7Z(SI&=4VH`TJ^8\,QIN&WZQSUZN1;RX$S>0CB_#'<,Q2G*`K7
M;(L8KV\P!L7LOMCD)T%!=(=_0V,)/9AB6W%2>QX^Q.$F7)'^-ZRO>1@_W&!Z
MJQ"FY>"4`O'HLNG%D9'%M%#2Q8V`WE;@!`&5)*`0Q>DDXLI@D6O$OR#CC`1V
M69.>9MMY^<E5E'($H!H"J,;`;JAT6S;XK9H\1BI=16G1+RQ[^02S+3FK*-]0
MKJ37BJ`:Q/5.7E3YV*I.$SX\/>I1F3:<:+`ZIP1=<7*&N9<-Z_!&A0G`OR+.
M._#HSMG:U6^@7ZK1U;WI*<W"1LD8Z28I?@)J3'?4`A`-T>)$P,K]KZMUI%//
M*W;%9VAWCZ=U,L4/]#E9BEH`RA&W\5811BL-6V\5C^5GBG`A/<UY#TWN505+
MP/%TZDUSO$J.'\+["+*0/-"5I,CI'O3U4;9RFIHS]6#&4H$*:2C.;UBB%D2<
M>H^=O9GU39D?NS$0QN#N<)^&ZS!('.>.ANW*1MF..=J'^;G]HH?[6Q2ML64Q
M":]1!@?ZG0)1O=(K6?H6"N4XUG\(]BC]2T=_G='JY)1!1-K*G`)@T3%61?:#
M\'7J<+3[&>G(1LXCASJ:!#$MO'KI6CA)=][43QX9I*PIGU&(>`!HRS[*SZF7
M5+P7&UH[=XJ%6^.]'GDOF!VND)Y8#^P$XO2E^DQ^_C]["I*UED\99ZV%O6$I
M+$V$;RA'P(OETH-M60VRC,OKL9`\EG"A`\<3RAD<FPK@!20WZO@/YD("*N7X
M`>@R"!-:\UH-1:_"HH>0%O2=-"V<-&!V@/+#NY>`<'-^!B@'#U)2F:]01$<H
M<+S<'1N<PW25A/N\T,%0/9(&\4$9:VD^YKWJFCR@0KN8%L+X<+J@CJK@H$%1
MJU-"L'G\P+&G1WM>%+Q<A7BSN\;;W:';RTXZ>GN:#I(VRK-S;D[WE3)H(!45
M>:KYJ*%TISO(6BT;=<47S?JN+CJ:]4#M)&UTT*9O*43L0>`:;[=57!+X(!6E
M>8I%68;%UU8R3@X6;T$:IN0IU:JLTTI=^3`^>@N"`2S->QV5AC@<+X_3!9X)
MY)%)=4\4Y8@'>%$'V,_ZY\_D"8.+-`MW0:9V3Z_Y32W(ZD3,N]IG]A9$R<&E
ME[6H&G5KPQNU1I5&%QT:';&5U2U,LR1<97#=TGJ(3J1*"[I!?`QV39)C::F9
M?"!HI>1?_RM%]'O[8:FH?*)(1QS(PGY9E3"@HZD6E6BLC=H*\V1=\V[#]/>S
M!.+=(_E)<9_63D9W:]!&T48C#(X9W:A19H!P<[Q-ZT4'*>C,3R0B$0B$?!<,
MELJ(B[JP`3F+#B*:M:DM]%[M';-^&)"T>GQ4>=34MK.,1.N]G`'V+T_3[%6B
M$7)Y^5VB@+]%Y.7M+PF_4=/C!*"*&BB);GRY\K.?$%H_A5&$I6E>-1C@:2I4
MM0"49S#"I160'N[_`5<9R!`(=BC)\HOS+AU0`U>DK]Y)8)B[8<&6.N`QEJX<
M<1[3ESY3LBN$&&BR'SR'CS!"7&!26^U)$=1<ADC0MN%Y;W*^H&`,_A#L]G\!
M''/P]?SFEO[V_!NW:T450)&6<GT'KUQ/@B/<B/?QJ$FE%EK:/+)7+1\P&7*<
M%J[S7OL:$Y@2.?6>A7*4K;2(Y`[=T08$U0'$G@6\#4K`JA2/_%C)!U#U*CM(
M8!20+!&9[+@[T.ZZ3BJBCS2P\!OI1L*H@+#&6+=QY9CCB+J'X&QJ9G>$2'X6
MI=G1!4'UF5F.WH!+C-VDS1O=IS!&":GLR6]3>9*M4<+MZ+JIC!(]QRAWJ!P5
MFM$G77\$=TV'S+[7&`GLLI@C_NQ#T==;9_NH1$X])LM1=C;[QBA^P\D'PD)`
M=U.K(K1(0]%^PUBKS*[Q!25C<L_^4_`/&@'?+)YBO#;JNW;OVS"CGA&ZFGEO
M\08A/L!;N$(/<3BP9%."F%8\[Z5KH2\Y8PDXGBXG6GF8D++:?(8D:D7#F<<L
MDV!->H;2KM=YF1G>Z*]@^!C<1U!]L2I)4*\9M0QM"ZV[Z%,>V*KIM'N.#O?9
MYA`517E.EZQJ\"$M5?H.5>Y5E"-=M+(.[@534'$=LQY%G"R[>";75C7<2HJ<
M9NSKI6QC0LK3>D$]K>=V5I)'#&GHSV]TH@8PS7QKSG),%[H(DABO*\F[D/1*
M]X"U7"\IO9UY-U7S;E,P!%]?H33]!NQQG*.<G:9-)&%"BHKS%Y*H@<9-`8.S
M99RX<\.BN,\ZIP5IX2,DI00:&4@M\GHMGM0Y?1E-288@C`SH=UIHYA[:VC)D
M45VU+H6@=3:CUBR?PP0O3`GO(<4S753T6L*T$C3O:A6OHJ""K`B+][`<=Z&4
MP`?)J\U++*(F#"XK6E9H!Y?!\Z"2Y38:FJ4/8G(V2E4()X!9N37Y7A"0K'8\
M5'C4U+4S6[^&3]P-TP3%^,<5Y`[T!OB`.FTMJ%39V$@BD)D[>@'L05S^ENQ=
MAJ>1(%D[]25MD-%0+4\(T.(H"3[5;CG7V!=NZLI;?X;1>HD^D4Y+8?9R!U?D
MO[H]#22(:<'72]?"/NFPVP7)"SFBOMNB)&-K-Q0_O,&?VOE2UB&/'E+6IL](
MY9Y%N)%73`M^H&+HT34=LQ=TK%W-&<>9)G0_1^]FCM4[.0YNXXR?[UMMX?H0
MP<6F>14""U;<6%B2,R\MQ](BKY<A4N=DP?5R(8CO-6]X.,WY#4`9&=#QM!"-
M&F`NCL%,J=^6-WJH%"Z=5_R@P:\!:6B<I8OD-GS89GK+S`%,!L*NR,_J3#J/
M-RC9Y<\EWZ-#!@HY_/!K70,0>K>6XJ<(ML#36Q_I*$0!BP0P85PZ_.6!=.O]
M%,;A[K"C3R7D#<K32Y2<!?LP"R+V@H*)R5N?VT"KT&5LH>DXE03DH@#*M&@*
MGX)#C.T%Y`*%_X)KX/[]$(/&(HP2P["9M&$(XD:W?6"A"NO(+</]FJ&FPEMR
M92#B=+C8T]M/\8.E**+*T*2]J/%V$TM*D?R-))HVTQ],=/"9NGWTAQ0F53VF
M-*W$?5015VK0516KE4AGJRQ\Q,LJ$R%%G]O0Y:HF8UN;%+SF$.Q1J#QYC8HG
M$62P?8AW+(/@F+0MB/8P;=5*-7L`A50^!0W^+:B+W3Y"+Q!2J6^P7K9DF8>1
M(:_.L%;+:7K8L=&8C2;&Q#!F6H8DLG"II6(%/J>L/P-[%LCKZ&/:T'K"DE'X
M7J=1]02R^@-LA;2YD17RTD,54$H,>./T*,KQ0;GJ?TN'\CD.LY2.T?XZ29FU
ME8E240K+U0?$X,J)\;9J.<.U*68F1^7T+:J9,"R%!986=*_'B%267F+[R:.9
M/RNQ\OW`\J2-*Z'.7UM<+["Z5X<DP?M.^NR$D>20"<9#DP##91CMM4MZA5A<
MZ5Y\;@V"#'!?IU:8BPZH['Z$+Y,V)TXNF<+UM=B7*-E4V0EWPBVTJL61';F*
M6PV%MJGP<XSN4YC0J]OS>'_(2,.$>(4'1F.S5N0RSGK8<Z]FI+!26LTQ(DNL
MYD4=+Y[M-6P_HH=^32+T>FPE.IKD\NC3%6UX$0&5$33L3"$2M307X[55;"%Q
M1&0MS%"$'EXN4<*%1_4UD!$VZEVLAG&TTJ2,HO](T0^X#3M9UNPJL>B*)ZH$
M<]>=S)!M((.(?&MYH@WC`+M7$,UCO(VAV,V>0Z6WVUI)Z`4S,34+R^^"$:@X
M.9VR>I!`DCKR3^M1N\+!;X3-:(VLXG2#+8"\XX@GF7"%)QZ\=C\>>KK$8TW%
M?SI'NR",5?S#+%_=7DO&1!C'$UWWS#)O*<@F'*_$*O)(40K&GCDM1*.[69&M
M`"I>^Y]_8S*.$V;R<M)/<'</$Y4XT?BB%J0U&N8]-2?OTC?%ZD6=*O!%E5%-
MB^`W1OO(+*>TX.\\,`[9B1UQ72XYT-.Z8RHC%VYPR_&3P,6)0VNZ^)R;Z[R:
M1'[2:G+-*/]A61.#HHR<9BLD/^I%Y"359L.D1/DVXWB],O,Y#DRRR7ZCZ3?#
M`>OTI;3VLRA(4^4L13>A838@HFD^%I0\`&7BA=-WPB+RWG95^0K!L3^=OH`&
M%F/F,0Q&GJ;2U),;(PCC.CR+Y;):#W!_9&!>.+MU@[,SW7<!^)J-R^9"0!0"
MY;(L+<=R%\^K+58\9#=PY;,G'5]6/T(3T;%R,%8P`@GEY.[$JU/MJ%<M/JFX
MU@:[KE_=/(,]8:.&G,7%\Y:4D.7BP--#&L80+YJXYQ=/7[A_M3S:-[`TT`#;
M@85;@R6P\-XB,X@PKE7X;4#K(X:+ZBE-/\K^S%F3L.C/$&:OPW($!7^%9(`7
MC4S8W+_;K6EX@<TUS,Z"=,MZ^\'U/+X,G\E_2$M5KN&?].0N34_CX3<YTE:6
M`)@W6&'FV-,9=^+R&\(?_T#;SX:5!`X?[%-$$^FHUG*1"]>TE/0'Q:O?V7V:
M)<$J4YFWNJAH!9-V@D9C`]\T-><#?BLX"0^?QIHR)'!!\NKR$H/:^9@2$-:[
M`I8^2,^B]%9PQU0&=X2K$[38RH]V?ZL>K/V-\G/J#Q+HM#3M$RG-2R0$ZQ4)
M$.SX`KL=6!LI?1ANB5?@W._F<7Y;\"9(2.;D](64FZB>/YC@IH?H8,:6^^^5
M$ISD[_)E6+":581Q>6$S%^Z$I$B)?$[=U9P!(?-X3=I8HKJ=-*($,Y-ETTSF
M1V9"=CU$L#&/9T0J9.I1/UWIIV4,99[L>`[OJ1<+\>KQT6,%>HQ-MW^57C-F
MW>0IBM<*>7_AU[0TSE&PD,U#NQU,:$4JY>/2TD4:1AUZ\$.;N:E2NJ[RXYQS
M7(4QG&=PI[;XZZ%D;JE>$AUQXT1X`LK4O]W3,5Q].ZB&!KV%IF\GU8.*Y$A(
M#F\6K\E_2,_DQR`BU&?969`D+V'\0(\GS`SH$2;WJ`J<)#6:(;`YQ&N`]GEZ
M^BA^6GIU\3ZK[@\4SZ*<XY7E.4Q724AK?%7\7Y*@YOM_$K3-1X/RL9AUQ<7M
M2XPJF"$M_?F.3QX2"$?^CET)%6$*SMOQLO1HH]*1C_!KFB\%&C[`J;_&Z,7+
M52TG,*TJ\$.1D90.!\U0-S`)$3EN2DC[W'/(_FO>#L@I7IAS`5^O<S[?D)05
M.=P;,*Z;!*T@7*>7&'#R?&&`C6&1W`5D5<&>+[`V[1(;`V'.D^S9(>6G6T7#
MC^3BF>R&4CR&XMD%<OF0ZZAJ=U`P9T\&]52\^Q#0%49K`85W!\E-^Y,^19[$
MZ*)J8!2W@BM)[U&^('^=U4SXR,>&;?0Q7,/UZ0NYN3:/R_[;>0>W$*:L9(+<
M9EN4R]&!0_[(AAS#!Y*UY*T5';)-A)Y`4C4J7)7\B_4P_BDHQ1L2:O+.XTM$
M2T02V/IRFAWO9,\GP.<]C-<A:8T^SC*_ZMPGGD-4EBO]M+2FWCZR-BZ<E>T,
MSUHFL+$6-]+X(%6%>8Q%)(2!WB>E/W`,1W$2PO3R?'Z&]Q.D6GRV(R4,*I[1
M0D`+`B$M"X4:E"Z>.5F!/"G%Q$P!#HDXWM(:#I=NT8T(DM*6;]J/N*GO$IR#
M.3@#.1O`^(PS(Y#26]63?>Y+>G&E^+Z%8$Y(.PWA1PI%K0/W07D1I[<Q#XTI
M0_7#K]K7]/5GZ_#+#_-K/_$Z&KP?*JP;X9@G7OF+1.J&V/BBEAYK-"PDK!EY
ME^8H5B_J5($OJHQJ6AS9+(-G3;.L?U%/ESP-&^<HS\[-4JA>U*D"7U09U;0X
MKEFV9DD^IW!SB*["C5)5M10Y+;U+4#9OV`73$_IT2T:SK"7C$\!8`\+;I>VK
M8(@T-.HW7E$=JARI&8]4%U!R]\'.4)JQ5EA5QG:694EX?\AH7RYTC7%"<89%
MPM0>YC$V(_PY&=\9R$#]QI@N+RM7R(@P>2-E+LT/`DX>DCB.:Q+A3S*1W-TI
M&VP1R`@:4T._L9I%]$R?'<UQ\)^`>X1^9UVW=0]\W(ZS2`81ZV92<&<]@)<#
M+!&H2P(*4?1BU<\P6B]143!Q1]IBT,.5V0H[WH$>Q7R.$[A"#S%Y#/QG%*TQ
MTY\DR[H'LU"W6'UN5B)6GEE%&Y)(+00`!RQ!_KKZ`^9,WK/A3BU)_G5-2EK2
M4GJP(AU'PDU(GL))P18/\DV&WNSR8;J+;`;L!QE"KO5.K5'3OT*I_$WN(2S&
M,GW"S8WI1YCS%V?Z-?L99OH5<I:OD[/J&YTKY,UO:NT.ZD3,MJ-ABPD_;H>W
MJ!EU:\(;E=;:$?7IU5+:[!\H(1=YTL6&U(3F.\F:1RF>=4F3U,P/25&WD83#
MC/,N\K3%[GV5K\"X5>S=ING4X$2:BO4?NN@8M46.VDR$VI@G>1**4+\'JD#4
M%GJV;H:^%M=KORRJJ-PI`*CN@(-Z0U:7**]1AD=R@+^&V3:,%S'\.PP2Q6:1
MDM1TLD,2A"TE`LM;IC%A#=8'")XH<[RC@.`%LW>9[E.!#ZEKTVNH6FX#4[X`
M,P:,,\"L`>&MG[,;;4B1_&AD3^2D/7^VP0K-Q\1X+3$%^D_5KK%ZQ$T86S^?
M\<)$0&0IHP3(M@DZ/&Q!]H3H+QRVGAL$?GL8D57^E(#N#3)4D,HK<R^EPM#?
M:-\-<3?FKBC4.]S!CR^Y3JS7[U#\E)#DX><JF4@8:6/J>FPYLD0,<L)3WE_E
M%I2<*("7!>3"4`6,.WX#F6/A?:`C;`DC_;>S7*?%38!+I!G[\G+9]/\\3%<1
M(K7I*EOX/DI#;^8*B-H(-%5/:D^N/7?!(KX)W:HI;R'(789O[\'U!J^X#;@"
M^"E(?H?T3+WRP[-#DMBZ\]=<B7XMV+%^<T+N?B09=7U2#6!X?*1R8.PA-E;;
M^8@SNC"AR^W>05O*6AZK1RU!*?J^9BKKF)2A13+*@BA'9TE^=IM2[-`XDE&'
M9]HM<X(%@X[<[;CEN#HGM1+$S)9V6CG/[2SL]..45QXUF?);`V?!(R$D*I56
MA,ERT[M610SH%]Y'<V"WM6[R=EOB=8/H4W-Q26"%C?)D-#P!$",S^(T[CUWI
MM)Z4H68V3E[9:T'9C=&5'WTH%?"3F=*N#/2C'`LKJ65'!TQRAT*W,,4[I=6V
MI"E]XB/XIGJ6_XB(E;.:@@LM\*=LW!W$M"L<=>O$<B%F\=(5WFK?AS%5W&V9
M+)ROL1CA)B2!>Y:F,$OSYD9K;(_<0YCX;UCO:Z.[AY$%TVO4/*:,9EM!%P^<
M<:*#2G;`"P^8]*`0GP8C_AG4?`0]T[\76R4WYHZ<FLR78MK\*L<G^[;S@ODA
MB6F?-RS%9?A,.[[14RZ5&-M!1.]1YS9Z5D[H]P?RBQ.`-IMP!:M)GM8^;@I1
MG+[ZW0L2DE:>CX#DDTG)A;I$P0=01KI'K)96B(TV?8WEH6?"1@TY+]KDM-2U
MCO:4).&R<+8[M,F>@@0J!YI^6IK=U+K)6LA6Y>3=-J^3!`:I:LIC$(I*I8H9
M*+B!@ITXXEAQCBO2HGJ+HO5\MT_0(Z0GRLINT45%"XMV@N9=H>0%0HZ92\>0
M``7)Z\I+`**F[GD^(]I_ZY)>V0?Z*)E-UIGTA>91.'B@56:L<WA`]Q1>YE!;
M/4)&:]["(9,W'<\_N/*[<[A/X"JD6U#\<P3)#UBNO$2%_KY502J>9(ZG[C/0
M1MC;J/^\@FGZ8ZTF<LV)2#>,`2>;XP>]S5H.L@71E*WDZ'GWTC!XJ4`I%@TD
MO&"=R:!A3Y:(!WP-36V!N7FK'`3Q@'(;?`)BJ-G\1Y`V/$-Q&J[SUQXPPUV8
MIBAY(1<-R)LL<"U]]*1'7/UT2H>/E0.L,HNYXK*8*UX4L"]EH262],D9N'9W
MSC7(`-!@`%0[]A2<:.XW#0EQ=O.VZ(&5,NK7!W+39;&YV^)]9JIIMWI,].U7
MAY]=.PXJB:JN:[E,N>F"F$I%+K*G5"YO3'J0C31-6Q^;\0^$4T/GMZGYX]9T
MM-/1U-\3S&-\N@\<4SOG@X:QZ#O.ZP+$<EFGP(G3TQ?N7P/*.V5I#ZP0E&-C
MM]RS1)47@KR<SOW;K[)/1>"%Y9\JFI\0R)%9?*W.;1Q_U>Y=K20&1=$&-8L!
ME./DPRS6AH1@`A/JR#^M-Y<0-5L?KX>6:(RLO@6J]\Z2(&8,B!K=<1SAI"C]
M<7JL*X]8CW,(-.@S.ET.4_"3;7YES7>N=.X-=-,QA4E)<AQG\>:.@!1*W:[2
M4)VGB'3.*#U@^)WNK+T&3^B2K$\SHYDA<(OPJG)ZP^O()H":"*"2@3;@`4R*
MH2-VE_\3`DMN\^.QTI?*ISNT+F_,FS:6LN0X`B8-V1(Q>5KPE4M9S_;[*%R1
M3=/BD%V%*QBG<`F3G70ZNIV`>JJYC9:=]N\E,_*V-X@8.X"5O7.7'>Z%`TFI
MRC?5U][RK>G]#:]W73^V*WQT)#?F`G(V8"F06\[U;B`6!)OC`UQL;M%+$&4O
MQ3V!%VGWZR:B;@==]*RX8<601/6$L<3>F/-TYXI2\"!IM:F>)2[NH_"!ZFB)
M;H(71E2R"4P/`76K:*-EQ2(J9F2UM@]><JO`_-Q90R\<2$I5/CID[3YWMS?J
M!FC[@XB.Y,?KHYQ5>?U*6WZ[]L\#T&'\?@H?'<F]1`"S`;=M<DO.CE@8C"3M
MJ+;8X`U.%L8/Y)9?M4*N[7KD9TQEPAI.J\C#SLS*A&`/SQ%W7I5RU$HG:B5`
M#N=;7<#1(*6/7P!125839Y8DY'UQ6GM/7QI?;/`Z<X5V,*5#ND)/`RLFAC`V
M=:RO+X.%6Y]!NB4AEEUW*#)#)V#G_F%R.V;37<@Q%)K78B(]B;8BA-9S;KQT
M@(I'%B"%@'EC4"SBJ$<.PY7Z<_BP=1-U&&?'-D6$&#'NN']YWI+E6`D\%3BO
MQDKLA1XBH_;NS<EJEO>8:YB!?<=RMK:$G=8PBXUK/CJ&UF+#P\T?"IQUC=2C
MR>1L2WZ<Q^R155Z=M:^4._/W]F<9#9%&#"S*TMGH@B)V*/`&;$AW<^9YP?H?
MA[SI^?1F*GVS'#R%:0+\^DUP^*3'!`?S&.1O.M?C9_V;E?BCA,^?$%H_A5$T
MB]?S.,-RAF6;J^J=`)TK$8J$M>Q(B8=1:R@XTZN0%>^BNU;%W9.+%'HPHT&J
M5CU2NGC>PU4&:U=BR>]B/`.H5*0I$%-/G<K0M9(N+1C7[FX#R%B#B%1&A82Y
MNPRI$GY(69]3B1#\DL5$F!CL/-+W<R0)&74:@Y<R5!S&2R\YND^CH#Q?0:F]
M:E\@4NLMD//LNOODSW"B`2.QTQHSC''8OPH?X5&`.WVA[RV?14&:JM[\42*K
MUZU1GH-Y2V3,WU#N@KA\_P+84]54!*=--37@10.4/`TH(QY%T(;B:0W%,>\C
M=2BD4L=UL-.XG:1,VC2B(BYC.^A)#5@BAZ<^VHFVG)^VZWLZR,KY:Q/3<>]!
MW0092=;(/PG>\D6]GG$\#0ME<XR\TP9]0O6B3A7XHLJHID79%^H-]5ZE==QA
M_#![2"#+)ZJ;:`<1O<:?;?0L-%XM6(&*E].VJ[UX(&D]^:C[J%WM@Y]`'R]W
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M;*9M&9(SJ6BC64I%(@F3"Q#!/(PA1*SE$[(7-4H&(UA#SLM)9`AC$@_^.)UX
MT$1>.P+4M#XUE`=X.9$#8$%\]6K,WE!VJ8?%6)@3;@Y]^X>)^78-_V'>76E^
M>E@/]O"MH"6H!SX^VV`K)A)>XB_8\_,&FQ'PKW%TX>\G).V5P(#(,1V?%]N#
MMM\+4)@F]@/\GTK#H@"11Z\`>8XW`ALY)<AXL3I-]0I8!?)6*I0K_E)XN:M9
MUL$6Z2I9]=H(YWFTRK^3W97R11)=\NKFJ,?)BF7F422B5DF>2PLK4V6_/#J[
M=&>=`PT`&5"_JLU6KU8H<56[R3&,B;K]#N%GQ8K+YSGP\F<S)8LV8A[(&"Q3
M-(6V9WAJZR-V*ZMW$AYX,\6],B(O].!R?CNN+5<<^M7P,C&7XQ?M#@P,W4I^
MH$<S%\^KZ+`.XX?B<J5*4D"=MM9N4)6-&9!99=E=%B19;NKSYIQ&7AD`Z>'^
M'W"5D=9.?"',";B'#V$<DZK/^P`/<N7T@%[;#-!0'"8$>53@W.O&I0"@D&`<
M9][M@S`AB[+CRH9*:KH"&^;8@_CH(3Z`I8UWWQ6=O1+?J9>;L`]D$I2IV4(C
M$I2"",M[0$,8B;#@;3:M]NZ*FNUW%0-Z.U[Y6#]P>#ZL8BYBS;`&XW7'`F;L
M`ZUKJ-0TJ8^2Z:,)3'2\I><TEIV28,H=.)7Z]18XN6,CS,[Y:O&RFK5,+0QK
M)(W/^QSU<99[$U[JB<"57-4=J=EC(-76:AS?`;.XU>KRH99I:*4RWA37M2[1
M7),HK<B.!C=:+FF)LB`"1Z.6G+Z]<L.ZU2ZY?43K(+M#J'^N*#4H8_N$<:VR
M\L'6D2GM`MJ>.'N*L1*WX;YZM6D>WQWNTW`=!HG\&WB]=#0>/.LF:>?=LX(G
MN<%<O&(5QB3JY6P=/G\F"152T9_EIW?F\2/,&U7/HFA!:O'X7VFTW)6EJ)G?
MEB%N.--1T@>8)Z!,`?];/YKK*B*)])3J/6KU?-PPZ+P)@K7'[WHCH-=#B9JC
MX%XCG,?@KG44DM/E(4OQ/$SFW5,V[2XV]>?&Y6=,"5(:DV8O53OS9L6V6(\(
M7GYW.'?*XX84-:E:%G=&B*W1S39(=L$*'K)P%43I/%[)M[R2HZ-N/#TDK5A.
MSA/LZTQQR%FY,Q=9C)"*XCS%H_XJ%@.CP1%'SI5NU!]E#%&O^(/[>HT56&MS
M,1=53ZNH6K$%A*_O(XK:![/H'8R57<DY)&_KH"A<TR!T"\FK.GG"XA9F01B3
M%%NQC/L)_WN17*$T92^;J.Q6AG+26@\/8VK>C!ORG`!.(F+/A4S<TOD$$+'`
MUT2L;T[R)V5<;G\,F0PRB])DS2,26D;-,!9"PV!VL4@`D:C%+N368?D+2T]P
M??JBD?!J^[KZ+"^F9&6QE3_-A#`OTO_=AZQ6#PQ(0DG*%U,RDCRN-H:+#9EY
MTEF\GJT?R;PD?W%*AI3&S8)>JG:NDE"V_+X?!V>R;TOI99(@Y^WPRH@\<$A1
ME7ZY;>..L]AG===]-@6/:C(3'N2%@O:LBV\>4;M1(^<.O@\IJHV&2X?A"99R
MI'<D9BVCD7R8Z9^','OY!+,MXI8.@H3?(CX/([PM>X2G02KW6LM`!AIO!FGR
MLO/`$Q4&[*@T(*S604B4I\7+IG4N$K@G,CE\`FJH22`C<%@^WY(63F73J$!4
M:P,@3=_"(PVU8(JXE$"Z#1)Q,!UKBZ>.)=+6Z11PRR>./`(QMOQ.3'3&HMU=
MWFG,;;=04<"=YAAUT`2+&!2B`"J+;MN4@LT\OL$?A$D"UW<96OTNO0#H(J'3
M%*6-FJ4>**6:PQCL"X8@)1Q==CSIA05)*DQU"]Y.[_2%)(K)4]$&;(,G9M)*
M*KKCVPO9!**<NX^V(P"PWXJ:"E6UI]E]%"1ANMS")-C3<Q^%%X3Z*&CD!MJ(
MV<GJ,6Z`9^<PH=<+!9+3DG=JKV5E!#K73LC8%3MJEWC<9[YN$K2"<)U>8F.9
MI^FA.'+D`\$L7K-?0/Q'Z27"4`YZC[!I,;-0AI;S9@4W];FBMW!KM*?QAF&/
MS*A]<CCGOEN(`(@,H`2<'I\7@%.N-)=72<)^J7_YU^XJ65Q+*5CR^#J`Z$CV
M>=Q$Q+SLIA>?TC#P*T__AR4##CF<6+2,2&[A>051'"1K=!JB]"4E_8/4*_DZ
M::BO@CK(65E^%OS`?<GPQ&WYG@PH2%9;'@)0>SNTT'[%;4BYGG79HTZQQUV0
M5DWK[DCV^31(X?H,[4C#8&K;LR3!VF*-I$]?JL_<!"_D=[,G/`+I=I46F&HM
M9XSQM]O#D#(&E#/@Q0.\?/1PF?M@+B.@0G:U\AMKV6O>PI`U)%^#-45C&I*=
MF-2GQC8M7JET?3;)3<]N!C.V$'XD+*7'4*ZZ.VB.%G;,&1$RC]FD#28:PU:L
M1):S8!]F0?0Y#K-T=LBV*`G_I=9FIHV"%J!B8C;NM%`^^18V*#F!#4I`F*=2
M7#IK#RY(3F7>81#5U4]Y@(K).!EGK(+K8`=GSW*U9N+OZ64-.1(6JA0P=4#(
M.\WIBK2+NE3@B2:CAA+!;X3V2(<@^6C.$7E74L<HBV\.4B8C\LH-LZ%C@6GR
M:O!&G\?FR:CW&6A+BG+YA)9;=$B#F"5:%WNR4"'4N;]<8BE9;=`\)M4_X2-L
M?&*Y#9,,PECP*=;I_;"BJYZ?\/HG4SU]=RJC>H;/H;A64KA8)I#E0N4+)42'
M!/;$"#/^SQO,#$!61A86(@L^E^6#:_EL_CQ)/D+P0(?H+F7L@Y,@][+HIKR=
MBVQR#L._?9>?#[%Q`"+`"<"__Q[D!92E;.7?WG]H^UO`WJ`H3)T)KYN@G[RF
M\]F-A)Q"F&-E@]J?R7#$RJU_KAA4RV=G(AQ&/G&`20C3T_K)I_Q<*45&+[W2
M3M%"HHTR`Z<R9^6CI<PDD$$*^O(3A:@;`!?.<&;&&5K(#(!!2-&:,YSYYPS=
MR!PY0X>^_$0AZ@9@7&<XSWFW9+=_#;,MGKO"QW!]""+\H1V*J92W,(7)(\13
M?G)YR`X)+*K#5%S(`G/-UA2&Y;!U2)0PAM[DD.U9#[*.SFNRE#RD%-*U'PT1
M`4$E(6`BYH&G$!(O?!/`Q"R+/C5S0/BOZ19%M?OFG%K*VU^?]ZA1EW>&XD?\
M-Y4GK0UQT]B&FF!L)\-22-;H)[!BN.<YE_(.WF&/CLLO5Z6(#O,D1@T)F<=M
MTD;#3S1F+48[W>"/<J*F7NJ]+&H1M+K-2N0Z6MF=M>I%+IQ^"I[#W6''T@R$
M<4@KC%G;D\_Q&B:SAP322"\=-)5HJENY`GDK`3#G7V2#5Z4$Y!D)TBSF0&0`
M02&$NQ"G`R[2U;+J1<<CR@6Y&_IJ@+2U]=+1[9O22M)F>Q3>F@JN@+VCX+H#
M2C]42$5_ZMV&T^UY$CS%Y.;09;`*(\Q#VDI:OJW3R59`R%(_X70+UH05(%B`
M3<[,93/A+@A0OX8L]["YA1'M1!4DV<L2[U#28$54F9Z^\']1+:%1H:JU`Y1G
M8'YMEG,`E(7+?;\&=DA?A9/`*1)`!'C&I"RS_M<1RW_X,:N7`(F^/1@46Z5`
M7CI)>TE0FTJ\TJ_0N(>5!]U@&;9!"LOE!DE-787Q"D4QIO][7L!YB=?G5R%>
MFD#\G^">3D\DNQ7$+XJU/N88JJ]#3/&VLG0IA./6L$\D31@Q^<`>"PA6>3WM
M!HN(_T)EQ/_-A20K82*EN]6.<7-"5J";NNG4:BX+NYG5[287CD2)WT%1ATWD
M.P%75V>Z&2&_]!"UJN#73A6`7#90"@=RZ0:_%#%ZIH6W!=4TRV0&&=7'EV_\
M*\YY+WA`>5=F,*Q9G^5D!@]<?R;#ZZ%$M5'PL)2CN!DT"HL9A/IM(7'ZP$.Q
M(TYBRH)UA[ELD5@R7U2E]B^>8;(*4WB3A'+5!#T$-+)&+;3L)([X<Q68LP-[
MPL]A[J@/#B2E*N6L87D^0HE@SZ5E#PI&T/)]'1L0DK)D`@4OACL)O*PQL4L+
MZ(8"R>A)N9WB`X[:Y(EE2FL1EVVODKN`W/5G85[:'&3):73\DZ)LI^MBP3JW
M%=(MN.S$E@#"G_R.+<0<MF-4@Q)I*-9R?IHQI*%-.1KUT]`K36PA9\;0L!_?
MHZK@+#<D.C&=-`.3TRK1/F"0K,8\!"'BM$^ZB-!E`>5#%K+L7K_VHM#JNJ:V
MG.6+(@I>;!A^"A_9D+NT&$*.1#*X/C\D8?S`MB04R_0:/M$_&3J&J#MQV;*1
M7K`CQ2NH7K&BCX;%Y5'=DNIK(R\%CHYD[?'8$?O<<GZC,G-)$#/8U92C:R%/
M670QI3OKD&M;R]>TG1Q5L1&?>0H2>EWK!,30Z4.0\N#V]JP]4K;/0$8-#(\Z
MT9J(9F,NYVO=O)MK^;AC+3^%P47-<;$XN(@YR/)Q8>@NA..2VRK>0G+VB.?2
MJW"#!_$K\U/IK6';U]6W@F)*5K9^)2L085[$,O+PY&Z;UP,#DE"2Y6W<612D
M:<ERD=R&#]M,N7MF%Q6]%DBM!"VLH0@OXG`Y-^*#E)\/K2HE\$'R:O,2BT@3
MAO'\0;7*KH.(.03LU-`Q%%"%`LI1\,X)VLKG>I3E(P#]'C!>*9QPJ.HU<9UD
MS&%@JTIN.F[07CK7JS`_8>AWAD&%=87@,50LD#O^HOIJN$G#RCJX--G8X0%9
MJYI1IRI\42D?"PI]OM?=8MH1,:I+AZG+MD;H]HSE$]+S#.Z+VC"6-*QZ1O:$
MG'O&L9I1IRI\4:G(,[X;Z!F&16QX!FE&9<8S\(<T9XW:5_6AK*C8]0_"Q[V'
M"-3=])&F0OQ1K<A//@SU$]-"-CV%T#?C*Z0YG)ZK\-_4AK,B8M512-=-YWXB
M4#7JUH8W:A4YR?<#G<2TC`T?H5T/S;A(^*@YF_#?U,>R)&+713`;]RYRK.JF
MBS2TX8U:12[RQZ$N8EC&IHN0WIY&7.0N?-;S$.Z+VDB6-*SZ1QH^.W>/8S6C
M3E7XHE*1;_PPT#<,B]AP#4S=D&?`1QAK^@;_57TH*RIV_8/P<>\A`G4W?:2I
M$']4*_*3/PWU$]-"-CV%T#?C*Q<D;:SG*[6O:@/*4;'J*Y#P<>XK(G6C'H7X
MHUJ1K_QYH*\8%[+A*Q?L7&3,QKC"8Z`KG<<.^RB9.Z6ZLO=(8<=IU94?CP]*
M`M9W?GAEX-'`,<#I/T7LP&4\CZG5ZI=_3/._#O>C7OKF`.QA9>%N=NTVJ/#I
M#J?.)8MMG\M)*79B./:Z9_UV"?>1M/S,$>+CN>WBD*59$*_#^&&PB]9HF8.1
M(VOCZLSU@:PUN`H9__Q/!%*?KQUIS6-`>GV(XZB[@+59OEWO2E;4;A-&((S!
MWV&0:#_'9%/L2"AQI7_-?E]<(^=YO$I@D,)Y/(OC0Q#=DC]$9RB5+^"7):?1
M<$F*LIU.7+6.VV'.G!A+0-F#A/('*RR`PU9;:D@B#;W:OMJ]VL+U@5Q^6>QA
M@I6/_8B(LYZE*<Q2Y=L!<O3T;AM+D+;PVDC.E7A]R1<PQH!Q]N'N@!*.2$>I
MGF,6#8;+UDU4+$7V<G>X_P=<94NT2&:/01@1"2Y14M>*\B/9ZL1U+SBJ\;%R
M<Y6*`'(90(9(G78I!GT'J`&XXTNJFKBCP7J?$L91"[Q+1-:V%;R7Q_".^F:X
MBG8T'A;7(6\?9FM/E+]F9^YX\EQ7]]-">I!+#[KO<8:2/<+TX,\P6/_S$"3$
MZ.;Q39`&:Q@'BL>"DM1T&JI)$+;47BWG#'C69%=5,'?894T%.Z2N2J]QJO=Y
M$8(T[P;)LP%%LF,9^2@3[?8HQ@[!;4@6V18F9,,]B]<7S^2Q0*AWN*E,6R_A
MJ,C&2DLK)D%]DT6%`$0*^LYW+H<_AZ*ZT*.ANI\0S)%IA*UX,5TK8.YA0N>U
M<QQ?WJMXJOC[6C")2)GWN`J"B"Z38,D0K#%'EV[5B062491G>L]=@*U'*PZ`
MLAC/O+&#L51P[F7*]GU,0%_135HV#H5H.A\R^LX-NE7[38L6:\8W3==LFH3N
M7-T7[>KV[7RHEC]0.!R:PMBBHV'A:;=@2A;+C&V!VIE@6'(;9#J!U^Q+:H7;
M_EWU396`C)6M+ENK)+6PDKH[*>S2/.I3C6KS\)O@A6@BI2]QY&^N4-^7/U-N
MIZ!QC-Q&S,[)<<XM?V>E>*V)+IP<GA3W0H+DM*5J"U7L^H3B;!N]4--:A^1)
M^_,#7*+/&7FL(H0I"2ORX4"9KKK=*+*P8DUS;G+9,2E8-&%B@/4!DNSUH9"$
MSCD.XXPNW&B(SE5M\A:F$`]H6SR4@ID%ZS!%JI><>NGH]+#L)&FIF27C63YU
M0XV-L779SU(.)*2B.4\!J>]$<C0N.31RGOHU:B,,(FJ3?U[*/VZR]5/P#Y04
MQT"T=%&UP*&-@M;^2DS,Q@-PF`\HC[\H)Y<;VAX8D)R&O%-YU*[M,2L#CH>H
M?OS?3L.0UFT=Y/MOZNVG\=U:\E#QG08O=VYNQN19&=W/,%H?[5%2^16<"C4M
M-/H)6VACSRH,"=-\_UD\><KXNG0.!=B0NA:]AB@Z1N>S`)W!#\]:2VZUI\I)
M]<8J.JQA\81'@/=O@`2##,;E@S?X=_@;:49.XK/@66R(3D>80\32=O7T]#B7
MO]3S(&W?U'(%&[D,WFH^US,4]/TRFM!P&9+:DQ%=:O%&OU%3M92V]HF#W31I
M;=V69[+V';E23X=1G)44D@OBN*[D3O*-/"Q\LC%#9#R"E*.V?3D97M08&<E%
MY&/BV`/,G]2']GB27':QR'N0(IE_'L(]L1,RH2@<I,O144]F]9"TDETLTT!D
M'0`+KO1DK%A#N$LRRF*%5!3H*2Z\ITN`HNOFHXPE:@R#EH.5PR#LVFH+[%7,
MI+/[-$N"E=3-V;9OZE=NE$3,EVR0A%9.W&D)98N:FS4Q#4UXHU+>`7OU:OFV
M+;\P(I<A!UZV[2`W\-YF*V6[5VUK"SIZ<]._F[;]&`HOVO9HU&^\HJ%0V2GK
M;PP:\[_2*N'OI*-7Q]U!TD)I_A$6%(HK3TKP96!"*KKS%))(%PWKWI%>'LB&
MZU,8A[O#KMA%LP8G>".]V%R&Z2J(2$<67<=18C$80`5NYMV-;#[!UTG!#*#-
M-[[XEP[0+:ZGK.+I@2IRV!0P*4`N!BAS3J4@9/ICHM`>1IYX\_D!GAT2LI<T
MZ\(\74L05RRL.*NPF;X_WBD`3LDEF]J;"$AJSD=2A3E[?_QM'B^?$&UC9MSE
M>-+V`*VX6'$\8:=^KQQ/@*"J[S5U.!VTU#UP'M.WUH2=^YRZ(7G6RIHC<L2M
M@EORL>*,PN<`?'/&8QPUW+&AQREAIN>2]%$W[YR2O*-ERR<YVC;A+=E8\4CA
MHP.>>>0QB.H.V=#BA`#3<D?Z?IQGWKC<P@0&FTRM2%.9M#UH*RY67/$C/9+-
M2B;>>Z8`4%7';*IT.N"IN^6R%5E'/CF/L2PPS>:LC'--^C&QOYAUT"X^E@!O
M9SD0_8\,_1@^!!E<ET>Z*2F&92S]=EL)S)5\N$_14\-7R[L+:4`A#FLSQO[J
MB;/?8`'Q?W\)H@-<;*YAUOB[69?OYV;),/H8&YJY28ED[OPW21BOPGT0^>WX
MTO@KN;^<NB>-M5HHR&4"5"AR2(/%.OJ41H&=2"N+^RA\H+66J9FL>/ODMF+T
MP1XEA-\H,4W8MUVKN**/DI9]=A.UV8G-SQ(+2;B0F@:]A2;21V4$;[%4;#&`
MB0$@_ZO@P@@2?8XX3M&%8VC%[NMIX86,KO1*+U0I6X/Z-9=?:,*GZ*!&2C!<
M0*7JBF.784CJ1*\00X.X36!?<S&&/H[JGFBD(,,19CK^.'I1AKQNM,HRM,A;
M!OD5EV8,05/+.4V49SA#3M=!1R[1D-:/5I&&#G6[,+_B0HT!4.JXIXEB#5>P
M:3KGR`4;DMK1*]G0(&X3XB^H;$,?5G4W-5*ZX0A"'2<=N7Q#4C,6_-(NE.8/
M8)?DYPEXW0!?L^]ASOQ*K]/.W39(X"DY<"$/1L$XI<>@LR3!^H"$]NE+]9&<
MW>PI2-;S>'U8T4_\A#^KT'7>($?U+C'&F%OI\T-9@WMZ_+7BY`-!)2"X?P$I
M][F\_Q<(B)0@+,4$#U1.=WV!S%L6L@-B:^M[,_//>9BN(I1BMUUL>'EO842*
M`VB7+"KN/2>N5B.<H9RTPN(PID:C924*[6G!.U`N#>M)!BIYJ@CJ1WL>0\:"
MS.(S6</@=QB6K$-NFET^H>46'5*\PTGO,K3Z?;$GG&^P&A4?S)"@I#XM]A*U
M,MV11'=6L`4IX0L090SVF+.[J4L>+:2F0&^1J6_%W[T#E!=@S`#AIMO+;J0!
MY%,`,:F2W?$@9!_/D/!BDF<B[?+(2R#DR;?P$0[TYAZ*PVRGD_@(WKTA:3E(
M!2#=KID$'KFY')PB=Y?0K/?0-=S_>\#X@9*AL1`PPF"$H8"FA86C,A@3EMLP
MR2",346$3GK#C*J#]`C1(,NY>QD*9%`4!8)>E7J.6",=_X'SD[TA[[<^!J'O
M%UPU'=_0Q2+ZM`-=D>17#^@^(R5O?26/<'V)$I;<FZ?I@3SZH++SUR"N^Z*]
M&A\+'48I0Y`PCGA=D8`P9^;TWI`VO&BP>J<$9>Z@C'N^0"]N!.70%A+@.3LI
M$M[S%HCMM/C5S2^RG4:Z.&1IAB-/&#]<'U3?4K+`7*\=K6DY;%SDH9Q8IAO;
M"SD^1A5;\JCK'M/?!FY?H[=G3L@Z7*_)=")N`@&4=ST+R`D(3E\`_[E<2$"E
M!(7=<7(")N@DPA,[^YC'-S`)T?JG!*5*]6)6V#NQ,X$DYH,4,PR`-B*S.0$_
ML=@UY?C494\&(U0K6J_+=HQ'*28I;:1`90546-W=G&<'Z%W+`;(4"->0N-Y1
MXH=L:%^+#HQ93"5>;C0#KM=[N@;84Q>XRX(DDXO/]_`AC&,RP]\'T61V(!?/
M^S!A#0V*$#7F%"]D[R1,"R2QT=JAQXC.B.%$T;2G^2Z;,CC-MR+V2NS'UC3/
M25K-]4,".$G-D+0+7)\?$FS&C"++T7`'N5A%,%F%6#`'CE7R?JTSU44LJ0G(
MMJ'3FJ0H>.2)H?'39`+FC@),0X[1=Z"<!-.>GMJLR>CD)$3K-5F.A8FIE'-*
M63+.1WZ%X<,6STFS1Y@$#["8=&Z24.V4;C217&=MNZ2SM8\K>(*<:;DV`)0M
M61`Q8Y78TTTI[JG:J9TS@W[$7[]-6CU?Z#%O/T)JJI0T'2VLFA3+CAF;D]#\
M\E$AL$[A,,."C:J$5--(?QGVJ!!:4\U3D5<18`7I*F^BK+)L;DQ;44RG\78:
M>65;1FLR[&JA_@49J/D`+,Q7OY8HS&3V,08K2>;*P!6$=!I_.X\?)A1_=<S5
M;/151OR+,4T;D3<?A'[<?:TIG.:AFT(LF/8!G"\I;FF17!^Y^#XGO:+CO+'3
MVDHHOWX[M'H@Z,UZ_[X?C7OE&8J]=8!_?X9BVCWD$$1+F.R^4PZI8XNG;];C
M2CI"J"UY`XXY(-R=QU='1MN,M2X@_[(,E(_!]W(A^%[W8+'=WK^;1#ANGQS;
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M)U'%:=((S1?+2"#ZR@W.5IE,K4R32N\N9Z8#1#G[S-+TL"NO,,`5GA_/P\=P
M#>/U+5[:CQ(AY849UUIEY;+Q*A*C#EY"&$TS`BI;F(GPIX;8:[8F8X&O6O8!
M3G!02`Y*4R6R3R_HW8;I[Y<))*E,B/6<D5'D[W@ZBWV=,KDWV@[QS$="PNS-
M!G,#8<X.))C?"=@QCJ\F-LH8HJT0V8OH%V!TM@,F&0`@(P#%$&C$+!X-?B61
M,WCV+W(6,GEJQ$R\,2,GX_BZ(V?#$$>-G#RB7X#1.8N<8CN>9N3T*F3Z:K:C
M!<E7'1N=!$6?H^&DP^#TPE^1.O@%19A,%&8O7F0:F^*XMU6Q9.:#8$7_U<2]
M'ANSG6L4(?:Z[6FT?&,E_,CA3Z=DL@N%\>ZX24@Q;B5IKT#F8UQI/U&X@>#K
M,`8O,$C2;YQ'/+MF9:(861*M5VE"AHJ1^X+:=.Z*=?88I7\\QU%9J=;2F6@>
M/%'7*Z7%N[M!?GV1EL6!-4FI5/65I.(RK]!$&YD*.N^7B0,-V-J;B9(F\.48
MJ_U2QJ,;O/03@(QE[#)'*ND2ZVKV'"H]^-KXHMZ=`9Z&A>M@%`5"W^F=#:&&
M4:<6?-%FU%0D^(T0_[]^+!5:^S)6FHC7-UAQU\$.GB-R2=[H>D"+_\@M*MM%
ML;#'8>^I4I9>3]%##,=(A],^5%Z9D2C,J#W=2KE(A&4%1%A`I`6_,7G'B4RW
M,,V2D.R<Z*W!SW&8I;=WGS]!U??J>@AIF4$G30LG6"4[0/D!RA!\C5FZS6[(
M@824%.<K(%$G%K?@#GP&OS&&GLS=;:&(S2'S&`^$WNE+%]D6)LMM$.>KZ6L4
M/^)APO6(KT.J"S7N;DE5/INO22:5#:;4!@_4!D/Z9BS^QQI_C!@-"&O/KGN]
M7C!NK"8V\WJ@?PF&:6P#GR]H.?D!'0`@(RBW]^486AZR?+V*/GYOD4J7GN")
MAW'CGU7$P6$O?']Z8C-0/2GEQP34E,DS-Z^+9Z%Y!S.[*;PT9]KL1IE*1/A]
M`28V\D32S!-//$[^0F<`O^)D4R;/C+@NGK4X"1B?UQDG6\QNE#@IPN\+,+&1
MXR0;PJN)DY<HV<#0NU`I$,LS4SZ2T%[`+%F]SIC9;H*CA,T6(+\,<QLY>):C
M:(^?7FC;8L*B>LGM.%V!__9J$A6E"OTHDS,JKV>Q05YT6YDWN;(Z/A_7\BCA
MZYC1-&Q_W*2\EV5WWMFYLU2^1R5Z8^7,)C)+>%YF;5I^5P78)^`+RJ9[-DE,
MH$#;3S-WG+#_,F:->@9Q(K.&LM">N9.B_.YFC2_G:,&S24/+0O[+RIV?7GP9
MDT:>=CQ@@"8R8ZA)[)DCJ0CO;J[X,DY5U&Q^S`,7!?/XXNW;S3$-&:#F!.$%
M3F[RXM4!CVPD@NS=R9:4N-QS45A?Z&D+@[7\/2#Q]]0?QVF0L/*L4LG#W=-'
M;1I&76KP1)NUB\D%`]VG@*Q(&#6$&_?&T,5N'Z$7".]@\ABNH#@DE>&$1I^4
M/GS!__T,I=DUROX.LUNX0@]Q^*_\TE4>CE16EB,)I#6QCB*;>;N_2>";+'@6
MOJ_H<@DXKNTA)SB^=CO+HU<A,<A%;G\:LCKK8W+GS^C4/D-$QQ_,`!8>5-+G
MMRMS^:<='O/7X%"2_XI\3JDMW-B2^67(0B%'V%'G#U)F""2%+&#_I877;ML=
M(\YVP/_%V.FHD;=X#!(E@!_)*#&XW*N>A^DJ0BG9G,_N\=XW6&4J$;.;CI;=
M=)$TBC+729!C!7XKF!UM%L8,-%(`(16M>0K&T7NS*HC8]8U9FL(LG<7KJS"X
M)WUR0YA^@@$1:KV(L<\>DB2,'_`'<!A(BG_B*!&FR^`^4DK^&V0Z#.BA_*U:
M!1..]LOAQ`.%?&`1@U)"^BE>1D"%!+]1,?UP;F,6)HH$9I!\#=9T'/`M&I+=
MF'3ZDLM(TIF7"?SG`<:K%]6.AU+DAB'?3ME\A.`X@9*5%PXN`9?(=?N4YS<T
MQ^YV^@*$&(W9@[$<OFCPZBT5I<@-PZF=LLU)]D0,E1?N)`&=R)WZ%.DW3,?N
MU.)+8_8-%(T^+:=,]?:!<O2,`=4D/9I#I2?5PL(WEVK%K\>GQ,KT'*M.KTJY
MU=^H1X?<'%W^^',($XSL]N4*/F(#T5_J=5(<NJ3H(&[7N4I^7KB3'&[B-5^O
M"KW'2+CRX_Y5\@64L>OE7WJL$#,+P0["YL)B&P^K&1B_O$T)R[Y9K%N?4\&M
M9UX3.J.;E>,\WA^RE`:"]P,6C"(RP\`ZIFC>I5C\.SKL<>)%'4"(?*9-/7XJ
M_=@?&"<V`[UWM+SC1ON=&=O_SKCM?V?7]K_SS?:;0/38_G=6;-^HTKMM_SOW
MMO_!C.U_,&[['^S:_@??;+\)1(_M?[!B^T:5WFW['QS9_H#SL*LPAO,,[O1V
M_V88.SL,+&7P_WB9B`JHK),_8SXV.</GS`U87XMY63IO[K`L*U'K+$BW6!;R
M'W([ZC&(:MO7JD1')2(I$-4R!VGZYB,)X0D"#-Z*_``K[B[C@#J(2%N94P`L
MXK`BCD9_X!CS&9**]RC^=@X3+`5Y1X:%"QP#2`3`4JDX6!<5+8#:"9IWH8H7
M""@SEZXC@0>25Y.7NH^.U)[/5!6C44S_])#BR2U-S]#N/HSSTN\XPY,?E@#_
ME(9KF-!?%]/GBXI/:)'7`DR#DX6)J.0(5CQ+@.ZC\"%@U[(3&`6D<#U#(%CA
M^)>&PBM`8SK<$"M`!C"8%N*Y[Q;\`2<`X"R@)D*Y^CPZOY&[&"X\T*BF2:4]
MJB)!]<O/LK2MW#&_+*_D@QU_`+,N^;N[?*Z,(M+2Z+=FC4NZIEZ!F'&C,EBU
M_'H,ZJA675&3/J/4DDJJ';I6C+MN'_@UKIYSY-&&-$[FKW5L/=D\_P:H@-NP
ML17KGT]!\CO,B`G<D80536R9&<HC3.Y1B1:[61G2^Y:[MJR*I,SSBLHHF2$N
M=J--UQCD)DJ\.2-IB]K*[A:N(-Z_K>?Q71#!Q68>8P$P&_SOPSW^6!@D+Z<H
M7LLOS09R40_:@QA:F7.Q1"R95]]&);E0&$F08K$8J$PP^KM2M!-P3X1S-S.;
M,15D#B'51>'G.%R_[.;Q2K$5U='WU.VQ0<**A3$>Y`5I=S;2IF+4I0=/U,E'
MV5R7F(/N5&U%Q*@I7>O9\X0"9>W%=$-1<L+JB"I-T`.%>M*E$(9TRB7B@,4&
M%`+1WY4B@5.1(BR=-MQG5;O#,]+((LE"O(QC/Z98\)LD7$&E#CH*1#7SX9+T
MS5LY0898>,$Q_YFP!'O"DS2R`2GI%.+VT$(55J2MWBE`6)YPW&=<HU+`\045
M8\`X3Z8FB'R?AI@E7&WC\)\'Z*;S1+L<SDHZVD3ROH"H%!Q4DK^6IA6]]FJX
MOJC;"%ZI;=JI/E(Q2]M7(^EXSJ(@30?<AFP2&7JYKD[/0J==0A]0!EZ$@588
MQ)<;1>KQ4>7'WG/Z`CC=.[FSR!Q8$%VH;WZ.T7T*DT?BB[3(F;23BU?8S:G#
M\GH:<+W1N`PFPJ\Q<5Z_O]JRH?8IVS`XK]!>6J=J\=3,9F)>5G:I`=2E/8I8
M8U[OK$K)+L,XP$(%$?>H0H&"ZJT?%:H#"^WZ&-@O>O2CYE$:/F$-I)P6)P%5
M=(12R;?V]$GNNI.[6"38C5RYNFO4+8M/&[9QZA+L[=QZ#O\GGE4X-F#[F84K
M3RXSV3?6,3,,'78Z6I^87\-L>[1"3.N+KOIZDNJ#DM&*H,9X&^M:,D0,D^]A
MW65!DN5QDA(_`:?P(8SCCC>OG,0ST^;3T[UF.#ZOR%0Z:^``D4^PB4J;NZCF
MOHMMJ2B]J46B&ZS!;9!"O?6<4?ZNS:P4Q?RZC1[S[S-6YU#N"UY)-#HV(3L1
MJ8'/*S,7FY&I%'5JT>FG((RO4)K.XU5T6).:G8L@(1-ZJE1[,I9$KDVR0S@;
MN:E5@B6&I&#K433U332<R=B<G0#7"]^KMR^;09`(#XCTH!"?%-B5`YA::+R#
M61:QJQN.0F%-`M>FR0ECH8P5FT]:,7@E@4YD078"VQ$XK\Y:;`:NNV[+F_1^
MO/F4>9ZXN3#P4OFO`7G:/4OG:7J`ZR6:D58&"3Q#NQV*Z=NF,G%3FI3ZK8=^
MJE;NE11L04CYEET>$E*W3%B#E/!V=^E$`3BDJ$K5*T;+)[3<HD,:Q.LEC`LN
MBO>-NHFHVTT7/2L6@QF"@B/`+$'!TYV-2`&#I!7F(PC\`@1;YKM2Z[J78>R+
MG,^"K?8B>P+>[XWI\@E&CW"X1[80&F000IK6/#,KN(*,L@5//GEG-U`"#^U0
MGJ^@-#SU.Y.>:E%L@;>F@+&SX+'+;9ADT,@DVD)I6!`7$K7NM/@'QM<OK^T!
M2S2Q=NC/6V`:COO!Z!1K46[A/%L84J_K^K8_X5'HV)PPOH`R]GU(46,TC!]8
M(C`S,YJR12HIXUUL<D:+Y#9\V&8+O(G/`KJ%MH@0JKA,*'=:=KEKSV6/GTZ5
M$LIASDQ"/BN]`][0W@$/)''_=839?@/(=`566SQN>NZTJ77/R;80K*M:W*BM
MH>'T\K4J5FL\A2N-_I=@H782O:7X/:=4HU>.'W9[VOOU-DQ_OTP@+'I3W`:9
M]E7R;IJ#BV.[R%NH[,%<<%2"L&I@DF!&7H0<6?Q:"J#[%3D!K([]E6,+*'J$
M<=5TY5:`WFAN=O&\AZL,KTQALAOJ7G5:QJ#BR9IWIX(ZGKPWWCF1$)T>YSE6
ME\=(=#M+B0UAZ-Q%SL/'<`WCM8F92$S3.%`\>0OU6#EU\!+":.VK[PAAD_2A
M8_U-`"))GRK1\V+^^05%>*%*%J0FW:M)U3AZ=0;F7:RB[ZM[M0`GZ6`B_4T"
M)$DGJU@[<#/%_6W:LL$=[>I8CP"C;O8[9?FO2V2FK,E`ZD@"J==F.4920FE'
M3FAJ%\M*R>FQA\M\>B&`#YE))HOY10FA2\+2J[M<UF9&]A+</$2OS61L)ZZ9
MK,X+E$<["*@_07%6'DD)KT)-(5@[O5`BEL(''S1W5>`C,YP8/I#7]8I3SM=V
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MLMB`,D+=#I+762Z@7ORKFPB8W+"CQHBI`&U/#U(9`!8"4"G`WT<9L='-]!"8
M4Y(D7H^$L]%1:Z),[O6.A+'9S>@0E,E%^-%`-CML79CIWGL<H,WNY08%;<PM
MVXX5M8T.6S=HDZWK2#`;W0P-FYLW.<J`=">XAR\XAD]-`=JS].,PO[:_!ZE=
MM&[;@)#-A[]#B&K2'RV%`68&[O1&4!QDGQ[2,(9I>H9V]V%,]P@8\"S$3.C[
MU-5#[N59M8WBHD(,TI^OD..$N%TN"?FQ$D7O]%HPU*)K.'WYNF7<Y5&_]'Y]
M."/U;>10GE;V_2)4P3X7*W\WO@UCKO&!N^R`,9-!1F%2S4+)._E-\")='J=-
MVHAU]W`9SYY;#7B?B^*5^<KBWF&P4IHW8**ET2\VK/9TWL9ZB+6J<#%BN/(,
MQ[/A>I.9JOE,FVU[9=(:=M)AW:KPM!JZF0KHN]46K@\1EJ:0E;;72D-:37CZ
MPOVK14SZ2KV,AQAGJ56?:HB[^3U$(1A9AY=.Q,M&7QZN_@TJ\4!-/O`;E=#I
MRY.FS0I9`G#Z)A2-9#U6HH]`?ZV[0XU'<[7(:YF$!B?S$42$>P?.5WX\4CO$
M!I`!!*:%=V0#:M]S.<,NED\GO<$[\XU<&F/:`VY:,R=-^>(>H/*T&W=UD\>@
M+D;9_?-PG_7M\J<VN"YH6[&\,3_8L;?#-5!;NJR.X,QC#[L+;NZN'5Z=YDJ9
MMYO!=*<HA5MQ^<]X9OX=_QO_"_]PC\,=_L?_#U!+`P04````"``I@`Q%<&?R
MWAU(``"=2@8`%0`<`&%R=W(M,C`Q-#`V,S!?<')E+GAM;%54"0`#C7+J4XUR
MZE-U>`L``00E#@``!#D!``#M?>MOY#B2Y_<#[G_P]0*'71RJRJ]Z-:9OD7YU
M&^>J-&S7],ZGABPQG=I2BAY):3OGKS]2RA25J1>#(BDEQ<'==E79"@9_)(/!
M>/[M/]\6P<$+BF(?A[_]<O3^\)<#%+K8\\.GWWY9QN^<V/7]7P[BQ`D])\`A
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M3(+@X(Y^$A_<H1A%+\A[OZ88;#`D*Q7&O_U2P._M,0K>X^CIP_'AX<F'S2_^
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M;^2?_LJHDR.ZP.%]@MV?]W.',#I=)JDT)!)R&YJ`[FT<;?XQ<!Y1\-LOO)0^
MR&?]R@]0=$YVYA..5C!>=SZ5RMSY,HK(^EV1^\()_D'6_3+TJ(SGY;#^>P48
MGI.1(B>X)OOX[?\A((JECQ4P>(>>_)B,$B;?G04WAM7?2F7O(7+HSKY?+1YQ
MP,O7SD=2&=H(CFSCW*+(Q]X5^;>8E[D&`@H9I3N\`YN%SY4PF<$`/,(U'TME
M<$(&\%(<`H=;4N]\I`2Q!\(#%*CLFUIVRM<[_1>NZYW<VN@Z00NN[25"58',
MN\`+QP]ALF[SC51V;M"3$V3T)V\^]PDM?:9B81^<QX!KGT$IJF!V\DCO(3>1
MRB\CFK-<U%<GD;LU&E%`-R.1/Y:4U>TWR/HW/CP[5!=YY\[](-=S9Q%>"+&Y
MY@;#UP1''HK(^YV\P`[?'Y)'_#,1K!'YU=]^.?[E8!F3J>!G^OM.0'^&9HCH
M4-Y-!FCM)-,9)N09C=+?'#B.VQL>UQPUAM2Q:4@U221<)0L9%B>F82&^:T3N
M.`;DZ6B!+"L2N$J'85!]L5#M0K6C?N98'=EM5;NM=MX0.6:$$8M9#6:EIR%#
M[9-%K1FUK7=_CMN)<=I$=]QVC#D,*ROY:Q2S78-<#MFIO0!J("O96'/,/MH+
MH(19O>V<P69O@)JMMN,4R1'[9&5_W>%L='DQ`#5<"'_[L.NKE.R4O2>4$<7I
M'(<Q#GR/_-4[<P+J`K^?(Y3D&#6Z9/G)].V0Y>"4Q]8Z<^+'=/66\;LGQWG.
M#*XH2.+-O^Q:7M?__->-[SSZ@9_X*"9[,]UE<QR0/15?_G-)MA&/,9&?%I?A
M6'PRY2&O0S=8TI-RBZ/TS"=)Y#\N$VJP>,#?<>AB<O7A@+#R=!V2'8]B+ONI
M[!$5`_/-#U.A(#+%\K?:5[';BBAG^`XE#I'AWJ43A615XXE+A/V2AK-X%VCF
MNSX(;QYJBB<T\3P_NS-N'=^[#L^=9S]Q@L)-!)D0#S7%$RJ,]7<G6'*Y=.J_
M5<SL[>:6%N.W\G/M1Q;BC.*ALA<WAYQ)=QM9PTGR$ZJQT#N>:"T)X0*%+KGS
MH8>JEHSB*134%`IF]IH3U'.*!!2S/4WF*.K,>Q,5U5LGD_LWR(G1]#'PGU(%
M6W`>',14;R,</CV@:/$=)RB^=5:\H0+-W_>Q]T7$5@LA?=,X[W1^SWLZO`)<
MUY)0S'IQ?PJP7?EY/Y)&@/LV2HHG<H$B_\6AF2&%A8?P7T-`.=N9!GJ'7E"X
M%-DU=104,WZY>`[P"J$[E+ZWNAU8#F*JWW&N&RV[3J.!B'KV\9)HB.+"IXZ"
M]NNIXQ5;HJ)O`I66O([3::&I>EO%<<D"W+*-UE_H4!*RL;[YL8N"P`D17G;1
M]%NHJ38[.M%/E+Y;[Q$9L\.SI8V2XHF09[83/OED^`S0[RBY?%N_TG_'V'OU
M`Z[T#!@]Y78F_(RB9'5+-D;JF"+'\)D^R0DW,(-3$QTMAUGD:MC^L(>3(,!T
M(QE]TDGT]:(7\]L(/3N^=_GVC,)81'NH(:!)Z[E#+B*Z.UEK<HXZZ#[5=)2_
MP.(Y->R1_U!Q\.($J:DO.7>B:$6$'-P*ST=0I[0148)J"&AA6YQ?C6;XM3O\
M!I)1U?2US9PJ<<2?.25Y4;FSJ>J^U,7H=':UJ:IQBV,?FEP%H]=';)+0C'']
MPK"P5.-2IUIV<6N*E'E!S>(I4B?&I4BU[XZFRXD!8UQH,L>-CNO5#(/#W%MT
MLA(H)5V1Q;,;%V3,IV9C\*N`Q64;>\ZX(6M^%AH<CPU&JN;YKS7B>N`055EU
M<GP^6_G4:*_+@?IBI5+='OHJ7PQAZL\?"C3-\J?)KKZ!Z.C0N!0M?HCX_"@,
M*L,E-E04%3UH.4A'AHMMSONLUF>:`W5LN-ANE]<%,!28.08BJ/E>L/S1#3ED
MI\8*;G#X2#60M4_?HU-C!3E'Z%#%8VXWOBD'RKQ$9&&@ZH+8<JP^&2O/85AQ
MQ"WFF'TVUDP`PZPN7C4'ZLL8A#T74)4!R0PG*]G7ELWFP/,<L*]6PJ>_79EG
ML$'IV+R:<F(HU2:1Y$@=68E>\]L%D!3411O(:T>2ZEZ5$\;0&X.,;TBO*T)6
MF028(W4R!N'.AQ1'PF<.V^D89!@?;$WYOCE>YE7Y$C^0;5#)EUT&2/[&=/X<
MNT_&2C,^&Z'L4@\YL)^-U6X5U>5H7)0*@+\8>Z'`SGEE;9D<I:_&7B-P:;A=
M,8A!)/WZ>$'1(]Y#D'BJ0FU@.SDT^.:`@,93&RP'S;R"YV*@556$RT$Z-MAO
MJ?KJ+%<&S&$]&=%5H%XC$:LIR1;#V#>+'-]\`2H%,=4EJ`901?<V17:.$M]U
M\L3UCB5U*VD.O[[N-MO:RE`*]4'EHZ.OEF8V^'4<+]EZ"?&_(:&;]<DRF9-S
M_J^.[!?)Z)L"V;G3*-W@7OK,N$51RH[@5.K)::UWVNE@M)+J82KPX]%$I8<)
MB!V2-DI:)R+CJ/!2M"GR-D5>>%%MBKSQ*?+F=1=M3X*V743'VT6T?7<T74X&
M=P6%&3%XU0^#>X-V`:RL@++&H`8[%T2!VCPW6$]+>_R:7Y8&%WR!(<5E4F!%
M+`QV%`#1:A!1YN8[":)4DD_F)CH)(E33)5"#&._'OY'_8SR=39]1E(6'BOLV
MFND-TJ]1P[):B\"?R'^:D\$G+V3`)_1]N7A$T726;L+"'CQS8M^=A-Z%'RP3
MF"51=`3%II`FMHJG3\0L`J>MNC'".N!D<X-W6,Y64JK[F:#D.B1'"]W@&&0[
MW?E0)YNRVU8*$%=?C'SF)]`E*7ZEO`3\!J\K<CU?^+&;1CD3+82)6@+K=/;@
MO$&F`*.K=9)9'/>2;`/&BNJ&JJHXT`(<6:)UM;`S%*(9K.]G+8G>U_P,S7"$
M<OY0?/E&;AVB4_JA$ZU2E53'PG=@0WF+K!!G;-)!*7_K-03)Y'HB.BK[2YE#
M&R7%$_D11L@)Z-OY=\</Z5Z:ABSA''2SM))2WW$DW;M;``(;<]334,P\@^S>
M"=!TME7)+"]C!ID*+T6MLC*+'OR&DCGVKD.R*[(,*'&I5TNP+_DE\G;A(*9:
MGFT/#U4J*S_7Q?(:*S&&V<>U[)9-(/1?_KI>/#M^E+FY=XOJ\;#"041YS\'G
M"+E^JBJ0/P<HU0U#;[*@:N*_TG^'@,I'3W6XQ?J!C+QSO*!K"YY&'07%C-^M
M;5CT78]>4(!3^2R@4;004GV1$1T\<@*Z[-["#WTJP.C]+S"15E*J6_HYCS@B
MHZ^K.@G,H(Z";M$H<BDU$%%^$M**4""!SKZ!RG&`7;CL3FB3[V+$;7AAB2/^
M\,+NR\P=42A(6(O&G7,@<O9K2?3IU6N;%Q9>$!:R85P@0K>]WQJ'>&Q<[)UX
M'*)Y\3Z=-T^'.Y#!^G'LL);5#ERE^##$OEK$&A!K4&Q9])!QFX[_;8#;WR\L
M.,;8R'P03JTO5=;AY;,%K-U&P9J9&*=?",%59Y)B;3J,$_E"./%9(%D[BG%+
M>0X+-&L?8`5]C=^`-0Z0+ZMZKAFB1NTJ^HA8)P'Y`LPD\#@\A*P>O+%2C=_I
MBL'^8E;WW%A))P0?;Q@!JX9NK(8KN/WJ(DI8R6J[XXJ(M<81L:+5=JN5"E<W
MA)*QJL+&OJJ$<..![+/53YKT$Z6AJ*P4K'S-QKQ%J`B'9O5-Y=TT7S,`0_24
M=KPR"D+YL?2L>*K\*\N\+<R;VL%J4!IWH4E%M9CSDV-FS17-+VYXOE<.K41C
MAIEB=B<O,`=.@>G"I#W9F@>Z`?+4/".&5"#AR<(YLN::-X2SLSF!;4H\S^$]
MT7"3]UQM@<!144^[&`<H5'2AB>RP:R]4<JXA2T"@SFSQN[\"_S`XUE`_4DYM
M>\`DI8RH"9[!9\%7HW.!W(CVY4N?.<C-CP4P5T6`N([MFAV0BV5$MPPBHCPK
M9D5./[D78L+&=/8C]&%Y?T#"_4PSDP\JYEE+64>F,XTZB=`<A;'_LK;AM5CI
M)Y$?$]Z+,Q`I]:!B]!X/P'?TFOY$VL8O$.QSP\N<5XFBXHE-O/]>KKW`#[BF
MQ5;*T^-N_-4=(I=C["?H'D4OOHLR_N^(P'T*4RKK5F;\D*CGI<?-G_YLFFKQ
M\>4;BEP_!BI?<.)]'@I5\VVD#DV+^I/H\0[9;CF)$K+<B5`\I*2REP$AA[\-
M+1W9R1W?'?;%T5?)(HV-).J*#J0[X`'_[@0!?G56WQ`UL'`?@;K/H6QLE_;-
MJ$Z2ASE>QD[H79!E<:+<2@GD48BV&(Z3Y#(U5Z$P(SL)O>]D;9+5%5$BS^DM
M+#@'4?*BTZ`$\S'205?W_IN,&0`HJV[C%#A$R\],1?S9S$U?ZY(6Q;%Y<YXY
MB/1BM^#?1GQTE)<2V.[^"F>_CH+R5TFE\@_GOX60UIY2<.ZKO]?7,`[.<<7'
MJ@O-I@H3?0SBD`@*N&RL(:!+/.X,'PN+R&I"MIA&B2/;JZN-T2J75,=F74T$
M!U$LGVO.MEV7;==EVW5!=P?G5;6]7XZ-QJCQUL>MR@F#RMALMV:]KKJ1R4;E
M9/`8&Z[$#4_U&X+U,C/VMN)&J.6-R*"R9ZW.',`PL@>NV>+#D#*V9@5`$2B;
M];:5@%.C\:FUC.)FRZW!!?LXS-U8W$9O<+$Z`>"@[AF&GK'-!3G0$W+0C:#7
M)_?&*_M?&3KF]V04ZV4]]J:GLB(D&*#2+X#G+)`F<:)D?V"M;HWZ6;J0VB=P
M^*.E6)T^8]6)KE"M`]_RZDQ'(T6J2U!C#MZ)L7I7)_":(F!9>;J18Z<^MII5
M8#-6QY5PQ@N1_:SFFA6*/"D>.5[FOM[Y\%*1%L2*$-BG!B@!C14=L&(/DJ&8
MXS;VTRR0Q)IC=SIRK::JM,_I9^D2C.S=1[Q'L,A-8<^!_:K(+G`9]EG:1]QD
ML@O0QV/I.Z\:H`&6\+A-\9VCQ'?I+#/@)-?SJ!QC_XI[;$]#7\;=;92]WM)_
M`X5QUA,Q/N7,YGK97"^;Z[4/N5XVB<$F,=@D!IO$(.R)MTD,-HE!8NRBV0D,
MG6,7S<U<4!R[:&Y.@X[817-;!2J/730W5:1C=-Z1^=<AMTUTQSZD-3&D9[,H
M.7SG3CR_"O!K#E,'"V@5N6$;.[<X5OO*V_@H:/P*Y#&W_9WJI^CRF:P31<8)
M-L!<AS,<+;(S+/(8Y26IVD1%QB:W+OT/?66^.`%=_TER3K;3R@^?P+4?N0AJ
M*JK<S^1ZFE;FI;\.,W?SQNW<?79U=%77;4()9>0VPB\^$7MGJQ\Q(EQ4]]*!
MS!)(6,-:[K)RY8=.Z-(6!6[BO_B)C^+NT^XX4`\P9'U--<``&*@'&/*&PZIA
M``PTI+,O<OL*#M#/M"M.:55'-PGSYQX)[GS%+D)>UKIX'=0]G6T2#LB=4XSZ
M!KA=0535=W#(N:%/*((DFD99M^&J-B:MG1U:J2DO.OCLK-;/@1L</CV@:+$.
M,+^A*L#T,?"?X'L/1';0)TZBY`&/V`\P%3>E(E'$/9+&4TU/'Y$JWYQD22T?
MT]DW)_J)TM"[>^32?_-AK0,$B*N>[OIH/N")2Z1,A#I/D8^@YE7<Z?].;?:L
M!;SX^C62U;UR<F8(H#IHD2115H-'[`>8"G5>D:SF'DDQ$+LV"L(93;#)V;OQ
MG4<_`(LP$%GM4YRX;D2>*]+F5D6OCTGA);4].2MHE!('L9ZWX22.$:R7%B]%
M[1.[C8@R[WOK1NW=IK1+JY]5ND,N\E_H/I&Q0EO4M$](VESZG4:^S=>O1)&K
M'$)5_74-[<@-NJ%AQ#5Y8E()=;T@!SQ*O8YS)WJ"[<HZ"HH99PFX1=M+I@*F
MFC%D#AS$5*_#@J:-_2M5R*:S"_28I#9/<CT2\;OPEPO0DK034SR="_0<(==/
M.2!_#E#J.PV](F>0&?'1T]%<ZVRW>@,XSZ>"@F+&6]+6(3-H):7YV&\]>X5>
MTKP459^8*A<'NS+2+.6J7SE#,QRMRQ,`FY]*&U+GQ2Q\Z8Y,?]!ANAMX8^Q.
M1A&)=BGPB%`O'G_0V`TDRU.<MDTG*W'$GT[6>9&Y$\C$Z.I++\M'[IA55D%G
M$#&_33/$HLMC<"7<3N>@-?_LQ+@@<_'\LQ/C2@9UW3OBER$#U;B$K,[:!Y:O
M/#&XC4U$DJS9MI1[.CPU-A].'9`"[[4<[X_RTL"^9GB'Y!)(T!!J0&E"O(BF
M<5)7/9;2+$-L%>0)XQ'M:5[;9`[S)WF;?40PMQJU&;YV&PO@6^?V8/T0C'MZ
M:9#17"XQ!K%5XL`0<_A1<WR_&)N[K^]ZJW"[,WRMY!79P37!&:RQBM6.U;_M
M=LO8'IE;_$L=ZI!(,0:TL=M;(!RO$<RM4$+634B>8C8XJ2L;P7)@:0[CL<$6
M'=DP[H8;,Q`-U@"4[,52&#KK<R7O,6`\E*4LA1S%4WNY\&-8REUAC<.,??RK
M/=75:'ZRJJ6(0M\I?8Z!+]_EB&GZO=$>7G#:9@[WZ&Q:HCFU10\O('&8-1P<
MGUM!!M20+/0<ZZ_&7H<:-W5U,0.&L<%/"7W[F:,J!NO`:46U++6$NP)+#OZ1
M_(>*^6H)N/(/ZYXZ-@DN6I:IL`B@XE,YTB<&V]748<U3PHQ!/+8HR@X`BQ2_
MRX$>792EA)W<M5QB#KX"&Y3Y-V1;5<X<W='9I#@+HA8[N72K^\J@'INXE@,U
MH-)P#O5G8\W_2J$&U+;.H?XR-HT:#C6P>GH.[5?YLMF@FP]6>9^!*E^7,Q[4
M4K.&#9HG\H-XGM,%))Q'R9@PW8U#.Y'?<.IY`/WF9>+*W0Z&86KL.P[:;6?+
MEUWL"I1C=:Q!A1I0SZKMOO1KF"0UL*JDO3_=K+;95UMA(@VC*+F,SI8Q$01Q
M#*N'U4X+6N?C#KMS],WQ_!B'P$;K59^J;HR"%PL<IB8M>-.FTK?ZF"UVU!/D
M>9N$KJHHY=L*4@OEAJ-&3\V^S";Z@']W`G)@G15P;]9]KGK)ZWMV\JQVQ=>Z
M%KJV_R]DO<M$;&FF$D?\I9DD+S%WH::Z+VTI)DVEF.H6@'4]-M;$7=^ZM[F<
MTJ%QY:?$RRD=&FN_!#1V+M]%VWOEV&A\:J]SW*QN,(R,=3=P=Z4O:X\,'>E6
MEQ<4/>)!X-.Q>?JAL2Y!ON;IM4\VA>WE![AY>#':L;YKZ2NO_QZO?+G@!CM*
MCL?Q)]/P@&V5=HL7J\"G`2KEYEWJ00UPO(S0-'IRPG4Y$!K'Y3^%_LQW:2A_
MEB/HAT^W./#=0J^G1NMN-])]&W<%N5=LVRVPPHS.&5^W!6RFLW4<@A,P>S2;
M4=LL'@B49V0&/T&V8NV\[:.Q9R]LI-8ZU;]U*M_G(B:IBH_[O'KKYV*-3];X
M)/,Q:)PEJH-5SK@BYT!-7KL^PJ#_8M3+H*+M'*?B7]NP;@AZ?9$YU9[Y>),/
MG:R^H61.PROSP1E'0GJW`'&K.%O%V2K.5G'>?PW`*LY6<;:*LVQO"5BA,%7S
MO?+?D+>I+PC2?"N^'([F6V1.>1O-ZI)`'95>&%VK[UI]U^J[5M_=_XO;ZKM6
MW[7ZKEQ]%Z9+F*KJII$NL;].H`?INE6?#D?9W>).[56\"1,ZQXM'/TRGV5'/
MY:5H-5RKX5H-UVJX^W]56PW7:KA6PY6KX?)J$:;JMM=DD/#))\=(R)9;]_EP
M=-P2AVHOY-WA.BJY7.2LAFLU7*OA6@UW_Z]JJ^%:#==JN'(U7"X5PESU=A.=
M<1W>+Q]CW_.=")ZEUT9F2.IN#:=J;VDU\;LV<-<JP58)MDJP58*M$FR58*L$
MBRO!-F(W0FF1ESD.R.SB3;<GD!9<3V`X^F\%CZIUB-T!O^,$=51\`42MWFOU
M7JOW6KUW_R]PJ_=:O=?JO7+U7H`B8:K:FW:1A1I\MS\:CGJ[YDOMK9L-,IW=
MT+)^7559#F)6A;4JK%5AK0J[_W>Q56&M"FM56+DJ+(<"8:KJFFKO9V3ZWCE>
M/*,P3H<4L=K6$AF.:EO#I]K;N5#*>);6B"\Q,(DB)WS*2M^=K=COK`MA3UZ=
MR!-2C*4/;=5HJT9;-=JJT?NO#U@UVJK15HV6JT9+5S=,5;JO'#]*6^%\(P\/
M\G>1XKZ--(:C<E>SJ?8BS\=D;(@UU6@A9+5AJPU;;=AJP_M_K5MMV&K#5AN6
MJPVW*`^FZK930+\V#0WMS&ALIZG!W7?T6A@[(FPO0S=3V5,.5MG_%=*EX;05
M*SC7(5DF]."\=9A4/0W%S%^@R'\A6^=EO3?$V&^BHEH/KK0/3)_7IX$`2W8&
M88R6A5PS!U*61<@KGO*E$X5D[\>W*$K9Z[!PK:043^5N+>D(E!?H!04XK=AY
M^4:11O#5XB*G^KT3.1YM-Y6VH%U+JO@.N8B<$*(*PB?%25#Y2KV@<$DN>1>3
M^X5N_P[;CH-8[73*MWK:#OD[)B(T3,C=2'[WZ3HDN@N*$Q&A!B*G^JBG<;!D
M\6DWAU)*&'PO\=&#8G^.T\N8D*`=VGRBCSJ"&P1$3OF]3K0+%\5QM52!@\])
M4/&T?L?8>_6#(+V]MLMM=#C1$*J*)UA;"+K#]/AI*M^4F]/:2=NL):*8?7*@
MJ<*4'>@[/_YY3MZB?D+_!)E`(QG54W!B>G#I?^@N>'$"E-['<1+Y;H*\ZI_#
MI46W<12#\"-&T]EEG/@+)]E]$S=/:_=+Q8P2U=V/I[-BIU`E;=.[C:/^U+&^
MJ1WD1C,=Q9.X\<DN]ZB!L&.21R,=U=MQ7<+U`L5NY&]>D;+V()RX]3Q:SZ/U
M/%K/X_Z[4*SGT7H>K>=13<%Y@$*AU1LY9.R:U<P<IJ-/XX:I^4F1PW0\]I/8
MZ7F9PWAB_JW7"..N\2$'YO1PW,!T,S8Q&$<N]!OMDCE*'T<N\QO,SSE&GT8N
M\/D=#CEDGT<NW"$NJ!RT+R,7_)P^28;72"4\R#&=H_5UY)*>+]Q@`]?16-_;
MH(B3'*VCD<M[CB"B'*OCD8MYSA@RAM=(Q3PHD#!'ZV3L8KXMBC1'ZG2D$KY3
M.'&.WL>12_RF,/,<I$\C%_7UJ00,HI%+=W@*20[=9PVBOI>>8W'J+A1O-K;S
M_7#2H\HLJHTZ^`,%W@/^YB1+NC_ND4O_*QK2PT',AO#8$!X;PE/%JPWAV:\[
MVX;PV!`>&\(C5]7E4"!,+2!PY;\A+_/_".FVM=\/1[<ML]A3:I7<I"JKW5KM
MUFJW5KLUZIJVVJW5;JUVJRE*:@3J[6Z,DZ#]MHG(<!3=&CX5ZQ'N''G+`$UG
MN\.3K;:)-DLY$6N<*T+>ZL-6'[;ZL-6']_]BM_JPU8>M/BPYO$A$I3!502[W
M$Q92D=O(#$=)KN54EYI<W<'Y3X<VZTCB:73G/\T3L4"(#H-8E=FJS%9EMBKS
M_M_]5F6V*K-5F56IS&#%PE3%.>MB+*0L5WTZ'`5YBSM=2O'5,B%#?_-#?[%<
MW-$Y!^LN=?$5CJ;/:1)I^%3@K:."W&E`U7I5-9<I+P4FSYUGG["M"!/0:/;U
M8%\/]O5@7P_[KP;9UX-]/=C7@ZK7@[B&84LFRE5AM=96U.W/*.6.B_LT6D@-
MY]G6R*TVWT9EYCZKD)<R^2/TDSAM/CYQ$_]EXX'IZO&0,[2VIUUU._9+LI'P
M"F6K>;LDJT]E9."$M+=E)HSB>+E(3Z:4-Y\"-GJ`L+CD*<]9L8A8_0;C&<V^
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MF-5\J-KX0<:*B3)"H;LGV\%WR0:9SJ[\T"&;P0FN0Z((+;/KCS`?5_\(+K/D
MCJOZ7)>'!@NF.A*Z1%*6']2+-)(UM+Z@M6W.R1;E$*A2XM=D#&R-]=98;XWU
MUEB__R8<:ZRWQGIKK%<6?25#V;!V>U7:[IAL];5BK?;9M"WTCTU$I^W5B56]
MIIDOP]@>*TK,'KC6B,,0-5]%J9224BQV#,6OXT11K9V7M0__;#R\]1=.LP-A
M^]HY-1$C/E^,FMU8YWYBG<>-??3J\RCB1L<I@]JX1Z/H0TF"1YQU[]:P@36&
MATRC)R?T_Y6M'E&E_*?0G_DN+=/+.J_1+FMD-T\\S\^F>!W.<+1(/[I`B>,'
MP%`2R:,.)^Q$UL2`'MNJMLV3)(G\QV62ZF"XNFLQMZ]6?`#%YN3:RM(_8C1;
M!C?^#&0,YR*G>$K?G#>:3@=W/.]\J)K-+.M/@,WM#Q6S>4=O2#B36Y_I8!'J
MCRY\I)B]<R>>7UU<GY-W,]5E)@LJQR"LUA!0C6H>`4K'I[WMR7_H>7YQ`OKV
M!X'=2DNUF%MGU3[@5&N)4*V@`DD[`%7%$_R.$HHI8>"%J%_>V8H(7'+7Y"G$
MZ[!=<FUFNMJ2FGN>UWH::"V[C@2-IEJ/E]V;=*2T&536_;?0\Y3[*N:F!V64
M(.(BY,571->^?$.1Z\=$=][4U:+:3"$-@)M=(%7UZD+.S74<+YW0)3K;O4-?
M"5DM,:"VT$I-@W`NRZ-;1%XG=$]$-//^`F7_A<IL?KJ*)PD\)I6?*6;Q`CTF
MS+"\Z>-W0=ZI%RAV(S_=WQ#F.0GVLKTF1`)%T8H(QM3@T7U?E0AJBQ0K[)&R
M,0'8'*2*DN*)G.'0`\3;5WZF&NOE8N%$JRV`SE;4*0,/.FVGU<-DILD<10]S
M)RS\VW5XAP)R5KU;)Z*J1,8D5,>7,=H^!A.:%IM7)2/@<7H-5!1/H,)V)1"\
MUT2E3VLRQ^QJ6C?L+L,80OO:]_((P_PZ1+.9ZZ3AVBDRK[H1A!1)U#]:P-]6
MJQBT'XW=K[QZ*J[1HQE&YH9?P,YTR]N(`69N.!#?0Q.#'\@LN%3Z!?*"HD>\
MI^AQ6DT8>N:*,S!V6^8RAI`]FX)&41;M."X=KQ%"'I,Y`T[ZZ=Q'V2;B1F$0
M2M=%]A9";L?9&,*4P0>WJ]N4!2?+DX9?,U!#\O).UK^[;[!"7/`,0BL7"Q"V
M!V>,(2162)FIB,K)L?IH7[&[@58C2!XHQZ+M0E$R=WPR-B&W*G:P`,=.(",#
MQ-A\SS9`M@-0&2#FIA:+/(#:(XQ9MH&Q9PNHO(L'H.=8?C&K^V,!MMQT?3_'
M$=U4-SA\>D#1HO`[0GD:G<883E:&V#141_E'/U&Z=>]I:ECZ<H(%^U=]KSPU
MH3PH/7?+*`*&'K=1ZF$BYW)F<:YI"H4-FZ<>LBTO&"=920D:2/P'"KP'O#&^
M,V0FKKM<+%.WY(\P0BY^"OU_(>\/''BT212.^:.*NPRA9SJ_<X9(=1["_%#)
MVJ2WQ8(:0IV`]G^.+Y9H,B,W\C1$_R!WPY]^,O?#!T(A_2NT*+$8\>Y3R"BO
MA^G,<R4UY:+UOW&TKKE!W7%K';>XK>&!GP"B_4\/&N;)3=+&<I8XLK&<P`ED
M.TLD?G/WRSY?CS6SL'&:-D[3QFFJM(9SWU4C",:$J@(P&$<4>@E7&3%,Y1U!
M:*9,#'F>.F,-WNP>[7HT+J6CWJ;?Q>JA,()S'V,A.AO%6&R)O-UI0'A.FVF4
M19;8.#O,:1=76$K--,R*'A$&FXWX;X&M")9\I1DG3M"7T_?*?_/6U=ZE%>,#
MT1R.4Y>/;5M]3M:4A'P^/-1L.;V*8#(`F[:<7@_E]*R718^7I5:`=/"YM-'L
M2\**.&4XB/6IS_'/M=*2TK92HW+D<!X%Z]:Q;AW!?=.:\F"D&T<@Y<%<5XQ@
MRH.Y?A7!E(<Q>$7@@H7G.3@"/PG@C2V<.:*CLH5&PU<>M[]!H0B`D-D+0'$X
M1B\>IGMZO7Q'<AXN*1WU!0TW'K$+1!;2]=<V0[+`Z]8=DP6.DG4G#RG%UN6-
MV=?[]/>(,T2?EY+BB=S0.BQS''C7B^<(OZ0=@V+P))JH**^^_.PG3D"=M>=X
M\;PD$O@>SY)7<L&`I]%."QJ\?K>67*#34/>E8B2OEE'H)T2`DEUXY;_1/\%W
M0@.1<1KEK1'4&D%%"Y>O6[(16?3HA^F-=Y='IEQ[A`]_YE-.UBZ^K#B*M]WC
M.FU#BCRI!E7-C/7Y#.EG#3H:>HTU-"@P]!I7=J&#H=?:8SK;8XQM)BYFCVE0
M!QEFQM;O@&%6I_:/H*^ZV.9J?ZZQB%U[+K>@:WJP,]",NQL5&9=W@3N57]RJ
M%%"Y3\#),^NQRGOR+HW!A>!+WIVIL9C5&9-_B?09[%ML5RXOW!=(=3B^#U[&
MM1LN:KK'3VAMYJ?L^CF?TS]>AUF5S>FLYI/-NWIUU-%DH88E>$?1=)ND63/%
M`0HKN346MP$93EB_.8MC"=+8@NELNDQH#>HXG<X?_M-<_>+7C[PW0-W@UWYP
M2@>&'H7I8^`_I>0?\*VSNL,K)^`M^=9"`'PJ4>12X4TGEI%9Y8><_P0V$H&R
M-'E^#GR76BD(TC<^H1PC6I2/FYUZ`E!6-OND($JR/.I-1<F8MBU`WO<EC?BA
M=02)SK/^-VYVNPTB.J7MK<\V/-&N%GX<XVA%$\`%IP(CKDG*%/`5\I0UTP$[
M3+$[1]\<SX]Q""SM5?6I?@S7'@"!QJT<Q'J8#C!'I):$=98.R%E:L4KQV:KP
MMPY.4U[:^I4HH8ZLS70&YIKD[,K*NT2C2AT!G@F;0F)32#KNG]8[<P2))6TJ
M1PM,._K1"))/^%5.W*`7CRI61.K)K/3Z&WL]<CT2<:=G[@CZC`JA*&;W&$%/
M4A":]48OYN8V-OX$A%2SM9+YMNV^:C8U,Q>UL4HO+U**_`JL<)6Q43W](9QY
MN$;07`LF','.5(:@L5%4>C:I@`^>M3/38(/1VLXL(5CX+-M`6L"+`.7A!+U`
MF%><0N>'?H)N_!?:]GF'J4*`V^7;,]5#TQ+2M&#T%?D`8I/N-(SJ+$(0;Y2M
MM&ZVNND7AAC>U%^QXHG3`08U[3M$C50>?;E>D1/L!)1-=2#4#*<Z=[[`""W3
MNLTF9+9ME'I<6Q;46V12UE+64>]MPF+E2OGH0:,DZ.9V=Z!9;WA0#`>`F*U`
MZM@*I/M6@;1#78S45$C>&9,GHCJD#Q$XG@U$5!=#(()3B.6=#_N[7M)>+>>!
M$\??G85`-!68=']3/5LQCJ`G`D36QF"5..*/P8)?Q=Q!5)R$%._0WS'V7OT@
MF(2EK51(,!$(H0(2[M.D)88!YEY"@R.J8*?!AD^-.GP*O%F$[KL1Q$^)J!5\
M<%9K22.(L!)52G&M%CV":"L)H#6\E@PN42,L"6L+D)^:!$^]N:"U`/F1_"H,
M0P(#7H#\R%A/M&`!\F/CXD?`T@1@`3:X#A'<J,ZE0U46'3\V3BPI0J_>!Z2R
MT,X^8]GF+%19!&:?<9/B4MZ`>V0/>`=P\Z"%',Y3NU<[PID%O^2`?C1.#=0(
MZ$XP50ZJCCC9'B,-BSV'MWXB)=J0D_IP(P[;)J#6<;/+S7>47+ZYP9)VKM\X
M-"#^&AYZ?P7^87!L3""5INE<+YX=/Z*FK3(+F1P*J!P"+18?25T3[&$K]NFZ
M!S;T::9DV)DR^#09L^4T"`0/S>I9Z"@<8+1;SU=-B$?+.-#H5SC-'L\1XS/=
M^-W6J],X(]JH\"U:..5IZ$KC>.7G4-MN%25O`\Y*''4..&-O#="JP(+1N@UB
M`]64>[RZ!:IU6U[3@]BDG#`;X&8#W&1MI$YW,`/9N%1^&:H/[J*F*6PC]HP(
M*>\^<:+$((0[O0!4!+(,IOF')*3ACTL6F&"F7Z@_^;"Q-RALJ)1)B<O0@)W+
M:[!26)IF=#)WRZ3)JJ88V%M),JC<D39?+9;=#ORN$#V2K\8:*$3Y_&8LQD9Z
M(.R816EIRWZ4!^^V$'@P2\'B\]&K"&0R&E9(/$<.[B?I48S58E9K4-,+BA-Z
M?*_#^^5C['N^$]'V[!++J`F/,*3@)O@D@#Z,&T3(1!X^\W&\BNF^O0Y=8+N?
M1AIP%R^;\^UF5]\GV/UYMIHND[3,(,"WRT-,'HL2&%-?D"3"+D)>?$4$'*U5
M[81NVHV]R`01<]D_(/)#[IEU'0'<A^TQ(,<A?IBCR'E&R\1W`656VBB`JT^D
ME<&_H62./;:ZT]>0W&!S_[E0TSF\\`,RU`LZ<V(^;V7'`11O*&[&('L(0!3L
MMDVH9E$LLDV+X,>T];'W0O<J_YKPD`+OZJRZZBORSE:YT.=O=5CWN>)-<(%<
M',8X\+WT,KI#+TZP7*N/=_1F"E%A'7\G?Y]&-SB.,W8A.Z/K2.!>F.2>(%H;
M5='.G&`CRXK]$[C7AH<4E+US2LC#MW.'Z`%N*L.<0.`2;Z4#QJU\5@M:#/^&
M;J6CK5<;VU6PP!U>2C9&IT.,CL+%[M""KTQ%>?!</N`D"*8)T6R*_R00BL-+
ML<\8'."L*UOQE9?*X.@:P'ZWX3.C#I^![13>J\[@4!B@WH!YU1R%$2Y]0U:K
MKV!>Y90%I!A;UPFZGSC>&BS@Q-@28ORHR7I?,E"-JY`EN!7K3!(&%P\11(K'
MGL2ZFAE7,TG\T`+,A:STBKTJNEJ66028<2^D5IVDP7?`XK?L$>WL%6(!7!;,
M=N<A0\O>J1`?,`MJ,]*:T2C)&OWW.3`ZFO-J#$%)=\`<!V1V<78!R@L^$:(]
MG+`3&/M0]^;34Y3&=MU&/KD`POPJB.X=>J:S`?G=G9SD>@FJ.,>+!0XEQ4]L
M$0-["3&1@E'LT];O!">BTJ7-ROF]@W7?J_;'T.EF'=4OEI$?/MUFT:QII_7O
MZ#7]$<P)QTD1CG"^/)=O1&/VXVQ+`B"N(Z`:X_2@I`.#-T<[#;@_.YY?1,YK
M2'?_E>.NNYYS>[$KOQ8+YJ$KXJ>:0UX'/=LLP)B=!CI0QM;UDTMT4PO+#UH*
M,Q^"FTD032C#MTMR[3@QRDG\Z2=S<I.Y.`AOG>CGN?/L)TYPM0R]&Y^,3%2'
M3?M@PLJS$ZZ`<0SR!E3==@VE]70)3Q`W?=/7&AE^B)PP=ERJ!L1GJ^)/P(WD
M`%2AFX_6VXRI(E.TJ!7D;&[B^/&,=]X&[,+CWGF21E,>J)6-2S<[(FAG#Y"\
MR3<]+=>AY[_XWM()"MS?$14R>D'>%8ZNE@D-3EYK)K#8+>F#*U?LBNN4:0D%
MUPI,K6LAI7@J!3P[S:.9CFIE!=$`^/-M+.'-%1O):)G"F9PIU)!1O95H#YFU
MO@>_NZJ^5OZ.(%<)%3'%L:%750,1\,WTBA_F>!F34Y/=#:D)Y39PPL)/KO`R
MRK2RZY!>*/X+VOF-A[D?)0B%%;^592HMW93AWXF(A?0@[9]'U6*=C"[6S73W
M2TV,0O?J]G=:+TFBL$VCS)/Y=R=8"KTG>2GV</M/ELD<1_Z_8.5,VRCIN_ME
M+`\7.=WJC-C"-))1/87L+?HC]!-1[FLHJ+Y.*5)GY)5=I\F?K=BOW#JKU)[P
MZD1>V4W#<^]*&,W&UI<XZB^VOG5!X[H5[1"*WWE0+6ET(A'ZNU_VZ9RMF45E
M:'#G%1E5@+ZL0V/C^6T\OZJ-)?/&'D.*@#PU"K?KA`8G$"@&M.F)P#(/C!.;
MVE"M?T,R=*T0`*';9F\806]F'<#R[%QSI:U*%6+;@+FMG!Z;B&:EI;<"D)*.
M>FRLCEICI<=#<%",*G=.Q1.AWIFV?=A/C82VU1]9U)0J_*4&UPKG<#(7]U&3
M&YS5^S8V=P2"4DV\`T/)/F&Z/0RW(F%8>JN%M?/;I1K9CQ99$+(*XN]8.JU=
M"ZZUD!DKRO)OS05?I1(*"3[>UDH_F8BU0(1W#9@E-?6SL<4P&N+XL?2<!)99
M;J['4[ZT!66XL`QJ"S$_Q*V93@Q6<\MNR(>U)I^-9:L;:_M3HP#7YRGFD!Y+
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MAW_%@H.S#P6'GH:"\RY\V(?`$DZ;KR;3QQ2@.<D-1&QZ7HDCW>EYE:L#SK=K
MHF(3Z*0DT#5!/(*,.(Y]:E/<;(H;]T[AN)U&$'W>?L&W057>6,8&1O,H=+A6
MVV0`&>L)%0"H\!)@`!D;-"("4/&=QK*+QG7/-T-4?$@SA,9UO[4@5+!S,(2L
MH*ZT0HV@J9@(0$4;(8/(BNH:*R[+U!F7J(8IVC<5A1_,36SD=&&T@=;JB6%0
MCDN"P:&LSB_Y)'T'#B>PAA^X1G<M"T74(-XT1A[<("=&L;R>,-STAA-)T,XR
MT&6S"6"=A!XU<S[3`)@[\O\OWVBT#'^KC%8Z4%_2=>A&=++7X3<<)O-@E5(B
M\R8H7"S1`_Z1T`%I"B6.^5SH8G3![16R**(X#6)?IQ&DR\;-8@,%Q?9Z.*9U
M7T)12QO$TPWC!.LMP[^DE=\J1FH2QRB)_T"!5UHE0%%G"#7%$_KF_#>.;B/\
MC*)DE5Y$<'=H/0WMS$,=H744H/OX;BW.-_*0B!G'\V,,C?YHI0,62X6L1B8#
M)V&X=(+L[-"3RR^C.,DI7OCTB)`[9^OT0]:]AH`.MLE@?I1=W4Z"CL!<E[Y7
M7]WY&8<$I^EL2HX)&3E\2D4O76EZ[V?@E?55OI+/0-KP9F#1,R:$T1]$Z?KG
MTHFH*GL=WCJQXZ'0`1Y/3FKJ6]RE\NI^^?C?R$T>\#2:O!`ED#[SKW"4(YEN
M%X&Z^B+DAS1E<(5^.'$;)5/BJ+\BUML+Y&5:58?ZU$WT%$_J;!D361<3=7KQ
MZ(>IE(]%XFB:Z?1I[.":8661ZJ9E&4&T#6B_V[@;&W<CL&<ZW(@CB,P15T)$
MH1U1)$\7I1;#U/,1A/V('GSX@VP,T1VB+V#<]G0?0UR#+/#*UIHQ^/,[H`<R
MV(V@B*Z,&Z;5/LLJ>)I;N$#P;JFSM8^@R'"+HZ(1I)(.>&)L@%>K,PK#?&>L
M[JN](.HNB$HO*BOK:NQM($,OV?5^,]B,/:+=%9+Z*`>%P5[&P`>.8V&@VB=&
M':BM44RL>*H&$+6'UF6%I+_Y(2W-F?Y3U2&EW8JRW^\0===MJ*$%Y`G.1DLK
MXW3$Z6/@/V4^EN\X=)<1/4H@!WT[,3V=F7<Y.)<VE_,>)K*]<S:;YC;;R6G[
MJNGL.TIV?BXZ6='1>@?D.B32$<4)N?2")3G%U)2K`HJF<7H'@=[JY"Y#SBR!
M11>"20]AJM<A31W\!Q'%DM=XE_8P)INFDJJ:;9'X0*;[BI5--B<]A*EVO)[:
MZ?8^R2P+A6@YT]D548N<@*(O=[XU0VB<^MJD67XY`.=7IF,#R`840+:[5!WC
MQQK(Z0@P%@H8V_VRS_=\S2PJ@\(:L!Y#EVW`%FX/"3/.:"D>$G9D;)="X);A
MN\W&4`2%1RVH`0RDWHRA&(AT+(NJ\1@J8:@`L/B&&D/E!T48%A[=8RCZH`;%
M@J&&Q3W8NT74LL<PM'>*%*NPBF"<KQF@8=IEQ#,2TG:?`PO9D7_Q8,K<?L-:
MY;=BD,F[98S:BS6.2X:;!CUQ:$[][=!-A2[]QH'VS*%?/1>U)KV=,>MN>XBM
MCYND8FLE)Q]BWD\!XL.8KJ`'5(3Z4"8LY@45(C^8*0MX0@6(#V.Z`MY0*.4!
M3+2S1[3#(%JGW\4KVD;)^D4'Y!<UJ+#&^#RC?.4RC#5,2BZ789P+N4.Y#&/=
M*J*9C6V7V@C<RIP:0BUH@BY28Y-LU>!9[28U3K8I![':56I<224=.%:Z2S]9
M)+O8=9AWRMXW70R"(RCFH`S'(GKR+YB2*T^C?^4^P>[/,XH633Q%89RME[3^
M!,+TA^--@4]!<4-:`@E>(72/HA??1?=S<BY*['W'X0N*$W((7IW(BQ]P6AR'
M_9QF$W_'R3]0<H=<_!32O,Y;1/:T=X6C]3_1WP.5=-;-F>K.OZJFD^ZH:2HN
M0/9&30Q!RU)/-N<*6("Z])WB];Q#`0T`N'4BB!VUZ6N-##]$#EE`-UVBLU7Q
M)]`*T1"JJJVSE3MX0GL`/2%Z^9ZMV*^L[^-T6V?MK*_#.(F6Z26=EDAXF#OA
M>A?GI^#[$MK(0B-3RO</8<5WD_4!_T$$9WQW_P/>VZ.%4-^[)*Y;D?3_/)`)
M3D+O-G#"[\Y"H(:\FO%5-W?)AP:*AYT/^U[;.FBO'#]*0^^(EK]<9.>+ECBA
MF_3"?_$]H@O>$6FFY>3S,S-4.*<;IK/6?[30;*ISI>K#=4A.?QC[;CI'+8B"
M^($J+%VY^CWMA[AA*5]\;L5'V?BJ94J03HK<`I43$&A=PTM1VPI?A][237\C
M`UG]FI9''+B,V-Y]OT<X!MTO2H8?.&2%-J`:]='ZP=5W65K@,%45UZ'+*8,Q
M+3@;O2#ZD,\L;=?DNG1"%R0R!(@/=7<(!1W)&`TJ3A]>\<,<+V.RB^*'N1\E
M"(77(:W%[+\@JM@"7_[<]+HP2GT(FR>9'%9;*'9AMF"!Z<AD#275/:V$7U>:
MWT6;X<!]M;:^LY%])8[ZB^P3?Y]W"/_K/*AB>)C_8CHK<KBV\:4%55/^'@O\
M"<44=AVI3X^A))0J8Q8[[Y!1]0&3=8AMLS#;+$S5QJK6!<;0+*Q*::H`9$PM
MOJH57LROD8\@;AT`4LO;:@0!VP"P&M_,(ZA?I52ZRS"PC*`7FD2K%^YDW1M!
MYS0U6"LP++,R%,9>_,-<BTJOR`C:I<A=#=F>O'P!OM@%`!T'7K_P!N`C@W6=
M`>WPMOB#?#E.S#4L#%+\\\7)Y,MC;B>\@2T/?V!8OC8ZNG(9^&K;"5L<01_6
MZ@A/R*X5BEO--^H7XPSI6@*."PO4$E;-D#8V8V]@XAH>P9^OT5=CLU.5BFU(
M,LJV3/]D(M8"&3\U8.Z*ZV-S*TXWY'5M7CRE5#,&BWVI@&2KIAS$?'W,[7:^
M9^M3DX/+%LJL;L+56=_WR\7"B0@<A:3OR2->)L7=*S%17F"\H2?.0Z:D(6[[
ML?T`/C8;7:AJLVUI`27-J^1BJ('O90=2?REF#4SH@$_.RO^)_*<YE><O*'*>
M4%9JC,SH'(=II.+2"1Y0M.AK8_*S-W#("YN%<T['.B$78F_@0J)^&VV,WK>1
M#TLATL;2P*&MWRZ]0<O)TE^!?Q@,8._6&CSJ_#+:<);,V?"!?O:C]*,A0@WD
M;>A@;_M_!X,SA*V^(396,@\>VL+EK3\7NV+P@<,UK-1U7?<^-470"%/D72S)
MD_`I$RE9*&K13K'9^AX(%0'J`]\E%5><WF-5,?S`(;-E-/9<%@T7KK*#H.^Z
M$C8MWJ;%V[1XFQ9OT^)M6KQ-BS=L8RE)G#RT,8^#2>:3WS#L.7OQ)DZ4V!41
M2ND[-C?>=)"K46EB8%U!Y-V>@^M6KV@]!(Q@++M8WN4P%KA566+S-?DHO<]5
M=DE<AG95`.X$EA%K;-^Q8:X%MW^,)<E*5W&M6B7939ROU:D]37I7"1PTP9*;
MC6T!.MBE`H42L4QG^X09X@VUJ]DI2/2UFIVT$%.6?V.<`5?#"NF.M<Y7ZY.5
M?5I72R@9(5^MS_9L]753U=6P.38XX7[H)ZB49[99E!,=7L3>DT`+M7Q^D!\]
MX!0&11F@T,&&GO[)/9^!QE;Q&!'2'UXX"0*UANN-M:'FW#45S]*7S<C!Q5#C
M`)M8_SL.")F`R.A!=,G<96>?(+WSXY]7$:+7(B(B,ND5T&IF]AW.;\Z;OU@N
M!H5JSM/>@TN>/X,#=\/3/H%K^P\;&K(N#LA:2,!;KN]\J)K-[+@)L+G]H>J&
M]G1A!=K7%S_3P2*TN6#A(YM"4>+(IE#`!K4I%#:%PJ90V!0*FT*Q-QNK0A$8
M05O!LJZT"T6Y_9NQG0NJ=%M<JVB/H'E@&R#;#Z01-`C<G^2M(V-/Z<#\Y?#^
M(H='YIZ/X:]-HZF391/9XS.P)=J8^EFVB[D/I_U<(MOM<!AK4^?0S5?GL[U_
M],1M<00NY(ORU=XX6@,<P3$Z+*U/PTKU'F&7]0A836<[';(F;D*4VF0EO<,"
M[U!#CZ[CG,U`G<#\[;>&$7`GD=^A%+06GNH5CF;(IYW9XSU9'!C'>[LP?T\W
MX+`B5>4SO;?+,\1`8OE,[^WRF'OCF+`H&JO`0IDRY4)G4G@8,%>PM;<0;]]R
MP\!WEZ>]!7?[CAH&N+L\[2VX^R"!APMOV;1D1K!S2S]S0#QL,Z&^U[5+^W>E
MC7":QE<,&AL:&/N\\Z&-?[;QSS;^V<8_V_CG`0:+V?AG&_^L-`IQ1QD800QT
MM=XDI3Q?DS8X@H!JI6H\YGZLC"!2>W\"DPT.#A]6G`O<6,,"E*5?G;8LLDRC
M)6M!8:[RO&=+M&NT9TMDY=U`EJC";\7B_<W5#/9LE6J<N*SQB'1MV99"UA/L
MP+(#%%6SMNJ%IE@BEDE@*\`.9`W!X7IL#6VSAH&L(2P<-E_`+[8QRD`6$!YL
MSM)_%'4BVE5K-":6Y)/]AASZ]Q2RZG_$T22.41)/"+>^\TB3UGP4KW_%FR3Y
M5]/P#KG+B':K(\OCBY5YUL_8<))6-,Y=K0_X;!F30Q['Y`P_^F$*(FT?0'@@
MS),_Q3XY66ML,^97$,>O$'G5;F]RHE_(F"^HL!X@;W8U`6UL9_N)2$FZ6PB.
M8KR7J2B>P+D3S\DAH/^A5\"+$VP=&G:X(/,!$%4\O6*6:NUQ+YQQ\@L$_&CK
MR`O%TTD>6!=,U^'S,HEOT`L*3N"!=8UD>IC"L9PI'/<XA2,Y4SC2/87**_@/
MG]PKY#H'Q,P)$M8US;-5F8<4<&B<(B_%/M8O%U(=]F(CO1XF=16A?RY1Z$K:
MBB5R^C9@%1<==E\].1L[VWOLK`RM`AP[*W%07?`P#5,H,K:93I]6(ZX98B5K
M-X*H5OG'RT:UVJA651L+='F/(-85HA-5P=>DSHT@H!6B);?`5];P1Q"FJNN,
M-SX/MX_YJ=$X\[V]V[9JO0V!A8P:ZX04,]=405IE:V(`&NN&5P+@<0G`8V-C
M490`>%(&T#@U6^^U(\>+P99#>D2`2<O1&.$!\*TQN,V7OZK@;G+-LKA=\\6S
M>GRWW/:L$KH5W*+0"H5YL$!F#2*Z[X"MB>?YV5RNPQF.%BD;\L*N.,@//'BJ
M:08V!*IA>]!_^2O+\IC.+M_<.8V_O*.!DY,(W6,F$YJ8Y2`"96F+RCD-Z8P2
MGRA_V1]C6D&#SOH*1U=$)/^#[!]N1D5(*V0?+R-5[.>DU;'_0.BH@K]`6^$$
M7K$J]C>45>[]*$Z4;?Z<-G0"M*W"CB#@\E0W?`QE8?(8.!%Y,,Z)='Q&R\1W
M8_Z@D#8*/82!_.DG\Q\A?HQ1]$(?P9D1@>A<1,TG4G]=4VA;Y5K?![\[?GB#
MX_@Z=(.E1_-3+ITH)+\F%GFAGBG5D:2!$\?3V9\.339(IE&ZQ::$\<0)/<(!
M*("TE19TXZY)Q==QO$3>`YZXY/$<D?.Y6.`PK:S!O8-Y2(&/]BM^F.-E3*;W
M,/>C!*%P,PSP?'%0ZL!<_/"*@A?4G;<:0EUPDP(9`"V%QP8>E-9(IH\I0$/0
M&H@HC^%_3%CB4^7E?1OY+CJ"A?1S$P4_*\A;Q8GG6Z\4<AT@HE43>7_OT$HY
MF]YEY._+1_)KOA.MSC`Y=OSOCFZC0"?U(_2]U8)<6\"S6_I.>1':M,#@K1-!
MHA>;OM;(\`,Y6K'CIOE\9ZOB3Z"G%4)5\02OT[S$1:T5G']2;9043^2;$_U$
M"57X[JER!\Z`JOZ^!Z;%DJ#:*/4PD7,YLSAOG4*-4*RTR;$=6;;^MDE+?H(V
MV+O$$7^PM]AR<@=F`XC9@&M-`=>`-3$XD!J^S6V`]*@#I(4V#/`J8_`9%W4B
MIB5@3G6%`6=<_(@2X"IC0XZ,BPU1@ET1,>D2_P5%CWB_,6M[FS+T1BGD:B,8
M(8:*$>3("%B#:L`L1\D;6PRVP>:'Z\R0!I<Q%I9E,NS*!M<>[GQ'`'P.K#BP
M<?ELG:Z+!B_4"%*KVAUY;5"5;H53X]01B.-V(_2:/<P,+&,3S03!JHD28(`9
M]S#MNKMJ0CY8/+U]CFYAQQ/,H["X]]Z"QQ^IQ6KYVJVWBY[&Z#]6C==8F<GQ
M3FN(/MT`=&1>%Z=N(K(Z<CB'RSYPM^$2"@5G:!I7'T,7FGE>0([ER2C=95*P
M9"DB#$TK%D7/>9XPE(,IO]//:,#,D\=R,#_:&VC;Q-J8,LA@LU?-KC[>*67Z
MZ)-T"5GEN.P[:7K[)3*=[51(D)<^#1IHX(G4?'/9A_RWE-]UFQZ!`#])8V]Z
MS.Q%RF#*]CU*DB#;##T!M\7!_@!7;]0`)>3HXFA_@+U=$IGFQ+`D`S7C[P]H
MO4N^O:@Q3K]/9_&`W'GH_W.)^NNBTLR+MOY`5T2?)*M+*ZGD/=:R6<&[*D"H
MZMTM%6N2+D)IMV]O]K-5^GGJ3.C0D$$Z#_JZ.+"Q._1NV"5BDWA*'.UCQX8*
M"=9+$X=Z/FR:T1[V=:A?3H,SE+2>2YO<-.KD)MU[C4,C&$&(>[M252]'):J.
M8^H8H4KWKZP3V_[DL<TFU(D490]QMFC&^9FU6U:D1Y@5S4\LX4?ZA9VU=;]/
MG"BQRR71O#J"'*T]7ZQ&EP++>1J+*K%OR[?E6F.Y5?;U/,SEVG(AL^A^Z<N5
MW6>7H3>H``X"P7*1SBC^$5-10W^#X%/9BD%B-7SQ80<>W"$RLRZUJZ'U3:L_
MUFCXWJ!S^?:,W`1Y?\<!@85&3]TYB;`9NXUJCQ.\\%]\CVQ`F=/;IMGCY&@^
M@*Q)9;1ZF,R='_^\BA#:I)K+6*EJFOOI8-HW=[VMJVWK:E>?B^8MR&>AS*-]
MNT8HJ&-&7ZC"]O@=PA6J"-F0!1NR8$,6;,B"#5FP(0LV9,'XO<:I%8PK;*%!
MP:J"3)U..:88!N7/!&`MJ!'$+O0!>5M%J2.[TY7L]+:Z5,?V*MV_4!WKX%3B
MX&PU*1M<O7-H"[#MJ&"%!ZVXT@3\MMN+U3&THD?3`NRZ5=D2F!],IDU5JG;1
ML]I+&@K#]AV64E\B(T=01VV1FL$&'H+"/Y_Q!)X`X\3BFJ*:VC+^&QG8JX(G
M.>N]%CVIYF*_`+1-YI7"FU9][A/*#0,#A6W8,G%?/>'[%ELE!\RUZ0]>[63G
M0\5LIEV1B")-$;XG.]-W"7K36576X0-A/J[^$3Q$2.ZXJ@]&>6AP'%`="1L7
M9N/";%R8C0NS<6$V+LS&A0W(P6CCPFQ<F(T+LW%AXXH+T[71ZYY#(V@[V?::
MQ*I>R08WN%=JSL"UQAF#V][W?@6JC^<Z-O88[%/!BA:;-PO^DJYQV_I+BMP[
M;,WL"1ON:G&USY3?T+JJR8]=0QF^?A5=C[]FBQ:B)]IKU"Z:_!`7MFK2H]ZJ
M"S+9(,.L,;`&"VG?08;G*0#78?[#Z:RFP=OT,?"?LDTK+^Q0PO`##T3L,D.U
MGA>AWG[\#AD!\JTQ?34QF15#%>%>KT#-Z-S!FQU'D3"I&MJWSHH[HE"8M`3V
M-P58;R/?134#YHAVF0QP(,4>SN&=,VU3GKC_7/JQW\B30.B7$'D;,-%[P,2]
M.T?>,B#2LF(%X[-5^WJ"8R.D#6G#(#2'04A;N1%$/,@^6#:XP08WJ-E6G:YP
M!KETF^-0(.^B.<GJVZ[`^SLL1TI'D"4].YAKV#AAJACHUL<J@]98]Y(B:"$6
M#>8FM^)8NC@N&_^E@PSHQO"W#W1.CT2XD;_\?U!+`P04````"``I@`Q%=Y0V
MHZX2``#WSP``$0`<`&%R=W(M,C`Q-#`V,S`N>'-D550)``.-<NI3C7+J4W5X
M"P`!!"4.```$.0$``.T]VV[C.++O"^P_:/.PZ,%9QW:2[I[D=._"23HS`9)V
MX*3W\K2@)=HF1B8]I)3$^_6G2-THZT))MA/YK!H#C"-6%:M8Q6)5D:*^_.UU
MZ5K/F`O"Z->CX?'@R,+49@ZA\Z]'ON@A81-R]+>__O$/7_[4ZUF3R;4ULCWR
MC*^)L%TF?(X_/-[_9/WS<G)G/=H+O$36-;/])::>U;,6GK>ZZ/=?7EZ.9X0B
M:A/D'G/N'-MLV;=ZO8CN%<?(`Q:L:^1A2_V[L$X&P[/>X.?>\.1I^/'BX_G%
MV?!X.#P[^73V\7\&@XO!0"/P]T`$2_MW80V/SX\'QZ<:V`.R?T-S;-U>:V`W
M9Z/1Z'QP]OGR_'KXZ?/EM\'UU7#T\_GG3Z=75U>7H]X`_OW\^?QL\!E^#L\&
MGW3.V6K-R7SA61_LGQ3+UN18_G?-*,6NB]?6GZU'1@5`+E>(KH^MD>M:$XDB
MK`D6F#]CYSBD*((1!*50<4&!@K_\>J0-XNN4N\>,S_N.Q_O>>H7[`-0#*,R)
M?13B@=IDDX@Q9TA,%5;4T@<^3WN#8>]T&"$);\5C!-6-P/;QG#WW98M$&&X@
M$+L`GM@YX(0^8^'E8P1M.4Q)*&<#2<IQ,AA\[`>-$2CB+SPU5(AS]K+`R.$P
MQHC;"V5S)TI_IP-MK.8(K7*'2C;D,.5@DB\&-!3(0/*5"&*<@O#"@XF!(WB;
M^=3CZ_PNPL:<;EQ"?ROI139/D8A[><W`OYPJZ.'Y^7E?M<8,^9R#3RCB*&R5
M+)VD6:*(V"(?2S7E6`E^M1?Y&+(E1^P*$R2:',CS.)GZ'KYA?'F-9\AWP;1\
M^KN/7#(CV`'7YV+IN%(`6K.'^!Q[W]$2BQ6R<7USRQMP4,^P_\_[N\!Y'H$7
ML*PO9+EBW+,"=W#';.4<2]0K_^I%EM23C\!KPC`=OPK@F^9R7&2&_2U8B,RL
M$0N)C39B(?((LN^/1;WFNY#Z_6V:E^ST7`H\_%1)X*QY;L,#H]^W94-?1BJQ
MHFCDNLL^=CT1KS6]9-(6L52^/NV*&_FD)C.9%:`Z+YN+@OQ1H??2!:5^[]K*
M&OZNRT/.VER?#7W9BOZHRTC>TM>`$WVYBO_J)8M7-5[R%KWZS,1KFOI5=T`R
M*V)]!I)E./C92U;D2BQDE_'Z/$3AHOQ1M__-4+-![U%PJW[5[G\S-`X90)0R
M3_6J_I9/5BM"9RS\$Q[(Q>Z",Q<_@<.SB//UZ`DO5RZD/W<J]I)-/R:W-6*,
MOD3IIZG4BPUC[B+^'`Q9&U%RR!P($BX]N8NZLF1?7_J;&)O$?(&=,?VK^KV2
M$M!@B#3L$*0,TT:N[;L-$!/.BO'"IY%:-K05C=,$SRP5(4/284O8\CBZO^)L
MA;E'8%W3PG!%8,'Q[.N1S%UZD1K_#1(>@]XBD$P':>4II6\,2LAD1,$CGB1Q
ME0`IC8F_6,B-NY'K[M<C`5/'Q?O,*?KO,ZB@_;J#FC:8_#&]CF&,0_I.@KMH
M6E=P0,%NL<QWLKFMXH)CJ2ONIB_*E_I!@ZHM?.SG&WAU#[TRRI;K@-G(_4;_
M'U'G&P46U[>PNO"E8N](+2<3`/]W)?`RMS_,\?OQ3T0=*R!G:?3JK02-_7GS
M)63[E6!W^GP$`53-X8I1P5SBP)_.)7)E*OZXP-@3FC8K`)MT.92ZC.E8LGZ9
MD+)"6E9`K%/D3A7Y@"!G\!;8(S!4M;2:QC2I^*2&BJT/*=H_=2K?5N7Q0S&>
MC6'E4C(:)W$!EDG5IZ6J3HA:;&8E9#LE[TS)X]FCQ^S?%LQU,!???O=A+:RL
MZUQDD\K/JJE<:ERG_F>T8N)_K:"3S@#V:@"U''T-2B;3^+@#T^@6A'TN"%=(
M+&Y<]E)K/4B03`;PJ<9R(*E:BFRGXKVHN)D7**9@4O[G1LKOYOLVR7A\!F;,
MYXB2_RAY(,=^)'-*9C"@D'';:N."T/D#*,,F6)_[#0F83.%GE;#'M.$/G;Q*
MV[4.K*0'*^JB,X-&9G"K-LO4-,O5LMYN4N)Y1HD:=J>?1OJY(:_8&0F!"_2C
MMQOT,QQD]*.PK0"]4U`C!8ULB$(%V<R9"P!,*AIF5*2C=RIJZ.,\1.=DZN*2
MB90!,JGJ),?;122Z*;6;->F6/OI301R">%$84@ALTM]IR6IE$6KIQ#I%-E)D
M::6I%,RDO+.,\KK2T6YU=X>1*)AR89-)1Q\S.@H0.X4TGTR7,("./):/J<CL
MG)I`30K[E#^I>HJ2I9/J5-@LF$>$_QVY/KZ'B0!_%Z==^9`F!7[.!OA`QU*$
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M-8UZ%$Q&4>.,6&<3;V83<5J@C?)HRGSO']`%*B\P-*=FLI5L,;/,5K0D1+<5
M)#NVHIX[T]G%3E)=%V+&,IE"ME09[CEU/F*?BK[Q/?A]#_PM_:5Z](#6JFSW
M@\(<O$(KXB&7_`<[`;S1!AH2-)E'MAP9FT?0HQ5V&3RWHDXM7_9J:=W&>YF=
M^>S=?,*K).A\-\:33\YD.MGZ92W3B3OM#&>/F^"-8M9:5$QFDE/T+-HN[Y:D
MMS2-(.P#U[T9;"KP\4I5)VN;2AVJ!M,YRQ9.2TPG[C@GB%5H5MAY9TU[<31"
M^,M@@']`TQ-3)R>V,J7*)$UVE*V^EKF@I%=+=FMY+#P%TEG1&_DD2(`G6'B<
MV.IF#@!4GSR!;+6A.S(2-%E0P9'+,D^D\NFDU]!ZHGX[\]G#T;#\AXR'^S?4
MN2-H2EPB+S,-09R1%V.-Z03+B\4A)@6]DC*']8;=FTPS6RPN.KA6W`+K9;3K
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M'Z.H]-&%T10R<V1[P2>&OA[5PPF^-J&^+'DA,WPZO_7P4O)\9`D?P(CG2XQ?
M./-7$2`!D",K^+T"3\*<)T7&\0.]`BO$=>7+15^//.X#*11V&/W=WT)@&'4L
MF11U)-:0#E!D]:)6'7%#A`:B.M[%`MJY[4_5@.U'Z-OE"CQ$<%EU]AJX0,YR
M&%VT):/@._AZSWJ<(5=],D8A3X.O'P`FGA*O6-(:E_1G#+L9;LOLNX80*3.O
MC]=::X^.'GU[A9X(K!37ON3N077RN$`<QRJO!)H25#U[&\MO))^*`BJ)%T*V
M9F;;'#ME4_L6TC15^)0?,6=`FTM7+#_'O7XDKU?22D$PI;1[O)QB'GNV^HC!
MH`3?\;YPV!(1^JZS.A)!<8TQC<7X#H[(6TO)*@Q`7>RVC<(#QS/,>;@5$TGU
MM&"^0-0)I"H8@D:H;9,_8/N)_8)<E[V@=9Z6LZUMD^*!,QMC1]QPMHP<TW@6
MN2KY^K6V4YOHKQ92:YS:MN%*_$V!^M%*'NJA!2NQ#/5BE4VTUH8J$V8O\#UR
MB&`T/9OS6MHVDPNJ'NJN@O43?O4N79B4D415H5-2>M'S]PVYOC-J`_L<U@EI
M/-3#$`5ZHD#2JM!ME#0N:FE5<7"O]]A;,(>Y;+Z^85PKA:L9EAF!;:FT<62^
MO=JJX#:1491(S];\MK;-U^_8DYXQ>"E,;K2HB_ANP5B7Z2]@A&9<%;PUJZTI
MA;ABP@ML,.%_Y,&",/4]98$L?^HF+JPI_HZ'B%#A0>"S\WCD5^Q"!'F//,@3
M(3N2)S74_!S9MK^4A5_L_*`<VVQ.Y=G]7YGK@)B_@&%'0[0-A?_7@W3'A-AN
MD`(*;1DD\UQ;+F6<CMSOS,/BVL?_(-Z"T#'%_\*(I_UG1>"V.=0LVZ,9S/B0
MZT"$IP7'ZD]A$KD*;MM&8!+NV<47C\3Q:[:A+99KF-Z7OH"$20A0T)10-3[I
M@!524"($XVNIN"#KCJ1NAGM@`Z/=0A*\"QI'N(%`WWUIJ_+2*U4KS1V@9C1V
M6HFM/DQ%`S):K2"BEZACW[LC-J8"R]N](F&+VW5!HDGXOM'M`_@BN4$[Q^/9
MA*V1ZZWCHPIQ$:84)G1-X)=6`=R[ZB;9ZWYB#V@=L$N2RG]Q^YO72$R:";;.
M,R<-M"F4\C%:R;,FWL'$\=]>5U@>CA\M&??"VQ/E,YA?F3I9-=B6%<9*F$Y5
MPLQPK2U]W=+P9`>HX5FFE1NW)FD2Q17N.B@'8\PWB40CZAADS)AW4^R6&7QR
M,5(M@=)EX:UHM':BC%\HYF)!5LGRJUT9%"_.1K!=KL\[6-8@)))KO*->6U%3
M1=V1J(7'L605(-L20ANS8@GHL`<(7I?(QK[Z>+.XI?9&<F@":UL>"+[7I][X
M!3N7ZZQM%K6V16M5=ND</?I5*3NXEI'S+"FD-^4,D.V*DX/L:[.HF>-,QO2:
MN+X\PZQ>VXHCD,;X[1H'_3ZV]&&!)/HHAC@00RX6X7(MO:S,!<SBZK`'(OAH
MZB).Q-,"<IV5<J<;U;@2@+:YVCO,*.(.NR1,K(6,YC++1RE(V^1Y>F'1.1SM
M$,<#*%9KN6$^CPI%TE>`&]F`>%H0+@\WY4`%,:!OJXY_42=&TN/UKBRT3A\+
MCH6\\DU?QF2UFM%@<"+?_F/%-CS#%0.GP866LNV(6+O6BGOT*N\G"M0LA2'!
M3J"*<M3-2*,YQU@OA]=".1"GFA$FDB`X7YJ.$$K`VE<,E=O>UQR]4'G<[`;9
MJ2IH0>.!*.W!Y_8""1QK0>XTW1%J,Y<^(/Y;>#/;C2^O'0"-X?CV`:G"%:(;
MIPYW1Z]M?E#S4M&)PP=.[#@M+6Y/>2NU@_'.YAQ[4L5@=,Q5.YB5W[Q3.7:P
MW3('&YM#@J78'%.Y*Z2J`?P1R:I/]&WU,**K"-V:.J%AXDZPG!'R&`"9)4=?
MD^W6_-;V^=:0M3'=.*&=?=XVAQ!R"`%?+N?:\[9R+H\3Y/.NM[24>QE_YS*O
M-[25=T@#\GG7&EK*^R-YS65=>]Y6SO$SIOF\ZRTMY5Z]K9/+?:JE;=SKB1ZD
MP%Q>TGH+^2_UD3N1#:X\19EWI*`,NF6;%U>,KQA0P;]BY/SN(TC[N;B%@%<@
M!U.T>=*K$G#;%#GV%I@'.@BWE)/#$WE-AQ)(Y=U_K:X2CFVR&.!09$RFTCVC
MWL)=*S4Y1%ZO?.WC)_;#"T_>R^F5O`->%^U0QB,ZC1BEZR!@[DLW)K"VS=&(
M4?VC<G)>AK,R>1W#`'8H>E1):/;"5[DJSA7HY3H!">?QZ`7Q3/$UWK#;'<'4
M`8(6O":N%:;%1E6[L/I=!-@VN]=9+JC+%\MH0&BSK-$.0T5)2\';)F?CJ1B^
M]1O,0XBK%%?Q&VA;SW03^4/QG:/HGJV-G<_-QVVSB]P[N+0O561.Q%6&;W#D
MZQT%39UUJP;;0,"W.=/VG5&YC9(Z?SS!-@[.YP4%VNB-`/T4VR4#KZ:]9KL-
MD4.9MS\H<=;+S!Y_YG';YFUT.4-T+X4Z=\ZQMFVR4=8HA=QI=+7]7H2^ZX]I
M)$#A2IP#TS9UI>*&%^P^8Z-4!7`MEBP*B,P**P!LG6R8+\>S].OGL3BY;>W;
M$4IQ&&Q&>O)X=K(O.9%=W#!^0[CPY/N0R?L/#5#U$5CY[[TY6UT$,,]FLL>(
M!RMY]!YL`]D3U$.57N:K#8T^QCQ8V2&8:SKAGUNI]^C-UI0D(XX?F1L?F2J'
M:5NA*>>EY^A4D#I[47#Q3R9#WYY.6\Y@F=X"R7]-//=VI'`OHF2,C)@'/"KZ
M%=OAK=L%XI8,4!TB;1RK+WUA+_`2P<__`U!+`0(>`Q0````(`"F`#$5<$Q$0
M.?T``%DA#P`1`!@```````$```"D@0````!A<G=R+3(P,30P-C,P+GAM;%54
M!0`#C7+J4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"F`#$71IY:.!PX`
M`%G;```5`!@```````$```"D@83]``!A<G=R+3(P,30P-C,P7V-A;"YX;6Q5
M5`4``XURZE-U>`L``00E#@``!#D!``!02P$"'@,4````"``I@`Q%KG8LPF)$
M```%6`4`%0`8```````!````I(':"P$`87)W<BTR,#$T,#8S,%]D968N>&UL
M550%``.-<NI3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`*8`,10&<KL0$
M<P``K>,&`!4`&````````0```*2!BU`!`&%R=W(M,C`Q-#`V,S!?;&%B+GAM
M;%54!0`#C7+J4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"F`#$5P9_+>
M'4@``)U*!@`5`!@```````$```"D@=[#`0!A<G=R+3(P,30P-C,P7W!R92YX
M;6Q55`4``XURZE-U>`L``00E#@``!#D!``!02P$"'@,4````"``I@`Q%=Y0V
MHZX2``#WSP``$0`8```````!````I(%*#`(`87)W<BTR,#$T,#8S,"YX<V15
M5`4``XURZE-U>`L``00E#@``!#D!``!02P4&``````8`!@`:`@``0Q\"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5GAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements - Assumptions Used in Valuing Derivative Liabilities (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2010 Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.11%<span></span></td>
        <td class="nump">0.33%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">1 year 6 months<span></span></td>
        <td class="text">2 years 2 months 12 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">69.00%<span></span></td>
        <td class="nump">69.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2012 Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.88%<span></span></td>
        <td class="nump">1.39%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">3 years 6 months<span></span></td>
        <td class="text">4 years 2 months 12 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">69.00%<span></span></td>
        <td class="nump">69.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2013 Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.88%<span></span></td>
        <td class="nump">1.39%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">3 years 7 months 6 days<span></span></td>
        <td class="text">4 years 3 months 18 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">69.00%<span></span></td>
        <td class="nump">69.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Exchange rights</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.88%<span></span></td>
        <td class="nump">1.39%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
        <td class="text">3 years 6 months<span></span></td>
        <td class="text">4 years 3 months 18 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">69.00%<span></span></td>
        <td class="nump">69.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1. <font style="font-style:italic;">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nature of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary Dynamic Polyconjugate (DPC) delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead&#8217;s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Company&#8217;s primary source of financing has been through the sale of equity securities.&nbsp;&nbsp;Research and development activities have required significant capital investment since the Company&#8217;s inception and the Company expects its operations to continue to require cash investment in fiscal 2014 and beyond as the Company advances its research and development efforts, including clinical trials, and related drug manufacturing costs.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 201<font style="color:#;">4</font>, the Company had $138.3 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 27 months.&nbsp;&nbsp;These bonds provide a source of liquidity, though the Company plans to hold them until maturity.&nbsp;&nbsp;At June 30, 2014, the Company had invested $50.1 million in bonds.&nbsp;&nbsp;During the nine months ended June 30, 2014, the Company&#8217;s cash position increased by $119.2 million, which was the result of the receipt of cash from the issuance of equity of $172.6 million and cash from the exercise of warrants and options of $12.4 million, partially offset by net cash invested in fixed income investments of $39.8 million, cash outflows of $24.5 million related to continuing operating activities and capital expenditures of $<font style="color:#;">1.3</font> million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries.&nbsp;&nbsp;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facilities are located.&nbsp;&nbsp;All significant intercompany accounts and transactions are eliminated in consolidation, and non-controlling interests are accounted for in the Company&#8217;s financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation&#8212;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Article&#160;8 of Regulation S-X.&nbsp;&nbsp;Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year.&nbsp;&nbsp;The September 30, 2013 Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended September&#160;30, 2013.&nbsp;&nbsp;Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates&#8212;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&nbsp;&nbsp;The Company had no restricted cash at June 30, 2014 and September 30, 2013.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several checking accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities.&#160;This statement requires certain securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At <font style="color:#;">June 30, 2014</font>, the Company classified all of its investments as held-to-maturity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.&nbsp;&nbsp;See further information regarding the Company&#8217;s short and long term investments in Note 2 &#8211; Investments.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See further information regarding fair market value of marketable debt securities in Note 10 &#8211; Fair Value Measurements, such fair market data is obtained from independent pricing services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization included certain license agreements acquired through business combinations. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-Process Research&#160;&amp; Development (IPR&amp;D)&#8212;IPR&amp;D assets represent capitalized on-going research projects that Arrowhead acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&amp;D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets are impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration - The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event.&nbsp;&nbsp;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&nbsp;&nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within our consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minority Equity Investments&#8212;The Company had a minority equity investment in Leonardo, a privately held biotechnology company.&nbsp;&nbsp;Based on the status of the development of Leonardo&#8217;s program, this investment has been fully impaired and the net book value at June 30, 2014 is $0.&nbsp;&nbsp;The operations of Leonardo ceased in December 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling Interests in Majority-Owned Subsidiaries&#8212;Operating losses applicable to majority-owned Calando, Ablaris and, prior to its disposal, Unidym have periodically exceeded the non-controlling interests in the equity capital of either Subsidiary. Such excess losses applicable to the non-controlling interests have been and are borne by the Company as there is no obligation of the non-controlling interests to fund any losses in excess of their original investment. There is also no obligation or commitment on the part of the Company to fund operating losses of any Subsidiary whether wholly-owned or majority-owned. The Company allocates the non-controlling interests&#8217; share of net loss in excess of the non-controlling interests&#8217; initial investment in accordance with FASB ASC 810-10. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When there is a change in the Company&#8217;s proportionate ownership share of a development-stage Subsidiary resulting from additional equity transactions in the Subsidiary, the change is accounted for as an equity transaction in consolidation. To the extent that the increase in the calculated value of the Company&#8217;s interest in the equity of the Subsidiary exceeds the Company&#8217;s investment in the transaction, that increase in value is referred to as the Company&#8217;s &#8220;increase in its proportionate share of the Subsidiary&#8217;s equity&#8221; and the amount is recorded as an increase in the Company&#8217;s Additional Paid-in Capital. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212;Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. The Company may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments under collaborative research and development agreements are recognized ratably over the relevant periods specified in the agreement, generally the period during which research and development is conducted. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earnings (Loss) per Share&#8212;Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options issued to employees and consultants and warrants to purchase Common Stock of the Company.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative Assets and Liabilities &#8211; The Company accounts for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on the Company&#8217;s Consolidated Balance Sheet and no further adjustments to their valuation are made. Some of the Company&#8217;s warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on the Company&#8217;s Consolidated Balance Sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2014, the FASB issued ASU 2014-10, <font style="font-style:italic;">Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance</font>, which eliminates the distinction and separate requirements for development stage entities and other reporting entities under U.S. GAAP.&nbsp;&nbsp;Specifically the amendment eliminates the requirement for development stage entities to 1) present inception-to-date information in the statements of income, cash flow and shareholders&#8217; equity, 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.&nbsp;&nbsp;ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 with early adoption permitted.&nbsp;&nbsp;The Company has adopted ASU 2014-10 effectively with the filing of this Form 10-Q.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font>, which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and will become effective for the Company in the first quarter of 2018. The Company is evaluating the potential effects of the adoption of this update on its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the FASB issued ASU 2013-11, <font style="font-style:italic;">Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</font>, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity&#8217;s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. The Company is evaluating the impact, if any, of the adoption of ASU 2013-11 on its Consolidated Balance Sheet.</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>25
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N=%]O9E]3=&]C/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N=%]O9E]3=&]C,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O
M;&ED871E9%]3=&%T96UE;G1S7V]F7T-A<S$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A;FEZ871I;VY?86YD7U-I9VYI9FEC
M86YT7T$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)
M;G9E<W1M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9I>&5D7T%S<V5T<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D%C<75I<VET:6]N<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?07-S971S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YV97-T;65N=%]I;E]3=6)S
M:61I87)I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=&]C:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3&5A<V5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VX\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE
M87-U<F5M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D]R9V%N:7IA=&EO;E]A;F1?4VEG;FEF:6-A;G1?03$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E<W1M96YT<U]486)L
M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&:7AE
M9%]!<W-E='-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Q+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^26YT86YG:6)L95]!<W-E='-?5&%B;&5S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET
M>5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y,96%S97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?5&%B;&5S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-
M96%S=7)E;65N='-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]3:6=N:69I8V%N=%]!,CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=F5S=&UE
M;G1S7U-U;6UA<GE?;V9?4VAO<G1?83PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D9I>&1?07-S971S7T%D9&ET:6]N86Q?26YF;W)M
M83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA
M<GE?;V9?4')O<&5R='E?86YD7T5Q=6EP;3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D%C<75I<VET:6]N<U]!9&1I=&EO;F%L7TEN
M9F]R;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN
M=&%N9VEB;&5?07-S971S7T%D9&ET:6]N86Q?23PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?07-S971S7U-C:&5D
M=6QE7V]F7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DEN=F5S=&UE;G1?:6Y?4W5B<VED:6%R:65S7T%D9#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?
M061D:71I;VYA;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-T;V-K:&]L9&5R<U]%<75I='E?4W5M;6%R>5]O9CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E<U]!9&1I=&EO;F%L
M7TEN9F]R;6%T:6]N7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DQE87-E<U]&=71U<F5?36EN:6UU;5],96%S95]083PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E<U]&=71U<F5?
M36EN:6UU;5],96%S95]083$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,SDN:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]!9&1I=&D\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-#`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D
M7T-O;7!E;G-A=&EO;E]3=6UM87(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#$N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]!<W-U;7`\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A
M<V5D7T-O;7!E;G-A=&EO;E]3=6UM87(Q/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N='-?1F%I
M<E]6/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#0T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I
M<E]686QU95]-96%S=7)E;65N='-?061D:71I/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N='-?
M4F5C;VYC/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M1F%I<E]686QU95]-96%S=7)E;65N='-?07-S=6UP/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0W
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N
M='-?4F5C;VYC,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970T."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S7T-H86YG93PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970T.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%
M>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K
M<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!
M8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0
M<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO
M>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL
M/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@
M<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0
M(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U
M7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#`Q+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%,D-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U
M;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^075G+B`Q,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!$;V-U;65N
M="!!;F0@16YT:71Y($EN9F]R;6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"U1/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B=F86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^2G5N(#,P+`T*"0DR,#$T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE
M;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<R,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3
M>6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=!4E=2/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)T%24D]72$5!1"!215-%05)#2"!#3U)0/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E
M;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,#`P,#@W.30P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<M+3`Y+3,P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM
M;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4R+#DP."PU-C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X
M7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T
M<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%3U=!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0U524D5.5"!!4U-%5%,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S."PS
M-#DL-S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q.2PQ,30L-#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D92!R96-E:79A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#`L,#8S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,R
M+#,U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4S."PW-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,2PV-C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H;W)T('1E<FT@:6YV97-T
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#@S-"PT
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY+#`S,"PR-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y43U1!3"!#55)214Y4($%34T544SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38S+#0R,BPY-#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR."PX-#,L-S$Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-C<T+#$S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-3$S+#(S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%T96YT<R!A;F0@
M;W1H97(@:6YT86YG:6)L92!A<W-E=',L(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPQ.3DL-3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-#`L-3$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L,C@T+#@V,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-S`R+#$U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,2PT,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,"PP,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y43U1!3"!!4U-%5%,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y-BPV,C(L.#<V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L,S(Y+#8S,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#55)214Y4($Q)04))3$E42453/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ-3@L,3,S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.3DL
M-C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#`V."PV-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,S@L.#@T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D('!A>7)O;&P@86YD
M(&)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3$L
M,#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3`U+#<W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S$L.#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`S+#$R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,3@L
M-S$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PP.38L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87!I=&%L(&QE87-E(&]B;&EG871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,RPQ,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C$L,S0U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E
M<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY-S$L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU."PU,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#@L,S0S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@
M0U524D5.5"!,24%"24Q)5$E%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^."PR-3`L,#DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^."PW,C4L,#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQ/3D<M5$5232!,
M24%"24Q)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYO=&5S('!A>6%B;&4L(&YE="!O9B!C=7)R96YT('!O<G1I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<&ET86P@;&5A<V4@;V)L:6=A=&EO;BP@;F5T(&]F(&-U<G)E;G0@<&]R=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$R+#$V.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#8Q
M+#$Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W1H97(@;F]N+6-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S4R+#@R,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S4X+#<P.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1/
M5$%,($Q/3D<M5$5232!,24%"24Q)5$E%4SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPU-C0L.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-CDL.#(R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A
M;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07)R;W=H
M96%D(%)E<V5A<F-H($-O<G!O<F%T:6]N('-T;V-K:&]L9&5R<R<@97%U:71Y
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R969E<G)E9"!S=&]C:RP@)#`N,#`Q('!A<B!V86QU93L@-2PP,#`L,#`P
M('-H87)E<R!A=71H;W)I>F5D.R`R,2PR.3$@86YD(#DL.3`P('-H87)E<R!I
M<W-U960@86YD(&]U='-T86YD:6YG(&%S(&]F($IU;F4@,S`L(#(P,30@86YD
M(%-E<'1E;6)E<B`S,"P@,C`Q,RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P
M,2!P87(@=F%L=64[(#$T-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R`U
M,BPY,#@L-38W(&%N9"`S,BPT.#DL-#0T('-H87)E<R!I<W-U960@86YD(&]U
M='-T86YD:6YG(&%S(&]F($IU;F4@,S`L(#(P,30@86YD(%-E<'1E;6)E<B`S
M,"P@,C`Q,RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#4L,C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(T+#@U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A
M<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X."PU-3@L
M,S`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3DS+#4Q-"PW-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(P,BPS-#`L-S$W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V-BPQ-#`L.38Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L($%R<F]W:&5A9"!297-E87)C:"!#;W)P;W)A=&EO;B!S=&]C
M:VAO;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3@V+#,V,BPX.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-RPT.3@L-C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V]N=')O;&QI;F<@:6YT
M97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4U-2PP.3@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PW-C,L.#<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1/5$%,(%-43T-+2$],1$524^*`F2!%455)5%D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X-2PX,#<L-S@Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-S,T
M+#<X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1/5$%,($Q)04))3$E42453($%.1"!35$]#2TA/3$1%4E/B@)D@
M15%52519/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y-BPV
M,C(L.#<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S-RPS,CDL-C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14--04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A087)E;G1H971I8V%L*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$L,CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.2PY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,2PR.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-2PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4R+#DP."PU-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,BPT.#DL-#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E
M<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3(L.3`X+#4V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,R+#0X.2PT-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W
M.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y
M,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E
M=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%04A"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N="!#;VYS;VQI9&%T960@
M4W1A=&5M96YT<R!/9B!/<&5R871I;VYS(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5614Y5
M13PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,RPW-3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0S
M+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3,Q+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,C0V+#4Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/4$52051)3D<@15A0
M14Y315,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-A;&%R:65S(&%N9"!P87ER;VQL+7)E;&%T960@8V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#4T+#0T.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C4Q+#<R
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L-C,T+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L,#`V+#,R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-3@R+#0V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@Y.2PV,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#@V-2PX-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4Y-RPR-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPS.3(L,C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW-38L-3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30L-S$Y+#<S.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-#4X+#(Q,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#`S."PV.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-C,L-3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPW-3@L,C8T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,30L,S<U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R
M96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C<V+#`U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0U-"PP.#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`W-2PR,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,U,BPT-#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEM<&%I<FUE;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S`X+#`T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,P."PP-#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y43U1!3"!/4$52051)3D<@
M15A014Y315,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#<T
M,RPX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#0S,RPV,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PP-3,L,C(X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L.#,V+#8X.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]015)!5$E.
M1R!,3U-3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPW,#`L
M,3`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8L,S@Y+#@V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S,"PY,C$L.3<X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#4Y,"PQ-S,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]42$52($E.0T]-12`H15A014Y312D\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!I;B!I;F-O;64@*&QO
M<W,I(&]F('5N8V]N<V]L:61A=&5D(&%F9FEL:6%T97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<X+#<P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U.2PU,S`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-CDL,S4P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X,"PV
M.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y'86EN("AL;W-S*2!O;B!S86QE(&]F(&9I>&5D(&%S<V5T<RP@;F5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,SDL.30Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4X+#@W
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W-BPS.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64@*&5X<&5N<V4I+"!N970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R-BPT,C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T."PR-3(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@V
M+#,Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8X+#0P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-H86YG92!I;B!V86QU92!O9B!D97)I=F%T:79E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4X+#0V.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PW-#<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M+#<Q,BPS,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$U+#8R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(@:6YC;VUE("AE>'!E;G-E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#4T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4Y+#(R,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q+#(V
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#DY-RPY-S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5$]404P@3U1(15(@24Y#3TU%("A%6%!%3E-%*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-S,L-C0Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$R+#(S-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L
M,S<R+#DP,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q+#,P-RPX-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3$]34R!&4D]-($-/3E1)3E5)3D<@3U!%
M4D%424].4R!"149/4D4@24Y#3TU%(%1!6$53/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,2PV,C8L-#4Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,3<W+#8R."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPR.30L.#@P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$W+#@Y."PP,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQ/4U,@1E)/
M32!#3TY424Y524Y'($]015)!5$E/3E,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$Q+#8R-BPT-3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-BPQ-S<L-C(X*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V+#(Y-"PX.#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L
M.#DX+#`Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DY%5"!)3D-/344@*$Q/4U,I($923TT@1$E30T].5$E.545$
M($]015)!5$E/3E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,U-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.150@3$]34SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3$L-C(V+#0U,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V+#$W-RPV,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8L,CDT+#@X,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-RPX.3@L,S<S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T("AG86EN*2!L;W-S(&%T=')I8G5T86)L92!T;R!N;VXM8V]N=')O
M;&QI;F<@:6YT97)E<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R+#0V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY."PV,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY-2PQ,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-#<L,C8X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($Q/4U,@05144DE"
M551!0DQ%(%1/($%24D]72$5!1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q,2PV,C@L.3$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H-BPP-SDL,#$P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,S8L,3DY+#<T."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$W+#0U,2PQ,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.150@3$]34R!015(@4TA!4D4@05144DE"551!0DQ%
M(%1/($%24D]72$5!1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,"XR,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#`N.#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+CDR*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY32$%214A/
M3$1%4E,@+2!"05-)0R`F86UP.R!$24Q55$5$.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G
M92!S:&%R97,@;W5T<W1A;F1I;F<@+2!B87-I8R!A;F0@9&EL=71E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L.3,Q+#DX.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#$S-"PQ
M.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-"PU-C4L,#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3@L.#DS+#$Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T
M9C<X-V0X-SDX#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB
M83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y."]7;W)K<VAE971S+U-H
M965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$595D%+/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G0@;V8@4W1O8VMH;VQD97)S)R!%
M<75I='D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y4;W1A;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y#;VUM;VX@<W1O8VL@:7-S=65D($`@)#4N.#8\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N('-T;V-K(&ES<W5E9"!`("0Q
M."XY-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y0<F5F97)R
M960@<W1O8VL@:7-S=65D($`@)#$L,#`P('!E<B!S:&%R93QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL@27-S=65D('1O
M($=A;&QO=V%Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O
M;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#
M;VUM;VX@4W1O8VL\8G(^0V]M;6]N('-T;V-K(&ES<W5E9"!`("0U+C@V/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB
M<CY#;VUM;VX@<W1O8VL@:7-S=65D($`@)#$X+CDU/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY#;VUM;VX@4W1O
M8VL@27-S=65D('1O($=A;&QO=V%Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E!R969E<G)E9"!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y0<F5F97)R960@4W1O8VL\8G(^4')E9F5R<F5D('-T
M;V-K(&ES<W5E9"!`("0Q+#`P,"!P97(@<VAA<F4\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!086ED+6EN($-A<&ET86P\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!0
M86ED+6EN($-A<&ET86P\8G(^0V]M;6]N('-T;V-K(&ES<W5E9"!`("0U+C@V
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@
M4&%I9"UI;B!#87!I=&%L/&)R/D-O;6UO;B!S=&]C:R!I<W-U960@0"`D,3@N
M.34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA
M;"!086ED+6EN($-A<&ET86P\8G(^4')E9F5R<F5D('-T;V-K(&ES<W5E9"!`
M("0Q+#`P,"!P97(@<VAA<F4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^061D:71I;VYA;"!086ED+6EN($-A<&ET86P\8G(^0V]M;6]N(%-T
M;V-K($ES<W5E9"!T;R!'86QL;W=A>3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!8V-U;75L871E9"!$969I8VET/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DYO;BUC;VYT<F]L;&EN9R!);G1E<F5S=#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG
M($)A;&%N8V4@06UO=6YT(&%T(%-E<"X@,S`L(#(P,3,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C4L-S,T+#<X.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R-"PX-3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3DS+#4Q-"PW-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-C8L,30P+#DV.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L-S8S
M+#@W-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E(%-H87)E<R!A="!397`N(#,P+"`R
M,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#0X
M.2PT-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!W87)R86YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@W-2PW,C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F('=A<G)A;G1S+"!!;6]U;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P-"PW.3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#`P,2PY,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@97AE<F-I
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-S<L,3$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,W-RPQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@97AE<F-I<V5D
M+"!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S8Y
M+#(V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,S8X+#@X-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#<U."PR-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPW-3@L,C8T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U
M86YC97,L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPP-S$L-C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPS,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Q+#4W.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!I<W-U86YC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-"PP-C`L,3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3$R+#4X,2PU-3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#`W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T+#`U-RPP-#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3(L-3<U+#(S-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#DY.2PY
M-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT.3DL.#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-E='1L96UE;G1S(')E;&%T960@=&\@9&5R:79A=&EV
M92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-S@Y+#DW.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#<X.2PY-SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S
M=&]C:R!C;VYV97)T960@=&\@8V]M;6]N('-T;V-K+"!3:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPV,S@L,#,S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S0L
M-C`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@8V]N=F5R=&5D('1O(&-O
M;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW+#8S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W+#8P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8V]N<V]L:61A=&EO;B!O
M9B!#86QA;F1O(%!H87)M86-E=71I8V%L<RP@26YC+CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PS,#,L.3$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S`S+#DQ,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&QO<W,@9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!*
M=6YE(#,P+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M-BPR.30L.#@P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V+#$Y.2PW-#@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.34L,3,R*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YD:6YG($)A;&%N8V4@06UO=6YT(&%T($IU;BX@,S`L(#(P,30\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@U+#@P-RPW.#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-#4L,C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,X."PU-3@L,S`U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C`R+#,T,"PW,3<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@U-34L,#DX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@4VAA<F5S(&%T($IU;BX@,S`L
M(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(L
M.3`X+#4V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Q+#(Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14),04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N="!O9B!3=&]C:VAO;&1E<G,G
M($5Q=6ET>2`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@:7-S=65D($`@)#4N.#8\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960L('!R:6-E('!E<B!S:&%R93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C@V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VL@:7-S=65D($`@)#$X+CDU/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D+"!P<FEC92!P97(@<VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@N.34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S=&]C:R!I<W-U960@0"`D,2PP,#`@<&5R('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S
M=65D+"!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U
M7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#`W+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%4T-"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS
M;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-!4T@@1DQ/5U,@1E)/32!/4$52051)3D<@04-4259)5$E%4R!/1B!#3TY4
M24Y524Y'($]015)!5$E/3E,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,S8L,CDT+#@X,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$W+#@Y."PS-S,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M*&=A:6XI(&QO<W,@871T<FEB=71A8FQE('1O(&YO;BUC;VYT<F]L;&EN9R!I
M;G1E<F5S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+#$S
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0T-RPR-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO<W,I(&%T=')I8G5T86)L92!T;R!!
M<G)O=VAE860\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V+#$Y
M.2PW-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3<L-#4Q+#$P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/BA);F-O;64I(&QO<W,@9G)O;2!D:7-C;VYT
M:6YU960@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^*$=A:6XI(&QO<W,@;VX@9&ES<&]S86P@;V8@9FEX960@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU."PX-S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-BPS
M.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-H86YG92!I;B!V86QU92!O9B!D97)I=F%T:79E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW,3(L,S,U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$U+#8R,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPW-3@L,C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PQ,30L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M
M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP
M-S4L,C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PS-3(L-#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@*&%C8W)E=&EO;BD@;V8@
M;F]T92!D:7-C;W5N=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#$V+#(Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@R+#,T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@9V%I;B!I;B!E<75I='D@
M:6YV97-T;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#<L
M,3DW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYO;BUC87-H(&EM<&%I<FUE;G0@97AP96YS93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S$U+#<R,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-O;G1R;VQL
M:6YG(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y
M-2PQ,S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-#0W+#(V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@
M87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PS-S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(')E8V5I
M=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,3<L.3@V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,C<L,C0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0T,2PS-S,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#0P,BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@Q,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDY,"PY,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.#,L.34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-3DL-CDP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34L,3,R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PT.#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,S$S+#,U-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.150@0T%32"!54T5$($E.($]015)!5$E.1R!!0U1)5DE4
M2453($]&($-/3E1)3E5)3D<@3U!%4D%424].4SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C0L-#DV+#4V-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPV,SDL,S8P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#05-(($9,3U=3($923TT@24Y615-424Y'($%#5$E6251)15,@3T8@0T].
M5$E.54E.1R!/4$52051)3TY3.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E<R!O9B!P<F]P97)T>2!A;F0@
M97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(U
M,2PY.#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3DQ+#8U-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!F:7AE9"!A
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.2PU,#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!U<F-H87-E(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-#8L,S8U+#4R."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#`U."PP,#,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]C965D<R!F<F]M('-A;&4@;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4Y,"PX,C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$V,"PQ
M.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.150@0T%32"!04D]6241%1"!"62`H55-%1"!)3BD@24Y615-424Y'
M($%#5$E6251)15,@3T8@0T].5$E.54E.1R!/4$52051)3TY3/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,2PP,C8L-CDQ*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.3DY+#DW,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($9)3D%.0TE.1R!!0U1)5DE42453
M($]&($-/3E1)3E5)3D<@3U!%4D%424].4SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@<&%Y;65N=',@
M;VX@8V%P:71A;"!L96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(U-RPQ-S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,38P+#0Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K(&%N9"!P<F5F97)R960@<W1O8VLL(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<R+#8T,2PW,C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,BPT-#@L
M.#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M('1H92!E>&5R8VES92!O9B!W87)R86YT<R!A
M;F0@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(L,S<T+#`P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.150@0T%32"!04D]6241%1"!"62!&24Y!3D-)
M3D<@04-4259)5$E%4R!/1B!#3TY424Y524Y'($]015)!5$E/3E,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X-"PW-3@L-30W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L,C@X+#,R
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9&ES8V]N=&EN=65D(&]P97)A
M=&EO;G,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W!E<F%T:6YG(&-A<V@@9FQO=W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1I;F<@8V%S:"!F;&]W<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9I;F%N8VEN9R!C87-H(&9L;W=S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!D:7-C;VYT:6YU960@
M;W!E<F%T:6]N<SH\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3D54($E.0U)%05-%($E.($-!4T@\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q.2PR,S4L,C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-C0X+#8T,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T%32"!!5"!"
M14=)3DY)3D<@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.2PQ,30L-#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPS-S<L,C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#05-(($%4($5.1"!/1B!015))
M3T0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S."PS-#DL-S,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,CDL,#(U+#DS,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT87)Y(&1I<V-L;W-U<F5S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN=&5R97-T('!A:60\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C$L-#<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S,BPQ,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D
M.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V
M8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#`X
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%04=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A087)E;G1H
M971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D9E8BX@,3@L(#(P,30\8G(^1V%L;&]W87D@3&EM:71E
M9#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#(Q+"`R
M,#$R/&)R/E)O8VAE($UA9&ES;VX@26YC/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,2PU-SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,SDL.#DT
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!S971T;&5M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y.#8L,#0Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VX@86YD(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M24Y'(%!/3$E#2453/"]F;VYT/B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.871U<F4@;V8@0G5S:6YE
M<W,@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M,C`@9F]R(&-H<F]N:6,@:&5P871I=&ES($(@=FER=7,L($%20RU!050@9F]R
M(&QI=F5R(&1I<V5A<V4@87-S;V-I871E9"!W:71H($%L<&AA+3$@86YT:71R
M>7!S:6X@9&5F:6-I96YC>2P@86YD('!A<G1N97(M8F%S960@<')O9W)A;7,@
M:6X@;V)E<VET>2!A;F0@;VYC;VQO9WDN/"]P/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HV<'0[=&5X="UI;F1E;G0Z-"XU
M-"4[9F]N="US:7IE.C$R<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.R<^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HQ.'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<W1Y;&4Z:71A
M;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/DQI<75I9&ET>2`\+W`^#0H\<"!S='EL93TS
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M:71Y('-E8W5R:71I97,N)FYB<W`[)FYB<W`[4F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&%C=&EV:71I97,@:&%V92!R97%U:7)E9"!S:6=N:69I8V%N="!C
M87!I=&%L(&EN=F5S=&UE;G0@<VEN8V4@=&AE($-O;7!A;GDF(S@R,3<[<R!I
M;F-E<'1I;VX@86YD('1H92!#;VUP86YY(&5X<&5C=',@:71S(&]P97)A=&EO
M;G,@=&\@8V]N=&EN=64@=&\@<F5Q=6ER92!C87-H(&EN=F5S=&UE;G0@:6X@
M9FES8V%L(#(P,30@86YD(&)E>6]N9"!A<R!T:&4@0V]M<&%N>2!A9'9A;F-E
M<R!I=',@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5F9F]R=',L(&EN8VQU
M9&EN9R!C;&EN:6-A;"!T<FEA;',L(&%N9"!R96QA=&5D(&1R=6<@;6%N=69A
M8W1U<FEN9R!C;W-T<RXF;F)S<#LF;F)S<#L@/"]P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT
M.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%T($IU
M;F4@,S`L(#(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^-#PO9F]N=#XL('1H
M92!#;VUP86YY(&AA9"`D,3,X+C,@;6EL;&EO;B!I;B!C87-H('1O(&9U;F0@
M;W!E<F%T:6]N<RX@26X@861D:71I;VX@=&\@:71S(&-A<V@@<F5S;W5R8V5S
M+"!T:&4@0V]M<&%N>2!H87,@:6YV97-T960@97AC97-S(&-A<V@@:6X@:6YV
M97-T;65N="!G<F%D92!C;VUM97)C:6%L(&)O;F1S(&UA='5R:6YG(&EN(&QE
M<W,@=&AA;B`R-R!M;VYT:',N)FYB<W`[)FYB<W`[5&AE<V4@8F]N9',@<')O
M=FED92!A('-O=7)C92!O9B!L:7%U:61I='DL('1H;W5G:"!T:&4@0V]M<&%N
M>2!P;&%N<R!T;R!H;VQD('1H96T@=6YT:6P@;6%T=7)I='DN)FYB<W`[)FYB
M<W`[070@2G5N92`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@:&%D(&EN=F5S=&5D
M("0U,"XQ(&UI;&QI;VX@:6X@8F]N9',N)FYB<W`[)FYB<W`[1'5R:6YG('1H
M92!N:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T+"!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&-A<V@@<&]S:71I;VX@:6YC<F5A<V5D(&)Y("0Q,3DN,B!M
M:6QL:6]N+"!W:&EC:"!W87,@=&AE(')E<W5L="!O9B!T:&4@<F5C96EP="!O
M9B!C87-H(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&5Q=6ET>2!O9B`D,3<R+C8@
M;6EL;&EO;B!A;F0@8V%S:"!F<F]M('1H92!E>&5R8VES92!O9B!W87)R86YT
M<R!A;F0@;W!T:6]N<R!O9B`D,3(N-"!M:6QL:6]N+"!P87)T:6%L;'D@;V9F
M<V5T(&)Y(&YE="!C87-H(&EN=F5S=&5D(&EN(&9I>&5D(&EN8V]M92!I;G9E
M<W1M96YT<R!O9B`D,SDN."!M:6QL:6]N+"!C87-H(&]U=&9L;W=S(&]F("0R
M-"XU(&UI;&QI;VX@<F5L871E9"!T;R!C;VYT:6YU:6YG(&]P97)A=&EN9R!A
M8W1I=FET:65S(&%N9"!C87!I=&%L(&5X<&5N9&ET=7)E<R!O9B`D/&9O;G0@
M<W1Y;&4],T1C;VQO<CHC.SXQ+C,\+V9O;G0^(&UI;&QI;VXN(#PO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3AP=#MT
M97AT+6EN9&5N=#HP)3MF;VYT+7-T>6QE.FET86QI8SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M>28C.#(Q-SMS(&9I;F%N8VEA;"!S=&%T96UE;G1S+B`\+W`^#0H\<"!S='EL
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M(&EN<W1R=6-T:6]N<R!T;R!&;W)M)B,Q-C`[,3`M42!A;F0@07)T:6-L928C
M,38P.S@@;V8@4F5G=6QA=&EO;B!3+5@N)FYB<W`[)FYB<W`[06-C;W)D:6YG
M;'DL('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!D;R!N;W0@:6YC;'5D92!A
M;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N9"!N;W1E<R!R97%U:7)E9"!B>2!'
M04%0(&9O<B!C;VUP;&5T92!F:6YA;F-I86P@<W1A=&5M96YT<RX@26X@=&AE
M(&]P:6YI;VX@;V8@;6%N86=E;65N="P@86QL(&%D:G5S=&UE;G1S+"!I;F-L
M=61I;F<@;F]R;6%L(')E8W5R<FEN9R!A8V-R=6%L<RP@8V]N<VED97)E9"!N
M96-E<W-A<GD@9F]R(&$@9F%I<B!P<F5S96YT871I;VX@:&%V92!B965N(&EN
M8VQU9&5D+B!);G1E<FEM(')E<W5L=',@87)E(&YO="!N96-E<W-A<FEL>2!I
M;F1I8V%T:79E(&]F(')E<W5L=',@9F]R(&$@9G5L;"!Y96%R+B9N8G-P.R9N
M8G-P.U1H92!397!T96UB97(@,S`L(#(P,3,@0V]N<V]L:61A=&5D($)A;&%N
M8V4@4VAE970@=V%S(&1E<FEV960@9G)O;2!A=61I=&5D(&9I;F%N8VEA;"!S
M=&%T96UE;G1S+"!B=70@9&]E<R!N;W0@:6YC;'5D92!A;&P@9&ES8VQO<W5R
M97,@<F5Q=6ER960@8GD@1T%!4"X@5&AI<R!F:6YA;F-I86P@:6YF;W)M871I
M;VX@<VAO=6QD(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!N;W1E<R!I;F-L
M=61E9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS($%N;G5A;"!297!O<G0@;VX@
M1F]R;28C,38P.S$P+4L@9F]R('1H92!Y96%R(&5N9&5D(%-E<'1E;6)E<B8C
M,38P.S,P+"`R,#$S+B9N8G-P.R9N8G-P.T-E<G1A:6X@<F5C;&%S<VEF:6-A
M=&EO;G,@:&%V92!B965N(&UA9&4@=&\@<')I;W(@<&5R:6]D(&9I;F%N8VEA
M;"!S=&%T96UE;G1S('1O(&-O;F9O<FT@=&\@=&AE(&-U<G)E;G0@<&5R:6]D
M('!R97-E;G1A=&EO;BXF;F)S<#LF;F)S<#L\+W`^#0H\<"!S='EL93TS1"=M
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
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M86YY(&AA9"!N;R!R97-T<FEC=&5D(&-A<V@@870@2G5N92`S,"P@,C`Q-"!A
M;F0@4V5P=&5M8F5R(#,P+"`R,#$S+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T
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M8V4@0V]R<&]R871I;VX@*$9$24,I(&9O<B!U<"!T;R`D,C4P+#`P,"!P97(@
M86-C;W5N="X@36%N86=E;65N="!B96QI979E<R!T:&4@0V]M<&%N>2!I<R!N
M;W0@97AP;W-E9"!T;R!S:6=N:69I8V%N="!C<F5D:70@<FES:R!D=64@=&\@
M=&AE(&9I;F%N8VEA;"!P;W-I=&EO;B!O9B!T:&4@9&5P;W-I=&]R>2!I;G-T
M:71U=&EO;G,@:6X@=VAI8V@@=&AE<V4@9&5P;W-I=',@87)E(&AE;&0N(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY);G9E<W1M96YT<R8C.#(Q,CM4:&4@0V]M<&%N>2!I;G9E
M<W1S(&5X8V5S<R!C87-H(&)A;&%N8V5S(&EN('-H;W)T+71E<FT@86YD(&QO
M;F<M=&5R;2!M87)K971A8FQE(&1E8G0@<V5C=7)I=&EE<RX@26YV97-T;65N
M=',@;6%Y(&-O;G-I<W0@;V8@8V5R=&EF:6-A=&5S(&]F(&1E<&]S:71S+"!M
M;VYE>2!M87)K970@86-C;W5N=',L(&=O=F5R;FUE;G0M<W!O;G-O<F5D(&5N
M=&5R<')I<V4@<V5C=7)I=&EE<RP@8V]R<&]R871E(&)O;F1S(&%N9"]O<B!C
M;VUM97)C:6%L('!A<&5R+B!4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@:71S
M(&EN=F5S=&UE;G0@:6X@;6%R:V5T86)L92!S96-U<FET:65S(&EN(&%C8V]R
M9&%N8V4@=VET:"!&05-"($%30R`S,C`L($EN=F5S=&UE;G1S("8C.#(Q,3L@
M1&5B="!A;F0@17%U:71Y(%-E8W5R:71I97,N)B,Q-C`[5&AI<R!S=&%T96UE
M;G0@<F5Q=6ER97,@8V5R=&%I;B!S96-U<FET:65S('1O(&)E(&-L87-S:69I
M960@:6YT;R!T:')E92!C871E9V]R:65S.B`\+W`^#0H\<"!S='EL93TS1"=M
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M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.VUA<F=I;BUL969T.C0N-30E.W1E>'0M
M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M;F0@;&]S<V5S(&EN8VQU9&5D(&EN(&5A<FYI;F=S+B`\+W`^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MM87)G:6XM
M;&5F=#HT+C4T)3MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY!=F%I;&%B;&4M9F]R+5-A;&4F(S@R,3([1&5B="!A
M;F0@97%U:71Y('-E8W5R:71I97,@;F]T(&-L87-S:69I960@87,@96ET:&5R
M('-E8W5R:71I97,@:&5L9"UT;RUM871U<FET>2!O<B!T<F%D:6YG('-E8W5R
M:71I97,@87)E(')E<&]R=&5D(&%T(&9A:7(@=F%L=64@=VET:"!U;G)E86QI
M>F5D(&=A:6YS(&]R(&QO<W-E<R!E>&-L=61E9"!F<F]M(&5A<FYI;F=S(&%N
M9"!R97!O<G1E9"!A<R!A('-E<&%R871E(&-O;7!O;F5N="!O9B!S:&%R96AO
M;&1E<G,F(S@R,3<[(&5Q=6ET>2X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M96-U<FET:65S+B!!="`\9F]N="!S='EL93TS1&-O;&]R.B,[/DIU;F4@,S`L
M(#(P,30\+V9O;G0^+"!T:&4@0V]M<&%N>2!C;&%S<VEF:65D(&%L;"!O9B!I
M=',@:6YV97-T;65N=',@87,@:&5L9"UT;RUM871U<FET>2X@/"]P/@T*/'`@
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M=&UE;G1S(&EN($YO=&4@,B`F(S@R,3$[($EN=F5S=&UE;G1S+B`@/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T
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M;F]T(&)E(')E8V]V97)A8FQE+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT
M+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY);BU0<F]C97-S(%)E<V5A
M<F-H)B,Q-C`[)F%M<#L@1&5V96QO<&UE;G0@*$E04B9A;7`[1"DF(S@R,3([
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M+"!T:')O=6=H(&$@='=O+7-T97`@<')O8V5S<RX@5&AE(&9I<G-T('-T97`@
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M<F4@:6UP86ER960L(&$@<V5C;VYD('-T97`@:7,@<&5R9F]R;65D('=H:6-H
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M;GD@;6%Y(&%L<V\@96QE8W0@=&\@8GEP87-S('-T97`@;VYE+"!A;F0@<')O
M8V5E9"!D:7)E8W1L>2!T;R!T:&4@<V5C;VYD('-T97`N(#PO<#X-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT
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M<W,@<F%T97,N)FYB<W`[)FYB<W`[17-T:6UA=&5D('!A>6UE;G1S(&%R92!D
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M:79E;B!P97)I;V0N/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M:6]T96-H;F]L;V=Y(&-O;7!A;GDN)FYB<W`[)FYB<W`[0F%S960@;VX@=&AE
M('-T871U<R!O9B!T:&4@9&5V96QO<&UE;G0@;V8@3&5O;F%R9&\F(S@R,3<[
M<R!P<F]G<F%M+"!T:&ES(&EN=F5S=&UE;G0@:&%S(&)E96X@9G5L;'D@:6UP
M86ER960@86YD('1H92!N970@8F]O:R!V86QU92!A="!*=6YE(#,P+"`R,#$T
M(&ES("0P+B9N8G-P.R9N8G-P.U1H92!O<&5R871I;VYS(&]F($QE;VYA<F1O
M(&-E87-E9"!I;B!$96-E;6)E<B`R,#$S+B`\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z
M-"XU-"4[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3F]N+6-O
M;G1R;VQL:6YG($EN=&5R97-T<R!I;B!-86IO<FET>2U/=VYE9"!3=6)S:61I
M87)I97,F(S@R,3([3W!E<F%T:6YG(&QO<W-E<R!A<'!L:6-A8FQE('1O(&UA
M:F]R:71Y+6]W;F5D($-A;&%N9&\L($%B;&%R:7,@86YD+"!P<FEO<B!T;R!I
M=',@9&ES<&]S86PL(%5N:61Y;2!H879E('!E<FEO9&EC86QL>2!E>&-E961E
M9"!T:&4@;F]N+6-O;G1R;VQL:6YG(&EN=&5R97-T<R!I;B!T:&4@97%U:71Y
M(&-A<&ET86P@;V8@96ET:&5R(%-U8G-I9&EA<GDN(%-U8V@@97AC97-S(&QO
M<W-E<R!A<'!L:6-A8FQE('1O('1H92!N;VXM8V]N=')O;&QI;F<@:6YT97)E
M<W1S(&AA=F4@8F5E;B!A;F0@87)E(&)O<FYE(&)Y('1H92!#;VUP86YY(&%S
M('1H97)E(&ES(&YO(&]B;&EG871I;VX@;V8@=&AE(&YO;BUC;VYT<F]L;&EN
M9R!I;G1E<F5S=',@=&\@9G5N9"!A;GD@;&]S<V5S(&EN(&5X8V5S<R!O9B!T
M:&5I<B!O<FEG:6YA;"!I;G9E<W1M96YT+B!4:&5R92!I<R!A;'-O(&YO(&]B
M;&EG871I;VX@;W(@8V]M;6ET;65N="!O;B!T:&4@<&%R="!O9B!T:&4@0V]M
M<&%N>2!T;R!F=6YD(&]P97)A=&EN9R!L;W-S97,@;V8@86YY(%-U8G-I9&EA
M<GD@=VAE=&AE<B!W:&]L;'DM;W=N960@;W(@;6%J;W)I='DM;W=N960N(%1H
M92!#;VUP86YY(&%L;&]C871E<R!T:&4@;F]N+6-O;G1R;VQL:6YG(&EN=&5R
M97-T<R8C.#(Q-SL@<VAA<F4@;V8@;F5T(&QO<W,@:6X@97AC97-S(&]F('1H
M92!N;VXM8V]N=')O;&QI;F<@:6YT97)E<W1S)B,X,C$W.R!I;FET:6%L(&EN
M=F5S=&UE;G0@:6X@86-C;W)D86YC92!W:71H($9!4T(@05-#(#@Q,"TQ,"X@
M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
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M8V]L;&5C=&EO;B!A='1E;7!T<R!H879E(&9A:6QE9"X@/"]P/@T*/'`@<W1Y
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M(&EN8W5R<F5D(&EN(&%C8V]R9&%N8V4@=VET:"!&05-"($%30R`W,S`M,3`N
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY%87)N:6YG<R`H3&]S<RD@<&5R(%-H87)E)B,X,C$R
M.T)A<VEC(&5A<FYI;F=S("AL;W-S*2!P97(@<VAA<F4@:7,@8V]M<'5T960@
M=7-I;F<@=&AE('=E:6=H=&5D+6%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S
M:&%R97,@;W5T<W1A;F1I;F<@9'5R:6YG('1H92!P97)I;V0N($1I;'5T960@
M96%R;FEN9W,@*&QO<W,I('!E<B!S:&%R92!A<F4@8V]M<'5T960@=7-I;F<@
M=&AE('=E:6=H=&5D+6%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@
M86YD(&1I;'5T:79E('!O=&5N=&EA;"!C;VUM;VX@<VAA<F5S(&]U='-T86YD
M:6YG(&1U<FEN9R!T:&4@<&5R:6]D+B!$:6QU=&EV92!P;W1E;G1I86P@8V]M
M;6]N('-H87)E<R!P<FEM87)I;'D@8V]N<VES="!O9B!S=&]C:R!O<'1I;VYS
M(&ES<W5E9"!T;R!E;7!L;WEE97,@86YD(&-O;G-U;'1A;G1S(&%N9"!W87)R
M86YT<R!T;R!P=7)C:&%S92!#;VUM;VX@4W1O8VL@;V8@=&AE($-O;7!A;GDN
M)FYB<W`[)FYB<W`[(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I
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M92!R871E+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
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M86YD(&QI86)I;&ET:65S(&1U<FEN9R!T:&4@<&5R:6]D+B`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$X<'0[=&5X
M="UI;F1E;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E)E
M8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG(%-T86YD87)D<R`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT
M+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY);B!*=6YE(#(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@,C`Q-"TQ,"P@
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M('-T86=E+B9N8G-P.R9N8G-P.T%352`R,#$T+3$P(&ES(&5F9F5C=&EV92!F
M;W(@9FES8V%L('EE87)S(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@
M,C`Q-"!W:71H(&5A<FQY(&%D;W!T:6]N('!E<FUI='1E9"XF;F)S<#LF;F)S
M<#M4:&4@0V]M<&%N>2!H87,@861O<'1E9"!!4U4@,C`Q-"TQ,"!E9F9E8W1I
M=F5L>2!W:71H('1H92!F:6QI;F<@;V8@=&AI<R!&;W)M(#$P+5$N)FYB<W`[
M)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/DEN($UA>2`R,#$T+"!T:&4@1D%30B!I<W-U
M960@05-5($YO+B`R,#$T+3`Y(#QF;VYT('-T>6QE/3-$9F]N="US='EL93II
M=&%L:6,[/E)E=F5N=64@9G)O;2!#;VYT<F%C=',@=VET:"!#=7-T;VUE<G,@
M*%1O<&EC(#8P-BD\+V9O;G0^+"!W:&EC:"!W:6QL('-U<&5R<V5D92!N96%R
M;'D@86QL(&5X:7-T:6YG(')E=F5N=64@<F5C;V=N:71I;VX@9W5I9&%N8V4@
M=6YD97(@1T%!4"X@05-5($YO+B`R,#$T+3`Y('!R;W9I9&5S('1H870@86X@
M96YT:71Y(')E8V]G;FEZ92!R979E;G5E('=H96X@:70@=')A;G-F97)S('!R
M;VUI<V5D(&=O;V1S(&]R('-E<G9I8V5S('1O(&-U<W1O;65R<R!I;B!A;B!A
M;6]U;G0@=&AA="!R969L96-T<R!T:&4@8V]N<VED97)A=&EO;B!T;R!W:&EC
M:"!T:&4@96YT:71Y(&5X<&5C=',@=&\@8F4@96YT:71L960@:6X@97AC:&%N
M9V4@9F]R('1H;W-E(&=O;V1S(&]R('-E<G9I8V5S+B!4:&ES('5P9&%T92!A
M;'-O(')E<75I<F5S(&%D9&ET:6]N86P@9&ES8VQO<W5R92!A8F]U="!T:&4@
M;F%T=7)E+"!A;6]U;G0L('1I;6EN9R!A;F0@=6YC97)T86EN='D@;V8@<F5V
M96YU92!A;F0@8V%S:"!F;&]W<R!A<FES:6YG(&9R;VT@8W5S=&]M97(@8V]N
M=')A8W1S+"!I;F-L=61I;F<@<VEG;FEF:6-A;G0@:G5D9VUE;G1S(&%N9"!C
M:&%N9V5S(&EN(&IU9&=M96YT<RP@86YD(&%S<V5T<R!R96-O9VYI>F5D(&9R
M;VT@8V]S=',@:6YC=7)R960@=&\@;V)T86EN(&]R(&9U;&9I;&P@82!C;VYT
M<F%C="X@05-5($YO+B`R,#$T+3`Y(&%L;&]W<R!F;W(@96ET:&5R(&9U;&P@
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M=',N/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DEN($IU;'D@,C`Q,RP@=&AE($9!4T(@:7-S=65D
M($%352`R,#$S+3$Q+"`\9F]N="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC
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M(&$@=&%X('!O<VET:6]N+B!!4U4@,C`Q,RTQ,2!A9F9E8W1S(&]N;'D@=&AE
M('!R97-E;G1A=&EO;B!O9B!S=6-H(&%M;W5N=',@:6X@86X@96YT:71Y)B,X
M,C$W.W,@8F%L86YC92!S:&5E="!A;F0@:7,@969F96-T:79E(&9O<B!F:7-C
M86P@>65A<G,@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$S(&%N
M9"!I;G1E<FEM('!E<FEO9',@=VET:&EN('1H;W-E('EE87)S+B!%87)L>2!A
M9&]P=&EO;B!I<R!P97)M:71T960N(%1H92!#;VUP86YY(&ES(&5V86QU871I
M;F<@=&AE(&EM<&%C="P@:68@86YY+"!O9B!T:&4@861O<'1I;VX@;V8@05-5
M(#(P,3,M,3$@;VX@:71S($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T+CPO
M<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?
M869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YV97-T;65N=',\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E1H92!#;VUP86YY(&EN=F5S
M=',@:71S(&5X8V5S<R!C87-H(&)A;&%N8V5S(&EN('-H;W)T+71E<FT@86YD
M(&QO;F<M=&5R;2!D96)T('-E8W5R:71I97,N)FYB<W`[)FYB<W`[26YV97-T
M;65N=',@870@2G5N92`S,"P@,C`Q-"!C;VYS:7-T960@;V8@8V]R<&]R871E
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M86YD+V]R(&-O;6UE<F-I86P@<&%P97(N)FYB<W`[)FYB<W`[5&AE($-O;7!A
M;GD@86-C;W5N=',@9F]R(&ET<R!I;G9E<W1M96YT<R!I;B!A8V-O<F1A;F-E
M('=I=&@@1D%30B!!4T,@,S(P+"!);G9E<W1M96YT<R`F(S@R,3$[($1E8G0@
M86YD($5Q=6ET>2!396-U<FET:65S+B9N8G-P.R9N8G-P.T%T(#QF;VYT('-T
M>6QE/3-$8V]L;W(Z(SL^2G5N92`S,"P@,C`Q-#PO9F]N=#XL(&%L;"!I;G9E
M<W1M96YT<R!W97)E(&-L87-S:69I960@87,@:&5L9"UT;RUM871U<FET>2!S
M96-U<FET:65S+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY4:&4@9F]L;&]W:6YG('1A8FQE<R!S
M=6UM87)I>F4@=&AE($-O;7!A;GDF(S@R,3<[<R!S:&]R="!A;F0@;&]N9RUT
M97)M(&EN=F5S=&UE;G1S(&%S(&]F($IU;F4@,S`L(#(P,30L(&%N9"!397!T
M96UB97(@,S`L(#(P,3,N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ
M93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\
M=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
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M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY!<R!O9B!*=6YE(#,P+"`R
M,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP
M=#L^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C0Q)3L^#0H\<"!S='EL93TS1'1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY!;6]R=&EZ960@0V]S
M=#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
M<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY'<F]S<R!5;G)E86QI>F5D
M($=A:6YS/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ93HX<'0[/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
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M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ93HX<'0[/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D9A:7(@
M5F%L=64\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z
M.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED
M=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXR,RPX,S0L-#`X/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
M;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I
M>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T
M>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US
M:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PX
M-3`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT
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M.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXI/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR,RPU.3DL,#<W/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G
M=VED=&@Z-#$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RPX.3D\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ
M93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
M;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I
M>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@Q-3(L,C(R/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US
M:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H
M.C0Q)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXU,"PQ,3DL,C<P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M
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M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^-2PW-#D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
M;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I
M>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z
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M;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXI/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXT.2PW,S4L-C$V/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G
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M(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.CDR)3LG/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C0Q)3L^#0H\
M<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,30@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z
M.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^07,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T
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M;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M.V9O;G0M<VEZ93HX<'0[/B9N8G-P.SPO<#X\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/D=R;W-S(%5N<F5A;&EZ960@1V%I;G,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[.V9O;G0M<VEZ93HX<'0[/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^1W)O<W,@56YR96%L:7IE9"!,;W-S97,\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ93HX<'0[/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T
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M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@<W1Y;&4],T0G;6%R
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M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C<L-3`P/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXI/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXX+#DY."PT.#`\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^0V]M;65R8VEA;"!N;W1E<R`H9'5E(&%F
M=&5R(&]N92!Y96%R('=I=&AI;B!T:')E92!Y96%R<RD\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXQ+#<P,BPQ-3,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
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M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXI/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
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M<"!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C0Q)3L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R+C(U
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M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ,"PW,S(L-#$T/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H
M.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-RPU,#`\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXH-#$L-C0S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$P+#8Y."PR-S$\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R
M96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B
M9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W
M.3@O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^1FEX960@07-S971S/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I>&5D($%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.CAP=#MT97AT+6EN9&5N=#HP
M)3MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3D]412`S+B`\9F]N
M="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC.SY&25A%1"!!4U-%5%,\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT
M.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO
M<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z-S8E.R<^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D
M:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU"
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT
M+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN
M9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HU,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
M,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
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M(#,P+"`R,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
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M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D
M:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO
M<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P
M=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D
M9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M
M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY397!T96UB97(@,S`L(#(P,3,\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M
M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C,S-"PQ-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ,"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M,S(S+#,W-CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I
M9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXT+#(T."PV,#8\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ07)I86P[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,3`E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C,L-#4R
M+#`Q,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
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M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z-3$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-CDL-C(S/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
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M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.D%R:6%L.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C$P)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXV.2PV,C,\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4Q)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY,96%S96AO;&0@:6UP<F]V96UE;G1S/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.D%R:6%L.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,BPW-#DL-#`Y/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M;&5F
M=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/E1O=&%L(&=R;W-S(&9I>&5D(&%S<V5T<R`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXW+#8P-RPV,#@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ07)I86P[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
M<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXV+#4Y
M-"PT,C$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP
M+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4Q)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z
M;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B@S+#DS,RPT-S<\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.D%R:6%L.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
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M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP<'0[<&%D
M9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW-7!T.W=I9'1H.C4Q
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C8N.#5P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY0<F]P97)T>2!A;F0@97%U:7!M
M96YT+"!N970@/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXS+#8W-"PQ,S$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UW96EG:'0Z8F]L9#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS+#4Q,RPR
M,S4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE
M/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E
M;G0Z,"4[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.C$P<'0[/B9N8G-P
M.SPO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V
M9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-Q=6ES:71I
M;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M<75I<VET:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#MM87)G:6XM8F]T=&]M
M.C!P=#MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.W1E>'0M:6YD96YT
M.C`E.R<^3D]412`T+B`\9F]N="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC
M.SY!0U%525-)5$E/3E,@/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY2;V-H92!-861I<V]N(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/D]N($]C=&]B97(F(S$V,#LR,2P@,C`Q,2P@=&AE($-O;7!A
M;GD@96YT97)E9"!I;G1O(&$@4W1O8VL@86YD($%S<V5T(%!U<F-H87-E($%G
M<F5E;65N="`H=&AE("8C.#(R,#M23D%I(%!U<F-H87-E($%G<F5E;65N="8C
M.#(R,3LI('=I=&@@2&]F9FUA;FXM3&$@4F]C:&4@26YC+B!A;F0@1B!(;V9F
M;6%N;BU,82!2;V-H92!,=&0@*&-O;&QE8W1I=F5L>2P@)B,X,C(P.U)O8VAE
M)B,X,C(Q.RDL('!U<G-U86YT('1O('=H:6-H('1H92!#;VUP86YY('!U<F-H
M87-E9"!F<F]M(%)O8VAE("AI*28C,38P.V%L;"!O9B!T:&4@;W5T<W1A;F1I
M;F<@8V]M;6]N('-T;V-K(&]F(%)O8VAE($UA9&ES;VX@26YC+B`H)B,X,C(P
M.U)O8VAE($UA9&ES;VXF(S@R,C$[+"!N;W<@)B,X,C(P.T%R<F]W:&5A9"!-
M861I<V]N)B,X,C(Q.RD@86YD("AI:2DF(S$V,#MT:&4@:6YT96QL96-T=6%L
M('!R;W!E<G1Y(')I9VAT<R!T:&5N(&AE;&0@8GD@4F]C:&4@<F5L871E9"!T
M;R!I=',@4DY!:2!B=7-I;F5S<R!A;F0@:61E;G1I9FEE9"!I;B!T:&4@4DY!
M:2!0=7)C:&%S92!!9W)E96UE;G0@*'1H92`F(S@R,C`[5')A;G-A8W1I;VXF
M(S@R,C$[*2X@26X@8V]N<VED97)A=&EO;B!F;W(@=&AE('!U<F-H87-E(&]F
M(%)O8VAE($UA9&ES;VX@86YD('1H92!2;V-H92!23D%I(&%S<V5T<RP@=&AE
M($-O;7!A;GD@:7-S=65D('1O(%)O8VAE(&$@<')O;6ES<V]R>2!N;W1E('=I
M=&@@82!P<FEN8VEP86P@=F%L=64@;V8@)#4P+#`P,"!A;F0@,2PR.#@L,34X
M('-H87)E<R!O9B!#;VUM;VX@4W1O8VLN(#PO<#X-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT
M+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY0=7)S=6%N
M="!T;R!T:&4@4DY!:2!0=7)C:&%S92!!9W)E96UE;G0L(%)O8VAE(&AA<R!A
M(')I9VAT(&]F(&9I<G-T(&YE9V]T:6%T:6]N(&]N(&-E<G1A:6X@<')O9'5C
M="!C86YD:61A=&5S(&1E=F5L;W!E9"!B>2!T:&4@0V]M<&%N>2!A;F0@:71S
M(&%F9FEL:6%T97,@<F5L871I;F<@=&\@=&AE('!U<F-H87-E9"!A<W-E=',N
M($EF('1H92!#;VUP86YY('!R;W!O<V5S('1O(&]U="UL:6-E;G-E(&]R(&5N
M=&5R<R!I;G1O('-U8G-T86YT:79E(&YE9V]T:6%T:6]N<R!T;R!O=70M;&EC
M96YS92P@86YY($-L:6YI8V%L($-A;F1I9&%T92!O<B!%>&ES=&EN9R!#86YD
M:61A=&4@*&%S('-U8V@@=&5R;7,@87)E(&1E9FEN960@:6X@=&AE(%).06D@
M4'5R8VAA<V4@06=R965M96YT*2P@=&AE($-O;7!A;GD@;75S="!G:79E(&YO
M=&EC92!O9B!T:&4@0V%N9&ED871E(&ET('!R;W!O<V5S('1O(&]U="UL:6-E
M;G-E(&%N9"!N96=O=&EA=&4@97AC;'5S:79E;'D@86YD(&EN(&=O;V0@9F%I
M=&@@=VET:"!2;V-H92!F;W(@.3`@9&%Y<R!R96=A<F1I;F<@=&AE(&%P<&QI
M8V%B;&4@;W5T+6QI8V5N<V4N(%1H:7,@<FEG:'0@;V8@9FER<W0@;F5G;W1I
M871I;VX@87!P;&EE<R!T;R!A;&P@17AI<W1I;F<@0V%N9&ED871E<R`H87,@
M9&5F:6YE9"!I;B!T:&4@4DY!:2!0=7)C:&%S92!!9W)E96UE;G0I(&%N9"!T
M:&4@9FER<W0@9FEV92!#;&EN:6-A;"!#86YD:61A=&5S(&9O<B!W:&EC:"!T
M:&4@0V]M<&%N>2!D96QI=F5R<R!N;W1I8V4@=&\@4F]C:&4@86YD('-U8G-E
M<75E;G1L>2!E;G1E<G,@:6YT;R!A;B!O=70M;&EC96YS92X@/"]P/@T*/'`@
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M;&%S="!U;G1I;"!T:&4@;&%T97(@;V8@*&DI)B,Q-C`[=&AE(&5X<&ER871I
M;VX@;V8@=&AE(&QA<W0@=&\@97AP:7)E('!A=&5N="!R:6=H="!R96QA=&5D
M('1O('-U8V@@<')O9'5C="!C86YD:61A=&4@=&AA="!W87,@=')A;G-F97)R
M960@:6X@=&AE(%1R86YS86-T:6]N(&%N9"`H:6DI)B,Q-C`[=&5N('EE87)S
M(&%F=&5R('1H92!F:7)S="!C;VUM97)C:6%L('-A;&4@;V8@<W5C:"!P<F]D
M=6-T(&-A;F1I9&%T92X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M<&]T96YT:6%L('!A>6UE;G1S(')A;F=E(&9R;VT@)#(L-3`P+#`P,"!T;R`D
M-BPP,#`L,#`P('!E<B!M:6QE<W1O;F4N($%T('1H92!T:6UE(&]F(&%C<75I
M<VET:6]N+"!T:&4@0V]M<&%N>28C.#(Q-SMS(&5S=&EM871E(&]F(&9U='5R
M92!P87EM96YT<R!F;W(@<&]T96YT:6%L(')O>6%L=&EE<R!A;F0@;6EL97-T
M;VYE<R!H860@82!N970@<')E<V5N="!V86QU92!O9B`D.#0L.3,U('=H:6-H
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M:7-C86P@,C`Q,RP@=&AE(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;B!L:6%B
M:6QI='D@=V%S(&EN8W)E87-E9"!B>2`D,2XT(&UI;&QI;VXL('=H:6-H(&ES
M(')E8V]R9&5D(&%S(&$@<&%R="!O9B!O=&AE<B!N;VXM8W5R<F5N="!L:6%B
M:6QI=&EE<R!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS($-O;G-O;&ED871E9"!"
M86QA;F-E(%-H965T+B!4:&5R92!H879E(&)E96X@;F\@8VAA;F=E<R!T;R!T
M:&4@;&EA8FEL:71Y(&1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@2G5N
M92`S,"P@,C`Q-"XF;F)S<#LF;F)S<#M&;W(@861D:71I;VYA;"!I;F9O<FUA
M=&EO;B!R96QA=&5D('1O(&]U<B!V86QU871I;VX@;V8@=&AI<R!O8FQI9V%T
M:6]N+"!S964@/&9O;G0@<W1Y;&4],T1F;VYT+7-T>6QE.FET86QI8SL^3F]T
M92`Q,"P@1F%I<B!686QU92!-96%S=7)E;65N=',\+V9O;G0^+CPO<#X\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R
M,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W
M,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YT86YG:6)L92!!<W-E=',\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT86YG
M:6)L92!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT
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M;BX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/DE04B9A;7`[1"!R97!R97-E;G1S('!R;VIE8W1S
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M;W5T(&]F($E04B9A;7`[1"!A;F0@8F5G:6X@86UO<G1I>F%T:6]N+B!)9B!T
M:&4@87-S;V-I871E9"!2)F%M<#M$(&5F9F]R="!I<R!A8F%N9&]N960@=&AE
M(')E;&%T960@25!2)F%M<#M$(&%S<V5T<R!W:6QL(&QI:V5L>2!B92!W<FET
M=&5N(&]F9B!A;F0@=V4@=V]U;&0@<F5C;W)D(&%N(&EM<&%I<FUE;G0@;&]S
M<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M($UA9&ES;VXN)FYB<W`[)FYB<W`[(%1H92!L:6-E;G-E(&%G<F5E;65N=',@
M87)E(&)E:6YG(&%M;W)T:7IE9"!O=F5R('1H92!E<W1I;6%T960@;&EF92!R
M96UA:6YI;F<@870@=&AE('1I;64@;V8@86-Q=6ES:71I;VX@=VAI8V@@=V%S
M(#0@>65A<G,L(&%N9"!T:&4@86-C=6UU;&%T960@86UO<G1I>F%T:6]N(&]F
M('1H92!A<W-E=',@:7,@87!P<F]X:6UA=&5L>2`D,30W+#@P,"X@4&%T96YT
M<R!H879E(&)E96X@86UO<G1I>F5D(&]V97(@82!P97)I;V0@;V8@=&AR964@
M>65A<G,@=&\@='=E;G1Y('EE87)S+"!H;W=E=F5R('1H92!P871E;G0@87-S
M971S('=E<F4@9G5L;'D@:6UP86ER960@87,@;V8@4V5P=&5M8F5R(#,P+"`R
M,#$S+B!!;6]R=&EZ871I;VX@97AP96YS92!F;W(@=&AE('1H<F5E(&%N9"!N
M:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T('=A<R!A<'!R;WAI;6%T
M96QY("0Q,RPV-C,@86YD("0T,"PY.3`L(')E<W!E8W1I=F5L>2XF;F)S<#LF
M;F)S<#M!;6]R=&EZ871I;VX@97AP96YS92!F;W(@=&AE('1H<F5E(&%N9"!N
M:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$S('=A<R!A<'!R;WAI;6%T
M96QY("0W-"PQ,34@86YD("0R,C(L,S0U+"!R97-P96-T:79E;'DN($%M;W)T
M:7IA=&EO;B!O9B!L:6-E;G-E(&%G<F5E;65N=',@:7,@97AP96-T960@=&\@
M8F4@87!P<F]X:6UA=&5L>2`D,30L,#`P(&9O<B!T:&4@<F5M86EN9&5R(&]F
M(&9I<V-A;"!Y96%R(#(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^-"P@)#4U
M+#`P,"!I;B`\+V9O;G0^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXU/"]F
M;VYT/BP@)#$T+#`P,"!I;B`R,#$V+"!A;F0@>F5R;R!T:&5R96%F=&5R+B`\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
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M+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C$R<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US:7IE.C$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^5&AE(&9O;&QO=VEN9R!T86)L92!P<F]V:61E<R!D
M971A:6QS(&]N(&]U<B!I;G1A;F=I8FQE(&%S<V5T(&)A;&%N8V5S.B`\+W`^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L
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M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#%P="`C,#`P,#`P.R<^#0H\<"!S
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
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M;W)D97(M8F]T=&]M.G-O;&ED(#%P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
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M<V5T<SQB<B`O/G-U8FIE8W0@=&\\8G(@+SYA;6]R=&EZ871I;VX\+W`^/"]T
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M="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI
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M.G-O;&ED(#%P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^5&]T86P\8G(@+SY);G1A;F=I8FQE)B,Q-C`[87-S
M971S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^
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M;6%L.R<^0F%L86YC92!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q,CPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXT+#<X-"PU-CD\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C0V
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z
M(SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY);7!A:7)M96YT
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^*#$L,S`X+#`T-SPO<#X\+W1D/@T*/'1D('9A
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M;#LG/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM
M8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B@Q+#,P."PP-#<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M86YT.B!N;W)M86P[)SY!;6]R=&EZ871I;VX\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@R,S8L,#`Y(#PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXH,C,V+#`P.3PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#8E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY"86QA;F-E(&%T(%-E<'1E;6)E<B8C,38P
M.S,P+"`R,#$S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS+#$Q-RPS,C(\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E
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M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M,RPR-#`L-3$S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z-#8E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O
M;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^+3PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH-#`L.3DP/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T
M:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXH-#`L.3DP/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US
M<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$)W=I9'1H.C0V)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/D)A;&%N8V4@870@2G5N92`S,"P@,C`Q-#PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C,L,3$W+#,R,CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RPQ.3DL-3(S/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/"]D
M:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DEN=F5S=&UE;G0@:6X@4W5B<VED:6%R:65S/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE
M;G0@:6X@4W5B<VED:6%R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z.'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY.3U1%(#8N(#QF;VYT('-T>6QE/3-$9F]N="US='EL
M93II=&%L:6,[/DE.5D535$U%3E0@24X@4U5"4TE$24%22453/"]F;VYT/B`\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C9P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY);B!A9&1I=&EO;B!T;R`Q,#`E(&]W;F5R<VAI<"!I;G1E
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M<F=I;BUT;W`Z,3AP=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-T>6QE.FET86QI
M8SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY#86QA;F1O(%!H87)M86-E=71I8V%L<RP@26YC
M+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
M97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY);B`R,#`Y+"!#86QA;F1O(&]U=&QI8V5N<V5D(&ET<R!S;6%L;"!M
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M97)U;&5A;BXF;F)S<#LF;F)S<#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M(&]F('!R:6YC:7!A;"!A;F0@:6YT97)E<W0@=&]T86QI;F<@)#$L,C4S+#`P
M,"!A<R!O9B!*=6YE(#,P+"`R,#$T+B9N8G-P.R9N8G-P.U1H92!P<F]M:7-S
M;W)Y(&YO=&4@8F5C86UE(&1U92!O;B!.;W9E;6)E<B`R-BP@,C`Q,RP@8G5T
M('=A<R!N;W0@<F5P86ED(&1U92!T;R!L86-K(&]F(&-A<V@@<F5S;W5R8V5S
M(&%T($-A;&%N9&\N)B,Q-C`[)B,Q-C`[5&AE(&AO;&1E<B!O9B!T:&4@3F]T
M92!I;FET:6%T960@86X@:6YV;VQU;G1A<GD@<&5T:71I;VX@;V8@8F%N:W)U
M<'1C>2!A9V%I;G-T($-A;&%N9&\N)B,Q-C`[)B,Q-C`[02!T<G5S=&5E(&AA
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M<W`[)FYB<W`[1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P
M+"`R,#$T+"!!<G)O=VAE860@9&5C;VYS;VQI9&%T960@0V%L86YD;R!B87-E
M9"!O;B!T:&4@9F%C="!T:&%T($-A;&%N9&\@:7,@;F]W('-U8FIE8W0@=&\@
M=&AE(&-O;G1R;VP@;V8@=&AE(&)A;FMR=7!T8WD@=')U<W1E92XF;F)S<#LF
M;F)S<#M4:&4@9&5C;VYS;VQI9&%T:6]N(&]F($-A;&%N9&\@<F5S=6QT960@
M:6X@86X@87!P<F]X:6UA=&5L>2`D.#<L,#`P(&=A:6X@=&\@=&AE($-O;7!A
M;GDF(S@R,3<[<R!#;VYS;VQI9&%T960@4W1A=&5M96YT(&]F($]P97)A=&EO
M;G,N)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT
M.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%S(&]F
M($IU;F4@,S`L(#(P,30L($-A;&%N9&\@;W=E9"!T;R!!<G)O=VAE860@)#QF
M;VYT('-T>6QE/3-$8V]L;W(Z(SL^-"XU/"]F;VYT/B!M:6QL:6]N('5N9&5R
M(&$@<V5R:65S(&]F(#@E('-I;7!L92!I;G1E<F5S="!N;W1E<R!A;F0@861V
M86YC97,N($ET(&ES('5N;&EK96QY('1H97-E(&YO=&5S('=I;&P@8F4@<F5P
M86ED(&EN(&9U;&PN(%1H92!B86QA;F-E(&]F('1H92!N;W1E<R!A;F0@861V
M86YC97,@:&%S(&)E96X@9G5L;'D@<F5S97)V960N("`F;F)S<#LF;F)S<#L\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C$R<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US:7IE.C$P<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^07,@;V8@2G5N92`S,"P@,C`Q-"P@07)R;W=H96%D(&]W
M;F5D(#QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^-SD\+V9O;G0^)2!O9B!T:&4@
M;W5T<W1A;F1I;F<@<VAA<F5S(&]F($-A;&%N9&\@86YD(#QF;VYT('-T>6QE
M/3-$8V]L;W(Z(SL^-S8\+V9O;G0^)2!O;B!A(&9U;&QY(&1I;'5T960@8F%S
M:7,N)FYB<W`[)FYB<W`[07,@82!R97-U;'0@;V8@=&AE(&]N9V]I;F<@8F%N
M:W)U<'1C>2!P<F]C965D:6YG(&9O<B!#86QA;F1O+"!W92!D;R!N;W0@97AP
M96-T(&]U<B!E<75I='D@;W=N97)S:&EP('1O(')E<W5L="!I;B!A;GD@<F5T
M=7)N(&]F(&-A<&ET86P@87,@<&%R="!O9B!T:&4@;&EQ=6ED871I;VX@;V8@
M0V%L86YD;RXF;F)S<#LF;F)S<#L@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ.'!T.W1E>'0M:6YD96YT.C`E.V9O
M;G0M<W1Y;&4Z:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%B;&%R:7,@5&AE<F%P
M975T:6-S+"!);F,N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%B;&%R:7,@=V%S(&9O<FUE9"!A
M;F0@8F5G86X@;W!E<F%T:6]N<R!I;B!F:7-C86P@,C`Q,2P@8F%S960@;VX@
M=&AE(&QI8V5N<V4@;V8@8V5R=&%I;B!A;G1I+6]B97-I='D@=&5C:&YO;&]G
M>2!D979E;&]P960@870@=&AE($U$($%N9&5R<V]N($-A;F-E<B!#96YT97(@
M870@=&AE(%5N:79E<G-I='D@;V8@5&5X87,N($1U<FEN9R!F:7-C86P@,C`Q
M,2P@06)L87)I<R!R86ES960@)#(N.2!M:6QL:6]N(&EN(&-A<V@L(&]F('=H
M:6-H("0Q+C,@;6EL;&EO;B!W87,@:6YV97-T960@8GD@07)R;W=H96%D(&%N
M9"`D,2XV(&UI;&QI;VX@=V%S(&EN=F5S=&5D(&)Y(&]U='-I9&4@:6YV97-T
M;W)S+"!T:')O=6=H('1H92!I<W-U86YC92!O9B!!8FQA<FES(%-E<FEE<R!!
M(%!R969E<G)E9"!S=&]C:RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%S(&]F($IU;F4@,S`L
M(#(P,30L($%R<F]W:&5A9"!O=VYE9"`\9F]N="!S='EL93TS1&-O;&]R.B,[
M/C8T/"]F;VYT/B4@;V8@=&AE(&]U='-T86YD:6YG('-H87)E<R!O9B!!8FQA
M<FES(&%N9"`\9F]N="!S='EL93TS1&-O;&]R.B,[/C8T/"]F;VYT/B4@;VX@
M82!F=6QL>2!D:6QU=&5D(&)A<VES+B`\+W`^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$X<'0[=&5X="UI;F1E;G0Z,"4[
M9F]N="US='EL93II=&%L:6,[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3&5O;F%R9&\@0FEO
M<WES=&5M<RP@26YC+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
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M=&EO;G,@:6X@1&5C96UB97(@,C`Q,RX@07)R;W=H96%D)B,X,C$W.W,@:6YV
M97-T;65N="!I;B!,96]N87)D;R!A;F0@:71S(')E8V5I=F%B;&4@9G)O;2!,
M96]N87)D;R!H879E(&)E96X@9G5L;'D@<F5S97)V960N)FYB<W`[)FYB<W`[
M(#PO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V
M9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD
M97)S)R!%<75I='D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VMH;VQD97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D%T($IU;F4@,S`L(#(P,30L('1H92!#;VUP
M86YY(&AA9"!A('1O=&%L(&]F(#$U,"PP,#`L,#`P('-H87)E<R!O9B!C87!I
M=&%L('-T;V-K(&%U=&AO<FEZ960@9F]R(&ES<W5A;F-E+"!C;VYS:7-T:6YG
M(&]F(#$T-2PP,#`L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VLL('!A<B!V
M86QU92`D,"XP,#$L(&%N9"`U+#`P,"PP,#`@<VAA<F5S(&]F(%!R969E<G)E
M9"!3=&]C:RP@<&%R('9A;'5E("0P+C`P,2X@/"]P/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD96YT
M.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%T($IU
M;F4@,S`L(#(P,30L(#QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^-3(L.3`X+#4V
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M8VLL(&%N9"`Q-BPP,#`@<VAA<F5S(&]F(%-E<FEE<R!#(%!R969E<G)E9"!3
M=&]C:RP@8V]N=F5R=&EB;&4@:6YT;R`R+#<S,"PS-S4@<VAA<F5S(&]F($-O
M;6UO;B!3=&]C:RP@*&-O;&QE8W1I=F5L>2P@=&AE("8C.#(R,#M/=71S=&%N
M9&EN9R!0<F5F97)R960@4W1O8VLF(S@R,C$[*2X@070@2G5N92`S,"P@,C`Q
M-"P@-RPQ.#(L.3(U('-H87)E<R!W97)E(')E<V5R=F5D(&9O<B!I<W-U86YC
M92!U<&]N('9E<W1I;F<@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!A;F0@
M97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<R!G<F%N=&5D('5N9&5R($%R<F]W
M:&5A9"8C.#(Q-SMS(#(P,#`@4W1O8VL@3W!T:6]N(%!L86XL(#(P,#0@17%U
M:71Y($EN8V5N=&EV92!0;&%N+"!A;F0@,C`Q,R!);F-E;G1I=F4@4&QA;BP@
M87,@=V5L;"!A<R!F;W(@:6YD=6-E;65N="!G<F%N=',@;6%D92!T;R!N97<@
M96UP;&]Y965S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
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M=6)J96-T('1O(&$@.2XY.24@8F5N969I8VEA;"!O=VYE<G-H:7`@;&EM:70@
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M:6YG('1H92`Y+CDY)2!O=VYE<G-H:7`@;&EM:71A=&EO;BX@5&AE($]U='-T
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M;B!3=&]C:RX\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US:7IE.C$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^3VX@3V-T;V)E<B8C,38P.S(P+"`R,#$Q
M+"!T:&4@0V]M<&%N>2!A;F0@3&EN8V]L;B!087)K($-A<&ET86P@1G5N9"P@
M3$Q#+"!A;B!);&QI;F]I<R!L:6UI=&5D(&QI86)I;&ET>2!C;VUP86YY("@F
M(S@R,C`[3%!#)B,X,C(Q.RD@96YT97)E9"!I;G1O(&$@)#$U(&UI;&QI;VX@
M<'5R8VAA<V4@86=R965M96YT("AT:&4@)B,X,C(P.U!U<F-H87-E($%G<F5E
M;65N="8C.#(R,3LI+"!W:&5R96)Y($Q00R!A9W)E960@=&\@<'5R8VAA<V4@
M=7`@=&\@)#$U(&UI;&QI;VX@;V8@0V]M;6]N(%-T;V-K+"!S=6)J96-T('1O
M(&-E<G1A:6X@;&EM:71A=&EO;G,L(&9R;VT@=&EM92!T;R!T:6UE(&1U<FEN
M9R!T:&4@=&AR964M>65A<B!T97)M(&]F('1H92!0=7)C:&%S92!!9W)E96UE
M;G0N(%1H92!#;VUP86YY(&AA<R!T:&4@<FEG:'0L(&EN(&ET<R!S;VQE(&1I
M<V-R971I;VXL(&]V97(@82`S-BUM;VYT:"!P97)I;V0@=&\@<V5L;"!U<"!T
M;R`D,34@;6EL;&EO;B!O9B!#;VUM;VX@4W1O8VL@*'-U8FIE8W0@=&\@8V5R
M=&%I;B!L:6UI=&%T:6]N<RD@=&\@3%!#+"!D97!E;F1I;F<@;VX@8V5R=&%I
M;B!C;VYD:71I;VYS(&%S('-E="!F;W)T:"!I;B!T:&4@4'5R8VAA<V4@06=R
M965M96YT+B!!<R!O9B!*=6YE(#,P+"`R,#$T+"!T:&4@0V]M<&%N>2!H860@
M9')A=VX@)#$@;6EL;&EO;B!F<F]M('1H92!F86-I;&ET>2X@/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.VUA<F=I;BUB;W1T;VTZ,'!T.W1E
M>'0M:6YD96YT.C0N-30E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/D]N($]C=&]B97(F(S$V,#LQ,2P@,C`Q,RP@=&AE($-O;7!A;GD@<V]L
M9"`S+#`W,2PV-S(@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@870@82!P<FEC
M92!O9B`D-2XX-B!P97(@<VAA<F4L(&%N9"`T-BPP,#`@<VAA<F5S(&]F(%-E
M<FEE<R8C,38P.T,@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K("AT:&4@
M)B,X,C(P.U!R969E<G)E9"!3:&%R97,F(S@R,C$[*2P@870@82!P<FEC92!O
M9B`D,2PP,#`@<&5R('-H87)E+B!4:&4@4')E9F5R<F5D(%-H87)E<R!A<F4@
M8V]N=F5R=&EB;&4@:6YT;R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T(&$@
M8V]N=F5R<VEO;B!P<FEC92!O9B`D-2XX-BX@5&AE(&%G9W)E9V%T92!P=7)C
M:&%S92!P<FEC92!P86ED(&)Y('1H92!0=7)C:&%S97)S(&9O<B!T:&4@4VAA
M<F5S(&%N9"!0<F5F97)R960@4VAA<F5S('=A<R`D-C0L,#`P+#`P,"!A;F0@
M=&AE($-O;7!A;GD@<F5C96EV960@;F5T('!R;V-E961S(&]F(&%P<')O>&EM
M871E;'D@)#8P+#`P,"PP,#`L(&%F=&5R(&%D=FES;W)Y(&9E97,@86YD(&]F
M9F5R:6YG(&5X<&5N<V5S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$R<'0[;6%R9VEN+6)O='1O;3HP<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3VX@1F5B<G5A<GD@,C0L
M(#(P,30L('1H92!#;VUP86YY('-O;&0@-BPS,C4L,#`P('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VLL(&%T(&$@<'5B;&EC(&]F9F5R:6YG('!R:6-E(&]F("0Q
M."XY-2!P97(@<VAA<F4N)FYB<W`[)FYB<W`[3F5T('!R;V-E961S('=E<F4@
M87!P<F]X:6UA=&5L>2`D,3$R+C8@;6EL;&EO;B!A9G1E<B!U;F1E<G=R:71I
M;F<@8V]M;6ES<VEO;G,@86YD(&1I<V-O=6YT<R!A;F0@;W1H97(@;V9F97)I
M;F<@97AP96YS92X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
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M:6YG(&%T($IU;F4@,S`L(#(P,30Z(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O
M;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD
M:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93L@=VED=&@Z-S8E.R<^#0H\='(^#0H\=&0@8V]L<W!A
M;CTS1#,@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C4X+C@T)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US
M:7IE.CAP=#L^)FYB<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D5X97)C
M:7-E)B,Q-C`[<')I8V5S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N.F-E
M;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[
M9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P
M=#MP861D:6YG+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG
M+4)O='1O;3HP<'0[=VED=&@Z,3<N."4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY.=6UB97(F(S$V,#MO9B8C,38P.SQB<B`O/E=A<G)A;G1S/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT
M-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT-"4[/@T*/'`@
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M,#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW
M<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M-RXW."4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY296UA:6YI;F<\
M9F]N="!S='EL93TS1&9O;G0M=V5I9VAT.FYO<FUA;#L^/&)R("\^/"]F;VYT
M/DQI9F4F(S$V,#MI;B8C,38P.UEE87)S/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XS,B4[/@T*/'`@<W1Y;&4],T1M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$N.3@E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z."XU-B4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M-S`N-C`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT."XR."4[/@T*/'`@<W1Y;&4],T0G
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M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ-BXT,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$N-#0E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,2XS-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ-BXT,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HQ+CDX)3L^#0H\<"!S='EL
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M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4N,#`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT."XR."4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ-BXT,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C0Q-BPR,C4\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C0T)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M+C0T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C$N,S8E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
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M86YT.B!N;W)M86P[)SXQ+C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ+C,R)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,2XY."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z
M+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HX+C4V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXU+C`Y/"]P/CPO=&0^#0H\=&0@
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M+79A<FEA;G0Z(&YO<FUA;#LG("\^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$N,S@E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
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M;W)M86P[)SXR.3$L,C`T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XT-"4[=VAI=&4M
M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,2XT-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MT97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM
M8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,V)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$V+C0R
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
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M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1'=I9'1H.C$N.3@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD
M96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z."XU
M-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)R`O/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
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M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
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M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT-"4[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MT97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P
M.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C,V)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C$V+C0R)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O
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M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$N.3@E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)R`O
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
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M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2PP,#`\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ+C0T)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C0T)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.W1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1'=I9'1H.C$N,S8E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ+C,R)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,2XY."4[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@<W1Y;&4],T1W:61T:#HX+C4V)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M(&YO<FUA;#LG("\^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W
M:61T:#HQ+C,X)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
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M;6%L.R<^)B,Q-C`[(#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$V+C0R)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,S,T+#,T-R`\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M+C0T)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ+C0T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$N,S8E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
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M="UV87)I86YT.B!N;W)M86P[)SXR+C$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C,R)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,2XY."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI
M;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HX+C4V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF
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M,T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M;6%L.R<^-S4L,#`P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XT-"4[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,2XT-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MT97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T
M=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,V)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$V+C0R)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z
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M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$N.#,\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M-#@N,C@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<@+SX\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!S='EL93TS
M1"=W:61T:#HQ+C,X)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$N,S@E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ-BXT,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$N-#0E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MT97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,2XS-B4[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ-BXT,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RXU/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$N,S(E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
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M;F1I;F<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G=VED=&@Z,2XS."4[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,2XS."4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.R`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G=VED=&@Z,38N-#(E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
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M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z
M,2XT-"4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=W:61T:#HQ+C,V)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W
M:61T:#HQ-BXT,B4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=W:61T:#HQ+C,R)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A
M;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?
M-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y."]7;W)K<VAE971S+U-H965T,38N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,96%S97,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z.'!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.3U1%
M(#@N(#QF;VYT('-T>6QE/3-$9F]N="US='EL93II=&%L:6,[/DQ%05-%4SPO
M9F]N=#X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M;F5W('-P86-E('=I;&P@8F4@879A:6QA8FQE(&EN(%-E<'1E;6)E<B`R,#$T
M+B9N8G-P.R9N8G-P.U1H92!L96%S97,@9F]R('1H92!E>'!A;G-I;VX@<W!A
M8V4@86YD('1H92!C=7)R96YT('-P86-E('=I;&P@97AP:7)E(&EN($%U9W5S
M="`R,#$Y+B9N8G-P.R9N8G-P.R!296YT86P@8V]S=',L(&EN8VQU9&EN9R!T
M:&4@97AP86YS:6]N('-P86-E(&%R92!A<'!R;WAI;6%T96QY("0R,BPP,#`@
M<&5R(&UO;G1H+"!I;F-R96%S:6YG(&%P<')O>&EM871E;'D@,R4@86YN=6%L
M;'DN("`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M<F]U9V@@1F5B<G5A<GDF(S$V,#LR."P@,C`Q.2X@36]N=&AL>2!R96YT86P@
M97AP96YS92!I<R!A<'!R;WAI;6%T96QY("0R-2PP,#`N($]T:&5R(&UO;G1H
M;'D@<F5N=&%L(&5X<&5N<V5S(&EN8VQU9&4@8V]M;6]N(&%R96$@;6%I;G1E
M;F%N8V4@86YD(')E86P@97-T871E('1A>&5S('1O=&%L:6YG(&%P<')O>&EM
M871E;'D@)#$V+#`P,"!P97(@;6]N=&@N(%5T:6QI=&EE<R!C;W-T<R!A<F4@
M87!P<F]X:6UA=&5L>2`D,34L,#`P('!E<B!M;VYT:"X@26YC;'5D:6YG(&UO
M;G1H;'D@<&%Y;65N=',@<F5C;W)D960@=6YD97(@82!C87!I=&%L(&QE87-E
M(&]F(&%P<')O>&EM871E;'D@)#$Y+#`P,"P@=&]T86P@;6]N=&AL>2!C;W-T
M<R!A<F4@87!P<F]X:6UA=&5L>2`D-S4L,#`P('!E<B!M;VYT:"X@/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
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M92!A;F0@;FEN92!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!W87,@)#$S
M."PP,#`@86YD("0T,#,L,#`P+"!R97-P96-T:79E;'DN)FYB<W`[)FYB<W`[
M1F%C:6QI='D@86YD(&5Q=6EP;65N="!R96YT(&5X<&5N<V4L(')E;&%T960@
M=&\@8V]N=&EN=6EN9R!O<&5R871I;VYS+"!F;W(@=&AE('1H<F5E(&%N9"!N
M:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$S('=A<R`D,3(V+#`P,"!A
M;F0@)#0P-RPP,#`L(')E<W!E8W1I=F5L>2XF;F)S<#LF;F)S<#L\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[
M=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^07,@;V8@2G5N92`S,"P@,C`Q-"P@9G5T=7)E(&UI;FEM=6T@;&5A
M<V4@<&%Y;65N=',@9'5E(&EN(&9I<V-A;"!Y96%R<R!U;F1E<B!C87!I=&%L
M:7IE9"!L96%S97,@87)E(&%S(&9O;&QO=W,Z(#PO<#X-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT
M.C`E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO
M<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z-38E.R<^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED
M=&@Z-#0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T
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M>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXU-RPQ,#4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
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M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXU
M(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(R."PT,C`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q/&9O
M;G0@<W1Y;&4],T1C;VQO<CHC.SXV(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V
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M,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(R."PT
M,C`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
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M;6%L.R<^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXW(#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C(R."PT,C`\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q/&9O;G0@<W1Y;&4],T1C
M;VQO<CHC.SXX(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(R."PT,C`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q/&9O
M;G0@<W1Y;&4],T1C;VQO<CHC.SXY(#PO9F]N=#YA;F0@=&AE<F5A9G1E<CPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^.34L,3<U/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z-#0E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE<W,@:6YT97)E<W0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M,38P.R`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#0P+#8X,2`\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
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M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXQ+#`R-2PR-SD\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
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M<G1I;VX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXH,C$S+#$Q,"`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/C@Q,BPQ-CD\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
M97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY!<R!O9B!*=6YE(#,P+"`R,#$T+"!F=71U<F4@;6EN:6UU;2!L96%S
M92!P87EM96YT<R!D=64@:6X@9FES8V%L('EE87)S('5N9&5R(&]P97)A=&EN
M9R!L96%S97,@87)E(&%S(&9O;&QO=W,Z(#PO<#X-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=VED=&@Z-38E.R<^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#0E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$=VED=&@Z-#0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^-3@P+#8R-CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#0E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ
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M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-#0E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O
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M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z-#0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
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M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
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M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
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M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C0T)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[
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M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^-#,R+#@V,2`\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M;G0M=F%R:6%N=#H@;F]R;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,BPY.3<L,#0X/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^/"]D:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E
M;G-A=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M;VYT/B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M97(@=&AE(#(P,#`@4W1O8VL@3W!T:6]N(%!L86XL(#,X+#`P,"!S:&%R97,@
M;V8@07)R;W=H96%D)B,X,C$W.W,@0V]M;6]N(%-T;V-K(&%R92!R97-E<G9E
M9"!F;W(@:7-S=6%N8V4@=7!O;B!E>&5R8VES92!O9B!N;VXM<75A;&EF:65D
M('-T;V-K(&]P=&EO;G,N($YO(&9U<G1H97(@9W)A;G1S(&-A;B!B92!M861E
M('5N9&5R('1H92`R,#`P(%-T;V-K($]P=&EO;B!0;&%N+B!4:&4@,C`P-"!%
M<75I='D@26YC96YT:79E(%!L86X@<F5S97)V97,@,BPW,S0L.#0P('-H87)E
M<R!F;W(@=&AE(&=R86YT(&]F('-T;V-K(&]P=&EO;G,L('-T;V-K(&%P<')E
M8VEA=&EO;B!R:6=H=',L(')E<W1R:6-T960@<W1O8VL@87=A<F1S(&%N9"!P
M97)F;W)M86YC92!U;FET+W-H87)E(&%W87)D<R!T;R!E;7!L;WEE97,L(&-O
M;G-U;'1A;G1S(&%N9"!O=&AE<G,N("!4:&4@,C`Q,R!);F-E;G1I=F4@4&QA
M;B!R97-E<G9E<R`T+#`P,"PP,#`@<VAA<F5S(&9O<B!T:&4@9W)A;G0@;V8@
M<W1O8VL@;W!T:6]N<RP@<W1O8VL@87!P<F5C:6%T:6]N(')I9VAT<RP@<F5S
M=')I8W1E9"!S=&]C:R!A=V%R9',@86YD('!E<F9O<FUA;F-E(&%W87)D<R!T
M;R!E;7!L;WEE97,L(&-O;G-U;'1A;G0@86YD(&]T:&5R<RXF;F)S<#LF;F)S
M<#M!<R!O9B!*=6YE(#,P+"`R,#$T+"!T:&5R92!W97)E(&]P=&EO;G,@9W)A
M;G1E9"!A;F0@;W5T<W1A;F1I;F<@=&\@<'5R8VAA<V4@,S@L,#`P+"`R+#8S
M."PV-3(@86YD(#<S-BPX-S4@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!U;F1E
M<B!T:&4@,C`P,"!3=&]C:R!/<'1I;VX@4&QA;BP@=&AE(#(P,#0@17%U:71Y
M($EN8V5N=&EV92!0;&%N(&%N9"!T:&4@,C`Q,R!);F-E;G1I=F4@4&QA;BP@
M<F5S<&5C=&EV96QY+B!!;'-O+"!A<R!O9B!*=6YE(#,P+"`R,#$T+"!T:&5R
M92!W97)E(#0Q,"PP.#4@<VAA<F5S(')E<V5R=F5D(&9O<B!O<'1I;VYS(&ES
M<W5E9"!O=71S:61E(&]F(&5Q=6ET>2!C;VUP96YS871I;VX@<&QA;G,@87,@
M:6YD=6-E;65N="!G<F%N=',@=&\@;F5W(&5M<&QO>65E<RX@1'5R:6YG('1H
M92!N:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T+"!N;R!O<'1I;VYS
M('=E<F4@9W)A;G1E9"!U;F1E<B!T:&4@,C`P-"!%<75I='D@26YC96YT:79E
M(%!L86XL(#<V-2PP,#`@=V5R92!I<W-U960@=6YD97(@=&AE(#(P,3,@26YC
M96YT:79E(%!L86X@86YD(#$V-2PP,#`@;W!T:6]N<R!W97)E(&=R86YT960@
M;W5T<VED92!O9B!E<75I='D@:6YC96YT:79E('!L86YS(&%S(&EN9'5C96UE
M;G0@<W1O8VL@;W!T:6]N<R!T;R!N97<@96UP;&]Y965S+B`\+W`^#0H\<"!S
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M(&%B;W5T('-T;V-K(&]P=&EO;G,Z/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N
M="US:7IE.C$R<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/@T*/&1I
M=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA
M<'-E.F-O;&QA<'-E.R!W:61T:#HY,B4[)SX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/DYU;6)E<B8C,38P.V]F/&)R("\^3W!T:6]N<SQB<B`O
M/D]U='-T86YD:6YG/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z
M,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@
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M<B`O/D%V97)A9V4\8G(@+SY%>&5R8VES93QB<B`O/E!R:6-E/&)R("\^4&5R
M)B,Q-C`[4VAA<F4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
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M.W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#%P="`C,#`P,#`P.R<^
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M960M/&)R("\^079E<F%G93QB<B`O/E)E;6%I;FEN9SQB<B`O/D-O;G1R86-T
M=6%L/&)R("\^5&5R;3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)B,Q-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG
M+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D)A;&%N8V4@070@4V5P=&5M8F5R)B,Q-C`[
M,S`L(#(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^,CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ+#DQ,"PW.30\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B0F(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ
M,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T9#X-
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M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ
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M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXD)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM
M8F]T=&]M.C!P=#MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R
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M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HT,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
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M;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+7=E
M:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[
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M>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN
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M;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C0Q)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY%>&5R8VES960\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH-C<U(#PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A
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M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
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M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0F(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#LF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
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M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$;6ED9&QE('-T>6QE/3-$
M)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&UI9&1L92!S='EL93TS1"=W:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z-#$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
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M-C`[,S`L(#(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^,SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
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M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
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M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
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M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HT,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z
M+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D=R86YT
M960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXY,S`L,#`P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^*#$T."PU-C$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H
M.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z-#$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@S-S<L,3$R/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
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M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
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M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z-#$E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D)A;&%N8V4@070@2G5N92`S,"P@,C`Q-#PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
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M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T
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M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,S`L,C<Q+#`Q,3PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E
M;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C0Q)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY%>&5R8VES86)L92!!="!*
M=6YE(#,P+"`R,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B
M;W)D97(M=&]P.F1O=6)L92`R+C5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O
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M86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI
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M:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4N.#`\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O
M;3HP<'0[9F]N="UW96EG:'0Z8F]L9#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.R8C
M,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O
M<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXW+C,@>65A<G,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.F1O=6)L
M92`R+C5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
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M9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
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M9"!N:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T('=A<R`D,2PP-S`L
M-C,Q(&%N9"`D,BPQ.#8L-C4S+"!R97-P96-T:79E;'DN(%-T;V-K+6)A<V5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O<B!T:&4@=&AR964@86YD(&YI;F4@
M;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z
M(SL^,SPO9F]N=#X@=V%S("0S-C,L-3DS(&%N9"`D,2PQ,30L,S<U+"!R97-P
M96-T:79E;'DN(%1H97)E(&ES(&YO(&EN8V]M92!T87@@8F5N969I="!A<R!T
M:&4@0V]M<&%N>2!I<R!C=7)R96YT;'D@;W!E<F%T:6YG(&%T(&$@;&]S<R!A
M;F0@86X@86-T=6%L(&EN8V]M92!T87@@8F5N969I="!M87D@;F]T(&)E(')E
M86QI>F5D+B!4:&4@;&]S<R!C<F5A=&5S(&$@=&EM:6YG(&1I9F9E<F5N8V4L
M(')E<W5L=&EN9R!I;B!A(&1E9F5R<F5D('1A>"!A<W-E="P@=VAI8V@@:7,@
M9G5L;'D@<F5S97)V960@8GD@82!V86QU871I;VX@86QL;W=A;F-E+B`\+W`^
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M=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T
M(&ES(&5S=&EM871E9"!A="`D/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXQ+#$W
M-BPP,#`\+V9O;G0^(&%N9"`D/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXX+#(Y
M-2PV,#`\+V9O;G0^+"!R97-P96-T:79E;'DN(%1H92!A9V=R96=A=&4@9W)A
M;G0@9&%T92!F86ER('9A;'5E(&]F('1H92!O<'1I;VYS(&=R86YT960@8GD@
M=&AE($-O;7!A;GD@9'5R:6YG('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@
M96YD960@2G5N92`S,"P@,C`Q,R!I<R!E<W1I;6%T960@870@)#QF;VYT('-T
M>6QE/3-$8V]L;W(Z(SL^,2PP.30L,CDU/"]F;VYT/B!A;F0@)#QF;VYT('-T
M>6QE/3-$8V]L;W(Z(SL^,2PQ.3<L-3@X/"]F;VYT/BP@<F5S<&5C=&EV96QY
M+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
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M:',@96YD960@2G5N92`S,"P@,C`Q-"!W87,@)#,W,2PS,S0@86YD("0S+#8P
M-BPP-C$L(')E<W!E8W1I=F5L>2XF;F)S<#LF;F)S<#M.;R!O<'1I;VYS('=E
M<F4@97AE<F-I<V5D(&1U<FEN9R!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS
M(&5N9&5D($IU;F4@,S`L(#(P,3,N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T
M)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY!<R!O9B!*=6YE
M(#,P+"`R,#$T+"!T:&4@<')E+71A>"!C;VUP96YS871I;VX@97AP96YS92!F
M;W(@86QL('5N=F5S=&5D('-T;V-K(&]P=&EO;G,@:6X@=&AE(&%M;W5N="!O
M9B!A<'!R;WAI;6%T96QY("0Q,"PU,30L-C$Y('=I;&P@8F4@<F5C;V=N:7IE
M9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS(')E<W5L=',@;V8@;W!E<F%T:6]N
M<R!O=F5R(&$@=V5I9VAT960@879E<F%G92!P97)I;V0@;V8@/&9O;G0@<W1Y
M;&4],T1C;VQO<CHC.SXS+C(@/"]F;VYT/GEE87)S+B`\+W`^#0H\<"!S='EL
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O
M;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD
M:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93L@=VED=&@Z-S8E.R<^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C(N,S(E.SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,2XT-B4[/@T*/'`@<W1Y
M;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG+5)I9VAT.C`N-W!T.W!A9&1I
M;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,S8N,C(E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#%P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
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M;F1E9"8C,38P.TIU;F4@,S`L/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
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M+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ+C0V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4
M;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-RXS."4[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M/B`\+V9O;G0^/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ+C0V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,3<N,S@E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ+C0V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M:#HV,BXS,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M>6QE/3-$=VED=&@Z,2XT-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
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M)SXQ+C@E('1O(#(N-24F;F)S<#LF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C0V)3L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HQ-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X
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M;R8C,38P.S$N,R4\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-C(N
M,S(E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY6;VQA=&EL:71Y/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,2XT-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
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M="UV87)I86YT.B!N;W)M86P[)SXV.24\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C0V
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P
M.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HQ-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^17AP96-T960@;&EF92`H:6X@
M>65A<G,I/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED
M=&@Z,2XT-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
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M(#DN-S(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ+C0V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^-2XU('1O(#8N,C4\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z-C(N,S(E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD
M96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY7
M96EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92!P97(@<VAA
M<F4@;V8@;W!T:6]N<R!G<F%N=&5D/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XT-B4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$W+C,X)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD
M."XY,CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'=I9'1H.C$N-#8E.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
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M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY4:&4@9&EV:61E;F0@>6EE;&0@:7,@>F5R;R!A
M<R!T:&4@0V]M<&%N>2!C=7)R96YT;'D@9&]E<R!N;W0@<&%Y(&$@9&EV:61E
M;F0N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY4:&4@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@
M:7,@8F%S960@;VX@=&AE(%4N4RX@5')E87-U<GD@8F]N9"X@/"]P/@T*/'`@
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M:R!P<FEC92X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HQ.'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/E)E<W1R:6-T960@4W1O8VL@56YI=',\+W`^
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M(%!L86XN)FYB<W`[)FYB<W`[1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E
M9"!*=6YE(#,P+"`R,#$T+"!T:&4@0V]M<&%N>2!I<W-U960@-#<P+#`P,"!R
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M87(@86YN:79E<G-A<GD@;V8@=&AE(&1A=&4@;V8@9W)A;G0N)FYB<W`[)FYB
M<W`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ
M93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\
M=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC
M;VQL87!S93L@=VED=&@Z-S8E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z-C0N-C@E.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#HP+C=P=#MP861D:6YG+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP
M861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38N-S8E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^#0H\<"!S='EL93TS1"=T
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`N.38E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG+5)I9VAT.C`N
M-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z
M,3$N.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$N,S@E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,"XW."4[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
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M.R<^56YV97-T960@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3QF;VYT('-T
M>6QE/3-$8V]L;W(Z(SL^,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,2XP
M."4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=W:61T:#HQ-2XW)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C`N.38E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ+C0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"XU)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BT\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C`N
M-S@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C`N-S8E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z-C0N-C@E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
M<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY'<F%N=&5D/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,2XP."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,34N-R4[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/C0W,"PP,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ+C,X)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,"XY-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"XU)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C$T+C4T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,2XS."4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$N
M,S@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T
M;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`N-S@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`N-S8E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED
M=&@Z-C0N-C@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ
M,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY697-T960\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ+C`X)3L^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ-2XW)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF
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M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HP+CDV)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C0E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HP+C<X)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HP
M+C<V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
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M,#@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,34N-R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP+CDV)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ+C0E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C4E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M,S@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ+C,X)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP+C<X
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP+C<V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C8T+C8X)3L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
M<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY5;G9E<W1E9"!A="!*=6YE(#,P+"`R,#$T/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W=I9'1H.C$N,#@E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,34N-R4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT-S`L,#`P/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W=I9'1H.C$N,S@E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HP+CDV)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ+C0E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M=F%R:6%N=#H@;F]R;6%L.R<^,30N-30\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,2XS
M."4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H
M:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H
M.C$N,S@E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O
M;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C`N-S@E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C`N-S8E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/"]D:78^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY4:&4@0V]M<&%N>2!R96-O<F1E9"`D.38X+#`U,2!A;F0@
M)#$L-3<Q+#8Q,2!O9B!E>'!E;G-E(')E;&%T:6YG('1O(')E<W1R:6-T960@
M<W1O8VL@=6YI=',@9'5R:6YG('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@
M96YD960@2G5N92`S,"P@,C`Q-"!R97-P96-T:79E;'DL(&%N9"!S=6-H(&5X
M<&5N<V4@:7,@:6YC;'5D960@:6X@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M(&5X<&5N<V4N)FYB<W`[)FYB<W`[5&AE<F4@=V%S(&YO(&5X<&5N<V4@<F5L
M871I;F<@=&\@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!D=7)I;F<@=&AE('1H
M<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$S+B`\+W`^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R
M<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US:7IE.C$P<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^07,@;V8@2G5N92`S,"P@,C`Q-"P@=&AE('!R92UT87@@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&%L;"!U;G9E<W1E9"!R97-T<FEC=&5D
M('-T;V-K('5N:71S(&EN('1H92!A;6]U;G0@;V8@87!P<F]X:6UA=&5L>2`D
M-2PR.3$L,S`R('=I;&P@8F4@<F5C;V=N:7IE9"!I;B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(')E<W5L=',@;V8@;W!E<F%T:6]N<R!O=F5R(&$@=V5I9VAT960@
M879E<F%G92!P97)I;V0@;V8@/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXQ+C4@
M/"]F;VYT/GEE87)S+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.3U1%
M(#$P+B`\9F]N="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC.SY&04E2(%9!
M3%5%($U%05-54D5-14Y44SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G
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M970@;W(@<&%I9"!T;R!T<F%N<V9E<B!A(&QI86)I;&ET>2`H:2YE+BP@97AI
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M9B!F86ER('9A;'5E('=H:6QE($QE=F5L)B,Q-C`[,R!G96YE<F%L;'D@<F5Q
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M;&]W<SH@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HV<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US:7IE.C$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^3&5V96PF(S$V,#LQ)B,X,C$R.U9A;'5A=&EO
M;G,@87)E(&)A<V5D(&]N('5N861J=7-T960@<75O=&5D('!R:6-E<R!I;B!A
M8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI
M=&EE<RX@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M97(@9&ER96-T;'D@;W(@:6YD:7)E8W1L>2X@/"]P/@T*/'`@<W1Y;&4],T0G
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M/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HQ,G!T.W1E>'0M:6YD96YT.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!F
M86ER('9A;'5E(&UE87-U<F5M96YT<R!A="!*=6YE(#,P+"`R,#$T(&%N9"!3
M97!T96UB97(F(S$V,#LS,"P@,C`Q,R!F;W(@87-S971S(&%N9"!L:6%B:6QI
M=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A
M<VES.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^2G5N92`S,"P@,C`Q-#H@/"]P/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7-I>F4Z,3)P=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L
M92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
M<'-E.R!W:61T:#HY,B4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T
M.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE
M.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A
M9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/DQE=F5L(#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I
M;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE
M=F5L(#,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T
M.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/E1O=&%L/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\
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M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ
M93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
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M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE
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M9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB
M;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
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M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@<W1Y;&4]
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M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
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M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX
M<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T
M;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z-#$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1&UA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
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M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E
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M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXT+#`Q."PW,3D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z-#$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY#;VYT:6YG96YT(&-O;G-I9&5R871I;VX@;V)L:6=A=&EO;G,@<F5L871E
M9"!T;R!A8W%U:7-I=&EO;G,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C$L-3DU+#(W,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ
M93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P
M=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
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M8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M
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M)B,Q-C`[,S`L(#QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^,C`Q,SPO9F]N=#XZ
M(#PO<#X-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[/B9N8G-P.SPO
M<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
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M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T
M.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M
M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE
M.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DQE=F5L(#$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A
M9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T
M=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/DQE=F5L(#(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I
M;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE
M=F5L(#,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M
M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P
M=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
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M,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="US
M:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ
M,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
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M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z
M.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T
M=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
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M,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z-#$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
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M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T
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M;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C0Q)3L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N="US:7IE
M.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1&5R:79A=&EV92!L:6%B:6QI=&EE
M<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
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M0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M
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M>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT
M+#`Y-BPS-C,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
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M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$
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M93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ+#4Y-2PR-S,\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C$L-3DU+#(W,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M;F4@,S`L(#(P,30L('1H92!#;VUP86YY(&AA9"!S:&]R="UT97)M(&EN=F5S
M=&UE;G1S(&]F("0R,RPX,S0L-#`X+"!A;F0@;&]N9RUT97)M(&EN=F5S=&UE
M;G1S(&]F("0R-BPR.#0L.#8R+"!F;W(@82!T;W1A;"!O9B`D-3`L,3$Y+#(W
M,"XF;F)S<#LF;F)S<#M4:&4@9F%I<B!V86QU92!O9B!I=',@:6YV97-T;65N
M="!A="!*=6YE(#,P+"`R,#$T('=A<R`D-#DL-S,U+#8Q-BXF;F)S<#LF;F)S
M<#M4:&4@0V]M<&%N>2!E>'!E8W1S('1O(&AO;&0@<W5C:"!I;G9E<W1M96YT
M<R!U;G1I;"!M871U<FET>2P@86YD('1H=7,@=6YR96%L:7IE9"!G86EN<R!A
M;F0@;&]S<V5S(&9R;VT@=&AE(&9L=6-T=6%T:6]N<R!I;B!T:&4@9F%I<B!V
M86QU92!O9B!T:&4@<V5C=7)I=&EE<R!A<F4@;F]T(&QI:V5L>2!T;R!B92!R
M96%L:7IE9"X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N="US:7IE.C$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^07,@<&%R="!O9B!T:&4@<')O8V5E9',@
M9G)O;2!T:&4@<V%L92!O9B!5;FED>6T@:6X@2F%N=6%R>2`R,#$Q+"!!<G)O
M=VAE860@<F5C96EV960@82!B;VYD(&9R;VT@5VES97!O=V5R(&EN('1H92!F
M86-E(&%M;W5N="!O9B`D,BXU(&UI;&QI;VXN(%1H92!B;VYD(&ES(&-O;G9E
M<G1I8FQE('1O(%=I<V5P;W=E<B!C;VUM;VX@<W1O8VL@870@82!P<FEC92!O
M9B`D,BXP,"!P97(@<VAA<F4N(%1H92!C;VYV97)S:6]N(&9E871U<F4@:7,@
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M,#LS,2P@,C`Q,RP@=&AE('1R861I;F<@;V8@5VES97!O=V5R('-T;V-K('=A
M<R!H86QT960N(%1R861I;F<@<F5S=6UE9"!I;B!*=6QY(#(P,3,L(&)U="!T
M:&4@=')A9&EN9R!P<FEC92!I<R!S:6=N:69I8V%N=&QY(&)E;&]W('1H92!C
M;VYV97)S:6]N('!R:6-E+B9N8G-P.R9N8G-P.T1U<FEN9R!F:7-C86P@,C`Q
M,RP@=&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H92!P<F]B86)I;&ET
M>2!O9B!R96%L:7II;F<@=F%L=64@9G)O;2!T:&4@8V]N=F5R<VEO;B!F96%T
M=7)E('=A<R!R96UO=&4L(&%N9"!T:&4@9&5R:79A=&EV92!A<W-E="!V86QU
M92!W87,@<F5D=6-E9"!T;R!Z97)O+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T
M)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY$=7)I;F<@=&AE
M(&YI;F4@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30L('1H97)E('=A<R!N
M;R!C:&%N9V4@:6X@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&1E<FEV871I=F4@
M87-S970N(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P
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M;R!A="!*=6YE(#,P+"`R,#$T(&%N9"!397!T96UB97(@,S`L(#(P,3,N(#PO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=VED=&@Z-C@E.R<^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z
M-38E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY686QU92!A="!397!T
M96UB97(F(S$V,#LS,"P@,C`Q,CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(U,"PR-3`\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
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M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD
M96YT.BTQ,G!T.SMC;VQO<CHC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/D1E8W)E87-E(#QF;VYT('-T>6QE/3-$8V]L;W(Z(S`P,#`P,#L^
M:6X@=F%L=64\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M="!S='EL93TS1&-O;&]R.B,P,#`P,#`[/CPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW
M:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI
M;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/E9A;'5E(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E
M>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY296-E:7!T(&]F(&EN<W1R=6UE;G1S/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/D1E8W)E87-E(&EN('9A;'5E/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M
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M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z-38E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T
M:#HU-B4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5F%L=64@870@2G5N92`S
M,"P@,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
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M=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M.R<^07,@<&%R="!O9B!A;B!E<75I='D@9FEN86YC:6YG(&EN($IU;F4@,C`Q
M,"P@07)R;W=H96%D(&ES<W5E9"!W87)R86YT<R!T;R!A8W%U:7)E('5P('1O
M(#,R.2PV-#D@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R`H=&AE("8C.#(R,#LR
M,#$P(%=A<G)A;G1S)B,X,C(Q.RDL(&]F('=H:6-H(#(T+#,R-"!W87)R86YT
M<R!W97)E(&]U='-T86YD:6YG(&%T($IU;F4@,S`L(#(P,30N(%-I;6EL87)L
M>2P@87,@<&%R="!O9B!A(&9I;F%N8VEN9R!I;B!$96-E;6)E<B`R,#$R+"!!
M<G)O=VAE860@:7-S=65D('=A<G)A;G1S('1O(&%C<75I<F4@=7`@=&\@.3$R
M+#4T,R!S:&%R97,@;V8@0V]M;6]N(%-T;V-K("AT:&4@)B,X,C(P.S(P,3(@
M5V%R<F%N=',F(S@R,C$[*2!O9B!W:&EC:"`R-C4L,38Q('=A<G)A;G1S('=E
M<F4@;W5T<W1A;F1I;F<@870@2G5N92`S,"P@,C`Q-"XF;F)S<#LF;F)S<#M&
M=7)T:&5R+"!A<R!P87)T(&]F(&$@9FEN86YC:6YG(&EN($IA;G5A<GD@,C`Q
M,RP@07)R;W=H96%D(&ES<W5E9"!W87)R86YT<R!T;R!A8W%U:7)E('5P('1O
M(#@S,RPU,S`@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R`H=&AE("8C.#(R,#LR
M,#$S(%=A<G)A;G1S)B,X,C(Q.RD@;V8@=VAI8V@@,C0L-C(S('=A<G)A;G1S
M('=E<F4@;W5T<W1A;F1I;F<@870@2G5N92`S,"P@,C`Q-"XF;F)S<#LF;F)S
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M871U<F5S+"!T:&4@,C`Q,"!787)R86YT<RP@=&AE(#(P,3(@5V%R<F%N=',L
M(&%N9"!T:&4@,C`Q,R!787)R86YT<R!A<F4@<W5B:F5C="!T;R!D97)I=F%T
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M960@2G5N92`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@<F5C;W)D960@82!N;VXM
M8V%S:"!L;W-S(&9R;VT@=&AE(&-H86YG92!I;B!F86ER('9A;'5E(&]F('1H
M92!D97)I=F%T:79E(&QI86)I;&ET>2!O9B`D-2PV.#`L-30T+B`\+W`^#0H\
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M:79A=&EV92!L:6%B:6QI='D@=V5R92!A<R!F;VQL;W=S.B`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT
M+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E
M<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS
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M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,3`@
M5V%R<F%N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P
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M92`S,"P@,C`Q-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ+C4X)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(N-S0E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M0T9&,$9#('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
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M3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,BXW-"4[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C(U
M+C(V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXP+C,S)3PO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HT,2XR-"4[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P
M=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/D5X<&5C=&5D(&QI9F4\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
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M87)I86YT.B!N;W)M86P[)SXQ+C4@665A<G,\+W`^/"]T9#X-"CQT9"!V86QI
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,BXR)B,Q-C`[665A<G,\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$N,C0E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HR-RXP-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^3F]N93PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$N-3@E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR-RXP-"4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HR+C<T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO
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M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT,2XR-"4[/@T*/'`@
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR-RXP-"4[/@T*/'`@<W1Y;&4],T0G
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR+C<T)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,C4N,C8E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$N,C0E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q,B!787)R86YT<SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(N,30E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR-RXP-"4[/@T*/'`@<W1Y;&4],T0G
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M+61E8V]R871I;VXZ=6YD97)L:6YE.SY*=6YE(#,P+"`R,#$T/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$N
M-3@E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(U+C(V
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1'1E>'0M9&5C;W)A=&EO;CIU;F1E<FQI;F4[/E-E<'1E
M;6)E<B`S,"P@,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z-#$N,C0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT
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M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR
M-RXP-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^,"XX."4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C4X)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C(N-S0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,2XS.24\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$N,C0E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C,V<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RXU(%EE87)S/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XU
M."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(U+C(V)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M,$9#('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR+C<T)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M;F4\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z-#$N,C0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E
M>'0M:6YD96YT.BTQ,G!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY6;VQA=&EL:71Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C(W+C`T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXV.24\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ+C4X)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C(N-S0E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HR-2XR-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E
M;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XU."4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'=I9'1H.C(N-S0E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR-2XR
M-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
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M;W1T;VT@<W1Y;&4],T1W:61T:#HT,2XR-"4[/@T*/'`@<W1Y;&4],T0G;6%R
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M8F]T=&]M('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1'1E>'0M9&5C;W)A=&EO;CIU
M;F1E<FQI;F4[/DIU;F4@,S`L(#(P,30\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XU."4[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR+C<T)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
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M=&5X="UD96-O<F%T:6]N.G5N9&5R;&EN93L^4V5P=&5M8F5R(#,P+"`R,#$S
M/"]F;VYT/CPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT,2XR-"4[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
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M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,BXW-"4[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H
M.C(U+C(V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXQ+C,Y)3PO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,2XR-"4[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/D5X<&5C=&5D(&QI9F4\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M="UV87)I86YT.B!N;W)M86P[)SXS+C8@665A<G,\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C4X)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR+C<T)3L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
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M=F%R:6%N=#H@;F]R;6%L.R<^1&EV:61E;F0@>6EE;&0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO
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M<FEA;G0Z(&YO<FUA;#LG/DYO;F4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C4X)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C(N-S0E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@<W1Y;&4]
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M:#HT,2XR-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R
M<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9O;&%T:6QI
M='D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^
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M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(U+C(V
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXV
M.24\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4]
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HV."4[
M)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X
M="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/E9A;'5E(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
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M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
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M;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^,BPQ-3,L.#$Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D-H86YG92!I;B!V86QU93PO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z-38E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P
M=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V-O;&]R.B,[9F]N="US:7IE.C$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^3F5T('-E='1L96UE;G1S/&9O;G0@<W1Y;&4]
M,T1C;VQO<CHC,#`P,#`P.SX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#,L-S4T+#@P."`\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9A;'5E(&%T(%-E<'1E;6)E<B8C
M,38P.S,P+"`R,#$S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
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M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY#:&%N9V4@:6X@=F%L=64\+W`^/"]T9#X-
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M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C4L-C@P+#4T-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO
M=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C4V)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
M<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY.970@<V5T=&QE;65N=',\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#4L-S@Y+#DX
M,BD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
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M5F%L=64@870@2G5N92`S,"P@,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^,RPY.#(L,S4Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N="US:7IE.C%P=#L^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+7-I>F4Z,7!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O
M<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M<VEZ93HQ<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT
M+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY);B!C;VYJ=6YC=&EO;B!W:71H('1H92!F:6YA;F-I;F<@;V8@06)L87)I
M<R!I;B!F:7-C86P@,C`Q,2P@07)R;W=H96%D('-O;&0@97AC:&%N9V4@<FEG
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M:&]L9&5R('1O(&5X8VAA;F=E(&]N92!!8FQA<FES('-H87)E(&9O<B`P+C`V
M($%R<F]W:&5A9"!S:&%R97,@*&%S(&%D:G5S=&5D(&9O<B!A('-U8G-E<75E
M;G0@<F5V97)S92!S=&]C:R!S<&QI="DN(%1H:7,@<F%T:6\@9&5C;&EN97,@
M=&\@,"XP-"!I;B!T:&4@<V5C;VYD('EE87(L(#`N,#,@:6X@=&AE('1H:7)D
M('EE87(@86YD(#`N,#(@:6X@=&AE(&9O=7)T:"!Y96%R+B!);B!T:&4@9FEF
M=&@@>65A<B!A;F0@8F5Y;VYD('1H92!E>&-H86YG92!R871I;R!I<R`P+C`Q
M+B!%>&-H86YG92!R:6=H=',@9F]R(#8W-2PP,#`@06)L87)I<R!S:&%R97,@
M=V5R92!S;VQD(&EN(&9I<V-A;"`R,#$Q+"!A;F0@<F5M86EN(&]U='-T86YD
M:6YG(&%T($IU;F4@,S`L(#(P,30N(%1H92!E>&-H86YG92!R:6=H=',@87)E
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M;F4@,S`L(#(P,30L('1H92!#;VUP86YY(')E8V]R9&5D(&$@;F]N+6-A<V@@
M;&]S<R!F<F]M('1H92!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!T:&4@9&5R
M:79A=&EV92!L:6%B:6QI='D@;V8@)#,Q+#<Y,2X\+W`^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N
M=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[)SXF;F)S<#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L
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M8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DIU;F4@,S`L)B,Q-C`[(#(P
M,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^-#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C,R)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I
M;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ,RXQ-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY397!T96UB97(F(S$V,#LS,"PF(S$V,#L@,C`Q,SPO<#X\+W1D/@T*/"]T
M<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HW,BXS-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M:6%N=#H@;F]R;6%L.R<^,"XX."4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,R)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,RXQ-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D5X<&5C=&5D(&QI9F4\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,RXQ-B4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXS+C4@665A<G,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ+C,R)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ,RXQ-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXT+C,@665A<G,\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z-S(N,S8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E
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M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DYO;F4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,R)3L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,RXQ-B4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
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M<SH@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/@T*/&1I=CX-"CQT
M86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O
M;&QA<'-E.R!W:61T:#HW-B4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/E9A;'5E(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$\9F]N="!S='EL93TS
M1&-O;&]R.B,[/C(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,3`L,S<U/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT
M<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#4L.#`V/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED
M=&@Z-C0E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DYE="!S971T;&5M96YT
M<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
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M;6%L.R<^5F%L=64@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3QF;VYT('-T
M>6QE/3-$8V]L;W(Z(SL^,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^-"PU-CD\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M;65N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXS,2PW.3$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C8T)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT
M.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY686QU
M92!A="!*=6YE(#,P+"`R,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P
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M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
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M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+7-I>F4Z-'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R
M+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M<VEZ93HT<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+7-I>F4Z-'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T
M86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P
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M;FEF:6-A;G0@969F96-T+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z-"XU-"4[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1'5R:6YG(&9I<V-A;"`R
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M9R!,979E;"`S(&EN<'5T<RX@5&AE(&9A:7(@=F%L=64@;V8@8V]N=&EN9V5N
M="!C;VYS:61E<F%T:6]N(&]B;&EG871I;VYS(&ES(&)A<V5D(&]N(&$@9&ES
M8V]U;G1E9"!C87-H(&9L;W<@;6]D96P@=7-I;F<@82!P<F]B86)I;&ET>2UW
M96EG:'1E9"!I;F-O;64@87!P<F]A8V@N(%1H92!M96%S=7)E;65N="!I<R!B
M87-E9"!U<&]N('5N;V)S97)V86)L92!I;G!U=',@<W5P<&]R=&5D(&)Y(&QI
M='1L92!O<B!N;R!M87)K970@86-T:79I='D@8F%S960@;VX@=&AE($-O;7!A
M;GDF(S@R,3<[<R!O=VX@87-S=6UP=&EO;G,@86YD(&5X<&5R:65N8V4N($5S
M=&EM871I;F<@=&EM:6YG('1O(&-O;7!L971E('1H92!D979E;&]P;65N="P@
M86YD(&]B=&%I;B!A<'!R;W9A;"!O9B!P<F]D=6-T<R!I<R!D:69F:6-U;'0L
M(&%N9"!T:&5R92!A<F4@:6YH97)E;G0@=6YC97)T86EN=&EE<R!I;B!D979E
M;&]P:6YG(&$@<')O9'5C="!C86YD:61A=&4L('-U8V@@87,@;V)T86EN:6YG
M(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H1D1!*2!A;F0@
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M<&5N<V5S(&%S(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;B`F(S@R,3$[(&9A
M:7(@=F%L=64@861J=7-T;65N=',@:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!#
M;VYS;VQI9&%T960@4W1A=&5M96YT(&]F($]P97)A=&EO;G,N(#PO<#X-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M
M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CLG/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z
M-S8E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z-C0E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R+C(U
M<'0[.W1E>'0M:6YD96YT.BTQ,BXR-7!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY686QU92!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q
M/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXR/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$W,RPV,C$\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
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M=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
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M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C8T)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R+C(U<'0[.W1E
M>'0M:6YD96YT.BTQ,BXR-7!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!C;VYT:6YG96YT(&-O
M;G-I9&5R871I;VX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXQ+#0R,2PV-3(\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C8T)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N="US
M:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5F%L=64@870@4V5P=&5M8F5R
M(#,P+"`R,#$\9F]N="!S='EL93TS1&-O;&]R.B,[/C,\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z-C0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ
M,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY0=7)C:&%S
M92!P<FEC92!C;VYT:6YG96YT(&-O;G-I9&5R871I;VX\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
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M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z-C0E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E
M+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
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M870@2G5N92`S,"P@,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ+#4Y-2PR-S,\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N=#HT+C4T
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M(&EN8V]R<&]R871I;F<@97-T:6UA=&5D('-U8V-E<W,@<F%T97,N)FYB<W`[
M)FYB<W`[17-T:6UA=&5D('!A>6UE;G1S(&%R92!D:7-C;W5N=&5D('5S:6YG
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M;VX@;V8@8V]N=&EN9V5N="!C;VYS:61E<F%T:6]N+B`\+W`^#0H\<"!S='EL
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M=&5S+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P131*044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G
M86YI>F%T:6]N(&%N9"!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M("A0;VQI8VEE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F%T=7)E(&]F($)U<VEN97-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z-G!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<W1Y;&4Z
M:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DYA='5R92!O9B!"=7-I;F5S<R`\+W`^
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M:71S('!R;W!R:65T87)Y($1Y;F%M:6,@4&]L>6-O;FIU9V%T92`H1%!#*2!D
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M:71Y(&%N9"!O;F-O;&]G>2X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C9P=#MT97AT+6EN9&5N=#HT+C4T)3MF;VYT
M+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S
M<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,:7%U:61I='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HQ.'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<W1Y;&4Z
M:71A;&EC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQI<75I9&ET>2`\+W`^#0H\<"!S='EL
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M97%U:71Y('-E8W5R:71I97,N)FYB<W`[)FYB<W`[4F5S96%R8V@@86YD(&1E
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M=69A8W1U<FEN9R!C;W-T<RXF;F)S<#LF;F)S<#L@/"]P/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.W1E>'0M:6YD
M96YT.C0N-30E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D%T
M($IU;F4@,S`L(#(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^-#PO9F]N=#XL
M('1H92!#;VUP86YY(&AA9"`D,3,X+C,@;6EL;&EO;B!I;B!C87-H('1O(&9U
M;F0@;W!E<F%T:6]N<RX@26X@861D:71I;VX@=&\@:71S(&-A<V@@<F5S;W5R
M8V5S+"!T:&4@0V]M<&%N>2!H87,@:6YV97-T960@97AC97-S(&-A<V@@:6X@
M:6YV97-T;65N="!G<F%D92!C;VUM97)C:6%L(&)O;F1S(&UA='5R:6YG(&EN
M(&QE<W,@=&AA;B`R-R!M;VYT:',N)FYB<W`[)FYB<W`[5&AE<V4@8F]N9',@
M<')O=FED92!A('-O=7)C92!O9B!L:7%U:61I='DL('1H;W5G:"!T:&4@0V]M
M<&%N>2!P;&%N<R!T;R!H;VQD('1H96T@=6YT:6P@;6%T=7)I='DN)FYB<W`[
M)FYB<W`[070@2G5N92`S,"P@,C`Q-"P@=&AE($-O;7!A;GD@:&%D(&EN=F5S
M=&5D("0U,"XQ(&UI;&QI;VX@:6X@8F]N9',N)FYB<W`[)FYB<W`[1'5R:6YG
M('1H92!N:6YE(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T+"!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&-A<V@@<&]S:71I;VX@:6YC<F5A<V5D(&)Y("0Q,3DN
M,B!M:6QL:6]N+"!W:&EC:"!W87,@=&AE(')E<W5L="!O9B!T:&4@<F5C96EP
M="!O9B!C87-H(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&5Q=6ET>2!O9B`D,3<R
M+C8@;6EL;&EO;B!A;F0@8V%S:"!F<F]M('1H92!E>&5R8VES92!O9B!W87)R
M86YT<R!A;F0@;W!T:6]N<R!O9B`D,3(N-"!M:6QL:6]N+"!P87)T:6%L;'D@
M;V9F<V5T(&)Y(&YE="!C87-H(&EN=F5S=&5D(&EN(&9I>&5D(&EN8V]M92!I
M;G9E<W1M96YT<R!O9B`D,SDN."!M:6QL:6]N+"!C87-H(&]U=&9L;W=S(&]F
M("0R-"XU(&UI;&QI;VX@<F5L871E9"!T;R!C;VYT:6YU:6YG(&]P97)A=&EN
M9R!A8W1I=FET:65S(&%N9"!C87!I=&%L(&5X<&5N9&ET=7)E<R!O9B`D/&9O
M;G0@<W1Y;&4],T1C;VQO<CHC.SXQ+C,\+V9O;G0^(&UI;&QI;VXN(#PO<#X\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S='EL93TS1"=M87)G
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M=VAE860@86YD(&ET<R!3=6)S:61I87)I97,N)FYB<W`[)FYB<W`[07)R;W=H
M96%D)B,X,C$W.W,@<')I;6%R>2!O<&5R871I;F<@<W5B<VED:6%R>2!I<R!!
M<G)O=VAE860@36%D:7-O;BP@=VAI8V@@:7,@;&]C871E9"!I;B!-861I<V]N
M+"!7:7-C;VYS:6XL('=H97)E('1H92!#;VUP86YY)B,X,C$W.W,@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&9A8VEL:71I97,@87)E(&QO8V%T960N)FYB
M<W`[)FYB<W`[06QL('-I9VYI9FEC86YT(&EN=&5R8V]M<&%N>2!A8V-O=6YT
M<R!A;F0@=')A;G-A8W1I;VYS(&%R92!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED
M871I;VXL(&%N9"!N;VXM8V]N=')O;&QI;F<@:6YT97)E<W1S(&%R92!A8V-O
M=6YT960@9F]R(&EN('1H92!#;VUP86YY)B,X,C$W.W,@9FEN86YC:6%L('-T
M871E;65N=',N(#PO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S='EL
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M(&EN<W1R=6-T:6]N<R!T;R!&;W)M)B,Q-C`[,3`M42!A;F0@07)T:6-L928C
M,38P.S@@;V8@4F5G=6QA=&EO;B!3+5@N)FYB<W`[)FYB<W`[06-C;W)D:6YG
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M8G-P.U1H92!397!T96UB97(@,S`L(#(P,3,@0V]N<V]L:61A=&5D($)A;&%N
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M,38P.S,P+"`R,#$S+B9N8G-P.R9N8G-P.T-E<G1A:6X@<F5C;&%S<VEF:6-A
M=&EO;G,@:&%V92!B965N(&UA9&4@=&\@<')I;W(@<&5R:6]D(&9I;F%N8VEA
M;"!S=&%T96UE;G1S('1O(&-O;F9O<FT@=&\@=&AE(&-U<G)E;G0@<&5R:6]D
M('!R97-E;G1A=&EO;BXF;F)S<#LF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@
M17-T:6UA=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<W`[)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S
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M>2!H860@;F\@<F5S=')I8W1E9"!C87-H(&%T($IU;F4@,S`L(#(P,30@86YD
M(%-E<'1E;6)E<B`S,"P@,C`Q,RX\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T:6]N
M(&]F($-R961I="!2:7-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
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M24,I(&9O<B!U<"!T;R`D,C4P+#`P,"!P97(@86-C;W5N="X@36%N86=E;65N
M="!B96QI979E<R!T:&4@0V]M<&%N>2!I<R!N;W0@97AP;W-E9"!T;R!S:6=N
M:69I8V%N="!C<F5D:70@<FES:R!D=64@=&\@=&AE(&9I;F%N8VEA;"!P;W-I
M=&EO;B!O9B!T:&4@9&5P;W-I=&]R>2!I;G-T:71U=&EO;G,@:6X@=VAI8V@@
M=&AE<V4@9&5P;W-I=',@87)E(&AE;&0N(#PO<#X\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF
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M=VET:"!&05-"($%30R`S,C`L($EN=F5S=&UE;G1S("8C.#(Q,3L@1&5B="!A
M;F0@17%U:71Y(%-E8W5R:71I97,N)B,Q-C`[5&AI<R!S=&%T96UE;G0@<F5Q
M=6ER97,@8V5R=&%I;B!S96-U<FET:65S('1O(&)E(&-L87-S:69I960@:6YT
M;R!T:')E92!C871E9V]R:65S.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
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M.VUA<F=I;BUT;W`Z-G!T.VUA<F=I;BUL969T.C0N-30E.W1E>'0M:6YD96YT
M.C`E.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
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M<V5S(&EN8VQU9&5D(&EN(&5A<FYI;F=S+B`\+W`^#0H\<"!S='EL93TS1"=M
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M(S@R,3<[(&5Q=6ET>2X@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M:65S+B!!="`\9F]N="!S='EL93TS1&-O;&]R.B,[/DIU;F4@,S`L(#(P,30\
M+V9O;G0^+"!T:&4@0V]M<&%N>2!C;&%S<VEF:65D(&%L;"!O9B!I=',@:6YV
M97-T;65N=',@87,@:&5L9"UT;RUM871U<FET>2X@/"]P/@T*/'`@<W1Y;&4]
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M(&EN($YO=&4@,B`F(S@R,3$[($EN=F5S=&UE;G1S+B`@/"]P/@T*/'`@<W1Y
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M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#MT97AT+6EN9&5N=#HT
M+C4T)3LG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0F(S@R,3([4')O<&5R='D@
M86YD(&5Q=6EP;65N="!A<F4@<F5C;W)D960@870@8V]S="P@=VAI8V@@;6%Y
M(&5Q=6%L(&9A:7(@;6%R:V5T('9A;'5E(&EN('1H92!C87-E(&]F('!R;W!E
M<G1Y(&%N9"!E<75I<&UE;G0@86-Q=6ER960@:6X@8V]N:G5N8W1I;VX@=VET
M:"!A(&)U<VEN97-S(&%C<75I<VET:6]N+B!$97!R96-I871I;VX@;V8@<')O
M<&5R='D@86YD(&5Q=6EP;65N="!I<R!R96-O<F1E9"!U<VEN9R!T:&4@<W1R
M86EG:'0M;&EN92!M971H;V0@;W9E<B!T:&4@<F5S<&5C=&EV92!U<V5F=6P@
M;&EV97,@;V8@=&AE(&%S<V5T<R!R86YG:6YG(&9R;VT@=&AR964@=&\@<V5V
M96X@>65A<G,N($QE87-E:&]L9"!I;7!R;W9E;65N=',@87)E(&%M;W)T:7IE
M9"!O=F5R('1H92!L97-S97(@;V8@=&AE(&5X<&5C=&5D('5S969U;"!L:69E
M(&]R('1H92!R96UA:6YI;F<@;&5A<V4@=&5R;2X@3&]N9RUL:79E9"!A<W-E
M=',L(&EN8VQU9&EN9R!P<F]P97)T>2!A;F0@97%U:7!M96YT(&%R92!R979I
M97=E9"!F;W(@:6UP86ER;65N="!W:&5N979E<B!E=F5N=',@;W(@8VER8W5M
M<W1A;F-E<R!I;F1I8V%T92!T:&%T('1H92!C87)R>6EN9R!A;6]U;G0@;V8@
M=&AE<V4@87-S971S(&UA>2!N;W0@8F4@<F5C;W9E<F%B;&4N(#PO<#X\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&%N9VEB;&4@07-S971S('-U8FIE8W0@=&\@86UO<G1I>F%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26XM
M4')O8V5S<R!297-E87)C:"`F86UP.R!$979E;&]P;65N="`H25!2)F%M<#M$
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.W1E>'0M:6YD96YT.C0N-30E
M.R<^26XM4')O8V5S<R!297-E87)C:"8C,38P.R9A;7`[($1E=F5L;W!M96YT
M("A)4%(F86UP.T0I)B,X,C$R.TE04B9A;7`[1"!A<W-E=',@<F5P<F5S96YT
M(&-A<&ET86QI>F5D(&]N+6=O:6YG(')E<V5A<F-H('!R;VIE8W1S('1H870@
M07)R;W=H96%D(&%C<75I<F5D('1H<F]U9V@@8G5S:6YE<W,@8V]M8FEN871I
M;VYS+B!3=6-H(&%S<V5T<R!A<F4@:6YI=&EA;&QY(&UE87-U<F5D(&%T('1H
M96ER(&%C<75I<VET:6]N(&1A=&4@9F%I<B!V86QU97,N(%1H92!A;6]U;G1S
M(&-A<&ET86QI>F5D(&%R92!B96EN9R!A8V-O=6YT960@9F]R(&%S(&EN9&5F
M:6YI=&4M;&EV960@:6YT86YG:6)L92!A<W-E=',L('-U8FIE8W0@=&\@:6UP
M86ER;65N="!T97-T:6YG('5N=&EL(&-O;7!L971I;VX@;W(@86)A;F1O;FUE
M;G0@;V8@4B9A;7`[1"!E9F9O<G1S(&%S<V]C:6%T960@=VET:"!T:&4@<')O
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M9"!S=&5P+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT($-O;G-I9&5R871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#MT97AT+6EN9&5N=#HT+C4T)3LG
M/D-O;G1I;F=E;G0@0V]N<VED97)A=&EO;B`M(%1H92!C;VYS:61E<F%T:6]N
M(&9O<B!O=7(@86-Q=6ES:71I;VYS(&]F=&5N(&EN8VQU9&5S(&9U='5R92!P
M87EM96YT<R!T:&%T(&%R92!C;VYT:6YG96YT('5P;VX@=&AE(&]C8W5R<F5N
M8V4@;V8@82!P87)T:6-U;&%R(&5V96YT+B9N8G-P.R9N8G-P.T9O<B!E>&%M
M<&QE+"!M:6QE<W1O;F4@<&%Y;65N=',@;6EG:'0@8F4@8F%S960@;VX@=&AE
M(&%C:&EE=F5M96YT(&]F('9A<FEO=7,@<F5G=6QA=&]R>2!A<'!R;W9A;',@
M;W(@9G5T=7)E('-A;&5S(&UI;&5S=&]N97,L(&%N9"!R;WEA;'1Y('!A>6UE
M;G1S(&UI9VAT(&)E(&)A<V5D(&]N(&1R=6<@<')O9'5C="!S86QE<R!L979E
M;',N(%1H92!#;VUP86YY(')E8V]R9',@82!C;VYT:6YG96YT(&-O;G-I9&5R
M871I;VX@;V)L:6=A=&EO;B!F;W(@<W5C:"!C;VYT:6YG96YT('!A>6UE;G1S
M(&%T(&9A:7(@=F%L=64@;VX@=&AE(&%C<75I<VET:6]N(&1A=&4N(%1H92!#
M;VUP86YY(&5S=&EM871E<R!T:&4@9F%I<B!V86QU92!O9B!C;VYT:6YG96YT
M(&-O;G-I9&5R871I;VX@;V)L:6=A=&EO;G,@=&AR;W5G:"!V86QU871I;VX@
M;6]D96QS(&1E<VEG;F5D('1O(&5S=&EM871E('1H92!P<F]B86)I;&ET>2!O
M9B!S=6-H(&-O;G1I;F=E;G0@<&%Y;65N=',@8F%S960@;VX@=F%R:6]U<R!A
M<W-U;7!T:6]N<R!A;F0@:6YC;W)P;W)A=&EN9R!E<W1I;6%T960@<W5C8V5S
M<R!R871E<RXF;F)S<#LF;F)S<#M%<W1I;6%T960@<&%Y;65N=',@87)E(&1I
M<V-O=6YT960@=7-I;F<@<')E<V5N="!V86QU92!T96-H;FEQ=65S('1O(&%R
M<FEV92!A="!E<W1I;6%T960@9F%I<B!V86QU92!A="!T:&4@8F%L86YC92!S
M:&5E="!D871E+B!#:&%N9V5S(&EN('1H92!F86ER('9A;'5E(&]F(&]U<B!C
M;VYT:6YG96YT(&-O;G-I9&5R871I;VX@;V)L:6=A=&EO;G,@87)E(')E8V]G
M;FEZ960@=VET:&EN(&]U<B!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!O
M<&5R871I;VYS+B!#:&%N9V5S(&EN('1H92!F86ER('9A;'5E(&]F('1H92!C
M;VYT:6YG96YT(&-O;G-I9&5R871I;VX@;V)L:6=A=&EO;G,@8V%N(')E<W5L
M="!F<F]M(&-H86YG97,@=&\@;VYE(&]R(&UU;'1I<&QE(&EN<'5T<RP@:6YC
M;'5D:6YG(&%D:G5S=&UE;G1S('1O('1H92!D:7-C;W5N="!R871E<RP@8VAA
M;F=E<R!I;B!T:&4@86UO=6YT(&]R('1I;6EN9R!O9B!E>'!E8W1E9"!E>'!E
M;F1I='5R97,@87-S;V-I871E9"!W:71H('!R;V1U8W0@9&5V96QO<&UE;G0L
M(&-H86YG97,@:6X@=&AE(&%M;W5N="!O<B!T:6UI;F<@;V8@8V%S:"!F;&]W
M<R!F<F]M('!R;V1U8W1S('5P;VX@8V]M;65R8VEA;&EZ871I;VXL(&-H86YG
M97,@:6X@=&AE(&%S<W5M960@86-H:65V96UE;G0@;W(@=&EM:6YG(&]F(&%N
M>2!D979E;&]P;65N="!M:6QE<W1O;F5S+"!C:&%N9V5S(&EN('1H92!P<F]B
M86)I;&ET>2!O9B!C97)T86EN(&-L:6YI8V%L(&5V96YT<R!A;F0@8VAA;F=E
M<R!I;B!T:&4@87-S=6UE9"!P<F]B86)I;&ET>2!A<W-O8VEA=&5D('=I=&@@
M<F5G=6QA=&]R>2!A<'!R;W9A;"X@5&AE<V4@9F%I<B!V86QU92!M96%S=7)E
M;65N=',@87)E(&)A<V5D(&]N('-I9VYI9FEC86YT(&EN<'5T<R!N;W0@;V)S
M97)V86)L92!I;B!T:&4@;6%R:V5T+B!3=6)S=&%N=&EA;"!J=61G;65N="!I
M<R!E;7!L;WEE9"!I;B!D971E<FUI;FEN9R!T:&4@87!P<F]P<FEA=&5N97-S
M(&]F('1H97-E(&%S<W5M<'1I;VYS(&%S(&]F('1H92!A8W%U:7-I=&EO;B!D
M871E(&%N9"!F;W(@96%C:"!S=6)S97%U96YT('!E<FEO9"X@06-C;W)D:6YG
M;'DL(&-H86YG97,@:6X@87-S=6UP=&EO;G,@8V]U;&0@:&%V92!A(&UA=&5R
M:6%L(&EM<&%C="!O;B!T:&4@86UO=6YT(&]F(&-O;G1I;F=E;G0@8V]N<VED
M97)A=&EO;B!E>'!E;G-E('1H92!#;VUP86YY(')E8V]R9',@:6X@86YY(&=I
M=F5N('!E<FEO9"X\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YO<FET>2!%<75I='D@26YV97-T
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HQ,G!T
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M;GDN)FYB<W`[)FYB<W`[0F%S960@;VX@=&AE('-T871U<R!O9B!T:&4@9&5V
M96QO<&UE;G0@;V8@3&5O;F%R9&\F(S@R,3<[<R!P<F]G<F%M+"!T:&ES(&EN
M=F5S=&UE;G0@:&%S(&)E96X@9G5L;'D@:6UP86ER960@86YD('1H92!N970@
M8F]O:R!V86QU92!A="!*=6YE(#,P+"`R,#$T(&ES("0P+B9N8G-P.R9N8G-P
M.U1H92!O<&5R871I;VYS(&]F($QE;VYA<F1O(&-E87-E9"!I;B!$96-E;6)E
M<B`R,#$S+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYC;VYT<F]L;&EN9R!);G1E<F5S=',@
M:6X@36%J;W)I='DM3W=N960@4W5B<VED:6%R:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P=#MF;VYT
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M="!I;B!A8V-O<F1A;F-E('=I=&@@1D%30B!!4T,@.#$P+3$P+B`\+W`^#0H\
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M>28C.#(Q-SMS($%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L+B`\+W`^/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y2979E;G5E(%)E8V]G;FET:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL
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M;'1Y(&]R('!R;V9I="US:&%R:6YG('!A>6UE;G1S+B`\+W`^#0H\<"!S='EL
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M;VT@=7`M9G)O;G0@;&EC96YS92!F965S+"!M:6QE<W1O;F5S(&%N9"!P<F]D
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M;G5E+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R($1O=6)T9G5L($%C8V]U
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@86YD($1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL
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M;F-E('=I=&@@1D%30B!!4T,@-S,P+3$P+B`\+W`^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%87)N:6YG
M<R`H3&]S<RD@<&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M=&5X="UI;F1E;G0Z-"XU-"4[)SY%87)N:6YG<R`H3&]S<RD@<&5R(%-H87)E
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M;7!A;GDN)FYB<W`[)FYB<W`[(#PO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C$R<'0[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.W1E>'0M:6YD
M96YT.C0N-30E.R<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N)B,X,C$R.U1H
M92!#;VUP86YY(&%C8V]U;G1S(&9O<B!S:&%R92UB87-E9"!C;VUP96YS871I
M;VX@87)R86YG96UE;G1S(&EN(&%C8V]R9&%N8V4@=VET:"!&05-"($%30R`W
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5R:79A=&EV92!!<W-E=',@86YD($QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[=&5X="UI;F1E;G0Z-"XU-"4[)SY$97)I
M=F%T:79E($%S<V5T<R!A;F0@3&EA8FEL:71I97,@)B,X,C$Q.R!4:&4@0V]M
M<&%N>2!A8V-O=6YT<R!F;W(@=V%R<F%N=',@86YD(&]T:&5R(&1E<FEV871I
M=F4@9FEN86YC:6%L(&EN<W1R=6UE;G1S(&%S(&5I=&AE<B!E<75I='D@;W(@
M87-S971S+VQI86)I;&ET:65S(&)A<V5D('5P;VX@=&AE(&-H87)A8W1E<FES
M=&EC<R!A;F0@<')O=FES:6]N<R!O9B!E86-H(&EN<W1R=6UE;G0N(%=A<G)A
M;G1S(&-L87-S:69I960@87,@97%U:71Y(&%R92!R96-O<F1E9"!A<R!A9&1I
M=&EO;F%L('!A:60M:6X@8V%P:71A;"!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS
M($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T(&%N9"!N;R!F=7)T:&5R(&%D
M:G5S=&UE;G1S('1O('1H96ER('9A;'5A=&EO;B!A<F4@;6%D92X@4V]M92!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS('=A<G)A;G1S('=E<F4@9&5T97)M:6YE
M9"!T;R!B92!I;F5L:6=I8FQE(&9O<B!E<75I='D@8VQA<W-I9FEC871I;VX@
M8F5C875S92!O9B!P<F]V:7-I;VYS('1H870@;6%Y(')E<W5L="!I;B!A;B!A
M9&IU<W1M96YT('1O('1H96ER(&5X97)C:7-E('!R:6-E+B!787)R86YT<R!C
M;&%S<VEF:65D(&%S(&1E<FEV871I=F4@;&EA8FEL:71I97,@86YD(&]T:&5R
M(&1E<FEV871I=F4@9FEN86YC:6%L(&EN<W1R=6UE;G1S('1H870@<F5Q=6ER
M92!S97!A<F%T92!A8V-O=6YT:6YG(&%S(&%S<V5T<R!O<B!L:6%B:6QI=&EE
M<R!A<F4@<F5C;W)D960@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!#;VYS;VQI
M9&%T960@0F%L86YC92!3:&5E="!A="!T:&5I<B!F86ER('9A;'5E(&]N('1H
M92!D871E(&]F(&ES<W5A;F-E(&%N9"!A<F4@<F5V86QU960@;VX@96%C:"!S
M=6)S97%U96YT(&)A;&%N8V4@<VAE970@9&%T92!U;G1I;"!S=6-H(&EN<W1R
M=6UE;G1S(&%R92!E>&5R8VES960@;W(@97AP:7)E+"!W:71H(&%N>2!C:&%N
M9V5S(&EN('1H92!F86ER('9A;'5E(&)E='=E96X@<F5P;W)T:6YG('!E<FEO
M9',@<F5C;W)D960@87,@;W1H97(@:6YC;VUE(&]R(&5X<&5N<V4N(%1H92!#
M;VUP86YY(&5S=&EM871E<R!T:&4@9F%I<B!V86QU92!O9B!T:&5S92!A<W-E
M=',O;&EA8FEL:71I97,@=7-I;F<@;W!T:6]N('!R:6-I;F<@;6]D96QS('1H
M870@87)E(&)A<V5D(&]N('1H92!I;F1I=FED=6%L(&-H87)A8W1E<FES=&EC
M<R!O9B!T:&4@=V%R<F%N=',@;W(@:6YS=')U;65N=',@;VX@=&AE('9A;'5A
M=&EO;B!D871E+"!A<R!W96QL(&%S(&%S<W5M<'1I;VYS(&9O<B!E>'!E8W1E
M9"!V;VQA=&EL:71Y+"!E>'!E8W1E9"!L:69E(&%N9"!R:7-K+69R964@:6YT
M97)E<W0@<F%T92X@/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P
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M:65S(&1U<FEN9R!T:&4@<&5R:6]D+B`\+W`^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E;G1L>2!)
M<W-U960@06-C;W5N=&EN9R!3=&%N9&%R9',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HQ.'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY296-E;G1L>2!)<W-U960@06-C;W5N
M=&EN9R!3=&%N9&%R9',@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HV<'0[9F]N="US:7IE.C$P<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.W1E>'0M:6YD96YT.C0N-30E.R<^26X@2G5N92`R,#$T+"!T:&4@
M1D%30B!I<W-U960@05-5(#(P,30M,3`L(#QF;VYT('-T>6QE/3-$9F]N="US
M='EL93II=&%L:6,[/D1E=F5L;W!M96YT(%-T86=E($5N=&ET:65S("A4;W!I
M8R`Y,34I.B!%;&EM:6YA=&EO;B!O9B!#97)T86EN($9I;F%N8VEA;"!297!O
M<G1I;F<@4F5Q=6ER96UE;G1S+"!);F-L=61I;F<@86X@06UE;F1M96YT('1O
M(%9A<FEA8FQE($EN=&5R97-T($5N=&ET:65S($=U:61A;F-E/"]F;VYT/BP@
M=VAI8V@@96QI;6EN871E<R!T:&4@9&ES=&EN8W1I;VX@86YD('-E<&%R871E
M(')E<75I<F5M96YT<R!F;W(@9&5V96QO<&UE;G0@<W1A9V4@96YT:71I97,@
M86YD(&]T:&5R(')E<&]R=&EN9R!E;G1I=&EE<R!U;F1E<B!5+E,N($=!05`N
M)FYB<W`[)FYB<W`[4W!E8VEF:6-A;&QY('1H92!A;65N9&UE;G0@96QI;6EN
M871E<R!T:&4@<F5Q=6ER96UE;G0@9F]R(&1E=F5L;W!M96YT('-T86=E(&5N
M=&ET:65S('1O(#$I('!R97-E;G0@:6YC97!T:6]N+71O+61A=&4@:6YF;W)M
M871I;VX@:6X@=&AE('-T871E;65N=',@;V8@:6YC;VUE+"!C87-H(&9L;W<@
M86YD('-H87)E:&]L9&5R<R8C.#(Q-SL@97%U:71Y+"`R*2!L86)E;"!T:&4@
M9FEN86YC:6%L('-T871E;65N=',@87,@=&AO<V4@;V8@82!D979E;&]P;65N
M="!S=&%G92!E;G1I='DL(#,I(&1I<V-L;W-E(&$@9&5S8W)I<'1I;VX@;V8@
M=&AE(&1E=F5L;W!M96YT('-T86=E(&%C=&EV:71I97,@:6X@=VAI8V@@=&AE
M(&5N=&ET>2!I<R!E;F=A9V5D(&%N9"`T*2!D:7-C;&]S92!T:&4@9FER<W0@
M>65A<B!I;B!W:&EC:"!T:&4@96YT:71Y(&ES(&YO(&QO;F=E<B!A(&1E=F5L
M;W!M96YT('-T86=E(&5N=&ET>2!T:&%T(&EN('!R:6]R('EE87)S(&ET(&AA
M9"!B965N(&EN('1H92!D979E;&]P;65N="!S=&%G92XF;F)S<#LF;F)S<#M!
M4U4@,C`Q-"TQ,"!I<R!E9F9E8W1I=F4@9F]R(&9I<V-A;"!Y96%R<R!B96=I
M;FYI;F<@869T97(@1&5C96UB97(@,34L(#(P,30@=VET:"!E87)L>2!A9&]P
M=&EO;B!P97)M:71T960N)FYB<W`[)FYB<W`[5&AE($-O;7!A;GD@:&%S(&%D
M;W!T960@05-5(#(P,30M,3`@969F96-T:79E;'D@=VET:"!T:&4@9FEL:6YG
M(&]F('1H:7,@1F]R;2`Q,"U1+B9N8G-P.R9N8G-P.SPO<#X-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN
M9&5N=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY)
M;B!-87D@,C`Q-"P@=&AE($9!4T(@:7-S=65D($%352!.;RX@,C`Q-"TP.2`\
M9F]N="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC.SY2979E;G5E(&9R;VT@
M0V]N=')A8W1S('=I=&@@0W5S=&]M97)S("A4;W!I8R`V,#8I/"]F;VYT/BP@
M=VAI8V@@=VEL;"!S=7!E<G-E9&4@;F5A<FQY(&%L;"!E>&ES=&EN9R!R979E
M;G5E(')E8V]G;FET:6]N(&=U:61A;F-E('5N9&5R($=!05`N($%352!.;RX@
M,C`Q-"TP.2!P<F]V:61E<R!T:&%T(&%N(&5N=&ET>2!R96-O9VYI>F4@<F5V
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M(&]B=&%I;B!O<B!F=6QF:6QL(&$@8V]N=')A8W0N($%352!.;RX@,C`Q-"TP
M.2!A;&QO=W,@9F]R(&5I=&AE<B!F=6QL(')E=')O<W!E8W1I=F4@;W(@;6]D
M:69I960@<F5T<F]S<&5C=&EV92!A9&]P=&EO;B!A;F0@=VEL;"!B96-O;64@
M969F96-T:79E(&9O<B!T:&4@0V]M<&%N>2!I;B!T:&4@9FER<W0@<75A<G1E
M<B!O9B`R,#$X+B!4:&4@0V]M<&%N>2!I<R!E=F%L=6%T:6YG('1H92!P;W1E
M;G1I86P@969F96-T<R!O9B!T:&4@861O<'1I;VX@;V8@=&AI<R!U<&1A=&4@
M;VX@:71S(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MT97AT+6EN9&5N
M=#HT+C4T)3MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY);B!*
M=6QY(#(P,3,L('1H92!&05-"(&ES<W5E9"!!4U4@,C`Q,RTQ,2P@/&9O;G0@
M<W1Y;&4],T1F;VYT+7-T>6QE.FET86QI8SL^26YC;VUE(%1A>&5S("A4;W!I
M8R`W-#`I.B!0<F5S96YT871I;VX@;V8@86X@56YR96-O9VYI>F5D(%1A>"!"
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M9G1E<B!$96-E;6)E<B`Q-2P@,C`Q,R!A;F0@:6YT97)I;2!P97)I;V1S('=I
M=&AI;B!T:&]S92!Y96%R<RX@16%R;'D@861O<'1I;VX@:7,@<&5R;6ET=&5D
M+B!4:&4@0V]M<&%N>2!I<R!E=F%L=6%T:6YG('1H92!I;7!A8W0L(&EF(&%N
M>2P@;V8@=&AE(&%D;W!T:6]N(&]F($%352`R,#$S+3$Q(&]N(&ET<R!#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E="X\+W`^/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,C(Y8F$Y,E\V8F8U7S0V
M9CA?869F.%\W,31F-S@W9#@W.3@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX+U=O
M<FMS:&5E=',O4VAE970R,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DEN=F5S=&UE;G1S("A486)L97,I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@4VAO<G0@
M86YD($QO;F<M=&5R;2!);G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
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M;F<M=&5R;2!I;G9E<W1M96YT<R!A<R!O9B!*=6YE(#,P+"`R,#$T+"!A;F0@
M4V5P=&5M8F5R(#,P+"`R,#$S+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\9&EV
M/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P
M<V4Z8V]L;&%P<V4[('=I9'1H.CDR)3LG/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C0Q)3L^#0H\<"!S='EL93TS1'1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,30@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^07,@;V8@2G5N92`S
M,"P@,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ
M93HX<'0[/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@<W1Y;&4],T1T
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW
M96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
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M($-O<W0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ93HX<'0[/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
M<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
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M93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY'<F]S<R!5
M;G)E86QI>F5D($QO<W-E<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE
M.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY&
M86ER(%9A;'5E/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US
M:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
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M;"!N;W1E<R`H9'5E('=I=&AI;B!O;F4@>65A<BD\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
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M,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
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M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O
M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[
M9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#(S-RPQ.#$\+W`^
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M<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C,L-3DY+#`W
M-SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE
M/3-$)W=I9'1H.C0Q)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R+C(U<'0[.W1E>'0M:6YD96YT
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M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(V+#(X-"PX
M-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C,L.#DY/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
M<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXH,34R+#(R,CPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXI/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(V+#$S-BPU.3D\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^-3`L,3$Y+#(W,#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE
M.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS
M1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ
M,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R
M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[9F]N="US
M:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#,X.2PT,#,\+W`^/"]T9#X-
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY,B4[)SX-
M"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,24[
M/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#$T('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/D%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C0Q)3L^#0H\<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT
M+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG
M:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[.V9O;G0M<VEZ93HX<'0[/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
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M.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[.V9O;G0M<VEZ93HX<'0[/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D9A:7(@5F%L=64\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\
M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXY+#`S,"PR
M-C$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT
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M9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
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M='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B@S.2PR.#$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
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M;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT
M<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-#$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y
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M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ
M,'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF(S@R,3([/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z,3!P=#L[/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXH,BPS-C(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
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M1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXQ+#8Y.2PW.3$\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1T;W`@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HT,24[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HQ
M,BXR-7!T.SMT97AT+6EN9&5N=#HM,3(N,C5P=#L[9F]N="US:7IE.C$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^5&]T86P\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R
M9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID
M;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,3`L-S,R+#0Q-#PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="US:7IE.C$P<'0[.SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ,'!T.SL^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S
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M:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C<L
M-3`P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXI/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+7-I>F4Z,3!P=#L[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@
M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ,"PV.3@L,C<Q/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X,C(Y8F$Y
M,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X
M-V0X-SDX+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9I>&5D($%S<V5T<R`H5&%B;&5S*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y
M(&]F(%!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE
M.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/@T*/&1I=CX-"CQT
M86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O
M;&QA<'-E.R!W:61T:#HW-B4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW
M-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED
M=&@Z-3$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY"86QA;F-E(&%S
M(&]F/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$<&%D
M9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O
M<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H.C$E.W=H:71E+7-P
M86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UW96EG:'0Z8F]L9#MC;VQO<CHC.V9O;G0M<VEZ93HX<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P
M=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T;VTZ,'!T.W=I9'1H
M.C4Q)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L
M;W(Z(SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DIU;F4@,S`L(#(P,30\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6QE
M9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P
M=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE
M.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG
M:'0Z,"XW-7!T.W!A9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V-O;&]R.B,[9F]N="US:7IE.CAP=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E-E<'1E
M;6)E<B`S,"P@,C`Q,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'!A9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[
M<&%D9&EN9RU4;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[8V]L;W(Z(SMF;VYT+7-I
M>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A9&1I;F<M
M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4;W`Z,"XW
M-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,24[/@T*/'`@<W1Y;&4]
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
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M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
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M.C$P)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1P861D:6YG+6QE9G0Z,'!T.W!A9&1I;F<M4FEG:'0Z,"XW-7!T.W!A
M9&1I;F<M5&]P.C`N-S5P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z-3$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY297-E87)C:"!E<75I<&UE;G0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,3`E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
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M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
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M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'!A
M9&1I;F<M;&5F=#HP<'0[<&%D9&EN9RU2:6=H=#HP+C<U<'0[<&%D9&EN9RU4
M;W`Z,"XW-7!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HU,24[/@T*/'`@
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$P)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXV.2PV,C,\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ07)I86P[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
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M9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP
M+C<U<'0[=VED=&@Z-3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE87-E:&]L
M9"!I;7!R;W9E;65N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXR+#DU-2PR,3<\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M07)I86P[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXR+#<T.2PT,#D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$<&%D9&EN9RUL969T.C!P=#MP861D:6YG
M+5)I9VAT.C`N-S5P=#MP861D:6YG+51O<#HP+C<U<'0[<&%D9&EN9RU";W1T
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M8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@
M,"XW-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C<L
M-C`W+#8P.#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
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M9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
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M<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N-S5P=#MP861D:6YG
M+51O<#HP+C<U<'0[=VED=&@Z-3$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE
M<W,Z)FYB<W`[)FYB<W`[($%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@
M86UO<G1I>F%T:6]N/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
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M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ07)I86P[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
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M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D/@T*/"]T
M<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G<&%D9&EN9RUL969T.C!P=#MP861D:6YG+5)I9VAT.C`N
M-S5P=#MP861D:6YG+51O<#HP+C<U<'0[=VED=&@Z-3$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M-BXX-7!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE="`\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
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M/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T
M(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI=&4M<W!A8V4Z;F]W
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M='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[=VAI
M=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
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M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7=E
M:6=H=#IB;VQD.SMF;VYT+7-I>F4Z,3!P=#L^)FYB<W`[/"]P/CPO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(R.6)A
M.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W
M.#=D.#<Y."]7;W)K<VAE971S+U-H965T,C(N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1A;F=I8FQE($%S<V5T<R`H5&%B
M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M8VAE9'5L92!O9B!);G1A;F=I8FQE($%S<V5T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
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M.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\=&%B;&4@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S
M93L@=VED=&@Z.#0E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z-#8E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP
M861D:6YG+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O
M='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY);G1A;F=I8FQE)B,Q-C`[87-S971S/&9O;G0@<W1Y;&4],T1F;VYT+7=E
M:6=H=#IN;W)M86P[/CQB<B`O/CPO9F]N=#YN;W0@<W5B:F5C="!T;SQB<B`O
M/F%M;W)T:7IA=&EO;CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)B,Q-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG
M+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY);G1A
M;F=I8FQE)B,Q-C`[87-S971S/&)R("\^<W5B:F5C="!T;SQB<B`O/F%M;W)T
M:7IA=&EO;CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG+5)I9VAT.C`N-W!T
M.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY4;W1A;#QB<B`O/DEN=&%N
M9VEB;&4F(S$V,#MA<W-E=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#8E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY"86QA;F-E(&%T(%-E<'1E;6)E<B8C,38P
M.S,P+"`R,#$R/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
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M<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS+#$Q-RPS,C(\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6)O='1O;3HP<'0[9F]N="UW96EG:'0Z8F]L9#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#IS;VQI9"`P
M+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z
M<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$=VED=&@Z-#8E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMC;VQO<CHC.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/DEM<&%I<FUE;G0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/BT\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^*#$L,S`X+#`T-SPO<#X\+W1D/@T*/'1D('9A
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M;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C0V)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/BT\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@R,S8L,#`Y/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HT-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D)A;&%N8V4@870@
M4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G
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M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$R,RPQ.3$\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXS+#(T,"PU,3,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T
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M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B@T,"PY.3`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B@T,"PY.3`\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^*3PO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-#8E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="US:7IE.C$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^0F%L86YC92!A="!*=6YE(#,P+"`R,#$T/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O
M;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RPQ,3<L,S(R/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D
M97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C
M93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB
M;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
M:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^.#(L,C`Q/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R
M87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O
M<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS+#$Y.2PU
M,C,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F
M.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%
M<75I='D@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W5M;6%R>2!O9B!);F9O<FUA=&EO;B!A8F]U="!787)R86YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S
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M(&%B;W5T('=A<G)A;G1S(&]U='-T86YD:6YG(&%T($IU;F4@,S`L(#(P,30Z
M(#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z
M-S8E.R<^#0H\='(^#0H\=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$)W=I9'1H.C4X+C@T)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D5X97)C:7-E)B,Q-C`[<')I8V5S/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z,2XS."4[/@T*
M/'`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UW96EG:'0Z8F]L9#L[9F]N="US:7IE.CAP=#L^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG+5)I9VAT.C`N-W!T
M.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,3<N
M."4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.=6UB97(F(S$V,#MO
M9B8C,38P.SQB<B`O/E=A<G)A;G1S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT-"4[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T
M.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,2XT-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T9#X-"CQT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A
M9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ-RXW."4[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M=&@Z,2XS,B4[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
M/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I
M9'1H.C$N.3@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ
M,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z."XU-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[9F]N="US:7IE
M.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-S`N-C`\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HT."XR."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
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M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XS."4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ-BXT,B4[/@T*/'`@<W1Y
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
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M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XS-B4[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ-BXT,B4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
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M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4]
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M(&YO<FUA;#LG/C4N,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HT."XR."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ-BXT,B4[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/C0Q-BPR,C4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ+C0T)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C0T)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$N,S8E.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,38N-#(E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXQ+C(\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C,R
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XY."4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HX+C4V)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXU+C`Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
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M/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^
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M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR.3$L,C`T/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,2XT-"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XT-"4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MT97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ+C,V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C$V+C0R)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C$N.3@E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$=VED=&@Z."XU-B4[/@T*/'`@<W1Y;&4],T0G=&5X
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)R`O/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C,X)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$V+C0R)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C0L,S(T/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT
M-"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
M=&@Z,2XT-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MT97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ+C,V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$V+C0R
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
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M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'=I9'1H.C$N.3@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD
M96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$=&]P(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z."XU-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#L[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-"XQ-CPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C0X+C(X)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)R`O/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XS."4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,X
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
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M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,2PP,#`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C0T)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
M=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ+C0T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
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M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
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M="UV87)I86YT.B!N;W)M86P[)SXR+C4\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,R
M)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$=VED=&@Z,2XY."4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI
M;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HX
M+C4V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXS+C(U/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z-#@N,C@E.SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG("\^/"]T9#X-"CQT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[(#PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$V+C0R)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,S,T+#,T-R`\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C0T)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C0T)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$N,S8E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M+C$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HQ+C,R)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M=&]P(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XY."4[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HX+C4V
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
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M;#LG("\^/"]T9#X-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
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M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-S4L,#`P/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,2XT-"4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XT-"4[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MT97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ+C,V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'=I9'1H.C$V+C0R)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z,2XY."4[(&)O<F1E<BUB;W1T;VTZ
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M1"=W:61T:#HX+C4V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/C$N.#,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z-#@N,C@E.R!B;W)D97(M8F]T=&]M
M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<@+SX\+W1D/@T*
M/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HQ+C,X)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$N,S@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-BXT,B4[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E
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M)W=I9'1H.C$N-#0E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$N-#0E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MT
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,2XS-B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-BXT
M,B4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,RXU/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$N,S(E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
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M.R<^5&]T86P@=V%R<F%N=',@;W5T<W1A;F1I;F<\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z
M,2XS."4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,2XS."4[(&)O<F1E<BUT
M;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.R`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,38N-#(E.R!B;W)D
M97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,2XT-"4[(&)O<F1E<BUB;W1T;VTZ
M9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ
M+C,V)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
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M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO
M9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(R.6)A.3)?-F)F
M-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y
M."]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5013X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY,96%S97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5T=7)E($UI;FEM=6T@3&5A
M<V4@4&%Y;65N=',@=6YD97(@0V%P:71A;&EZ960@3&5A<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[=&5X="UI;F1E;G0Z-"XU-"4[)SY!<R!O9B!*
M=6YE(#,P+"`R,#$T+"!F=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<R!D
M=64@:6X@9FES8V%L('EE87)S('5N9&5R(&-A<&ET86QI>F5D(&QE87-E<R!A
M<F4@87,@9F]L;&]W<SH@/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE
M.C$R<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/@T*/&1I=CX-"CQT
M86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O
M;&QA<'-E.R!W:61T:#HU-B4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT-"4[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z
M(SL^-"`H<F5M86EN9&5R(&]F*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI
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M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z-#0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E
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M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
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M)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#0E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z-#0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
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M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
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M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#0E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
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M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#0E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXY-2PQ-S4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
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M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[(#PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXH-#`L-C@Q(#PO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#0E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY0<FEN8VEP86P\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C$L,#(U+#(W.3PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C0T)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C0T)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.;VYC=7)R96YT('!O
M<G1I;VX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
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M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1G5T=7)E($UI;FEM=6T@3&5A<V4@4&%Y;65N
M=',@=6YD97(@3W!E<F%T:6YG($QE87-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C$R<'0[9F]N="US:7IE.C$P<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.W1E>'0M:6YD96YT.C0N-30E.R<^07,@;V8@2G5N92`S,"P@,C`Q
M-"P@9G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',@9'5E(&EN(&9I<V-A
M;"!Y96%R<R!U;F1E<B!O<&5R871I;F<@;&5A<V5S(&%R92!A<R!F;VQL;W=S
M.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E
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M;6%L.R<^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXT("AR96UA:6YD97(@
M;V8I/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C$S-"PQ-C0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO
M<CHC.SXU(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4X,"PV,C8\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*
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M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q
M/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXV(#PO9F]N=#X\+W`^/"]T9#X-"CQT
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M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4Y
M-RPQ.38\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
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M;6%L.R<^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXW(#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C8Q,RPY.#0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1'1O<"!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C0T)3L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N="US:7IE
M.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO
M<CHC.SXX(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C8S."PR,3<\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T
M:#HT-"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q/&9O;G0@<W1Y;&4]
M,T1C;VQO<CHC.SXY(#PO9F]N=#YA;F0@=&AE<F5A9G1E<CPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N
M=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T
M<CX-"CQT<CX-"CQT9"!V86QI9VX],T1T;W`@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G=VED=&@Z-#0E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
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M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC
M;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C(L.3DW
M+#`T.#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?
M-S$T9C<X-V0X-SDX#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R
M,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y."]7;W)K<VAE971S
M+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4U1CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*%1A8FQE<RD\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R:7IE($EN
M9F]R;6%T:6]N(&%B;W5T(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED
M=&@Z.3(E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z-#$E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG
M+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY.=6UB
M97(F(S$V,#MO9CQB<B`O/D]P=&EO;G,\8G(@+SY/=71S=&%N9&EN9SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HP+C=P=#MP861D:6YG+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P
M.C!P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY796EG:'1E9"T\8G(@+SY!=F5R86=E/&)R("\^
M17AE<F-I<V4\8G(@+SY0<FEC93QB<B`O/E!E<B8C,38P.U-H87)E/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M<VEZ93HX
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIC96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN
M9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E=E:6=H=&5D+3QB<B`O/D%V97)A9V4\
M8G(@+SY296UA:6YI;F<\8G(@+SY#;VYT<F%C='5A;#QB<B`O/E1E<FT\+W`^
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M9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V
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M97(M8F]T=&]M.G-O;&ED(#%P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T
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M<VEC/&)R("\^5F%L=64\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^
M#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z-#$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY"86QA;F-E($%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$\9F]N="!S='EL
M93TS1&-O;&]R.B,[/C(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED
M=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^,2PY,3`L-SDT/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-
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M)SXD)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^-BXQ,#PO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^
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M;6%L.R<^)B,Q-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
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M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D=R86YT960\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C$L-3`Y+#$V-CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
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M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C(N,#,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
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M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@
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M>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T
M;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY#86YC96QL960\+W`^/"]T9#X-"CQT
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M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0F(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF(S@R,3([/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[
M=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM
M8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
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M/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^*#8W-2`\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L
M;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXI/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
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M-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
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M;2!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U
M<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&UI9&1L92!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R
M+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1M:61D;&4@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ
M<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W=I9'1H.C0Q)3L@8F]R9&5R+6)O='1O;3IS;VQI
M9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E
M>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SY"86QA;F-E($%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$\9F]N="!S
M='EL93TS1&-O;&]R.B,[/C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RPT
M,3DL,C@U(#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@
M,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/C0N-C@\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A
M<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O
M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ,"4[
M(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M
M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M
M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^.3,P
M+#`P,#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^,30N,#4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O
M;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[
M.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y
M;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N
M;W)M86P[)SY#86YC96QL960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/BD\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
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M=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C0Q)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY%>&5R8VES960\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
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M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
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M;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M
M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4]
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M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C8N,C@\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED
M(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T
M;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E
M;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W=I9'1H.C0Q)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@
M,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY"86QA;F-E($%T($IU;F4@,S`L(#(P,30\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z
M,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXS+#@R,RPV,3(\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B
M;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L
M92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C8N-S4\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H
M.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R
M86YS<&%R96YT.R<^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z
M,3`E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/C,P+#(W,2PP,3$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
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M=#H@;F]R;6%L.R<^17AE<F-I<V%B;&4@070@2G5N92`S,"P@,C`Q-#PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ)3L@
M8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O
M;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$L-3,R+#$X,"`\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN
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M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXU+C@P/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
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M)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#LF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT
M;W`Z9&]U8FQE(#(N-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE
M(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z9&]U8FQE(#(N-7!T(",P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-
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M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P
M="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P,#L@
M8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUT;W`Z
M9&]U8FQE(#(N-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S=6UP=&EO
M;G,@57-E9"!T;R!686QU92!3=&]C:R!/<'1I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[=&5X="UI;F1E;G0Z-"XU-"4[)SY4:&4@87-S=6UP=&EO
M;G,@=7-E9"!T;R!V86QU92!S=&]C:R!O<'1I;VYS(&%R92!A<R!F;VQL;W=S
M.B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E
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M;W1T;VTZ,'!T.W=I9'1H.C,V+C(R)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/DYI;F4@;6]N=&AS)B,Q-C`[96YD960F(S$V,#M*=6YE(#,P+#PO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HV,BXS,B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T1W:61T:#HQ+C0V)3L^#0H\<"!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB
M;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I
M;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ-RXS."4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P
M,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXR,#$\9F]N="!S='EL93TS1&-O;&]R.B,[/C0\+V9O;G0^/&9O;G0@<W1Y
M;&4],T1F;VYT+7=E:6=H=#IN;W)M86P[/B`\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT-B4[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IB;VQD.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D
M:6YG+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O
M;3HP<'0[=VED=&@Z,3<N,S@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#%P="`C
M,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z
M.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^,C`Q/&9O;G0@<W1Y;&4],T1C;VQO<CHC.SXS/"]F;VYT/CQF;VYT('-T
M>6QE/3-$9F]N="UW96EG:'0Z;F]R;6%L.SX@/"]F;VYT/CPO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HV,BXS,B4[/@T*/'`@<W1Y;&4],T0G;6%R
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M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$W+C,X)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF(S@R,3([/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XT-B4[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IB;VQD.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3<N,S@E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C(N,S(E.SX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
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M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,2XX)2!T;R`R+C4E)FYB<W`[
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,2XT-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,3<N,S@E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C`N-R4F(S$V,#L@=&\F(S$V,#LQ+C,E/"]P/CPO=&0^
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M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ-RXS."4[/@T*/'`@
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M0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XT-B4[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIC96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IB;VQD.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3<N,S@E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/C8Y)3PO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HV,BXS,B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^-BXR-2!T;R`Y+C<R/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT-B4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IB;VQD.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3<N,S@E.SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C4N-2!T;R`V
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M9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC
M96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE
M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#@N.3(\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ+C0V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ-RXS."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#$N,C8\+W`^/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W5M;6%R>2!O9B!3:&%R92!!8W1I=FET>2!296QA=&5D('1O
M(%)E<W1R:6-T960@4W1O8VL@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X-
M"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93L@=VED=&@Z-S8E.R<^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C0N-C@E.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG+5)I9VAT.C`N-W!T.W!A9&1I;F<M
M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP<'0[=VED=&@Z,38N-S8E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+7=E:6=H=#IB;VQD.SMF;VYT+7-I>F4Z.'!T.SXF;F)S<#L\+W`^#0H\<"!S
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z.'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`N.38E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HP+C=P=#MP861D:6YG
M+5)I9VAT.C`N-W!T.W!A9&1I;F<M5&]P.C!P=#MP861D:6YG+4)O='1O;3HP
M<'0[=VED=&@Z,3$N.24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE
M.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R<^)B,Q-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,"XW."4[/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^
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M=#H@;F]R;6%L.R<^56YV97-T960@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P
M,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^,SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,2XP."4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1"=W:61T:#HQ-2XW)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U
M<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.R8C,38P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I
M9'1H.C`N.38E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C0E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"XU)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/BT\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L
M;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XS."4[/@T*/'`@<W1Y;&4]
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M1'=I9'1H.C`N-S@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C`N-S8E.W=H:71E+7-P86-E
M.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C0N-C@E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY'<F%N=&5D/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XP."4[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,34N
M-R4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/C0W,"PP,#`\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C,X)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,"XY-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XT)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M,"XU)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/C$T+C4T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,2XS."4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$N,S@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`N-S@E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`N-S8E.W=H
M:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z-C0N-C@E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY697-T960\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C`X)3L^#0H\<"!S='EL93TS
M1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HQ-2XW)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HP+CDV)3L^#0H\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ+C0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
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M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C,X)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HP+C<X)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HP+C<V)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
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M)W=I9'1H.C$N,#@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,34N-R4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN
M;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP+CDV)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ+C0E.R!B;W)D97(M8F]T
M=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C4E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXM/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$N,S@E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N
M<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ+C,X)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP+C<X)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP+C<V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C8T+C8X)3L@8F]R
M9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY5;G9E<W1E9"!A="!*=6YE(#,P+"`R,#$T
M/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&
M,$9#('-T>6QE/3-$)W=I9'1H.C$N,#@E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,34N-R4[(&)O<F1E
M<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U
M8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT-S`L,#`P/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$)W=I9'1H.C$N,S@E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R
M+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1"=W:61T:#HP+CDV)3L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W
M:61T:#HQ+C0E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A
M<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,30N-30\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G
M=VED=&@Z,2XS."4[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T('1R86YS
M<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$)W=I9'1H.C$N,S@E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C`N-S@E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C`N-S8E.R!B;W)D97(M8F]T=&]M
M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/"]D:78^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT
M97AT+6EN9&5N=#HP)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15A*04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!6
M86QU92!-96%S=7)E;65N=',@9F]R($%S<V5T<R!A;F0@3&EA8FEL:71I97,@
M365A<W5R960@870@1F%I<B!686QU92!O;B!296-U<G)I;F<@0F%S:7,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4]
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M<F5M96YT<R!A="!*=6YE(#,P+"`R,#$T(&%N9"!397!T96UB97(F(S$V,#LS
M,"P@,C`Q,R!F;W(@87-S971S(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E9"!A
M="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES.B`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[=&5X
M="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M2G5N92`S,"P@,C`Q-#H@/"]P/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+7-I>F4Z
M,3)P=#L^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HY,B4[
M)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT
M,24[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z
M,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#$\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z
M.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW
M<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#(\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z.'!T
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[
M<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#,\+W`^/"]T9#X-
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M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I
M;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M
M.C!P=#MW:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
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M=&@Z,24[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="US:7IE.CAP=#L^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
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M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
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M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C
M93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
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M<W1Y;&4],T1W:61T:#HT,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^
M#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
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M=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
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M/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
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M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX
M<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
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M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
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M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
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M/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[
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M)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S
M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT+#`Q."PW
M,3D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
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M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
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M;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CPO
M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M-#$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY#;VYT:6YG96YT(&-O
M;G-I9&5R871I;VX@;V)L:6=A=&EO;G,@<F5L871E9"!T;R!A8W%U:7-I=&EO
M;G,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E
M>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y
M;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I
M>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
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M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
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M=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^,2PU.34L,C<S/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W
M<F%P.SX-"CQP('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[9F]N="US:7IE.CAP=#L[/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^/"]D:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C$R<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$P
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^4V5P=&5M8F5R)B,Q-C`[,S`L(#QF;VYT
M('-T>6QE/3-$8V]L;W(Z(SL^,C`Q,SPO9F]N=#XZ(#PO<#X-"CQP('-T>6QE
M/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI;F1E
M;G0Z,"4[9F]N="US:7IE.C$R<'0[/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B
M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z
M,"XW<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T
M:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N
M<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#$\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^
M#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z
M.'!T.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E
M<CMM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S
M<#L\+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW
M<'0[<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ
M)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O
M<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#(\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z.'!T
M.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[
M<&%D9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@
M8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DQE=F5L(#,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S
M='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7-I>F4Z.'!T.SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G
M:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[
M.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D
M9&EN9RU4;W`Z,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ)3L@8F]R
M9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G
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M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F
M=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="US:7IE.CAP=#L^)FYB<W`[
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M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4]
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M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O
M;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW
M:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
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M93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ
M93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G
M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,3DL
M,3$T+#0T-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A
M<#L^#0H\<"!S='EL93TS1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$E.SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)#PO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS
M1&UA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX
M<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
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M=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T
M;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^
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M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
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M<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\
M<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXD/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I
M9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXT+#`Y-BPS-C,\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+7-I>F4Z
M.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG
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M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G
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M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[.SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#MM87)G:6XM
M8F]T=&]M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG
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M"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SXQ+#4Y-2PR-S,\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[
M/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MF;VYT+7-I>F4Z.'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
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M;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C$L
M-3DU+#(W,SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL93TS1&UA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HX<'0[
M.SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO9&EV/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X
M="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;VYC:6QI871I;VX@
M;V8@1&5R:79A=&EV92!!<W-E=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
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M8VEL:6%T:6]N(&]F('1H92!D97)I=F%T:79E(&%S<V5T.B`\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT
M+6EN9&5N=#HP)3MF;VYT+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('=I9'1H.C8X)3LG/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'=I9'1H.C4V)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN9&5N
M=#HM,3)P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5F%L
M=64@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(\+W`^/"]T9#X-"CQT9"!V
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M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[8V]L;W(Z
M(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXR-3`L,C4P/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#
M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P
M.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI
M;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/E)E8V5I<'0@;V8@:6YS=')U;65N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P
M=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C
M.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'=I9'1H.C4V)3L^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HQ,G!T
M.SMT97AT+6EN9&5N=#HM,3)P=#L[8V]L;W(Z(SMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L
M.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV
M87)I86YT.B!N;W)M86P[)SY$96-R96%S92`\9F]N="!S='EL93TS1&-O;&]R
M.B,P,#`P,#`[/FEN('9A;'5E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
M.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#(U,"PR-3`\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
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M-38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V-O;&]R
M.B,[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R
M86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^3F5T('-E='1L
M96UE;G1S/&9O;G0@<W1Y;&4],T1C;VQO<CHC,#`P,#`P.SX\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^)B,X,C$R.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
M<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY686QU92!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN
M;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA
M;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN
M;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
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M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL
M93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO
M<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
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M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C4V)3L@8F]R9&5R+6)O
M='1O;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O
M;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I
M86YT.B!N;W)M86P[)SY.970@<V5T=&QE;65N=',\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T
M;VTZ<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L
M:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT
M<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T0G=VED=&@Z-38E.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T
M<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z
M+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9A;'5E
M(&%T($IU;F4@,S`L(#(P,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E
M<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
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M:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\+W1A8FQE/CPO
M9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[=&5X="UI;F1E;G0Z,"4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;VYC
M:6QI871I;VX@;V8@1&5R:79A=&EV92!,:6%B:6QI='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*/'`@<W1Y;&4],T0G;6%R9VEN
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M:6QI='D@<F5L871E9"!T;R!T:&5S92!W87)R86YT<SH@/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[=&5X="UI
M;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]P/@T*/&1I=CX-"CQT86)L92!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!W:61T:#HV."4[)SX-"CQT<CX-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4]
M,T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z
M+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9A;'5E
M(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z
M,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
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M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[
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M+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4],T0G;6%R
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M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R
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M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z-38E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="!T<F%N<W!A<F5N=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
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M,#`P,#`P.SX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB
M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#,L-S4T+#@P."`\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO
M=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*3PO
M<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/E9A;'5E(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R
M,#$S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXD/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#IS;VQI
M9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-38E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
M<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY#:&%N9V4@:6X@=F%L=64\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
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M;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C4V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P
M+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M
M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R
M;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[
M)SY.970@<V5T=&QE;65N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P
M="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#4L-S@Y+#DX,BD\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O
M<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.W=H:71E+7-P
M86-E.FYO=W)A<#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
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M2G5N92`S,"P@,C`Q-#PO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B
M9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O
M='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z,3`E
M.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R!B;W)D97(M8F]T
M=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT
M97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,RPY
M.#(L,S4Y/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.F1O
M=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-
M"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HU-B4[/@T*/'`@<W1Y;&4],T1M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HQ,G!T.SMT
M97AT+6EN9&5N=#HM,3)P=#L[9F]N="US:7IE.C%P=#L^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*
M/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF
M;VYT+7-I>F4Z,7!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID;W5B;&4@
M,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M<VEZ93HQ
M<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P
M/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\+V1I=CX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT.C`E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!&86ER(%9A;'5E(&]F($-O
M;G1I;F=E;G0@0V]N<VED97)A=&EO;B!/8FQI9V%T:6]N<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C$R<'0[9F]N="US:7IE.C$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.W1E>'0M:6YD96YT.C0N-30E.R<^5&AE(&9O;&QO
M=VEN9R!I<R!A(')E8V]N8VEL:6%T:6]N(&]F(&-O;G1I;F=E;G0@8V]N<VED
M97)A=&EO;B!F86ER('9A;'5E+B`\+W`^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT
M+7-I>F4Z,3)P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S
M<#L\+W`^#0H\9&EV/@T*/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
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M5F%L=64@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3QF;VYT('-T>6QE/3-$
M8V]L;W(Z(SL^,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T
M:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3(N,C5P=#L[=&5X="UI;F1E;G0Z+3$R
M+C(U<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E!U<F-H
M87-E('!R:6-E(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;CPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$P)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
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M<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-C0E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C$R+C(U<'0[.W1E>'0M:6YD96YT.BTQ,BXR-7!T.SMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY#;VYT:6YG96YT(&-O;G-I9&5R
M871I;VX@<&%Y;65N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO
M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ,"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^
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M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW
M96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M
M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D
M97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO
M<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R<^,2PT,C$L-C4R/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T
M<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\
M+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO
M<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G
M;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z
M,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N
M="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA
M;G0Z(&YO<FUA;#LG/E9A;'5E(&%T(%-E<'1E;6)E<B`S,"P@,C`Q/&9O;G0@
M<W1Y;&4],T1C;VQO<CHC.SXS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HQ
M)3L@8F]R9&5R+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y
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M:#HQ,"4[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T(",P,#`P,#`[)SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ+#4Y-2PR-S,\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R
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M=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T
M<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O
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M.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
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M;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
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M.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C8T)3L@8F]R9&5R+6)O='1O
M;3IS;VQI9"`P+C<U<'0@=')A;G-P87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
M<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SY#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!C;VYT:6YG96YT
M(&-O;G-I9&5R871I;VX\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,"4[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O
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M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#MW:&ET92US<&%C93IN;W=R87`[
M)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z-C0E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H
M=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N
M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9A;'5E(&%T($IU;F4@,S`L(#(P
M,30\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#
M1D8P1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW
M-7!T(",P,#`P,#`[(&)O<F1E<BUB;W1T;VTZ9&]U8FQE(#(N-7!T(",P,#`P
M,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B0\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C
M,#`P,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF
M;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R<^,2PU.34L,C<S/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$E
M.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="!T<F%N<W!A<F5N=#MW:&ET
M92US<&%C93IN;W=R87`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^/"]D:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&-H86YG92!R:6=H=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%S<W5M<'1I;VYS(%5S960@:6X@5F%L=6EN9R!$97)I=F%T:79E
M($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B
M;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL
M87!S93L@=VED=&@Z-S8E.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z-S(N,S8E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ8V5N=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA
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M,'!T.W=I9'1H.C$S+C$V)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`Q<'0@(S`P
M,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/DIU;F4@,S`L)B,Q-C`[(#(P,3QF;VYT('-T>6QE/3-$8V]L;W(Z(SL^-#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HQ+C,R)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM
M87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP
M<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C`N-W!T.W!A9&1I;F<M4FEG:'0Z,"XW<'0[<&%D9&EN9RU4;W`Z
M,'!T.W!A9&1I;F<M0F]T=&]M.C!P=#MW:61T:#HQ,RXQ-B4[(&)O<F1E<BUB
M;W1T;VTZ<V]L:60@,7!T(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+7=E:6=H
M=#IB;VQD.V9O;G0M<VEZ93HX<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SY397!T96UB97(F(S$V,#LS,"PF(S$V,#L@
M,C`Q,SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HW,BXS-B4[/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,"XX."4\+W`^/"]T
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M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,RXQ-B4[/@T*/'`@<W1Y;&4],T0G
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M,T1W:61T:#HW,BXS-B4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E
M;G0Z+3$R<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/D5X
M<&5C=&5D(&QI9F4\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HQ,RXQ-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SXS+C4@665A<G,\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C,R)3L^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P
M=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ,RXQ-B4[/@T*/'`@<W1Y;&4]
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M<G,\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-S(N,S8E.SX-"CQP
M('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T.SMF;VYT+7-I>F4Z
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY$:79I9&5N9"!Y:65L9#PO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1'=I9'1H.C$S+C$V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I
M9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN
M;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF
M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DYO;F4\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ
M+C,R)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM
M=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HQ,RXQ-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
M:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[8V]L;W(Z(SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[
M9F]N="UV87)I86YT.B!N;W)M86P[)SY.;VYE/"]P/CPO=&0^#0H\+W1R/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C<R+C,V
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N
M="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^5F]L871I;&ET>3PO<#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C$S+C$V
M)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
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M=&5R.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C$S+C$V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[
M9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A
M<FEA;G0Z(&YO<FUA;#LG/C8Y)3PO<#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M/"]D:78^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-O
M;F-I;&EA=&EO;B!O9B!$97)I=F%T:79E($QI86)I;&ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H\<"!S='EL93TS1"=M87)G
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[=&5X="UI;F1E;G0Z,"4[9F]N="US:7IE.C$R<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/@T*/&1I=CX-"CQT86)L92!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E
M.R!W:61T:#HW-B4[)SX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X
M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9A;'5E
M(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$\9F]N="!S='EL93TS1&-O;&]R
M.B,[/C(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,3`L,S<U/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R
M<'0[.V9O;G0M<VEZ93HQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DES<W5A;F-E
M(&]F(&EN<W1R=6UE;G1S/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,3`E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R
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M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+W1D
M/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HV-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
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M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C$P)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN
M;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^*#4L.#`V/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T
M>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R<^*3PO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T0G=VED=&@Z-C0E
M.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="!T<F%N<W!A<F5N=#LG/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[
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M='EL93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@
M(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R
M9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+6)O='1O;3IS
M;VQI9"`P+C<U<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MC;VQO
M<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/B8C.#(Q,CL\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUB;W1T;VTZ<V]L:60@,"XW
M-7!T('1R86YS<&%R96YT.W=H:71E+7-P86-E.FYO=W)A<#LG/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB<W`[
M/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C8T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HQ,G!T.SMT97AT+6EN
M9&5N=#HM,3)P=#L[9F]N="US:7IE.C$P<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA
M;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^
M5F%L=64@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3QF;VYT('-T>6QE/3-$
M8V]L;W(Z(SL^,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,24[(&)O<F1E<BUT;W`Z<V]L:60@,"XW-7!T
M(",P,#`P,#`[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA
M<F=I;BUT;W`Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M
M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG
M/B0\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,3`E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P,#`P.R<^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT
M+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R<^-"PU-CD\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HQ)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ,"4[/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM
M87)G:6XM=&]P.C!P=#MC;VQO<CHC.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/B8C.#(Q,CL\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US
M<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*
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M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,24[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,3`E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[8V]L;W(Z(SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXS,2PW.3$\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1"=W:61T:#HV-"4[(&)O<F1E
M<BUB;W1T;VTZ<V]L:60@,"XW-7!T('1R86YS<&%R96YT.R<^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HQ,G!T.SMT97AT+6EN9&5N=#HM,3)P=#L[9F]N="US:7IE.C$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M=V5I9VAT.FYO<FUA
M;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R<^3F5T('-E='1L96UE;G1S/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M)W=I9'1H.C$E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N-S5P="`C,#`P,#`P
M.R<^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P
M<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M
M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T0G=VED=&@Z,3`E.R!B;W)D97(M8F]T=&]M.G-O;&ED(#`N
M-S5P="`C,#`P,#`P.R<^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V-O;&]R.B,[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R
M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,X,C$R.SPO<#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+6)O='1O;3IS;VQI9"`P+C<U<'0@=')A
M;G-P87)E;G0[=VAI=&4M<W!A8V4Z;F]W<F%P.R<^#0H\<"!S='EL93TS1"=M
M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T
M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C8T)3L@8F]R9&5R+6)O='1O;3ID;W5B;&4@,BXU<'0@=')A;G-P
M87)E;G0[)SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T
M.SMF;VYT+7-I>F4Z,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A
M;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SY686QU92!A="!*
M=6YE(#,P+"`R,#$T/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$E.R!B;W)D97(M=&]P.G-O;&ED(#`N-S5P="`C,#`P
M,#`P.R!B;W)D97(M8F]T=&]M.F1O=6)L92`R+C5P="`C,#`P,#`P.R<^#0H\
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M+71O<#IS;VQI9"`P+C<U<'0@(S`P,#`P,#L@8F]R9&5R+6)O='1O;3ID;W5B
M;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR
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M9F]N="US:7IE.C$P<'0[)SXF;F)S<#L\+W`^/"]T9#X-"CPO='(^#0H\='(^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C0E.SX-"CQP
M('-T>6QE/3-$;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R
M9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M<VEZ93HT
M<'0[/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ)3L@8F]R9&5R+71O<#ID;W5B;&4@,BXU<'0@(S`P,#`P
M,#LG/@T*/'`@<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MF;VYT+7-I>F4Z-'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P)3L@8F]R9&5R+71O<#ID
M;W5B;&4@,BXU<'0@(S`P,#`P,#LG/@T*/'`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.V9O;G0M
M<VEZ93HT<'0[.SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HQ)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@
M<W1Y;&4],T1M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MF;VYT
M+7-I>F4Z-'!T.SL^)FYB<W`[/"]P/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\
M+V1I=CX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.W1E>'0M:6YD96YT.C`E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO<#X\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<W5M<'1I
M;VYS(%5S960@:6X@5F%L=6EN9R!$97)I=F%T:79E($QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"CQP('-T>6QE
M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,3)P=#MF;VYT+7-I
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M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.W1E>'0M:6YD96YT
M.C0N-30E.V9O;G0M<VEZ93HQ,G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CLG/B9N8G-P.SPO<#X-"CQD:78^#0H\=&%B;&4@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=VED=&@Z-S8E
M.R<^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M-#$N,C0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R<'0[.W1E>'0M:6YD96YT.BTQ,G!T
M.SMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS
M9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^,C`Q,"!787)R86YT
M<SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C(N,30E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR-RXP-"4[/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.FYO<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT
M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^/&9O;G0@
M<W1Y;&4],T1T97AT+61E8V]R871I;VXZ=6YD97)L:6YE.SY*=6YE(#,P+"`R
M,#$T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C$N-3@E.W=H:71E+7-P86-E.FYO=W)A<#L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C(U+C(V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
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M=F%R:6%N=#H@;F]R;6%L.R<^4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@
M<W1Y;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
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M93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C`N,3$E/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED
M=&@Z,2XU."4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR+C<T)3L^#0H\<"!S='EL
M93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM
M;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C`N,S,E
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M;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X
M="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF
M;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HR-RXP-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
M.VUA<F=I;BUL969T.C,V<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C(U+C(V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
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M1D8P1D,@<W1Y;&4],T1W:61T:#HT,2XR-"4[/@T*/'`@<W1Y;&4],T0G;6%R
M9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P
M=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US
M='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z
M(&YO<FUA;#LG/D1I=FED96YD('EI96QD/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,BXQ
M-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I
M9'1H.C(W+C`T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
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M<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HR+C<T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[
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M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DYO;F4\+W`^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#$N,C0E
M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
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M/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP
M<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F
M;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXV.24\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C4X)3MW:&ET
M92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(N
M-S0E.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@
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M;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N
M=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO
M<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&
M0R!S='EL93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,2XU
M."4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R9VEN+6)O
M='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT
M+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N
M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$
M(T-&1C!&0R!S='EL93TS1'=I9'1H.C(N-S0E.SX-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T
M:#HR-2XR-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT97([;6%R
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M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,2XR-"4[/@T*/'`@<W1Y;&4]
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M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE
M9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C(W+C`T)3L^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA
M<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R
M;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N
M="UV87)I86YT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1'1E>'0M9&5C;W)A
M=&EO;CIU;F1E<FQI;F4[/DIU;F4@,S`L(#(P,30\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,2XU."4[=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR
M+C<T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\
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M+"`R,#$S/"]F;VYT/CPO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HT
M,2XR-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
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M8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,BXQ-"4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C(W+C`T)3L^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ
M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
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M;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z
M,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&1C!&0R!S='EL93TS
M1'=I9'1H.C(U+C(V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT
M.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M
M<W1Y;&4Z;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT
M.B!N;W)M86P[)SXQ+C,Y)3PO<#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT,2XR-"4[/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN
M+6QE9G0Z,3)P=#L[=&5X="UI;F1E;G0Z+3$R<'0[.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M
M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT
M+79A<FEA;G0Z(&YO<FUA;#LG/D5X<&5C=&5D(&QI9F4\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXS+C4@665A<G,\+W`^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C4X)3L^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z
M,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR+C<T
M)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
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M.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^1&EV:61E;F0@>6EE;&0\+W`^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y
M;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M
M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD
M96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[
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M;VYT+79A<FEA;G0Z(&YO<FUA;#LG/DYO;F4\+W`^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ
M+C4X)3MW:&ET92US<&%C93IN;W=R87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN
M+6)O='1O;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT
M97AT+6EN9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG
M/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R
M/3-$(T-&1C!&0R!S='EL93TS1'=I9'1H.C(N-S0E.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@
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M,T1W:61T:#HT,2XR-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP
M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,3)P=#L[=&5X="UI;F1E
M;G0Z+3$R<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[
M=&5X="UT<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/E9O
M;&%T:6QI='D\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT
M.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P
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M;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C(U+C(V)3L^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA<F=I
M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z
M;F]R;6%L.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M
M86P[)SXV.24\+W`^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$N,C0E
M.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA<F=I;BUB;W1T
M;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI
M;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[9F]N="UW96EG:'0Z;F]R;6%L.V9O;G0M<W1Y;&4Z;F]R;6%L
M.W1E>'0M=')A;G-F;W)M.FYO;F4[9F]N="UV87)I86YT.B!N;W)M86P[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS
M1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P
M.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$=VED
M=&@Z,C<N,#0E.SX-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P
M=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C
M;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HQ+C4X)3L^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.F-E;G1E<CMM87)G:6XM8F]T=&]M.C!P=#MM87)G
M:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE
M/3-$=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIC96YT
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M+71R86YS9F]R;3IN;VYE.V9O;G0M=F%R:6%N=#H@;F]R;6%L.R<^)B,Q-C`[
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M/C(P,3,@5V%R<F%N=',\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T
M=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M
M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB
M<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED
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M93L^2G5N92`S,"P@,C`Q-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T1W:61T:#HQ+C4X)3MW:&ET92US<&%C93IN;W=R
M87`[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P.SPO<#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C(N-S0E.SX-"CQP('-T
M>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@<W1Y;&4],T0G=&5X
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M8V]R871I;VXZ=6YD97)L:6YE.SY397!T96UB97(@,S`L(#(P,3,\+V9O;G0^
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M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P
M1D,@<W1Y;&4],T1W:61T:#HR+C$T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM
M8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E
M>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^
M)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(]
M,T0C0T9&,$9#('-T>6QE/3-$=VED=&@Z,C<N,#0E.SX-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[;6%R9VEN+71O
M<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP<'0[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT<F%N<V9O<FTZ
M;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C`N.#@E/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T>6QE/3-$
M=VED=&@Z,2XU."4[=VAI=&4M<W!A8V4Z;F]W<F%P.SX-"CQP('-T>6QE/3-$
M)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T
M.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W:61T:#HR+C<T)3L^#0H\<"!S
M='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\=&0@=F%L:6=N/3-$
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M;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[
M=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T1W:61T:#HR-RXP-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H
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M/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL
M969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T1W:61T:#HR-2XR-B4[/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CIR:6=H=#MM87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.FYO
M<FUA;#MF;VYT+7-T>6QE.FYO<FUA;#MT97AT+71R86YS9F]R;3IN;VYE.V9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R<^-"XS)B,Q-C`[665A<G,\+W`^/"]T9#X-
M"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C
M0T9&,$9#('-T>6QE/3-$=VED=&@Z-#$N,C0E.SX-"CQP('-T>6QE/3-$)VUA
M<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C$R
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M;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@8F=C;VQO<CTS1"-#1D8P1D,@<W1Y;&4],T1W
M:61T:#HR-RXP-"4[/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CIR:6=H=#MM
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M=#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&)G8V]L;W(],T0C0T9&,$9#('-T
M>6QE/3-$=VED=&@Z,BXW-"4[/@T*/'`@<W1Y;&4],T0G;6%R9VEN+6)O='1O
M;3HP<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN
M9&5N=#HP<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/B9N8G-P
M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!B9V-O;&]R/3-$(T-&
M1C!&0R!S='EL93TS1'=I9'1H.C(U+C(V)3L^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.G)I9VAT.VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z,'!T
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M.SX-"CQP('-T>6QE/3-$)VUA<F=I;BUB;W1T;VTZ,'!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E;G0Z,'!T.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\+W`^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR-RXP-"4[/@T*/'`@<W1Y
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M,'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUL969T.C!P=#L[=&5X="UI;F1E
M;G0Z,'!T.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SXF;F)S<#L\
M+W`^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HR
M+C<T)3L^#0H\<"!S='EL93TS1"=M87)G:6XM8F]T=&]M.C!P=#MM87)G:6XM
M=&]P.C!P=#MM87)G:6XM;&5F=#HP<'0[.W1E>'0M:6YD96YT.C!P=#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^)FYB<W`[/"]P/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,C4N,C8E.SX-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ<FEG:'0[;6%R9VEN+6)O='1O;3HP<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6QE9G0Z,'!T.SMT97AT+6EN9&5N=#HP
M<'0[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IN;W)M86P[9F]N="US='EL93IN;W)M86P[=&5X="UT
M<F%N<V9O<FTZ;F]N93MF;VYT+79A<FEA;G0Z(&YO<FUA;#LG/C8Y)3PO<#X\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^/"]D:78^#0H\<"!S='EL93TS1"=M87)G
M:6XM8F]T=&]M.C!P=#MM87)G:6XM=&]P.C!P=#MT97AT+6EN9&5N=#HP)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[)SXF
M;F)S<#L\+W`^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15=704<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G
M86YI>F%T:6]N(&%N9"!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4V-H961U;&4@3V8@26YV97-T;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('1O
M(&9U;F0@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,S@L,S0Y+#<S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,CDL,#(U+#DS,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL,3$T+#0T-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPS
M-S<L,C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-871U<FET>2!D97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)VQE<W,@=&AA;B`R-R!M;VYT:',\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I
M;F-R96%S92`H9&5C<F5A<V4I(&EN(&-A<V@\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q.2PR,S4L,C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-C0X+#8T,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&9R
M;VT@:7-S=6%N8V4@;V8@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-S(L-C0Q+#<R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0R+#0T."PX,C0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!F<F]M(&5X
M97)C:7-E(&]F('=A<G)A;G1S(&%N9"!O<'1I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,BPS-S0L,#`U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!I;G9E
M<W1E9"!I;B!F:7AE9"!I;F-O;64@:6YV97-T;65N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,Y+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@;W5T9FQO
M=R!R96QA=&5D('1O(&-O;G1I;G5I;F<@;W!E<F%T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T+#0Y-BPU-C<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPV
M,SDL,S8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<&ET86P@97AP96YD:71U<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#(U,2PY.#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3$L-C4V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T
M960@0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UO=6YT(&EN<W5R960@:6X@1D1)0R!P97(@86-C;W5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN;W)I='D@97%U
M:71Y(&EN=F5S=&UE;G0L(&)O;VL@=F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@3V8@26YV97-T
M;65N=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP
M;65N="P@57-E9G5L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE($]F($EN=F5S=&UE
M;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE
M;G0L(%5S969U;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;65R8VEA;"!";VYD<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!/9B!)
M;G9E<W1M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4P+#$P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B
M9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W
M.3@O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5%1!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY);G9E<W1M96YT<R`M(%-U;6UA<GD@;V8@
M4VAO<G0@86YD($QO;F<M=&5R;2!);G9E<W1M96YT<R`H1&5T86EL*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!/9B!);G9E<W1M96YT<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'<F]S<R!5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#4L-S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#4P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L
M:7IE9"!,;W-S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X
M.2PT,#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-#$L-C0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#DL-S,U+#8Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#8Y."PR-S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UE<F-I86P@
M;F]T97,@*&1U92!W:71H:6X@;VYE('EE87(I+"!!;6]R=&EZ960@0V]S=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L.#,T+#0P.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,#,P
M+#(V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;65R8VEA;"!N;W1E<R`H9'5E(&%F=&5R(&]N92!Y96%R('=I
M=&AI;B!T:')E92!Y96%R<RDL($%M;W)T:7IE9"!#;W-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-BPR.#0L.#8R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,#(L,34S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#$Q.2PR-S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PW,S(L-#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM97)C:6%L($YO=&5S($1U92!7:71H:6X@3VYE(%EE
M87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-C:&5D=6QE($]F($EN=F5S=&UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N
M<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@3&]S<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,S<L,3@Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,Y+#(X,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@
M5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#4Y.2PP
M-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#DY."PT.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UE<F-I86P@3F]T97,@1'5E($%F=&5R($]N92!9
M96%R(%=I=&AI;B!4:')E92!996%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U;&4@3V8@26YV97-T;65N=',@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"!'86EN<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX.3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!5;G)E86QI>F5D
M($QO<W-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34R+#(R
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R+#,V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,C8L,3,V+#4Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2PV.3DL-SDQ/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14=&04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^1FEX9"!!<W-E=',@+2!!9&1I=&EO;F%L($EN9F]R;6%T
M:6]N("A$971A:6PI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DUI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!5<V5F=6P@
M3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4')O<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!5<V5F=6P@3&EF93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B
M9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W
M.3@O5V]R:W-H965T<R]3:&5E=#,P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Q!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY3=6UM87)Y(&]F(%!R;W!E<G1Y(&%N9"!%
M<75I<&UE;G0@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='D@4&QA;G0@06YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP=71E<G,L
M(&]F9FEC92!E<75I<&UE;G0@86YD(&9U<FYI='5R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S,S0L,38R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,C,L,S<V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M,C0X+#8P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-#4R+#`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V]F='=A<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8Y+#8R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8Y+#8R,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD(&EM<')O=F5M
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-34L,C$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPW-#DL-#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@9W)O<W,@9FEX960@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#8P-RPV,#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4Y-"PT,C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M<W,Z($%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#DS,RPT-S<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPP
M.#$L,3@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#8W-"PQ,S$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-3$S+#(S
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(R
M.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q
M-&8W.#=D.#<Y."]7;W)K<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U
M4$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C<75I<VET:6]N<R`M($%D
M9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D]C="X@,C$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)U<VEN97-S($%C<75I<VET:6]N(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/8FQI9V%T:6]N('1O('!A>2!R;WEA;'1I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG;&%T97(@;V8@*&DI('1H92!E
M>'!I<F%T:6]N(&]F('1H92!L87-T('1O(&5X<&ER92!P871E;G0@<FEG:'0@
M<F5L871E9"!T;R!S=6-H('!R;V1U8W0@8V%N9&ED871E('1H870@=V%S('1R
M86YS9F5R<F5D(&EN('1H92!4<F%N<V%C=&EO;B!A;F0@*&EI*2!T96X@>65A
M<G,@869T97(@=&AE(&9I<G-T(&-O;6UE<F-I86P@<V%L92!O9B!S=6-H('!R
M;V1U8W0@8V%N9&ED871E+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!P<F5S96YT('9A;'5E(&]F(&-O;G1I
M;F=E;G0@8V]N<VED97)A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`X-"PY,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N="!C;VYS:61E<F%T:6]N("T@
M9F%I<B!V86QU92!A9&IU<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O8VAE($UA9&ES;VX@26YC/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE
M<W,@06-Q=6ES:71I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5E(&]F('!R;VUI<W-O
M<GD@;F]T92!T;R!2;V-H93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5E(&]F($-O;6UO;B!3=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.#@L,34X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%P<&QI8V%B;&4@
M;W5T+6QI8V5N<V4@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<Y,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!R;WEA;'1Y(&QI86)I;&ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!P87EM96YT<R!T;R!2;V-H92P@;6EN:6UU;3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%Y;65N=',@=&\@
M4F]C:&4L(&UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#X@-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?
M-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y."]7;W)K<VAE971S+U-H965T,S(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5*2$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=&%N
M9VEB;&4@07-S971S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$-3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q-#QB<CY0871E;G1S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,3,\8G(^4&%T96YT<SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/E!A=&5N=',\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB
M<CY0871E;G1S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^4&%T96YT<SQB<CY-:6YI;75M/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^4&%T96YT
M<SQB<CY-87AI;75M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^3&EC96YS:6YG($%G<F5E;65N=',\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17AP96-T
M960@06UO<G1I>F%T:6]N($5X<&5N<V4@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M
M;W)T:7IA=&EO;B!P97)I;V0@;V8@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P('EE
M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;B!O9B!T:&4@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,30W+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P+#DY,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S-BPP,#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPV-C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-"PQ,34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,"PY.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,C(L,S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@;&EC96YS92!A9W)E
M96UE;G1S(')E;6%I;F1E<B!O9B`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&QI
M8V5N<V4@86=R965M96YT<R!I;B`R,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&QI
M8V5N<V4@86=R965M96YT<R!I;B`R,#$V/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&QI
M8V5N<V4@86=R965M96YT<RP@=&AE<F5A9G1E<CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X
M7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T
M<R]3:&5E=#,S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%2D9!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY);G1A;F=I8FQE($%S<V5T<R`M(%-C:&5D=6QE(&]F($EN=&%N
M9VEB;&4@07-S970@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1FEN:71E($QI=F5D($%N9"!);F1E9FEN:71E($QI=F5D($EN=&%N9VEB;&4@
M07-S971S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S(&YO="!S=6)J
M96-T('1O(&%M;W)T:7IA=&EO;BP@8F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPQ,3<L,S(R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#$Q-RPS
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&%N9VEB;&4@87-S971S(&YO="!S=6)J96-T('1O(&%M;W)T:7IA
M=&EO;BP@26UP86ER;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S(&YO="!S=6)J
M96-T('1O(&%M;W)T:7IA=&EO;BP@06UO<G1I>F%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT86YG:6)L92!A<W-E=',@;F]T('-U8FIE8W0@=&\@86UO<G1I>F%T
M:6]N+"!E;F1I;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPQ,3<L,S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPQ,3<L,S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<R!S
M=6)J96-T('1O(&%M;W)T:7IA=&EO;BP@8F5G:6YN:6YG(&)A;&%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,RPQ.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8V-RPR-#<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN=&%N9VEB;&4@87-S971S('-U8FIE8W0@=&\@86UO<G1I>F%T:6]N+"!)
M;7!A:7)M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS
M,#@L,#0W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YT86YG:6)L92!A<W-E=',@<W5B:F5C="!T;R!A;6]R=&EZ
M871I;VXL($%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-#`L.3DP*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(S-BPP,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<R!S=6)J
M96-T('1O(&%M;W)T:7IA=&EO;BP@96YD:6YG(&)A;&%N8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@R+#(P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,RPQ.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($EN
M=&%N9VEB;&4@87-S971S+"!B96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-#`L-3$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PW.#0L-38Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!);G1A;F=I8FQE(&%S<V5T<RP@26UP86ER;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$L,S`X+#`T-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($EN=&%N9VEB
M;&4@87-S971S+"!!;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0P+#DY,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R,S8L,#`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@26YT86YG:6)L92!A
M<W-E=',L(&5N9&EN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,L,3DY+#4R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPR-#`L-3$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14]:044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^26YV97-T;65N="!I;B!3=6)S:61I87)I97,@+2!!9&1I
M=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^0V%L86YD;R!0:&%R;6%C975T:6-A;',@26YC
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3$\8G(^06)L87)I<R!4:&5R87!E=71I8W,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY!8FQA<FES(%1H97)A
M<&5U=&EC<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/DQE;VYA<F1O($)I;W-Y<W1E;7,@26YC/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE
M($]F($EN=F5S=&UE;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]W;F5R<VAI<"!P97)C
M96YT86=E(&EN('-U8G-I9&EA<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@0F%L86YC92!O
M9B!0<F]M:7-S;W)Y($YO=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L,C4S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5C;VYS;VQI9&%T:6]N+"!2979A;'5A
M=&EO;B!O9B!2971A:6YE9"!);G9E<W1M96YT+"!'86EN("A,;W-S*2P@06UO
M=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;6]U;G0@;W=E9"!B>2!S=6)S:61I87)Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T960@<&5R8V5N=&%G
M92!O9B!N;W1E<R!A;F0@861V86YC97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!O=71S=&%N9&EN
M9R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.2XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C0N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!I;G9E<W1M96YT(&]W;F5R<VAI
M<#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U86YC92!O9B!P<F5F97)R960@<W1O8VL@:6X@<W5B<VED:6%R
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DP,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YV97-T;65N="!I;B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G0@
M:6X@<')E9F5R<F5D('-T;V-K(&)Y(&]U='-I9&5R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2PV,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F
M.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R
M:W-H965T<R]3:&5E=#,U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,4)!23X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`M($%D9&ET:6]N
M86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R-"P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#$Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/E!U<F-H87-E($%G<F5E;65N="!W:71H($QI;F-O;&X@4&%R
M:R!#87!I=&%L($9U;F0L($Q,0SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/E-E<FEE<R!"(%!R969E<G)E9"!3
M=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#$Q
M+"`R,#$S/&)R/E-E<FEE<R!#(%!R969E<G)E9"!3=&]C:SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/E-E<FEE
M<R!#(%!R969E<G)E9"!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/C(P,#`@4W1O8VL@3W!T:6]N(%!L
M86XL(#(P,#0@17%U:71Y($EN8V5N=&EV92!0;&%N+"`R,#$S($5Q=6ET>2!)
M;F-E;G1I=F4@4&QA;BP@86YD($EN9'5C96UE;G0@1W)A;G1S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"87-E9"!0
M87EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L('-T;V-K
M(&%U=&AO<FEZ960@9F]R(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R
M97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P
M87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(L.3`X
M+#4V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,R+#0X.2PT-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPX.3$L,C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S,P+#,W-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Q+#(Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL.3`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,CDQ/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E(')E<V5R=F4@9F]R(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<L,3@R+#DR-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&AR97-H;VQD('!E<F-E
M;G1A9V4@;V8@8V]M;6]N('-T;V-K(&]W;F5R<VAI<"!U<&]N('!R969E<G)E
M9"!S=&]C:R!C;VYV97)S:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDN.3DE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(&5Q=6ET>2!C;VUM:71M96YT
M(&%M;W5N="!U;F1E<B!A9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D@8V]M;6ET
M;65N="!A9W)E96UE;G0@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&1R87=N(&9R;VT@9F%C
M:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y386QE(&]F('-T;V-K+"!P<FEC92!P97(@<VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@N.34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N.#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y)<W-U86YC92!A;F0@<V]L9"!O9B!#;VUM;VX@4W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,S(U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#<Q
M+#8W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P<FEC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XX-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S
M(&9R;VT@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!P<F5F97)R960@<W1O
M8VL@86YD('=A<G)A;G1S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q,BPV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T
M92!P<FEC92!O;B!I<W-U86YC92!O<B!386QE(&]F(&5Q=6ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C0L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB
M83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F
M-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#,V+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1T="
M1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET
M>2`M(%-U;6UA<GD@;V8@26YF;W)M871I;VX@86)O=70@5V%R<F%N=',@*$1E
M=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-L87-S($]F(%=A<G)A;G0@3W(@4FEG:'0@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-3(V+#<X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="`Q/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S($]F(%=A<G)A
M;G0@3W(@4FEG:'0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S`N-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%=A
M<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-"PX.3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E;6%I;FEN9R!,:69E(&EN(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,B!Y96%R<R`Q,"!M;VYT:',@,C0@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M="`R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-L87-S($]F(%=A<G)A;G0@3W(@4FEG:'0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES
M92!P<FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(%=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,38L,C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296UA:6YI;F<@3&EF92!I;B!996%R<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$@>65A<B`R(&UO;G1H<R`Q,B!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT(#,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0VQA<W,@3V8@5V%R<F%N="!/<B!2:6=H="!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X97)C:7-E('!R:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U+C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@5V%R<F%N=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(Y,2PR,#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!,:69E(&EN
M(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!M;VYT
M:',@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N="`T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S($]F(%=A<G)A;G0@3W(@4FEG:'0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%=A<G)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PS,C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!,
M:69E(&EN(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M,2!Y96%R(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(#4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@3V8@5V%R<F%N="!/<B!2
M:6=H="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T+C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@5V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296UA:6YI
M;F<@3&EF92!I;B!996%R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S(@>65A<G,@-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@-CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!/9B!787)R86YT
M($]R(%)I9VAT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!787)R
M86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,T+#,T-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5M86EN:6YG($QI9F4@:6X@665A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<R('EE87)S(#$@;6]N=&@@-B!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(#<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA
M<W,@3V8@5V%R<F%N="!/<B!2:6=H="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R
M:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5M86EN:6YG($QI9F4@:6X@665A<G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S(#8@;6]N=&AS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT(#@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0VQA<W,@3V8@5V%R<F%N="!/<B!2:6=H="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E('!R:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(X.2PW.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!,:69E(&EN(%EE87)S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<R`V(&UO;G1H
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(R
M.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q
M-&8W.#=D.#<Y."]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V
M3D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQE87-E<R`M($%D9&ET:6]N
M86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]M<&]N96YT($]F($]P97)A=&EN9R!/=&AE<B!#;W-T($%N9"!%
M>'!E;G-E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5N=&%L(&5X<&5N<V5S(&EN8VQU9&4@
M8V]M;6]N(&%R96$@;6%I;G1E;F%N8V4@86YD(')E86P@97-T871E('1A>&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M571I;&ET:65S(&-O<W1S('!E<B!M;VYT:#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!T;W1A;"!M;VYT
M:&QY(&5X<&5N9&ET=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86-I;&ET>2!A;F0@97%U:7!M96YT(')E;G0@97AP
M96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,X+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#`W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S($AE;&0@=6YD97(@0V%P:71A
M;"!,96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V]M<&]N96YT($]F($]P97)A=&EN9R!/=&AE<B!#;W-T($%N
M9"!%>'!E;G-E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36]N=&AL>2!P87EM96YT<R!U;F1E
M<B!C87!I=&%L(&QE87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O<G!O<F%T92!(96%D<75A<G1E<G,@26X@4&%S861E
M;F$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M<&]N96YT($]F($]P97)A=&EN9R!/=&AE<B!#;W-T($%N9"!%>'!E
M;G-E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&QE87-E(&5X<&ER871I;VX@
M9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!=6<@,S$L
M#0H)"3(P,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y296YT86P@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&EN8W)E87-E
M(&EN(&%N;G5A;"!R96YT86P@8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H($9A8VEL:71Y(&EN($UA9&ES
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M<&]N96YT($]F($]P97)A=&EN9R!/=&AE<B!#;W-T($%N9"!%>'!E
M;G-E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&QE87-E(&5X<&ER871I;VX@
M9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y&96(@,C@L
M#0H)"3(P,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y296YT86P@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q
M-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y
M8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3
M:&5E=#,X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%0D)!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY,96%S97,@+2!&=71U<F4@36EN:6UU;2!,96%S92!087EM96YT<R!U
M;F1E<B!#87!I=&%L:7IE9"!,96%S97,@*$1E=&%I;"D@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V%P:71A;"!,96%S960@07-S971S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,30@*')E;6%I;F1E<B!O9BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-3<L,3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C(X+#0R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R."PT,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,C@L-#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^,C`Q.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C(X+#0R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3D@86YD('1H97)E869T97(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+#$W-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@:6YT97)E
M<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P+#8X,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')I;F-I<&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`R
M-2PR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,97-S(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,C$S+#$Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,C$L,S0U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A;"!L96%S
M92!O8FQI9V%T:6]N+"!N970@;V8@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@Q,BPQ-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#8Q+#$Q,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(R.6)A
M.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W
M.#=D.#<Y."]7;W)K<VAE971S+U-H965T,SDN:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5/1D%#
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DQE87-E<R`M($9U='5R92!-:6YI
M;75M($QE87-E(%!A>6UE;G1S('5N9&5R($]P97)A=&EN9R!,96%S97,@*$1E
M=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!,96%S960@07-S
M971S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^,C`Q-"`H<F5M86EN9&5R(&]F*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,S0L,38T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#`L-C(V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$V/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.3<L,3DV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3,L.3@T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$X/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S@L,C$W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$Y(&%N9"!T:&5R
M96%F=&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,S(L.#8Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPY
M.3<L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P144S0DD^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@
M0V]M<&5N<V%T:6]N("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!R97-E
M<G9E(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#$P+#`X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,3`L,#@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&=R86YT960@86YD(&]U
M='-T86YD:6YG('1O('!U<F-H87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#@R,RPV,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPX,C,L-C$R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#$Y+#(X-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3$P+#<Y
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F($]P=&EO;G,@3W5T<W1A;F1I;F<L($=R86YT960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P.2PQ
M-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<'1I;VYS(&=R86YT960@;W5T<VED92!O9B!%<75I='D@26YC96YT
M:79E('!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E+"!O
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#<P
M+#8S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S8S+#4Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPQ.#8L-C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#$Q-"PS-S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V
M86QU92!O9B!T:&4@;W!T:6]N<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#$W-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`Y-"PR.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#(Y-2PV,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Y
M-RPU.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YT<FEN<VEC('9A;'5E(&]F('1H92!O<'1I;VYS(&5X97)C
M:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<Q+#,S-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#8P-BPP-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1I=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07)R;W=H96%D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R92UT87@@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#4Q-"PV,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`L-3$T+#8Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G
M92!P97)I;V0@=&\@<F5C;V=N:7IE('!R92UT87@@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A
M<G,@,B!M;VYT:',@,3(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!3=&]C:R!5;FET
M<R`H4E-5<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3:&%R92!"87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4L(&]P=&EO;G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV."PP-3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-S$L
M-C$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!I<W-U
M960@=6YD97(@,C`Q,R!I;F-E;G1I=F4@<&QA;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-S`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-T<FEC=&5D(%-T;V-K(%5N:71S("A24U5S*2!\($%R<F]W:&5A9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R
M92!"87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F4M=&%X
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4L,CDQ+#,P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,CDQ+#,P,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M879E<F%G92!P97)I;V0@=&\@<F5C;V=N:7IE('!R92UT87@@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S$@>65A<B`V(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^,C`P,"!3=&]C:R!/<'1I;VX@4&QA;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R
M92!"87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@
M<F5S97)V92!F;W(@:7-S=6%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@9W)A;G1E9"!A;F0@
M;W5T<W1A;F1I;F<@=&\@<'5R8VAA<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,#0@17%U:71Y($EN8V5N
M=&EV92!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT($)Y(%-H87)E($)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E<R!R97-E<G9E(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPW,S0L.#0P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S,T+#@T,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!G<F%N=&5D(&%N9"!O=71S=&%N9&EN9R!T;R!P=7)C:&%S93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV,S@L-C4R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C,X+#8U
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@3W5T<W1A;F1I;F<L($=R86YT960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,R!)
M;F-E;G1I=F4@<&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!">2!3:&%R92!"87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R97,@<F5S97)V92!F;W(@:7-S=6%N8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@9W)A;G1E9"!A;F0@;W5T<W1A;F1I;F<@=&\@<'5R8VAA<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S-BPX-S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,V+#@W
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@3W5T<W1A;F1I;F<L($=R86YT960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(R.6)A
M.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W
M.#=D.#<Y."]7;W)K<VAE971S+U-H965T-#$N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$543T%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A
M=&EO;B`M(%-U;6UA<FEZ92!);F9O<FUA=&EO;B!A8F]U="!3=&]C:R!/<'1I
M;VYS("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"87-E9"!0
M87EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS($]U
M='-T86YD:6YG+"!B96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPT,3DL,C@U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,3`L-SDT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M3W!T:6]N<R!/=71S=&%N9&EN9RP@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`Y+#$V-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P
M=&EO;G,@3W5T<W1A;F1I;F<L($-A;F-E;&QE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,30X+#4V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@3W!T:6]N<R!/=71S=&%N9&EN9RP@17AE<F-I<V5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S-S<L,3$R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8W-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/
M<'1I;VYS($]U='-T86YD:6YG+"!E;F1I;F<@8F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX,C,L-C$R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT,3DL,C@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@3W!T:6]N<R!/=71S=&%N9&EN9RP@17AE<F-I<V%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3,R+#$X,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M($%V97)A9V4@17AE<F-I<V4@4')I8V4@4&5R(%-H87)E+"!B96=I;FYI;F<@
M8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C8X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`V+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@4&5R(%-H
M87)E+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$T+C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E
M(%!E<B!3:&%R92P@0V%N8V5L;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4N.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M($5X97)C:7-E(%!R:6-E(%!E<B!3:&%R92P@17AE<F-I<V5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N.3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M($%V97)A9V4@17AE<F-I<V4@4')I8V4@4&5R(%-H87)E+"!E;F1I;F<@8F%L
M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M+C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E(%!E<B!3:&%R
M92P@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-2XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U
M86P@5&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S@@>65A
M<G,@,R!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN
M:6YG($-O;G1R86-T=6%L(%1E<FTL($5X97)C:7-A8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<R`S(&UO;G1H<R`Q."!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06=G<F5G871E($EN=')I;G-I8R!686QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S,"PR-S$L,#$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I
M;G-I8R!686QU92P@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,3,L-C8V+#<Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q
M-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y
M8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3
M:&5E=#0R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%,DI!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@+2!!<W-U;7!T:6]N<R!5
M<V5D('1O(%9A;'5E(%-T;V-K($]P=&EO;G,@*$1E=&%I;"D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H
M87)E($)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@
M>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R871E+"!M:6YI;75M/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C@P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-S`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@
M:6YT97)E<W0@<F%T92P@;6%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+C,P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-CDN,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-CDN,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R
M86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92!P97(@<VAA<F4@;V8@;W!T:6]N
M<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@N
M.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$N,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!">2!3:&%R92!"87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D(&QI9F4@*&EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S8@>65A<G,@,R!M;VYT:',\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`V(&UO
M;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT($)Y(%-H87)E($)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AP96-T960@;&EF92`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG.2!Y96%R<R`X(&UO;G1H<R`Q.2!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A<G,@
M,R!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?
M869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#0S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,T%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E
M9"!#;VUP96YS871I;VX@+2!3=6UM87)Y(&]F(%)E<W1R:6-T960@4W1O8VL@
M06-T:79I='D@*$1E=&%I;"D@*%)E<W1R:6-T960@4W1O8VL@56YI=',@*%)3
M57,I+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S=')I8W1E9"!3=&]C:R!5;FET<R`H4E-5<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4@0F%S960@
M0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A<V5D(%!A>6UE
M;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,L(%5N=F5S=&5D+"!B96=I;FYI
M;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,L1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S+"!697-T960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M<RP@1F]R9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,L(%5N=F5S=&5D+"!%;F0@;V8@<&5R:6]D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-S`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92P@8F5G:6YN:6YG
M(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@9W)A;G0@9&%T92!F86ER('9A
M;'5E+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$T+C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU
M92P@5F5S=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V
M86QU92P@1F]R9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&=R86YT(&1A=&4@
M9F%I<B!V86QU92P@96YD:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,30N-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W
M.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y
M,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E
M=#0T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2T-!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY&86ER(%9A;'5E($UE87-U<F5M96YT<R`M($9A:7(@5F%L=64@365A<W5R
M96UE;G1S(&9O<B!!<W-E=',@86YD($QI86)I;&ET:65S($UE87-U<F5D(&%T
M($9A:7(@5F%L=64@;VX@4F5C=7)R:6YG($)A<VES("A$971A:6PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!!<W-E=',@06YD($QI86)I
M;&ET:65S($UE87-U<F5D($]N(%)E8W5R<FEN9R!!;F0@3F]N<F5C=7)R:6YG
M($)A<VES(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L,#$X+#<Q.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PP
M.38L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N=&EN9V5N="!C;VYS:61E<F%T:6]N(&]B;&EG871I;VYS
M(')E;&%T960@=&\@86-Q=6ES:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#4Y-2PR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4Y-2PR-S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S,L-C(Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A
M;'5E+"!-96%S=7)E;65N=',L(%)E8W5R<FEN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@07-S971S
M($%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!/;B!296-U<G)I;F<@06YD($YO
M;G)E8W5R<FEN9R!"87-I<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,X
M+#,T.2PW,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.2PQ,30L-#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PP,3@L-S$Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP.38L,S8S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN
M9V5N="!C;VYS:61E<F%T:6]N(&]B;&EG871I;VYS(')E;&%T960@=&\@86-Q
M=6ES:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4Y
M-2PR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#4Y-2PR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!-96%S=7)E;65N=',L(%)E
M8W5R<FEN9R!\($QE=F5L(#$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($%S<V5T<R!!;F0@3&EA8FEL
M:71I97,@365A<W5R960@3VX@4F5C=7)R:6YG($%N9"!.;VYR96-U<G)I;F<@
M0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S."PS-#DL-S,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL
M,3$T+#0T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@5F%L=64L($UE87-U<F5M96YT<RP@4F5C=7)R:6YG
M('P@3&5V96P@,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D9A:7(@5F%L=64@07-S971S($%N9"!,:6%B:6QI=&EE<R!-
M96%S=7)E9"!/;B!296-U<G)I;F<@06YD($YO;G)E8W5R<FEN9R!"87-I<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5R:79A=&EV92!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PP,3@L-S$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PP.38L,S8S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N="!C;VYS
M:61E<F%T:6]N(&]B;&EG871I;VYS(')E;&%T960@=&\@86-Q=6ES:71I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3DU+#(W,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PU.34L,C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F
M.%]A9F8X7S<Q-&8W.#=D.#<Y."]7;W)K<VAE971S+U-H965T-#4N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5:54)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@5F%L
M=64@365A<W5R96UE;G1S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T
M86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/C(P,3`@5V%R
M<F%N=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S
M,"P@,C`Q-#QB<CXR,#$R(%=A<G)A;G1S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^,C`Q,R!787)R86YT<SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$Q
M/&)R/E5N:61Y;2!);F,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CY!8FQA<FES(%1H97)A<&5U=&EC<SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER
M(%9A;'5E($UE87-U<F5M96YT<R!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H;W)T('1E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,C,L.#,T+#0P.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2PP,S`L,C8Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L
M,C@T+#@V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-S`R+#$U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@:6YV97-T;65N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#$Q.2PR-S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PW,S(L
M-#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&EN=F5S=&UE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.2PW,S4L-C$V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-CDX+#(W,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]N(&-A<V@@8V]N<VED97)A=&EO;B!R96-E:79E9"!I;B!S86QE
M(&]F(&EN=&5R97-T(&EN('-U8G-I9&EA<GDL(&)O;F1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y";VYD(&-O
M;G9E<G1I8FQE(&-O;G9E<G-I;VX@<')I8V4@<&5R('-H87)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I
M<W-U960@=&\@86-Q=6ER92!#;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,R.2PV-#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3(L-30S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,S+#4S,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU,C8L-S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-"PS,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C4L,38Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L-C(S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC
M87-H(&=A:6X@*&QO<W,I(&9R;VT@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@
M=&AE(&1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#8X,"PU-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PW.3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1U<F%T:6]N(&]F
M(&5X8VAA;F=E(')I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<W('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-H86YG92!R:6=H="!C;VYV97)T:6)L
M92!C;VYV97)S:6]N(')A=&EO(&9O<B!F:7)S="!Y96%R/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AC:&%N9V4@<FEG
M:'0@8V]N=F5R=&EB;&4@8V]N=F5R<VEO;B!R871I;R!F;W(@<V5C;VYD('EE
M87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&-H86YG92!R:6=H="!C;VYV97)T:6)L92!C;VYV97)S:6]N(')A=&EO
M(&9O<B!T:&ER9"!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,"XP,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AC:&%N9V4@<FEG:'0@8V]N=F5R=&EB;&4@8V]N
M=F5R<VEO;B!R871I;R!F;W(@9F]U<G1H('EE87(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-H86YG92!R:6=H="!C
M;VYV97)T:6)L92!C;VYV97)S:6]N(')A=&EO(&9O<B!F:69T:"!Y96%R(&%N
M9"!B97EO;F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@97AC:&%N9V4@<FEG:'0@<V]L9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)U<VEN
M97-S(&-O;6)I;F%T:6]N+"!C;VYT:6YG96YT(&-O;G-I9&5R871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PU.34L,C<S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4Y
M-2PR-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$W,RPV,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X
M-V0X-SDX#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR
M7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y."]7;W)K<VAE971S+U-H965T
M-#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5)3D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D9A:7(@5F%L=64@365A<W5R96UE;G1S("T@4F5C;VYC:6QI871I;VX@;V8@
M1&5R:79A=&EV92!!<W-E="`H1&5T86EL*2`H1&5R:79A=&EV92!A<W-E="P@
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!A<W-E=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!!<W-E
M=',@06YD($QI86)I;&ET:65S($UE87-U<F5D($]N(%)E8W5R<FEN9R!!;F0@
M3F]N<F5C=7)R:6YG($)A<VES(%9A;'5A=&EO;B!496-H;FEQ=65S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E9A;'5E+"!"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4P+#(U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C
M96EP="!O9B!I;G-T<G5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E(&EN
M('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C4P+#(U,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!S971T;&5M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E9A;'5E+"!%;F1I;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,CEB83DR7S9B9C5?
M-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W,31F-S@W9#@W.3@O
M5V]R:W-H965T<R]3:&5E=#0W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-4=!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<R`M($%S
M<W5M<'1I;VYS(%5S960@:6X@5F%L=6EN9R!$97)I=F%T:79E($QI86)I;&ET
M:65S("A$971A:6PI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,"!787)R86YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!!
M<W-E=',@06YD($QI86)I;&ET:65S($UE87-U<F5D($]N(%)E8W5R<FEN9R!!
M;F0@3F]N<F5C=7)R:6YG($)A<VES(%9A;'5A=&EO;B!496-H;FEQ=65S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C$Q)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,S,E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R(#8@;6]N
M=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S(@>65A<G,@,B!M;VYT:',@,3(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@>6EE;&0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y6;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV.2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV.2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3(@5V%R<F%N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L
M=64@07-S971S($%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!/;B!296-U<G)I
M;F<@06YD($YO;G)E8W5R<FEN9R!"87-I<R!686QU871I;VX@5&5C:&YI<75E
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XX."4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C,Y)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@
M;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,@
M-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-"!Y96%R<R`R(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:79I9&5N9"!Y
M:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8Y+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,R!787)R86YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I
M<B!686QU92!!<W-E=',@06YD($QI86)I;&ET:65S($UE87-U<F5D($]N(%)E
M8W5R<FEN9R!!;F0@3F]N<F5C=7)R:6YG($)A<VES(%9A;'5A=&EO;B!496-H
M;FEQ=65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C@X)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,SDE/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E
M8W1E9"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y
M96%R<R`W(&UO;G1H<R`V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<R`S(&UO;G1H<R`Q."!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AC
M:&%N9V4@<FEG:'1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&86ER(%9A;'5E($%S<V5T<R!!;F0@3&EA8FEL:71I97,@
M365A<W5R960@3VX@4F5C=7)R:6YG($%N9"!.;VYR96-U<G)I;F<@0F%S:7,@
M5F%L=6%T:6]N(%1E8VAN:7%U97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(&EN
M=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M.#@E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2XS.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<S('EE87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@>65A<G,@,R!M;VYT:',@
M,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6;VQA=&EL
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R
M,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W
M,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#0X+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M,E)!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U
M<F5M96YT<R`M(%)E8V]N8VEL:6%T:6]N(&]F($1E<FEV871I=F4@3&EA8FEL
M:71Y("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L
M=64@07-S971S($%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!/;B!296-U<G)I
M;F<@06YD($YO;G)E8W5R<FEN9R!"87-I<R!686QU871I;VX@5&5C:&YI<75E
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-2PV.#`L-30T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU
M92!!<W-E=',@06YD($QI86)I;&ET:65S($UE87-U<F5D($]N(%)E8W5R<FEN
M9R!!;F0@3F]N<F5C=7)R:6YG($)A<VES(%9A;'5A=&EO;B!496-H;FEQ=65S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E9A;'5E+"!"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP.3$L-SDW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(V+#$Y-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@:6YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#$U,RPX,3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV.#`L-30T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP
M-C8L-3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@<V5T=&QE;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4L-S@Y+#DX,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S+#<U-"PX,#@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU92P@16YD:6YG
M(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.3@R
M+#,U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,#DQ+#<Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AC:&%N9V4@<FEG:'1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($%S<V5T
M<R!!;F0@3&EA8FEL:71I97,@365A<W5R960@3VX@4F5C=7)R:6YG($%N9"!.
M;VYR96-U<G)I;F<@0F%S:7,@5F%L=6%T:6]N(%1E8VAN:7%U97,@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5F%L=64L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#4V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#,W-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@:6YS
M=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#<Y,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L.#`V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('-E
M='1L96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64L($5N9&EN9R!B86QA;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,V+#,V,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PU
M-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R
M,CEB83DR7S9B9C5?-#9F.%]A9F8X7S<Q-&8W.#=D.#<Y.`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X,C(Y8F$Y,E\V8F8U7S0V9CA?869F.%\W
M,31F-S@W9#@W.3@O5V]R:W-H965T<R]3:&5E=#0Y+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M44Q!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U
M<F5M96YT<R`M($-H86YG92!I;B!&86ER(%9A;'5E(&]F($-O;G1I;F=E;G0@
M0V]N<VED97)A=&EO;B!/8FQI9V%T:6]N<R`H1&5T86EL*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D)U<VEN97-S($%C<75I<VET:6]N($-O;G1I;F=E;G0@
M0V]N<VED97)A=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64L($)E9VEN;FEN9R!B
M86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3DU
M+#(W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PU.34L,C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q-S,L-C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!P<FEC92!C;VYT
M:6YG96YT(&-O;G-I9&5R871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N
M="!C;VYS:61E<F%T:6]N('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG
M92!I;B!F86ER('9A;'5E(&]F(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#0R,2PV-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E9A;'5E+"!%;F1I;F<@8F%L86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4Y-2PR-S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3DU+#(W,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<S
M+#8R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.#(R.6)A.3)?-F)F-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,CEB83DR7S9B9C5?-#9F.%]A9F8X
M7S<Q-&8W.#=D.#<Y."]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL
M('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z
M;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970T,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970T,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#0X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T.2YH
M=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?.#(R.6)A.3)?-F)F
<-5\T-F8X7V%F9CA?-S$T9C<X-V0X-SDX+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) (Restricted Stock Units (RSUs), USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock Units (RSUs)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested, beginning of period</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares,Granted</a></td>
        <td class="nump">470,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, Unvested, End of period</a></td>
        <td class="nump">470,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning balance</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
        <td class="nump">$ 14.54<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Forfeited</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending balance</a></td>
        <td class="nump">$ 14.54<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fixd Assets - Additional Information (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
        <td class="text">7 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Investments - Summary of Short and Long-term Investments (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross Unrealized Gains</a></td>
        <td class="nump">$ 5,749<span></span></td>
        <td class="nump">$ 7,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross Unrealized Losses</a></td>
        <td class="num">(389,403)<span></span></td>
        <td class="num">(41,643)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
        <td class="nump">49,735,616<span></span></td>
        <td class="nump">10,698,271<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Commercial notes (due within one year), Amortized Cost</a></td>
        <td class="nump">23,834,408<span></span></td>
        <td class="nump">9,030,261<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Commercial notes (due after one year within three years), Amortized Cost</a></td>
        <td class="nump">26,284,862<span></span></td>
        <td class="nump">1,702,153<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
        <td class="nump">50,119,270<span></span></td>
        <td class="nump">10,732,414<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Commercial Notes Due Within One Year</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross Unrealized Gains</a></td>
        <td class="nump">1,850<span></span></td>
        <td class="nump">7,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross Unrealized Losses</a></td>
        <td class="num">(237,181)<span></span></td>
        <td class="num">(39,281)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
        <td class="nump">23,599,077<span></span></td>
        <td class="nump">8,998,480<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Commercial Notes Due After One Year Within Three Years</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross Unrealized Gains</a></td>
        <td class="nump">3,899<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross Unrealized Losses</a></td>
        <td class="num">(152,222)<span></span></td>
        <td class="num">(2,362)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
        <td class="nump">$ 26,136,599<span></span></td>
        <td class="nump">$ 1,699,791<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated unrealized gain on investments in debt securities classified as held-to-maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated unrealized loss on investments in debt securities classified as held-to-maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Available-for-Sale Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Trading Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a, f, g<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInvestmentsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
        <td class="nump">$ 4,018,719<span></span></td>
        <td class="nump">$ 4,096,363<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations related to acquisitions</a></td>
        <td class="nump">1,595,273<span></span></td>
        <td class="nump">1,595,273<span></span></td>
        <td class="nump">173,621<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Measurements, Recurring</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">138,349,733<span></span></td>
        <td class="nump">19,114,444<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
        <td class="nump">4,018,719<span></span></td>
        <td class="nump">4,096,363<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations related to acquisitions</a></td>
        <td class="nump">1,595,273<span></span></td>
        <td class="nump">1,595,273<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Measurements, Recurring | Level 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">138,349,733<span></span></td>
        <td class="nump">19,114,444<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Measurements, Recurring | Level 3</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Derivative assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
        <td class="nump">4,018,719<span></span></td>
        <td class="nump">4,096,363<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations related to acquisitions</a></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph b<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EALAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Property and Equipment (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Computers, office equipment and furniture</a></td>
        <td class="nump">$ 334,162<span></span></td>
        <td class="nump">$ 323,376<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ResearchEquipment', window );">Research equipment</a></td>
        <td class="nump">4,248,606<span></span></td>
        <td class="nump">3,452,013<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Software</a></td>
        <td class="nump">69,623<span></span></td>
        <td class="nump">69,623<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
        <td class="nump">2,955,217<span></span></td>
        <td class="nump">2,749,409<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total gross fixed assets</a></td>
        <td class="nump">7,607,608<span></span></td>
        <td class="nump">6,594,421<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
        <td class="num">(3,933,477)<span></span></td>
        <td class="num">(3,081,186)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">$ 3,674,131<span></span></td>
        <td class="nump">$ 3,513,235<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ResearchEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalizedComputerSoftwareGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FurnitureAndFixturesGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseholdImprovementsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5PAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisitions - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 21, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ObligationToPayRoyalties', window );">Obligation to pay royalties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">later of (i) the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii) ten years after the first commercial sale of such product candidate.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PresentValueOfContingentAcquisitionConsideration', window );">Net present value of contingent consideration</a></td>
        <td class="nump">$ 84,935<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration - fair value adjustments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,400,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Roche Madison Inc</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_BusinessCombinationConsiderationPromissoryNoteIssued', window );">Issue of promissory note to Roche</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued', window );">Issue of Common Stock</a></td>
        <td class="nump">1,288,158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ApplicableOutLicenseTerm', window );">Applicable out-license term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfRoyaltyLiability', window );">Percentage of royalty liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow', window );">Cash payments to Roche, minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Cash payments to Roche, maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ApplicableOutLicenseTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Applicable out license term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ApplicableOutLicenseTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business acquisition equity interests issued number of shares issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_BusinessAcquisitionEquityInterestsIssuedNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BusinessCombinationConsiderationPromissoryNoteIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business combination consideration promissory note issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_BusinessCombinationConsiderationPromissoryNoteIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ObligationToPayRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Obligation to pay royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ObligationToPayRoyalties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfRoyaltyLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalty liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_PercentageOfRoyaltyLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PresentValueOfContingentAcquisitionConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Present value of contingent acquisition consideration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_PresentValueOfContingentAcquisitionConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 18, 2014

</div>
          <div>Galloway Limited</div>
        </th>
        <th class="th">
          <div>Oct. 21, 2012

</div>
          <div>Roche Madison Inc</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">131,579<span></span></td>
        <td class="nump">239,894<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
        <td class="nump">$ 500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Liability settlement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 986,049<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherPaymentsToAcquireBusinesses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="5">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Patents</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Patents</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Patents</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Patents</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Patents

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Patents

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Licensing Agreements</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExpectedAmortizationExpenseLineItems', window );"><strong>Expected Amortization Expense [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">20 years<span></span></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization of the assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 147,800<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
        <td class="nump">40,990<span></span></td>
        <td class="nump">236,009<span></span></td>
        <td class="nump">13,663<span></span></td>
        <td class="nump">74,115<span></span></td>
        <td class="nump">40,990<span></span></td>
        <td class="nump">222,345<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Amortization of license agreements remainder of 2014</a></td>
        <td class="nump">14,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of license agreements in 2015</a></td>
        <td class="nump">55,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of license agreements in 2016</a></td>
        <td class="nump">14,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Amortization of license agreements, thereafter</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExpectedAmortizationExpenseLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ExpectedAmortizationExpenseLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized after the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized in the remainder of the fiscal year following the latest fiscal year ended for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EE3BI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
        <td class="nump">410,085<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">410,085<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options granted and outstanding to purchase</a></td>
        <td class="nump">3,823,612<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,823,612<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,419,285<span></span></td>
        <td class="nump">1,910,794<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">930,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,509,166<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants', window );">Options granted outside of Equity Incentive plans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">165,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, options</a></td>
        <td class="nump">$ 1,070,631<span></span></td>
        <td class="nump">$ 363,593<span></span></td>
        <td class="nump">$ 2,186,653<span></span></td>
        <td class="nump">$ 1,114,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Fair value of the options granted</a></td>
        <td class="nump">1,176,000<span></span></td>
        <td class="nump">1,094,295<span></span></td>
        <td class="nump">8,295,600<span></span></td>
        <td class="nump">1,197,588<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of the options exercised</a></td>
        <td class="nump">371,334<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,606,061<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Arrowhead</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Pre-tax compensation expense</a></td>
        <td class="nump">10,514,619<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,514,619<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 2 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock Units (RSUs)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, options</a></td>
        <td class="nump">968,051<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,571,611<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of restricted stock units issued under 2013 incentive plan</a></td>
        <td class="nump">470,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">470,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock Units (RSUs) | Arrowhead</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Pre-tax compensation expense</a></td>
        <td class="nump">$ 5,291,302<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,291,302<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2000 Stock Option Plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
        <td class="nump">38,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">38,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options granted and outstanding to purchase</a></td>
        <td class="nump">38,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">38,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2004 Equity Incentive Plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
        <td class="nump">2,734,840<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,734,840<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options granted and outstanding to purchase</a></td>
        <td class="nump">2,638,652<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,638,652<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2013 Incentive plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options granted and outstanding to purchase</a></td>
        <td class="nump">736,875<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">736,875<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">765,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award inducement grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options grants in period fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOWAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 138,349,733<span></span></td>
        <td class="nump">$ 19,114,444<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">700,063<span></span></td>
        <td class="nump">532,354<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">538,742<span></span></td>
        <td class="nump">91,660<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short term investments</a></td>
        <td class="nump">23,834,408<span></span></td>
        <td class="nump">9,030,261<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
        <td class="nump">163,422,946<span></span></td>
        <td class="nump">28,843,719<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">3,674,131<span></span></td>
        <td class="nump">3,513,235<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Patents and other intangible assets, net</a></td>
        <td class="nump">3,199,523<span></span></td>
        <td class="nump">3,240,513<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
        <td class="nump">26,284,862<span></span></td>
        <td class="nump">1,702,153<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other assets</a></td>
        <td class="nump">41,414<span></span></td>
        <td class="nump">30,011<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump">196,622,876<span></span></td>
        <td class="nump">37,329,631<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,158,133<span></span></td>
        <td class="nump">1,199,632<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">1,068,667<span></span></td>
        <td class="nump">638,884<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
        <td class="nump">611,092<span></span></td>
        <td class="nump">905,771<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">71,875<span></span></td>
        <td class="nump">103,125<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
        <td class="nump">4,018,719<span></span></td>
        <td class="nump">4,096,363<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligation</a></td>
        <td class="nump">213,110<span></span></td>
        <td class="nump">221,345<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">971,557<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
        <td class="nump">58,500<span></span></td>
        <td class="nump">588,343<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
        <td class="nump">8,250,096<span></span></td>
        <td class="nump">8,725,020<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligation, net of current portion</a></td>
        <td class="nump">812,169<span></span></td>
        <td class="nump">1,061,113<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
        <td class="nump">1,752,822<span></span></td>
        <td class="nump">1,758,709<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
        <td class="nump">2,564,991<span></span></td>
        <td class="nump">2,869,822<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Arrowhead Research Corporation stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; 21,291 and 9,900 shares issued and outstanding as of June 30, 2014 and September 30, 2013, respectively</a></td>
        <td class="nump">21<span></span></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 145,000,000 shares authorized; 52,908,567 and 32,489,444 shares issued and outstanding as of June 30, 2014 and September 30, 2013, respectively</a></td>
        <td class="nump">145,278<span></span></td>
        <td class="nump">124,859<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">388,558,305<span></span></td>
        <td class="nump">193,514,766<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(202,340,717)<span></span></td>
        <td class="num">(166,140,969)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Research Corporation stockholders' equity</a></td>
        <td class="nump">186,362,887<span></span></td>
        <td class="nump">27,498,666<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
        <td class="num">(555,098)<span></span></td>
        <td class="num">(1,763,877)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL STOCKHOLDERS&#x2019; EQUITY</a></td>
        <td class="nump">185,807,789<span></span></td>
        <td class="nump">25,734,789<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</a></td>
        <td class="nump">$ 196,622,876<span></span></td>
        <td class="nump">$ 37,329,631<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226008-175313<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MinorityInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsMiscellaneousNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZUBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>2010 Warrants</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>2012 Warrants</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>2013 Warrants</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011

</div>
          <div>Unidym Inc</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Ablaris Therapeutics</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FairValueMeasurementsDisclosureLineItems', window );"><strong>Fair Value Measurements Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short term investments</a></td>
        <td class="nump">$ 23,834,408<span></span></td>
        <td class="nump">$ 9,030,261<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
        <td class="nump">26,284,862<span></span></td>
        <td class="nump">1,702,153<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total investments</a></td>
        <td class="nump">50,119,270<span></span></td>
        <td class="nump">10,732,414<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value of investments</a></td>
        <td class="nump">49,735,616<span></span></td>
        <td class="nump">10,698,271<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds', window );">Non cash consideration received in sale of interest in subsidiary, bonds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Bond convertible conversion price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_WarrantsIssuedToAcquireCommonStock', window );">Warrants issued to acquire Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">329,649<span></span></td>
        <td class="nump">912,543<span></span></td>
        <td class="nump">833,530<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
        <td class="nump">1,526,781<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,324<span></span></td>
        <td class="nump">265,161<span></span></td>
        <td class="nump">24,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Non-cash gain (loss) from change in fair value of the derivative liability</a></td>
        <td class="nump">5,680,544<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,791<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_TermOfExchangeRights', window );">Duration of exchange rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExchangeRightConvertibleConversionRatioForFirstYear', window );">Exchange right convertible conversion ratio for first year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.06<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExchangeRightConvertibleConversionRatioForTwoYear', window );">Exchange right convertible conversion ratio for second year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.04<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExchangeRightConvertibleConversionRatioForThreeYear', window );">Exchange right convertible conversion ratio for third year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.03<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExchangeRightConvertibleConversionRatioForFourYear', window );">Exchange right convertible conversion ratio for fourth year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.02<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExchangeRightConvertibleConversionRatioForFiveYear', window );">Exchange right convertible conversion ratio for fifth year and beyond</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfExchangeRightAreSold', window );">Number of exchange right sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">675,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration</a></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="nump">$ 173,621<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExchangeRightConvertibleConversionRatioForFirstYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchange right convertible conversion ratio for first year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ExchangeRightConvertibleConversionRatioForFirstYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExchangeRightConvertibleConversionRatioForFiveYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchange right convertible conversion ratio for five year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ExchangeRightConvertibleConversionRatioForFiveYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExchangeRightConvertibleConversionRatioForFourYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchange right convertible conversion ratio for four year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ExchangeRightConvertibleConversionRatioForFourYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExchangeRightConvertibleConversionRatioForThreeYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchange right convertible conversion ratio for three year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ExchangeRightConvertibleConversionRatioForThreeYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExchangeRightConvertibleConversionRatioForTwoYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchange right convertible conversion ratio for two year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ExchangeRightConvertibleConversionRatioForTwoYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FairValueMeasurementsDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_FairValueMeasurementsDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non cash consideration received in sale of interest in subsidiary, bonds.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_NonCashConsiderationReceivedInSaleOfInterestInSubsidiaryBonds</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfExchangeRightAreSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of exchange right are sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_NumberOfExchangeRightAreSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TermOfExchangeRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of exchange rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_TermOfExchangeRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_WarrantsIssuedToAcquireCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued to acquire common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_WarrantsIssuedToAcquireCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph b<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Available-for-Sale Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Trading Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a, f, g<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity and (2) securities available-for-sale that will be held for the long-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock issued @ $5.86</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued, price per share</a></td>
        <td class="nump">$ 5.86<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock issued @ $18.95</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued, price per share</a></td>
        <td class="nump">$ 18.95<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Preferred stock issued @ $1,000 per share</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock issued, price per share</a></td>
        <td class="nump">$ 1,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssuedPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1BAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 24, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 11, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Purchase Agreement with Lincoln Park Capital Fund, LLC</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Series B Preferred Stock</div>
        </th>
        <th class="th">
          <div>Oct. 11, 2013

</div>
          <div>Series C Preferred Stock</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Series C Preferred Stock</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>2000 Stock Option Plan, 2004 Equity Incentive Plan, 2013 Equity Incentive Plan, and Inducement Grants</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital stock authorized for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145,000,000<span></span></td>
        <td class="nump">145,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">52,908,567<span></span></td>
        <td class="nump">32,489,444<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,891,257<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,730,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,291<span></span></td>
        <td class="nump">9,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,291<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance', window );">Share reserve for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,182,925<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion', window );">Threshold percentage of common stock ownership upon preferred stock conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.99%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MaximumEquityCommitmentAmountUnderAgreement', window );">Maximum equity commitment amount under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquityCommitmentAgreementPeriod', window );">Equity commitment agreement period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashDrawnFromFacility', window );">Cash drawn from facility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
        <td class="nump">$ 18.95<span></span></td>
        <td class="nump">$ 5.86<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance and sold of Common Stock</a></td>
        <td class="nump">6,325,000<span></span></td>
        <td class="nump">3,071,672<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ConversionPricePerShare', window );">Conversion price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.86<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, preferred stock and warrants, net</a></td>
        <td class="nump">112,600,000<span></span></td>
        <td class="nump">60,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AggregatePriceOnIssuanceOrSaleOfEquity', window );">Aggregate price on issuance or Sale of equity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 64,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AggregatePriceOnIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate price of issuance or Sale of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_AggregatePriceOnIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashDrawnFromFacility">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash drawn from facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_CashDrawnFromFacility</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ConversionPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ConversionPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquityCommitmentAgreementPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity commitment agreement period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_EquityCommitmentAgreementPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MaximumEquityCommitmentAmountUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum equity commitment amount under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_MaximumEquityCommitmentAmountUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Threshold percentage of common stock ownership upon preferred stock conversion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ThresholdPercentageOfCommonStockOwnershipUponPreferredStockConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-04.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalUnitsAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Asset</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table provides details on our intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;">
<tr>
<td valign="bottom" style="width:46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible&#160;assets<font style="font-weight:normal;"><br /></font>not subject to<br />amortization</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible&#160;assets<br />subject to<br />amortization</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total<br />Intangible&#160;assets</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September&#160;30, 2012</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667,247</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,784,569</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,308,047</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,308,047</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(236,009 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(236,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September&#160;30, 2013</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,191</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240,513</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,990</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,990</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="width:46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2014</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,201</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,199,523</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGGBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Summary of Information about Warrants (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">1,526,781<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 70.60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">94,897<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">2 years 10 months 24 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 2</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 5.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">416,225<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">1 year 2 months 12 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 3</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 5.09<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">291,204<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">4 months 24 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 4</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 1.38<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">24,324<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">1 year 6 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 5</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 4.16<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">1,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">2 years 6 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 6</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 3.25<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">334,347<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">2 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 7</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 2.12<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">75,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">3 years 6 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant 8</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise prices</a></td>
        <td class="nump">$ 1.83<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
        <td class="nump">289,784<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RemainingLifeOfWarrant', window );">Remaining Life in Years</a></td>
        <td class="text">3 years 6 months<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RemainingLifeOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Remaining life of warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_RemainingLifeOfWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future Minimum Lease Payments under Capitalized Leases</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">As of June 30, 2014, future minimum lease payments due in fiscal years under capitalized leases are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4 (remainder of)</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">5 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">6 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">7 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">8 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">9 </font>and thereafter</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,175</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less interest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,681 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,025,279</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,110 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">812,169</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Lease Payments under Operating Leases</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">As of June 30, 2014, future minimum lease payments due in fiscal years under operating leases are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4 (remainder of)</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,164</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">5 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580,626</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">6 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597,196</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">7 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613,984</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">8 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638,217</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">9 </font>and thereafter</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,861 </p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,997,048</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESCBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES OF CONTINUING OPERATIONS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
        <td class="num">$ (36,294,880)<span></span></td>
        <td class="num">$ (17,898,373)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (gain) loss attributable to non-controlling interests</a></td>
        <td class="nump">95,132<span></span></td>
        <td class="nump">447,268<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Arrowhead</a></td>
        <td class="num">(36,199,748)<span></span></td>
        <td class="num">(17,451,105)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">(Income) loss from discontinued operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">354<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of fixed assets</a></td>
        <td class="nump">58,878<span></span></td>
        <td class="nump">76,388<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in value of derivatives</a></td>
        <td class="nump">5,712,335<span></span></td>
        <td class="num">(215,620)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">3,758,264<span></span></td>
        <td class="nump">1,114,375<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">1,075,238<span></span></td>
        <td class="nump">1,352,448<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization (accretion) of note discounts, net</a></td>
        <td class="nump">416,292<span></span></td>
        <td class="nump">82,341<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Non-cash gain in equity investment</a></td>
        <td class="num">(87,197)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Non-cash impairment expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,315,721<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
        <td class="num">(95,132)<span></span></td>
        <td class="num">(447,268)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
        <td class="nump">75,000<span></span></td>
        <td class="nump">9,375<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
        <td class="num">(517,986)<span></span></td>
        <td class="nump">1,080<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="num">(127,248)<span></span></td>
        <td class="num">(441,373)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num">(11,402)<span></span></td>
        <td class="num">(1,813)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">990,929<span></span></td>
        <td class="nump">183,959<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="nump">459,690<span></span></td>
        <td class="nump">95,132<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
        <td class="num">(4,480)<span></span></td>
        <td class="num">(313,354)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATIONS</a></td>
        <td class="num">(24,496,567)<span></span></td>
        <td class="num">(13,639,360)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES OF CONTINUING OPERATIONS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(1,251,987)<span></span></td>
        <td class="num">(191,656)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of fixed assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">89,505<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
        <td class="num">(46,365,528)<span></span></td>
        <td class="num">(4,058,003)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
        <td class="nump">6,590,824<span></span></td>
        <td class="nump">1,160,181<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS</a></td>
        <td class="num">(41,026,691)<span></span></td>
        <td class="num">(2,999,973)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES OF CONTINUING OPERATIONS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on capital leases</a></td>
        <td class="num">(257,178)<span></span></td>
        <td class="num">(160,495)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and preferred stock, net</a></td>
        <td class="nump">172,641,720<span></span></td>
        <td class="nump">42,448,824<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ProceedsFromExerciseOfWarrantsAndStockOptions', window );">Proceeds from the exercise of warrants and stock options</a></td>
        <td class="nump">12,374,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS</a></td>
        <td class="nump">184,758,547<span></span></td>
        <td class="nump">42,288,329<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Cash flows from discontinued operations:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Operating cash flows</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(354)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Investing cash flows</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Financing cash flows</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations', window );">Net cash provided by (used in) discontinued operations:</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(354)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE IN CASH</a></td>
        <td class="nump">119,235,289<span></span></td>
        <td class="nump">25,648,642<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AT BEGINNING OF PERIOD</a></td>
        <td class="nump">19,114,444<span></span></td>
        <td class="nump">3,377,288<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AT END OF PERIOD</a></td>
        <td class="nump">138,349,733<span></span></td>
        <td class="nump">29,025,930<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="nump">$ 21,478<span></span></td>
        <td class="nump">$ 32,139<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromExerciseOfWarrantsAndStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from exercise of warrants and stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ProceedsFromExerciseOfWarrantsAndStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetImpairmentCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Overall income (loss) from a disposal group that is classified as a component of the entity, before income tax, reported as a separate component of income before extraordinary items. Includes the following (before income tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 13<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.13(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfEquityInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase (decrease) in cash associated with the entity's discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInDiscontinuedOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4K<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591552-111686<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (a),(c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4J<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">21,291<span></span></td>
        <td class="nump">9,900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">21,291<span></span></td>
        <td class="nump">9,900<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">145,000,000<span></span></td>
        <td class="nump">145,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">52,908,567<span></span></td>
        <td class="nump">32,489,444<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">52,908,567<span></span></td>
        <td class="nump">32,489,444<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9. <font style="font-style:italic;">STOCK-BASED COMPENSATION</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has three plans that provide for equity-based compensation. Under the 2000 Stock Option Plan, 38,000 shares of Arrowhead&#8217;s Common Stock are reserved for issuance upon exercise of non-qualified stock options. No further grants can be made under the 2000 Stock Option Plan. The 2004 Equity Incentive Plan reserves 2,734,840 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others.  The 2013 Incentive Plan reserves 4,000,000 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance awards to employees, consultant and others.&nbsp;&nbsp;As of June 30, 2014, there were options granted and outstanding to purchase 38,000, 2,638,652 and 736,875 shares of Common Stock under the 2000 Stock Option Plan, the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively. Also, as of June 30, 2014, there were 410,085 shares reserved for options issued outside of equity compensation plans as inducement grants to new employees. During the nine months ended June 30, 2014, no options were granted under the 2004 Equity Incentive Plan, 765,000 were issued under the 2013 Incentive Plan and 165,000 options were granted outside of equity incentive plans as inducement stock options to new employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of<br />Options<br />Outstanding</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br />Average<br />Exercise<br />Price<br />Per&#160;Share</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate<br />Intrinsic<br />Value</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910,794</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,509,166</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.03</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(675 </p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)<font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.93</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419,285 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">930,000</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.05</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148,561</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(377,112</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.28</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,823,612</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.75</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,271,011</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At June 30, 2014</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532,180 </p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.80</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3 years</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,666,712</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the three and nine months ended June 30, 2014 was $1,070,631 and $2,186,653, respectively. Stock-based compensation expense for the three and nine months ended June 30, 201<font style="color:#;">3</font> was $363,593 and $1,114,375, respectively. There is no income tax benefit as the Company is currently operating at a loss and an actual income tax benefit may not be realized. The loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate grant date fair value of the options granted by the Company during the three and nine months ended June 30, 2014 is estimated at $<font style="color:#;">1,176,000</font> and $<font style="color:#;">8,295,600</font>, respectively. The aggregate grant date fair value of the options granted by the Company during the three and nine months ended June 30, 2013 is estimated at $<font style="color:#;">1,094,295</font> and $<font style="color:#;">1,197,588</font>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of the options exercised during the three and nine months ended June 30, 2014 was $371,334 and $3,606,061, respectively.&nbsp;&nbsp;No options were exercised during the three and nine months ended June 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, the pre-tax compensation expense for all unvested stock options in the amount of approximately $10,514,619 will be recognized in the Company&#8217;s results of operations over a weighted average period of <font style="color:#;">3.2 </font>years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="3" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:36.22%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months&#160;ended&#160;June 30,</p></td>
</tr>
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4</font><font style="font-weight:normal;"> </font></p></td>
<td valign="bottom" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">3</font><font style="font-weight:normal;"> </font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8% to 2.5%&nbsp;&nbsp;</p></td>
<td valign="bottom" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7%&#160; to&#160;1.3%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</p></td>
<td valign="top" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25 to 9.72</p></td>
<td valign="bottom" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 to 6.25</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:62.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average grant date fair value per share of options granted</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:17.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.26</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dividend yield is zero as the Company currently does not pay a dividend. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on the U.S. Treasury bond. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (RSUs) are granted under the Company&#8217;s 2013 Incentive Plan.&nbsp;&nbsp;During the nine months ended June 30, 2014, the Company issued 470,000 restricted stock units to certain members of management and certain members of its Board of Directors.&nbsp;&nbsp;At vesting each RSU will be exchanged for one share of the Company&#8217;s Common Stock. The RSUs issued to management vest in equal installments on the one and two year anniversary of the date of grant.&nbsp;&nbsp;The RSUs issued to the members of the Board of Directors vest upon the one year anniversary of the date of grant.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s Restricted Stock Units:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:64.68%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br />Number of<br />RSUs</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-<br />Average<br />Grant<br />Date<br />Fair Value</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:15.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,000</p></td>
<td valign="bottom" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td valign="bottom" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="width:1.08%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:15.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:0.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">470,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:0.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $968,051 and $1,571,611 of expense relating to restricted stock units during the three and nine months ended June 30, 2014 respectively, and such expense is included in stock-based compensation expense.&nbsp;&nbsp;There was no expense relating to restricted stock units during the three and nine months ended June 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, the pre-tax compensation expense for all unvested restricted stock units in the amount of approximately $5,291,302 will be recognized in the Company&#8217;s results of operations over a weighted average period of <font style="color:#;">1.5 </font>years. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Aug. 11, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DocumentDocumentAndEntityInformationLineItems', window );"><strong>Document Document And Entity Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">ARWR<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ARROWHEAD RESEARCH CORP<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000879407<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--09-30<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">52,908,567<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DocumentDocumentAndEntityInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_DocumentDocumentAndEntityInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10. <font style="font-style:italic;">FAIR VALUE MEASUREMENTS</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at June 30, 2014 and September&#160;30, 2013 for assets and liabilities measured at fair value on a recurring basis: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative assets</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,018,719</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,018,719</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations related to acquisitions</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <font style="color:#;">2013</font>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative assets</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096,363</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096,363</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations related to acquisitions</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash balances in short and long-term corporate bonds, generally with remaining maturities of less than two years.&nbsp;&nbsp;At June 30, 2014, the Company had short-term investments of $23,834,408, and long-term investments of $26,284,862, for a total of $50,119,270.&nbsp;&nbsp;The fair value of its investment at June 30, 2014 was $49,735,616.&nbsp;&nbsp;The Company expects to hold such investments until maturity, and thus unrealized gains and losses from the fluctuations in the fair value of the securities are not likely to be realized.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the proceeds from the sale of Unidym in January 2011, Arrowhead received a bond from Wisepower in the face amount of $2.5 million. The bond is convertible to Wisepower common stock at a price of $2.00 per share. The conversion feature is subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the conversion feature on the date of issuance was estimated using an option pricing model and recorded on the Company&#8217;s Consolidated Balance Sheet as a derivative asset. The fair value of the conversion feature is estimated at the end of each reporting period and the change in the fair value of the conversion feature is recorded as a non-operating gain/loss as change in value of derivatives in Company&#8217;s Consolidated Statement of Operations. During the quarter ended March&#160;31, 2013, the trading of Wisepower stock was halted. Trading resumed in July 2013, but the trading price is significantly below the conversion price.&nbsp;&nbsp;During fiscal 2013, the Company determined that the probability of realizing value from the conversion feature was remote, and the derivative asset value was reduced to zero.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended June 30, 2014, there was no change in the fair value of the derivative asset. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in valuing the derivative asset were not applicable as the value has been determined to be zero at June 30, 2014 and September 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the derivative asset: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2012</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease <font style="color:#000000;">in value</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements<font style="color:#000000;"></font></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2013</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease in value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of an equity financing in June 2010, Arrowhead issued warrants to acquire up to 329,649 shares of Common Stock (the &#8220;2010 Warrants&#8221;), of which 24,324 warrants were outstanding at June 30, 2014. Similarly, as part of a financing in December 2012, Arrowhead issued warrants to acquire up to 912,543 shares of Common Stock (the &#8220;2012 Warrants&#8221;) of which 265,161 warrants were outstanding at June 30, 2014.&nbsp;&nbsp;Further, as part of a financing in January 2013, Arrowhead issued warrants to acquire up to 833,530 shares of Common Stock (the &#8220;2013 Warrants&#8221;) of which 24,623 warrants were outstanding at June 30, 2014.&nbsp;&nbsp;Each of the warrants discussed above contains a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the terms of the Warrants, the Company issues Common Stock at a price lower than the exercise price for the Warrants, the exercise price would be reduced to the amount equal to the issuance price of the Common Stock.&nbsp;&nbsp;As a result of these features, the 2010 Warrants, the 2012 Warrants, and the 2013 Warrants are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the Warrants on the date of issuance was estimated using an option pricing model and recorded on the Company&#8217;s Consolidated Balance Sheet as a derivative liability. The fair value of the Warrants is estimated at the end of each reporting period and the change in the fair value of the Warrants is recorded as a non-operating gain or loss as change in value of derivatives in the Company&#8217;s Consolidated Statement of Operations. During the nine months ended June 30, 2014, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $5,680,544. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in valuing the derivative liability were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2010 Warrants</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September&#160;30,&#160;2013</font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.11%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 Years</p></td>
<td valign="bottom" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2012 Warrants</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September 30, 2013</font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5 Years</p></td>
<td valign="bottom" style="width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013 Warrants</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September 30, 2013</font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6 Years</p></td>
<td valign="bottom" style="width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the derivative liability related to these warrants: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2012</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626,195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,153,819</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,066,591</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements<font style="color:#000000;"></font></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,754,808 </p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2013</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,091,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,680,544</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,789,982)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,982,359</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:1pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:1pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the financing of Ablaris in fiscal 2011, Arrowhead sold exchange rights to certain investors whereby the investors have the right to exchange their shares of Ablaris for a prescribed number of Arrowhead shares based upon a predefined ratio. The exchange rights have a seven-year term. During the first year, the exchange right allows the holder to exchange one Ablaris share for 0.06 Arrowhead shares (as adjusted for a subsequent reverse stock split). This ratio declines to 0.04 in the second year, 0.03 in the third year and 0.02 in the fourth year. In the fifth year and beyond the exchange ratio is 0.01. Exchange rights for 675,000 Ablaris shares were sold in fiscal 2011, and remain outstanding at June 30, 2014. The exchange rights are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the exchange rights on the date of issuance was estimated using an option pricing model and recorded on the Company&#8217;s Consolidated Balance Sheet as a derivative liability. The fair value of the exchange rights is estimated at the end of each reporting period and the change in the fair value of the exchange rights is recorded as a non-operating gain or loss as change in value of derivatives in the Company&#8217;s Consolidated Statement of Operations. During the nine months ended June 30, 2014, the Company recorded a non-cash loss from the change in fair value of the derivative liability of $31,791.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:72.36%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160; 201<font style="color:#;">4</font></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,&#160; 2013</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5 Years</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3 Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the derivative liability related to these exchange rights: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,375</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,806</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,569</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,791</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,360</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The derivative assets/liabilities are estimated using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. Changes in the assumptions used could have a material impact on the resulting fair value. The primary input affecting the value of the Company&#8217;s derivatives liabilities is the Company&#8217;s stock price. Other inputs have a comparatively insignificant effect. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal 2012, contingent consideration was recorded upon the acquisitions of Roche Madison Inc. and Alvos Therapeutics, Inc., totaling $173,621. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions and experience. Estimating timing to complete the development, and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and the Company&#8217;s experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded as operating expenses as contingent consideration &#8211; fair value adjustments in the Company&#8217;s Consolidated Statement of Operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of contingent consideration fair value. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,621</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price contingent consideration</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421,652</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September 30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price contingent consideration</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of contingent consideration obligations is estimated through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&nbsp;&nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date.&nbsp;&nbsp;Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. Each of these assumptions can have a significant impact on the calculation of contingent consideration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s other financial instruments, which include accounts receivable, accounts payable, and accrued expenses approximate their respective fair values due to the relatively short-term nature of these instruments. The carrying value of the Company&#8217;s debt obligations approximates fair value based on market interest rates. </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAHBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_StatementConsolidatedStatementsOfOperationsLineItems', window );"><strong>Statement Consolidated Statements Of Operations [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
        <td class="nump">$ 43,750<span></span></td>
        <td class="nump">$ 43,750<span></span></td>
        <td class="nump">$ 131,250<span></span></td>
        <td class="nump">$ 246,516<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and payroll-related costs</a></td>
        <td class="nump">2,454,449<span></span></td>
        <td class="nump">1,651,729<span></span></td>
        <td class="nump">7,634,142<span></span></td>
        <td class="nump">5,006,328<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
        <td class="nump">1,582,465<span></span></td>
        <td class="nump">899,633<span></span></td>
        <td class="nump">3,865,845<span></span></td>
        <td class="nump">2,597,279<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">6,392,200<span></span></td>
        <td class="nump">1,756,527<span></span></td>
        <td class="nump">14,719,739<span></span></td>
        <td class="nump">5,458,212<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">2,038,682<span></span></td>
        <td class="nump">363,593<span></span></td>
        <td class="nump">3,758,264<span></span></td>
        <td class="nump">1,114,375<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">276,054<span></span></td>
        <td class="nump">454,086<span></span></td>
        <td class="nump">1,075,238<span></span></td>
        <td class="nump">1,352,448<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ImpairmentOfIntangibleAssets', window );">Impairment expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,308,047<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,308,047<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
        <td class="nump">12,743,850<span></span></td>
        <td class="nump">6,433,615<span></span></td>
        <td class="nump">31,053,228<span></span></td>
        <td class="nump">16,836,689<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(12,700,100)<span></span></td>
        <td class="num">(6,389,865)<span></span></td>
        <td class="num">(30,921,978)<span></span></td>
        <td class="num">(16,590,173)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in income (loss) of unconsolidated affiliates</a></td>
        <td class="nump">78,702<span></span></td>
        <td class="num">(159,530)<span></span></td>
        <td class="num">(69,350)<span></span></td>
        <td class="num">(380,699)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on sale of fixed assets, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(39,949)<span></span></td>
        <td class="num">(58,878)<span></span></td>
        <td class="num">(76,388)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
        <td class="nump">226,424<span></span></td>
        <td class="num">(48,252)<span></span></td>
        <td class="nump">386,392<span></span></td>
        <td class="num">(68,403)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in value of derivatives</a></td>
        <td class="nump">758,469<span></span></td>
        <td class="nump">200,747<span></span></td>
        <td class="num">(5,712,335)<span></span></td>
        <td class="nump">215,620<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
        <td class="nump">10,054<span></span></td>
        <td class="nump">259,221<span></span></td>
        <td class="nump">81,269<span></span></td>
        <td class="num">(997,976)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE)</a></td>
        <td class="nump">1,073,649<span></span></td>
        <td class="nump">212,237<span></span></td>
        <td class="num">(5,372,902)<span></span></td>
        <td class="num">(1,307,846)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</a></td>
        <td class="num">(11,626,451)<span></span></td>
        <td class="num">(6,177,628)<span></span></td>
        <td class="num">(36,294,880)<span></span></td>
        <td class="num">(17,898,019)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">LOSS FROM CONTINUING OPERATIONS</a></td>
        <td class="num">(11,626,451)<span></span></td>
        <td class="num">(6,177,628)<span></span></td>
        <td class="num">(36,294,880)<span></span></td>
        <td class="num">(17,898,019)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(354)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
        <td class="num">(11,626,451)<span></span></td>
        <td class="num">(6,177,628)<span></span></td>
        <td class="num">(36,294,880)<span></span></td>
        <td class="num">(17,898,373)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (gain) loss attributable to non-controlling interests</a></td>
        <td class="num">(2,468)<span></span></td>
        <td class="nump">98,618<span></span></td>
        <td class="nump">95,132<span></span></td>
        <td class="nump">447,268<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO ARROWHEAD</a></td>
        <td class="num">$ (11,628,919)<span></span></td>
        <td class="num">$ (6,079,010)<span></span></td>
        <td class="num">$ (36,199,748)<span></span></td>
        <td class="num">$ (17,451,105)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD</a></td>
        <td class="num">$ (0.22)<span></span></td>
        <td class="num">$ (0.23)<span></span></td>
        <td class="num">$ (0.81)<span></span></td>
        <td class="num">$ (0.92)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>SHAREHOLDERS - BASIC &amp; DILUTED:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic and diluted</a></td>
        <td class="nump">51,931,989<span></span></td>
        <td class="nump">26,134,183<span></span></td>
        <td class="nump">44,565,008<span></span></td>
        <td class="nump">18,893,197<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ImpairmentOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Impairment of intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ImpairmentOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_StatementConsolidatedStatementsOfOperationsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_StatementConsolidatedStatementsOfOperationsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from a disposal group, net of income tax before extraordinary items allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 13<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33749-111570<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 11<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of operating interest income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 10<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestIncomeExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LaborAndRelatedExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainLossOnDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisitions<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
        <td class="text"><div>
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">NOTE 4. <font style="font-style:italic;">ACQUISITIONS </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Roche Madison </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;21, 2011, the Company entered into a Stock and Asset Purchase Agreement (the &#8220;RNAi Purchase Agreement&#8221;) with Hoffmann-La Roche Inc. and F Hoffmann-La Roche Ltd (collectively, &#8220;Roche&#8221;), pursuant to which the Company purchased from Roche (i)&#160;all of the outstanding common stock of Roche Madison Inc. (&#8220;Roche Madison&#8221;, now &#8220;Arrowhead Madison&#8221;) and (ii)&#160;the intellectual property rights then held by Roche related to its RNAi business and identified in the RNAi Purchase Agreement (the &#8220;Transaction&#8221;). In consideration for the purchase of Roche Madison and the Roche RNAi assets, the Company issued to Roche a promissory note with a principal value of $50,000 and 1,288,158 shares of Common Stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the RNAi Purchase Agreement, Roche has a right of first negotiation on certain product candidates developed by the Company and its affiliates relating to the purchased assets. If the Company proposes to out-license or enters into substantive negotiations to out-license, any Clinical Candidate or Existing Candidate (as such terms are defined in the RNAi Purchase Agreement), the Company must give notice of the Candidate it proposes to out-license and negotiate exclusively and in good faith with Roche for 90 days regarding the applicable out-license. This right of first negotiation applies to all Existing Candidates (as defined in the RNAi Purchase Agreement) and the first five Clinical Candidates for which the Company delivers notice to Roche and subsequently enters into an out-license. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the consideration paid by the Company as per the closing terms, the Company is obligated to make certain royalty and milestone payments to Roche upon the occurrence of certain events. For certain product candidates that are developed by the Company that are covered by a valid claim by the patent rights transferred in the Transaction for which the Company and Roche do not enter into a licensing arrangement, the Company will be obligated to pay a 3% royalty on Net Sales (as defined in the RNAi Purchase Agreement), provided that the royalty rate may be reduced or offset in certain circumstances. The obligation to pay royalties on such candidates will last until the later of (i)&#160;the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii)&#160;ten years after the first commercial sale of such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will also be obligated to make cash payments to Roche upon the achievement of various milestones for certain clinical candidates, for which the Company and Roche do not enter into a licensing arrangement, including the first regulatory approval in certain jurisdictions, and upon certain annual sales milestones for candidates that receive regulatory approval. The potential payments range from $2,500,000 to $6,000,000 per milestone. At the time of acquisition, the Company&#8217;s estimate of future payments for potential royalties and milestones had a net present value of $84,935 which was recorded as contingent consideration as a part of other non-current liabilities.&nbsp;&nbsp;Contingent consideration is calculated by modeling research and development activities for clinical candidates, forecasting timelines to market, and using &#8220;peak sales&#8221; estimate modeling, cash flows and potential milestone and royalty payments are calculated.&nbsp;&nbsp;The modeling assumes certain success rates, and discount factors related to riskiness of projects and the time value of money to calculate a net present value of future consideration payments to Roche.&nbsp;&nbsp;These estimates are based on many unknown variables that are difficult to estimate, and due to the extended process of drug development prior to marketing of drug candidates, the models must extend many years into the future.&nbsp;&nbsp;Such predictions are inherently uncertain.&nbsp;&nbsp;On a quarterly basis, the Company re-evaluates its contingent consideration, and if material, makes adjustments to the recorded liability.&nbsp;&nbsp;Any adjustment to the contingent consideration liability is reflected in the Company&#8217;s Statement of Operations.&nbsp;&nbsp;During fiscal 2013, the contingent consideration liability was increased by $1.4 million, which is recorded as a part of other non-current liabilities on the Company&#8217;s Consolidated Balance Sheet. There have been no changes to the liability during the nine months ended June 30, 2014.&nbsp;&nbsp;For additional information related to our valuation of this obligation, see <font style="font-style:italic;">Note 10, Fair Value Measurements</font>.</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1383-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6996-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7000-128479<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1497-128463<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1490-128463<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1524-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fixed Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3. <font style="font-style:italic;">FIXED ASSETS</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and other fixed assets are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2013</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,162</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323,376</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,248,606</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,452,013</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,623</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,623</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,955,217</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,749,409</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,607,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,594,421</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&nbsp;&nbsp; Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,933,477</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,081,186</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,674,131</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,513,235</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Information about Warrants</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes information about warrants outstanding at June 30, 2014: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td colspan="3" valign="top" style="width:58.84%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;prices</p></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;<br />Warrants</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining<font style="font-weight:normal;"><br /></font>Life&#160;in&#160;Years</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">416,225</p></td>
<td valign="bottom" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="bottom" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="bottom" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,324</p></td>
<td valign="bottom" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="bottom" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.25</p></td>
<td valign="bottom" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,347 </p></td>
<td valign="bottom" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.12</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom" style="width:48.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,784</p></td>
<td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom" style="width:1.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" bgcolor="#CFF0FC" style="width:58.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total warrants outstanding</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,526,781 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4JAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Nature of Business</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nature of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary Dynamic Polyconjugate (DPC) delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead&#8217;s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Liquidity</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Historically, the Company&#8217;s primary source of financing has been through the sale of equity securities.&nbsp;&nbsp;Research and development activities have required significant capital investment since the Company&#8217;s inception and the Company expects its operations to continue to require cash investment in fiscal 2014 and beyond as the Company advances its research and development efforts, including clinical trials, and related drug manufacturing costs.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 201<font style="color:#;">4</font>, the Company had $138.3 million in cash to fund operations. In addition to its cash resources, the Company has invested excess cash in investment grade commercial bonds maturing in less than 27 months.&nbsp;&nbsp;These bonds provide a source of liquidity, though the Company plans to hold them until maturity.&nbsp;&nbsp;At June 30, 2014, the Company had invested $50.1 million in bonds.&nbsp;&nbsp;During the nine months ended June 30, 2014, the Company&#8217;s cash position increased by $119.2 million, which was the result of the receipt of cash from the issuance of equity of $172.6 million and cash from the exercise of warrants and options of $12.4 million, partially offset by net cash invested in fixed income investments of $39.8 million, cash outflows of $24.5 million related to continuing operating activities and capital expenditures of $<font style="color:#;">1.3</font> million. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Principles of Consolidation&#8212;The consolidated financial statements include the accounts of Arrowhead and its Subsidiaries.&nbsp;&nbsp;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facilities are located.&nbsp;&nbsp;All significant intercompany accounts and transactions are eliminated in consolidation, and non-controlling interests are accounted for in the Company&#8217;s financial statements. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Basis of Presentation&#8212;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form&#160;10-Q and Article&#160;8 of Regulation S-X.&nbsp;&nbsp;Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year.&nbsp;&nbsp;The September 30, 2013 Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended September&#160;30, 2013.&nbsp;&nbsp;Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.&nbsp;&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates&#8212;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.&nbsp;&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&nbsp;&nbsp;The Company had no restricted cash at June 30, 2014 and September 30, 2013.</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Concentration of Credit Risk&#8212;The Company maintains several checking accounts for its operations at two financial institutions. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Investments&#8212;The Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities.&#160;This statement requires certain securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At <font style="color:#;">June 30, 2014</font>, the Company classified all of its investments as held-to-maturity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.&nbsp;&nbsp;See further information regarding the Company&#8217;s short and long term investments in Note 2 &#8211; Investments.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See further information regarding fair market value of marketable debt securities in Note 10 &#8211; Fair Value Measurements, such fair market data is obtained from independent pricing services. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets subject to amortization</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization included certain license agreements acquired through business combinations. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research &amp; Development (IPR&amp;D)</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In-Process Research&#160;&amp; Development (IPR&amp;D)&#8212;IPR&amp;D assets represent capitalized on-going research projects that Arrowhead acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of R&amp;D efforts associated with the project. Upon successful completion of a project, Arrowhead will make a determination as to the then remaining useful life of the intangible asset and begin amortization. Arrowhead tests its indefinite-lived assets for impairment at least annually, through a two-step process. The first step is a qualitative assessment to determine if it is more likely than not that the indefinite lived assets are impaired. Arrowhead considers relevant events and circumstances that could affect the inputs used to determine the fair value of the intangible assets. If the qualitative assessment indicates that it is more likely than not that the intangible assets are impaired, a second step is performed which is a quantitative test to determine the fair value of the intangible asset. If the carrying amount of the intangible assets exceeds its fair value, an impairment loss is recorded in the amount of that excess. If circumstances determine that it is appropriate, the Company may also elect to bypass step one, and proceed directly to the second step. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Contingent Consideration - The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event.&nbsp;&nbsp;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&nbsp;&nbsp;Estimated payments are discounted using present value techniques to arrive at estimated fair value at the balance sheet date. Changes in the fair value of our contingent consideration obligations are recognized within our consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAndCostMethodInvestmentsPolicy', window );">Minority Equity Investments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Minority Equity Investments&#8212;The Company had a minority equity investment in Leonardo, a privately held biotechnology company.&nbsp;&nbsp;Based on the status of the development of Leonardo&#8217;s program, this investment has been fully impaired and the net book value at June 30, 2014 is $0.&nbsp;&nbsp;The operations of Leonardo ceased in December 2013. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NoncontrollingInterestsPolicyTextBlock', window );">Noncontrolling Interests in Majority-Owned Subsidiaries</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Non-controlling Interests in Majority-Owned Subsidiaries&#8212;Operating losses applicable to majority-owned Calando, Ablaris and, prior to its disposal, Unidym have periodically exceeded the non-controlling interests in the equity capital of either Subsidiary. Such excess losses applicable to the non-controlling interests have been and are borne by the Company as there is no obligation of the non-controlling interests to fund any losses in excess of their original investment. There is also no obligation or commitment on the part of the Company to fund operating losses of any Subsidiary whether wholly-owned or majority-owned. The Company allocates the non-controlling interests&#8217; share of net loss in excess of the non-controlling interests&#8217; initial investment in accordance with FASB ASC 810-10. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When there is a change in the Company&#8217;s proportionate ownership share of a development-stage Subsidiary resulting from additional equity transactions in the Subsidiary, the change is accounted for as an equity transaction in consolidation. To the extent that the increase in the calculated value of the Company&#8217;s interest in the equity of the Subsidiary exceeds the Company&#8217;s investment in the transaction, that increase in value is referred to as the Company&#8217;s &#8220;increase in its proportionate share of the Subsidiary&#8217;s equity&#8221; and the amount is recorded as an increase in the Company&#8217;s Additional Paid-in Capital. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenue Recognition&#8212;Revenue from license fees are recorded when persuasive evidence of an arrangement exists, title has passed or services have been rendered, a price is fixed and determinable, and collection is reasonably assured. The Company may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding and various milestone and future product royalty or profit-sharing payments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments under collaborative research and development agreements are recognized ratably over the relevant periods specified in the agreement, generally the period during which research and development is conducted. Revenue from up-front license fees, milestones and product royalties are recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Allowance for Doubtful Accounts</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Earnings (Loss) per Share&#8212;Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options issued to employees and consultants and warrants to purchase Common Stock of the Company.&nbsp;&nbsp; </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Assets and Liabilities</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Derivative Assets and Liabilities &#8211; The Company accounts for warrants and other derivative financial instruments as either equity or assets/liabilities based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded as additional paid-in capital on the Company&#8217;s Consolidated Balance Sheet and no further adjustments to their valuation are made. Some of the Company&#8217;s warrants were determined to be ineligible for equity classification because of provisions that may result in an adjustment to their exercise price. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as assets or liabilities are recorded on the Company&#8217;s Consolidated Balance Sheet at their fair value on the date of issuance and are revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. The Company estimates the fair value of these assets/liabilities using option pricing models that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life and risk-free interest rate. </p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period. </p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Standards </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In June 2014, the FASB issued ASU 2014-10, <font style="font-style:italic;">Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance</font>, which eliminates the distinction and separate requirements for development stage entities and other reporting entities under U.S. GAAP.&nbsp;&nbsp;Specifically the amendment eliminates the requirement for development stage entities to 1) present inception-to-date information in the statements of income, cash flow and shareholders&#8217; equity, 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.&nbsp;&nbsp;ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 with early adoption permitted.&nbsp;&nbsp;The Company has adopted ASU 2014-10 effectively with the filing of this Form 10-Q.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 <font style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font>, which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and will become effective for the Company in the first quarter of 2018. The Company is evaluating the potential effects of the adoption of this update on its financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the FASB issued ASU 2013-11, <font style="font-style:italic;">Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</font>, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity&#8217;s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. The Company is evaluating the impact, if any, of the adoption of ASU 2013-11 on its Consolidated Balance Sheet.</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ContingentConsiderationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ContingentConsiderationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NoncontrollingInterestsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for non-controlling interests.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_NoncontrollingInterestsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAndCostMethodInvestmentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The disclosure provided may include how equity method or cost investments are assessed for impairment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196929<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 12<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAndCostMethodInvestmentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144439<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144471<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.15)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 15<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InProcessResearchAndDevelopmentPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section M<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2, 12<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TradeAndOtherAccountsReceivablePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7. <font style="font-style:italic;">STOCKHOLDERS&#8217; EQUITY</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2014, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001, and 5,000,000 shares of Preferred Stock, par value $0.001. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2014, <font style="color:#;">52,908,567</font> shares of Common Stock were outstanding.&nbsp;&nbsp;Additionally, 21,291 shares of Preferred Stock were outstanding, including 5,291 shares of Series B Preferred Stock, convertible into 2,891,257 shares of Common Stock, and 16,000 shares of Series C Preferred Stock, convertible into 2,730,375 shares of Common Stock, (collectively, the &#8220;Outstanding Preferred Stock&#8221;). At June 30, 2014, 7,182,925 shares were reserved for issuance upon vesting of restricted stock units and exercise of stock options granted under Arrowhead&#8217;s 2000 Stock Option Plan, 2004 Equity Incentive Plan, and 2013 Incentive Plan, as well as for inducement grants made to new employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Outstanding Preferred Stock is convertible to Common Stock by each holder at its stated conversion price, subject to a 9.99% beneficial ownership limit for each holder.&nbsp;&nbsp;The holders of Outstanding Preferred Stock are eligible to vote with the Common Stock of the Company on an as-converted basis, but only to the extent they are eligible for conversion without exceeding the 9.99% ownership limitation. The Outstanding Preferred Stock does not carry a coupon, but is entitled to receive dividends on a pari passu basis with the Common Stock, when and if declared.&nbsp;&nbsp;In any liquidation or dissolution of the Company, the holders of Outstanding Preferred Stock are entitled to participate in the distribution of the assets, to the extent legally available for distribution, on a pari passu basis with the Common Stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;20, 2011, the Company and Lincoln Park Capital Fund, LLC, an Illinois limited liability company (&#8220;LPC&#8221;) entered into a $15 million purchase agreement (the &#8220;Purchase Agreement&#8221;), whereby LPC agreed to purchase up to $15 million of Common Stock, subject to certain limitations, from time to time during the three-year term of the Purchase Agreement. The Company has the right, in its sole discretion, over a 36-month period to sell up to $15 million of Common Stock (subject to certain limitations) to LPC, depending on certain conditions as set forth in the Purchase Agreement. As of June 30, 2014, the Company had drawn $1 million from the facility. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;11, 2013, the Company sold 3,071,672 shares of common stock, at a price of $5.86 per share, and 46,000 shares of Series&#160;C Convertible Preferred Stock (the &#8220;Preferred Shares&#8221;), at a price of $1,000 per share. The Preferred Shares are convertible into shares of common stock at a conversion price of $5.86. The aggregate purchase price paid by the Purchasers for the Shares and Preferred Shares was $64,000,000 and the Company received net proceeds of approximately $60,000,000, after advisory fees and offering expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 24, 2014, the Company sold 6,325,000 shares of common stock, at a public offering price of $18.95 per share.&nbsp;&nbsp;Net proceeds were approximately $112.6 million after underwriting commissions and discounts and other offering expense.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about warrants outstanding at June 30, 2014: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td colspan="3" valign="top" style="width:58.84%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;prices</p></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;<br />Warrants</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining<font style="font-weight:normal;"><br /></font>Life&#160;in&#160;Years</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">416,225</p></td>
<td valign="bottom" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="bottom" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,204</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38</p></td>
<td valign="bottom" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,324</p></td>
<td valign="bottom" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td valign="bottom" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.16</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.25</p></td>
<td valign="bottom" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,347 </p></td>
<td valign="bottom" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.12</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:48.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="width:8.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.83</p></td>
<td valign="bottom" style="width:48.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" /></td>
<td valign="top" style="width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,784</p></td>
<td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:16.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="bottom" style="width:1.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" bgcolor="#CFF0FC" style="width:58.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total warrants outstanding</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,526,781 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;text-align:center;margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:16.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5. <font style="font-style:italic;">INTANGIBLE ASSETS</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets consist of in-process research and development (&#8220;IPR&amp;D&#8221;) not subject to amortization, and other intangible assets subject to amortization, which were capitalized as a part of a business combination. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&amp;D represents projects that have not yet received regulatory approval and are required to be classified as indefinite assets until the successful completion or the abandonment of the associated R&amp;D efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in one or more jurisdictions which, individually or combined, are expected to generate a significant portion of the total revenue expected to be earned by an IPR&amp;D project. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is abandoned the related IPR&amp;D assets will likely be written off and we would record an impairment loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization include patents capitalized as part of a business combination as well as license agreements capitalized as part of a business combination from the acquisition of Roche Madison.&nbsp;&nbsp; The license agreements are being amortized over the estimated life remaining at the time of acquisition which was 4 years, and the accumulated amortization of the assets is approximately $147,800. Patents have been amortized over a period of three years to twenty years, however the patent assets were fully impaired as of September 30, 2013. Amortization expense for the three and nine months ended June 30, 2014 was approximately $13,663 and $40,990, respectively.&nbsp;&nbsp;Amortization expense for the three and nine months ended June 30, 2013 was approximately $74,115 and $222,345, respectively. Amortization of license agreements is expected to be approximately $14,000 for the remainder of fiscal year 201<font style="color:#;">4, $55,000 in </font>201<font style="color:#;">5</font>, $14,000 in 2016, and zero thereafter. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review amounts capitalized as IPR&amp;D for impairment at least annually in the fourth quarter, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In the event the carrying value of the assets is not expected to be recovered, the assets are written down to their estimated fair values. We continue to test our indefinite-lived IPR&amp;D assets for potential impairment until the projects are completed or abandoned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on our intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:84%;">
<tr>
<td valign="bottom" style="width:46%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible&#160;assets<font style="font-weight:normal;"><br /></font>not subject to<br />amortization</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible&#160;assets<br />subject to<br />amortization</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total<br />Intangible&#160;assets</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September&#160;30, 2012</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,667,247</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,784,569</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,308,047</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,308,047</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(236,009 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(236,009</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September&#160;30, 2013</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,191</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240,513</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" bgcolor="#CFF0FC" style="width:46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,990</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,990</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="width:46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2014</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,117,322</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,201</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,199,523</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investment in Subsidiaries<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Subsidiaries</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6. <font style="font-style:italic;">INVESTMENT IN SUBSIDIARIES</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to 100% ownership interest in Arrowhead Madison Inc., Arrowhead also maintains majority ownership in Calando Pharmaceuticals, Ablaris Therapeutics, Inc., and a minority investment in Leonardo Biosystems, Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Calando Pharmaceuticals, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calando is a developer of polymer delivery systems for siRNA and small molecule based therapeutics.&nbsp;&nbsp;Calando&#8217;s current cash resources preclude additional development of its platform technology and therapeutic candidates.&nbsp;&nbsp;Arrowhead has determined that it will not provide substantial further investment to Calando based on Arrowhead evaluation of Calando&#8217;s development and business prospects and Calando has been unsuccessful in its efforts to obtain capital from other sources.&nbsp;&nbsp;Calando has ceased operations and terminated its technology license with the California Institute of Technology on which its siRNA therapeutic development efforts were based.&nbsp;&nbsp;Further, pursuant to an involuntary petition by an unpaid Noteholder, Calando is undergoing Chapter 7 bankruptcy proceedings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2009, Calando outlicensed its small molecule program to Cerulean Pharma, Inc., a Boston, MA-based biotech company which has continued the development of the program.&nbsp;&nbsp;Under the license, as the development program progresses, Calando could collect partnership, milestone and royalty payments from Cerulean.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calando has an outstanding promissory note with a balance of principal and interest totaling $1,253,000 as of June 30, 2014.&nbsp;&nbsp;The promissory note became due on November 26, 2013, but was not repaid due to lack of cash resources at Calando.&#160;&#160;The holder of the Note initiated an involuntary petition of bankruptcy against Calando.&#160;&#160;A trustee has been appointed and a meeting of Calando creditors has occurred.&#160;&#160;It is expected that the trustee will dispose of Calando assets, primarily its license agreement with Cerulean.&#160;&#160;The Company cannot estimate the proceeds from the disposition of Calando&#8217;s assets, nor how it will be distributed amongst its various creditors, which includes Arrowhead and the holder of the Note.&nbsp;&nbsp;During the nine months ended June 30, 2014, Arrowhead deconsolidated Calando based on the fact that Calando is now subject to the control of the bankruptcy trustee.&nbsp;&nbsp;The deconsolidation of Calando resulted in an approximately $87,000 gain to the Company&#8217;s Consolidated Statement of Operations.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, Calando owed to Arrowhead $<font style="color:#;">4.5</font> million under a series of 8% simple interest notes and advances. It is unlikely these notes will be repaid in full. The balance of the notes and advances has been fully reserved.  &nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, Arrowhead owned <font style="color:#;">79</font>% of the outstanding shares of Calando and <font style="color:#;">76</font>% on a fully diluted basis.&nbsp;&nbsp;As a result of the ongoing bankruptcy proceeding for Calando, we do not expect our equity ownership to result in any return of capital as part of the liquidation of Calando.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ablaris Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ablaris was formed and began operations in fiscal 2011, based on the license of certain anti-obesity technology developed at the MD Anderson Cancer Center at the University of Texas. During fiscal 2011, Ablaris raised $2.9 million in cash, of which $1.3 million was invested by Arrowhead and $1.6 million was invested by outside investors, through the issuance of Ablaris Series A Preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, Arrowhead owned <font style="color:#;">64</font>% of the outstanding shares of Ablaris and <font style="color:#;">64</font>% on a fully diluted basis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Leonardo Biosystems, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leonardo, a privately-held drug-delivery company in which Arrowhead has a 3% ownership interest, ceased operations in December 2013. Arrowhead&#8217;s investment in Leonardo and its receivable from Leonardo have been fully reserved.&nbsp;&nbsp; </p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658923&amp;loc=d3e32847-111569<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658923&amp;loc=d3e32787-111569<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8. <font style="font-style:italic;">LEASES</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters in Pasadena, California. In March 2014, the Company signed a lease addendum to expand its corporate headquarters.&nbsp;&nbsp;It is expected the new space will be available in September 2014.&nbsp;&nbsp;The leases for the expansion space and the current space will expire in August 2019.&nbsp;&nbsp; Rental costs, including the expansion space are approximately $22,000 per month, increasing approximately 3% annually.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s research facility in Madison, Wisconsin is leased through February&#160;28, 2019. Monthly rental expense is approximately $25,000. Other monthly rental expenses include common area maintenance and real estate taxes totaling approximately $16,000 per month. Utilities costs are approximately $15,000 per month. Including monthly payments recorded under a capital lease of approximately $19,000, total monthly costs are approximately $75,000 per month. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility and equipment rent expense, related to continuing operations, for the three and nine months ended June 30, 2014 was $138,000 and $403,000, respectively.&nbsp;&nbsp;Facility and equipment rent expense, related to continuing operations, for the three and nine months ended June 30, 2013 was $126,000 and $407,000, respectively.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, future minimum lease payments due in fiscal years under capitalized leases are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4 (remainder of)</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">5 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">6 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">7 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">8 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">228,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">9 </font>and thereafter</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,175</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less interest</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,681 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,025,279</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,110 </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">812,169</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014, future minimum lease payments due in fiscal years under operating leases are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:56%;">
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">4 (remainder of)</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,164</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">5 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580,626</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">6 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">597,196</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">7 </font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613,984</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">8 </font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638,217</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201<font style="color:#;">9 </font>and thereafter</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,861 </p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,997,048</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 1,3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeasesOfLesseeDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investment in Subsidiaries - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Calando Pharmaceuticals Inc</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Ablaris Therapeutics</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Ablaris Therapeutics</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Leonardo Biosystems Inc</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OwnershipPercentageInSubsidiary', window );">Ownership percentage in subsidiary</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OutstandingBalanceOfPromissoryNote', window );">Outstanding Balance of Promissory Note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,253,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">87,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AmountOwedBySubsidiary', window );">Amount owed by subsidiary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_StatedPercentageOfNotesAndAdvances', window );">Stated percentage of notes and advances</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of outstanding shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">64.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis', window );">Percentage of investment ownership</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">76.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">64.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Issuance of preferred stock in subsidiary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InvestmentInPreferredStock', window );">Investment in preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InvestmentInPreferredStockByOutsider', window );">Investment in preferred stock by outsider</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountOwedBySubsidiary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount owed by subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_AmountOwedBySubsidiary</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity method investment ownership percentage on dilutive basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_EquityMethodInvestmentOwnershipPercentageOnDilutiveBasis</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InvestmentInPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investment in preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_InvestmentInPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InvestmentInPreferredStockByOutsider">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investment in preferred stock by outsider.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_InvestmentInPreferredStockByOutsider</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OutstandingBalanceOfPromissoryNote">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Outstanding balance of promissory note.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_OutstandingBalanceOfPromissoryNote</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OwnershipPercentageInSubsidiary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ownership percentage in subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_OwnershipPercentageInSubsidiary</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_StatedPercentageOfNotesAndAdvances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stated percentage of notes and advances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_StatedPercentageOfNotesAndAdvances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In connection with deconsolidation of a subsidiary or derecognition of a group of assets, the portion of any gain (loss) recognized by the parent, during the period, which is related to the remeasurement of any retained investment in the former subsidiary or group of assets to its fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4582445-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInvestmentsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2013</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,162</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323,376</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,248,606</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,452,013</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,623</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,623</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,955,217</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,749,409</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,607,608</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,594,421</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:&nbsp;&nbsp; Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,933,477</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,081,186</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net </p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,674,131</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,513,235</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes fair value measurements at June 30, 2014 and September&#160;30, 2013 for assets and liabilities measured at fair value on a recurring basis: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2014: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,349,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative assets</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,018,719</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,018,719</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations related to acquisitions</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <font style="color:#;">2013</font>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,114,444</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative assets</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096,363</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096,363</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations related to acquisitions</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Derivative Asset</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following is a reconciliation of the derivative asset: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2012</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease <font style="color:#000000;">in value</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements<font style="color:#000000;"></font></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2013</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease in value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Derivative Liability</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following is a reconciliation of the derivative liability related to these warrants: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2012</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626,195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,153,819</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,066,591</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;color:#;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements<font style="color:#000000;"></font></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,754,808 </p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 2013</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,091,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,680,544</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,789,982)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,982,359</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:1pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:1pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Change in Fair Value of Contingent Consideration Obligations</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following is a reconciliation of contingent consideration fair value. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,621</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price contingent consideration</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421,652</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September 30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price contingent consideration</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,595,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Exchange rights</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock', window );">Assumptions Used in Valuing Derivative Liabilities</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:72.36%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:0pt;;">&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,&#160; 201<font style="color:#;">4</font></p></td>
<td valign="bottom" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,&#160; 2013</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5 Years</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3 Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p></td>
<td valign="bottom" style="width:13.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Derivative Liability</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following is a reconciliation of the derivative liability related to these exchange rights: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">2</font></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,375</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,806</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at September&#160;30, 201<font style="color:#;">3</font></p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,569</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of instruments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,791</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net settlements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value at June 30, 2014</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,360</p></td>
<td valign="bottom" style="width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:4pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock', window );">Assumptions Used in Valuing Derivative Liabilities</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The assumptions used in valuing the derivative liability were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76%;">
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2010 Warrants</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September&#160;30,&#160;2013</font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.11%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 Years</p></td>
<td valign="bottom" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2012 Warrants</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September 30, 2013</font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5 Years</p></td>
<td valign="bottom" style="width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2013 Warrants</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">June 30, 2014</font></p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">September 30, 2013</font></p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.88%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39%</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6 Years</p></td>
<td valign="bottom" style="width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3&#160;Years</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:27.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
<td valign="bottom" style="width:1.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom" style="width:25.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value assumptions and methodology for liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_FairValueAssumptionsAndMethodologyForLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements - Change in Fair Value of Contingent Consideration Obligations (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition Contingent Consideration [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value, Beginning balance</a></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="nump">$ 173,621<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue', window );">Purchase price contingent consideration</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_BusinessCombinationContingentConsiderationPayments', window );">Contingent consideration payments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_BusinessCombinationFairValueOfChangeInContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,421,652<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Value, Ending balance</a></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="nump">$ 1,595,273<span></span></td>
        <td class="nump">$ 173,621<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BusinessCombinationContingentConsiderationPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business combination contingent consideration payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_BusinessCombinationContingentConsiderationPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BusinessCombinationFairValueOfChangeInContingentConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business combination fair value of change in contingent consideration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_BusinessCombinationFairValueOfChangeInContingentConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business combination purchase price contingent consideration fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_BusinessCombinationPurchasePriceContingentConsiderationFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionContingentConsiderationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph b<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationContingentConsiderationLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, beginning balance</a></td>
        <td class="nump">3,419,285<span></span></td>
        <td class="nump">1,910,794<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted</a></td>
        <td class="nump">930,000<span></span></td>
        <td class="nump">1,509,166<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options Outstanding, Cancelled</a></td>
        <td class="num">(148,561)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Outstanding, Exercised</a></td>
        <td class="num">(377,112)<span></span></td>
        <td class="num">(675)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, ending balance</a></td>
        <td class="nump">3,823,612<span></span></td>
        <td class="nump">3,419,285<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable</a></td>
        <td class="nump">1,532,180<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, beginning balance</a></td>
        <td class="nump">$ 4.68<span></span></td>
        <td class="nump">$ 6.10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
        <td class="nump">$ 14.05<span></span></td>
        <td class="nump">$ 2.03<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Cancelled</a></td>
        <td class="nump">$ 5.88<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
        <td class="nump">$ 6.28<span></span></td>
        <td class="nump">$ 3.93<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, ending balance</a></td>
        <td class="nump">$ 6.75<span></span></td>
        <td class="nump">$ 4.68<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable</a></td>
        <td class="nump">$ 5.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
        <td class="text">8 years 3 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
        <td class="text">7 years 3 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
        <td class="nump">$ 30,271,011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump">$ 13,666,712<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYVAK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common stock issued @ $5.86</div>
        </th>
        <th class="th">
          <div>Common stock issued @ $18.95</div>
        </th>
        <th class="th">
          <div>Preferred stock issued @ $1,000 per share</div>
        </th>
        <th class="th">
          <div>Common Stock Issued to Galloway</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Common stock issued @ $5.86</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Common stock issued @ $18.95</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Common Stock Issued to Galloway</div>
        </th>
        <th class="th">
          <div>Preferred Stock</div>
        </th>
        <th class="th">
          <div>Preferred Stock

</div>
          <div>Preferred stock issued @ $1,000 per share</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital

</div>
          <div>Common stock issued @ $5.86</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital

</div>
          <div>Common stock issued @ $18.95</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital

</div>
          <div>Preferred stock issued @ $1,000 per share</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital

</div>
          <div>Common Stock Issued to Galloway</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
        <th class="th">
          <div>Non-controlling Interest</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance Amount at Sep. 30, 2013</a></td>
        <td class="nump">$ 25,734,789<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 124,859<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 193,514,766<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (166,140,969)<span></span></td>
        <td class="num">$ (1,763,877)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance Shares at Sep. 30, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">32,489,444<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_WarrantsExercisedDuringPeriodShares', window );">Exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,875,727<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_WarrantsExercisedDuringPeriodValue', window );">Exercise of warrants, Amount</a></td>
        <td class="nump">10,004,793<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,875<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,001,918<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
        <td class="nump">377,112<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">377,112<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, Amount</a></td>
        <td class="nump">2,369,262<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,368,885<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump">3,758,264<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,758,264<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issuances, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,071,672<span></span></td>
        <td class="nump">6,325,000<span></span></td>
        <td class="nump">131,579<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issuances</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,060,112<span></span></td>
        <td class="nump">112,581,559<span></span></td>
        <td class="nump">46,000,000<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,072<span></span></td>
        <td class="nump">6,325<span></span></td>
        <td class="nump">132<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,057,040<span></span></td>
        <td class="nump">112,575,234<span></span></td>
        <td class="nump">45,999,954<span></span></td>
        <td class="nump">499,868<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Settlements related to derivative liability</a></td>
        <td class="nump">5,789,979<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,789,979<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Preferred stock converted to common stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,638,033<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(34,609)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Preferred stock converted to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,638<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(35)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7,603)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Calando Pharmaceuticals, Inc.</a></td>
        <td class="nump">1,303,911<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,303,911<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the nine months ended June 30, 2014</a></td>
        <td class="num">(36,294,880)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(36,199,748)<span></span></td>
        <td class="num">(95,132)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance Amount at Jun. 30, 2014</a></td>
        <td class="nump">$ 185,807,789<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 145,278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 21<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 388,558,305<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (202,340,717)<span></span></td>
        <td class="num">$ (555,098)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance Shares at Jun. 30, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">52,908,567<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,291<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_WarrantsExercisedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercised during period shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_WarrantsExercisedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_WarrantsExercisedDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercised during period value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_WarrantsExercisedDuringPeriodValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4I<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4590271-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock', window );">Investments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2. <font style="font-style:italic;">INVESTMENTS</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash balances in short-term and long-term debt securities.&nbsp;&nbsp;Investments at June 30, 2014 consisted of corporate bonds with maturities remaining of less than three years at the time of purchase.&nbsp;&nbsp;The Company may also invest excess cash balances in certificates of deposit, money market accounts, US Treasuries, US government agency obligations, corporate debt securities, and/or commercial paper.&nbsp;&nbsp;The Company accounts for its investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities.&nbsp;&nbsp;At <font style="color:#;">June 30, 2014</font>, all investments were classified as held-to-maturity securities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short and long-term investments as of June 30, 2014, and September 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,834,408</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,850</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(237,181</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,599,077</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due after one year within three years)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,284,862</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,899</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,222</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,136,599</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,119,270</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,749</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(389,403</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,735,616</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2013</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,030,261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,998,480</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due after one year within three years)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702,153</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,362</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699,791</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,732,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,643</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,698,271</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for cost method and equity method investments included basis, impairment losses, recognized or unrecognized gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWWAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash to fund operations</a></td>
        <td class="nump">$ 138,349,733<span></span></td>
        <td class="nump">$ 29,025,930<span></span></td>
        <td class="nump">$ 19,114,444<span></span></td>
        <td class="nump">$ 3,377,288<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity description</a></td>
        <td class="text">less than 27 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash</a></td>
        <td class="nump">119,235,289<span></span></td>
        <td class="nump">25,648,642<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Cash from issuance of equity</a></td>
        <td class="nump">172,641,720<span></span></td>
        <td class="nump">42,448,824<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ProceedsFromExerciseOfWarrantsAndStockOptions', window );">Cash from exercise of warrants and options</a></td>
        <td class="nump">12,374,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NetCashInvestedInFixedIncomeInvestments', window );">Net cash invested in fixed income investments</a></td>
        <td class="nump">39,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash outflow related to continuing operating activities</a></td>
        <td class="nump">24,496,567<span></span></td>
        <td class="nump">13,639,360<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
        <td class="nump">1,251,987<span></span></td>
        <td class="nump">191,656<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Amount insured in FDIC per account</a></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CostMethodInvestmentAttributableToNoncontrollingInterest', window );">Minority equity investment, book value</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Commercial Bonds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
        <td class="nump">$ 50,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CostMethodInvestmentAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cost method investment attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_CostMethodInvestmentAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NetCashInvestedInFixedIncomeInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net cash invested in fixed income investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_NetCashInvestedInFixedIncomeInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromExerciseOfWarrantsAndStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from exercise of warrants and stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>arwr_ProceedsFromExerciseOfWarrantsAndStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>arwr_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFDICInsuredAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDateDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.1(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph h<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Investments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInvestmentsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>148</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Investment in Subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiaries</Role>
      <ShortName>Investment in Subsidiaries</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Investments - Summary of Short and Long-term Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentsSummaryOfShortAndLongTermInvestmentsDetail</Role>
      <ShortName>Investments - Summary of Short and Long-term Investments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fixd Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFixdAssetsAdditionalInformationDetail</Role>
      <ShortName>Fixd Assets - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Summary of Property and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Acquisitions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureAcquisitionsAdditionalInformationDetail</Role>
      <ShortName>Acquisitions - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Intangible Assets - Schedule of Intangible Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetDetail</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Asset (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Investment in Subsidiaries - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureInvestmentInSubsidiariesAdditionalInformationDetail</Role>
      <ShortName>Investment in Subsidiaries - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stockholders' Equity - Summary of Information about Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockholdersEquitySummaryOfInformationAboutWarrantsDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Information about Warrants (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Leases - Future Minimum Lease Payments under Capitalized Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderCapitalizedLeasesDetail</Role>
      <ShortName>Leases - Future Minimum Lease Payments under Capitalized Leases (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Leases - Future Minimum Lease Payments under Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail</Role>
      <ShortName>Leases - Future Minimum Lease Payments under Operating Leases (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Reconciliation of Derivative Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeAssetDetail</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Derivative Asset (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value Measurements - Assumptions Used in Valuing Derivative Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedInValuingDerivativeLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Assumptions Used in Valuing Derivative Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair Value Measurements - Reconciliation of Derivative Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsReconciliationOfDerivativeLiabilityDetail</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Derivative Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20140630/taxonomy/role/DisclosureFairValueMeasurementsChangeInFairValueOfContingentConsiderationObligationsDetail</Role>
      <ShortName>Fair Value Measurements - Change in Fair Value of Contingent Consideration Obligations (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">'Monetary' elements on report '100340 - Disclosure - Stockholders' Equity - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 100010 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">Process Flow-Through: 100020 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 100030 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 100050 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 100060 - Statement - Consolidated Statements of Cash Flows</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">Process Flow-Through: 100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2013'</Log>
  </Logs>
  <InputFiles>
    <File>arwr-20140630.xml</File>
    <File>arwr-20140630.xsd</File>
    <File>arwr-20140630_cal.xml</File>
    <File>arwr-20140630_def.xml</File>
    <File>arwr-20140630_lab.xml</File>
    <File>arwr-20140630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments under Capitalized Leases (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsLineItems', window );"><strong>Capital Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2014 (remainder of)</a></td>
        <td class="nump">$ 57,105<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump">228,420<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump">228,420<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump">228,420<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump">228,420<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">2019 and thereafter</a></td>
        <td class="nump">95,175<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less interest</a></td>
        <td class="num">(40,681)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Principal</a></td>
        <td class="nump">1,025,279<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less current portion</a></td>
        <td class="num">(213,110)<span></span></td>
        <td class="num">(221,345)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligation, net of current portion</a></td>
        <td class="nump">$ 812,169<span></span></td>
        <td class="nump">$ 1,061,113<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasedAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments maturing in the next fiscal year following the latest fiscal year for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments maturing in the forth fiscal year following the latest fiscal year for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments maturing in the third fiscal year following the latest fiscal year for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments maturing in the second fiscal year following the latest fiscal year for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments maturing after the fifth fiscal year following the latest fiscal year for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments maturing in the remainder of the fiscal year following the latest fiscal year ended for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Summary of Short and Long-term Investments</a></td>
        <td class="text"><div>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following tables summarize the Company&#8217;s short and long-term investments as of June 30, 2014, and September 30, 2013. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2014</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,834,408</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,850</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(237,181</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,599,077</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due after one year within three years)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,284,862</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,899</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,222</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,136,599</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,119,270</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,749</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(389,403</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,735,616</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="14" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2013</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:41%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Gains</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Unrealized Losses</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,030,261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,281</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,998,480</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="width:41%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due after one year within three years)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702,153</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,362</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699,791</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="width:41%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,732,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,643</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,698,271</p></td>
<td valign="top" bgcolor="#CFF0FC" style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5086-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6435544&amp;loc=d3e41834-113960<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_HeldToMaturitySecuritiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
